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SUMMARY
The data acquisition, analysis and interpretation, which inform the text of this 
thesis, were conducted in the period after the award of my MSc (McMaster)(1982) and 
this DSc thesis submission (2005). In 1982 there existed only rudimentary guidelines for 
the conduct of osteoarthritis (OA) clinical trials, few health status measures suitable for 
performing measurement in rheumatology environments, no agreement on core set 
measures, or preferred instruments, and no responder or state attainment criteria. My 
MSc thesis was a design thesis, in which I had conducted a review o f the OA clinical 
trials and outcome measurement literatures and proposed a theoretical construct for the 
development of an evaluative index for OA clinical trials. That review confirmed a high 
degree of heterogeneity in outcome measurement methods, a paucity of standardised 
methods for assessing disease-specific health-related quality of life, and a lack of 
international consensus on core set measurement requirements and preferred methods. 
Following my MSc graduation I developed a programme of research to develop, validate 
and globalise a valid, reliable and responsive standard of measurement (Western Ontario 
and McMaster Osteoarthritis Index -  WOMAC Index) for OA clinical trials. This 
programme was initiated at The University o f Western Ontario (UWO) (1982-1999) and 
continued at The University of Queensland (UQ) (1999-2005). In addition to my own 
research programme, which I led as Professor of Medicine at UWO and subsequently as 
Professor of Rehabilitation Medicine at UQ, I also collaborated with other research 
groups, organisations and agencies to progress international research agendas in OA 
clinical research methodology, many of which were based on WOMAC data.
The initial phase (1982-1992) of WOMAC development involved development 
and validation. Specification of the item content was achieved through face-to-face 
interview of 100 patients with hip and/or knee OA. The resulting test index was 
composed o f five subscales. Two independent validation studies, involving two different 
scaling formats, were designed and executed, one in an orthopaedic environment 
involving total joint arthroplasty, and the other in a rheumatology environment involving 
a double-blind randomised controlled clinical trial of two nonsteroidal anti-inflammatory 
drugs (NSAIDs). Four of the five subscales were successfully validated, of which three 
were retained in the final Index. The face, content and construct validity, reliability and 
responsiveness of the WOMAC Index were established. From these and other early 
studies several other performance-based features of the Index were characterized. These 
included the effects of prior score availability versus non-availability, time frame 
variations from 24 hours to two weeks, relative responsiveness versus other measures, 
selecting signal items versus using the entire Index, and parametric versus non-parametric 
analysis.
The intermediate phase (1993-1999) of WOMAC development involved 
globalisation, and occurred pari passu with international attempts to harmonise OA 
clinical trials methodology; evidence-based and consensus processes that I was involved 
in through OMERACT and OARS I Task Force participation. Most importantly for the 
WOMAC Index were growing opportunities to develop and validate alternate-language 
translations of the Index, based on the original WOMAC 3.0 Index English for Canada 
source questionnaire. The resulting 32 linguistically validated alternate-language 
translations, eventually increased to over 60 alternate-language forms, most being
available in both adjectival and visual analogue scaling formats. The end result of the 
aforementioned processes was the globalisation of the WOMAC Index, international 
consensus on core set domains for OA outcome measurement and specification of 
preferred measures, one of which was the WOMAC Index. Rapidly expanding utilisation 
o f the WOMAC Index by academically-based and industry-based researchers, was 
shortly thereafter followed by a sharp increase in the number of studies reporting use of 
the WOMAC Index, such that by 1999 it was often the most commonly used health status 
questionnaire in osteoarthritis clinical research reported at major rheumatology 
conferences in Europe, N. America and Australasia.
The late phase of development (2000-2005) has involved the further development 
of other language forms, other scaling formats, short forms and versions amenable to 
telephone administration and electronic data capture. This phase has also involved using 
WOMAC Index data to facilitate the development, by various research groups with 
whom I have collaborated, of definitions of responder criteria and state-attainment 
criteria. In particular, we have used WOMAC data, in whole or part, in the development 
of the following definitions of responder criteria: OARSI responder criteria, OMERACT- 
OARSI responder criteria. Minimum Perceptible Clinical Improvement (MPCl), Minimal 
Clinically Important Improvement (MCII), and in the development of the following 
definition of state-attainment criteria: Patient Acceptable Symptom State (PASS).
The now fully developed WOMAC Index is a tri-dimensional, disease-specific, 
self-administered, health status measure. It probes clinically-important, patient-relevant 
symptoms in the areas of pain, stiffness and physical function in patients with OA of the 
hip and/or knee. The index consists of 24 questions (5 pain, 2 stiffness, 17 physical 
function) and can be completed in less than 5 minutes. It is available in Likert (WOMAC 
LK-series), Visual Analogue (WOMAC VA-series) and Numerical Rating (WOMAC 
NRS-series) scaled formats. WOMAC is valid, reliable, and sufficiently sensitive to 
detect clinically-important changes in health status following a variety of interventions 
(pharmacologic, surgical, physiotherapy, etc). It has been translated into many different 
languages and has been requested for use by more than 500 researchers in over 50 
different countries. Several different formats of the WOMAC Index have been produced 
including the WOMAC 3.0, 3.0S, 3.1, 3 .IS, 3.1W, 3.1M and 3.1SLV, 3.1IK, SF- 
WOMAC and e-WOMAC.
The WOMAC Index has become a global standard of measurement for clinical 
trials in hip and knee OA in rheumatology, is widely used in clinical research, and has 
been incorporated into several major regulatory and guidelines documents. The WOMAC 
Index has been important to the development o f global harmonisation in outcome 
measurement, in formulating response and state attainment criteria, and in adjudicating 
the clinical benefit of new treatments for knee OA.
SECTION 1 -  Introduction
Following the successful completion, in June 1982, of an MSc in Clinical 
Epidemiology and Biostatistics at McMaster University in Hamilton, Ontario, Canada, 
and subsequent relocation to a faculty position at The University of Western Ontario in 
London, Ontario, Canada, I embarked on a series of studies conducted between late-1982 
and mid-2004 that resulted in the development of an internationally recognised, and 
widely used, measurement tool called the Western Ontario and McMaster Osteoarthritis 
(WOMAC) Index.
By completion of my MSc degree in 1982,1 had recognised a lack of 
standardisation in outcome measurement procedures in osteoarthritis (OA) research 
publications in rheumatology, as well as a paucity of detailed guidelines specific to the 
conduct of outcome measurement in OA clinical trials of pharmacologic agents. In 
particular, I had recognised that in clinical trials reports not only did the variables 
measured greatly differ, but there was considerable variability in the scales and 
instruments employed to capture data on even a single variable, for example pain. 
Furthermore, apart from physician and patient global assessments, pain and stiffness were 
the only other two variables monitored in more than half of the 63 trials critically 
appraised, while the second most important symptom of OA, physical disability, was 
monitored in only 35% of the studies. The European League Against Rheumatism 
(EULAR) OA clinical trails guidelines only existed in draft form in 1982, and the United 
States Food and Drug Administration (FDA) guidelines gave relatively little guidance 
regarding outcome measurement in OA clinical trials, the latter recommending 
measurement of joint range of motion and walking or stair climbing time, but not 
specifically recommending measurement of physical functioning or disability.
The need for a standardised method of capturing patient-centred outcomes or 
patient reported outcomes (PROs) was timely and attainable. Following completion of 
my MSc degree, I relocated from Hamilton, Ontario to London, Ontario in July 1982, to 
take up faculty appointments, at the Assistant Professor level, in Medicine, Epidemiology 
and Biostatistics at The University o f Western Ontario and a consultancy in 
rheumatology at Victoria Hospital. I also retained a part-time faculty level appointment at 
McMaster University as Assistant Professor o f Clinical Epidemiology and Biostatistics,
Soon after arriving in London, I initiated the first studies directed at developing 
the WOMAC Index. This thesis describes the research work undertaken in Ontario, 
Canada, and after 1999, in Queensland, Australia, that resulted in the development, 
validation and globalisation of the WOMAC Index, a patient-centred health status 
questionnaire, now cited in international guidelines for outcome measurement in clinical 
trials, widely used globally in 65 languages in clinical research environments in 
rheumatology, and which has played an important role in setting standards for proposed 
response and state-attainment criteria.
Following this Introduction, the thesis is divided into nine other sections as 
follows: Development, Validation, Exploration of Special Measurement Characteristics, 
Applications in Clinical Research, Globalisation, Flexible Delivery, Responder Criteria 
and State-Attainment Criteria, WOMAC Index: A Global Perspective, and WOMAC 
Index: Contemporary Context. The sections follow a basic sequence from the earliest 
stage of development through to the most recent publications, and within each section
and subsection are generally divided according to chronology. All except the WOMAC 
User Guide have been previously published in peer review journals, and represent 
important contributions to the history of outcome measurement development in OA, and 
the WOMAC Index development in particular.
Section 2 -  Development, describes the patient-based method used to develop the 
item inventory for the WOMAC Index, a process that conferred the necessary face and 
content validity to the Index. Section 3 -  Validation, contains a review of the two major 
validation studies that confirmed the construct validity, test-retest validity, internal 
consistency and responsiveness of the WOMAC Index, and resulted in the selection of 
three of the original five dimensions for further development. Section 4 - Exploration of 
Special Measurement Characteristics, reviews sub-analyses and sub-studies conducted to 
explore issues of blind versus informed presentation, signal vs aggregate strategies of 
measurement, time frame dependency of responses to the WOMAC Index and the 
relative responsiveness of the WOMAC Index compared to other methods of outcome 
assessment. Section 5 - Applications in Clinical Research, describes post-validation 
experience with the WOMAC Index in different research environments including 
NSAIDs, a complex analgesic, a slow-acting drug for osteoarthritis and a 
viscosupplement. Section 6 -  Globalisation, describes contributions made, in 
collaboration with working groups and task forces of the Outcome Measures in 
Rheumatology Clinical Trials (OMERACT) Group, Osteoarthritis Research Society 
International (OARSI), World Health Organisation / International League of Associations 
o f Rheumatology (WHO/ILAR) and the Initiative on Methods, Measurement and Pain 
Assessment in Clinical Trials (IMMPACT) Group, to the development of international 
consensus and harmonisation in outcome measurement in OA clinical trials, 
developments in which the WOMAC Index played an important role. The section also 
details the methods used to successfully globalise the WOMAC Index in over 60 
alternate-language translations. Section 7 - Flexible Delivery, describes collaborative 
projects directed at validating the WOMAC Index for delivery by telephone interview, 
and for electronic data capture using mouse-driven cursor and touch-screen technology 
on personal computers, as well as documenting the validation of a short form of the 
WOMAC Index. This section also describes, based on surveys undertaken in Canada and 
Australia, the limited use in clinical practice of quantitative methods of health status 
assessment, which were frequently used in clinical research environments. Section 8 - 
Responder Criteria and State-Attainment Criteria, describes the contributions made by 
the author and the role of the WOMAC Index in the development of proposed definitions 
for responder and state-attainment criteria in OA. Section 9 - WOMAC Index: A Global 
Perspective, reviews the current status of the WOMAC Index, and summarises 
contributions made by the author and the Index, in the development o f global 
opportunities for standardised health status measurement in OA in rheumatology.
Section 10 - WOMAC Index: Contemporary Context, describes the placement of 
WOMAC Index, within the context of other measures for hip and knee OA in 
rheumatology, that have emerged subsequent to validation of the WOMAC Index.
A list of the publications that contribute to this thesis, is provided after the ten 
aforementioned sections. Finally, copies of the WOMAC Copyright Certificate and the 
WOMAC Trademark Certificate issued to me, by the Government of Canada, are 
provided in Appendix A, and OA measurement alternatives are listed in Appendix B.
SECTION 2 - Development
My research goal was to develop a valid, reliable and responsive patient self- 
reported health status questionnaire, to meet a global measurement need in clinical trials 
of pharmacologic agents in hip and knee OA. Therefore, in order to construct the item 
inventory o f WOMAC, the dimensionality of the symptomatology o f hip and knee OA 
was explored in 100 patients with hip and/or knee involvement (1). The survey 
questionnaire was developed by a peer review process involving the opinions of four 
academic rheumatologists and two clinical epidemiologists experienced in clinical 
measurement in the rheumatic diseases. Initial questions were open-ended and probed the 
clinical importance and characteristics of any pain, stiffness, physical, social or emotional 
dysfunction. Once spontaneous responses to these questions were exhausted, a battery of 
closed-ended questions, derived from (and modified where necessary) six existing 
questionnaires (Health Assessment Questionnaire -  HAQ, Functional Status Index -  FSI, 
Arthritis Impact Measurement Scales -  AIMS, Pooled Index, McMaster/Toronto 
Assessment Index -  MACTAR, McMaster Health Index Questionnaire -  MHIQ), was 
used to complete the assessment of each dimension and quantify any sources of 
discomfort and disability. The survey questionnaire was administered by face-to-face 
interview. The following data were recorded: 1) the presence or absence of each of 
several types of discomfort or disability, 2) the frequency with which each type of 
discomfort or disability occurred (daily, weekly, fortnightly, monthly or less), and 3) the 
importance of each type of discomfort or disability to the patient (0 = none, 1 = slight, 2 
= moderate, 3 = very, 4 = extreme).
Patients were specifically questioned about sources o f discomfort and disability 
recently experienced, and attributed to OA in the hips and/or knees. They were 
questioned regarding the perceived importance of each type o f discomfort and disability, 
in order to assess their clinical relevance. Gender-specific questions relating to physical 
disability (e.g. ironing) were avoided, and questions phrased in more general terms (e.g. 
light domestic duties). Questions relating to sexual function were not included, since this 
had been previously noted to result in low response rates, and inhibit responses to 
subsequent non-sexual function questions.
Using this approach the item inventory for a prototype WOMAC Index was 
specified, based on the prevalence, frequency and mean importance of reported 
symptoms on each of the five dimensions (pain, stiffness, physical function, emotional 
function, social function). A prototype WOMAC Index was prepared in both 5-point 
adjectival (syn:Likert or LK) and 100 mm visual analogue (VA) scaling formats. The 
questions included in the prototype WOMAC Index inventory targeted symptoms, that 
patients generally considered important, and which recurred with relative frequency.
This method of development, based on literature review, consultation with key 
informants and structured face-to-face inteiwiews with 100 patients with hip and/or knee 
OA, using both closed and open-ended questions, was considered sufficient to confer the 
necessary face and content validity to the prototype WOMAC Index. Indeed this patient- 
based approach is considered a key determinant of the global success of the WOMAC 
Index, and differentiates it from health status measurement tools based only on expert 
opinion. While expert opinion can be informative, it may not adequately reflect the 
patient’s perspective, and may be at risk of being considered paternalistic. In contrast, the
approach used in the development of the WOMAC Index was predominantly driven by 
the opinion and experience of patients with symptomatic hip and/or knee OA.
Reference:
1.Bellamy, N. and Buchanan, W.W. A preliminary evaluation of the dimensionality and 
clinical importance of pain and disability in osteoarthritis of the hip and knee. Clinical 
Rlieumatology 1986;5(2):231-241.
Clinical rh eu m a to lo g y , 1986, 5, N “ 2 231-241
A  preliminary evaluation o f  the dimensionality and clinical 
importance of pain and disability in osteoarthritis o f  the hip 
and knee
N .  B E L L A M Y ,  W . W .  B U C H A N A N
D epartm ent o f  Rheum atology, University o f W estern O n tario , L ondon, C an ad a  ; 
D epartm ent o f Rheum atology, M cM aster University, H am ilton , O ntario , C an ad a .
SUMMARY Current methods o f  clinical assessment in osteoarthritis show a high degree 
o f  variability. By contrast, patients with rheumatoid arthritis may be evaluated using a 
number o f  standardised and validated indices. One hundred patients with primary os­
teoarthritis o f  the hip and knee were interviewed in order to determine the dimensionality o f  
their discomfort and disability and to define the clinical importance o f  each component 
item. The symptomatology o f  osteoarthritis was captured by five  pain, one stiffness, twenty- 
two physical, eight social and eleven emotional items. In spite o f  a high degree o f  variability 
in the frequency o f  involvement o f  the individual items, their clinical importance was similar 
both within as well as across dimensions. Further studies are indicated to determine the 
reliability, validity and responsiveness o f  each o f  the items identified as a prelude to devel­
oping a standardized method o f  assessing patients with osteoarthritis o f  the hip and knee.
Key words : Osteoarthritis, Pain, Disability, Clinical Importance.
INTRODUCTION
Discomfort (pain and stiffness) and dis­
ability (physical, social and emotional) arc 
the major symptoms of osteoarthritis. In 
spite o f the greater prevalence of osteoar­
thritis, more attention has been directed to­
wards the study of functional decrements 
and the quality of life of patients with rheu­
matoid arthritis (1) than to patients with de­
generative forms of arthritis (2,3). In respect 
to outcome measurement in osteoarthritis
Received IS March 1985,
RevhioQ - accepted 10 February 1986 
Corrcspoadcncc to : DR. N. BELLAMY 
Suite 402 A, Victoria Hospt^ {Westminster Tower), 
SOO Commissioners Road East London, Ontario, 
Canada, N6A 405
clinical trials, we have reported in a previous 
edition of this journal, a review of 63 clini­
cal studies o f nonsteroidal anti-inflammato­
ry drugs reported between 1962 and 1982 
and have observed a high degree of variabili­
ty in the outcome measures employed (4). In 
addition to lacking any standardisation, cur­
rent measures presume a validity extrapolat­
ed from the rheumatoid arthritis literature. 
Tims, the majority o f indices which have 
been developed for use in rheumatic diseases 
have been based on patients with 
rheumatoid arthritis (5-29). However, fun­
damental differences exist between patients 
with rheumatoid and osteoarthritis in re­
spect of the age o f onset, distribution of 
joint involvement, natural history of the dis­
ease and response to treatment. Only the 
Doyle (7) and Lcquesnc (24) indices have
232 N . Bellamy. W .W . Buchanan
been expressly developed for evaluating 
patients with osteoarthritis. However, the 
Doyle Index is unidimensional and is a mod­
ification of the Ritchie Index while the Lc~ 
quesnc Index is oligodimensional and uti­
lizes a restricted number of response alterna­
tives.
In view of these deficiencies in outcome 
measurement in osteoarthritis clinical trials, 
we are currently undertaking a series of 
studies to rationalize the measurement pro­
cess pertaining to patients with primary os­
teoarthritis of the hip and/or knee. In the 
present study the extent of each of five con­
tent domains was assessed and component 
items ranked according to their prevalence 
and clinical importance. The objective was 
to define the dimensionality of pain and dis­
ability and identify those component items 
having the greatest clinical importance in a 
group o f potential drug-study patients.
MATERIALS AND METHODS
One hundred out-patients with osteoar­
thritis of the hip and/or knee were selected 
for study. To be eligible patients had to ful­
fill the following criteria: 1) Attend a 
rheumatological clinic at either the Univer­
sity o f Western Ontario, London, or 
McMaster University Medical Centre, Ham­
ilton; 2) Be ambulatory; 3) Have symptom­
atic primary osteoarthritis affecting at least 
one hip or knee and requiring treatment with 
a nonsteroidal anti-inflammatory analgesic 
medication; 4) Have minimal or no spinal 
symptoms ; 5) Be unrestricted (in their 
functional capacity) by any co-morbid con­
dition and; 6) Not have had prior hip or 
knee replacement surgery or an osteotomy. 
The patients selected for study would all 
have been eligible for a clinical trial of ndn- 
steroidal anti-inflammatory drug therapy 
since they were all typical of patients com­
monly used in such trials.
The survey questionnaire was developed 
by a peer review process utilizing the opin­
ions of four rheumatologists (WWB, NB,
PT, PJR) and two clinical epidemiologists 
experienced in clinical measurement in the 
rheumatic diseases (CG, LG). Initial 
questions were open-ended and probed the 
clinical importance and characteristics o f 
any pain, stiffness, physical, social or em o­
tional dysfunction. Once spontaneous re­
sponses to these questions were exhausted, a 
battery of closed-ended questions derived 
from six existing questionnaires (10-13, 25, 
27, 31, 32) was used to complete the assess­
ment of each dimension and quantitative 
any sources of discomfort or disability de­
tected.
The following data were recorded : I) The 
presence or absence of each of several types 
of discomfort or disability (Table TIV); 2) 
The frequency with which each type of d is­
comfort or disability occurred (daily, 
weekly, fortnightly, monthly or less) and 3) 
The importance of the discomfort or disabil­
ity to the patient (0 = none, I = slight, 2 = 
moderate, 3 = very, 4 = extremely). It 
should be noted that patients were specifi­
cally asked to record the perceived im por­
tance of each type of discomfort or disabili­
ty reported in order to assess its clinical rele­
vance. Furthermore, the discomfort and d is­
ability sought was specified as having been 
recently experienced and directly related to 
osteoarthritis of the hip and/or knee. Thus, 
each patient was asked to report only those 
symptoms which they felt were the direct re­
sult of their articular disease.
During questionnaire construction, items 
directed specifically at patients of one or 
other sex (e.g. ironing) were avoided and the 
questions rephrased in more general term s 
(e.g. light domestic duties). Patients were 
not asked about sexual function in order to 
avoid embarrassment and because this has 
been previously noted to inhibit responses 
even to subsequent non-sexual questions.
Before being formally applied the 
questionnaire was pro-tested in 15 osteoar- 
thritic patients in order to assess its com pre­
hensibility and feasibility. Tliercaftcr, the 
questionnaire was administered to 90
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patients by face-to-face interview (using 
trained interviewers) and to a further 10 
patients by telephone. Telephone interviews 
were permitted in order to be able to survey 
patients, at either end o f the severity spec­
trum, who though ambulatory did not wish 
to make a non-essential journey. Patients 
who were confined to a bed or wheelchair 
were excluded from the survey as they would 
not normally have been admitted to a drug
Table I Pain rank ordcfed by prevalence (P)
Table III Social Junction rank ordered by prevalence
(P)
ITEM MIS [DW%)
Walking .77 2.58 96
Stairs .75 2.62 94
In bed .67 2.63 96
Weight bearing .57 2.51 94
Sitting/lying .56 2.57 95
Bending .01 3.00 100
Strenuous exercise .01 3.00 100
Table II Physical disability rank ordered by preva­
lence (P)
ITEM P MIS fDWV.I
Rising from sitting .70 2.32 99
Descending stairs .69 2.60 94
Ascending stairs .69 2.54 89
Standing .57 2.64 96
Walking on flat sur­
faces .56 2.40 96
Getting in/out o f car .56 2.26 91
Bending to floor .55 2.51 95
Going shopping .49 2.40 94
Going shopping .49 2.40 94
Putting on socks .46 2.38 96
Rising from bed .45 2.37 100
Taking off socks .43 2.37 95
Getting in/out of bath .40 2.30 98
Lying in bed .39 2.36 95
Heavy domestic duties .36 2.43 71
Light domestic duties .36 2.26 88
Sitting .35 2.54 100
Getting on /off toilet .33 2.67 85
Getting on /off bus .30 2.38 66
Getting in/out shower .16 2.31 94
Driving a car .16 2.25 75
Going from bed to
chair .15 2.21 85
Running on flat sur­
faces .13 2.42 75
ITEM P MIS [DW%1
Restricted leisure activ­
ities .54 2.56 87
Attendance at commu­
nity events .27 2.15 77
Attendance at church .23 2.52 74
Relations with spouse .20 2.65 90
Relations with family .18 2.67 89
Relations with friends .14 2.64 79
Relations with others .11 2.55 91
Dancing .03 2.33 33
Table IV Emotional function rank ordered by preva­
lence (P)
ITEM P MIS [DW%J
Frustration .56 2.44 86
Anxiety .55 2.64 74
Irritability .53 2.59 81
Depression .45 2.49 65
Difficulty relaxing .44 2.39 73
Difficulty sleeping .36 2.58 98
Boredom .26 2.62 88
Loneliness .23 2.26 78
Difficulty coping with
stress .17 2.19 75
Disturbed sense of well­
being .14 2.62 54
Poor self-control .09 2.11 78
trial. The response rate amongst those invit­
ed to participate was 97%.
Following completion of 100 interviews, 
the data were summarized to provide the fol­
lowing values : 1) Prevalence of each type of 
discomfort or disability (P) ; 2) Mean impor­
tance score (MIS = the sum of the indivi­
dual importance scores given by n affected 
individuals divided by n ; and 3) The percen­
tage of symptomatic patients experiencing 
daily or weekly symptoms (DW% = High 
Frequency). The individual items were then 
ranked within each dimension in order of 
their prevalence. In this study prevalence 
was defined as the proportion of patients in 
the “ at risk”  population who were con­
cerned by ongoing symptomatology on a given 
variable (Tables Ï-IV). Subsequent analyses 
examined the effects of age, sex and disease
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duration on the key symptoms within each 
dimension (Tables V and VI, Fig. 1-3).
RESULTS
Sixty-three female and 37 male patients 
were interviewed. The mean age was 61.07 
years (range = 27-93) and mean disease du­
ration (i.e. symptomatic) 10.07 years (range 
= 0.25 - 51). Eleven patients had hip disease 
alone, 57 knee disease alone, and in 32 the 
disease affected both hip and knee. Eight 
patients had previously undergone menisec- 
tomy some years earlier bu t none had been 
subject to arthroplastic surgery or osteoto­
my. All patients were symptomatic at the 
time of assessment.
Pain
Pain was disaggregated into pain occur­
ring during five types o f activity (Table I). 
Only two additional components o f pain 
were identified by open-ended questions and 
it can therefore be assumed that these five 
principle items adequately represent the di­
mension of pain. Only one patient
complained of pain while bending from the 
waist and a second of pain during strenuous 
exercise. The prevalence of different sources 
of pain varied from 56 to 77%, walking 
being the most frequent cause of pain. 
Amongst the five principle items, pain on 
sitting or lying was the least frequent (56%). 
Mean importance (MI) scores for pain 
varied from 2.509 to 2.627, and pain occur­
red with high frequency, being present at 
least daily or weekly in 94-96% of affected 
patients.
Pain prevalancc for pain in bed and while 
negotiating stairs showed little variation 
with age but there was a tendency for pain 
experienced while sitting and while walking 
to increase prevalence with advancing age 
(Fig. I). Overall MI scores (Fig. 1) failed to 
show any correlation (r = 0.00) with age 
(Table V) and there was no significant dif­
ference (p =  0.88) in MI scores for pain 
between males and females (Table VI). 
There was a low level of correlation 
(r =  0.26) between MI scores for pain and 
disease duration and there were modest but 
significant correlations between MI scores 
for pain and those for stiffness, physical
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fîg . J: Prevalence and mean importance scores for selected sources o f  pain as a function o f age (• -  Walking, 
0 = Negotiating stairs, x =  In bed at night, ■ = sitting or lying).
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Fig. 2 :  Prevalence and mean importance scores for selected physical disabilities as a function o f  age {* =  Standing, 
o =  Ascending stairs, x =  Walking on a flat surface, ■ = Descending stairs).
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Fig. 3 : Prevalence and mean importance scores for selected sodocmotionai disabilities as a function o f  age (• = 
Anxiety, x =  Frustration, ■ =  Restricted leisure activities).
dysfunction, and key social and emotional morning and 73% after prolonged sitting or
items (Table V). lying at other times. Mean importance
scores were 2.524 and 2.303 respectively. 
Stiffness The mean duration o f morning stiffness was
14.5 minutes (range 1-120). Stiffness occur- 
Forty-scven percent of patients complain- red on a daily basis in almost all affected
ed of joint stiffness after wakening in the individuals.
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Tabic V Correlation matrix Jar mean importance scores fo r  pain, stiffness, physical, social and emotional 
function, age and disease duration
Pain Stiffness Physical Social Emotional function
function function Anxiety Frus- Irritability 
tration
Age Disease
Duration
pain 1.00
Stiffness 0.21 1.00
Physical 0.74 0.22 1.00
Social 0.39 0.23 0.44 1.00
Anxiety 0.44 0.23 0.52 0.49 1.00
Frustration 0.46 0.23 0.50 0.41 0.59 1.00
Irritability 0.40 0.16 0.40 0.21 0.57 0.55 1.00
Age 0.00 -0.03 0.06 -0.14 -0.14 -0.13 -0.20 1.00
Disease duration 0.26 -0.01 0.08 -0.03 0.14 -0.01 -0.02 0.14 1.00
Table VI Comparison o f  the mean importance scores given by sym ptom atic male versus fem ale patients fo r  each
dimension
Pain Stiffness Physical Social Emotional
Male 2.56 2.28 2.16 2.38 2.44
Female 2.52 2.32 2.38 2.23 2.35
p value 0.88(NS) 0,84{NS) 0.22(NS) 0.43(NS) 0.5I(NS)
{2-iailcd)
No significant correlation was noted 
between MI scores for stiffness and either 
age (r = -0.03) or disease duration (r=  -0.01) 
(Table V). Low levels o f correlation were de­
tected between stiffness scores and those of 
pain, physical function, restricted leisure ac­
tivity, anxiety and frustration (Table V). 
Although morning stiffness was more pro­
longed in females (mean =  13.55 minutes) 
than males (mean = 7.42 minutes) this differ­
ence was not statistically significant 
(p = 0.24). Similarly, no significant differ­
ences (p = 0.84) were detected in MI scores 
for stiffness between males and females 
(Table V).
Physical Dysfunction
Physical dysfunction was disaggregated 
into disability occurring during 22 types of 
activity (Table II). No additional compo­
nents of physical disability were identified
by open-ended questions and therefore these 
22 questions are considered as adequately re­
presenting this dimension- The prevalence o f 
physical disability varied from 13 to 70% . 
Negotiating stairs, rising from the seated po­
sition, standing, bending, walking and get­
ting in and out of a car were the most fre­
quent forms o f disability. It may be interest­
ing to note that running on a fiat surface, 
transferring from bed to chair, driving a car 
and getting in and out of the shower were 
infrequent causes of disability. Mean im por­
tance scores varied from 2.214 to 2.667. 
Physical disability occurred with high fre­
quency, being present daily or weekly in 80 
to 100% of affected patients in the m ajority 
of instances.
The prevalence of the four principal 
forms of physical dysfunction displayed a 
tendency to increase with advancing age 
(Fig. 2). In contrast MI scores for these four 
items showed little variation with age (Fig. 2)
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and MI scores for the entire dimension were 
poorly correlated with both age (r = 0.06) 
and disease duration (r = 0.08) (Table V). MI 
scores for physical dysfunction were highly 
correlated with those for pain (r = 0.74), 
moderately correlated with those for the key 
social and emotional items and poorly corre­
lated with that for stiffness (Table V). No 
significant difference (p = 0.22) was detected 
in MI scores for physical dysfunction 
between males and females (Table VI).
Social Dysfunction
Social function was disaggregated into 
seven component items which essentially 
captured the dimension (Table III). With the 
exception of restricted leisure activities 
(54%) social dysfunction was relatively un­
common (3 to 27%). In spite of this infre­
quency, the mean importance scores 
amongst affected individuals range from 
2.154 to 2.667, and were comparable with 
scores for discomfort and disability on other 
dimensions. With the exception o f dancing, 
social dysfunction occurred with high fre­
quency in affected individuals (74-91%).
The prevalence of the key social disability 
(restricted leisure activities) showed no con­
stant relationship to age (Fig. 3). MI scores 
for this item showed little variation (Fig. 3) 
and were poorly correlated with age 
(r = -0.14) and disease duration (r = -0.03) 
(Table V). In contrast modest corrcltions 
were noted between social dysfunction and 
pain, stiffness, physical and emotional dys­
function (Table V). No significant differ­
ences (p = 0.43) were noted in MI scores for 
social items between males and females 
(Table VI).
Emotional Dysfunction
Emotional function was disaggregated 
into 11 component items (Table IV). Since 
no additional items were added, these items 
are considered representative of this di­
mension. The prevalence of emotional dys­
function ranged from 9 to 56% : anxiety, ir­
ritability, and frustration being most com­
mon. Difficulty coping with stress (17%), 
disturbed sense of well-being (14%) and 
poor self-control (9%) were infrequent 
problems. Mean importance scores varied 
from 2.111 to 2.636. With the exception of a 
disturbed sense of well-being and de­
pression, emotional dysfunction occurred 
with high frequency in the majority of af­
fected individuals (73-98%).
The prevalence of the key emotional disa­
bilities showed no consistent relationship to 
age (Fig. 3). MI scores for these items 
showed little variation (Fig. 3) and were 
poorly correlated with both age (r = -0.13, 
-0.14, -0.20) and disease duration (r = 0 .14, 
-0.01, -0.01) (Table V). In contrast modest 
correlations were noted between key emo­
tional items and both pain and physical 
function and low levels of correlation were 
demonstrated with stiffness (Table V). No 
significant differences (p = 0,51) were noted 
in MI scores for emotional items between 
males and females (Table VI).
CONCLUSION
The assessment of pain (34) and disability 
(35) is a complex process which may be af­
fected by a multiplicity o f interacting biolog­
ical and environmental factors (36). Not 
only is there significant day-to-day variabili­
ty in an individual’s pain sensitivity and phy­
sical performance but there is also often sig­
nificant diurnal or circadian variation 
(37,38). Furthermore, patients with chronic 
musculoskeletal disease frequently show a 
high and unpredictable degree of individual 
variability in their response to therapeutic 
interventions (39). Thus, in attempting to 
measure the dimensionality o f discomfort 
and disability in osteoarthritis, the clinical 
methodologist must address issues which re­
late to the reliability, validity and respon­
siveness of the measuring instrument (4). A 
variety of validated scales are currently
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available to measure qualitative and quanti­
tative aspects of pain (40) and various forms 
of physical, social and emotional disability 
(41). The majority of such scales are not 
based on musculoskeletal populations and 
of those which are, few have been designed 
to assess multidimensional symptoms in os- 
tcoarthritic patients (43).
This evaluation was specifically based on 
100 patients who could fulfill musculoskele­
tal criteria for entry into a clinical trial of 
nonsteroidal anti-inflammatory drug thera­
py. It is evident from the data that the ma­
jority of patients surveyed experienced some 
form of discomfort or disability on each of 
the five dimensions. Pain was the most com­
mon symptom, particularly while walking, 
on negotiating stairs or in bed at night. Stat­
ic pain whereas rated somewhat higher in 
importance nevertheless occurred less often. 
This observation is in keeping with the fact 
that pain at rest occurs with more severe dis­
ease and is usually preceded by pain with 
those activities which place joints under 
greater mechanical stress. It is commonly 
taught that joint stiffness is mild and of 
short duration in osteoarthritis (33). Our ob­
servations arc consistent with this doctrine, 
at least in respect o f duration, although a 
minority of individuals had prolonged 
morning stiffness. The mean importance 
score indicates that while often reported as 
“ mild” , for the affected individuals it is 
nevertheless an important source of discom­
fort. Difficulty negotiating stairs, standing 
up from a sitting position, standing still, 
bending, walking and getting in and out of 
the car occurred in the majority of patients. 
These locomotor disabilities were more com­
mon than those associated with less dynamic 
activities, e.g. putting on and taking off 
socks, lying in bed and sitting. However, 
there is one qualitative aspect of these data 
which should be noted. While tasks such as 
getting on and off the toilet cannot be 
avoided, others, such as heavy domestic 
duties and driving a car arc generally avoid­
able and thus assume less importance than
might at first be thought. Thus, amongst the 
patients who reported no difficulty with a 
given activity some were able to perform the 
activity without difficulty and other avoided 
it and therefore did not encounter any actual 
disability. The question regarding transfer 
from bed to chair proved to be a poor 
question since the majority o f ambulant 
patients did not require undertaking this ac­
tivity. These different conditions clearly dis­
tort the true prevalence of various forms o f 
physical disability, nevertheless, the study 
provides a reasonable estimate o f the p ro ­
portion of patients who were concerned with 
any ongoing functional restriction. Since 
this survey was conducted for the purpose o f 
identifying the dimensionality o f pain and 
disability and not as an epidemiologic survey 
to determine the exact prevalence of each 
item, the principal objective was not com ­
promised by this nuance. Restricted leisure 
activities were the only frequent source o f 
social disability. The relative infrequency o f 
other sources of social disability, clearly re­
flect not only avoidance of these activities 
due to disease but also the restriction in 
social activity which attends the process of 
ageing. Thus ageing osteoarthritics are more 
likely to be widowed, geographically dis­
placed from their offspring or financially 
constrained.
Anxiety, irritability and frustration are 
common emotional responses even in heal­
thy individuals. It is not surprising therefore 
that patients with osteoarthritis experience 
similar, albeit more intense, symptoms in 
this area. It is of interest that less than half 
the patients complained of depression and 
that while 67% of patients experienced pain 
in bed only 36% had difficulty sleeping. 
Furthermore, in spite of nocturnal and diur­
nal pain, only 17% had difficulty coping 
with stress and only 14% a disturbed sense 
of well-being. These data can likely be 
explained by the recurrent observation in 
clinical practice that patients with chronic 
disease accommodate to their illness. Thus, 
just as the expectation of cure or successful
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treatment changes with time, so does the 
perception of pain. In addition patients find 
ways of minimizing the discomfort and disa­
bility which the disease causes.
We consider the questionnaire used in this 
survey as having face and content validity 
(44) by virtue of the development strategy 
employed, i.e. the utilization of both open- 
ended and closed-ended questions. Further­
more, the questionnaire was pre-tested in 15 
patients with osteoarthritis and no difficulty 
was encountered in patient comprehension 
of the terminology used. Nevertheless, 
it might be wondered whether the 
questionnaire in fact probed the severity 
rather than the clinical importance of the 
patients symptoms. We do not believe this to 
be the case since no significant correlation 
was detected between either age and scores 
on any of the five dimensions or between 
disease duration and scores on any of the 
five dimensions. If, in fact, the 
questionnaire had probed severity of symp­
toms then given the insidiously progressive 
nature of the disease a time-dependent in­
crease in symptomatology would have been 
expected and a moderate level of correlation 
detected. As anticipated the prevalence o f 
pain and physical disability did in fact in­
crease as a function of age although social 
and emotional forms of disability showed a 
rather inconsistent relationship. The rela­
tively low level of correlation between age 
and disease duration is not entirely unex­
pected given the documented plateau-form 
age-prcvalcnce profile o f certain types of 
osteoarthritis (45) and the highly variable in­
terval between the age of onset of disease 
and the age of onset of symptoms (46). 
Finally, it is only to be expected in a disease 
in which pain leads to disability that pain 
scores and disability scores would be moder­
ately correlated.
This study highlights the multidimension­
ality of discomfort and disability in patients 
with osteoarthritis of the hip and/or knee. 
Health care providers and clinical investiga­
tors, therefore, require the assessment not
only of the pain and of physical disability 
produced by this disorder but also recog­
nition of its social and emotional conse­
quences. Furthermore, while pain and physi­
cal disability are regarded as the most im­
portant symptoms of the disease, these data 
indicate that in affected individuals each 
symptom is regarded with similar clinical 
importance. Although certain physical and 
social activities cân be avoided these data 
also suggest that for those disabled indivi­
duals who are still able to attempt a given 
activity, the importance o f being able to per­
form the activity is similar to that of being 
able to perform other activities in the same 
and different dimensions.
At the present time no standard method 
exists for evaluating patients with osteoar­
thritis either in clinical practice or in clinical 
trials. Given the nature of the disease and its 
many differences from rheumatoid arthritis, 
we believe that it is timely to attempt the 
development of a multidimensional outcome 
measure for use in patients with osteoarthri­
tis of the hip and knee. To date we have 
identified the dimensionality and clinical im­
portance o f a variety of pain and function 
items in a group of potential nonsteroidal 
anti-inflammatory drug trial subjects. Fur­
ther work is required to assess the reliability, 
construct validity and responsiveness of each 
item and to address the issues of scaling, ag­
gregation within- and across-dimensions and 
to establish the preferred method for statisti­
cal analysis. The value of using multiple 
items on several dimensions versus one or a 
few items on a restricted number of di­
mensions, in discriminating between an ac­
tive drug and a placebo or, between two ac­
tive drugs cannot be assessed from the cur­
rent data but is the subject of ongoing re­
search. Nevertheless, the items which have 
been identified serve as a useful battery of 
questions having both face and content val­
idity which can be used to evaluate indivi­
dual patients or groups o f patients with os­
teoarthritis for descriptive purposes.
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SECTION 3 - Validation
Two major validation studies of the WOMAC Index were completed (2-4). The 
goal was to assess the reliability and validity o f the Index, and evaluate Index 
responsiveness. Originally, only a single validation study, conducted within a 
pharmacologic randomised clinical trial (RCT), was contemplated. However, due to a 
lack of certainty over funding for the RCT, a trial in a total joint replacement 
environment was the first to be initiated. Ultimately, validation was successfully 
accomplished in both research settings, and undoubtedly added to the generalisibility of 
the observations. For the purpose of validation, responses to WOMAC questions were 
scaled in two different formats. The LK-scaled version allowed patients to make their 
responses on five-point adjectival scales (0 = none, 1 = mild, 2 = moderate, 3 = severe, 4 
= extreme). In contrast, the VA-scaled version permitted responses to be made on 100 
mm horizontal visual analogue scales with end markers, outside which were placed the 
following descriptive anchors (left end = none, right end = extreme). The validation 
Index used a 24-hour recall period, and instructed patients to consider the severity of their 
symptoms (pain, stiffness, physical function, emotional function and social function), due 
to OA in their hips and/or biees.
The orthopaedic study employed a quasi-experimental, one-group repeated 
measures design (2) in 30 OA patients undergoing total arthroplasty o f the hip (n=16) or 
knee (n=I4). Patients were evaluated the day before surgery and at six weeks, three 
months and six months post-operatively. In addition to LK- and VA-scaled versions of 
WOMAC, the following measures were administered concurrently for validation 
purposes: 1) Modified Doyle Index, 2) Lequesne Index, 3) Bradburn Index of Well 
Being, and 4) Social component of the MHIQ. Additional measures included inteiwiewer 
global assessment, patient global assessment, 50 foot walk time, joint range of motion, 
intermalleolar straddle, and intercondylar distance.
The pharmacologic study employed a double-blind, randomised controlled trial 
(RCT) design (3,4) and compared two NSAIDs [Isoxicam (n== 28), Piroxicam (n = 29)] in 
57 patients with OA hip (n=I8) or knee (n=39). One of the major strengths of the 
pharmacologic validation study design was that randomisation created two groups similar 
in baseline characteristics and response potential. Independent evaluations of reliability, 
validity and responsiveness were undertaken on these two separate treatment groups, an 
approach which was innovative in the research environment of 1982. Patients were 
evaluated at enrollment and again one week later without any change in therapy in order 
to obtain test-retest reliability estimates at steady state. Thereafter, patients underwent a 
one-week NS AID-free washout period. Finally they were evaluated after two, four and 
six weeks of active treatment. In addition to LK- and VA-scaled versions of WOMAC, 
the following measures were administered concurrently for validation purposes: 1) 
Modified Doyle Index, 2) Lequesne Index, 3) Bradburn Index of Well Being, and 4) 
Social component of the MHIQ. Additional measures included interviewer global 
assessment, patient global assessment, 50 foot walk time, total range of motion, and 
intermalleolar straddle. The resulting WOMAC data were analysed by both parametric 
and non-parametric statistical methods to examine whether the method o f analysis 
influenced the interpretation of the results. In the event, while the non-parametric
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approach provided a more conservative estimate, both methods produced comparable 
results, and the method did not influence data interpretation.
The results from both studies, including both treatment groups in the 
pharmacologic validation study, attested to the reliability (test-retest and internal ;
consistency), construct validity, and responsiveness of the pain, stiffness, physical 
function and emotional function items and subscales of the WOMAC Index. The social 
items did not validate well, and the social function subscale was dropped. As a !
consequence of decisions regarding the social function subscale, I decided to hold the 
emotional subscale in abeyance, and postpone its further development, pending a future I
redevelopment of the social function subscale. The other three subscales (pain, stiffness, |
physical function) performed exceptionally well, and all 24 component items were j
retained. i
On the basis of these two validation studies, the final version of WOMAC was i
established. Since LK- and VA-scaled formats of the Index had been separately validated, I
two versions of the Index were produced: WOMAC LK 3.0 and WOMAC VA 3.0. These |
versions were identical with respect to item inventory and differed only in the scales on j
which patients responded to the component questions. The WOMAC 3.0 Index contained |
24 items on three subscales: pain (5 items), stiffness (2 items), physical function (17 j
items), used a 24-hour time frame, and questioned patients regarding the symptom |
experience in their hips and/or knees. The development strategy and the results of the two 
validation studies, supported claims regarding the face, content and construct validity, 
test-retest reliability and internal consistency, and responsiveness of the WOMAC Index.
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V alida tion  s tudy  of W OM AC: a h ea lth  s ta tu s  
instrument for measuring clinically-important 
patient-relevant outcomes folloAving total hip or 
knee arthroplasty in osteoarthritis
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and L. STITT
University o f Western Otttario, London, Ontario and McMaster University, Hamilton, Ontario, Canada
T he assessm ent o f  osteoarthritis patients after total jo int arthroplasty o f  hip or knee requires the 
use o f high perform ance outcom e instruments o f  dem onstrated validity, reliability, and responsive­
ness. W e have previously developed a multi dim ensional, self-adm inistered questionnaire with 
which to prove clinically-im portant patient-relevant outcom es. In order to  validate the subscales 
and address issues o f  scaling and analysis, w e  have evaluated the progress o f  30 osteoarthritis 
patients undergoing total jo int arthroplasty using primary, secondary and tertiary outcom e  
measures. The pain, stiffness and physical function subscales arc valid and reliable com ponents o f  
a m ultidim ensional health status instrument termed the W O M A C  Osteoarthritis Index. Index 
responsiveness is high and the relative efficiency is greater than that o f several traditional m easures 
o f surgical outcom e. W O M A C  com plies with current clinim etric standards for evaluative instru­
m ents. In contrast to several other existing m easures, its clinimetric properties arc w ell defined , it 
probes clinically-im portant patient-relevant outcom es and it is o f superior efficiency.
K eyw ords: outcom e m easurem ent, arthroplasty, osteoarthritis
Introduction
The main objective of evaluative research is to detect differential change in two o r more 
treatment groups exposed to different interventions (Bellamy, 1982). The outcome 
instruments employed to detect change require simultaneously to be valid, reliable 
(Carmines and Zeller, 1979; Guion, 1974) and responsive (syn : sensitive). O f these 
three clinimetric properties responsiveness is of paramount importance for evaluative 
measures (Kirshner and Guyatt, 1985). We have recently examined the methods used in 
assessing the response of patients with osteoarthritis (OA) to non-steroidal anti­
inflammatory agents, and have detected a high degree of variability in the outcome 
measurement procedures employed (Bellamy and Buchanan, 1984). A similar variability 
exists in the orthopaedic literature reporting the results of hip and knee arthroplasty 
studies.
In order to rationalize the measurement of patient-relevant outcomes in OA, we have 
previously probed the extent of OA symptomatology of the hip and knee by interviewing 
100 consecutive consenting patients using a structured pre-tested questionnaire contain­
ing both open- and closed-ended questions probing the five dimensions of pain, stiffness, 
physical, social and emotional dysfunction (Bellamy and Buchanan, 1986). In that study
0951-9580/88 $03.00 -f .12 ©  Chapman and Hall Ltd.
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Table L Summary of item content of original test form of WOMAC*
Variable M m Variable M m
Paint Social Function1 Walking (2.58)t 1 Leisure activities (2.56)1
2 Stair climbing (2.62)t 2 Community events (2.15)t
3 Nocturnal (2.63)t 3 Church attendance (2.52)
4 Rest (2.57)1 4 With spouse (2.65)
5 Weight bearing (2.51)1 5 With family (2.67)
Stiffnesst 
1 AMS (2.52)t
6 With friends
7 With others
(2.64)
(2.55)
2 GEL (2.30)t Emotional Function
Physical Functiont
1 Descending stairs
2 Ascending stairs
3 Rising from sitting
4 Standing
5 Bending to floor
6 Walking on flat
7 Getting in/out car
8 Going shopping
9 Putting on socks
(2.60)t
(2.54)t
(2.32)t
(2.64)t
(2.51)t
(2.40)t 
(2.26)t
(2.40) 
(2.38)
1 Anxiety
2 Irritability
3 Frustration
4 Depression
5 Relaxation
6 Insomnia
7 Boredom
8 Loneliness
9 Stress
10 Well-being
(2.64)t
(2.59)t
(2.44)t
(2.49)
(2.39)
(2.58)
(2.62)
(2.26)
(2.19)
(2.62)
10 Rising from bed (2.37)
11 Taking off socks (2.37)
12 Lying in bed (2.36)
13 Getting in/out bath (2.30)
14 Sitting (2.54)
15 Getting on/off toilet (2.67)
16 Heavy domestic duties (2.43)
17 Light domestic duties (2.26)
18 Getting on/off bus (2.38)
* These item numbers correspond to those in text and Tabic TV. 
f  These items were duplicated on VA scales.
^Dimensions retained in final WOMAC instrument.
$ Numbers in parentheses, represent previously published (Bellamy and Buchanan, 1986) 
mean importance scores (MIS) for each item.
(Scale; 0 = none, 1 -  slight, 2 =  moderate, 3 = very, 4 = extreme importance.)
we identified 50 items which characterized the clinical expression of the disorder and 
defined the clinical importance (MIS =  mean importance score) of each. Eight of these 
items were subsequently discarded from further consideration for the following reasons: 
relevant to <10% of patients (n =  4), overlap with other items on same dimension {n =  
4), In order to validate the remaining 42 items (Table I), we have recently conducted the 
following quasi-experiniental trial (Cook and Campbell, 1979), employing a one-group 
repeated-measures design in patients undergoing total joint arthroplasty for OA of the 
hip or knee. In addition to defining the three main clinimetric properties (responsive­
ness, reliability and validity) of the instrument, we have also examined issues relating to 
scaling and statistical analysis. For convenience we have referred to this self­
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administered instrument as the WOMAC (Western Ontario and McMaster Universities) 
Osteoarthritis Index (Bellamy, 1982). The original test instrument is illustrated in 
Table I.
Subjects and methods
Thirty consecutive cpnsenting patients with primary OA of the hip or knee requiring a 
total joint replacement were selected for study. To be eligible patients had to fulfil the 
following criteria: (1) be arnbulatory, (2) be unrestricted (in their functional capacity) by 
any associated condition, (3) not have undergone prior replacement surgery on the joint 
under study, (4) attend an orthopaedic clinic at one of two tertiary referral centres 
(University of Western Ontario or McMaster University).
Patients were assessed by trained interviewers (S O. in London and E.G . in Hamilton) 
the day before surgery and at 6 weeks, 3 months and 6 months post-operatively. The 
same interviewer who did the initial assessment also performed all subsequent assess­
ments on that same patient. The primary outcome measures employed were the 
W OM AC Osteoarthritis Index (Test Form is shown in Table I) and global assessments 
(on each of the five dimensions) made by both the interviewer (IGA) and patient (PGA). 
IG A  and PGA were essential measures, since expert observers and patients themselves 
are regarded as key appraisers of treatment outcome (Bellamy, 1988). In order to 
address issues relating to scaling, patients were given (in random sequence) two versions 
of WOMAC to complete. Both contained identical questions but one required responses 
on Likert scales (Likert, 1932) while the other required responses on 10 cm horizontal 
visual analogue (VA) scales with terminal descriptors (Huskisson, 1982). For reasons of 
feasibility, while all pain and stiffness items of WOMAC were duplicated on both scales, 
only the first seven physical, two social, and three emotional questions (Table I) were 
duplicated on the VA scale. Patients completed WOMAC, IGA and PGA scales at all 
four assessment points. In order to test the construct validity of WOMAC, the following 
secondary outcome measures were concurrently applied:
(1) modified (hip and knee only) Doyle index (Doyle et al., 1981)
(2) Lequesne index (Lequesne, 1980)
(3) Bradburn index of well being (Bradburn, 1969)
(4) social component of the McMaster Health Index Questionnaire (M HIQ) (Cham­
bers, 1980).
These measures were selected as being capable of validating the five different WOMAC 
dimensions. Finally, four tertiary outcome measures were utilized: 50 foot walking time 
(W T -  all patients), total range of movement {ROM ~ operated knees only), intermalleo- 
lar straddle {IMS), and intercondylar distance (/CD) (hip patients only). These com­
monly used measures of surgical outcome were selected in order to assess the Relative 
Efficiency {RE) of the final WOMAC question battery. Individual item (II) and 
aggregated item (AI =  sum of all II for a given dimension) data were analysed for each 
separate WOMAC dimension using both Student’s t-test (Colton, 1974a) and Wilcoxon’s 
non-parametric test (Armitage, 1977) to assess item and dimension responsiveness and 
the effect of parametric versus non-parametric statistical treatment of the data. Reli­
ability was tested on a single pre-operative administration of the instrument using 
Cronbach’s alpha (Cronbach, 1951) and construct validity determined using Pearson’s
98 Bellamy et al.
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correlation coefficient (Colton, 1974b). Relative Efficiency {RE) was calculated using the 
method described by Liang and co-workers (1985) as follows:
RE  for W OMAC versus W T  = (/woMAc/^ivr)“-
Results
Fourteen male and 16 female patients were studied. The mean age was 68.3 years (varying 
from 54-83) and mean disease duration (i.e. symptomatology) was 11.1 years (varying 
from 1-52). Fourteen patients underwent a total knee replacement and 16 received a 
total hip replacement. The pre-operative means and standard deviations of the study 
group for primary, secondary and tertiary outcome measures are illustrated in Tables II 
and III. One patient refused to return for assessment at 6 months and was, therefore, lost 
to follow-up. Therefore, the pre-operative and 6-week post operative analyses are each 
based on 30 patients, while the 6-month post-operative analyses are based on 29 patients. 
The 3-month data, which have previously been presented in abstract form (Bellamy et 
al., 1985), do not contribute to the interpretation of these results and have not, 
therefore, been reported in this paper.
PAIN
Responsi veness
On Likert scaling using Wilcoxon’s test, all five pain items significantly improved by 6 
weeks post-operatively {p <  0.005) and attained p values ^  0.001 by 6 months 
post-operatively, while on VA scaling all items achieved p values of <  0.001 at both 6 
weeks and 6 month assessments. With the IGA, PGA and AI strategies, p values of ^  
0.001 were achieved at both post operative time points regardless of scale. When the p 
values derived by parametric (t-test) and non-parametric (Wilcoxon’s) analysis were 
compared for all 64 analyses performed using II, AI, IGA and PGA strategies, there was
Table III. Secondary and tertiary outcome measures: 
pre-operative means (m) and standard deviations (so)
m SD
Secondary
Bradburn Total Score 1.7 4.6
Modified Doyle Total Score 2.8 1.6
Lequesne Pain Score 4.0 1.8
Lequesne Stiffness Score 1.3 0.6
Lequesne Physical Score 7.1 2.6
MHIQ Social Score 17.0 2.2
Tertiary
WT (sec) (Hip and Knee) 26.4 12.6
IMS (cm) (Hip only) 64.6 16.5
ICD (cm) (Hip only) 45.9 9.8
ROM (“) (Operated knee only) 89.2 25.0
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exact agreement (to three decimal places) in 84% of the cases while in 16% the 
parametric value was smaller. Correlation coefficients (Pearson’s) (Colton, 1974b) 
between scores on Likert and VA scales were 0.88 for IGA and 0.70 for PGA.
Reliability
From Lickert-scaled responses to the five component items the reliability of the pain 
dimension was 0.80 pre-operaliveiy, 0.78 at 6 weeks and 0.93 at 6 months. The 
corresponding values for VA-scaled responses were 0.88, 0.88 and 0.93 respectively.
Validity
Higher levels of correlation (as expressed by the correlation coefficients and the 
proportion of items displaying a statistically significant correlation) were noted on both 
Likert and VA responses between the test items and the Lequesne pain and physical 
function components and the Doyle Index, than between these same items and the 
Lequesne'stiffness component, the Bradburn Index and the MHIQ social component 
(Table IV).
STIFFNESS
Responsiveness
On Likert scaling using Wilcoxon’s test, only morning stiffness (AMS) attained statisti­
cally significant improvement by 6 weeks post-operatively (jp =  0.019) although both 
AMS and gelling (stiffness occurring later in the day = GEL) significantly improved by 6 
months (p ^  0.001). On VA-scaled responses both items demonstrated significant 
improvement at both 6 weeks (p <  0.001) and 6 months (p <  0.001). With the IG A , 
PGA and AI strategies, significant improvement was detected at both post-operative 
time points. However, p  values were smaller for these strategies (0.003, <0.001, <0.001 
at 6 weeks and <0.001 for all strategies at 6 months) for VA responses than for Likert 
responses (0.009, 0.002, and 0.024 at 6 weeks and <0.001 for all strategies at 6 months). 
When the p  values derived by parametric and non-parametric analyses were compared 
for all 40 analyses performed using II, A I, IGA and PGA strategies, there was exact 
agreement (to three decimal places) in 65% of the cases while in 35% the parametric 
value was smaller. Correlation coefficients between scores on Likert and VA scales were 
0-80 for IGA and 0,56 for PGA.
Reliability
From Likert-scaied responses to the two component items, the reliability of the stiffness 
dimension was 0.88 pre-operatively, 0.75 at 6 weeks and 0.88 at 6 months. The 
corresponding values for VA-scaled responses were 0.87, 0.73, and 0.96 respectively.
Validity
Significant correlation was observed between both test items and the Lequesne stiffness 
component (AMS, r =  0.45; GEL, r =  0.56) and between one of the test items and the 
Lequesne pain component (GEL, r ~  0.43). No significant correlation was noted 
between the test items and the other scales (Table IV).
A  validation study o f the WOM AC osteoarthritis index 103
P H Y SIC A L  F U N C T IO N
Responsiveness
On Likert scaling using Wilcoxon’s test 17 of the 18 physical function items significantly 
improved by 6 weeks post-operatively (0.01 < p < 0.05 for one item, 0.001 <  p  <  0.01 
for 6 items, and p  <  0.001 for 10 items). Item 11 achieved a p  value of 0.088 at 6 weeks. 
At 6 months, however, 17 items achieved p  values of <0.001 while item eighteen 
attained a p  value of 0.004. On VA scaling significant improvement occurred on all 
items, the p  value being 0.01 < p < 0.05 for one item, 0.001 < p <  0.01 for three items, 
and p  <  0.001 for three items. At 6 months post-operatively all seven items achieved 
statistically significant improvement {p <  0.001). With the exception of the Likert-scaied 
IGA response (p =  0,133) at 6 weeks post-operatively, the PGA and AI strategies 
reflected significant improvements which were mainly in the p  <  0.001 region. When p 
values derived by parametric and non-parametric tests were compared for all 124 
analyses perforrried using II, AI, IGA and PGA strategies there was exact agreement (to 
three decimal places) in 53% of the cases, while in 47% the parametric values were 
smaller. Correlation coefficients between scores on Likert and VA scales were 0.72 for 
IGA and 0.65 for PGA.
Reliability
From Likert-scaied responses to the 18 component items, the reliability of the physical 
function dimension was 0.93 pre-operatively, 0.92 at 6 weeks, and 0.97 at 6 months 
post-operatively. Corresponding values for the seven VA-scaled responses were 0.88, 
0-91 and 0.94, respectively.
Validity
Higher levels of correlation were noted on both Likert- and VA-scaled responses 
between the test items and the physical component of the Lequesne Index than with 
these items and the Lequesne pain and stiffness components, the Doyle and Bradburn 
Indices, and the MHIQ social component (Table IV).
SOCIAL FUNCTION
Responsiveness
On Likert scaling using Wilcoxon’s test, only the first item achieved statistically significant 
improvement (p = 0,023) at 6 weeks. By 6 months, however, five of the items had sig­
nificantly improved, items six and seven attainingp values of 0.103 and 0.075, respectively. 
Only two items were tested on the VA scale, item one attaining a p  value of <0.001 at 6 
weeks, while item two was not significant (p = 0.066). Both items were significantly 
improved however by the 6 month assessment (p <  0.001). Although the IGA, PGA and 
AI strategies resulted in p  values <0.004 at 6 months, the AI and PGA values at 6 weeks 
on Likert scaling were non significant (0.183 and 0.211, respectively).
When the p  values derived from parametric and non-parametric analyses were 
compared for all 60 analyses performed using II, AI, IGA and PGA strategies, there was 
absolute agreement (to three decimal places) in 30% of the cases, while in 57% the 
parametric values were smaller and in 13% the non-parametric values were smaller.
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Correlation coefficients between scores on Likert and VA scales were 0.79 for IGA and 
0.74 for PGA.
Reliabiiuy
From Likert-scaied responses to the seven component items, the reliability of the social 
function dimension was 0.86 pre-operatively, 0.88 at 6 weeks, and 0.95 at 6 months 
post-operatively. Corresponding values for the two VA-scaled items were 0.77, 0.88 and 
0.90, respectively.
Validity
Higher levels of correlation were noted between the test items and the Doyle and 
Bradburn Indices (on Likert-scaied responses) than with the Lequesne stiffness or 
physical components (Table IV). No significant correlation was noted on the Likert scale 
between the test items and the Lequesne pain component or indeed with the MHIQ 
social component. With VA-scaled responses, higher levels of correlation were noted 
between test items and the Lequesne physical and stiffness component. However, no 
significant correlation was noted with the Lequesne pain component, the Doyle or 
Bradburn Indices, or again with the MHIQ social component.
E M O T IO N A L  F U N C T IO N
Responsi veness
On Likert scaling using Wilcoxon’s test, none of the ten emotional function items 
significantly improved by 6 weeks, although by 6 months four items achieved p  values 
<0.006, and a fifth improved to p — 0.016. In contrast, the three VA-scaled responses 
achieved p values of <0.006 at 6 weeks, and p <  0.001 at 6 months. A similar pattern 
emerged for Likert responses at 6 weeks on IGA (p = 0.005), PGA (p = 0.170), and AI 
(p = 0.473) strategies, with these values improving by 6 months (<0.001, 0.007 and 0.005 
respectively). The corresponding VA values for IGA, PGA and AI strategies were 
0.003, <0.001 and <0.001 at 6 weeks, and 0.001, 0.002 and <0.001 at 6 months. When 
the p values derived from parametric and non-parametric analyses were compared for all 
76 analyses performed using II, AI, IGA and PGA strategies, there was exact agreement 
(to three decimal places) in 24% of the cases, while in 55% the parametric values were 
smaller, and in 21% the non-parametric values were smaller. Correlation coefficients 
between scores on Likert and VA scales were 0.86 for IGA and 0.78 for PGA.
Reliability
From Likert-scaied responses to the ten component questions, the reliability of the 
emotional function dimension was 0.89 pre-operatively, 0.92 at 6 weeks and 0.96 at 6 
months post-operatively. The corresponding values for VA-scaled responses were 0.86,
0.92 and 0.97 respectively.
Validity
Higher levels of correlation were noted on both Likert- and VA-scaled responses 
between the test items and the Bradburn Index than with the Lequesne, Doyle or MHIQ 
social component (Table IV). No significant correlation was noted between test items
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and the Lequesne stiffness component (on Likert responses), or between test items and 
VA-scaled responses on the Lequesne pain or stiffness component, the Doyle Index, or 
the MHIQ social component.
R E L A T IV E  E FFIC IE N C Y
R E  was only calculated for those three dimensions showing acceptable reliability, 
validity and responsiveness as well as for the final (Table I) WOMAC battery (FB = AI 
(pain) + AI (stiffness) T AI (physical function)) (Table V). Paired t analyses of the 
individual hip and knee groups showed statistically significant improvements on the three 
dimensions and FB for each separate anatomical area. In all instances R E  was > 1 , i.e. 
WOMAC was more efficient than any of the tertiary outcome variables (varying from
1.08-141.61).
Discussion
In developing a new health status measure we have been guided by four principles: 
adequate responsiveness, reliability and validity, and superior efficiency over selected 
existing indices.
Responsiveness
The success of total joint arthroplasty was acknowledged by both patients and interview­
ers, and is reflected in their PGA and IGA scores. Thirty (5 pain, 2 stiffness, 18 physical,
1 social, 4 emotional) of the original 42 WOMAC items achieved statistical significance 
of <0.006 by 6 months post-operatively. The more variable response at 6 weeks was due 
to some patients requiring further rehabilitation following surgery. The use of multiple 
analytic comparisons may result in an increase in Type I errors. Even correcting for this 
statistical nuance, however, and accepting a high degree of covariance amongst Index
Table V. R elative efficiency o f W O M A C  versus tertiary outcom e variables
Relative efficiency*
Tertiary
Outcome
Variable
Pain Stiffness
Physical
function
WOMAC final 
battery (FB)f
Likert VA Likert VA Likert VA Likert VA
WT
(Hip Only) 2.6 2.2 1.5 2.4 3.7 3.4 3.7 3.8
IMS
(Hip Only) 2.6 1.7 1.1 1.3 4.9 2.3 4.7 2.3
ICD
(Hip Only) 3.7 2.5 1.5 1.8 6.9 3.3 6.6 3.2
ROM
(Knee Only) 134.8 79.2 104.0 86.0 132.0 67.9 141.6 88.2
* Relative Efficiency = eg. (tpai„(VA/t»T)^  = 2.2HWOMAC (FB) = (A/p,i„ + /t/s(iffncss + function)
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items, the p  values attained were extremely good and indicative of a high level of re­
sponsiveness for these 29 WOMAC items. Likert and VA responses showed good corre­
lation, however, since 6-month p values were often <0.001 on both scales it was difficult 
to distinguish between scales. The higher RE  values generally achieved for Likert 
responses suggest that the Likert scale may be more responsive although we have a 
personal preference for VA scales and are now conducting additional comparative 
studies on scale responsiveness. At present, however, we regard both scales as legitimate 
for measurement purposes. Comparative analyses of non-parametric versus parametric 
treatment of the data suggest that while in many instances there is agreement between 
the two (and therefore that either analysis may be used), nevertheless, non-parametric 
methods provide a more conservative estimate of the response and for conceptual 
reasons may be regarded as the preferred analytic technique. These data show that after 
excluding the non-responsive social and emotional items, the remaining 30 items (5 pain, 
2 stiffness, 18 physical, 1 social, 4 emotional) are of adequate responsiveness irrespective 
of scaling or analytic technique.
Reliability
Reliability coefficients of 5=0.80 are generally regarded as acceptable. Index items 
exceeded 0.80 on both VA and Likert scales in all except one instance (social — pre-op — 
VA = 0.77). These data indicate that all five WOMAC dimensions on both VA and 
Likert scales are of adequate reliability.
Validity
Face and content validity were conferred on Index items during an earlier investigation 
(Bellamy and Buchanan, 1986). For criterion validity testing coefficients 50.80 are 
generally regarded as acceptable. However, no gold standards currently exist against 
which to test criterion validity. We have, therefore, tested construct validity against 
other indices that probe the five Index dimensions of interest. Since these comparators 
are not gold standards, much lower levels of correlation are expected. In general, 
however, the Index items should show a statistically significant correlation with other 
indices probing the same dimension (convergent construct validity). Furthermore, Index 
items should show higher levels of correlation with indices that probe the same 
dimension than with indices probing other dimensions (divergent construct validity). 
These criteria were fulfilled by the pain, stiffness and physical function components of 
the Index. Since physical disability is often secondary to pain, it is not surprising that 
these two dimensions are often associated. In contrast, the social component failed to 
correlate with the MHIQ social component, and although some items were reliable and 
responsive, this dimension was excluded from the Index. Moreover, in spite of the 
emotional component fulfilling construct validity criteria, and some items being reliable 
and responsive, we have elected to withdraw the component pending a re-evaluation of 
the social dimension. The final Index, therefore, utilizes the pain (5 items), stiffness (2 
items) and physical function (18 items) subscales only (Table I).
Relative efficiency
To be useful, a new health status measure should offer advantages over existing indices.
In tliis respect, WOMAC offers two advantages. First, WOMAC and its subscales offer 
superior efficiency over the traditional unidimensional outcome measures selected, both
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in assessing the results of total hip arthroplasty and also the results of total knee 
arthroplasty. Such a measure has potential for reducing sample size requirements for 
clinical trials using WOMAC as the primary outcome measure (cf. these other mea­
sures). It should be noted, however, that there are several other measures (some of 
which are also multi-dimensional) against which WOMAC has yet to be compared. 
Secondly, many of the traditional unidimensional measures lack patient relevance. In 
contrast, WOMAC probes patient-relevant outcomes, the clinical importance (Table I) 
of which have been documented and reported previously (Bellamy and Buchanan, 1986).
WOMAC is a reliable, valid and responsive multi-dimensional, self-administered 
questionnaire having greater efficiency than several traditional unidimensional mea­
sures. We are now conducting further studies on aggregating scores across different 
dimensions, on the relative responsiveness of Likert and VA scales, and the relative 
efficiency of WOMAC against several other multi-dimensional instruments used in 
assessing the results of total hip and knee joint arthroplasty.
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Double-blind randomized controlled trial of isoxicam vs 
piroxicam in elderly patients with osteoarthritis of the hip 
and knee
N. BELLAMY'-^. W. W. BUCHANAN^ & E. GRACE^
^University of'Western Ontario, London, Canada and ^McMaster University, Hamilton, Ontario, Canada
1 Fifty-seven elderly patients with primary osteoarthritis of the hip and knee were 
entered into a double-blind, randomized, controlled parallel group trial to compare the 
efficacy and tolerability of isoxicam (maximum = 200 mg day"^) and piroxicam (maximum
= 20 mg day“b-
2 Clinical assessments were made following a 1 week NS AID-free washout period and at 
biweekly intervals during the next 6 weeks of active treatment.
3 The majority of patients in both groups experienced a clinically important and 
statistically significant therapeutic response.
4 No statistically significant between-group differences were noted with respect to drug 
efficacy.
5 One patient was withdrawn from the piroxicam group because of lack of effect, but 
there were no such withdrawals from the isoxicam group.
6 Five patients were withdrawn from the piroxicam group because of adverse reactions 
compared to only one withdrawal from the isoxicam group.
7 This study indicates that isoxicam is an efficacious and well-tolerated once-daily 
NSAID for elderly patients with osteoarthritis.
Keywords osteoarthritis isoxicam piroxicam elderly
Introduction
Osteoarthritis is primarily a disease of the elderly Since there are currently no disease-modifying
(Kellgren & Lawrence, 1958). Although many anti-rheumatic drugs with which to treat osteo-individuals have subclinical or pre-radio- arthritis, the principal objective of therapy is tographic disease, the prevalence of symptomatic relieve pain and improve function. Thus thedisease shows a positive correlation with non-steroidal, analgesic anti-inflammatory drug
chronologic age. Although primary osteo- remain the treatment of choice for patients witharthritis may affect the distal and proximal this disorder. The response to any given agent,
interphalangeal joints and the first carpometa- varies between individuals and has in recentcarpal joints of the hands as well as the apophyseal years resulted in the development of a number
joints of the axial skeleton and the first meta- of new non-steroidal anti-inflammatory drugstarsophalangeal joint of the toe, it is involve- (NSAIDs) (Rosenbloom et a i, 1985). The
ment of the hip and knee which results in the elderly in particular require an agent which is notgreatest discomfort and locomotor disability, only efficacious and well tolerated but also can
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be taken according to a sim ple dosing regim en. 
T here has been a steadily growing interest in 
studying therapeutic responsiveness and to ler­
ability in elderly subjects since they represent a 
large proportion o f the population with chronic 
musculoskeletal disease. Furthermore, they have 
a lim ited potential for response and dem onstrate  
an increased propensity for developing adverse 
reactions to certain classes o f drugs. In the re­
port which follow s, the efficacy and tolerability  
o f isoxicam , a new N S A ID , have b een  com pared  
to those o f piroxicam in a group o f elderly  
patients with osteoarthritis o f the hip and knee. 
Isoxicam  has the chem ical formula 4-hydroxy- 
2-methyl-A/-(5-methyl-3-isoxolyl)-2H-l, 2-benzo- 
thiazine-3-carboxam ide 1,1-dioxide and is a ben- 
zothiazine derivative o f the oxicam  class o f drugs 
(Yakatan, 1982). In addition to its com parative  
objectives, this trial was used to validate a new  
m ultidim ensional outcom e m easure for clinical 
trials in osteoarthritis (Bellamy, 1982). T lie results 
o f the validation study form the. basis o f  a separate 
report and are not discussed in this paper.
M ethods
T he trial was conducted in two centres and 
em ployed a double-blind, random ized, con­
trolled parallel design. Elderly patients w ith  
primary osteoarthritis o f the hip and/or knee  
were enrolled in the study program m e if they  
were 55-85 years o f age and showed radiographic 
evidence o f  osteoarthritis. They w ere excluded if 
they had undergone prior replacem ent surgery 
on  the joint o f interest or had secondary o steo ­
arthritis, active peptic ulceration or prior gastro­
intestinal b leeding. O ther exclusion criteria 
included cardiorespiratory insufficiency, signifi­
cant disease o f any other major organ system , a 
B U N  greater than 30 mg 100 ml“ ,^ SG O T  greater 
than 50 units m l" \  allergy to aspirin or other  
N S A ID s, concurrent anticoagulant therapy, or 
recent system ic or intra-articular corticosteroid  
therapy. Following enrollm ent, patients w ere  
assessed and random ized to receive either isoxi­
cam  or piroxicam according to a random ization  
code developed by an independent statistician. 
Thereafter patients underwent a 1-week N SA ID - 
free washout period during which tim e analgesia  
with paracetam ol (325 m g tablets) was perm itted  
but m onitored.
Following this washout period, baseline  
assessm ents w ere made and active treatm ent 
started with either isoxicam , 100 m g day“ \  or 
piroxicam , 10 mg day“  ^ (L evel 1). Each m edica­
tion was identical in appearance and presented  
in capsule form. Patients were instructed to take 
the m edication once daily with their breakfast 
and were advised against the concom itant use o f  
salicylate-containing com pounds during the 
study period. Patients were reassessed 2 weeks 
later and a decision m ade to continue at this 
treatm ent level or, if the response had been  
suboptim al, to increase the dosage to either 
isoxicam , 200 mg d a y " ', or piroxicam , 20 mg 
day"' (L evel 2).
Patients were again assessed 2 weeks later and 
a final assessm ent was m ade 2 w eeks after that. 
Tire total period o f active treatment was 6 weeks. 
Tire following outcom e measures were em ployed, 
assessm ents being m ade at each o f the four 
assessm ent points;
1. Night pain (four-point Likert scale (Nunnally, 
1967))
2. Pain on walking (four-point Likert scale)
3. D egree o f starting pain (four-point Likert 
scale)
4. Pain on joint m otion (four-point Likert 
scale)
5. Joint tenderness (m odified D oyle  index) 
(D oyle  et a l. , 1981)
6. K nee total range o f  m ovem ent (degrees)
7. Intermalleolar straddle (cm )
8. Visual analogue scale o f  pain (vertical, 21- 
com partm ent, terminal descriptors only)
9. Physician overall assessm ent (five-point 
Likert scale)
10. Patient overall assessm ent (five-point 
Likert scale)
11. Walking tim e (50 feet)
12. Laboratory values: CBC , SM A-12, 
urinalysis.
M any patients had m ultijoint involvem ent but 
for each patient a single (either a hip or a knee) 
joint was identified as being m ore severely  
affected and was se lected  as the target joint for 
outcom e m easures num bers 1 -7 . In addition, 
the investigators recorded any adverse reactions 
to drug therapy and concurrent illness. A t the 
final assessment (visit 4 ), both  patients and phy­
sicians compared the efficacy and tolerability o f  
the study drugs to both the drug-free washout 
period and their pre-study anti-inflammatory 
medication. During the course o f the trial patients 
were allowed to take concom itant analgesia with 
paracetamol (325 mg tablets) although patients 
were instructed to use the tablets sparingly and 
their requirements were monitored. CompUance 
to  the study m edications w as m easured by both  
direct report and by pill count.
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T he analysis was conducted using an intention- 
to-treat philosophy rather than an explicative  
approach (Sackett & G ent, 1979). Thus w ith­
drawals w ere accounted for in the analysis rather 
than being excluded from consideration. The  
follow ing statistical tests were em ployed; chi 
square (F leiss, 1981), F ischer’s exact (F leiss, 
1981), unpaired two-tailed Student’s r-test 
(A rm itage, 1971), Mann W hitney U  (for visual 
analogue and Likert-type scales) (C onover, 
1980), and log rank chi square (for life table  
analysis (Friedm an et a l., 1981).
Results
O f the 57 patients enrolled in the study, 28 
received isoxicam  and 29 received piroxicam . 
T he m ean age was exactly the sam e in each  
group (66.5 years) and the age ranges w ere  
similar (Table 1). M ean disease duration was 
slightly greater for isoxicam  (9.3 years) than for  
piroxicam  (8 .7  years), but this difference was 
not statistically significant. Furtherm ore no sig­
nificant differences were noted in the proportion  
o f  hips and knees represented in the two treat­
m ent groups, although in general the knee joint 
was frequently the m ore severely affected o f  
the two jo ints. M ales and fem ales were repre­
sented in similar proportions although there  
was a sliglit female predominance in the piroxicam  
group (Table 1). Post-random ization group  
com parability was assessed at the end o f the  
washout period. N o statistically significant 
betw een-group differences were detected for  
any dem ographic or disease variable (Table 2 ).
In order to  evaluate the response achieved at 
the initial level o f therapy ( i .e . , isoxicam , 100 mg 
d ay" ', or piroxicam , 10 mg day" ') data were  
analyzed at visit 2 and com pared with baseline  
values (Table 3). Significant im provem ents w ere  
noted in pain on joint m ovem ent, visual analogue  
scale for pain, and the physician’s overall assess­
m ent in both groups. In the isoxicam  group, sig­
nificant im provem ent was also detected in pain  
on walking and patient overall assessm ent, while  
in the piroxicam  group significant im provem ent 
was noted in night pain and joint tenderness.
O verall, both groups showed im provem ent at 
the initial level o f  therapy, although only six 
isoxicam  and four piroxicam patients remained 
at this level ( i .e .,  isoxicam , 100 m g day" ', or 
piroxicam, 10 mg day"'). A  between-group com­
parison m ade at visit 3 showed no statistically 
significant difference other than in relief o f pain 
on walking, which favoured the isoxicam  group.
In order to assess response to the optim al 
dose, i .e .,  after any necessary dose titra tion ,. 
com parisons were m ade betw een visit 4 and 
baseline. Statistically significant im provem ent 
over baseline (Table 4) was noted in both treat­
m ent groups with respect to night pain, pain on  
walking, starting pain, pain on m ovem ent, joint 
tenderness, visual analogue scale o f pain, overall 
assessm ent by physician, and overall assessm ent 
by patient. A lthough joint sw elling in the knee  
declined in both groups (Table 2) a statistically 
significant response was achieved only in the 
isoxicam  group (Table 4). K nee range o f m ove­
m ent and interm alleolar straddle increased and 
the walking tim e decreased in both groups 
(T able 2) although none of these m easures 
reached statistical significance in either group 
(Table 4). B etw een-group com parisons were  
m ade for all disease variables at visit 4 ( i .e . , after 
6 w eek s o f  active treatm ent); no significant dif­
ferences were detected, indicating that the 
therapeutic response was similar in the two 
treatm ent groups (Table 4 ). O ne patient was 
withdrawn from the piroxicam group because o f  
inefficacy; there were no such withdrawals from  
the isoxicam  group. Com pliance levels for study 
m edications w ere exceptionally high both when  
m easured by direct report and by pill count. 
D ata collection on concom itant analgesia was 
incom plete and while no apparent betw een- 
group differences were noted no formal analysis 
could be perform ed.
T w elve adverse reactions in six patients were 
reported on  isoxicam  vs 24 adverse reactions in 
12 patients on piroxicam (P  =  0 .105) (Table 5). 
Fluid retention, gastrointestinal upset and 
neurological sym ptom s accounted for the 
m ajority o f adverse reactions. R eactions were 
graded by the investigators as being either mild, 
m oderate or severe. Although five severe adverse
Table 1 Post-randomization -  pre-intervention comparison of treatment groups
Variable Isoxicam (n = 28) Piroxicam (n = 29) P value
Age (range) (years) 66.5 (55-80) 66.5 yrs. (55-82) NS
Disease duration (years) 9.3 (1-26) 8.7 yrs. (1-30) NS
Sex 14 male 14 female 12 male 17 female NS
Most severèly affected joint 7 hip 21 knee 11 hip 18 knee NS
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Table 2 Mean values for outcome variables at baseline and visits 2, 3 and 4. S.d. given for 
baseline values
Baseline Visit 2 Visit 3 Visit 4
Night pain (I) 1.68 ± (0.72) 1.26 0.93 0.63
(P) 1.83 ± (1.00) 1.25 1.19 0.77Pain on walking (I) 2.00 + (0.82) 1.30 1.30 1.00
(P) 2.14 ± (0.92) 1.86 1.36 1.05Standing pain (I) 1.39 ± (0.99) 1.04 0.78 0.65
(P) 1.79 ± (1.11) 1.54 1.04 0.82Pain on movement (I) 1.57 + (1.00) 1.04 0.59 0.52
(P) 2.07 ± (0.75) 1.36 1.23 0.59Joint tenderness (I) 1.50 ± (0.92) 1.00 0.62 0.56
(P) 1.89 ± (0.82) 1.04 0.91 0.55Joint swelling (knee) (I) 0.52 ± (0.75) 0.30 0.35 0.15
(P) 0.94 ± (1.03) 0.59 0.65 0.38Range of movement (knee) (°) (I) 106.48 ± (22.17) 113.75 116.55 115.55
(P) 102.44 ± (15.47) 106.24 106.88 109.50Intermalleolar straddle (hip) (mm) (I) 71.14 ± (27.01) 77.86 85.14 91.29
(P) 60.00 ± (19.10) 60.20 67.63 74.17Analogue scale of pain (mm) (I) 13.71 ± (5.33) 8.85 7.41 6.19
(P) 14.17 ± (5.34) 10.79 8.68 8.68Overall àssessment.(MD) (1) 3.44 ± (0.85) 2.67 2.46 2.15
(P) 3.52 ± (0.87) 2.96 2.56 2.27Overall assessment (patient) (I) 3.48 + (0.80) 2.70 2.54 2.26
(P) 3.52 ± (0.83) 3.00 2.68 2.32Walking time (s) (I) 17.14 ± (8.26) 15.27 • 14.41 14.72
(P) 15.25 ± (6.02) 15.96 15.90 14.39
I isoxicam, P piroxicam
reactions were noted on  piroxicam , non e o f  the  
reactions obserVed on isoxicam  (Table 5) w ere  
graded as severe {JP =  0 .03). Furtherm ore, five 
patients were withdrawn from piroxicam  due to  
adverse reactions com pared to only on e  w ith­
drawal from  isoxicam  (a m oderate adverse re­
action) {P  =  0 .105).
T hus, the total num ber o f patients withdrawn  
due to  either inefficacy or intolerance was six in
the piroxicam group and one in the isoxicam  
group. T he ability o f  patients to  stay in treat­
ment was com pared using a life table approach  
(Friedman et a l., 1981). A lthough the betw een- 
group differences were not statistically signifi­
cant {P  >  0 .05), it can be seen from  Figure 1 that 
apart from one early withdrawal on isoxicam , 
tire remaining patients stayed on treatm ent. In 
contrast, patients dropped out o f  piroxicam
Table 3 Statistical analysis of outcome variables
Baseline Level 1
Isoxicam vs 
piroxicam
Visit 2 vs 
baseline 
isoxicam
Visit 2 vs 
baseline 
piroxicam
Visit 2 
Isoxicam 
vs piroxicam
Night pain 0.36 0.06 0.04* 0.99
Pain on walking 0.37 < 0.01* 0.07 0.02*
Standing pain 0.17 0.21 0.34 0.07
Pain on movement >  0.05 0.05* <  0.01* 0.16
Joint tenderness 0.09 0.06 <  0.01* 0.99
Joint swelling (knee) 0.21 0.32 0.36 0.16
Range of movement (knee) 0.52 0.22 0.43 0.10
Intermalleolar straddle (hips) 0.33 0.64 0.98 0.15
Analogue scale of pain 0.66 < 0.01* 0.02* 0.24
Overall assessment (MD) 0.65 < 0.01* 0.04* 0.21
Overall assessment (patient) 0.90 < 0.01* 0.07 0.28
Walking time 0.96 0.40 0.42 0.72
* F ^ 0 .05
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Table 4 Statistical analysis of outcome variables
Baseline
Isoxicam vs 
piroxicam
Visit 4 vs 
baseline 
isoxicam
Level 1 3 - 2  
Visit 4 vs 
baseline 
piroxicam
Visit 4 
Isoxicam 
vs piroxicam
Night pain 0.36 <  0.01* <  0.01* 0.51
Pain on walking 0.37 <  0.01* <  0.01* 0.75
Standing pain 0.17 <0.01* <0.01* 0.46
Pain on movement > 0 .0 5 <0 .01* <0.01* 0.49
Joint tenderness 0.09 <0 .01* <0.01* 0.91
Joint swelling (knee) 0.21 0.04* 0.10 0.13
Range of movement (knee) 0.52 0.14 0.14 0.20
Intermalleolar straddle (hips) 0.33 0.16 0.18 0.19
Analogue scale of pain 0.66 <0 .01* <  0.01* 0.18
Overall assessment (MD) 0.65 <0.01* <  0.01* 0.66
Overall assessment (patient) 0.90 <  0.01* <  0.01* 0.99
Walking time 0.96 0.24 0.07 0.84
*P^0 .05
therapy at intervals and as late as the thirty- 
eighth day o f treatm ent.
A n  end-of-study com parison betw een  the 
active treatm ent phase and the washout period, 
based on patient evaluations, indicated that 93% 
o f  isoxicam  patients had im proved vf 69% o f  
piroxicam  patients. Physician-based estim ates 
for these sam e com parisons w ere 93% and 75% 
respectively. In the isoxicam  group, 73% o f
patients and 72% o f physicians considered the  
study drug better than the patient’s pre-study 
m edication. In the piroxicam group, 61% o f  
patients and 73% of physicians considered the  
study drug better than patient’s pre-study 
m edication. Eighty-nine percent o f  patients and 
96% o f  physicians rated isoxicam  to  have been as 
w ell or better tolerated than the pre-study m edi­
cation.
Table 5 Adverse reactions reported by the two treatment groups
Reactions Isoxicam (n =  28) Piroxicam (n =  29)
Abdominal cramps 1 1
Ankle swelling 1 5
Asthenia 0 1
Diarrhoea 0 1
Dizziness 0 2
Drowsiness 1 2
Dry mouth 2 1
Epigastric pain 0 2
Hot flushes 1 1
Metallic taste 1 1
Nausea and vomiting 0 1
Oral ulcer 0 1
Nightmare 1 0
Shortness of breath 1 3
Skin rash 0 1
Swollen ear, 0 1
Difficulty swallowing 
Tinnitus 2 0
Tingling of tongue 1 0
Total number of adverse reactions (ADR) + 12 24
Total number of patients experiencing ADR 6 12 F =  0.105
Total number of patients with severe ADR 0 5 P  =  0.03*
Total number of patients withdrawn due to A D R + + 1 5 F =  0.105
Total number of patients withdrawn due to either inefficacy or ADR 1 6 F =  0.056
-4- Some patients had more than one adverse reaction.
+ + One patient withdrawn due to a moderate adverse reaction. 
=5 0.05
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1.00
0,90
0,80
OJ 0,70
>  CD 0,60
^ cE ‘^  0.50a ;  .
30 36 42Days of treatment
Figure 1 Log rank Chi square comparison of cumu­
lative rates (for continuing treatment (a isoxicam, A 
piroxicam). Note break in vertical scale.
D erangem ents o f  haem atological and b io­
chem ical variables were infrequent and no  
extrem e abnorm alities w ere noted. The haem o­
globin fell below  the low er limit o f the norm al 
range in three isoxicam  and three piroxicam  
treated patients. Elevation o f the serum creatinine 
was observed in one isoxicam  and two piroxicam  
treated patients, e levation  o f the SG O T  in two  
piroxicam  treated patients, and elevation o f  the  
alkaline phosphatase in tw o isoxicam  patients.
Discussion
The elderly represent a subset o f  the general 
population in whom  degenerative forms o f  arth­
ritis are com m on, concurrent illness not infre­
quent, and m ultiple drug therapy is prevalent. 
Tire study o f  the elderly is particularly im portant 
since individuals in this age group are frequent 
recipients o f  drugs which have been evaluated  
largely in younger subjects. Thus, given the  
relative frequency o f osteoarthritis and its 
tendency to  affect the m iddle-aged and elderly, 
this trial provides im portant efficacy and toler­
ability data on isoxicam in this subset o f the popu­
lation with m usculoskeletal-disease. A lthough  
the titration strategy for dose adjustment does  
not allow  sim ple dose-by-dose com parison  
(because o f the small residual sam ple sizes), it 
does nevertheless allow isoxicam  and piroxicam  
to  be com pared under sim ulated practice condi­
tions.
The results o f  this study can be generalized to  
similar elderly patients fulfilling the defined  
inclusion and exclusion criteria and those who  
are treated under the described titration strategy.
It is traditional in com parative studies o f this 
type to exclude high-risk patients, particularly 
those with severe disease o f any major organ 
system  or prior gastrointestinal bleeding. 
Accordingly, the results o f this clinical trial can­
not necessarily be extrapolated to patients with 
serious concom itant disease.
The result o f this study indicate that isoxicam  
is an efficacious non-steroidal anti-inflammatory 
agent which significantly reduces pain , swelling  
and joint tenderness in elderly patients with 
osteoarthritis. A lthough som e patients dem on­
strate a response to 100 mg day"' o f isoxicam , 
the majority require a dosage o f 200 mg day" '. 
The beneficial effects o f  isoxicam  are in general 
similar to those o f the drug piroxicam .
Three measures o f  physical function (knee  
range o f m ovem ent, interm alleolar straddle, 
and 50 foot walking tim e) failed to im prove on 
either agent. Two factors m ay explain this 
failure in response. First, since range o f knee  
m ovem ent was analyzed only for patients in 
whom  the knee was the m ost severely  affected  
joint and interm alleolar straddle only analyzed  
for those in whom  the hip was the m ost severely  
affected joint, the sample sizes em ployed in the 
analysis were small and therefore the statistical 
pow er was low. Second, both these m easures are 
attended by significant inter-observer variation  
which may have reduced the chance o f  detecting  
a statistically significant improvement. Response  
failure on the 50-foot walking tim e was not 
entirely unexpected as this outcom e m easure has 
previously displayed poor perform ance charac­
teristics in clinical trials in osteoarthritis (Bellamy 
& Buchanan, 1984). Since pain is often  the  
lim iting factor in degenerative forms o f  arthritis, 
it is not surprising that relief o f  pain might 
enhance the ease o f perform ing a particular task 
without necessarily im proving the speed at 
which it can be accom plished. A lthough  it is 
purely speculative, this may provide an explana­
tion for the poor perform ance o f the 50-foot 
walking tim e. A n  alternate explanation is that 
the difference betw een a healthy and a diseased  
elderly patient with osteoarthritis in respect o f  
the ability to perform  the walking tim e is less 
than betw een a healthy young individual and a 
young arthritic patient and, therefore, the 
response potential is m ore restricted in the 
elderly.
It is important that a new non-steroidal anti­
inflammatory agent for elderly patients be not 
only efficacious but also well tolerated . The 
discontinuation o f only one isoxicam  patient due 
to  a m oderate adverse reaction com pared to five 
piroxicam patients suggests that, in general, 
isoxicam  may be better tolerated by the elderly
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than piroxicam. Although the life table approach 
is infrequently used in the analysis o f drug trials 
it has the ability to discrim inate betw een dif­
ferent patterns o f withdrawal from  treatm ent. 
W hilst between-group differences w ere not
statistically significant, nevertheless the ability 
of patients to stay on treatment with isoxicam  
was notable. These data suggest that isoxicam  
may be a useful drug in the treatm ent o f o steo ­
arthritis in the elderly.
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Validation Study of WOMAC; A Health Status Instrument 
for Measuring Clinically Important Patient Relevant 
Outcomes to Antirheumatic Drug Therapy in 
Patients with Osteoarthritis of the Hip or Knee
NICHOLAS BELLAMY, W. WATSON BUCHANAN, CHARLES H. GOLDSMITH, JANE CAMPBELL, and 
LARRY W. STITT
Abstraa. Within the context of a double blind randomized controlled parallel trial of 2 non­
steroidal antiinflanimatory drugs, we validated WOMAC, a new multidimensioaal, self- 
administered health status instrument for patients with osteoarthritis of the hip or knee. The 
pain, stiffness and physical function subscales fulfil conventioaal criteria for face, content and 
construct validity, ndiability, responsiveness and relative efGcicncy. WOMAC is a cfiscase-spcdBc 
purpose boat high performance instrument for evaluative research in osteoarthritis clinical 
trials. (/ Bheumatol /9<S5;15:1833-1840)
Key Indexing Terms:
WOMAC OSTEOARTmUTIS
HEALTH STATUS INSTRUMENT RELIABILITY
VALIDrrY
RESPONSIVENESS
We reported on the inadequacy of outcome measurement 
procedures in osteoarthritis (OA) trials of nonsteroidal anti­
inflammatory (NSAID) drugs'. In an attempt to rationalize 
meastirement in OA, we first probed the symptomatology 
of hip and knee OA by interviewing 100 patients with OA, 
and identified 41 items on 5 dimensions (Table 1) which 
characterize the disordcN- .^ To validate these items, we 
have now conducted a double blind, randomized, controlled 
parallel design trial of isoxicam versus piroxicam in elderly 
patients with primary OA of the hip or knee. Our goal was 
to assess the reliability, construct validity and responsive­
ness of the 41 items previously mentioned. The 2 separate 
arms of the trial served as independent tests of item respon­
siveness. To circumvent the problem of simultaneously at­
tempting to assess the performance of a new health status 
instrument as well as a new antirheumatic compound, we 
used other reported^ outcome measures to evaluate the com­
parative efficacy and tolerability of isoxicam and piroxicam.
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Thus, using this innovative approach, we defined the ciim'- 
metric properties of a health status instrument termed 
"WOMAC" (the Western Ontario and McMaster Univer­
sities Osteoarthritis Index), within the context of a traditional 
clinical trial.
MATERIALS AND METHODS
Fifiy-scVcn paricms wiih symptomatic OA of the hip or knee requiring 
NSAID therapy were entered in the study. To be eligible patients had to 
be 55-85 years of age, have definite radiographic.cvidciicc of primary OA 
in the hip or knee, and fulfil defined inclusion and exclusion criteria"*.
Patients were assessed at enrolment (Visit 1), and again one week later 
without any change in therapy (Visit 2). Thereafter, patients underwent a 
one-week NSAID-frcc washout period and were then reassessed (Visit 3). 
Finally, patients were evaluated following 2 (Visit 4), 4 (Visit 5), and 6 
(Visit 6) weeks of active treatment. The initial drug dosage was piroxicam 
10 ms OD or isoxicam 100 mg OD, ifiis being increased at Visit 4 to 20 
mg OD or 200 mg OD. respectively, in patients failing to respond to the 
lower dosage^.
The primary outcome measures employed were the WOMAC OA Index 
(Test Form. Tabic I) and 2 forms of global assessment. WOMAC was self- 
administered while the global assessments (on each o f the 5 dimensions) 
were made both by trained interviewers (interviewer global assessment) and 
study patients (patient global assessment). To address issues relating to scal­
ing, patients were given (in ratKlom sequence) 2 versions of WOMAC to 
complete. Both contained identical questions but one required responses 
on 5-point (none, slight, moderate, severe, extreme) Likert scales^ while 
the other required responses on 10 cm horizontal visual analogue scales 
(VAS) with terminal descriptors*. Individual item scores were determined 
by reading the patient’s response lo each qucstron. Aggregate scores for 
each dimension were determined by sumnung tfie compoticnt item scores 
for each dimension. The WOMAC final battery was determined by sum­
ming tfrc aggregate scores for the pain, srifbcss and physical function dimen­
sions. For reasons of feasibility, only the first 3 pain and? physical questions 
were duplicated on both scales (TaWe I). Similariy. only die tpicstion per­
taining to severity of morning stiffness, die 1st. 2nd and 6th social, and 
the 1st. 2nd. 4th and 5th emotional questions were duplicated on  tlie VAS
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scale (Tabic 1). As with WOMAC. the interviewer and patient global assess­
ment scores on single questions which separately probed the overall status 
of the patient on each of the 5 dimensions were made on both Likert and 
VAS scales. Patients completed WOMAC, interviewer and patient global 
assessments at all 6 visits. To test the construct validity of WOMAC. the 
following secondajy outcome measures were concurrently applied; O) joint 
tenderness (modified Doyle Index [hip and knee only])^, (2) Lequesne 
Index*, (3) Bradburn Index of WcU Being', and (4) social component of 
the McMaster Health Index Qucstioanaiie (MHIQ)'°. These measures were 
selected as being capable of validatiog the 5 different WOMAC dimensions 
i.e.. Pain (Doyle, Lequesae-Pain), Stiffness (Lequesne-Stiffhess). Physi­
cal Function (Lcquesne-Physical Function), Emotional Function (Bradburn), 
and Social Function (MfUQ-Social). The Doyle and Lequesne indices were 
selected since they were developed specifically for patients with OA- The 
Bradburn and MHIQ indices were selected because of our familiarity with 
them. Finally, 3 tertiary outcome measures were used: 50' walking time, 
total range of movement (ROM), intermalleolar straddle. These commonly 
used measures of drug efficacy were selected to assess the relative effici­
ency of the final WOMAC battery against traditional measures, and not 
as supplementary measures required for validation purposes. We have not, 
therefore, reported statistical p values for these variables but used the data 
to calculate the relative efficiency of WOMAC. Individual item and aggre­
gate item data were analyzed for each separate WOMAC dimension using 
both Student's t test' ' and Wilcoxon's nooparametric test'  ^ to assess item 
and dimension responsiveness (Visit 6 vs Visit 3) and the effect of para­
metric versus nonparamctric statistical treatment of the data. Internal con­
sistency (Visit 3) was tested using Cronbach’s alpha", test-retcst reliability 
(Visit I vs Visit 2) using Kendall's tau c statistic'*, and construct validity 
(Visit 3) determined using Pearson's correlation coefficient". Relative 
efficiency was calculated (Visit 6 vs Visit 3) using the method employed 
by Liang, er oL- "  e.g., relative efficiency for WOMAC vs Walktime (WT) 
=  (t^QM^c/t^)^. We have not reported response data for Visit 4 (as this 
represented a titration step) or for Visit 5 (as this was used to assess tolcia- 
bUity after incremental dosing at Visit 4). However, data on these visits 
can be found in the paper reporting drug efficacy*.
RESULTS
Fifty-seven patients were enrolled in the study: 28 (14 males, 
14 females) received isoxicam and 29 (12 males, 17 females) 
received piroxicam. The mean age was 66.5 years in each 
group (varying from 55 to 82). The mean disease duration 
(i.e., symptomatology) was 8.7 years (varying from 1 to 30) 
in the piroxicam group and 9.3 years (varying from 2 to 26) 
in the isoxicam group. The knee was selected as the most 
severely affected joint in 39 patients (isoxicarh 21, piroxi­
cam 18) compared to the hip in 18 patients (isoxicam 7, 
piroxicam 11). The above differences between the 2 groups 
were not statistically significanL The means and standard 
deviations (Visit 3) for primary, secondary, and tertiary out­
come measures are illustrated in Tables 2 and 3.
Fain — Responsiveness (Table 1)
Isoxicam, On Likert scaling using Wilcoxon’s test, all 5 items 
significantly improved by Visit 6 (p <  0.019), while on VAS 
scaling all items achieved p values of <  0.001. With the 
interviewer and patient global assessments and aggregate 
score strategics, p values of <  0.001 were achieved regard­
less of scale (Likert vs VAS) or type of analysis (Student’s 
t test vs WUcoxon). When the p values derived by paramet­
ric and nonparamctric analysis were compared for all 13 
analyses performed using individual item =  8, aggregate
Table 1. Siwmtan: o f item contetu o f original test form o f  
WOMAC**
Pain*
1 Walking (2.58)*
2 Stair climbing (2.62)*
3 Nocturnal (2.63)*
i  Rest (2.57)
5 Weight bearing (2.51)
Stiffness*
1 Morning stiffness (2.52)*
2 Stifihcss occurring later in the day (2.30)
Physical Function*
1 Descending stairs (2.60)*
2 Ascending stairs (2.54)*
3 Rising from sitting (2.32)*
4 Standing (2.64)*
5 Bending to floor (2.51)*
6 Walking on flat (2.40)*
7 Getting in/out car (2.26)*
S Going shopping (2.40)
9 Putting on socks (2.38)
10 Rising from bed (2.37)
11 Taking off socks (2.37)
12 Lying in bed (2.36)
13 Getting in/out bath (2,30)
14 Sitting (2-54)
15 Getting on/off toilet (2.67)
16 Heavy domestic duties (2.43)
17 Light domestic duties (2.26)
Social Function
1 Leisure activities (2.56)*
2 Community events (2.15)*
3 Church attendance (2.52)
4 With spouse (2.65)
5 With family (2.67)
6 With friends (2.64)*
7 With others (2.55)
EmotKKul Function
1 Anxiety (2.64)*
2 Irritability (2.59)*
3 Frustration (2.44)
4 Depression (2.49)*
5 Relaxation (2.39)*
6 Insomnia (2.58)
7 Boredom (2.62)
S Loneliness (2.26)
9 Stress (2.19)
10 Wellbeing (2.62)
•  These items were duplicated on VAS scales
These Item numbos correspond to those in text and Table 4. 
t  Dimensxns retained in final WOMAC ÎDStnuDcnc 
( ) Numbers in parentheses represent previously published^ mean 
iropoctance scores for each item. (Scale: 0 —nooc, 1—ifigbt, 
2=modaate, 3«vciy, 4 —extreme importance.)
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Tabic 2- Primary ouicome measures: Visit 3 means (m) and standard deviations (s)
Variable
Pain Stiffiicsx Physical
Functioa
Social
Fimcdon EmotionalFunction
Liken* vast Likert* VAS^ Likert* VASl Likert* VA5f Likert* VASi
WOMACtt C m 10.3 158.9 4.4 51.7 32.2 342.4 5.9 100.5 10.1 104.8s 4.4 69.0 1.8 28.5 13-8 154.1 5 J 75.8 8.5 90.1
I m 9.6 153.1 4.3 52.9 31.0 334.4 6.0 102.7 10.8 112.5s 4.0 66.3 1.6 29.7 13.5 152.6 5.2 79 j5 9.6 107.3
P ra 10.9 165.4 4.6 50.5 33.4 350.4 5.9 98.3 9.5 97.0
s 4.7 72.6 1.9 27.7 14.3 157.9 6.0 73.3 7.5 69.3
Patient C 2.5 55.3 2.4 53.3 1.9 42.1 1.1 27.2 0.7 21.0global s 1-0 28.2 1.0 29.0 1.0 26.4 1.0 27.1 0.9 22.6
assessment I m 2.3 51.7 2.3 50.1 1.8 40.1 1.1 28.5 0.8 22.8
s 1.1 29.8 1.1 30.9 1.0 25.9 1.0 29.0 1.0 26.4
P m 2.6 58.6 2.4 56.1 2.0 43.8 1.1 25.9 0.6 19.4
s I.O 26.7 1,0 27.4 0.9 27.2 1.0 25.7 0.7 18.9
Interviewer C m 2-6 2.1 — 2.3 — 1.1 — IJZ
global s . 0-9 — 1.0 — 0.8 — 1.1 — 1-0 --
assessment I m 2.5 — 2.2 _ 2.1 1.1 — 1.2
s 0.9 — 1.0 - 0.8 — 1.1 ~ 1-1 —
P m 2-7 — 2.0 2.4 — 1.0 — 1.1 -Mb
s 0.8 *—' 0.9 — 0.9 — 1.0 0.8 —
* Scored on values 0-4. where O=nonc, I =  slight, 2 = moderate, 3»=vciy, 4=cxticmc. 
t  0-100 mm horizontal VAS scale with terminal descriptors None and Extreme
ri Sum o f WOMAC test questionnaire items: Aggregate score (pain), AI (stiffhcss), AI (physical), AI (social), AI (emotional). 
** IgA only scored oo Likeit scale, not on VAS scale. Interviewer global assessment 
C -  Combined group (isoxicam +  piroxicam), I -  isoxicam, P -  piroxicam.
Table 3. Secondary and tertiary outcome measures: Visit 3 means (m) and standard devi-
axions (s)
Secondary
Combined 
m s
Isoxicam 
m s
Piroxicam 
m s
Bradburn total score -3 -6 3.3 -3 .0 3.3 -4 .2  3.2
Modified Doyle total score 2.8 1.6 1.5 1.5 3.0 1.6
Lequesne pain score 4.4 1.1 4.5 1.1 4.3 1.1
Lequesne stiffitess score 1.5 0.5 1.5 0.6 1.4 0.5
Lequesne physical score 5.7 23 5.6 2.5 5.9 2.0
MHIQ social score 15.8 1.7 15.6 1.9 16.0 1.5
Combined Isoxicam Piroxicam
Tcrtiaiy m s tn s m 5
Walk time (s) 17.2 7.2 17.1 8.3 I7J 6.0
Intermalleolar straddle 79.2 18.2 80.6 17.8 77.7 18.8
ROM (•) 225.1 26.3 224.8 26.9 225J 26.1
scorc =  2, interviewer global assessment = 1, and patient 
global assessment =  2 strategics, there was exact agreement 
(to 3 decimal places) in 46% of the cases, while in 54% the 
parametric value was smaller. The correlation coefficient be­
tween scores on Likert and VAS scales was 0,82 for patient 
global assessment.
Piroxicam. Regardless of the type of statistical analysis used, 
80% of the items significantly improved on Likert scaling 
by Visit 6 (p 0.005), but #2 failed to significantly improve.
On VAS scaling using Wilcoxon’s test, all 3 items achieved 
p values of < 0,019. With respect to the interviewer and 
patient global assessments and aggregate score strategies, p 
values of 0.003 were achieved regardless of scale. When 
all 13 comparative analyses (individual item =  8, aggregate 
score =  2, interviewer global assessment =  I, patient global 
assessment = 2) were considered, the parametric p values 
were smaller in 77% of the cases and larger in 15%, while 
in 8% there was exact agreement. The correlation cocffi-
Bellamy, et at: Validation o f  WOMAC 1835
cieni berwcen scores on Liken and VAS scales was 0.86 for 
patient giobai assessment.
Pa/fi _  reliabiliry. From Liken scaled responses to the 5 
component items the internai consistency of the pain dimen­
sion was 0.86 for isoxicam and 0.89 for piroxicam. The cor­
responding values for the 3 VAS scaled responses were 0.81 
and 0.73, respectively. The test-retcst reliability for the com­
bined group (i.e., isoxicam + piroxicam) was 0.68 on the 
Liken scale and 0.64 on the VAS scale.
Pain — validiry. Higher levels of correlation (as expressed 
by the correlation coefficients and the proportion of items 
displaying a statistically significant correlation) were noted 
on both Liken and VAS responses between the test items 
and the Lequesne pain and physical function components and 
the Doyle Index, than between these same items and the 
Lequesne stiffiiess component, the Bradburn Index and the 
MHIQ social component (Tabic 4).
Stiffitess — Responsiveness (Table 1)
Isoxicam. On Likert scaling using Wilcoxon’s test, both items 
(morning stiffness, stiffness occurring later in the day) sig­
nificantly improved by Visit 6 (p <  0.004), while on VAS 
scaling morning stiffhess achieved a p value of <  0.001 
regardless of type of analysis used. With the interviewer 
global assessment, patient global assessment, and aggregate 
score strategics, p values of <  0.001 were achieved regard­
less of scale or type of analysis. When all 7 comparative 
analyses (individual item = 3, aggregate score =  1, inter­
viewer global assessment = 1, patient global assessment =
2) were considered, the p values showed exact agreement 
in 43 % of the cases, while in 57% of the cases the para­
metric value was smaller. The correlation coefficient between 
scores on Likert and VAS scales was 0.91 for patient global 
assessment.
Piroxicam. On Likert scaling using Wilcoxon’s test, both 
items significandy improved by Visit 6 (p <  0.030), while 
on VAS scaling, morning stiffness achieved a p value of 
0.002. With respect to the interviewer and patient global 
assessments and aggregate score strategies, significant 
improvement was detected on each (p :<0.013). However, 
p values were smaller for patient global assessment on VAS 
scaling than on Likert scaling. When all 7 comparative analy­
ses (individual item = 3, aggregate score = 1, interviewer 
global assessment = 1, patient global assessment -  2) were 
considered the parametric p value was smaller in 100% of 
cases. The correlation coefficient between scores on Likert 
and VAS scales was 0.87 for patient global assessment.
Stiffness — reliability. From Likert scaled responses to the 
2 component items, the intcmal consistency of the stifhacss 
dimension was 0.90 for isoxicam and 0.91 for piroxicam. 
Only morning stiffiicss was probed on the VAS scale, and, 
consequently, intcritcm reliability was not determined, Test- 
retcst reliabühy for tire combined group was 0.48 on the 
Likert scale and 0.61 on the VAS.
Stijffhess — validity. The highest levels of correlation noted 
on both Likert and VAS scaled responses were between the 
2 test items and the Doyle Index (morning stiffness r = 0.45, 
late day stiffhess r = 0,46) and the Lequesne pain, physical 
function and stiffness components (morning stiffness r =  
0.22, late day stiffhess r = 0.23). No significant correla­
tion was noted between the test items and the other scales 
(Table 4).
Physical function — Responsiveness (Table I)
Isoxicam. On Liken scaling using Wilcoxon’s test, 15 of the 
17 physical function items significantly improved by Visit 
6 (p <  0.001 for 4 items, 0.002 < p ^  0.005 for 8 items, 
and 0.008 <  p <  0.009 for 3 items). Items 10 and 14 
achieved p values of 0.057 and 0.059, respectively, at Visit
6. On VAS scaling significant improvement occurred on all 
items, the p value being <  0,001 regardless of type of analy­
sis used. The interviewer and patient global assessments and 
aggregate score strategies detected significant improvements 
(p <  0.003). When p values derived by parametric and non- 
parametric tests were compared for all 29 analyses (individ­
ual item = 24, aggregate score =  2, interviewer global 
assessment = 1, patient global assessment = 2) performed, 
the parametric value was smaller in 62 % of the cases, while 
in 38 % of the cases there was exact agreemenL The corre­
lation coefficient between scores on Likert and VAS scales 
was 0.83 for patient global assessment.
Piroxicam. On Likert scaling using Wilcoxon’s test, 12 of 
the 17 physical function items significantly improved by Visit 
6 (0.002 <  p ^  0.009 for 6 items, 0.013 <  p 0.019 
for 4 items, and 0.024 <  p 0.027 for 2 items). On VAS 
scaling significant improvement occurred on all items, the 
p value being <  0.001 for 3 items, 0.006 for one item, 0.010 
<  p :< 0.011 for 2 items, and 0.044 for one item. With 
the interviewer and patient global assessments and aggregate 
score strategies, significant improvement was detected by 
Visit 6 (p <  0.002 for aggregate score and interviewer global. 
assessment; 0.004 <  p 0.010 for patient global assess­
ment). When p values derived by parametric and nonpara- 
metric tests were compared for all 29 analyses performed 
using individual item =  24, aggregate score =  2, interviewer 
global assessment =  1, and patient global assessment ~  2 
strategies, the. parametric p value was smaller in 79% of the 
cases, larger in 7%, while in 14% there was exact agree­
ment. The correlation coefficient between scores on Likert 
and VAS scales was 0.90 for patient global assessment. 
Physical Junction — reliability. From Likert scaled responses 
to the 17 component items, the intcmal consistency of the 
physical function dimension was 0.95 for isoxicam and 0.95 
for piroxicam. The corresponding values for the 7 VAS 
scaled responses were 0.91 and 0-89, respectively. Test-retcst 
reliability for the combined group was 0.68 on the Likert 
scale and 0.72 on the VAS scale.
Physical Junction — validity. Higher levels of correlation 
were noted on both Likert and VAS scaled responses between
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Tabic 4. Construct vaUdiiy analysis: Correlation o f WOMAC test items with Lequesne, 
Modified Doyle, Bradbum, and MHIQ indices
Domain • Lcqucsoc 
Paul
Lequesne
Stiffness
Lequesne
Physical
Doyle
Tenderness
Bradbtira
EroodonaJ
MHIQ
Social
Pain
Liken 1 (0.46/0.57 (0L14A).35) (020/0.55) (025/0.46) (-0.06/0.15) (-0 ,1 6 /-0 .0 0 )
2 1-5 1,4,5 1-5 1,3-5 — —
3 ■. ICO 60 too 80 0 0
VA5 1 V: (0.39/0.62) (0.04/0.24) (0.36/0.50) (0.36/0.57) (-0.08/0.04) (-0.07/0.03)
(a=3) 2 ~ 1-3 — 1-3 1-3 — —
3 ' 100 0 100 100 0 0
Stif&icss
Liken I (0.32/0.45) (0.22/0.23) (0.29/0.32) (0.45/0.46) (-0.22/-0.09) ( -0 .I3 /-0 .0 8 )
(n=2) 2 AMS*, GEL  ^ ~ AMS,GEL AMS.GEL — —
3 100 0 100 ICO 0 0
VAS 1 (0.32) (027) (0.35) (0.47) ■ ( -0 2 1 ) (-0 .11 )
(n = l) 2 AMS AMS AMS AMS — —
3 ICO 100 100 100 0 0
Physical Functioa 
Likcrt I (0.15/0.51) (-0.04/0.33) (020/0.54) (0,14/0.52) (-0.14/0.24) (-0.21/0.15)
(n=17) 2 W .6.8, 7,15.16 3-17 3,4,6-17 — —
10,12-17 
3 77 18 88 82 0 0
VAS 1 (0.32/0.50) e0.01A)Jl) (026/0.59) (028/0.54) (-0.14/0-22) (-0 .3 1 /-0 .0 0 )
(a=7) 2 1-7 6 . 1-7 1-7 — 5
3 100 - ' l 4 100 . 100 0 14
Social FuxKtioo 
Liken 1 (0.21/0.35) (p. 17/0.34) (0.24/0.37) (0.09/0.35) (-0.03/0-29) (-0.12Æ .1I)
(n=7) 2 l,2,5-7 2 12 ,4-7 1-3' — —
3 71 14 86 43 ■ 0 0
VAS 1 (0.28/0,35) (022/0.37) (0.42/0.49) (0.36/0.46) (-0.14/0.09) (-0.06/0.05)
(n=3) 2 1-3 12 1-3 1-3 — —
3 100 67 100 100 0 0
Emodooai Function 
Likcrt 1 (0.15/0.35) (0.03/0.37) (0.18/0.46) (-0.04/0.20) (0.14/0.45) (-0 .3 0 /-0 .0 4 )
(a=10) 2 4-6,10 2,5 1-6,9,10 — 1,7-9 -3 40 20 80 0 40 0
VAS 1 (0.30/0.34) (020ÆI.36) (0.44/0.54) (0.14/0.23) (0.34/0.38) (-0 .2 5 /-0 .1 8 )
(n=4) 2 1-4 4 1-4 — 1-4
3 100 25 100 0 100 0
1 Miu/max of Pearson coctcUtioa coeffideocs between individual test âam and comparison indices.
2 Test item number showing statistically significant coireiation with comparison indices ^ ^ 0 .0 5 ).
3 Percentage of test items showing statistically significant correlation with comparison indices.
4 AMS -  stiffness after first wakening in the morning.
5 GEL -  stiffness after sitting, lying, or testing later in the day.
NB -  Test item numbers correspond to those identified in Table 1.
the test items and the physical component of the Lequesne 
Index than with these same items and the Doyle Index, the 
Lequesne pain and stifBoess components, the Bradbum Index, 
and the MHIQ social component (Table 4).
Social Junction — Responsiveness (Table Î)
Isoodcam. On Likcit scaling using Wîlcoxon’s test, 4 o f the
items achieved statistically significant improvement at Visit 
6 (p =  0.011, 0.018, 0.033, and 0.043). On VAS scaling 
p values of 0.001 were achieved by the first 2 items, while 
a p value of 0.023 was attained by the 3rd item. Although 
the patient global assessment strategy resulted in a p value 
o f0.020 on VAS scaling, it did not statistically improve on
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Liken scaling (p = 0.110). The aggregate score and inter­
viewer global assessment strategics resulted in p values of 
^  0.001 and 0.015, respectively. When all 15 comparative 
analyses (individual item = 10, aggregate score =  2, inter­
viewer global assessment = 1, patient global assessment = 
2) were considered, there was absolute agreement of the p 
value in 13% of the cases, while in 67% the parametric p 
values were smaller and in 20% the nonparamctric p values 
were smaller. The correlation coefficient between scores on 
Likert and VAS scales was 0.87 for patient global 
assessment.
Piroxicam. On Likcrt scaling none of the items improved 
significantly by Visit 6 regardless of type of analysis. 
However, on VAS scaling item one achieved a p value of 
0.002, while item 2 achieved p values of 0.010 (t test) and 
0.006 (Wilcoxon). Neither the interviewer global assessment 
nor patient global assessment strategics detected significant 
improvement regardless of scale or type of analysis. 
However, the aggregate score strategy resulted in improve­
ment on the VAS’ (p <  0.008). When all 15 comparative 
scale analyses (individual item =  10, aggregate score = 2, 
interviewer global assessment = 1, patient global assessment 
=  2) were considered there was exact agreement of the p 
value in 7 % of the cases, while in 73 % the parametric p 
values were smaller and in 20% the nonparamctric p values 
were smaller. The correlation coefficient between scores on 
Likcrt and VAS scales was 0.62 for patient global as­
sessment.
Social junction — reliability. From Likert scaled responses 
to the 7 component items, the internal consistency of the 
social function dimension was 0.89 for isoxicam and 0.93 
for piroxicam. Corresponding values for the 3 VAS scaled 
items were 0.89 and 0.93, respectively. Tcst-retest reliabil­
ity for the combined groups was 0.61 on the Likcrt scale, 
and 0.59 on the VAS scale.
Social Junction — validity. Higher levels of correlation were 
noted between the test items and the Lequesne physical func­
tion and pain components (on Likcrt scaled responses) than 
with the Doyle Index or Lequesne stif&xrss component (Table 
4). With VAS scaled responses, higher levels of correlation 
were noted between test hems and the Lequesne physical 
function component, the Doyle Index, and the Lequesne pain 
component than with these same items and the Lequesne stiff­
ness component. Regardless of scale, no significant corre­
lation was noted between the test items and the Bradbum 
Index or with the MHIQ social component.
Emotional Junction — Responsiveness (Table 1)
Isoxicam. On Likcrt scaling using Wilcoxon’s test, half of 
the items improved significantly by Visit 6 (p <  0.043). In 
contrast, all VAS scaled responses achieved p values of ^  
0.014. Both the aggregate score and interviewer global 
assessment strategies showed significant improvement on 
Likert scaling (p ^  0,004). However, the patient global
assessment strategy did not detect improvement on cither 
scale (p >  0.090). When all 19 comparative analyses 
(individual item = 14, aggregate score = 2, interviewer 
global assessment = 1, patient global assessment = 2) were 
considered, there was exact agreement of the p value in 10 % 
of the cases, while in 74% the parametric p values were 
smaller, and in 16% the nonparamctric p values were 
smaller. The correlation coefficient between scores on Likcrt 
and VAS scales was 0.91 for patient global assessment.
Piroxicam. On Likcrt scaling using Wilcoxon’s test, 4 of the 
10 items improved significantly by Visit 6 (p 0.050). In 
contrast, the 4 VAS scaled responses all achieved p values 
^  0.032. Although both the interviewer global assessment 
and aggregate score strategics demonstrated significant 
improvement on Likcrt scaling (p = 0.004 and p — 0,022, 
respectively), the patient global assessment strategy did not 
detect improvement (Likcrt p = 0.779, VAS p = 0,187). 
When all 19 comparative analyses (individual item =  14, 
aggregate score =  2, interviewer global assessment =  1, 
patient global assessment = 2) were considered, there was 
exact agreement of the p value in 8% of the cases while in 
92 % the parametric p values were smaller on Likert scal­
ing. On VAS scaling, however, the nonparamctric p values 
were smaller in 100% of cases. The correlation coefficient 
between scores on Likcrt and VAS scales was 0.66 for patient 
global assessmcnt-
Emotional Junction — reliability. From Likcrt scaled 
. responses to the 10 component questions, the internal con­
sistency of the emotional function dimension was 0.96 for 
isoxicam and 0.91 for piroxicam. The corresponding values 
for the 4 VAS scaled items were 0.98 and 0.88, respectively. 
The tcst-retest reliability for the combined group was 0.72 
on the Likcrt scale and 0.66 on the VAS scale.
Emotional Junction — validity. Higher levels of correlation 
were noted on both Likcrt and VAS scaled responses between 
the test items and the Lequesne physical function component, 
the Bradbum Index, and the Lequesne pain component than 
with the Lequesne stiffiiess component (Table 4). No sig­
nificant correlation was noted between test items and the 
MHIQ social component or the Doyle Index.
Relative efficiency. When considering both treatment groups 
combined, 5 pain, 2 stiffiness and 17 physical function items 
achieved statistical significance (p <  0.005) by Visit 6. Since 
only 3 emotional items and none of the social items achieved 
this level of significance, emotional and social dimensions 
were not subjected to relative efficiency testing (Table 5).
In 83 % of analyses the relative efficiency of WOMAC was 
>  1, i.e., more efficient than the tertiaiy measures. Rela­
tive efficiency values <  1 were largely accounted for by 
walking time scores for the piroxicam group. In 78% of com­
parisons the relative efficiency for VAS scaled responses was 
numerically greater than the corresponding Likcrt scaled 
responses.
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Table 5. Relarive efficiency* o f WOMAC versus ternary outcome variables
Tertiary
Outcome
Variable
Study
Group
Pain Stiffness Physical
Functioa
WOMAC FinaJ 
Battery (FB)**
Likcrt VAS Liken VAS Likcrt VAS Liken VAS
Waikttimc C 1.4 1.5 0.7 1.4 1.2 1.3 1.4 1.5
I 2-3 2.9 2-0 2.2 2.9 2.4 3.1 2.8
P 0.8 0.7 0 3 0.9 0.5 0.7 0.6 0.8
IntcrmaJlcoiar C 5.2 5.8 2.8 5.5 4.8 5.1 5.4 6.0
straddle I 2.7 3.4 2.4 2.6 3.4 2.9 3.6 3.3
P 11.8 11.0 4.5 13.4 7.7 10.2 9.4 12.5
ROM c 1.4 1.6 0.8 1.5 1.3 1.4 1.4 1.7
I 1.3 1.6 1.1 13 1.6 1.4 1.7 1.6
p 1.6 1.6 0.7 1.9 l.O 1.6 1.3 1.9
Relative efficiency = e.g.. for isoxicam (tpû„ (vasi'^W  ii<iKÎ^=2.9.
-  WOMAC (FB) = Alp^ +  A I ^ ^  +
C—Combined group (isoxicam +  piroxicam), I-isoxicara, P-piroxkam
DISCUSSION
In developing a new hcalth“status measure we were guided 
by 4 principles; adequate responsiveness, reliability and 
validity, and superior relative efficiency over selected tradi­
tional measures. We elected to employ a double blind, ran­
domized, controlled parallel design since both groups of 
patients at Visit 3 would have a high probability of being 
similar with respect to their pretreatmcnt status and response 
potential. Furthermore, if the 2 agents arc similar in effi­
cacy then the 2 arms of the study may be used for conduct­
ing separate tests of index responsiveness in 2 clinically 
equivalent groups of patients. Indeed, since no significant 
between-group differences were detected (Tables 2 and 3) 
and DO significant bctwcen-drug differences were identified 
using the reported independent outcome measures*, and 
accepting the possibility of a Type II error, nevertheless we 
regard the design as a legitimate and novel approach to index 
validation.
Responsiveness. Although isoxicam was voluntarily sus­
pended worldwide by Warner-Lambert International in 
October 1985, this was not for lack of efficacy but rather 
for reasons of toxicity apparently related to a manufactur­
ing problem in France'^. Since drug efficacy was not at 
issue, we regard this voluntary suspension as irrelevant to 
the validation of WOMAC. Twenty-seven (5 pain, 2 stiff­
ness, 17 physical, 0 social, 3 emotional) of the original 41 
WOMAC items achieved statistical significance with p values 
^  0.005 by Visit 6 for the combined group. The use of mul­
tiple analytic comparisons may result in an increase in Type 
I errors". Even correcting for this statistical nuance, 
however, and accepting a high degree of covariance among 
Index items, the p values attained were extremely good and 
indicative of a high level of responsiveness for these 27 
WOMAC items. Comparative analyses of nonparamctric vs 
parametric treatment of the data suggest that while in many 
instances there is agreement between the 2 (and therefore
that either analysis may be used), nonparamctric methods 
may provide a more conservative estimate of the response, 
and for conceptual reasons relating to normality of the data, 
may be regarded as the preferred analytic technique. Since 
these observations are of limited gcncralizability, we are con­
tinuing to perform both parametric and nonparamctric com­
parisons on instrument data.
Reliability. Reliability coefficients (i.e., Cronbach’s alpha) 
of >  0.80 arc generally regarded as acceptable. Index items 
exceeded 0.85 on both VAS and Likcrt scales in aU but one 
instance (pain — VAS piroxicam group =  0.73). The values 
achieved for tcst-retest reliability were somewhat lower than 
those lor internal consistency. Nevertheless, we regard them 
as entirely adequate considering that (a) the tcst-retest inter­
val was one week, and (b) the Kendall’s tau c statistic tends 
to generate slightly lower coefficients of correlation". We 
believe that the principal explanation for our lower test-rctest 
values lies in the excessive interval (1 week) between the 
2 administrations. Indeed, given the high internal consistency 
and sensitivity of WOMAC, and considering the constantly 
fluctuating symptomatology of DA, one can predict that test- 
rctest reliability values will only be moderate. These data 
indicate, therefore, that all 5 WOMAC dimensions on both 
VAS and Likert scales are of adequate reliability.
Validity. Opinions differ as to which items should be incor­
porated in outcome measurement, and which numerical 
weights assigned to the clinical importance of different 
itcms“ . We believe, however, that the item content of 
WOMAC should be generally acceptable since it is based 
not only on a review of both the clinimctric and OA 
literatures', but on the opinions of 100 patients with symp­
tomatic OA who provided data on the dimensionality of their 
symptoms and assigned importance scores for each Item sub- 
scqucndy used in constructing W0MAC7. For criterion 
validity testing, coefficients >  0.80 are generally regarded 
as acceptable. However, no irrefutable gold standard cur-
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rentiy exists against which to test criterion validity. We have, 
therefore, tested construct validity against other indices which 
probe the 5 Index dimensions of interest. Since these com­
parators are not gold standards, lower levels of correlation 
arc expected- In general, however, the Index items should 
show a st^isticaUy significant corrclatioD with other indices 
probing the same dimension (convcigcnt construct validity). 
Furthermore, Index items should also show higher levels of 
correlation with other indices probing the same dimension 
than with indices probing other (particulariy unrelated) 
dimensions (divergent construct validity). These criteria were 
fulfilled by the pain, stiffiiess and physical function compo­
nents of the Index. It should be noted that since physical dis­
ability is often secondary to pain, it is not surprising that 
these 2 dimensions are often associated. We observed that 
both stiffiiess items showed a better correlation with the 
modified Doyle score than with the Lequesne stiffiiess com­
ponent. However, we believe this to be due to the fact that 
the Lequesne Index probes duration of stiffness while 
WOMAC probes its severity. Given the interrelationship 
between discomfort and disability, an association between 
stiffiiess, pain, tenderness and physical function is predic­
table. Of note, the VAS scaled stiffiiess item showed a statisti­
cally significant correlation with the Lequesne stifihcss 
componenL The social component of WOMAC failed to 
correlate with the fdHIQ social component, and although 
some items were reliable and responsive, this dimension was 
excluded fipom the Index. Moreover, in spite of the emotional 
component fulfilling construct validity criteria, and most 
items being reliable and responsive, we elected to withdraw 
the component pending a réévaluation of the social dimen­
sion. The final Index, therefore, utilizes the pain (5 items), 
stiffiiess (2 Items), and physical (17 items) function subscales 
only (Table 1).
Relative efficiency. To be useful, a new health status meas­
ure should offer advantages over existing indices. In this 
respect, WOMAC offers 2 advantages. First, WOMAC and 
its subscales offer superior efficiency (as measured by rela­
tive efficiency scores) over selected traditional measures in 
assessing the efficacy of antirhcumatic drugs. Such a meas­
ure, therefore, has potential for reducing sample size require­
ments for clinical trials using WOMAC as the primary 
outcome measure. Secondly, traditional measures often lack 
patient relevance. In contrast, WOMAC probes patient rele­
vant outcomes, the clinical importance (Table 1) of which 
have been documcntccF.
We believe WOMAC to be a reliable, valid, and respon­
sive multidimensional, sclf-admmistercd outcome measure 
designed specifically to evaluate patients with OA of the hip 
or Imee. We are currently conducting further studies on 
aggregating scores across different dimensions, on the rela­
tive responsiveness of Likcrt and VAS scales, and the rela­
tive efficiency of WOMAC against several other health status 
instruments.
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SECTION 4 - Exploration of Special Measurement Characteristics
Following the establishment of the basic clinimetric properties (validity, 
reliability and responsiveness) of the WOMAC Index, other studies and subanalyses were 
undertaken to explore other properties of the WOMAC Index, in particular the following: 
blind versus informed presentation (5,6), signal versus aggregate strategies of 
measurement (7,8), time frame dependency (9), and the relative responsiveness of the 
WOMAC Index (10,11).
Blind versus informed presentation.
In the 1980s, the measurement literature was divided as to whether patients 
should be shown (informed) or not shown (blind) their prior scores when self-completing 
a health status questionnaire. Some authorities believed that access to prior scores might 
bias results by creating a comparison with prior status, while others believed it provided a 
positive influence by allowing patients to calibrate their current status against prior 
scores. This issue had rarely been explored with questionnaires used in rheumatology 
research. One sub-analysis and one sub-study were undertaken with the WOMAC Index 
(5,6). The sub-analysis was part of the original pharmacologic validation study (5), while 
the sub-study was part of an RCT comparing flurbiprofen SR vs diclofenac sodium SR
(6). No statistically significant or clinically important differences were detected in either 
the sub-analysis or sub-study, suggesting that changes with treatment, recorded by the 
WOMAC Index, were comparable using blind and informed methods of Index 
presentation (5,6).
Incidental to the flurbiprofen SR versus diclofenac sodium SR study, a 
preliminary factor analysis was undertaken o f the pain and function subscales (6). Factor 
1 accounted for 88% of the variance in pain and 83% of the variance in physical function. 
The factor loading was high on each individual pain item (0.92-0.95) and each individual 
physical function item (0.70-0.97). Although this was a preliminary factor analysis, based 
on a study of relatively small sample size, and recognizing the limitations of the 
methodology, the factor structure of the WOMAC Index was generally upheld.
Signal versus aggregate strategies of measurement
A recurrent theme in outcome measurement concerns whether the patient should 
be presented with a fixed battery of items or whether the battery should be tailored to the 
different symptom experience of each individual, within a predefined specification of 
domains or items. The potential advantages of the flexible battery are in individualisation 
of the questionnaire and increased index responsiveness, the potential disadvantage being 
in comparing “apples with oranges” in group analyses. To explore this issue with the 
WOMAC Index, we conducted a sub-analysis of the original orthopaedic validation study
(7), and a sub-study within an RCT of tenoxicam versus diclofenac (8). Both the sub­
analysis and sub-study suggested that signal measurement, where patients selected one 
pain, one stiffness and one physical function item from the WOMAC inventory, 
according to pre-specified criteria, was feasible. Both studies also indicated between- 
subject variability in signal selection (7,8). The signal approach was more responsive 
than using the entire WOMAC Index in the tenoxicam versus diclofenac study (8), but 
not in the orthopaedic study (7). The signal method failed to detect deterioration in non­
signal items, which occurred more commonly in the tenoxicam versus diclofenac study
(8) than the orthopaedic study (7). Finally, the tenoxicam versus diclofenac study (8)
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suggested the occurrence of within-subject variability in signal selection over time, this 
observation being based on the same subjects being given a second opportunity to select a 
signal at the end of study. These studies suggested while signal measurement was feasible 
and might provide a more responsive alternative to traditional methods of measurement 
based on fixed item inventories, that the gain in responsiveness might be variable, and 
non-signal deterioration might go undetected. Collectively these data suggested that 
administering the entire WOMAC Index might be preferable to monitoring patient 
progress based only on single individualized signal items.
Time frame dependency
The most appropriate time frame over which to ask patients to recall their 
symptoms has rarely been studied in health status questionnaires used in rheumatology. 
Indeed rheumatology measures differ significantly with respect to the time period over 
which they require patients to rate their symptom experience. In order to explore this 
aspect of the WOMAC Index, a small study was conducted in which patients were 
presented, in random order, with three WOMAC questionnaires identical in content, but 
differing in their recall period (24 hours, 48 hours, two weeks) (9). No clinically 
important or statistically significant differences were observed between the responses to 
the three variations in time frame. This study provided support for varying the time 
frame of the WOMAC Index between one and 14 days, depending on the dynamic 
requirements of future studies. Ultimately, 48 hours was chosen, for conceptual reasons, 
as the standard time frame for the 3.1 series of WOMAC questionnaires. It was reasoned 
that the 48-hour time frame permitted patients more time, than the 24-hour time frame, to 
experience their symptoms, without becoming excessively vulnerable to recall and 
memory effects.
Relative responsiveness
Responsiveness or sensitivity to change is a quintessential characteristic o f a 
health status measure for evaluating the clinical benefit of interventions in patients with 
OA . In addition to establishing an instrumenf s capacity to detect change, it is important 
to compare the relative responsiveness to other commonly used measures. In the two 
original validation studies the responsiveness of the WOMAC Index had been compared 
to other methods of assessment used in OA clinical trials (2,4). The comparative 
analyses, based on the relative efficiency statistic, suggested that the WOMAC Index was 
superior in responsiveness to the following observer-dependent measures: walk time, 
intermalleolar straddle, intercondylar distance and knee range of motion (2,4). Two 
additional studies were undertaken to explore the relative responsiveness of the WOMAC 
Index to three other standard patient self-reported health status measures (10,11). In an 
orthopaedic study of total knee replacement, responsiveness of the WOMAC Index was 
compared to that o f the Health Assessment Questionnaire (HAQ) and the Arthritis Impact 
Measurement Scales (AIMS). The WOMAC was superior in responsiveness, as assessed 
by the relative efficiency statistic, in three out of four analyses (10). In a second study, 
conducted in an RCT of ibuprofen versus placebo, the responsiveness of the WOMAC 
Index was compared to the Short-Form Medical Outcomes Survey (SF-36) (11). The 
WOMAC was superior in responsiveness, as assessed by the effect size statistic, in 15 out 
of 18 analyses of pain and function scores.
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Collectively these comparisons suggested that the WOMAC Index compared 
favourably to other commonly used measures in OA clinical research studies, and was 
superior in responsiveness to several of the measures.
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LETTERS TO THE EDITOR
P rior  Score A vailab ility : O b servation s U sin g  T h e  
W O M A C  O steo a rth ritis  Index
— W h eth er  p a tien ts  sh o u ld  be sh ow n  their p rior sc o r es  
w h en  rep ea ted ly  se lf-a sse ss in g  health  status rem a in s c o n ­
troversia l [1 -4 ] . T o e v a lu a te  th is issu e w e a sse s se d  th e  
effec t o f  prior score a v a ila b ility  during a v a lid a tio n  stu d y  
o f  a n ew  o u tco m e  m ea su re  for osteo a rth ritis  ( O A )  [5 ], 
term ed  W O M A C  (th e  W estern  O n tario  and M cM a ste r  
U n iv e r sit ie s  O steo a rth ritis  In d e x ) . Its c lin im etric  p ro p er ­
ties h a v e  b een  rep orted  [6 -8 ] .  W e d escr ib e  a fu rth er  a n a l­
ysis com p a rin g  ou r  e x p e r ie n c e  o f  b lind  versus in fo r m ed  
p resen ta tio n  o f  the q u e s t io n n a ir e . W e use th e  term s  
L K 3 .0  and V A 3 .0  to  d e fin e  certa in  fea tu res o f  th e  
W O M A C  In d ex .
T w en ty -e ig h t p a tien ts  w ith  O A  o f  the h ip  or  k n e e  
req u iring  N S A I D  e n te re d  a m u lticen tre  stu dy  c o m p a r in g  
p irox icam  w ith  iso x ica m . T o  b e  e lig ib le , p a tien ts  h ad  to  
fulfil d efin ed  criteria  [6]. P a tie n ts  w ere  a ssessed  at e n r o l­
m en t and again  1 w e e k  la ter . T h erea fter , p a tien ts  u n d er ­
w en t a 1 -w eek  N S A I D -fr e e  w a sh o u t p e r io d  and w ere  th e n  
r ea ssesse d . F inally , p a tie n ts  w ere  ev a lu a ted  fo llo w in g  2 , 4  
and 6 w e ek s o f  active  tr ea tm e n t. T h e  W O M A C  q u e s t io n ­
naire [9] w as d e v e lo p ed  w ith in  a m e th o d o lo g ica l fr a m e ­
w ork  sim ilar  to  that p r e v io u s ly  d iscu ssed  [10] W O M A C  
co n sists  o f  24  item s in th ree  d im en sio n s: pain  =  5 , s t if f ­
ness =  2 . ph ysica l fu n c tio n  =  17 item s resp ectiv e ly . S u b ­
jects  c o m p lete d  tw o  v ers io n s  o f  th e  q u estio n n a ire  at ea ch  
v isit. T h e  L K 3 .0  v ers io n  req u ired  resp o n ses o n  5 -p o in t  
L ikert sca les  [11], and th e  V A 3 .0  vers io n  on  100 m m  h o r i­
z o n ta l v isu a l a n a lo g u e  (V A )  sca les  [12]. O n ly  11 o f  th e  
item s w e re  d u p lica ted  in  th e  V A 3 .0  vers io n  (p a in  =  3; 
s tiffn ess  =  1; p h ysica l fu n c tio n  =  7 ) . A g g reg a te  sc o r e s  fo r  
ea ch  d im en sio n  w ere  d e te rm in e d  by su m m in g  th e  c o m ­
p o n e n t item  sco res . P a tie n ts  c o m p le te d  W O M A C  b lin d  
to  p rev io u s  sco res at all v is its . A t  th e  final v isit, W O M A C  
w as in itia lly  p r e se n ted  to  p a tie n ts  b lin d , i .e .  as a b la n k  
q u estio n n a ire  w ith o u t a c ce ss  to  an y  p rior  sc o r es . H a v in g  
c o m p le te d  W O M A C  fo llo w e d  by  th ree  o th er  q u e s t io n ­
n a ires [6 ], an in fo rm ed  r e sp o n se  w as o b ta in ed  b y  h a v in g  
p a tien ts  aga in  sco re  th e ir  cu rren t h ea lth  sta tu s o n  th e  
sa m e  W O M A C  q u es t io n n a ir e  on  w h ich  th ey  had  p r e ­
v io u sly  m ark ed  their  e n d -o f-w a sh o u t sco res. D e sc r ip tiv e  
sta tistic s  w ere  ca lcu la ted  fo r  d ise a se  and d e m o g r a p h ic  
v a r ia b le s . S tu d e n t’s r-test w a s  u sed  to  com p a re  b lin d  v er­
su s in fo rm ed  sco res at stu d y  term in a tio n  [13]. T h e  s ig n  
te st w a s used  to  test d iffe r e n c e s  in  th e  p ro p o r tio n  o f  
p a tien ts  u n d erestim a tin g  or  o v erestim a tin g  sc o r es  u n d er  
b lin d  versu s in fo rm ed  a d m in istra tio n  o f  the term in a l  
q u es tio n n a ir e  [14]. W e h a v e  m a d e  12 statistica l c o m p a r i­
so n s  a n d , th e r e fo r e , c o rr ec ted  th e  le v e l o f  s ig n ifica n ce  to
0 .0 0 4 .
O f  th e  o r ig in a l 2 8  p a t ie n ts , five w ere  w ithd raw n d u e  to  
to x ic ity , co n cu rren t i lln e ss  o r  in c o m p le te  d ata . O f  th e  
r em a in in g  23  p a tie n ts , 10  w e re  m a les  and 13 w e r e  
fe m a le s;  th e ir  m ea n  a ge  w a s 6 4 .3  y ea rs , varying fro m  55  to  
78  y ea rs . T h ir tee n  r e c e iv e d  iso x ica m  and  10 p ir o x ic a m . 
N o  o v era ll d ifferen ces  w e r e  n o te d  b e tw e e n  th e  tw o  tr e a t­
m e n t gro u p s [6 ], and w e  c o m b in e d  th em  for th is a n a ly sis .
T h e  m ea n  v a lu es at te rm in a tio n  fo r  W O M A C  L K 3 .0  
are illu stra ted  in T ab le  I. T h e  m o d e  o f  a d m in istra tio n  
r esu lted  in d ifferen t sc o r es  in 4 8 -8 7 %  o f  in sta n ces b u t d if­
fe re d  b e tw e en  d im e n sio n s . W h ere  sco res  d e p e n d e d  o n
th e  m e th o d  o f  a d m in is tra tio n , th e r e  w as a te n d e n c y  to  
o v e r e s t im a te  pain  w h ile  u n d e re stim a tin g  s t iffn e ss  and
TABLE I
C omparison of B u n d  versus I nform ed  S cores at 
T ermination
Termination
blind
Termination
informed D ifference
Pain
LK 3.0 6.56 (4.0) 6.65 (4.4) -0 .0 9  (2.8) 
- 0 .1 5 .  0.881
V A 3.0
Stiffness
85.13 (70.6) 85.13 (72.5) 0.00 (32.2) 
0.00. 1.000
LK 3.0 3.26 (1.5) 3.04 (1.4) 0.22 (0.7) 
1.55. 0.135
VA 3.0
Physical
function
25.78 (19.3) 31-00 (25.2) - 5 .2 2  (11.8) 
-2 .1 3 .  0.045
LK3-0 21.00 (13.7) 19.74 (12.4) 1.26 (6.4) 
0.95. 0 .354
VA 3.0 204.39(155.5) 197 .00(149 .6) 7.39 (60.7) 
0 .58. 0.565
Entries are mean (so); /-statistic, P-value.
p h y sica l fu n ctio n  u n d er  b lin d  a d m in is tr a tio n . T h e  m a g n i­
tu d e  o f  su ch  v a r ia tion , e x p r e s se d  by  su b tra ctin g  b lind  
fro m  in fo rm ed  sc o r es , is illu s tra ted  in  T a b le  II. N o n e  o f  
th e se  d iffe re n c es  w as sta tistica lly  s ig n ifica n t. V T ien  c o n ­
sid er in g  th e  n u m b er  o f  su b je c ts  o v e r e s t im a tin g  v ersu s  
u n d e re stim a tin g , th e  s ign  te s t  d id  n o t  d e te c t  any s ta t is ­
tica lly  sign ifica n t d iffe re n c e  o n  a n y  d im e n sio n .
T A B L E  II
N umber of S ubjects over/ u n d er - estim .^ ting  S cores
Under Sam e Over
Binomial 
(2-tailed P)
Pain
LK3.0 5 8 10 0.3018
VA 3.0 9 0 14 0.4049
Stiffness
LK3.0 8 12 3 0.2266
VA 3.0 7 1 15 0.1338
Physical function
LK3.0 12 3 8 0.5034
VA 3.0 10 0 13 0.6776
Entries are number o f subjects.
The sign test was used to test differences in proportions under/ 
over-estimating scores. Since fewer than 23 differences w ere  
observed in each case, the binomial distribution was used to 
com pute an exact significance level.
T lie  m e a n  v a lu e s  at te rm in a tio n  fo r  W O M A C  V A 3 .0  
are  illu stra ted  in  T ab le  I. T h e  m o d e  o f  a d m in is tra tio n  
resu lted  in  d ifferen t sc o r es  in  9 6 -1 0 0 %  o f  in sta n ce s  b u t  
va r ied  b e tw e e n  d im e n sio n s . W h e r e  sc o r es  d e p e n d e d  o n  
th e  m e th o d  o f  a d m in is tra tio n , th e r e  w as a te n d e n c y  to  
o v e r e st im a te  all th ree* W O M A C  d im e n s io n s  u n d er  b lin d  
ad m in is tra tio n . T h e  m a g n itu d e  o f  su ch  v a r ia t io n .
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expressed by subtracting blind from informed scores, is 
illustrated in Table II. None of these differences was 
statistically significant. When considering the number of 
subjects overestimating versus underestimating, the sign 
test did not detect any statistically significant difference 
on any dimension.The results of the study suggest that showing patients 
their previous scores made no significant difference to 
outcome measurement. In particular, the direction of the 
differences detected was not entirely predictable and 
varied from dimension to dimension and between the two 
types of scales. Furthermore, the magnitude of the differ­
ence was small, both when considering the LK3.0 and 
VA3.0 versions. Overall, the Informed approach resulted 
in a more conservative estimate of the response, although 
the difference was neither statistically significant nor clini­
cally important. However, this study, like its predeces­
sors, has not established the superiority of the informed 
method of administration, since the appropriateness of 
underestimation versus overestimation was not verified 
by any external gold standard. Furthermore, given the 
dynamic nature of the study in which patients were first 
washed out and then treated with active therapy, we were 
unable to verify the claim by Guyatt and colleagues [4] 
that the informed mode may result in less within-patient 
variability and that this may decrease the sample size 
needed to detect changes in quality of fife in clinical trials. 
We have, however, confirmed their observation that 
change with treatment is comparable using blind and 
informed methods of administration and have demon­
strated this using a different questionnaire m a different 
patient population.N. BELLAMY*  ^ C. H. G oldsm tth", W. W. B u c h a n a n ,^
J. C a m pbell*, E. D u k u ’ 
* Department o f  Medicine, University o f  Western Ontario, 
London, Ontario, Canada; Departments o f Clinical Epi­
demiology and Biostatistics, and ^Medicine, McMaster 
University, Hamilton, Ontario, Canada 
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HLA Class H Antigens in Susceptibility to Rheumatoid 
Arthritis
Sir—The reclassification of rheumatoid arthritis along the unmunogenetic lines recently proposed by Professors 
Buchanan and Singal [1] is laudable in principle but 
flawed in practice. They suggest that HLA-DR antigens 
may predispose to mild RA while DQ antigens Influence 
the severity of the disease. Furthermore, DR 1 is proposed 
to be preferentially associated with mUd RA although the 
evidence for this is tenuous. The results from studies con­
ducted in Professor SingaPs laboratory showed associ­
ations of mild RA with both D Rl and DR4. Those with 
more severe RA (i.e. requiring gold therapy) showed, not 
surprisingly, a still stronger association with DR4, thereby 
confirming the results of other studies [2, 3]. Despite this 
D R l was still Increased (25%) compared to random 
normal controls (14%) in this group with relatively severe disease despite the fact that it was already heavily 
weighted for DR4-bearing haplotypes (56%). The 
authors comment that this difference was insignificant, 
even if the DR4-negative patients only were considered, 
but this is likely to represent a type II statistical error as a 
result of the relatively small number of DR4-negative 
individuals who were available for analysis. It is note­
worthy in this context that Woodrow et al. in their land­
mark paper on the immunogenetics of RA [4] calculated a 
very small excess risk from D R l (1.5) which was never­
theless highly significant (F<2.5 x 10“ °^) because they 
analysed the combined results from many studies. The 
proposal that only those subtypes of DR4 capable of pres­
enting a particular MH C/ligand epitope (also shared with 
D R l and possibly DRwlO) are associated with RA has • 
now been rigorously tested [5]: the shared epitope may be 
found in at least 85% of patients. The relatively smaller 
association of D Rl with severe RA than mild RA claimed 
by Buchanan and Singal [1] is a direct consequence of the 
preferential association of DR4 with severe disease [2, 3]. 
Since the fall-off in D R l with increasing disease severity is 
therefore a secondary phenomenon it clearly does not 
constitute a firm basis for any diagnostic recategorization.
The role of DQ in RA has been incompletely evaluated 
so far. Certainly the extraordinarily strong association of 
DQw7 reported by Singal et al. [6] in moderately severe 
RA has not been confirmed by other studies In patients 
requiring disease-modifying drugs [5]. The’ most recent data from Professor Singal’s group [1] are statistically 
flawed since the frequency of DQw7 in the severe RA 
group (93%) is contrasted with that in a randonr control 
group (19%) despite the fact that the former is highly 
selected for the DQw7- and DQwS-bearing DR4 haplo­
types. Anv increase in DQw7 could also be accounted for bv linkage disequilibrium with DR4:Dw4 (see below). Our results of DQ DN A haplotyping previously reported 
[5] have now been extended to a larger group of 119
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Relationship between Severity and Clinical 
Importance of Symptoms in Osteoarthritis
N. B E L L A M Y ,  G.  W E L L S * ,  J.  C A M P B E L L
Summary Seventeen patients with primary osteoarthritis of the knee were eval­
uated with respect to the severity and clinical importance of pain, stiffness and 
physical function during the conduct of a double-blind randomized controlled trial 
of flurbiprofen SR versus diclofenac sodium SR using the WOMAC Osteoarthritis 
Index. Mean importance scores were similar for items within the same dimension 
as well as between items in different dimensions. In general, low levels of correlation 
were noted between the severity and importance of symptoms. Analysis of individual 
WOMAC items within a given subscale indicated that, although highly correlated, 
they differed from one another. Factor analysis further supported the contention 
that scores from items within a subscale could be summated into subscale scores.
These observations are of importance in the weighting and aggregation of items 
within discrete dimensions and have the potential for reducing sample size require­
ments for clinical trials in osteoarthritis.
Key words: Clinical Metrology, Importance, Osteoarthritis.
INTRODUCTION
The principal objective of outcome measurement pro­
cedures for therapeutic trials of nonsteroidal anti-in­
flammatory drugs (NSAIDs) is to detect statistically sig­
nificant, clinically important, differences in health status 
between competing treatment programmes. Although 
much attention has been focused on outcome measures 
for rheumatoid arthritis (RA) (1,2), much less attention 
has been paid to the study of patients with osteoarthritis 
(OA). In general, clinical investigators and international 
agencies have recommended the use of multiple out­
come measures for OA trials (3-6). The use of multiple 
outcome measures, however, necessitates a downward 
correction in the statistical p value which results in in­
creased sample size requirements (7). Such problems 
can be overcome by weighting and aggregating different 
measures into a single composite index (8). Such a pro­
cedure, however, requires respect to relative clinical im­
portance of different items, as well as differences in the 
lengths of the scales on which the different components 
are measured, Sraythe et al have constructed a compos­
ite index, termed the Pooled Index, for application in pa­
tients with RA (9). However, their statistical techniques,
Department of Rheumatology, University of Western Ontario, Lon­
don, Ontario, Canada; ^Division of Biometrics, Health and Welfare 
Canada, Ottawa, Ontario, Canada.
while correcting for variability in scale length, do not re­
spect the relative clinical importance of the component 
items (9). In contrast, Gade (10) and Freeman et al (11) 
have suggested diametrically opposed weighting and ag­
gregation systems for assessing range of movement. We 
have recently conducted a series of studies (12-16) val­
idating a tridimensional self-administered questionnaire 
probing pain, stiffness and physical function in patients 
with OA of the hip or knee. The resulting index is 
termed the Western Ontario and McMaster Universities 
(WOMAC) OA Index. An earlier study (13) had indi­
cated that the twenty-four component questions of the 
Index were regarded by symptomatic patients as being 
of similar mean clinical importance. In that study (13) 
importance was measured on 5-point Likert (17) scales. 
We were unable to determine the extent to which the 
severity of the patients’ symptoms influenced their de­
termination of importance scores. Since we are now us­
ing a battery of 10 cm visual analogue (VA) (18) scales 
as the scaling base for the WOMAC Index, and since we 
wish to aggregate the component questions within, and, 
if possible, across the three subscales, we have admin­
istered the WOMAC instrument during the conduct of 
a double-blind randomized controlled multi-centre trial 
of flurbiprofen (Ansaid-SR) versus diclofenac (Voltaren 
SR) m OA knee. The study had two major objectives : 
1) To examine the relationship between importance and 
severity scores using WOMAC ; 2) To examine whether
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Table 1 ‘ Pain : Mean severity score (standard deviation) with blind and informed administration ; mean importance score (standard deviation); Pearson 
correla tion  coefficient and p -v a lu c  of severity and importance with blind administration
iicm Score-Blind Mean s.d.
Score-Informed 
Mean s.d.
p value 
paired t-lest
Correlalion
Blind/In­
formed
Importance 
Mean s.d.
Correlation-Blind 
r P
p-value
t-test
from
average
V '^alking on a flat surface 
Going up or down stairs 
At night while in bed 
Sitting or lying 
Standing upright_ _ _ _ _ _ _
4135 2731 44.24 30.18 37 .91 77.88 15.24 .23 37 34
52.18 26.67 54.59 28.19 .43 .90 8135 11.78 .05 .85 .00
37.18 27.86 38.94 30.00 34 .97 71.18 21.76 31 .23 .02
3733 29.84 40.94 28.96 .14 .95 71.18 22.92 .17 32 .05
45.06 30.21 47.12 28.14 35 .96 67.77 26.77 .60 .01 38
a simple addition of component item scores into three 
separate subscale scores was justified. In order to ensure 
generalizability of our observations to different modes 
of index presentation, we compared severity scores at 
termination with prior scores both unavailable (blind 
presentation) and available (informed administration).
MATERIALS AND METHODS
Seventeen patients attending the rheumatology out­
patient clinic at Victoria Hospital, London, with definite 
radiographic and clinical evidence of primary OA knee 
were entered as part of a multi-centre double-blind ran­
domized controlled trial comparing Ansaid-SR with 
Voltaren SR. To be eligible patients had to fulfil the fol­
lowing criteria ; Inclusion criteria : symptoms requiring 
NSAID medication, age 5=18 years, symptoms ^ 2  
months, informed consent obtained ; Exclusion criteria : 
Gastrointestinal ulceration or bleeding, NSAID hyper­
sensitivity, significant uncontrolled impairment of major 
organ function, pregnancy or lactation, concomitant use 
of lithium or anticoagulants, clinically significant abnor­
malities in haematology or biochemistry. Following en­
rollment, patients underwent a 3-7 day washout period 
during which only acetaminophen was allowed. Subse­
quently, patients were randomly allocated to receive 
either Ansaid-SR (200 mg po once daily) or Voltaren SR 
(100 mg po once daily) for six weeks. The medications 
were identical in appearance thus maintaining physician 
and patient blinding. Patients were assessed at the end 
of Week 3 and Week 6. In addition to the WOMAC in­
strument, data were collected on several other variables. 
It should be noted, however, the WOMAC Index was 
only applied in our centre and that this report is con­
fined to severity versus importance issues of the WOM­
AC instrument in our 17 patients. Data collected from 
other locations in this multi-centre study, as well as com­
parison of the two drugs for efficacy and tolerability, will 
be reported in a separate publication by the other inves­
tigators. At the end of the study patients completed all 
three subscales of the WOMAC Index rating the severity
of their symptoms on 10 cm horizontal VA scales (ter­
minal descriptors : None, Extreme) first without their 
prior WOMAC scores being available (i.e. blind), and 
again, some five minutes later with their prior scores 
available (i.e. informed) (13). The reliability, face, con­
tent validity, construct validity, and responsiveness of 
each of the 24 questions posed have been previously de­
fined, verified and reported (14,15). After another five 
minutes, patients were shown an alternate form of 
WOMAC, in which they were asked to separately rate 
on 10 cm horizontal VA scales (terminal descriptors: 
None, Extreme) the importance, which they attached to 
being completely symptom free of each of those 24 symp­
toms. From these data, the mean and standard deviation 
for severity and importance scores of each item at study 
termination were calculated. For severity scores, these 
parameters were calculated for both blind and informed 
assessments. To examine the relationship between se­
verity and importance, Pearson correlation matrices 
were constructed for each individual item and the level 
of correlation and statistical significance determined. 
The effect of administering the WOMAC Index under 
blind and informed conditions (i.e., prior score availabil­
ity) was examined by comparing the mean severity scores 
under both types of administration using Student’s 
t-test. The issue of whether a simple addition of com­
ponent items to form subscale totals was examined using 
Student’s t-test, correlation coefficients and factor anal­
ysis techniques. Since the 24 component items of WOM­
AC were considered in each of the three different sta­
tistical analyses, the p value, defining statistical signif­
icance, was corrected downward by a factor of 24 result­
ing in a value of <.002 (7).
RESULTS
The results are summarized in Tables I-III. The mean 
age of the study population was 60.24 years (range = 
52- 65) and the mean disease duration 8.57 years (range 
= 8 months - 20 years). There were 7 male and 10 fe­
male subjects. Their radiographic ratings according to
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Table II : Stiffiiess: Mean severity score (standard deviation) with blind and informed administration ; mean importance score (standard deviation]-
Pearson correlation coefficient and p-value of severity and Unportance with blind administration.
p-value
Item Score-Blind Score-Informed p-value Conelaiicn Importance Correlation-Blind t-test
Mean s.d. Mean s.d. paired t-test Blind/In­
formed
Mean s.d. r P fromaverage
Morning 42.47 30.01 42.65 33.05 .94 .96 66.71 25.01 .41 .11 . 74
Gelling 43.88 28.62 43.94 30.70 .98 .93 66.88 22.20 .43 .09 . 74
the Atlas of Standard Radiographs (19) were as follows : 
Grade 1 = 3, Grade II = 4, Grade III = 6, Grade IV 
= 4. The functional status ratings according to the 
Steinbrocker classification (20) were as follows : Grade 
II = 13, Grade III = 4. Of the seventeen patients, 8 
received Ansaid-SR and 9 received Voltaren SR. The 
range of possible values for severity and importance on 
the VA scales was 0-100 mm.
Blind versus informed administration
For blind administration the range of severity scores 
calculated from the component questions of each di­
mension was as follows : Fain = 37.18 - 52.18 (Table I); 
Stiffness = 42.47 - 43.88 (Table II); Physical Function 
= 34.24 - 60.82 (Table III). For informed administration, 
the range of severity scores was as follows : pain = 38.94 
- 54.59 (Table I); Stiffness = 42.65 - 43.94 (Table II); 
Physical Function = 35.77 - 63.65 (Table III). No sta­
tistically significant differences were noted between the 
severity scores at termination under blind versus in­
formed administration (Tables I - III). The item scores 
for the two forms of administration were highly corre­
lated (Tables I - III). Since there was no difference be­
tween severity scores obtained by blind and informed ad­
ministration, we have reported the importance issue 
only with respect to blind administration.
Importance scores
Mean importance scores for component items were as 
follows; Pain = 67.77-81.35 (Table I), Stiffness = 
66,71-67.88 (Table II), Physical Function = 56.29-76.24 
(Table III). In all but one instance (bending to floor), 
the standard deviation for importance scores was less 
than for the corresponding severity scores.
Severity versus importance scores
We examined the relationship between severity scores 
and importance scores using correlation coefficients.
Table III : Physical Function: Mean severity score (standard deviation) with blind and informed administration; mean importance score (standard 
deviation); Pearson correlation coefficient and p-value of severity and importance with blind administration
p-value
Item Score-Blind Score-Informed p-value Correlation Importance Correlation-Blind t-test
Mean s.d. Mean s.d. paired t-test Blind/In- Mean s.d. r p
fnrmptH avcrflsc
Descending stairs 49.53 28.56 49.29 28.70 .96 .83 71.77 18.36 30 .24 .19
Ascending stairs 51.29 25,39 54.41 25.64 .29 .89 71.24 1733 .20 .43 .18
Rising from sitting 46.77 26.94 50.06 31,16 35 .71 66.29 24.93 21 .39 .21
Standing 43.18 28.31 4629 28.34 .24 ,93 68.82 2735 33 .03 .47
Bending to floor 48.24 30.22 48.41 32.22 .94 .95 59.65 30.75 .64 .01 .25
Walking on flat surface 44.94 28.18 46.35 28.14 .49 .93 76.24 21.93 34 .20 .63
Getting in/out of car 49.12 26.76 48.94 27.15 .94 .93 72.06 18.38 36 .15 .16
Going shopping 48.77 30.33 5335 29.24 .04 .96 68.77 25.84 .15 36 .12
Putting on socks 4177 31.44 42,88 32.68 .94 .98 61.41 30.06 34 .03 .69
Rising from bed 3633 31.18 40.65 32.31 .03 .98 55.29 29.10 .62 .01 .01
Taking off socks 41.41 31.97 41.47 31.35 .98 .96 58.53 ■ 27.69 .49 .05 .49
Lying in bed 34.24 28.31 3833 29,69 .07 .95 6035 20.89 39 .01 .01
Getting in/out of bath 53.12 30.90 53.82 31.60 .71 .97 71.65 2137 .47 .06 .09
Sitting 3539 29.32 35.77 29.08 .94 .94 59.24 2331 .69 .00 .00
Getting on/off toilet 37.65 29.89 4135 30.37 .08 .97 63.65 28.01 39 .13 .03
Heavy domestic duties 60.82 27.91 63.65 28.72 .30 .93 75.47 21.66 ■ .48 .05 .00
Light domestic duties 38.88 29.51 4335 31.72 .11 .94 71.59 2736 .23 .38 .02
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The following guidelines were used to interpret corre­
lation coefficients : poor correlation = 0 < 0.3; mod­
erate correlation 0.3 < 0.6 ; good correlation 0.6 < 0.8 ; 
excellent correlation ^0.8. Seven coefficients were poor, 
13 moderate, 4 good but none were excellent. No sta­
tistically significant correlation was noted between the 
importance and severity scores for any of the 24 WOM­
AC items.
Item -aggregation
Using Student’s t-test no significant difference was de­
tected between the scores of individual items and the av­
erage score for the subscale to which that item belonged, 
except in two instances of physical function (sitting, 
heavy domestic duties) (Tables I - III). The level of in­
teritem correlation for components of each of the three 
subscales was high : pain = 0.79-0.96, stiffness = .83, 
physical function = 0.52-0.98. Most correlation coeffi­
cients were =$0.80. Principal component analysis was not 
performed for stiffness because the subscale contains 
only two items. However, analysis of the pain and phys­
ical function subscales showed that Factor I accounted 
for 88% of the variance in pain and 83% of the variance 
in physical function. The factor loading was high on each 
individual pain item (0.92-0.95) and each individual 
physical function item (0.70-0.97). There was relatively 
little additional variance accounted for by Factor II 
(pain = 7%, physical function = 6%).
DISCUSSION
In this study we have defined the severity and impor­
tance of 24 different symptoms of knee OA using the 
WOMAC Osteoarthritis Index. There is controversy in 
the literature as to whether serial questionnaires should 
be administered with or without access to prior scores 
(21,22). The conservative view prefers blind administra­
tion. Since we detected no difference between severity 
scores obtained by blind versus informed administration 
of the index in this study, we have based our report on 
blind administration. However, we have performed par­
allel analyses using informed scores, obtaining similar 
results and no interpretative differences.
In a previous study using a Likert-scaled version of 
WOMAC, we noted that the importance ascribed to 
symptoms was similar for different items in the same di­
mensions, as well as for symptoms in different dhnen- 
sions. If direct comparison can be drawn between Likert 
and VA scaled responses, then it is of note that the mean 
importance scores on VA scales, in this study, 56.29 - 
81.35 (i.e., 56%-81% along the length of the scale), were
similar to mean importance scores reported 2.26 - 2.69 
(i.e. 57%-66% along the length of the scale) on the
5-point Likert scales (0 = none, 1=  slight, 2 = moderate, 
3 = veiy important, 4 = extremely important) for the 24 
items in our previous study (13). Thus, given that 2 is 
the mid-point of the Likert scale, and 50 the mid point 
of the VA scale, we interpret our data as indicating that 
the majority of patients rate their symptoms somewhere 
between moderate and very important, and that there 
is a relatively narrow range for such values. These data 
support the contention that symptomatic patients regard 
their own particular symptoms of similar importance to 
those of other patients.
We had originally considered the possibility of using 
differences in importance scores as a method of weight­
ing subscale items in the WOMAC Index. From the cor­
relation analysis of severity versus importance, it can be 
seen that these two elements are distinct and require 
separate consideration. From a conceptual standpoint, 
the similarity in importance scores would suggest that 
items could be simply added together. We wish, howev­
er, to explore the statistical justification for such a sys­
tem of weighting and aggregation. The fact that several 
items differed significantly from the subscale average, 
suggests that the items measure different aspects of the 
dimension and that all were relevant in aggregation. 
Likewise, although the factor analysis was only conduct­
ed on 17 subjects, the high percent of variability account­
ed for by Factor I and the very high Factor loading on 
each individual component item, further supports the 
contention that there are no redundant items in the 
WOMAC inventory. The high interitem correlation not­
ed within each subscale and the fact that every single 
item had a high factor loading support the assumption 
that WOMAC subscale scores for pain, stiffness and 
physical function can be derived by the simple process 
of addition. The practical applications of our observa­
tions are as follows : 1) The fact that individual patients 
ascribe moderate levels of importance to each of the 24 
WOMAC symptoms provides adequate justification for 
routinely measuring these symptoms as outcomes in clin­
ical trials provided they fall within the dimensionality of 
the potential response to the inteiwention (i.e. NSAID 
therapy). Other investigators have suggested that the 
measurement process should focus on clinically relevant 
outcomes (23), and, indeed in this, as well as our pre­
vious study (13), we have demonstrated the clinical rel­
evance of the WOMAC question inventory; 2) The dif­
ferent methods of analysis employed suggest that each 
item carries the same weight and that the three subscale 
scores can be derived by the process of simple addition ; 
3) If some dimensions carry consistently greater impor­
tance, then they should also carry more weight in the
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construction of any composite index; 4) Aggregation has 
important implications for sample size requirements for 
clinical trials. For example, without aggregation 24 sta­
tistical tests of independent variables would necessitate 
a reduction in the Type I error from .05 by 24 fold (i.e. 
p <.002). However, aggregation of the WOMAC inven­
tory within each of its three dimensions would necessi­
tate as maximum Type I error correction from .05 by 
only a factor of 3 (i.e. p ^.017). Furthermore, the con­
struction of a composite index, which combined the pain, 
stiffness and physical function subscales into a single val­
ue, would result in only a single statistical comparison 
and obviate the need for any Type I error correction be­
low .05. The standard formula for calculating sample 
size for clinical trials is as follows : n per group = 
2 where a  = standard deviation, and A =
the change the investigator is interested in detecting 
(24). As the value for the Type I error is reduced, the 
value of Za increases and the sample size requirements 
for a proposed trial increase correspondingly.
In this study we have demonstrated that there is no 
difference in termination scores between blind and in­
formed methods of administration of the WOMAC Os­
teoarthritis Index. Although symptomatic patients re­
gard their symptoms of similar importance regardless of
severity, our observations suggest that importance and 
severity are little associated. We have also shown that 
there are no redundant items in the WOMAC Index and 
demonstrated a justification for deriving subscale scores 
by the simple addition of component items. We did not 
address the issue of whether the three separate dimen­
sions can be aggregated into a single total score in this 
study. This issue is the subject of a current study. At 
present we recommend that WOMAC subscale scores 
be constructed by the simple aggregation of items within 
each of the three different dimensions and that any com­
parative analysis treats each dimension as a separate en­
tity. For the definitive studies we recommend setting the 
Type I error at $.017 to make adequate correction for 
multiple comparisons. When the instrument is being 
used for pilot studies, however, we do not recommend 
any correction and prefer to set the Type I error at 
$0.05. We make this differentiation to respect the sci­
entific rigour of a definitive study and to reflect the view 
of Dr. A. Feinstein that the purpose of a fishing expe­
dition is to catch fish.
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SIGNAL M EASUREM ENT STRATEGIES; ARE THEY FEA SIB LE AND 
DO TH EY  O FFER ANY ADVANTAGE IN OUTCOME M EA SU REM EN T 
IN OSTEOARTHRITIS?
N IC H O L A S B E L L A M Y . W . W A T SO N  B U C H A N A N , C H A R L E S H . G O LD SM ITH , J A N E  C A M P B E L L , 
and ERIC D U K U
The applicability of a signal measurement strat­
egy was compared with a traditional method of measur­
ing outcome in osteoarthritis. The signal method de­
tected statistically significant alterations in health status 
with small sample sizes and with a relative efficiency 
close to or at unity. The prevalence of deterioration in 
nonsignal items was low. Signal methods of measure­
ment may provide an alternative approach to outcome 
measurement in osteoarthritis clinical trials.
Signal measurement is a méthodologie tech­
nique in which the measurement of disease is based on 
well-defined, individualized targets. Thus, in arthritis, 
measurement is restricted to only 1, or a few, selected 
joint(s) or symptom(s). This technique has 2 objec­
tives: 1) to tailor the measurement process to the 
symptom profile of the individual patient, and 2) to 
improve the efficiency of the measurement process by 
excluding joints or other items that lack response
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potential. In spite of the possible advantages of signal 
measurement and the success of the technique as 
reported by Dixon et al (1), it is noteworthy that 
neither Ward et al (2) nor Egger et al (3) demonstrated 
any clear superiority of this technique over more 
traditional methods. However, Tugwell et a! (4) re­
cently replicated the success of a signal technique in 
potentially reducing sample size requirements for clin­
ical trials.
Since all of the above-mentioned studies were 
conducted with rheumatoid arthritis patients, the gen­
eralizability of the observations to the measurement of 
disease in osteoarthritis (OA) patients is unknown. For 
this reason, during the validation of a new outcome 
measure for OA clinical trials, designated the W estern 
Ontario and McMaster Universities (WOMAC) Os­
teoarthritis Index (5), we compared the performance 
of a signal method of measurement with that of a 
measure based on aggregated items, in each of 3 
different dimensions. The reliability, validity, and re­
sponsiveness of the WOMAC Index have been docu­
mented (5).
This report presents a further analysis of data 
from that study, comparing signal measurement versus 
aggregate techniques of measurement. Specifically, we 
wished to examine whether there was any advantage 
in using the WOMAC question inventory as a menu for 
identifying signal symptoms for each individual in each 
o f 3 dimensions, compared with administering the 
inventory in its entirety. To address this, we identified 
(a) the nature and severity of symptoms in the 
WOMAC inventory that were selected as signals, (b) 
whether the signal strategy could be successfully ap­
plied in outcome measurement in OA of the hip or 
knee, (c) the relative efficiency of the 2 techniques, (d)
trthritis and Rheumatism, Vol. 33, No. S (May 1990)
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whether deterioration in nonsignal items was over­
looked using the signal strategy, and (e) the sample 
size implications of the 2 techniques.
PATIENTS AND METHODS
Thirty patients with primary OA of the hip or 
knee were interviewed prior to total joint replacement 
surgery and at 6 weeks, 3 months, and 6 months after 
surgery. The criteria used for patient selection, as well 
as the disease and demographic profiles of the study 
group, have been reported previously (5).
At the initial interview, each patient was shown 
the item inventory of the WOMAC Index and asked to 
select 1 item from each of the 3 dimensions that was of 
inlportance to him or her as the focus for further 
measurement during the study. Specifically, patients 
were asked to select 1 pain item, 1 stiffness item, and 
1 physical function item that was most important to 
them, i.e ., that they most hoped the treatment they 
were about to receive would improve. However, in 
order to compare signal and aggregate strategies at 
each of the assessment points, the full WOMAC Index 
was self-administered throughout the study, thus ob­
taining serial measurements on each of the compo­
nents of its 3 dimensions.
The present analysis was confined to a compar­
ison of baseline results versus results at 6 months, 
because these represent the extremes of the response 
for both signal and aggregate strategies. Since we 
wished to com pare the scores of the same individuals 
at these 2 time points using both parametric and
nonparametric statistics for paired data, we restricted 
our analysis to those patients who both completed the
6-month study and completed all WOMAC question­
naires in their entirety. This reduced the available 
sample for analysis to 20 patients for the pain dimen­
sion, 27 for the stiffness dimension, and 24 for the 
physical function dimension. The remaining question­
naires could not be analyzed using paired statistics 
because they were not entirely complete.
All responses in this study were made on 5- 
point Likert scales (0 = none, 1 = mild, 2 =  moderate, 
3 = severe, and 4 = extreme). For pain and stiffness, 
these scales required responses to questions aboi ' 
severity, while for physical function, the questions 
were phrased in terms of degree of difficulty experi­
enced. Aggregate values for each dimension were 
calculated by totaling the scores across all component 
items. Signal values for each dimension were repre­
sented by the score of the individual item selected.
To examine the possibility that patients tended 
to focus on signals pertaining to the aspects of their 
physical condition that were most severely affecter.- 
the relative ranking of the signal measurement among 
other items in the same dimension was determined. 
Values were tied for some items; that is, signal values 
had the same severity score as nonsignal items. Such 
occurrences are indicated in the tables. In instances 
where signal severity scores were lower than scores 
for some nonsignal items, the rank is specified, regard­
less of any lies in higher-ranked items (for ranking 
rules, see Table 1).
Tabic 1. Pain dimension signals"
No. of patients 
selecting item 
as a signal
Signal score 
at baseline
Score at 
baseline
Change from baseline 
to 6 months (P)
/-test
(parametric)
Wilcoxon lest 
(nonparametric)Item ranking"! Meant SD MeantS SD
Individual item 
Pain while walking on a flat surface 5 3, III, HI, Hi. Hi 2.8 1.3 2.1 1.2 <0.001 0.001
Pain while walking up or down stairs 10 Hi, HI. HI, I, Hi 
2, HI. I, I, 1 
HI. HI, HI
2.8 0.8 2.6 0.9 <0.001 <0.001
Pain at night while in bed 3 3.3 0.6 1.9 1.4 <0.001 0.001
Pain while sitting or lying 1 3H 2.0 ND 1.6 1.4 0.002 0.004
Pain while standing upright 1 HI 4.0 ND 2.4 1.0 <0.001 <0.001
Signal (n =  20) NA NA 2.9 0.9 2.9 0.9 <0.001 <0.001
Aggregate (n = 20) NA NA 10.5 4.4 10.5 4.4 <0.001 <0.001
* ND = not determined (due to lack of sufficient numbers); NA = not applicable, 
t  Item rank for each patient who selected item as a signal (possible number of ranks = 5), 
f  Except for the aggregate, possible scores could range from 0 (not affected) to 4 (most severe).
§ Derived by aggregating all scores at baseline for each individual item.
H Tied values. Note; In the case of a tied pair, there is a discontinuity of 1 category in the subsequent ranking. Thus, if there is a lied pair 
third rank, then the 5 ranks are expressed as follows: 1, 2, 3Ü, 5.
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Each of the 3 dimensions of WOMAC was 
analyzed separately using the Wilcoxon matched pairs 
signed rank test and Student’s paired /-test (6). The 
SPSS-X software program was used to calculate the 
test statistics (7). P values less than 0.05 were consid­
ered significant, and no correction was made for 
multiple comparisons. We elected to use both para­
metric and nonparametric techniques, since paramet­
ric techniques may be applicable for certain ordinal- 
level data. However, our data were generally not 
normally distributed, and we believe the use of the 
nonparametric technique provides a more conserva­
tive estimate of statistical significance (6); results of 2 
previous studies using the WOMAC Index support this 
contention (5,8).
Relative efficiency (RE) for the parametric ana­
lysis was calculated using the method reported by 
Liang et al (9), where RE (signal versus aggregate) = 
(Cignai/ a^ggregatc) -^ For the nonparamctric tests, RE (sig­
nal versus aggregate) = (Zsigna/Zaggregate) '^ Nonsignal 
deterioration was determined by comparing presur­
gery and postsurgery scores for each item not identi­
fied as a signal in the full WOMAC inventory and by 
noting the frequency and magnitude of any deteriora­
tion. Sample size requirements, based on matched 
pairs analysis, were calculated for both the .signal and 
aggregate strategies for each dimension, using a para­
metric technique. Calculations were based on the as­
sumptions that P  values less than 0.05 were significant, 
the power of the test was 90%, and the difference to be 
detected could be in either a positive or a negative 
direction, i.e., a 2-tailed test of the null hypothesis. For 
each strategy, the sample size formula used was as 
follows; n matched pairs of observations =  ([Zq 05 + 
Zo.îoH/D)^, where a  = the standard deviation of 
differences and D = the decimal difference (from 
baseline) to be detected (i.e., 0.25 of mean) (6).
RESULTS
Pain. Each of the 5 items included in the pain 
dimension was selected as a signal by 1 or more 
patients (Table I). Measures of pain under conditions 
of Activity were more frequently selected as signals 
than those under conditions of passivity; Pain ob­
served when walking up or down stairs was the most 
frequently selected signal. The mean scores at baseline 
for signal items indicated that patients selected items 
for which the severity was intermediate, and which 
could therefore potentially show response (i.e., could 
either improve or deteriorate). Six of 20 patients (30%)
selected as signals items for which they scored the 
pain as extreme (i.e., a score of 4); none selected 
signals scored as 0. The pain signal was usually ranked 
highest in severity, though it was often tied in severity 
with other nonsignal items.
Using both the signal and the aggregate strate­
gies, there was statistically significant improvement at 
6 months postsurgery versus baseline (F <  0.001), 
irrespective of the type of analysis (i.e., parametric or 
nonparametric). The relative efficiency (signal versus 
aggregate) was 1.00 for nonparametric analysis and 
1.30 for parametric analysis. When individual items 
were analyzed, all 5 pain items detected statistically 
significant improvement in the pain level (F <  0.004). 
Clinical deterioration in those items not selected as 
signals (nonsignal deterioration) occurred on 4 occa­
sions (i.e., 5% of item selections) in 3 patients. The 
magnitude of the deterioration was as follows; mean 
1.00, SD 0, range 0. Sample size requirements were 
lower for the signal strategy (n = 17) than for the 
aggregate strategy (n =  30).
Stiffness, Patients designated both stiffness 
items as signals, with morning stiffness being selected 
slightly more frequently than “ gelling” (Table 2). The 
mean scores at baseline suggested that patients were 
selecting potentially responsive signals. Two of 27 
patients (7%) selected items for which the severity was 
rated as extreme; in both cases, this was the morning 
stiffness item. No patient selected as a signal an item 
for which the severity was scored as 0. The stiffness, 
signal was often ranked highest, except in 2 instances, 
although it was tied in severity with the other nonsig­
nal item.
Use of both the signal and the aggregate strat­
egies enabled detection of statistically significant im­
provement (F <  0.001), regardless of the type of 
analysis. The techniques used were of similar relative 
efficiency (signal versus aggregate) for parametric 
analysis (RE = 1.00); the signal technique was slightly 
less efficient by nonparametric analysis (RE =  0.94). 
When the individual items were analyzed, both stiff­
ness items detected statistically significant improve­
ment (F <  0.001). Clinical deterioration in nonsignal 
items occuiTed in only 2 situations in 2 patients (i.e., 
7% of item selections). The magnitude of the deterio­
ration was as follows: mean 1.00, SD 0, range 0. 
Although the required sample sizes for the 2 strategies 
were quite similar, that for the aggregate strategy (n = 
23) was lower than that for the signal strategy (n = 26).
Physical function. Eleven of the 18 physical 
function items in the WOMAC inventory were se-
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Table 2. Stiffness dimension signals*
N o. o f patients 
selecting item 
as a signal
Signal score Score at 
baseline
Change from baseline 
to 6 months (P)
f-test
(parametric)
W ilcoxon test 
(nonparametric)Item rankingt M eant SD M eant§ SD
Individual item  
Morning stiffness 16 I, 1, I, HI. HI, HI 2.5 1.0 2.4 0.9 <0.001 <0.001
“ Gelling" 11
HI. HI, 1, 1. HI 
1. HI, I. 1, HI 
HI, I. HI, 1, 1, HI 2.1 0.7 2.0 0.8 <0.001 <0.001
Signal (n =  27) NA
HI, HI, HI, 2, 2 
NA 2.3 0.9 2.3 0.9 <0.001 <0.001
Aggregate (n =  27) NA N A 4.4 1.6 4.4 1.6 <0.001 <0.001
* Morning stiffness =  stiffness on first awakening; “ gelling” =  stiffness after sitting, lying, or resting later in the day; N A  =  not applicable, 
t  Item rank for each patient who selected item as a signal (possible number of ranks =  2).
$ Except for the aggregate, possible scores could range from 0 (not affected) to 4 (most severe).
§ Derived by aggregating all scores at baseline for each individual item.
H Tied values. S ec Table 1 for explanation o f ranking rules.
lected as signals (Table 3). Difficulty ascending stairs 
was the most frequently selected signal. The mean 
scores at baseline for signal items suggested that 
patients were selecting items for which there was 
potential response. Six bf-24 patients (25%) selected
items for which the degree of difficulty was rated as 
extreme (i.e., a score of 4); none selected a signal 
scored as 0. Rankings of the physical function signals 
selected varied from first to sixteenth, but they were 
usually ranked first, second, or third in severity.
Table 3. Physical function dimension signals*
Change from baseline
N o. o f patients 
selecting item 
as a signal
Signal score 
at baseline
Score at 
baseline
to 6 months (P)
/-test
(parametric)
W ilcoxon test 
(nonparametric)Item rankingt M eant SD MeantS SD
Individual item  
Descending stairs 2 HI, HI 3.5 0.7 2.7 1.0 <0.001 0.001
A scending stairs 5 2H, 2 1  HI, 6H, HI 3.2 0.8 2.9 1.0 <0.001 <0.001
Rising from sitting 0 NA NA NA 2.8 0.9 <0.001 <0.001
Standing 0 N A NA NA 2.4 1.1 <0.001 <0.001
Bending to floor 2 6H. 5H 2.0 0.0 2.4 1.3 <0.001 <0.001
Walking on flat surface 3 HI, IHI, 16(1 3.3 0.6 2.0 1.1 <0.001 <0.001
Getting in/out o f  car 3 311. 311, HI 2.7 0.6 2.8 1.1 <0.001 0.001
Going shopping 3 7H, HI, HI 2.7 0.6 2.9 0.8 <0.001 <0.001
Putting on socks 1 HI 4.0 ND 2.5 1.4 <0.001 0.001
Rising from bed 1 13H 2.0 ND 2.2 1.2 <0.001 <0.001
Taking off socks 0 N A N A NA 2.0 1.4 <0.001 0.001
Lying in bed 1 811 3.0 ND 1.5 1.3 <0.001 0.002
Getting in/out o f  bath 1 511 2.0 ND 2.8 1.2 <0.001 <0.001
Sitting 0 N A N A N A 1.6 1.1 <0.001 0.001
Getting on/off toilet 0 N A N A NA 2.1 1.3 <0.001 <0.001
H eavy dom estic duties 2 HI, 31 3.5 0.7 3.3 1.2 <0.001 0.002
Light dom estic duties 0 N A N A NA 1.8 1.2 <0.001 <0.001
Getting on/off a bus 0 N A N A N A 2.1 1.7 0.003 0.009
Signal (n =  24) N A N A 3.0 0.8 3.0 0.8 <0.001 <0.001
Aggregate (n =  24) N A N A 42.8 12.8 42.8 12.8 <0.001 <0.001
* N A  =  not applicable; N D  =  not determined (due to lack o f sufficient numbers), 
t  Item rank for each patient who selected item as a signal (possible number o f  ranks =  18). t  Except for the aggregate, possible scores could range from 0 (not affected) to 4 (most difficult). 
§ Derived by aggregating nil scores at baseline for each individual item.
H Tied values. S ee Table 1 for explanation o f ranking rules.
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Both signal and aggregate strategies detected 
statistically significant improvement {P < 0.001), irre­
spective of the type of analysis. The signal strategy 
was slightly more efficient by parametric analysis (RE 
= 1.02) but slightly less efficient by nonparametric 
analysis (RE = 0.96). When individual items were 
analyzed, all physical function items detected statisti­
cally significant improvement, regardless of the type of 
analysis {P s  0.002). Clinical deterioration in nonsig­
nal items occurred on 27 occasions in 7 patients (i.e., 
7% of item selections). The magnitude of the deterio­
ration was as follows; mean 1.56, SD 0.70, range 3. 
The sample size requirements were lower for the 
signal strategy (n = 12) than for the aggregate strategy 
(n = 16).
DISCUSSION
The principal objective of evaluative research is 
to detect clinically important and statistically signifi­
cant alterations in health status. This objective can be 
most readily achieved by the application of highly 
responsive instruments to probe aspects of disease 
that are of defined importance. We have developed 
and reported on such an instrument (5,8), which is of 
potential value in the self-assessment of patients with 
OA of the hip or knee who have had surgical or 
pharmacologic intervention. To further enhance the 
statistical efficiency of the WOMAC Index and more 
closely tailor the measurement process to the unique 
symptom profile of the individual patient, we investi­
gated the relative merits of using a single question 
from each o f the 3 dimensions in the WOMAC inven­
tory (signal technique).
To be considered an ideal alternative, the signal 
strategy would have to satisfy the following require­
ments: 1) Patients would differ in their selection of 
signal items, such that a single fixed item would not 
adequately convey the nature of all patients’ symp­
tomatology. 2) Patients would avoid signal items that 
lack response potential. This would certainly include 
the avoidance of items given a severity score of 0 and 
would likely entail the use of few, if any, items given a 
severity score of 4. 3) The signal strategy would be 
capable of detecting statistically significant {P ^  0.05) 
alterations in health status with conventional sample 
sizes. 4) Relative efficiency would be greater than 
unity for the technique to be judged more efficient than 
the aggregate technique. As a result of increased RE, 
sample size requirements would be lower for the signal 
strategy than for the aggregate strategy. 5) The signal
technique would adequately capture the patients’ 
symptoms, such that deterioration occurring among 
items not selected as signals would not be overlooked.
Of course, an index meeting all of these criteria 
is unusual. However, a signal strategy meeting most of 
these criteria might still provide a useful alternative to 
more traditional forms of measurement. Several com­
mon themes emerge from the present study. The 
selection of the majority of items in the WOMAC 
inventory suggests that different patients place impor­
tance on different symptoms. The use of only a single 
fixed item is, therefore, deemed inappropriate and 
justifies the use of either a signal or aggregate ap­
proach to measurement. Indeed, the patient global 
assessment, which is often recommended and used in 
clinical studies, may itself be the result of a process in 
which the patient selects, weights, and aggregates a 
limited number of symptoms into an overall score (i.e., 
a signal strategy). However, the issue of selection 
cannot be decided merely by adopting a policy of 
selecting the signal by the most severely affected item 
in each WOMAC dimension since, as indicated in 
Tables 1-3, 71% of the first-placed rankings were tied.
It is also important to note that not all items 
selected as signals were ranked first in severity, and 
some of those selected were tied in rank. It is of 
substantial advantage, then, to allow the patient to 
designate which item is most important and will there­
fore be the principal object of observation and therapy 
for that patient. The success of the signal strategy in 
the present study is likely due to the fact that the vast 
majority of patients selected potentially responsive 
items as signals: Very few selected items for which the 
severity was scored as 4, and none selected items 
scored as 0. However, as indicated by the rankings, 
patients tended to select more severely affected items 
as signals. In all 3 dimensions, the signal strategy was 
responsive to change, demonstrating P values <0.002 
in spite of the relatively small sample sizes used (n = 
20-27). It should be noted that such high levels of 
significance may be a reflection of the potency of the 
surgical intervention. However, we. have also ob­
served similar levels of significance in another valida­
tion study of the WOMAC, in the context of a double- 
blind, randomized controlled trial of 2 nonsteroidal 
antiinflammatory drugs (8). We do not regard the 
observed success in this study as being generalizable 
to other subscales containing components that do not 
have strong potential for improvement or deterioration. 
The pain, stiffness, and physical function dimensions of
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WOMAC contain only items that have been evaluated 
and found to have high response potential (5,8).
Relative efficiency is a crude, albeit convenient, 
method of comparing the effect size of different instru­
ments. As such, its value may be affected in different 
studies by the severity of involvement for individual 
items and the frequency with which they are selected 
as signals. The utility of the RE as a measure of 
statistical economy of one instrument over another is 
uncertain and merits further evaluation. Nevertheless, 
the 3 dimensions included in the final WOMAC Index 
showed RE values close to unity, especially when the 
preferred nonparametric comparisons were consid­
ered. It is possible that the greater response of signal 
variables is explained by the effects of regression to 
the mean or a limit effect. We think it is unlikely that 
the response is merely a statistical aberration due to 
repeated random sampling (i.e., regression to the 
mean), since the Index as a whole also reflected the 
benefits of surgery. However, the further elucidation 
of a regression effect would require a randomized, 
“placebo” -controlled study, a design that poses major 
practical and ethical problems in the surgical setting. A 
limit effect is also unlikely, since in many cases, 
patients selected signals that were either tied at rank I 
or of a lower rank. Although many of the signals 
selected were items for which severity was rated as 
extreme, we believe that the fact that not all were 
makes the signal measure different from the simple 
selection of items scored as extreme, even though the 
numbers may not be that different.
With respect to sample size requirements, we 
have demonstrated that the signal strategy may be less 
demanding. With the exception of the stiffness dimen­
sion, sample size requirements were lower with the 
signal strategy than with the aggregate strategy. This, 
however, does not indicate that the signal strategy is 
necessarily the technique of choice. If, indeed, com­
prehensiveness is the key objective, then regardless of 
the slightly larger sample size requirement, the aggre­
gate strategy remains the preferred technique. Indeed, 
investigators are frequently faced with the dilemma of 
selecting between simple and complex measures, each 
having different sample size requirements. The conse­
quence of applying standard measures by signal or 
traditional techniques has been reported for only a 
small number of musculoskeletal indices. We antici­
pate that the present data will allow potential users to 
select the preferred mode of administration for future 
studies using the WOMAC Index. Deterioration in 
items not selected as signals occurred in each of the 3
subscales. However, these deteriorations were infre­
quent (9%) and of a low order of magnitude (mean 
1.47; SD 0.74).
These data indicate that, while the signal strat­
egy does not fulfill all of the ideal criteria mentioned 
above, from a practical standpoint, such a strategy 
may nevertheless provide a useful alternative to aggre­
gate techniques of measurement, at least with respect 
to the WOMAC Index. In particular, it allows (a) a 
broader-based item selection than the use of a single 
fixed item, (b) the detection of statistically significant 
alterations in health status, (c) higher levels of RE tha 
the majority of either the aggregate or individual-item 
approaches to outcome measurement, and (d) reduced 
sample size requirements for studies using WOMAC 
as the principal outcome measure. It is limited by (a) 
the tendency of patients to select more severely af­
fected items and, in some instances, items of extreme 
severity lacking response potential, and (b) its inability 
to detect nonsignal deterioration. The generalizability 
of our observations to future applications of WOMA'^ 
or, indeed, to signal methods of administration oi 
other health status instruments, is, by necessity, lim­
ited. We do, however, agree with Tugwell and col­
leagues (4,10) that the signal technique merits further 
evaluation, since in some circumstances, it may facil­
itate attainment of high levels of statistical significance 
and clinical relevance,
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A Comparative Study of Signal Versus Aggregate Methods of 
Outcome Measurement Based on the WOMAC 
Osteoarthritis Index
SUSAN BARR, NICHOLAS BELLAMY, W. WATSON BUCHANAN, ANDREW CHALMERS, PETER M. FORD 
WALTER R KEAN, GUNNAR R. KRAAG, ERIKA GERECZ-SIMON, and JANE CAMPBELL
ABSTRACT. Objective. To com pare signal versus aggregate m easurement strategies using the V A 3 .0 S  version  
o f  the W estern Ontario and M cM aster U niversities (W O M AC) Osteoarthritis (O A) Index.
Methods. Seventy patients with OA o f  the knee w ere asked to identify a signal item for each o f  
tlie 3 dim ensions o f tire W O M AC OA Index at baseline and termination o f  a 12-w eek, double blind, 
randomized, controlled trial.
Results. The signal metlrod detected statistically significant alterations in healtli status at relatively 
sm all sam ple sizes and witlr a relative effic ien cy  c lo se  to or at unity. In addition to a low  prevalence 
o f  deterioration in nonsignal item s, w e observed  som e inconsistency in signal selection.
Conclusion. Signal methods o f  measurement m ay provide an alternative approach to outcom e m eas­
urement provided issues o f  nonsignal deterioration and the consistency o f  signal selection  can be 
addressed, ( i  Rheumatol 7994,-21:2106-12)
Key Indexing Terms:
CLINIM ETRJCS O STEOA RTH RITIS C LIN IC A L STUDIES
Signal measurement is a metliodologic technique in which 
measurement of disease is based on well defined, individu­
alized targets, e.g., one or a few selected joint(s) or 
symptom(s). This technique has 2 objectives: (1) to tailor 
tlie measurement process to tlie symptom profile of individual 
patients and (2) to improve the efficiency of the measure­
ment process by excluding aspects of disease tliat lack 
response potential. In spite of the possible advantages of sig­
nal measurement, it is notewortliy that neither Ward, et aB 
nor Egger, et aP demonstrated any clear superiority of the 
technique over more traditional methods in patients with 
rheumatoid arthritis (RA). However, Dixon, et aP and 
Tugwell, et aP have reported successful use of signal tech-
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niques in RA clinical trials, altliough Meenan and Pincus^ 
have expressed concern regarding tliis approach to measure­
ment. In the only previous comparative study of signal ver­
sus aggregate methods of outcome measurement in osteo­
arthritis (OA) clinical trials, we observed that the signal 
metlrod was capable of detecting statistically significant alter­
ations in healtli status witli a relative efficiency close to unity 
and attended by a low prevalence of deterioration in nonsig­
nal items^. However, that study was conducted in a group 
of patients undergoing total joint arthroplasty, an interven­
tion attended by relatively large changes and small variance 
(cf, pharmacologic interventional studies).
We have extended our previous work by undertaking a 
comparison of signal versus aggregate measurement 
strategies using tlie VA 3.OS version of tlie Western Ontario 
and McMaster Universities (WOMAC) Osteoartliritis 
Index''-* in the context of a double blind, randomized, con­
trolled trial of tenoxicam (Mobiflex™) and diclofenac 
(Voltaren™). The results of the between drug comparison 
of efficacy and tolerability have been reported in a separate 
publication’. WOMAC is a tri-dimensional, self-adminis­
tered questionnaire probing clinically important, patient rele­
vant outcomes in patients witli OA of the hip and/or knee. 
It is valid, reliable, and of demonstrated responsiveness in 
surgicaP, pharmacologic*-to, and physiotherapy" inteiven- 
tion studies and is capable of detecting a clinically impor­
tant and statistically significant difference between 2 non­
steroidal antiinflammatory drugs (NSAID)". The VA3.0S 
version is the 100 ram visual analog scale (VAS) version of 
the index that utilizes the signal (S) strategy. The 3.0 indi­
cates that this is the original 3-subscale version of the index. 
Similarly the LK3.0 version is the 5-point adjectival Likert
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form of the original 3-subscale version of the index. 
WOMAC VA3.0S is a form of the index in which patients 
not only respond to each of the 24 component items (5 pain, 
2 stiffness, 17 physical function), but also identify at tlie point 
of introduction of a new intervention, one pain, one stiff­
ness, and one physical function item of importance; i.e., they 
hope it will be favorably influenced by the subsequent inter­
vention. The 3 items selected represent the principal focus 
(i.e., signals) of subsequent measurement.
We specifically wished to examine whether there was any 
advantage in using the WOMAC question inventory as a 
means of identifying signal symptoms for each of the 3 
dimensions, compared with administering the inventory in 
its entirety. To address this issue, we identified (a) whether 
the signal strategy could be successfully applied in outcome 
measurement in OA of the knee, (b) the nature and severity 
of symptoms in the WOMAC inventory that were selected 
as signals, (c) the relative efficiency of the 2 techniques, (d) 
tlie sample size implications of the 2 techniques, (e) whether 
deterioration in nonsignal items was overlooked using the 
signal strategy, and (f) whether signal selection was the same 
at the beginning and end of the trial.
MATERIALS AND METHODS
The principal purpose o f  the original double blind randomized controlled 
trial was to compare the efficacy and tolerability o f tenoxicam and 
diclofenac’ . The méthodologie aspects o f the study, including tiie research 
architecture, inclusion and exclusion criteria, outcome measurement tech­
niques employed, and statistical analysis have been reported elsewhere’ . 
For current purposes, only tliose aspects o f the design relevant to the com ­
parison o f  different modes o f  utilization o f the W OM AC index will be 
described.
In brief, 100 consecutive consenting outpatients witli primary OA o f the 
knee, who attended 6 participating rheumatology centers across Canada, 
were entered in the study’  (Tables I and 2), At the screening visit, a his­
tory and examination were performed, and patients selected their worst knee 
as the primary focus o f  measurement for future assessment in the study. 
After NSAID-free washout period o f  3 to 7 days, patients were reassessed 
using a number o f measures including WOMAC VA 3 .OS (Week 0), and 
only diosc who had deteriorated symptomatically (i.e ., whose disease flared) 
were randomized in a double blind manner to receive either tenoxicam (one 
200 mg capsule plus 2 placebo capsules daily) or diclofenac (tlirce 50 mg 
capsules daily). At tiic baseline visit, patients not only completed the full 
WOMAC questionnaire, but also selected tlieir 3 signal items (primary sig­
nals); tills process being repeated at termination (secondaiy signals). The 
exact instructions were as follows: “ Now we would like you to think again 
about each o f the aforementioned symptoms, which you have just rated. 
Then select one pain item, one stiffness item, and one physical function 
item that is most important to you, i.e ., that you most hope the treatment 
you are about to receive will improve,” Patients were subsequently assessed 
at 2, 4, and 12 weeks. To maintain blinding, the capsules employed were 
identical in appearance and were taken 3 times daily with meals. During 
the washout period and tlie subsequent 12-week active treatment phase, rescue 
analgesia with monitored quantities o f acetaminophen was allowed when 
necessary (up to six 325 mg tablets daily). Compliance to analgesic and 
study medications was verified by pill counting.
The current analysis has been restricted to baseline (W eek 0) and termi­
nation (W eek 12) data derived from WOMAC VA 3 .OS and was similar 
to that described®. We have pooled the data from the tenoxicam and 
diclofenac groups since tliere was no statistically significant difference 
between the groups or llieir therapeutic response in tlie original study’ . The
mean baseline and tenuination scores for all primary signal items o f  each 
dimension, as well as for each individual item (i.e ., signal and nonsignal 
scores) were calculated. Aggregate values for each dimension were calcu­
lated as the sum of the response scores (nun) of the component items. For 
each dimension, the termination and baseline data were compared using 
both parametric (Student's paired t test) and nonparametric (W ilcoxon 
matched pairs signed rank test) statistics". The analysis was, therefore, 
restricted to patients who had (a) completed the study, (b) completed base­
line and termination questionnaires in their entirety, and (c) had identified 
signal items at baseline. The test statistics were calculated using the SPSS- 
X software program", and p values <  0 .05  were considered significant. 
Since this was an exploratory analysis, no correction was made for multi­
ple comparisons. Parametric leclmiqucs may be applicable for certain ordinal 
level data; however, our data were generally not normally distributed, and 
therefore, the use o f nonparametric techniques provided a more conserva­
tive estimate o f statistical significance". Since the results o f the nonpara­
metric and parametric analyses o f the change between baseline and termi­
nation were the same, we have reported only the nonparametric results. 
Results o f  studies using the W OM AC Index support this contention but sug­
gest that tliis does not make any important difference in data interpre­
tation’ -®.
The relative ranking of each signal item among other items in the same 
dimension was determined to assess whether patients selected signals per­
taining to those aspects o f their physical condition that were most severely  
affected. Nonsignal deterioration was determined by comparing baseline 
and termination scores for each item not identified as a primary signal in 
the full WOMAC inventory, and by noting the frequency and magnitude 
o f any deterioration®. Deterioration was arbitrarily defined as an increase 
above the baseline score by 10 nun or more. The corresponding signal scores 
were also examined for concurrent deterioration.
Relative efficiency (RE) for the parametric analysis was calculated ac­
cording to the method adopted by Liang, e l o /" , where RE (signal versus 
aggregate) =  (t;igna|/t,gg,gg.,,,.)’ . For tiie nonparametric tests, RE (signal ver­
sus aggregate) =  (2^ signa]‘'^aegregaic) -^ Sample size requirements, based on 
matched pairs analysis, were calculated for both the signal and aggregate 
strategies for each dimension, using a parametric technique®. Calculations 
were based on the assumptions that p values < 0 .0 5  were significant, the 
power o f the test was 90%, and the difference to be detected could be in 
either direction, i.e., a 2-tailed test o f  tlie null hypothesis. For each strategy, 
the sample size formula used was as follows: n matched pairs o f  observa­
tions =  ([Zg 0 5  +  Zq io]n/D)’ , where cr =  the standard deviation o f  differ­
ences and D =  the decimal difference (from baseline) to be detected (i.e .,  
0-25 o f m ean)".
RESULTS
Of the 100 patients entered in the study, 2 were excluded 
because of protocol violations (age >75, abnormal bio­
chemistry results) and another 2 were excluded because of 
allergy to acetylsalicylic acid or acetaminophen. An addi­
tional 26 patients were not included in this analysis because 
they either did not select a primary signal (n = 6), or com­
plete the WOMAC questionnaire in its entirety (n — 6), or 
because they witlidrew from tlie study early (n = 14). Among 
the remaining 70 patients that were included in the present 
analysis, all selected a primary signal, but only 56 selected 
a secondary signal at study termination.
Pain. A statistically significant improvement in pain severity 
(termination versus baseline) was detected using both signal 
(p < 0.001) and aggregate (p < 0.001) measurement strate­
gies. Pain scores improved significantly (p < 0.02) in each 
of the 5 individual items except for “ pain while sitting or
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lying” (p — 0.41). The percentage improvement in mean 
values was 30.5% for the signal and 21.7% for tlie aggregate 
technique. The signal strategy was relatively more efficient 
than the aggregate method based on both parametric (RE = 
2.52) and nonparametric (RE = 1.91) analyses. Estimated 
sample size requirements were lower for the signal strategy 
(n = 25) than for the aggregate strategy (n = 30).
Each of the 5 items of the pain dimension were selected 
as signals by 2 or more patients, both at baseline and at study 
termination (Table 1). Patients were more likely to choose 
signal items probing pain severity during movement (base­
line 71.4%, termination 76.8%) than at rest. The most fre­
quently selected signal at baseline was “ going up or down 
stairs” (47.1%) and at termination “ walking on the flat” 
(42.9%). Primary and secondary signals were ranked as the 
most severely affected item in 43 and 23% of cases, respec­
tively (Table 2). Only 10% of primary signal scores and 
5 .4 % of secondary signal scores exhibited limited response 
potential related to extreme severity (i.e.. >  90 mm on a 
100 mm VAS). None of tlie primary pain signals scored <  
10 mm, while 8 .9 % of secondary signal scores were < 10 
mm.
Stiffness. A statistically significant improvement in stiffness 
(termination versus baseline) was detected using both signal 
(p < 0 .001) and aggregate (p < 0 .001) measurement strate­
gies. Stiffness scores improved significantly (p <0.001) in 
each of the 2 individual items. The percentage improvement 
in mean values was 35.9% for the signal and 31.9% for the 
aggregate teclmique. The signal strategy was relatively more
efficient than the aggregate method based on both paramet­
ric (RE = 1.39) and nonparametric (RE = 1.23) analyses 
Estimated sample size requirements were lower for the sig­
nal strategy (n = 38) tlran for the aggregate strategy (n = 44) 
Morning stiffness was selected as the signal slightly more 
often than “ gelling” at baseline (58.6%) and at termination 
(51.8%) (Table 3). Primary and secondary signals were 
ranked as the most severely affected item in 73 and 82 % of 
cases, respectively (Table 2). Primary and secondary stiff­
ness signals were infrequently graded as being extreme in 
severity (5.7 and 1.8 % scored > 90 mm, respectively). Only 
2.9% of primary stiffness signals and 32.1% of secondary 
signals had scores of <  10 mm.
Physical function. A statistically significant improvement in 
physical function (termination versus baseline) was detect­
ed using both signal (p < 0 .001) and aggregate (p < 0 .001) 
measurement strategies. Scores of individual function items 
decreased significantly (p <0.001) in 14 of the 17 individu­
al items; items 9, 12, and 14 (p = 0.001,0.02, 0.003, respec­
tively). The percentage improvement in mean values was 
32.3 % for tlie signal and 24.9% for tire aggregate technique. 
The signal strategy was relatively more efficient than the ag­
gregate method based on boUr parametric (RE = 1.65) and 
nonparametric (RE =  1.15) analyses. Estimated sample size 
requirements were lower for the signal strategy (n = 28) 
than for the aggregate strategy (n = 40).
Of tire 17 items comprising the function dimension, 14 
were chosen as signals. Walking on the flat was the most 
frequently selected signal both at baseline (22 .9 %) and at
Table 1. Pain dimension signal arui aggregate scores
Number o f  Patients Primary Signal Scores (mm) * W OM AC Score (mm)*
Selecting Item as Signal (n = 70)
Baseline Termination Baseline Termination
Item Primary Secondary
Signal Signal Mean SD Mean SD Mean SD Mean SD
1. Walking on a fiat
surface 17 24 46.0** 19.3 35.6** 24.3 43.1 20.8 35.8 25.1
2. Going up or down
stairs 33 19 59.8 23.8 37 .7 26.6 58.8 23.4 40.9 27.9
3. At night w hile in bed 13 8 62.5 18.3 4 4 .6 30.7 39 .9 27.1 31.9 28.3
4. Sitting or lying 2 2 62.0 8.5 61.5 41.7 33.0 21 .4 30.6 27 .3
5. Standing upright 5 3 63.2 22 .0 46 .6 17.6 47.3 24.7 34.8 25.1
Signal 70 56 57.3 21 .9 39.8 26.4 N /A N /A
Aggregate ( 1 1  =  70) N /A N /A N /A N /A N /A N /A 222.1 93.9 174.0 126.4
* Responses scored on 100 nun VAS. ** n is based on patients selecting as signal at baseline, i.e ., primary signal.
Table 2. Rank ordering of severity o f selected signals at baseline {n ~ 70) and tennination (n — 56)
M ost Severe 2nd M ost Severe 3rd M ost Severe 4th M ost Severe Least Severe
Baseline Termination Baseline Termination Baseline Termination Baseline Termination Baseline Termination
Pain 43* 23 33 34 10 27 10 4 4 12
Stiffness 73 82 N /A N /A N /A N /A N /A N /A 27 18
Physical function 3 2 1 14 10 12 10 4 3 2
* The numbers are the percentage o f  patients ranking item in category.
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Table 3. Süfjhess dimension signal and aggregate scores
Number o f  Patients 
Selecting Item as Signai 
Primary Secondary
Primary Signal Scores (mm)* WOMAC Score (mm)*
Baseline Termination Baseline Termination
Item Signal Signal Mean SD Mean SD Mean SD Mean SD
1. Morning stiffness 41 29 50.5** 24.4 29.4** 24.4 46 .7  26.3 29.8 26.2
2. Gelling 29 27 48 .9 22 .9 35.4 26.2 4 2 .6  23.5 31 .0 25.1
Signal 70 56 49 .8 23.7 31.9 25.1 N /A N /A
Aggregate (n =  70) N/A N /A N /A N /A 89.3 45 .7 60.8 49 .8
* Responses scored on lOO mm VAS. ** n is based on patients selecting item as signal at baseline. i.e ., primary signal.
termination (23.2%) (Table 4). Primary and secondary sig­
nals were ranked as the most severely affected item in 3 and 
2% of cases, respectively (Table 2). Only 10% of primary 
signal scores and 1.8% of secondary signal scores were 
extreme, i.e., > 90 mm. Only 1.4% of primary function 
signals scored < 10 mm, while 10.7 % of secondary signals 
scores were < 10 mm. Few signal scores were extreme, 
i.e., > 90 mm (primary 10.0%; secondary 1.8%) or < 10 
mm (primary 1.4%; secondary 10.7%).
Nonsignal deterioration. Within the pain dimension, the base­
line scores of 68 nonsignal items (24.3%) from 28 patients 
had increased by 10 mm or more at study termination in­
dicating deterioration (Table 5). Among these 28 patients, 
the signal score had also deteriorated in 10 patients (35.7%). 
However the pain signal scores of the remaining 18 patients 
(64.3%) had remained the same (9/18) or improved (9/18). 
The mean increase in score of the 68 items was 26.2 mm 
with a range of 10 to 64 mm.
Nonsignal deterioration occurred in 12 stiffness items 
(17.1 %) and was associated with concurrent signal deterio­
ration in 5 of the 12 patients (41.7%). The remaining signal 
items had either improved (41.7%) or remained unchanged 
(16.6%). On average, tlie 12 nonsignal items had deterio­
rated by 24.4 mm (range 10-41 mm) (Table 5).
Physical function had declined in 145 nonsignal item scores 
(12.9%) of 32 patients (Table 5), Only 5 patients (15.6%) 
indicated concurrent worsening of the signal function item. 
Among the remaining 27 patients (84.4%), the signal had 
remained the same (9/32) or improved (18/32). The aver­
age magnitude of deterioration was 23.9 mm (range 10-75 
mm).
Signal stability. A secondary signal was selected by 56 of 
the 70 patients at study termination. Of these, a new signal 
(i.e. different from baseline) was chosen for the pain, stiff­
ness, and function dimensions by 44.6, 16.1 and 46.4% of 
patients, respectively. The remaining patients chose identi­
Table 4. Physical function dimension signal and aggregate scores
Number o f  Patients 
Selecting Item as Signal 
Primary Secondary
Primary Signal Scores (mm)* 
Baseline Termination
WOM AC Score (rmn)* 
Baseline Tennination
Item Signal Signal Mean** SD Mean** SD Mean SD Mean SD
I . Descending stairs 6 5 63 .0 22.7 35 .0 30.2 52.4 25.5 35.7 2 6 .0
2. Ascending stairs 7 6 61.9 28.3 47.3 31.8 51.0 27.8 38.5 27 .9
3. Rising from sitting 4 4 68.8 18.8 53.0 6.2 47.8 24.7 35.3 25.3
4. Standing 3 3 55.7 38.8 46.3 35.0 45 .2 27.3 31.9 25.1
5. Bending to floor 6 0 67.8 26.5 42.8 33.3 46.6 31.6 35.8 2 8 .6
6. Walking on flat 16 13 46.2 24.3 35.2 28.7 41.2 24 .0 32.6 24.4
7. Getting in/out o f  car 4 3 67 .0 30.8 34.8 27.7 52.4 26.7 37.6 25.2
8. Going shopping
9. Putting on
4 3 60.3 20 .2 37 .0 9 .5 50 .9 27.6 37.8 27.1
socks/stockings 2 2 45.5 7 .8 29.5 16.3 4 0 .6 27.9 32.5 26.7
10. Rising from bed
11. Taking o ff
0 0 N /A N /A N /A N/A 42.3 25.5 30.4 23 .9
socks/stockings 1 1 96 .0 N /A 93.0 N /A 38.9 26.5 29.7 25 .9
12. Lying in bed 2 1 47.5 6 .4 15.0 18.4 31.1 24.8 25.5 25.8
13. Getting in/out o f  bath 3 3 69 .0 29.5 66.7 28.1 47.2 28.3 35.8 27 .6
14. Sitting 0 1 N /A N /A N /A N /A 31.0 20.1 26.9 25 .2
15. Getting on /off toilet 1 4 3 0 .0 N /A 18.0 N /A 40.4 25.5 31.0 24.3
16. Heavy domestic duties 11 7 63.5 16.7 35.8 23.4 61.5 25.9 43.9 29.6
17. Light domestic duties 0 0 N /A N /A N /A N/A 36.5 22.5 27.6 23 .0
Signal 70 56 58 .9 24.0 39.9 27.0 N /A N /A N /A N /A
Aggregate (n =  70) N /A N /A N /A N /A N /A N /A 756.9 369.8 568.3 405 .4
* Responses scored on 100 mm V A S. ** n is based on patients selecting item as signal at baseline, i.e .,  primary signal.
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Table 5. Deterioration o f nonsignal items
Nonsignal Deterioration Signal Item at Termination
Worse Same Belter
N o, Items No. Patients (N o. o f  Patients)
(%) (%) {%) (%)
Pain 68 (24.3) 28 10 (35.7) 9 (32.1) 9 (32.1)
Stiffness 12 (17.1) 12 5 (41.7) 2 (16.6) 5 (41.7)
Physical function 145 (12.9) 32 5 (15.6) 9 (28.1) 18 (56.3)
cal primary and secondary signals; the signal score having 
improved (pain = 58%, stiffness = 66%, function = 50%), 
remained unchanged (pain = 32%, stiffness =23%,  func­
tion = 37%), or worsened (pain = 10%, stiffness = 11%,  
function = 13%).
Among those patients who changed signals, the primary 
signal had improved in the majority of cases (pain = 76%, 
stiffness =78%,  function = 89%), but remained the same 
in 11 to 16% (pain = 16%, stiffness = 11%, function = 
12%), and worsened in 8 to 11% (pain = 8%, stiffness = 
11%, function = 0%). Comparison of the scores of secon­
dary signals at termination versus baseline revealed that most 
of the newly selected signal items had improved (pain =  
60%, stiffness = 33%, function = 77%), although 19 to 
33% (pain = 24%, stiffness = 33%, function = 19%) re­
mained unchanged and 4 to 33% (pain = 16%,  stiffness = 
33%, function = 4%) worsened during the study. Scores 
of the secondary signal were compared with those of the 
primary signal at both baseline and termination. At Week 
0, the secondary signal tended to be the same as (pain = 
56%, stiffness = 56%, function = 62%) or less severely 
affected (pain = 36%, stiffness = 44%, function = 35%) 
than the primary signal item; although 4 to 8% (pain = 8%, 
stiffness = 0%, function = 4%) were more severely affect­
ed. At termination, however, the secondary signal tended 
to be the same as (pain = 76%, stiffness = 78%, function 
= 77%) or more severely affected (pain = 20%, stiffness 
= 22%, function = 19%) than the primary signal selected 
at baseline; although 4% (pain = 4%, stiffness = 0%, func­
tion = 4%) were less severely affected.
DISCUSSION
A fundamental goal of evaluative research is to develop effici­
ent outcome measurement techniques capable of detecting 
clinically important and statistically significant changes in 
the health status of patients exposed to different therapeutic 
interventions. In tlieory, signal methodology restricts the 
measurement process to clinically relevant and potentially 
responsive components of disease* .^ Signals may enhance 
the ability to detect changes in health status by minimizing 
the dilution of response that occurs when uninvolved or 
irreversibly affected items are evaluated. The resulting 
“ noise reduction” effect may offer several advantages, in­
cluding (1) increasing mean change scores and reducing var­
iance, (2) increasing the efficiency of outcome measurement.
and (3) reducing sample size requirements. However, 3 main 
concerns have been raised regarding signal techniques: (1) 
patients may select more severely affected (and potentially 
less responsive) items as signals; (2) signal techniques may 
overlook important information by failing to detect changes 
in the status of nonsignal items; and (3) it is not known how 
reliable or stable signal selections are over time.
The WOMAC Index is a responsive health status instru­
ment for the evaluation of patients with OA of the knee or 
hip. In a report on patients undergoing total joint arthro­
plasty^, we investigated whether tliere was any advantage in 
using the WOMAC question inventory for identifying sig­
nal symptoms in each of the 3 dimensions (signal technique), 
compared with administering the inventory in its entirety 
(aggregate technique)'*. In our present study, we have per­
formed a similar comparison to determine whether the sig­
nal strategy could be successfully applied in outcome meas­
urement in patients with knee OA undergoing a pharmaco­
logic intervention and have attempted to explore further the 
proposed advantages and disadvantages of signal methodol­
ogy described above.
The signal strategy was applied successfully in our study. 
As reported':, both the signal and aggregate techniques de­
tected a statistically significant improvement in pain, stiff­
ness, and function compared with pretreatment status. This 
difference was apparent even when the more conservative 
nonparametric statistics were used. The 2 NSAID were found 
to be similar in efficacy as reported in a separate publica­
tion®. The estimated percent improvement of the mean 
scores was greater for the signal technique than the aggregate 
in the pain, function, and stiffness dimensions, although the 
difference in the latter was rather small. This difference may 
result from bias in the signal measurement due to tlie patient’s 
hope for, or focus on, a particular outcome. Patients will 
tend to identify those items as primary signals where they 
are highly impaired and expect to gain the most improve­
ment. Naturally there will be more room for improvement, 
although this does not necessarily mean that these items are 
the most responsive. We would expect, as shown in this 
study, that signal methods have a higher percentage improve­
ment score than aggregate techniques.
The relative efficiency statistic is one method of compar­
ing tlie responsiveness of different measurement instruments; 
however, its utility remains to be fully evaluated. An RE 
value of 1.0 suggests equal efficiency of the instruments being
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compared; however, there are no standards for defining the 
significance of values < l.Oor > 1.0. For example, an RE 
value of 2.0 does not indicate that the numerator index is 
necessarily “ twice” as efficient as the denominator index. 
Nevertheless, if the RE is > 1.0, the instrument in the 
numerator can be inferred to be the more responsive out­
come measure requiring smaller sample sizes and/or capable 
of detecting smaller effect sizes than the instrument in the 
denominator. In the current analysis, tlie signal strategy was 
more responsive than the aggregate in all 3 symptom dimen­
sions, with RE values ranging from 1.39 to 2.52 by para­
metric analysis and 1.15 to 1.91 by nonparametric analysis. 
Accordingly, the sample size requirements for the signal 
strategy were lower. The results of our previous compari­
son of signal versus aggregate techniques in patients under­
going total joint arthroplasty were similar, although the RE 
values reported here are higher. Sample size requirements 
in the surgical setting were lower, likely as a result of the 
greater potency, and, therefore, magnitude of response to 
this intervention.
Responsiveness is of paramount importance for evaluative 
measures’^  The WOMAC Index contains 24 items that 
have been formerly evaluated and found to have high 
response potentiaF ». It seems likely that signal and global 
strategies compare favorably with respect to responsiveness 
only in those situations where patients select potentially 
responsive signal items from the men#. Our patients tend­
ed to select signal items that were ranked as relatively more 
severe compared witli the scores of the remaining items at 
baseline, tlie rankings being based on absolute scores in mm. 
Although other nonsignal items had scores similar in severity 
to those of signal items (e.g., within 5 or 10 mm), we felt 
that combining scores into artificial rank groupings based 
on an arbitrary cutoff (e.g. , ± 1 0  mm) might result in a loss 
of information. Despite a high severity ranking, signal items 
were evidently responsive as shown by their ability to detect 
statistically significant improvements in health status with 
pharmacologic therapy. Veiy few of the primary signals 
lacked the potential to detect deterioration because of extreme 
severity ( > 9 0  mm) or improvement because of relative 
noninvolvement (<  10 mm).
To assess nonsignal deterioration over time, we arbitrarily 
defined deterioration a priori as an increase in nonsignal item 
scores by > 1 0  mm at termination versus baseline. Although 
it is recognized that tliis definition is arbitrary, a 10 mm incre­
ment in score represents a 22.5% deterioration of the mean 
baseline score (45 mm) of all items in each dimension. This 
appears to-be a reasonable definition since, as a rule, changes 
of 20 to 25% are generally considered to be clinically 
important'®, and therefore, the importance of nonsignal 
deterioration would not be greatly over or underestimated. 
Using this definition, an average of 18.1 % of all nonsignal 
items had deteriorated with an average increase in score of 
25 mm (range 10-75). In many cases there was no concur­
rent deterioration of the signal items, i.e., important infor­
mation might have been overlooked if the signal technique 
had been used alone. Altliough the importance of this degree 
of nonsignal deterioration is not known, its occurrence is a 
concern. Furthermore, if comprehensiveness (construct 
validity) is a priority, tlien an aggregate strategy must be 
used. In fact, WOMAC VA3.0S (and LK3.0S) represents 
a hybrid approach that provides a priority based signal score 
in addition to the more comprehensive aggregate health sta­
tus score and maximizes the strengths of both techniques, 
an approach that has been suggested by Meenan and 
Pincus®.
With regard to signal stability, it is interesting that many 
patients changed their signal selections at study termination. 
Our study was not designed to address the reason(s) why 
patients changed signal selection. However, it is clear that 
heal til status changed during the study, and trends in tlie data 
suggest tliat patients may have selected secondary signal items 
that had not improved during the course of therapy and had 
become subjectively more important. Wliile it is not surpris­
ing tliat signal selection varies as functional status changes, 
it is not clear whether signal selection would remain stable 
over time if function did not actually change.
In conclusion signal method of measurement may provide 
an alternative approach to outcome measurement provided 
issues of nonsignal deterioration and tire consistency of sig­
nal selection can be addressed. We are concerned regarding 
dependency of the measurement process entirely on signal 
methodology. Although the potential for reducing sample size 
requirements is encouraging, we agree witlr Meenan and 
Pincus® that the relative strengths of comprehensive versus 
prioritized assessments require considerable additional study. 
This could be accomplished by studying more diverse patient 
groups and other prioritization procedures. At the present 
time, for evaluative purposes, we only recommend use of 
the full WOMAC LK3.0 or VA3.0 osteoartliritis indices.
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LETTER TO THE EDITOR 
A study of the time frame dependency of responses to the WOMAC 
Osteoarthritis Index
The last few years have seen the development of a number of fully validated 
high-performance health status instruments relevant to outcome assessment in 
musculoskeletal clinical trials of surgical, pharmacological and physiotherapeutic 
interventions. The measures, relevant to total joint arthroplasty, were reviewed in two 
previous publications [1,2]. It is of note that some of these measures assess symptoms 
over specific periods of time (time frames) while others do not specify the interval. 
For example, the Health Assessment Questionnaire (HAQ) [3] probes health status 
over the previous week, while the Arthritis Impact Measurement Scales (AIMS) [4] 
require consideration of symptoms in the previous one month. In a review of 
functional status measures. Bombardier and TugweU [5] have drawn attention to the 
importance of the appropriateness of the time frame for measuring the response to an 
intervention. Our experience with the WOMAC Osteoarthritis Index, in a number of 
different studies [6-10], has indicated that the time frame over which patients are 
asked to consider their symptoms often needs to be adjusted to respect varying 
induction-response dynamics of different interventions. We are aware from our 
previous work asking patients about their symptoms at precisely defined points in 
time (i.e. real time) and then applying sophisticated analytic techniques, that it is 
possible to detect circadian variation in the symptoms of osteoarthritis [11]. 
Furthermore, there is general concern that altering the wording of a questionnaire 
may alter its performance characteristics. Given the aforementioned time dependency 
of symptoms and the necessity to justify any changes in questionnaire wording, we 
have performed a preliminary evaluation of the effects of altering the time frame over 
which symptoms are rated on WOMAC subscale scores. Nineteen patients with 
primary knee osteoarthritis, who were enrolled in a 6-week, double-bhnd, randomized 
controlled trial of Meclomen versus Voltaren, participated in this study. The results of 
the betwecn-drug comparison have been reported elsewhere [12]. The patients 
considered in this analysis were not subject to any alterations in pharmacological 
intervention in the last 2 weeks of this 6-week study and could be considered in steady 
state. There were 8 males and 11 females of mean age 57.2 years (range 43-65 years) 
and meem disease duration 5.9 years (range 2 months to 20 years). At the final 
assessment each patient was asked to complete, in random order, three versions of 
WOMAC differing only in the time frame over which patients were asked to consider 
their symptoms. The three time frames were: previous 24 hours, previous 48 hours, 
and previous 2 weeks. A break of several minutes was taken between presentation of 
each questionnaire, the patient being blind to responses given on any preceeding 
completed questionnaires. Data were analysed using analysis of variance techniques, 
examining, in particular, the effects of time and order. Sine the data were collected by 
two different centres (Hamilton and London), they were examined for any centre 
effect. In fact, no order effects or centre effects were noted. No statistically signiTicant
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or clinically important time-dependent differences were noted in scores on the pain, 
stiffness or physical function subscales of the WOMAC Osteoarthritis Index (Table 
1)-
TABLE 1
Descriptive statistics by levels of time*
WOMAC subscalc Previous 24 h Previous 48 h 2 weeks before
X SD X SD X SD
Pain 158.11 151.61 163.90 152.07 168.26 137.90
Stiffcss 66.05 62.59 67.00 62.47 70.11 55.23
Physical function 566.21 494.47 554.78 494.88 573.16 450.07
*X = mean, SD = standard deviation
Although limited by the relatively small number of patients, we have observed no 
time dependency of questionnaire responses over the 14-day period. Given the 
dynamic nature of musculoskeletal symptomatology, it might be anticipated that the 
longer the interval, the more likely time might be a factor. If the interval is very short, 
one may detect symptom anomalies peculiar to a particular day, i.e. a good day or a 
bad day. If the interval is too long, patients may fail to recall adequately their 
symptoms. It seems likely, in this study, that patients are capable of averaging their 
symptoms over a specified time frame, and that, in doing do, any circadian or 
between-day effects arc smoothed out.
From the aforementioned data we feel justified in varying the time frame over 
which questions are asked (at least between 1 and 14 days) when using the WOMAC 
Osteoarthritis Index, depending on the dynamic requirements of the study. We are 
unaware of any similar data having been published on any other musculoskeletal 
health status instrument.
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ABSTRACT
Griffiths G, Bellamy N, Bailey WH, Bailey SI, McLaren AC, Campbell J. A  comparative study of the 
relative efficiency of the WOMAC, AIMS and HAQ instruments in evaluating the outcome of total Joiec 
arthroplasty. Inflammopharmacology. 1995:3:1-6.
The relative efficiency of the WOMAC, AIMS, and HAQ instruments was compared in 21 patients 
with osteoarthritis who received total knee replacement surgery. Assessments of pain and physical 
function were made prc-operatively and 6 months post-opcrativcly and the relative efficiency of the 
three instruments in detecting change was determined. Overall, the WOMAC Osteoarthritis Index 
was greater in relative efficiency than the HAQ and AIMS instruments, particularly in the detection 
of change in functional status. We conclude that the WOMAC Index can be used as an alternative to 
the HAQ or AIMS instruments in outcome assessment in osteoarthritis clinical trials.
Ktywords: arthroplasty, health measures, osteoarthritis, relative efficiency
INTRODUCTION
Total joint arthroplasty of the hip and knee is one of the most important orthopaedic 
surgical advances of recent decades. As a consequence, evaluation of the results 
obtained using total joint arthroplasty is of extreme importance. The methods used 
have been recently rewewed [1,2] and show considerable variability. In addition to the 
so-called ‘orthopaedic indices’, there have emerged several ‘rheumatologic indices’, 
which may be suitable for evaluating the outcome of total joint arthroplasty [3]. 
Indeed, Liang et al. compared four such indices [Health Assessment Questionnaire 
(HAQ), Arthritis Impact Measurement Scale (AIMS), Index of Well Being (IWB) 
and Functional Status Index (FSI)j with respect to their relative statistical efficiency in 
patients undergoing total joint arthroplasty [4]. We have previously compared the 
relative efficiency of our own index (WOMAC) and the Lequesne Algofunctional 
Index and found them similar in relative efficiency [5]. WOMAC (Western Ontario 
McMaster Universities Osteoarthritis Index) is a 24-item self-administered 
questionnaire which separately probes the three dimensions of pain, stiffness and 
physical function. The rehabüity, validity, and responsiveness of both the visual 
analogue-scaled (VA3.0) and Likert-scaled (LK3.0) versions have been evaluated [5,6]
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as have issues of parametric versus non-parametric analysis [5,6], prior score 
availabihty [7], weighting and aggregation [8], time frame dependency [9] and the 
responsiveness of WOMAC in surgical [5], pharmacologic [6,10,11] and physiotherapy 
[12] interventions. The favourable experience with WOMAC has prompted us to 
compare the relative efficiency of the WOMAC, HAQ [13], and AIMS [14] 
instruments in osteoarthritis patients undergoing total joint arthroplasty using the 
method described by Liang et al. [4].
METHODS
Twenty-six consenting patients with primary osteoarthritis (OA) scheduled for total 
knee arthroplasty at Victoria Hospital, London, Ontario, were chosen for study. 
Patients who had undergone prior total knee replacement surgery were excluded, as 
were patients with visual or hearing impahments, and those who could not read or 
understand English. The day prior to surgery one of the investigators (GO) personally 
interviewed each patient to collect the following pre-operative, baseline data: age, 
gender, disease duration, AIIA functional class, joint geometry measures, radio- 
graphic grading (Kellgren and Lawrence method [15]), and Hospital for Special 
Surgery (HSS) Knee Rating Scale [16].
In addition, three health status instruments were completed pre-operatively (day 
prior to surgery), and 6 months post-operatively: the AIMS, HAQ and WOMAC 
(VA3.0). The AIMS is a multidimensional instrument probing physical, social and 
emotional well-being. Although the index has nine components, only the mobihty, 
physical activity, dexterity, household activity, activities of daily liviug, and pain 
subscales were analysed; however, data were collected, but not reported, on the 
remaiuing 3 scales (social activity, depression, anxiety). The HAQ disability index 
assesses the patient’s functional ability over the past week. For each of 8 categories 
(dressing and grooming, arising, eating, walking, hygiene, reach, grip and activities), 
the. patient indicates the amount of difficulty experienced over the last week. The use 
of devices and/or help from another person is factored into the index. A  15-cm visual 
analogue scale is used to measure arthritis pain. The WOMAC OA Index (VA3.0) 
was administered with a one-week time frame, responses being made on 100 mm 
visual analogue scales. The 3 health status instruments were administered in random 
order to each patient pre-operatively and again by mail 6 months later. We had 
originally planned to obtain corresponding data on the HSS. However, while all 
patients agreed to be assessed prior to surgery, most were from outlying areas and did 
not wish to return to London for the 6-month post-operative clinical assessments.
Data analysis was performed using the SAS package of statistical programmes. 
Means and standard deviations were computed for pre-operative scores and 6-month 
post-operative scores. Relative efficiency (RE) was calculated using the method 
described by Liang et al. [4], e.g. RE for WOMAC verus HAQ = (VoMAc/'^HAQ^^* 
An R E > 1 means that the WOMAC is more efficient than the HAQ; while R E < 1 
means that the WOMAC is less efficient than the HAQ.
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RESULTS
Of the 26 consenting surgical candidates originally screened for this study, follow-up 
data were not obtained on 5 patients who failed to return their 6-month 
post-operative questionnaires. The demographic profile of the 21 patients analysed is 
indicated in Table 1. The mean age and disease duration were 65.1 years and 9.5 
years, respectively. Most patients were female. The mean HSS score was 61. Most 
patients were of Radiographic Grade II or III, and ARA Functional Class II or III. 
No Radiographic Grade I or Functional Class I or IV patients were included m the 
study.
TABLE 1
Characteristics of patients (n =21)
Mean SD
Age (years) 65.1 8.4
Disease duration (years) 9.5 8.0
Flexion (degrees) 106.5 21.4
Extension (degrees) 5.2 6.3
Varus (degrees) 4.3 4.3
Valgus (degrees) 1.5 2.6
Hospital for Special Surgery Score 61.0 11.5
Gender (male:female) 7:14
X-ray grading I n=0
II n=7
III /I = 12
IV n =2
ARA Functional Class II n = 16
III n=5
Mean and standard deviation values for pre-operative and 6-month post-operative 
assessments on the AIMS, HAQ and WOMAC instruments are illustrated in Table 2. 
Mean scores for pain and function declined following surgery on all 3 instruments, aU 
changes being statistically significant (p <0.001 to 0.004, Table 2).
The RE of the WOMAC versus the AIMS and HAQ instruments was based on t 
values obtained by Student’s paired t-test using pre-operative and 6-month 
post-operative scores for pain and function. The RE of WOMAC versus AIMS was as 
follows: pain = 0.81, physical function = 1.75. The relative efficiency of WOMAC 
versus HAQ was as follows: pain = 1.59, physical function = 1.13.
Griffiths et al.
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DISCUSSION AND CONCLUSIONS
The decision of which instrument to use in outcome measurement is based on a 
number of criteria, particularly validity, reliability and responsiveness. The clinimetric 
properties of the WOMAC, HAQ and AIMS instruments have been well established 
and meet acceptable standards [3]. Given that all tlnee are liigh performance 
instruments, they are differentiated mainly by conceptual and statistical issues. The 
HAQ and AIMS instruments were principally developed for RA patients, although 
they have subsequently been validated in OA and mixed arthritis populations. In 
contrast, the WOMAC is a purpose-built instrument based on comprehensive 
interviews of 100 OA hip and knee patients. The HAQ probes many upper extremity 
functions that are not relevant when assessing the symptomatology of patients with 
OA of the hip and knee. In contrast the AIMS is a more comprehensive measure of 
health status in arthritis patients but probes aspects of social and emotional 
functioning in addition to pain and physical disabihty. In contrast, WOMAC focuses 
exclusively on the discomfort and disability associated with OA of the hip and knee. 
Furthermore, the WOMAC is a shorter instrument requhing responses to only 22 
pain and physical function questions (cf HAQ = 44, AIMS = 29). There are, 
therefore, conceptual reasons to prefer the WOMAC instrument in situations when 
the goal is specifically to assess change in pain and physical disability due to OA of the 
liip and/or knee. Despite such advantages, a purpose-built instrument might be less 
desirable if the statistical efficiency with which it detected change was less than that of 
competing alternatives. The relative efficiency statistic is one method of comparing 
instruments. In this study, the WOMAC pain scale was slightly less efficient than that 
of the AIMS but more efficient than that of the HAQ. However, the WOMAC 
physical function scale was more efficient than that of the AIMS, and slightly more 
efficient than that of the HAQ. Given that RE values of WOMAC were > 1 in 3 out of 
4 comparisons, we conclude that overall the WOMAC is more efficient. Thus, for 
conceptual and statistical reasons the WOMAC offers some advantage over 
competing alternatives.
This study involved a spectrum of patients varying in age, gender, disease duration, 
Functional Class and Radiographic Grade. Total joint arthroplasty is a potent 
intervention in which changes are relatively large and the variance relatively small 
even in such diverse patients. This explains why very small p  values were obtained 
despite a sample size of only 21 patients. However, as Liang et al. have noted T he 
issue (sic, relative efficiency) is critical in situations where the expected changes are 
smaller than those seen in joint replacement, settings that include medical (sic, 
pharmacologic) and rehabilitative management of arthritis’. To date there are no 
international standards of measurement for OA clinical trials of anti-rheumatic drugs. 
Indeed, current Food and Drug Administration [17] and European League Against 
Rheumatism [18] guidelines for NSAID studies are not in complete agreement. At the 
Fifth Joint World Health Organization/International League Against Rheumatism 
Task Force Meeting on Rheumatic Diseases in Geneva, a proposal for 
standardization made at the First Osteoarthritis Research Society (OARS) Congress 
was discussed. The WOMAC index has been proposed as a potentially suitable 
outcome measure to assess pain and function in trials of slow-acting drugs in OA [19]. 
To date we have received requests from 89 investigators in 14 different countries for 
permission to use the WOMAC index in their studies. Given its widespread use, the
Griffiths et al.
results of this study support the contention that in the assessment of pain and physical 
disability in OA hip and knee studies, the WOMAC index offers some conceptual and 
statistical advantages over alternative instrmnents.
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Comparison of the Responsiveness and 
Relative Effect Size of the Western Ontario 
and McMaster Universities Osteoarthritis 
Index and the Short-Form Medical 
Outcomes Study Survey in a Randomized, 
Clinical Trial of Osteoarthritis Patients
Glenn M. Davies, Douglas J. Watson, and Nicholas Bellamy
Objective, This study compares the responsive­
ness and relative effect sizes o f the Western Ontario 
and McMaster Universities Osteoarthritis Index 
(WOMAC) with the Medical Outcomes Study Short 
Form Health Survey (SF-36) in a randomized clinical 
trial for treatment of osteoarthritis (OA).
Methods. Patients with OA o f the knee or hip were 
randomized to receive either placebo or 2,400 mg/ 
day o f ibuprofen for 28 days. Patients completed the 
WOMAC and SF-36 at baseline and days 7, 14, and 
28 of the trial.
Results. Patients receiving ibuprofen showed sig- 
nificant improvement in WOMAC pain, physical 
functioning, and the total score, while improvement 
was detected only for bodily pain on the SF-36. The 
WOMAC detected significant differences between 
ibuprofen and placebo for pain and physical func­
tioning, whereas the SF-36 detected differences for 
the bodily pain subscale.
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Conclusion. These results suggest the WOMAC 
has greater power to detect treatment differences 
than the SF-36, with respect to pain and physical 
functioning, in OA clinical trials.
Key words, Osteoarthritis; Western Ontario and 
McMaster Universities Osteoarthritis Index; Medi­
cal Outcomes Study Short Form Health Survey; 
Responsiveness; Relative effect size.
INTRODUCTION
Therapeutic drug trials for osteoarthritis (OA) typ­
ically involve a num ber of efficacy m easures, includ­
ing both investigator and patien t assessm ents of dis­
ease status, disease activity, and response to therapy. 
Usually, patient self-assessments w ill include m ea­
sures of pain  and stiffness in  affected joint(s), and 
physical function or disability. These m easures m ust 
be valid, reliable, and responsive to clinically  m ean­
ingful change in  order to differentiate betw een treat­
m ents (1). Several m easures originally developed for 
rheum atoid arthritis have been adapted for use in  
clinical studies of OA, These include the Arthritis 
Im pact M easurem ent Scales (1), the H ealth  Assess­
m ent Questionnaire (HAQ) (2), and  the Doyle Index 
(3). OA-specific m easures include the W estern On­
tario and McMaster Universities O steoarthritis Index 
(WOMAC) (4) and the Lequesne Index (5). The HAQ
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has been show n to be as sensitive as observer-based 
m easures in  clinical trials for OA (6) and was able to 
differentiate OA patients from individuals w itli 
other rheum atic diseases (7).
A n a lte rn a tiv e  to disease-specific m easures are 
generic in stru m en ts . T he M edical O utcom es S tudy  
36-item  S hort Form  H ealth  Survey (SF-36) is one 
such  general h ea lth  status in strum en t; it  includes 
bod ily  p a in  and physical func tion  scales as w ell as 
scales th a t evaluate social, m ental, and  em otional 
constructs. This in stru m en t has been used  in  con­
ju n c tio n  w ith  th e  WOMAC to evaluate the health  
status of patien ts  after to tal knee rep lacem ent 
(8,9).
A n in s tru m en t th a t efficiently  detects response 
to effective therapy  can significantly  reduce the 
num ber of p a tien ts  necessary  to detect m eaningful 
trea tm en t differences and allow  better clin ical de­
cisions w ith  respect to efficacy. This s tudy  com ­
pares the responsiveness and re la tive effect size of 
the  WOMAC w ith  that of the SF-36 in  a random ­
ized , con tro lled  tria l of 2,400 m g/day  of ibuprofen  
versus p lacebo  in  p a tien ts  w ith  OA of th e  h ip  or 
knee. Specifically , scores on the WOMAC p a in  and 
physical func tion  scales are com pared  w ith  those 
of the  SF-36 bod ily  pain  and physical function 
scales.
PATIENTS AND METHODS
The trial was a m ulticenter, double-blind, parallel 
group clinical trial of patients w ith Am erican Col­
lege of Rheumatology (ACR; formerly the Am erican 
Rheum atism  Association) functional class I-III OA 
of the hip or knee for greater than  6 m onths (10,11). 
Classification of functional status was based on the 
revised criteria of the ACR. Subjects were required to 
have a well-established diagnosis of OA of the hip or 
knee, m anifested by pain  in  the affected joint on 
m otion or w eight bearing for the m ajority of days 
during the m onth  prior to study entry. Radiographs 
were not required  as part of the diagnosis of OA. The 
diagnoses were made by prim ary care physicians 
from 20 different clinics across the continental 
U nited States.
Patients currently  taking nonsteroidal anti-inflam ­
m atory drugs (NSAIDs) for pain  relief were only 
entered into the study if they were taking short- 
acting form ulations. Patients were excluded if they 
were m entally  or legally incapacitated, had a history 
of a serious adverse event related to NSAID use, had 
a history of gastric or duodenal ulcer, or showed 
evidence of gastrointestinal (GI) bleeding on stool 
hem occult. Patients w ith  gastroesophageal reflux
disease; disease of the esophagus, stom ach, liver, 
gallbladder, pancreas, or small or large bowel; or 
other illness that, in  the opinion of the investigators, 
m ight pose an additional risk to the pa tien t or con­
found assessment of GI sym ptoms related to the use 
of the test treatm ent were excluded. Patients were 
also excluded if they  were taking m ethotrexate or 
oral or systemic corticosteroids.
Following an initial 4-day placebo run-in  period to 
assess adherence, subjects who m et the inclusion/ 
exclusion criteria were random ized 1:1 to receive 
either placebo or 800 mg of ibuprofen 3 times daily 
(2,400 mg/day) for 4 weeks. Both treatm ent groups 
were allowed to take 650 mg of open-label acetam in­
ophen 4 times daily as needed for pain  during the 
run-in and the 4-week treatment. Patients self-ad- 
m inistered the 48-hour visual analog scale (VAS) 
version 3.0 of the WOMAC, the l-w eek  (acute) ver­
sion of the SF-36, and  a global satisfaction w ith 
m edication question at baseline and days 7, 14, 17, 
and 28. Standard patien t and laboratory exams and 
safety assessments were conducted at baseline and 
during treatm ent, and m onitoring for adverse expe­
riences was done at each visit. Use of concom itant 
m edications, including acetam inophen, was recor­
ded during tlie course of the trial. Patients were 
discontinued from the study for lack of efficacy, side 
effects/toxicity, or other reasons. Patients gave in ­
formed consent before participating in  the study, 
and the protocol was approved by an institu tional 
review board.
Baseline dem ographic statistics w ere com puted  
overall and by trea tm en t group for age, race, sex, 
ACR functional class, cu rren t NSAID use, dura tion  
of arthritis , and location  of OA. M ean, s tandard  
deviation, m in im um , m axim um , and  m ed ian  were 
com puted for con tinuous variables, and  counts 
and percentages w ere com puted  for categoric vari­
ables.
All scales of the WOMAC (12), the SF-36 (13), and 
global satisfaction were scored on a 0 -1 0 0  scale. In 
addition to the WOMAC scale scores, a WOMAC 
total score based on im portance-w eighting was also 
com puted (12). WOMAC scale scores and the global 
satisfaction score were then  reverse-scored by taking 
100 m inus the original score. In add ition  to the 8 
SF-36 scale scores, tw o com ponent sum m ary scores, 
the physical com ponent sum m ary and the m ental 
com ponent sum m ary, were com puted (14). Higher 
scores indicate a better response to treatm ent on all 
measures. Detailed scoring inform ation for tbe 
WOMAC (12) and the SF-36 (13) have been pub­
lished previously.
Day 14 scores for all 8 scales and the com ponent 
sum m ary scores of the SF-36 were correlated, using
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Spearm an rank correlation coefficients, w ith the 3 
WOMAC scale scores and the total WOMAC score to 
assess congruent validity  (15). Day 14 change scores 
for the two instrum ents, and for the global satisfac­
tion w ith m edication question, were also correlated 
using the same m ethod to assess longitudinal con­
gruent validity  (15).
Analysis of variance (ANOVA) m ethods were used 
to evaluate the w ithin-treatm ent differences (respon­
siveness) and tlie betw een-treatm ent differences (rel­
ative effect size) of the SF-36, WOMAC, and global 
satisfaction. Change scores were com puted for days 
7, 14, and 28 for each of the scale scores as well as 
the com ponent sum m ary and total scores. M ean 
change scores adjusted for center effects were com ­
puted  for each treatm ent group using SAS PROC 
CLM (16). One-sam ple Mests were used to assess 
w ith in-treatm ent group changes, and 2-sample 
Mests were used to assess betw een-treatm ent group 
changes. U nadjusted m ean change scores and stan­
dard deviations of these changes were com puted for 
each treatm ent group. Effect sizes were com puted by 
dividing the estim ated m ean difference of scores 
between groups by tbe pooled standard deviation 
(mean square error) from the ANOVA model.
RESULTS
The study enrolled 104 OA patients, 50 to placebo 
and 54 to ibuprofen. Descriptive statistics, overall 
and by treatm ent group, are given in  Table 1. The 
m ean age of the sam ple subjects was 61.5 years, and 
the sam ple was prim arily  w hite (83.7%), well edu­
cated (92.3% w ith education >  Irigh school), and 
female (63.5%). W ith respect to OA disease history, 
the m ajority of patients had OA of the knee (68.3%), 
were either ACR functional class I or II (86.5%), and 
had an average duration of OA of 7.9 years. A pprox­
im ately 90% of the sam ple were taking short-acting 
NSAIDs prior to entering the study. There were no 
significant differences betw een treatm ent groups 
w ith respect to these baseline characteristics.
Table 2 shows the m eans and standard  deviations 
for scale scores over time for each treatm ent group. 
The ibuprofen group show ed im provem ent in  all 
WOMAC scale scores w ith in  the first week. These 
im provem ents were m aintained for the duration of 
the study. The ibuprofen group also show ed im ­
provem ent in  SF-36 pain  scores w ith in  the first week 
that lasted for the duration of the study; im prove­
m ents in  SF-36 physical functioning and role phys­
ical scores occurred w ith in  two weeks of study start, 
but were of a lesser m agnitude and attenuated som e­
w hat over time. M oderate im provem ents in  tbe
T able  1. S tu d y  dem ographics*’
Variable
Placebo 
(n  =  50)
Ibuprofen 
(n  =  54)
Total 
(n =  1 04)
Age, years
Mean 62 .1 6 1 .0 61 .5
SD 7.2 9.3 8.2
Minimum 4 5 .0 4 5 .0 4 5 .0
Median 61 .5 0 1 .0 61 .1
Maximum 79 77 79
Race, %
Black 12 .0 1 3 .0 12 .5
White 8 2 .0 85 .2 83 .7
Other 6 .0 1.8 3.8
Sex, %
Men 3 6 .0 3 7 .0 36 .5
Women 6 4 .0 6 3 .0 63 .5
Education, %
<HS 9 .2 6 .0 7.7
M-IS 90 .8 9 4 .0 92 .3
OA, %
Hip 12 .0 5 .6 8.7
Knee 70 .0 6 6 .7 68 .3
Both 18 .0 27 .8 23 .1
ACR functional 
class, %
I 28 .0 3 7 .0 3 2 .7
II 5 2 .0 5 5 .0 53 .8
III 2 0 .0 7.4 13 .5
Duration of 
artluritis, years
Mean 8 .4 7.6 7 .9
SD 9.7 5 .9 7 .9
Minimum 0 .7 0.5 0.5
Median 4 .9 6 .1 6 .0
Maximum 3 9 .0 2 6 .0 3 9 .0
* No significant differences between treatment groups, P  >  0.05. HS = high 
school; OA -  osteoarthritis; ACR =  American College o f Rheumatology 
(formerly the American Rlieumatism Association).
SF-36 energy/vitality score were also seen w ith ibu ­
profen. No other changes occurred in  the ibuprofen 
group with the SF-36 scales during the 28 days of the 
study. In the placebo group, no notable changes were 
seen over time on either the WOMAC or the SF-36, 
w ith the exception of a m odest increase in  scores on 
the role m ental scale.
Analyses to assess congruent valid ity  showed 
strong correlation betw een the pooled treatm ent 
WOMAC pain and physical function, and  the SF-36 
bodily pain and physical function scale scores (Fig­
ure 1). The correlation betw een day 14 scale scores 
was highly significant: r = 0.64 for WOMAC pain  
and SF-36 bodily pain, r = 0.72 for WOMAC phys­
ical function and SF-36 physical function. The cor­
relation coefficients for the ind iv idual treatm ent
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T ab le  2 . M ean  ±  SD for W estern O ntario and M cM aster U n iv e r sit ie s  O steoarthritis in d ex  (W OM AC) and M ed ica l 
O u tco m es S tu d y  3 6-item  Short Form  H ealth  S u rvey  (SF-36) sca les*
B aseline Dav 7 Day 14 Day 20
Scale
Placebo Ibuprofen
n  = 50 n  = 54
Placebo 
n  = 50
Ibuprofen  
n  = 50
Placebo 
n  = 47 Ibuprofen  n  = 47 Placebo Ibuprofenn  = 40 n  = 49
WOMAC scales
Pain 64.6 ± 24.4 59.7 ± 21.8 66.0 ± 28.0 71.6 23.1 69.8 ± 26.5 74.1 ± 22.3 70.3 ± 27.8 75.9 ± 23.0
Physical functioning 63.2 ± 24.2 59.2 ± 22.0 64.3 ± 27.2 09.4 22.1 66.2 i 27.4 71.9 ± 23.7 68.9 26.1 72.8 22.8
Stiffness 52.9 ± 30.3 46.1 ± 25.8 53.7 ± 29.9 59.9 ± 25.9 54.6 ± 29.7 67.1 ± 26.0 57.2 30.3 67.8 26.9
Total 61.7 ± 24.3 56.7 ± 23.9 62.8 ± 26.7 68.3 ± 21.9 65.3 ± 26,4 71.8 ± 22.2 67.0 ± 26.7 73.1 ± 22.4
SF-36 sca lest
Pain 53.6 20.1 48.7 18.4 54.4 20.1 56.7 ± 21.1 55.7 ± 21.7 59.3 ± 23.5 55.3 ± 21.4 61.5 ± 23.7
Physical functioning 52.3 ± 23.4 50.3 ± 23.3 51.3 ± 24.6 51.9 ± 23.0 52.0 ± 24,4 56.2 ± 25.1 50.5 ± 24.7 52.1 ± 25.7
Role physical 63.5 ± 41,4 58.6 42.3 61,5 39.2 61.0 ± 41.7 61.2 ± 44.8 67.6 ± 38.6 58.2 ± 41.0 65.3 ± 42.3
Mental function 76.3 16.7 79.7 15.0 79.7 ± 13.0 78.2 ± 18.6 81.2 ± 15.7 79.5 ± 17.3 79.7 i 16.4 80.9 ± 17.5
Role mental 74.7 ± 39.0 75.9 ± 38.5 84.0 ± 31.0 79.3 ± 33.6 81.6 ± 35.3 79.4 ± 35.1 81.9 34.9 73.5 ± 39.1
Social function 81.5 21.5 04.0 23.1 83.5 ± 22.8 80.5 24.5 82.4 ± 22.4 86.2 ± 21.2 85.3 ± 20.6 61.9 ± 25.0
Energy/vitality 51.0 17.7 56.5 ± 21.1 55.5 ± 18.0 57.8 ± 20.4 54.3 ± 18.9 61.6 22.4 50.8 ± 20.7 62.4 ± 22.5
General lioalth 68.9 ± 17.9 66.3 ± 20.9 68.4 ± 16.4 66.1 20,4 69.0 ± 17.6 65.9 ± 22.2 67.6 16.5 62.4 ± 22.3
MCS 53.0 ± 9.9 55.6 ± 9.1 56.0 ± 8.4 54.7 ± 11,1 55.7 ± 9.8 55.4 ± 9.6 55.6 ± 8.4 55,0 ± 10.2
PCS 38.9 ± 10.3 36.6 ± 9.0 37.7 ± 10.5 38.3 ± 10.4 37.9 ± 10.1 39.9 ± 10.5 37.2 ± 10.3 39.0 ± 11.2
Global satisfaction 66.0 ± 29.1 57.6 ± 33.1 55.0 ± 27.4 72.2 ± 30.2 59.8 ± 28.9 69.0 ± 32.1 61.6 ± 29.1 73.7 ± 26.6
* No significant differences betw een treatm ent groups at baseline , P > 0.05, 
t  MCS =  m ental com ponent sum m ary; PCS =  physica l com ponent sum m ary.
groups were also strong for the two pain  scales (ibu­
profen r = 0.63 and placebo r = 0.65) and tbe two 
physical functioning scales (ibuprofen r = 0.71 and 
placebo r = 0.72). The WOMAC total score and the 
SF-36 physical com ponent sum m ary also were 
highly correlated (r = 0.75), and this correlation was 
consistent across treatm ent (ibuprofen r = 0.70, p la­
cebo r = 0.78). The WOMAC p ain  and physical 
function scales both  show ed strong correlation w ith 
the SF-36 physical com ponent sum m ary (r = 0 .71- 
0.75) at day 14 as well. Scores at day 14 for the other 
com ponents of the SF-36 show ed low  to moderate 
correlations (r =  0 .20-0 .50) w ith  the WOMAC pain 
and physical function scales. Correlations of the day 
14 WOMAC and the SF-36 scores w ith  global satis­
faction were m oderate in m agnitude ranging from 
0.25 to 0.44 for day 14 scores.
Analyses to assess longitudinal congruent validity 
show ed only m oderate correlations betw een the 
WOMAC and SF-36 (Figure 2). The correlation coef­
ficients betw een change scores at day 14 on the two 
pain  scales and the two physical function scales 
were r = 0.26 (ibuprofen r = 0.23, placebo r = 0.21) 
and r = 0.25 (ibuprofen r = 0.24, placebo r = 0.18), 
respectively. Change in  the WOMAC total score was 
m ost highly correlated w ith  the SF-36 change scores 
for bodily  pain, physical functioning, and the phys­
ical com ponent sum m ary score (r = 0.32-0.34). 
W hen these analyses were stratified by treatm ent, 
correlations for the ibuprofen group ranged from 
0.13 to 0.50 com pared w ith 0.12 to 0.40 for the
placebo group. Correlations of change scores for the 
WOMAC w ith  the other SF-36 dom ains ranged from
0.05 to 0.20. Change scores for global satisfaction 
were m oderately correlated w ith  the WOMAC and 
SF-36 change scores, w ith estim ated coefficients 
ranging from 0.22 to 0.30.
Results for the ANOVA analyses are show n in  
Tables 3 and 4. In general, the WOMAC was m ore 
responsive (w ithin-treatm ent differences, Table 3) 
and show ed greater effect sizes (betw een-treatm ent 
differences, Table 4) than  tire corresponding scales 
on the SF-36. This was particularly  true for the 
WOMAC physical function and total scores; w ithin- 
and betw een-treatm ent differences were highly sig­
nificant at days 7, 14, and 28 w ith these measures. 
The SF-36 bodily pain  scale perform ed alm ost as 
w ell as the WOMAC pain  scale. W ith respect to the 
other SF-36 scales, only the energy/vitality scale (Ta­
ble 2) showed some im provem ent from baseline w ith 
ibuprofen, and this im provem ent appeared to be bet­
ter than  placebo. The im provem ent in  energy/vital­
ity for the ibuprofen group did not appear un til day 
14, whereas im provem ents in  both pain  scales ap­
peared w ith in  the first 7 days. N either questionnaire 
detected significant changes in  the placebo group, as 
expected (Table 3).
Patients receiving ibuprofen had consistently  
greater global satisfaction w ith m edication across the 
study period than placebo patients; how ever, the 
m agnitude of this difference was n o t consistent 
across time. Patients in  the ibuprofen group show ed
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Figure 1. A n a ly se s  to  a ssess  congru en t va lic iity . W O M A C =  W estern  O ntario and M cM aster U n iv ers itie s  O steoarthritis  
Index; S F -36  =  M ed ica l O utcom es S tu d y  3 6 -item  Short Form  H ealth  Survey; PCS =  p h y sica l co m p o n en t sum m ary, r =  
S p earm an  rank correlation  coeffic ien t.
increased satisfaction w ith treatm ent by day 7. The 
placebo group show ed reduced satisfaction w ith 
treatm ent com pared w ith baseline over the length of 
the study period.
DISCUSSION
Previous evaluations of the m easurem ent charac­
teristics of the WOMAC and the SF-36 in  OA pa­
tients have been done following joint replacem ent 
surgery (8,9,17,18), an intervention that results in  a 
dram atic change in  disease status. In that setting, the 
WOMAC perform ed better at discrim inating be­
tw een patients w ith  varying levels of knee problem s.
and the SF-36 perform ed better at discrim inating 
between patients w ith varying levels of general 
health  status and com orhidities.
In clinical trials of pharm aceutical interventions 
for OA, changes in  disease status following therapy 
may be less dram atic than those seen following joint 
replacem ent surgery. Therefore, it is im portant to 
choose the m ost sensitive instrum ent available to 
m ost efficiently detect differences among treatm ents. 
To our knowledge, this is the first published  report 
to evaluate the responsiveness and relative effect 
size of the WOMAC and applicable scales from the 
SF-36 in  a random ized, clinical trial of a pharm aceu­
tical intervention for OA.
In th is study, the  pain , physical function , and
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F igure 2. A n a ly s e s  to a ssess  lo n g itu d in a l congru en t v a lid ity . W OM AC =  W estern  O ntario and  M cM aster U n iv ers it ie s  
O steoarthritis In dex; SF-36 =  M ed ica l O u tcom es S tu d y  3 6-item  Short Form  H ealth  Survey; PCS =  p h y s ica l c o m p o n e n t  
sum m ary, r =  Sp earm an  rank correlation  co effic ien t.
total score from the WOMAC and the bodily  pain  
scale from the SF-36 w ere able to detect response 
to therapy  w ith  ibuprofen  and  show  differences 
betw een  active and  placebo trea tm en t in  patien ts 
w ith  OA of th e  h ip  and /o r knee. However, the 
WOMAC proved  to be the m ore efficient of the two 
instrum en ts. T his was dem onstrated  by the m ore 
rap id  and  greater su sta in ed  increase in  scores 
follow ing in itia tio n  of therapy , and by the gener­
ally  larger effect sizes for the trea tm ent group d if­
ferences w ith  th e  WOMAC pain , physical func­
tion , and to ta l scores com pared w ith  those of the 
SF-36 bodily  p a in , physical function , and physical 
com ponen t sum m ary  scores, respectively . Because 
th is com parison  w as based on a 28-day study, 
these resu lts m ay not p e rta in  to trials of longer 
duration .
Features of the study design may have posed prob­
lems in  the use of the SF-36. Some patients were 
receiving therapy for OA prior to entering the trial, 
w hich was d iscontinued during the 4-day run-in  
period. Baseline (day 0) assessm ents were m ade at 
the end of the placebo run-in  period. Therefore, in  
responding to questions on the SF-36 (acute ver­
sion), w hich has a recall period of one week, their 
responses necessarily reflected some days during 
which their prior therapy  may still have been exert­
ing some effect. Tliis w ould  n o t have been a problem  
w ith the WOMAC, w hich  has a recall period of 48 
hours.
The recall period for this version of the WOMAC 
was 48 hours com pared w ith  the 1-week version of 
the SF-36. Studies of the recall period for the 
WOMAC suggest that there is no tim e dependency in
1 7 8  D a v ie s  e t a! V ol. 12, N o. 3, June 1999
T ab le  3. E v a lu ation  o f  r e sp o n s iv e n e ss  o f the W estern O ntario and M cM aster U n iv ers it ie s  O steoarthritis In d ex  
(W OM AC) an d  co rresp o n d in g  sc a le s  and  sum m ary sc a le s  o n  the M ed ica l O utcom es S tu d y  3 6-item  Short Form  
H ealth  S u rv ey  (SF-36)*
Treatm ent Treatm ent Change score WOMAC SF-36 WOMAC SF-36 WOMAC SF-36 Global
day group statistic pain BP PF PF total PCS satisfaction
Day 7 Ibuprofen M ean 11.8 t 8. i t 10 .4 t 0.7 1 1 .9 t 1.5 14 .5 t
(n =  50) SD 17.3 17.3 14.2 13.3 14.0 6.6 31.4
Placebo M ean 1.4 0.8 1.0 - 1 .0 1.1 2.0 - l l . O t
(n =  50) SD 17.9 12.9 12.0 12.4 11.9 9.0 24.1
Day 14 Ibuprofen M ean 1 3 . l t 9 .6 t 12.Ot 3.8 1 4 .3 t 2.4 10.1
(n =  47) SD 17.3 17.9 14.2 14.9 13.4 6.3 33.6
Placebo M ean 5.9 1.9 3.3 - 0 .4 4.2 - 1 .4 - 5 .9
(n =  47) SD 13.2 14.0 15.2 12.2 12.6 6.4 34.5
Day 28 Ibuprofen M oan 1 5 .4 t 1 1 .9 t 1 3 .6 t 1.4 IG.Ot 2.0 14 .Ot
(n =  49) SD 16.5 20.5 15.2 15.7 14.1 7.3 29.8
Placebo M ean 5.3 1.0 5 .2 t - 3 .7 5.5 - 0 .4 - 5 .2
(n =  46) SD 18.2 14.1 15.7 11.9 15.6 11.7 32.4
* BP = bod ily  pain ; PF = physical function; PCS -  physical com ponont sum m ary , 
t  Tost of moan change Q, P rs 0.05.
the WOMAC for periods betw een 2 days and 2 weeks 
(12). This previous research suggests that the differ­
ence in  the recall periods should  not be an issue in 
com parisons of these two instrum ents.
Tw o com ponen t sum m ary m easu res for the 
SF-36 w ere also com puted  in  th is study. The scor­
ing  algorithm  for the phy sical com ponent sum ­
m ary and  m ental com ponent sum m ary  are based 
on estim ated  factor coefficients from  a su rvey of 
the general US p o p u la tio n  (14). The use of the 
sum m ary scores to assess responsiveness in  our 
study  m ay no t be valid  since the stu d y  pop u la tio n  
is no t rep resen ta tive  of the general US population . 
H ow ever, th is  bias sh o u ld  no t affect the results for 
the com parisons betw een  ibuprofen  and  placebo.
As expected , the global satisfaction w ith m edica­
tion  question show ed ibuprofen patients were more 
satisfied w ith  treatm ent than  placebo patients; how ­
ever, the estimates of variance were large relative to 
their mean. This result is not su rprising, because 
satisfaction encompasses physical and emotional 
constructs as well as effects from adverse events. 
Patients experiencing m edication side effects may 
have lower satisfaction even if their pa in  and phys­
ical functioning im proved substantially. This could 
cause increased variability in  this m easure.
There are several possible reasons w hy the SF-36 
was not as responsive as the WOMAC in  this study. 
The VAS response format of the WOMAC m ay ac­
count for the greater responsiveness of th is instru ­
ment. A Likert scaling version of the WOMAC does 
exist and has been show n to be slightly less sensitive 
than the VAS version (12). It w ould be difficult to say 
whether the Likert version of the WOMAC physical 
function scale w ould  have been as responsive in  this 
setting. In addition , patients w ith an ACR functional
T ab le  4. R esu lts o f  re la tiv e  e ffect s iz e  o f  ibu profen  v ersu s p la ceb o  (p oo led  SD)*
Change
score
WOMAC
pain
SF-36
BP
WOMAC
PF
SF-36
PF
WOMAC
total
SF-36
PCS
Global
satisfaction
Day 7 9 .4 t 6 .3 t 8 .7 t 1.1 lO.Ot 2.4 2 6 .3 t
17.4 15.5 13.3 13.1 13.2 6.0 27.5
0.54 0.41 0.65 0.08 0.76 0.40 0.96
Day 14 6.6 5.8 8 .4 t 3.6 9 .6 t 3 .2 t 13.9
15.9 15.6 14.8 13.8 13.0 6.5 33.7
0.42 0.37 0.57 0.26 0.74 0.49 0.41
Day 28 8 .9 t 1 0 . l t 7 .9 t 4.5 9 .5 t 4 .0 t 1 9 .4 t
17.7 18.3 15.9 14.5 14.9 7.1 32.1
0.50 0.55 0.50 0.28 0.64 0.56 0 .60
* WOMAC = W estern O ntario  and  M cM aster U niversities O steoartliritis Index; SF-36 = M edical O utcom es S tudy  36-ilem  Short Form  H ealth  Survey; BP 
bodily  pain; PF = physical function; PCS = physical com ponent sum m ary , 
d Test o f treatm ent difference #  0, P  <  0.05.
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class of IV were no t included in  the study; the SF-36 
physical function or physical com ponent sum m ary 
may be just as sensitive as the WOMAC in tliis type 
of patient.
The SF-36 is a generic health  status instrum ent 
that assesses psychosocial constructs as well as 
physical constructs. Conceptually , im provem ents in 
physical constructs could result in  future im prove­
m ents in  psychosocial and m ental health  com po­
nents. In this study, no changes were observed in  the 
rem aining scales of the SF-36 except for the energy 
and vitality  scale. It is possible that the duration  of 
this study was too b rief to detect any im provem ent 
in  the scales of the SF-36 that reflect m ental and 
psychosocial constructs.
Both tlie WOMAC and the SF-36 have similar con­
structs of pain and physical functioning. The WOMAC 
pain subscale was specifically developed for pain  re­
lated to OA. However, the SF-36 pain question refers to 
general bodily pain. If ibuprofen was more effective for 
OA pain tlian for pain from other sources, this could 
explain the differences in  responsiveness between the 
instrum ents in  this study. The items for the SF-36 and 
WOMAC physical function scales are very similar. The 
lack of response on the SF-36 physical function scale 
in  this study could be explained by the lack of suffi­
ciently sensitive response categories for these OA pa­
tients.
From this evaluation , it appears that the WOMAC 
is liighly responsive to changes in  OA disease status 
and is m ore efficient than  the corresponding scales 
of the SF-36 in  short-term  clinical trials of pharm a­
ceutical therapy for OA. As a result, use of the 
WOMAC to dem onstrate efficacy in  clinical drug 
trials of OA w ould  allow sm aller sam ple sizes and 
resource savings.
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SECTION 5 - Applications in Clinical Research
The value o f an outcome measure is reflected in its performance in post-validation 
applications. The WOMAC Index has been widely used since its development in 1982. 
The studies presented in this section of the thesis are interventional studies in which the 
originator of the WOMAC Index was either the principal investigator or a co­
investigator, and in which the WOMAC Index was used as a primary or secondary 
outcome measure (12-18). Some of the studies were also used to test measurement 
hypotheses or evaluate other aspects of the WOMAC Index.
The RCT of sodium meclofenamate versus diclofenac sodium was the first post­
validation application of the WOMAC VA3.0 Index, and used a joint-targeted version of 
the WOMAC Index (12). Statistically significant within-group improvements were 
detected in both treatment groups, and between-group differences favouring meclomen 
were detected in the WOMAC pain and stiffness subscales. In addition to detecting 
between-group differences between two active agents, the results of this study also 
suggested that the WOMAC Index was similar in responsiveness, as assessed by the 
relative efficiency statistic, to the Doyle Index and the Lequesne Index of Clinical 
Severity (12). Finally the study provided an improved estimate of the standard deviations 
of WOMAC subscale scores for calculating sample size for future studies using the 
WOMAC Index (12).
The RCT of tenoxicam versus diclofenac was the first Canadian study to compare 
the two agents in knee OA (13). The importance of this study is that separate WOMAC 
questionnaires were completed for each knee, an innovation that informed the 
development o f the WOMAC 3.1 series of questionnaires which are joint-specific, and 
require the patient to rate their symptom experience in a single joint. Statistically 
significant within-group improvements were detected in both treatment groups on all 
three WOMAC subscales. No significant between-group differences were observed 
between these two active agents (13).
The RCT of controlled-release codeine versus placebo permitted observation of 
the performance of the WOMAC Index in a different research environment, that of a 
complex analgesic (14). Statistically significant between-group differences in favour of 
controlled-release codeine were detected by all three WOMAC subscales (14). This study 
suggested that therapeutic agents having a primarily analgesic effect might produce 
clinical benefit not only on pain, but also on stiffness and physical function, and be 
detectable by the relevant subscales o f the WOMAC Index.
The RCT of diacerein versus placebo permitted observation of the performance of 
the WOMAC Index in a clinical study involving a symptom modifying slow-acting drug 
for OA (SAD0A)(15). In this trial the WOMAC Index was used as a secondary outcome 
measure, and detected statistically significant differences versus placebo and in favour of 
diacerein 100 mg/day in the intent-to-treat (ITT) analysis on all three WOMAC subscales 
(15).
An open-label study of an education-driven skills acquisition programme 
provided opportunity to study the performance of the pain and function subscales of the 
WOMAC Index in yet another research environment, involving the treatment of knee OA 
patients, in general practice, with a viscosupplementation product, hylan G-F 20 (16). 
Statistically significant within-patient improvements were noted on both WOMAC
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subscales (16). In addition, this study validated a patient global assessment question, that 
subsequently became part of two other indices, the Western Ontario Measurement 
Battery (WOMBAT) (16), and the Osteoarthritis Global Index (OGI).
The pragmatic RCT of the effectiveness, cost-effectiveness and cost-utility of 
“Appropriate Care + hylan G-F 20 versus Appropriate Care without hylan G-F 20” 
provided an opportunity to employ the WOMAC Index to pre-specify a definition of a 
responder, in order to perform a comparative analysis based on responder criteria (17), 
and also to employ the WOMAC Index in a cost-effectiveness evaluation (18). The time 
frame for the WOMAC Index for this study was set at one-month. The WOMAC was 
able to detect a clinically important, statistically significant between-group difference in 
favour of “Appropriate Care + hylan G-F 20” (17). In the cost-effectiveness analysis, the 
WOMAC Index was used to specify a definition for an improved patient, on the basis of 
which, the incremental cost of a patient improved over one year was calculated to be 
$2505 CDN (societal) and $9930 CDN (health care system)(18).
Collectively these post-validation applications of the WOMAC Index confirmed 
the responsiveness o f the three subscales of the WOMAC Index in such diverse research 
environments as trials of NSAIDs, a SADOA class agent, a complex analgesic and 
viscosuppplementation with hylan G-F 20. These studies also suggested that the 
WOMAC was a relatively robust measure, since its performance was maintained when 
focussing the patient’s symptom severity rating on only a single joint (12-18), and 
extending the time frame for recall to one month (17,18). These studies also confirmed 
the feasibility of applying the WOMAC Index in different clinical practice environments 
including orthopaedics (17,18), rheumatology (12-15, 17,18) and general practice (16).
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Double Blind Randomized Controlled Trial of Sodium 
Meclofenamate (Meclomen) and Diclofenac Sodium 
(Voltaren); Post Validation Reapplication 
of the WOMAC Osteoarthritis Index
NICHOLAS BELLAMY, WALTER F. KEAN, W. WATSON BUCHANAN, ERIKA GERECZ-SIMON, and 
JANE CAMPBELL
Abstract. Following several years o f developm ent and validation, we applied the W OMAC  
Osteoarthritis Index as the principal outcome m easure in a double blind random ized parallel 
trial of M eclomen (100 mg po tid) and Voltaren (25 mg po tid). Statistically significant improve­
m ents in clinical status were noted in both treatm ent groups. At the doses studied, between 
drug differences favoring M eclomen were observed in pain and stiffness, no difference being 
noted in physical function. No significant between drug difference was noted in tolerability 
at these sam e doses. Our study also demonstrated that the relative efficiency o f  W OM AC was 
sim ilar to that o f the Lequesne and Doyle indices. Finally, we defined the standard deviation 
necessary to calculate sam ple size for future studies using the W OM AC index, both for studies 
based on static scores and those based on change scores. {J Rheumatol 7992.19:153-9)
Key Indexing Terms:
CLINICAL METROLOGY
In recent years we identified significant variability in the out­
come measures used in osteoarthritis (OA) clinical trials'. 
Furthermore, we have noted that the ability to detect differ­
ences between an active drug and a placebo is greater than 
that between 2 active drugs. Nevertheless, some traditional 
measures (e.g., 50’ walk time) cannot predictably detect 
between treatment differences even in placebo controlled 
studies. In an attempt to standardize the measurement of pain, 
stiffness, and physical function in antirheumatic drug studies 
in OA, and to develop an instrument of superior responsive­
ness that might be capable of detecting between drug differ­
ences, we developed a tridimensional self-administered ques­
tionnaire probing patient relevant clinically important out­
comes termed the Western Ontario and McMaster Univer­
sities (WOMAC) Osteoarthritis Index^-’. The instrument 
consists of 24 questions, grouped into 3 (3.0) subscales (pain.
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OSTEOARTHRITIS NSAID
stiffness and physical function). There are 4 versions of this 
index (LK3.0, LK3.0S, VA 3.0, VA 3.OS), which differ only 
in the type of scale on which the response is scored (LK = 
5 point Likert scale, VA = 10 cm horizontal visual analog 
scale) and whether the patient is asked to identify one signal 
(S) item in each subscale to permit a signal rather than an 
aggregate approach to measurement^. Our major interest 
currently is to assess further other clinimetric properties of 
the WOMAC Index. We have reapplied WOMAC-VA 3.0, 
therefore, in a comparative study of Meclomen versus 
Voltaren in patients with primary OA of the knee. The 
efficacy and tolerability of Voltaren have been described®. 
Meclomen is not currently available in Canada and was desig­
nated, therefore, the “ test” drug. However, studies per­
formed elsewhere attest to the efficacy of Meclomen in the 
treatment of OA of the knee^-". Our goals were 4-fold; (1) 
to compare the efficacy of Meclomen 100 mg per os (po) 
3 times daily (tid) and Voltaren 25 mg po tid using WOMAC 
as the principal outcome measure, (2) to compare the 2 drugs 
with respect to any clinical or laboratory toxicity, (3) to 
examine the relative efficiency of WOMAC compared to 2 
other indices in assessing the clinical response, (4) to generate 
mean and standard deviation estimates for static scores and 
change scores for WOMAC-VA 3.0 in order to calculate 
sample size for future antirheumatic drug studies.
MATERIALS AND METHODS
Sixly-nine consecuiive consenting outpatients willi primary OA o f  the knee 
were entered into the study. The following inclusion and exclusion criteria 
were applied; Inclusion — symptomatic primary OA o f at least one knee 
warranting treatment with nonsteroidal antiinflammatory drugs (NSAID),
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age 40-65  years, radiograpliic evidence o f at least one o f the following: 
osteophytes, joint space narrowing, periarticular sclerosis, subchondral cysts. 
A symptomatic patient was defined as a patient with pain and disability from 
OA of the knee. Primary OA was denned by the presence o f  typical joint 
symptoms (pain, stiffness, disability), signs (bony crepitus), and radiographic 
findings o f OA as illustrated in the S tan dard  A lla s  o f  Radiographs^^. 
Patients with an atypical distribution o f  OA were excluded if  they had ev i­
dence o f chondrocalcinosis or elevated ferritin, thyroid stimulating hormone 
or calcium level. All radiographs were graded according to S ta n d a rd  A lla s  
criteria (Grades 1-4). Patients were not enrolled if their disease was 
confined only to the patcllofemoral compartment. Exclusion — any other 
form o f joint disease or prior knee replacement surgery, pregnancy or lac­
tation, active peptic ulceration in the past 2 years or upper gastrointestinal 
bleeding in the past 5 years, severe uncontrolled cardiorespiratory insuffi­
ciency, blood urea nitrogen (BU N ) >  30 mg/dl, aspartate aminotransfer­
ase (AST) >  50 units/ml, documented allergy to aspirin or any other NSAID, 
use o f  oral anticoagulants, systemic or intraarticular corticosteroid use in 
the past 3 months.
Following initial screening (medical history and clinical exmaination), 
there was a 3 to 7 day NSAÏD-free washout period during which patients 
were instructed to cease all NSAID therapy, to take placebo capsules tid 
and were permitted to take monitored quantities o f acetaminophen. Patients 
were then reassessed (baseline) and thereafter randomized to receive cither 
Mcclomen 100 mg po tid or Voltaren 25 mg po lid for the next 6 weeks. 
Since the conventional dose range o f  Meclomen is 200-4CX) mg/day, and 
for Voltaren 5 0 -1 5 0  mg/day, this study represents a comparison o f  a 
midrange dose o f  Meclomen against a relatively low dose o f  Voltaren.
The allocation schedule used a blocked randomization technique (block­
ing factor =  10). Both assessors and patients were blind to the allocation 
until after completion o f  the study. All study capsules (Meclomen, Voltaren 
and placebo) were identical in appearance. During tlie active treatment phase, 
patients were permitted to take supplementary analgesia sparingly (if  
required, acetaminophen up to 6 x  325 mg/day). Compliance to 
study medication and analgesic ingestion were verified by pill 
counting. Patients were assessed at 5 points during the trial: screen­
ing, 0  (baseline), 2 , 4, and 6 (termination) weeks. The following clinical 
assessments were made at each time point: (I) W OM AC-VA3.0 OA 
Indcx^; (2) Lcquesne Knee I n d e x ( a  self-administered 11 item question­
naire probing pain, stiffness, maximum distance walked and activities o f  
daily living); (3) Doyle Articular Index''* (a modification o f  the Ritchie 
Index in which 48 Joints or joint units are assessed by palpation for tender­
ness on a scale o f 0  =  no tenderness, 1 -b patient complains o f  pain. 2 +  
patient complains o f  pain and winces, 3 +  patient complains o f  pain, winces 
and withdraws); (4) Night pain (4 point Likert scale); (5) Pain on walking 
(4 point); (6) Starting pain (4 point); (7) Stress pain (4 point); (8) Swelling 
(4 point); (9) Degree o f tenderness (4 point); (10) Limitation o f  movement 
(4 point); (I I )  Maximum knee flexion (degrees): (12) Maximum knee exten­
sion (degrees); (13) Overall assessment (separate patient and physician assess­
ments) (5 point); (14) Comparative assessment o f condition to previous visit 
(separate patient and physician global assessments) (3 point). At the screening 
visit, one knee was identified as the study joint (i.e ., the worst knee as the 
primary focus o f measurement for future assessment in the study). Records 
were kept o f  concomitant medications, study medication, blood pressure, 
body weight and temperature. Adverse reactions were ascertained by open 
ended indirect questioning. Routine hematology, clinical chemistry and urin­
alysis were completed at screening. Week 2 and termination.
After study completion, double data entry was performed in collabora­
tion with Innovus Inc., Hamilton, ON, using the SIR (Scientific Informa­
tion Retrieval) database'^ and data analysis conducted using SAS Version 
6.03'* and BM DP-UX software packages'^. Data were checked for valid­
ity, normality, skewness and kurtosis. Continuous variables were analyzed 
by analysis o f  covariance using the respective baseline measures as the covar- 
iates. Descriptive analyses were conducted on all variables defining means 
and standard deviations. Categorical outcome measures were analyzed using 
tests to determine differences between the treatment groups, and
M cNemar's test to determine differences between treatment visits. The 
Bartlett test was used to test for homogeneity o f  variance between centers 
and treatments at baseline. In all statistical tests, the level o f  Type I error 
(2-tailed) was set at 0 .05 . Although 16 separate analyses were made we 
have made no correction for multiple comparisons. This is based on the 
following considerations: (1) A single primary efficacy variable was defined 
a p r io r i. (2) Efficacy variables were highly correlated. (3) The extent o f  
any correction remains contentious both statistically and clinically, (4) Prece­
dent indicates that in the OA literature such correction is rarely made®, and 
(5) Correction for multiple comparisons is generally not appropriate in 
exploratory studies'®, A decision had been made a p r io r i  to use the 
WOMAC OA Index (pain subscale) as the principal outcome measure, all 
other variables being relegated to secondary outcome status. This allowed 
the relative efficacy o f  the 2 active drugs to be defined by W OM AC, but 
also permitted an examination o f  the Relative Efficiency (RE)'^ o f 
WOMAC versus the Doyle and Lequesnc indices. RE is defined as tlie square 
o f the ratio o f 2 t values, i .e .,  RE (WOMAC vs D oyle) =  
(t WOMAC/t DOYLE)^. If the RE is >  1.0, the instrument in the numer­
ator can be inferred to be the more responsive measure o f  outcome requir­
ing smaller sample sizes and/or detecting smaller effect sizes tlian tlie instru­
ment in the denominator.
RESULTS
Sixty-six patients entered the trial of whom 5 were excluded 
from analysis for the following reasons: intolerance = 1 
(placebo), noncompliance = 4. Of the remaining 61 patients, 
30 received Meclomen and 31 received Voltaren. The dis­
ease and demographic profiles of participating patients are 
illustrated in Table 1. No significant between group differ­
ences were noted in age, disease duration, sex, or in any 
of the disease characteristics. The baseline and termination 
status (mean and standard deviation) of the outcome vari­
ables is illustrated in Table 2 (indices) and Table 3 (study 
joint and global/overall measures). Statistically significant 
between group differences at baseline were noted in the pain 
(p = 0.0313), stiffness (p = 0.0502) and physical function 
(p = 0.0080) subscales of the WOMAC Index.
As noted, to account for these differences, data were ana­
lyzed using analysis of covariance (ANCOVA) techniques 
using the baseline values as the covariate.
Efficacy. Within group comparisons (baseline versus end­
point) were made for all outcome variables (Tables 2 and 
3). Statistically significant improvements witli treatment were 
noted as follows: Both drugs — WOMAC (all 3 subscales), 
Lequesne Index (all components), Doyle Index, walking pain, 
starting pain, stress pain, physician overall assessment and 
physician comparative assessment; Meclomen only — night 
pain and patient global assessment; Voltaren only — swell­
ing. Although improvements occurred on other study joint 
measures (Table 3), none of these was statistically significant.
Between treatment comparisons were made for all outcome 
variables. A statistically significant difference favoring 
Meclomen was detected for the following variables: 
WOMAC Index (pain and stiffness), Lequesne Index 
(pain/discomfort and activities of daily living). Night Pain 
and Pain on Walking (Tables 2 and 3). The remaining index 
subscales, study joint measures and other overall/global
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Tabic 1. P ostrandom ization , pre in terven tion  com parison  o f  treatm ent g ro u p s (mean  +  SD)
Variable Mcclomen 
(n = 30)
Diclofenac 
(n = 31)
p Value
Age (years) 55.73 (6.32) 56.97 (6.11) NS
Disease duration (years) 6.04 (5.83) 8.03 (7.41) NS
Sex (F, M) I9F, IlM 24F, 7M NS
Bilateral (B) vs Unilateral (U) disease 24B, 6U 26B, 5U NS
Most severely affected knee (L, R) 15R, 14L 16R, 15L NS
Bony osteophytes 25 22 NS
Loss of joint space 23 28 NS
Eburnation of juxtaarticular bone 2 6 NS
Subchondral bony cysts 0 0 NS
Radiographic grading*
Grade 1 5 3 NS
Grade 2 11 17 NS
Grade 3 13 8 NS
Grade 4 1 3 NS
Tibiofemoral disease only 12 9 NS
Patcllofemoral disease only 0 0 NS
Tibiofemoral and patcllofemoral disease 18 22 NS
* Atlas of Standard Radiographs (1963).
T able 2. Mean values and standard deviations for OA indices
Index Baseline Baseline vs Termination Between Drugs at
Termination Termination
WOMAC
Pain (M)* 199.7 (105.3) 0.00 115.1 (117.6) 0.04
(D)t 275.6 (97.6) O.OI 224.3 (140.0)
Stiffness (M) 94.4 (54.1) 0.00 53.9 (53.0) 0.02
(D) 123.0 (37.8) O.OI 100.2 (57.2)
Physical function (M) 693.0 (336.8) 0.00 417.3 (392.3) 0.44
(D) 952.8 (317.7) 0.00 768.6 (451.4)
Lcquesne
Pain & discomfort (M) 5.8 (1.2) 0.00 3.7 (2.3) 0.03
(D) 6.2 (1.1) 0.00 5.2 (1.6)
Walking (M) 2.9 (1.7). 0.00 2.1 (1.7) 0.90
(D) 3.0 (1.4) 0.00 2.5 (1.4)
Activities of daily
living (M) 4.8 (1.5) 0.02 3.0 (2.0) 0.04
(D) 5.2 (1.1) 0.00 4.5 (1.7)
Total (M) 13.5 (3.6) 0.00 8.8 (5.5) 0.06
(D) 14.4 (2.9) 0.00 12.2 (4.1)
Doyle (M) 9.5 (9.1) 0.00 6.1 (9.7) 0.76
(D) 8.9 (6.1) 0.00 6.2 (4.8)
* M = Meclomen. 
t D = Diclofenac.
measures failed to detect any significant difference between 
the 2 drugs. It should be noted that there were no differences 
in analgesic consumption to account for the between drug 
differences in perceived pain. Only one patient was with­
drawn from each treatment group due to inefficacy 
(Table 4).
Tolerability. The frequency and nature of adverse reactions 
reported during the study are illustrated in Table 4. The 
majority of clinical adverse reactions reported were gastro­
intestinal in nature and accounted for about % of all events
in both treatment groups. Several patients reported more than 
one adverse event, resulting in numerically more adverse 
reactions on Meclomen (n=20) than Voltaren (n = 15). The 
actual number of patients experiencing adverse reactions was 
small (Meclomen=8, Voltaren=7), and was not significantly 
different between the 2 treatment groups (x^ = O.OI, p = 
0.9063). No significant difference was detected in the num­
ber of patients withdrawn due to adverse reactions 
(Meclomen = 5, Voltaren = 2, yf = 1.57, p = 0.2108), 
or the number of patients with severe reactions (Meclomen 
= 2, Voltaren = 1, x  ^ =  0.12, p = 0.7274). No significant
Bellamy, et al: W OM AC OA Index: Meclomen vs Voltaren 155
T able 3 . M ean  va lu es a n d  s ta n d a rd  d e v ia tio n s  f o r  un idim ensional v a r ia b le s
Outcome Variable Baseline Baseline vs 
Termination
Termination Between Drugs at 
Termination
Night pain (M)* 2.6 (0.8) 0.00 1.7 (I.O) 0.03
(D)t 2.7 (0.9) NS 2.2 (0.9)
Walking pain (M) 3.1 (0.6) 0.00 2.0 (0.9) 0.05
(D) 3.1 (0.7) 0.03 2.5 (0.9)
Starting pain (M) 3.0 (0.9) 0.00 1.9 (0.9) NS
(D) 3.3 (0.8) 0.01 2,4 (1.0)
Stress pain (M) 2.4 (1.0) 0.04 1.6 (0.8) NS
(D) 2,5 (0.8) 0.01 1.7 (0.8)
Swelling (M) 1.4 (0.7) NS 1.1 (0.3) NS
(D) 1.6 (0.8) 0.01 1.3 (0.6)
Limitation of movement (M) 1.2 (0.5) NS 1.0 (0.2) NS
(D) 1.2 (0.4) NS 1.1 (0.3)
Knee flexion (M) 113.0 (15.7) NS 120.8 (9.2) NS
(D) 110.8 (18.0) NS 117.0 (15.8)
Knee extension (M) 0.8 (2.5) NS 0.2 (0.9) NS
(D) 0.8 (3.6) NS 0.7 (2.1)
Overall assessment (M) 3.6 (0.8) 0.05 2.4 (0.9) NS
(MD) (D) 4.1 (0.8) 0.05 2.7 (1.1)
Overall assessment (Pt) (M) 3.7 (0.8) 0.00 2.4 (0.9) NS
(D) 4.9 (0.9) 0.01 2.7 (1.0)
Comparative assessment (M) 2.4 (0.5) 0.00 1.7 (0.7) NS
(Global-MD) (D) 2.6 (0.5) 0.01 1.9 (0.6)
Comparative assessment (M) 2.3 (0.6) 0.01 1.7 (0.7) NS
(Global-Pt) (D) 2.4 (0.6) NS 1.9 (0.6)
Analgesic consumption (M) 1.8 (2.0) NS 1.2 (1.9) ■ NS
(daily) (D) 1.3 (1.8) NS 1.0 (1.8)
* Mcclomen. 
t Diclofenac.
between group differences were noted in body temperature, 
systolic blood pressure, diastolic blood pressure, hematology, 
clinical chemistry or urinalysis. With the exception of a sig­
nificant increase (p = 0,0005) of BUN in the Meclomen 
group and a significant increase (p = 0.0027) in urine specif­
ic gravity with Voltaren, no within group alterations in hema­
tology, clinical chemistiy or urinalysis were noted on either 
drug.
RE. The RE of WOMAC versus Doyle and Lequesne Indices 
was calculated by combining data from tlie 2 treatment groups 
and is illustrated in Table 5. Although a total score can be 
developed for the Doyle and Lequesne indices, we have not 
previously attempted to aggregate the 3 subscales of 
WOMAC since their relative clinical importance has yet to 
be determined. However, to compare total index scores we 
have performed 2 types of aggregation in this analysis. The 
first was simple addition of the 3 subscale scores to give a 
total score. The total WOMAC score respects severity of 
symptoms but neglects both the relative clinical importance 
of the subscales and the difference in their scale lengths. The 
second aggregation was complex and involved combining 
subscale scores to give a pooled (P) score using the tech­
nique previously reported by Smythe, et aP'i. The pooled 
WOMAC score is based on derived standard deviation units 
and respects the severity of symptoms as well as the differ-
Table 4. Adverse reactions reported by the 2 treatment groups
Reactions Diclofenac 
(n = 31)
Mcclomen 
(n = 30)
Constipation 2 0
Depression (lassitude) 0 1
Diarrhea 2 3
Dyspepsia 0 2
Epigastric pain (low abdominal cramps) 0 1
Fluid retention (fingers/feet swollen) 1 0
Frequent bowel movement 0 1
Headache 2 1
Heartburn and gas 2 0
Hemorrhoidal bleeding 2 • 0
High blood pressure 0 1
Indigestion 0 1
Malaise 1 0
Migraine 0 1
Nausea 2 1
Rash 0 1
Shortness of breath 1 0
Stomach burning 0 4
Stomach cramps 0 2
Total number of adverse reactions (ADR)f 
Total number of patients experiencing
15 20
ADR 7 8
Total number of patients with severe ADR 
Total number of patients withdrawn due to
1 2
ADR
Total number of patients withdrawn due to
2 5
inefficacy 1 1
 ^ Some patients had more than one ADR.
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T able 5 . C om parison  o f  re la tiv e  efficiency o f  W O M A C , L equesnc a n d  D o y le  in d ices
WOMAC Doyle
Pain
Lequesnc 
Maximum Activities o f  
Distance Walked Daily Living
Total
Pain 1.09 0.81 1.54 1.04 0.68
Stiffness 0.87 0.64 1.26 0.83 0.55
Physical function 1.17 0.86 1.65 1.14 0.73
Total (simple)* 1.32 0.94 1.81 1.22 0.82
Pooled (complex) 1.37 0.99 1.91 1,29 0.89
* The total W OMAC index score is calculated by simple addition o f the 3 component subscale scores. The pooled 
WOMAC index score is calculated by a complex formula based on standard deviation unit and has been em­
ployed by Smythe, et in the pooled index.
ence in scale length of the 3 subscales, although it still does 
not account for any differences in their relative importance. 
RE values for both the total and pooled WOMAC versus the 
Doyle and Lequesne indices tended to be higher (range = 
0.82-1.91) than the RE values for the 3 individual WOMAC 
subscales and those same indices (range = 0.55-1.65). 
Nevertheless, the range of RE values observed was small 
(0.55-1.91), none being exactly unity. Overall, the RE of 
the WOMAC, Doyle and Lequesne indices was similar. 
Sample size calculation. From this study we calculated stan­
dard deviation values for estimating sample size for future 
trials using the VA 3.0 version of WOMAC. The calculated 
values are different for studies based on change scores than 
absolute or static scores. The recommended standard devia­
tion values are as follows: For calculations based on abso­
lute scores. Pain = 107.13, Stiffness = 48.16, Physical 
Function = 351.03. For calculations based on change scores. 
Pain = 91.06, Stiffness = 47.48, Physical Function = 
199.72. The percent changes in mean values detected in our 
study were as follows: Meclomen, Pain = 42%, Stiffness 
= 43%, Physical Function =40% ; Voltaren, Pain =19%,  
Stiffness = 19%, Physical Function = 19%.
DISCUSSION
The WOMAC Osteoarthritis Index has been validated with 
respect to reliability, face, content, construct validity and 
responsiveness, both in the context of an NSAID trial and 
a total joint arthroplasty study"* *. In those studies, the full 
version of LK3.0 (and LK3.0S) was used but the VA3.0 (and 
VA3.0S) version was only partially replicated owing to the 
large number of questions posed for purposes of construct 
validation. Our study, therefore, represents the first formal 
application of the full WOMAC VA 3.0 version. As well 
as permitting the comparison of Meclomen 100 mg po tid 
and Voltaren 25 mg po tid, our study also allowed additional 
characteristics of the WOMAC Index to be explored. In par­
ticular, we examined the relative efficiency of the instrument 
against 2 other validated indices and generated better esti­
mates for the standard deviation of WOMAC subscales both 
for studies using static scores as well as tliose based on change 
scores.
In our study, in spite of randomization, the groups differed 
on WOMAC subscale scores although they did not differ in 
age, sex or disease duration. This can be considered the ran­
dom result of the randomization process. The randomiza­
tion process does not guarantee group similarity, but merely 
increases the probability that the 2 treatment groups will not 
differ. To adjust for the baseline imbalance, we employed 
an analysis of covariance technique. This is the traditional 
statistical approach used to address imbalance in efficacy 
measures. In our study it is considered appropriate since tests 
of homogeneity of variance between centers and treatments, 
based on demographic and efficacy measures, revealed no 
extreme departures, i.e., variance was homogeneous.
With respect to drug efficacy, all 3 WOMAC subscales 
detected clinically important statistically significant improve­
ments on both drugs. The comparative analysis indicated a 
superiority of Meclomen 100 mg tid over Voltaren 25 mg 
tid for pain and stiffness, no difference being detected for 
physical function. The superiority of Meclomen 100 mg tid 
over Voltaren 25 mg tid was also verified by study joint 
measures of night pain and pain on walking and further con­
firmed by the pain/discomfort and activités of daily living 
subscales of the Lequesne Index. It should be noted that we 
have not compared Meclomen 100 mg tid with higher doses 
of Voltaren (i.e., 150 mg/day), and it may be that with the 
higher dosage, the 2 drugs are equal in potency. Overall 
the data indicate that Meclomen 100 mg tid is an efficacious 
NSAID in the treatment of OA of the knee and is superior 
to Voltaren 25 mg tid.
The percentage of patients experiencing adverse reactions 
was no different between the 2 drugs and was similar to that 
in many other NSAID trials in OA®. Although there were 
numerically more adverse reactions, more patients experienc­
ing adverse reactions, more severe adverse reactions and 
more withdrawals due to adverse reactions with Meclomen 
than Voltaren, these differences were not statistically sig­
nificant. Furthermore, the use of a relatively low dose of 
Voltaren may have restricted the frequency and severity of 
Voltaren related adverse reactions. At a higher dose (i.e., 
Voltaren 150 mg/day), a greater number of adverse reac­
tions might be expected, some of which might be severe and
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result in withdrawal. Qualitatively, the profile of adverse 
reactions was predictable, since gastrointestinal reactions arc 
characteristic of the NSAID class of antirheumatic drugs. 
No significant decline in hemoglobin was noted with either 
NSAID. It is of note that while elevation of the BUN occurred 
with Meclomen, there was no corresponding elevation of the 
serum creatinine and no patient was withdrawn due to renal 
impairment. Furthermore, there was no clinically important 
or statistically significant difference between the 2 drugs with 
respect to vital signs (temperature, blood pressure), or other 
laboratory variables (hematology, biochemistry and urinaly­
sis). We do not feel that the increase in urine specific gravity 
with Voltaren was clinically important. Overall we conclude 
that the tolerability profile of Meclomen is similar to that 
of Voltaren.
The relative efficiency statistic is one measure of the com­
parative responsiveness of different measures. However, 
statistical efficiency is not the only clinimetric property of 
importance. Indeed, as the content validity or comprehen­
siveness of a measurement process improves, so does its 
sample size requirements. This occurs by virtue of the inclu­
sion of additional relevant but poorly responsive, items. The 
RE value is rarely unity and yet there are no standards for 
defining the significance of values <  1.0 or > I.O. It should 
be noted that estimates of RE are subject to some variability 
and may differ between studies using the same instruments. 
Finally, it should be noted that the method of squaring the 
ratio of 2 t values results in a potential range of RE values 
that shows nonlinear progression. Finally, an RE value of, 
for example, 2.0 does not indicate that the numerator index 
is twice as efficient as tlie denominator index'®. In compar­
ing the WOMAC, Lequesne and Doyle indices, RE values 
were in general close to unity (0.55-1.91). We do not cur­
rently advocate the summation of the WOMAC subscales 
into a total or pooled index since complex issues of weight­
ing and aggregation have not been resolved, although are 
the subject of current study. Nevertheless, it does facilitate 
the comparison of WOMAC with other indices in which 
aggregation is performed. We conclude from these data that 
the WOMAC, Doyle and Lequesne indices are similar in 
their RE. Although similar in statistical efficiency the 3 
indices differ conceptually. The Doyle Index'"* only assess­
es articular tenderness and is subject to interobserver varia­
bility. Since it records joint disease in all target areas for 
OA it is not specific for knee disease and may detect 
improvements or deteriorations in other joint areas. For an 
OA knee study it collects unnecessary data and does not by 
itself have sufficient content validity (comprehensiveness) 
to act as the sole outcome measure. The Lequesne Knee 
Index'* measures several important aspects of OA (pain, 
stiffness, walking distance and 4 forms of physical activity). 
However, neither its pain or stiffness nor its physical activity 
inventory is as comprehensive as that of WOMAC. Further­
more, its clinimetric properties have been less extensively
documented. In contrast, WOMAC has a comprehensive 
inventory of questions developed by 100 patients with OA 
themselves*. The face, content and construct validity, test 
restest reliability, internal consistency and responsiveness 
have been determined for both Likert and VA scaled ver­
sions of the index" *. We have also examined issues of para­
metric versus nonparametric analysis of the data"-*, signal 
versus nonsignal approaches to measurement®, blind versus 
informed administrations®', the relationship between the 
severity of involvement and tlie corresponding clinical impor­
tance of discomfort or disability on each question®® and the 
effect of circadian variation on perceived pain®*. WOMAC 
is a high performance self-assessment outcome measure 
which assesses most of the important clinical consequences 
of OA knee and has been extensively validated in several 
different clinical settings (NSAID trials*-®", total joint 
arthroplasty"-®*, interferential current therapy® )^.
In general it is difficult to find accurate values for the delta 
and standard deviation of a measure on which to calculate 
sample size for clinical trials. Type II errors may account 
for some of the lack of between drug differences detected 
in comparative studies in OA in the last 20 years®. Data 
from our study allow the calculation of WOMAC subscale 
standard deviations, not only for studies using absolute or 
static scores, but also those using change scores. These stan­
dard deviations are based on pooled estimates from the 61 
participating patients. The selection of delta is an individual 
decision based on the research hypothesis being tested, the 
types of patients under study and the nature of the inter­
vention®®, However, the mean values at baseline and termi­
nation, as well as mean change scores, when considered in 
the context of the appropriate standard deviation, permit the 
calculation of sample size by future users of WOMAC. 
French and Swedish versions of WOMAC have been 
produced, the index having been applied in a variety of set­
tings including studies of other NSAID, total hip arthroplasty 
and interferential current therapy. To date it has proven a 
valid, reliable and responsive self-administered measure in 
patients with OA of the knee and/or hip.
This comparison of Meclomen and Voltaren achieved 4 
major objectives. We demonstrated in this group of patients 
that Meclomen 100 mg tid is a safe and efficacious NSAID, 
superior in efficacy and similar in tolerability to Voltaren 
25 mg tid. It should be noted that we have not compared 
both drugs at maximum dosage and therefore cannot make 
any comprehensive statement regarding comparative drug 
efficacy or tolerability. Indeed, lack of comparability in doses 
of Meclomen and Voltaren may account for both benefit and 
ADR differences noted. The lack of group comparability in 
outcome measures at baseline may have introduced a bias 
that could possibly operate in favor of Meclomen. However 
no clinical correction can be made for this but a traditional 
statistical correction has been applied that should adequately, 
if not entirely, deal with the problem. The data, notably the
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within group comparisons, suggest that Meclomen is a use­
ful agent in the treatment of OA knee patients. Furthermore, 
we have determined that WOMAC shares a similar statisti­
cal efficiency with 2 other validated indices (Lequesne-knee 
and Doyle), and can specify the standard deviation neces­
sary for calculating sample size for future OA studies using 
WOMAC as the principal outcome measure.
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A Multicenter Study of Tenoxicam and Diclofenac in 
Patients with Osteoarthritis of the Knee
NICHOLAS BELLAMY, W. WATSON BUCHANAN, ANDREW CHALMERS, PETER M. FORD, 
WALTER F. KEAN, GUNNAR R. KRAAG, ERIKA GERECZ-SIMON, and JANE CAMPBELL
ABSTRACT. Objective. T o conduct the first C an ad ian  study o f  the com parative efficacy and safety  o f  tenoxi­
cam  and  d iclo fenac in  patients w ith  p rim ary  osteoarth ritis (O A ) o f  the  k n ee .
Methods. T enoxicam  20  m g per os on ce  d aily  (po od) w as com p ared  to d ic lo fen a c  (Voltaren™) 
50  m g per os 3 tim es a day (po tid) in  a 12-w eek , d ou b le  b lin d , ran d om ized , con tro lled , m ulti- 
cen ter , parallel tr ia l. T h e prim ary  ou tcom e m easu re w as the  pain  d im ension  o f  the W O M A C  
O A  In d ex . F o llow ing  an in itia l screen in g  v isit  an d  a 3 to 7  day N S A ID -free  w ashou t period  
( i .e . ,  b aselin e), patients w ere a ssessed  at W eek s 2 , 4  and  12; assessm en ts in clu d in g  som e 15 
e fficacy  variab les and safety  varia b les.
Results. N in ety-eigh t patients [ten ox icam  (n =  4 8 ), d ic lo fen ac (n =  50)] p artic ip a ted  in the  
tr ia l. S tatistica lly  s ign ifican t (p <  0 .0 5 ) im p rovem en ts in all 3 d im ension s o f  the W O M A C  
O A  Index and six  efficacy variables w ere  noted  in both  treatm ent groups. N o  sign ificant betw een  
drug d ifferences w ere  n oted  on an y  effica cy  v a r ia b le . S ign ifican tly  few er  p a tien ts reported  
a d verse  events in the  tenoxicam  grou p  (21 v s  3 3 , p  =  0 .0 3 ).
Conclusion. T enoxicam  is effica c io u s an d  w e ll to lera ted  in patients w ith  O A  o f  the k n ee. In  
th is  group  o f  patients it w as s im ila r  in  e ffica c y  and  su p er io r  in  to lerab ility  to  d iclo fenac 150  
m g /d a y  (SO m g tid ). T h u s the  b en efit/r isk  ra tio  o f  ten ox icam  w as su p erior  to th a t o f  d iclofenac  
in  th is stu d y . (J Rheumatol J99J ;2 0 ;9 9 9 -1 0 0 4 )
Key Indexing Terms: 
N SA ID W O M A C  O A  IN D E X C LIN IC A L TRIAL
Nonsteroidal antiinflammatory drugs (NSAID) are one of the 
most frequently prescribed drugs in the treatment of osteo­
arthritis (OA). Tenoxicam is a new oxicam compound which 
has been shown to exert antiinflammatory, analgesic and anti­
pyretic activities, and to inhibit platelet aggregation, prosta­
glandin and thromboxane synthesis'. At an oral dose of 20 
mg/day, the peak plasma concentration is reached witliin I 
to 4 h with a half-life of about 70 h®. After multiple dose 
regimens, steady state conditions are reached 10 to 14 days
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after initiation of a 20 mg/day oral dose regimen*. The 
optimal daily dose of tenoxicam has been shown to be 20 
mg/day".
Our objective was to conduct the first Canadian study of 
the comparative efficacy and safety of tenoxicam and 
diclofenac (Voltaren™) in patients with OA under double 
blind conditions for a period of 12 weeks. Superior clinical 
efficacy to placebo has been demonstrated with both these 
NSAID*-®. In particular, we have applied the validated 
WOMAC Osteoarthritis Index"*" to assess comparative 
drug efficacy.
MATERIALS AND METHODS
Ninety-eight consecutive consenting outpatients who were considered by 
the investigators to have primary OA of the knee entered tiie study at 6 
centers across Canada. The following inclusion and exclusion criteria were 
applied: Inclusion — Symptomatic primary OA of at least one knee for at 
least 3 months requiring treatment with NSAID, age 18-75 years; radio- 
graphic evidence (within last 6 montlis) consisting of narrowing of joint 
space, sclerosis, marginal lipping, bone cysts, osteophyte formation, with 
a minimum Grade 2 and maximum Grade 3 severity'®; and written 
informed consent; Exclusion — Any other type of arthritis; pregnancy or 
lactation; hypersensitivity to salicylates, oxlcams or other NSAID, use of 
oral anticoagulants, systemic or intraarticular corticosteroid use in the past 
2 months; ARA Class IV functional capacity; clinically significant cardio­
vascular, gastrointestinal (GI), hepatic, renal or hematological disease; aspar­
tate aminotransferase (AST) or serum creatinine greater than 10% above 
upper limits of reference range; history of alcohol or drug abuse; collagen 
disease; concomitant diseases, such as psoriasis, sypliilitic neuropathy, ochro­
nosis, metabolic bone disease, acute trauma with or without degenerative 
joint disease, which may affect joints.
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FoUowing initial screening (medical history and examination), there was 
a 3 to 7 day NSAID-free washout period during which patients were in- 
stnicted to cease all NSAID therapy and lake monitored quantities of 
acetaminophen, 325 mg if necessary. Patients were then reassessed (base­
line), and only those patients who experienced a deterioration during the 
washout period and overall increase in disease activity thereafter, were ran­
domized to receive either one capsule of tenoxicam 20 mg and 2 placebo 
capsules or 3 50 mg diclofenac capsules daily. Randomization occurred in 
blocks of 4 within each center, and treatment by center interactions were 
done in every analysis. Study medications were taken at meal times in the 
morning, noon and night. The color, size and markings of all of the cap­
sules were identical. Both assessors and patients were blind to the alloca­
tion until after completion of the study. During the active treatment phase, 
patients were permitted to take supplementary analgesia sparingly, if 
required, with acetaminophen (supplied by tlie investigator) up to 6 x 325 
mg/day. Compliance to study medication was verified by pill counting and 
analgesic ingestion was also assessed from pill counts.
Patients were assessed at 5 points during the trial: Screening, 0 (Base­
line), 2, 4 and 12 (termination) weeks. The following efficacy variables 
were measured at Weeks 0, 2, 4 and 12: (1) WOMAC-VA3.0 OA Index'* 
(a 24-item self-administered questionnaire probing pain, stiffness and physical 
function). It should be noted that, although the WOMAC OA Index was 
completed for botli knees, tlie statistical analysis was based only on the worst 
knee; (2) Doyle Articular Index'" (a modification of the Ritchie Index in 
which 48 joints or joint units are assessed by palpation for tenderness on 
a seale of 0 -  no tenderness, 1 +  patient complains of pain, 2 + patient com­
plains of pain and winces, 3 + patient complains of pain, winces and with­
draws); (3) Swelling of the knee Joints was assessed using a 4-point scale,
i.e., 0 = none, 1 = no swelling visible but suggested on palpation, 2 =  
swelling visible and perceived on palpation, and 3 = obvious swelling causing 
tightened skin over the joint; (4) Articular function measured by knee flex­
ion/extension with a goniometer (key joint); (5) 50-foot walk time; (6) 
Duration of morning stiffness (min) in the past 2-3 days; (7) Duration of 
inactivity stiffness (min), i.e., after silting, lying or resting later in the day; 
(8) Pain at night in key joint [100 mm visual analog scale (VAS)]; (9) Pain 
on initiation of walking in key joint (100 mm VAS); (10) Pain on walking 
in key joint (100 mm VAS); (11) Pain after a day of normal activity in key 
joint (100 mm VAS); (12) Severity of general pain (100 mm VAS); (13) 
Global assessment by patient (improved, no change, worsened); (14) Global 
assessment by physician (improved, no change, worsened); and (15) Phy­
sician and patient global evaluation of the clinical efficacy of the treatment 
at study termination compared to baseline (markedly improved, moderately 
improved, slightly improved, no change, slightly worse, moderately worse, 
markedly worse). At tlie screening visit, one knee was identified as the key 
joint'* (i.e., the worst knee was the primary focus of measurement for 
future assessment in the study). All 6 of the investigators conducting the 
clinical assessment were standardized prior to the study'^. A decision had 
been made a priori to use the WOMAC OA Index pain subscale as the prin­
cipal outcome measure, all other variables being relegated to secondary out­
come status.
Safety variables included laboratory detenninations (performed in each 
investigator’s regional laboratory) at screening. Week 4 and termination 
(i.e., routine hematology, clinical chemistry, urinalysis, and occult blood) 
and clinical determinations (i.e., blood pressure, heart rate and weight). 
Records were kept of concomitant medications. Adverse reactions were 
ascertained by open ended indirect questioning of the patient. Tolerance 
was evaluated both by the patient (veiy good, good, fair, poor, veiy poor) 
and the physician (based on the severity and frequency of side effects).
Sample size calculation for this study was based on the WOMAC pain 
subscale'®, the data being derived from a previous NSAID study'® (A =  
25% of 240.984, SD =  107.126). This permitted the detection of the clini­
cally important between drug differences between active drugs with Type 
I and Type II error rates of a  =  0 . 0 5 2 . ,  ^ ~  0.20 respectively with 
a sample size of 50 patients/group. A post hoc power analysis for the 
WOMAC pain subscale using the between group mean square error term
and 3 repeated measures showed that a clinically important change of 20% 
from baseline could be detected with power of 0.99.
Following study completion, double data entry was perfonned by tlie spon­
sor, Hoffmann-La Roche Limited, using a SIR (Scientific Information 
Retrieval)'® database. Data analysis, performed in collaboration with 
Innovus Inc., Hamilton, ON, was accomplished using SAS Version 6.03®" 
and BMDP-UX®' (1988) software packages. Data were checked for valid­
ity, normality, skewness and kurtosis. Descriptive analyses were conduct­
ed on all parametric variables defining means and standard deviations. Base­
line comparability of demographic and efficacy variables was conducted. 
Continuous variables were analyzed by rc|)cated measures analysis of covar­
iance using the respective baseline scores (Week 0) as tlie covariatcs to com­
pare the 2 treatment groups and six centers.
Compliance data and acetaminophen use were analyzed by repeated meas­
ures analysis of variance, comparing treatment groups and centers at Weeks 
2, 4 and 12. All repeated measures analyses were adjusted for unequal time 
between measures. Categorical outcome measures were analyzed using 
Pearson x® analysis to compare treatment groups and McNemar’s analy­
sis was used to compare treatment groups and visits. Categories for the swell­
ing score and global assessments which had low frequencies were collapsed 
for analysis. In all statistical tests, the level of Type I error (2-tailed) was 
set at 0.05. We made no correction for multiple comparisons, justified on 
the basis that a single primary efficacy variable was defined a priori.
RESULTS
One hundred patients entered the trial of whom 2 were 
excluded from analysis for the following reasons: allergy to 
aspirin = 1 ; allergy to acetaminophen = 1. Of the remain­
ing 98 patients, 48 received tenoxicam and 50 received 
diclofenac. Included in all analyses, on an intent-to-treat 
basis, were-2 patients who committed protocol violations: 
one patient in the tenoxicam group had a history of alcohol 
or drug abuse and had a baseline ASOT or creatinine level 
greater than 10% above the upper limit of the reference 
range, and one patient in the diclofenac group was over 75 
years of age. The disease and demographic profiles of 
patients are illustrated in Table 1. No clinically important 
between group differences were noted for any of these vari­
ables. The mean values of the efficacy outcome measures 
are illustrated in Table 2 at each of the clinical assessments. 
The number of patients completing therapy and the reasons 
for discontinuation are reported in Table 3.
Table 1. Prerandomization, preintervention comparison o f 
treatment groups ' mean (standard deviation)
Variable Tenoxicam 
(n =  48)
Diclofenac 
(n =  50)
Sex (F, M) 34F, 14M 36F, I4M
Age (years) 62.5 (7.6) 62.7 (8.6)
Disease duration (years) 10.4 (8.9) 8.2 (7.6)
Definite osteophytes 34 40
Moderate multiple osteophytes 17 18
ARA Functional Class I 12 11
11 29 31
III 7 7
Weight (kg) 85.1 (17.6) 86.6 (18.6)
Height (cm) 166.2 (9.9) 166.9 (8.7)
Heart rate (bpm) 72.0 (9.5) 71.0 (10.3)
Systolic blood pressure (mm Hg) 139.6 (18.4) 140.7 (17.5)
Diastolic blood pressure (mm Hg) 83.5 (8.5) 82.5 (6.9)
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Table 2. Mean values for efficacy outcome measures at baseline (standard deviation) and visits at Weeks 2, 4 and 12
Within Group Between Group
Outcome Variable Group Baseline Week 2 Week 4 Week 12 Baseline vs Termination 
p Value
Baseline vs 
Termination 
p Value
WOMAC OA Index:
Pain (0-500 mm) T 230.9 (95.5) 195.4 179.7 188.8 0.0372 0.7560
D 231.7 (108.0) 177.3 146.3 157.4 0.0001
Stiffness (0-200 mm) T 97.4 (48.3) 75.6 65.6 71.0 0.0005 0.7447
D 91.2 (47.4) 68.5 56.5 51.5 0.0001
Physical function T 809.2 (361.2) 664.6 594.0 600.3 0.0005 0.4697
(0-1700 mm) D 773.9 (388.2) 585.6 494,9 503.2 0.0001
Doyle articular index T 13.8 (14.4) 11.0 8.9 9.0 0.0140 0.8899
tenderness score (0-144) D 14.8 (13.6) 10.0 8.7 8.6 0.0029
Pain severity (100 mm) T 60.0 (20.5) 45.3 45.0 48.8 0.0339 0.5616
D 57.8 (24.1) 43.8 39.7 43.3 0.0292
Pain at night (100 nun) T 45.2 (28.0) 35.5 34.0 36.4 0.0517 0.8670
D 47.7 (27.7) 36.5 33.1 30.3 0.0006
Pain on initiation of T 60.0 (24.1) 44.0 43.3 35.9 0.0001 0.7196
walking (100 mm) D 49.0 (24.7) 37.9 33.2 30.0 0.0001
Pain on walking (100 mm) T 56.4 (22.1) 47.2 42.1 38.4 0.0007 0.9987
D 55.1 (24.2) 39.2 33.7 33.4 0.0001
Pain after a normal day T 64.7 (22.5) 53.6 49.4 43.9 0.0001 0.8198
of activity (100 mm) D 59.9 (24.9) 46.0 37.3 38.9 0.0001
Morning stiffness (min) T 31.1 (45.7) 23.2 24.2 \9A 0.9652 0.2751
D 21.0 (23.2) 19.8 15.5 14.6 0.3981
Inactivity stiffness (min) T 12.6 (15.0) 9.2 9.2 ,8.3 0.0650 0.5236
D 14.3 (21.4) 7.8 7.8 13.3 0.0151
50' walk time (s) T 15.3 (7.1) 14.1 13.5 13.4 0.0047 0.7090
D 13.5 (3.6) 12.9 12.1 12.2 0.0083
Flexion (“) T 115.2 (24.5) 117.6 119.2 122.5 0.0868 0.4332
D 115.7 (19.5) 121.1 122.5 123.3 0.0003
Extension (°) T 1.4 (2.6) 1.3 1.2 1.9 0.3724 0.1954
D 4.0 (6.1) 2.6 2.4 2.6 0.0318
Total range (°) T 114.1 (24.9) 120.3 118.0 121.0 0.1107 0.9044
D 112.1 (20.7) 118.5 120.1 120.8 0.0001
Body weight (kg) T 85.6 (18.1) 86.5 85.6 84.0 0.7484 0.0252
D 86.1 (18.5) 87.0 86.3 84.9 0.9312
Heart rate (bpm) T 70.7 (10.1) 71.1 72,7 72.2 0.1440 0.0780
D 72.8 (II.O) 71.5 71.5 72.3 0.6663
Systolic blood pressure T 134.5 (15.7) 133.9 138.5 135.7 0.6842 0.5643
(mm Hg) D 137.5 (15.2) 135.7 137.2 140.6 0.2226
Diastolic blood pressure T 79.8 (9.6) 80.8 81.3 82.1 0.1063 0.7684
(mm Hg) D 80.6 (8.7) 81.2 81.5 82.3 0.4739
T = Tenoxicam, D =  Diclofenac.
Efficacy. Within group comparisons (baseline versus end­
point) were made for all outcome variables (Table 2). Statisti­
cally significant improvements with treatment were noted as 
follows: Both drugs -  WOMAC (all 3 subscales), Doyle 
Articular Index, pain severity, pain on initiation of walking, 
pain on walking, pain after a normal day of activity, and 
50-foot walk time; diclofenac only -  pain at night, inactivity 
stiffness, flexion, extension and total range of movement. 
With respect to key joint swelling, 25% of the tenoxicam 
group and 20% of tlie diclofenac group had either obvious 
or visible swelling at baseline. Both treatment groups ex­
perienced a reduction from baseline in swelling over the 
course of the study. By the end of the study, the global as­
sessments made by both the physician and patient showed
a similar improvement in both groups, i.e., tenoxicam (phy­
sician 40%, patient 38%), diclofenac (physician and patient 
34%). Physicians and patients rated global evaluation of clin­
ical efficacy similarly at study termination (i.e., tenoxi­
cam/diclofenac: improved markedly -  11,21 %/33,39%; 
improved moderately -  38,30%725,19%; improved slightly 
-  I3,6%/I8,14%; no change -  19,I9%/I4,I0%; worsened 
slightly -  2,2%/4,4%; worsened moderately -  9,11 %/6,8%, 
and worsened markedly 8,11 %/0,6%. No significant treat­
ment differences were found for any of these assessments.
Between treatment comparisons were made for all outcome 
variables. No statistically significant treatment differences 
were found between tenoxicam and diclofenac on any of the 
efficacy measures. There were no differences in analgesic
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Table 3. Number o f patients completing therapy and reasons 
for discontinuation
Tenoxicam Diclofenac Total
Randomized 48 50 98
Completed 12 weeks’ treatment 36 33 69
Discontinued therapy before
end of Week 12^ 11 16 27
Reason for discontinuation:
Lack of efficacy*’ 8 2 10
Adverse event‘d 3 11 14
Concurrent illness 0 1 I
Medication missing
(noncompliant) 0 I 1
Patient withdrew 0 1 1
 ^ = 1.02, p value = 0,3140.
b ^2 _  4.29, p value = 0.0384. 
c 2^ =  4.96, p value = 0.0259.
consumption. However, 2 patients in the diclofenac group 
and 8 in the tenoxicam group withdrew due to inefficacy (%® 
= 4.29, df = 1, p = 0.04) (Table 3).
Tolerability. The frequency and nature of adverse events 
reported during the study are illustrated in Table 4. The 
majority of clinical adverse events reported were gastroin­
testinal in nature and accounted for 40-44% of all events 
in both treatment groups. As shown in Table 4, 44% of 
patients in the tenoxicam group and 66% of patients in the 
diclofenac group reported one or more adverse event, and 
this rate significantly differed between the treatment groups
(x  ^ = 4.90, df =  1, p = 0.03). Likewise, there were 
numerically more adverse events reported in the diclofenac 
group (n = 85) than in the tenoxicam group (n = 52), No 
significant difference was detected in the number of patients 
with severe events (tenoxicam = 8, diclofenac = 13). There 
was, however, a significant difference in the number of 
patients withdrawn due to adverse events (tenoxicam = 3, 
diclofenac = 11, =  4.96, df = 1, p = 0.03). The rea­
sons for withdrawal were as follows: tenoxicam — dyspep­
sia = 1, fluid retention = 1, rash = 1; diclofenac — fluid 
retention = 1, headache = 1, weight gain = 1, asthma =
1, gastrointestinal events = 5, elevated glucose, leg cramps 
and epigastric pain = 1, bowel strangulation, headache, ab­
dominal pain = 1. At study termination, evaluation of toler­
ance by physicians and patients showed no significant treat­
ment differences. The physicians’ evaluation of adverse 
events was as follows, tenoxicam/diclofenac: no adverse 
events (AE) = 62/39%; mild AE = 4/15%; moderate AE 
= 21/27%; severe AE = 13/19%. The patients’ evaluation 
of tolerance showed similarity between drugs, i.e., tenoxi­
cam/diclofenac; very good = 60/45%; good =  23/21%; fair 
= 11/18%; poor = 0/4%; very poor = 6/12%. No signifi­
cant between group differences were noted in heart rate, sys­
tolic blood pressure, diastolic blood pressure, hematology, 
clinical chemistry or urinalysis. The number of normal base­
line and abnormal termination values are reported for all 
laboratory measures in Table 5. With the exception of a sig-
Table 4. Adverse events by the 2 treatment groups
Event Tenoxicam Diclofenac
(n = 48) (n = 50)
GI system disorders 23 34
Central and peripheral nervous
disorders 8 18
Body as a whole — general disorders® 7 8
Respiratory system disorders 5 5
Metabolic and nutritional disorders 5 5
Musculoskeletal disorders 0 6"
Psychiatric disorders 0 5'=
Skin and appendages disorders 2 2
Urinary system disorders 1 1
Vascular disorders 1 0
Autonomic nervous system disorders 0 1
Total number of adverse events (AE)t 52 85
Total number of patients experiencing
AE* 21 33
Total number of patients with severe
AE* 8 13
Table 5. Safety laboratory measures: Number o f normal base­
line and abnormal termination values
“ WHO Classification of Adverse Events (1990); i.e., fatigue, fever, cold, 
etc.
Musculoskeletal: leg pain (2), back pain (1), shoulder and neck pain (1), 
foot pain (2).
■= Psychiatric; depression (1), increased appetite (1), insomnia (3). 
t Some patients had more than one AE.
* X® =  4.901, p value =  0.0270.
t Side effects were graded on a 3-point scale (mild, moderate, severe) at 
tlie investigator’s discretion; x® = 0.000, p value =  0.9886.
Laboratory Measure Tenoxicam Diclofenac
Hematology
Hemoglobin 1 1
Hematocrit 2 0
Red blood cells 0 1
White blood cells 2 2
Platelets 1 0
Biochemistry
Total protein 1 0
Albumin 1 0
Phosphorus 0 0
Glucose 1 4
Blood urea nitrogen 13 9
Creatinine 2 1
Total bilirubin 2 1
Alkaline phosphatase 1 2
Chloride 4 7
Potassium 0 I
Sodium 1 2
Aspartate aminotransferase 0 7
Calcium .0 4
Urinalysis
Specific gravity 3 0
pH 2 1
Albumin I 1
Glucose 0 0
Fecal occult blood 1 1
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nificant increase in abnormal BUN at termination compared 
to baseline in both the tenoxicam (%® = 10.29, df = 1, p 
= 0.001) and the diclofenac groups (%® = 4.46, df = 1, 
p = 0.03), and significantly more abnormal SGOT at ter­
mination than at baseline in the diclofenac group (%® =  7.00, 
df = 1, p == 0.01), no other within group changes in hema­
tology, clinical chemistry or urinalysis were noted with either 
drug. Body weight was found to decrease significantly more 
in patients in the tenoxicam group than in patients in the 
diclofenac group (p = 0.03). Although this difference was 
statistically significant, the mean difference between groups 
was less than 2 kg.
DISCUSSION
The prescription of NSAID to patients with OA of the knee 
is a trade off between risk and benefit. Fortunately, for the 
majority of NSAID, the benefits are substantial and accrue 
to the majority of recipients, while adverse events are rela­
tively infrequent. The prediction of response in individual 
patients is largely speculative®® since we have an incomplete 
knowledge of those factors that determine the response®* 
which is often mild in degree and usually either self-limited 
or easily managed. Nevertheless, comparative drug efficacy 
and tolerability, among other factors such as cost and con­
venience, are important indications in selecting individual 
drugs from those available for treating individual patients. 
Our study used a rigorous méthodologie design and includ­
ed a fully validated primary outcome measure (WOMAC) 
of defined reliability, face, content, construct validity and 
responsiveness"*'" which has previously detected a clini­
cally important and statistically significant difference between 
2 NSAID'®. WOMAC is currently available in Likert scaled 
and visual analog scaled forms, in English, French and 
Swedish language translations and has been used in several 
different clinical settings (pharmacologic*®'®"'®*, surgical®®, 
physiotherapy®®’®®). We are aware that it is presently being 
used in 12 other studies (5 pharmacologic, 4 surgical, 3 phys­
iotherapy) in Canada, USA, Holland, Sweden and Australia. 
Many previous NSAID studies in OA have used outcome 
measures of poorly defined or undefined reliability, validity 
and responsiveness®". This has the disadvantages of lack of 
standardization of outcome measures and an inability to 
differentiate a Type II error from pharmacologic similarity 
of the test drugs.
In our study we observed beneficial pharmacologic effects 
with both tenoxicam and diclofenac but no significant differ­
ence between these 2 agents in their efficacy*"-*®. Given the 
use of a fully validated primary outcome measure and the 
well demonstrated efficacy of diclofenac**, this suggests 
that tenoxicam 20 mg od is efficacious in the treatment of 
OA knee and similar in efficacy to diclofenac 150 mg/day 
(50 mg tid). This contention is supported by the majority 
of other efficacy outcome measures that also show signifi­
cant within group improvements but no between group differ­
ences. It is particularly important to note that there was no 
between group difference in acetaminophen consumption in­
dicating a lack of difference in analgesic effect between the 
2 treatments. It is of interest that, while the WOMAC stiff­
ness subscale (which assesses severity of morning stiffness 
and gelling) detected improvement with treatment, stiffness 
measures, based on duration of stiffness, failed to detect simi­
lar improvement except for inactivity stiffness in the 
diclofenac group. It is our impression that in patients with 
OA NSAID treatment more frequently reduces the severity 
of morning stiffness than its duration. This likely explains 
these apparently discrepant results. An alternate explanation 
is that the sample size required for measuring duration of 
stiffness effects may be higher than that used in our study. 
Our recent experience determining variables for sample size 
calculation in trial eligible patients with OA suggests that 
the minimum requirements for detecting a clinically impor­
tant difference in the duration of morning stiffness are pos­
sibly 195-1368/group ^ = 0.05, 1Î = 0.20)*".
The issue of tolerability is paramount in NSAID prescrib­
ing since in most published double blind studies, investiga­
tors have generally concluded that there is no between group 
difference between any 2 NSAID. In general, both tenoxi­
cam and diclofenac were well tolerated by the majority of 
patients. However, tenoxicam may be significantly better 
tolerated as evidenced by the following: fewer patients report­
ing adverse events and withdrawals due to adverse events 
(p = 0.03), fewer GI events'and fewer SGOT elevations. 
The superior GI tolerability of tenoxicam has been noted in 
other comparative trials** *®, while a possible proclivity for 
diclofenac to produce hepatotoxicity has been the subject of 
a recent publication*®.
Clearly the efficacy and tolerability profile of an agent can­
not be defined by a single trial. The conclusions, by neces­
sity, are limited to patients of similar characteristics to those 
selected for study. Nevertheless, our trial provides additional 
data that support the contention that tenoxicam 20 mg po od 
is an efficacious agent similar in its effect to diclofenac 150 
mg/day (50 mg tid). In this group of patients, tenoxicam was 
better tolerated particularly with respect to GI and hepatic 
(SGOT) events. Our data suggest that tenoxicam is an 
efficacious, well tolerated agent in the treatment of patients 
with OA of the knee. Its benefit/risk ratio was superior to 
that of diclofenac in our study.
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Double Blind Randomized Placebo Control Trial of 
Controlled Release Codeine in the Treatment of 
Osteoarthritis of the Hip or Knee
PAUL M. PELOSO, NICHOLAS BELLAMY, WILLIAM BENSEN, GLEN T.D. THOMSON, ZOLTAN HARSANYI 
NAJIB BABUL, and ANDREW C. DARKE
ABSTRACT. Objective. Pain is the cardinal feature o f osteoarthritis (OA), and with advancing disease Uiere is loss 
of function and increasing pain even at times o f joint rest. Few studies have evaluated the role of opi­
oid analgesics in treating the pain of OA.
Methods. This randomized, double blind, parallel group study compared the efficacy and safety of a 12 
hourly controlled release codeine fonnulation (Codeine Contin®) witli placebo in patients witli chron­
ic pain due to OA of the liips and/or knees. The 4 week treatment period, following an analgesic 
washout phase of 2 -7  days, included weekly clinic evaluations, at which the dose was escalated as 
appropriate, and daily patient diary completion. Pain (daily), stiffness, and physical function (weekly) 
were assessed using the multidimensional, self-administered WOMAC (visual analog scale version) 
questionnaire.
Results. Sixty-six eligible patients completed tlie study. The mean initial and final daily doses of con­
trolled release codeine were 50 mg every 12 h at baseline and 159 mg every 12 h at tlie final assess­
ment. All variables in die efficacy analysis indicated superiority of controlled release codeine over 
placebo. The WOMAC pain scale showed an improvement of 44.8% over baseline in tlie controlled 
release codeine group compared witli 12.3% taking placebo (p =  0.0004). For the WOMAC stiffness 
and physical function scales the improvements over baseline on controlled release codeine were 47.7% 
and 49.3%, respectively compared with 17.0% and 17.0%, respectively, with placebo (p = 0.003; p =
0.0007). Controlled release codeine was also significantly better tlian placebo on measures o f sleep 
quality and requirement for supplemental acetaminophen.
Conclusion. Single entity controlled release codeine is an effective treatment for pain due to OA of tlie 
hip or knee. (J Rheumatol 2000;27:764-71)
Key Indexing Terms:
CODEINE 
RANDOMIZED CLINICAL TRIAL
CONTROLLED RELEASE OSTEOARTHRITIS
WOMAC
Osteoartliritis (OA) is a common clinical condition. Estimates 
suggest that about 52% of the population is affected, and in 
those over 65 years, up to 85% of individuals have some 
involvement. The prevalence of knee and hip OA increases 
progressively with age. Pain is the cardinal feature of clinical 
OA and is associated with the presence of radiographic 
changes and with increased mortality, morbidity, and func-
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tional dependence on others'. With advancing disease there is 
increasing pain and loss of function, witli intrusion of pain 
even at times of joint rest.
Current American and Canadian recommendations®  ^ for 
the treatment of OA pain favor tlie use of simple analgesics, 
physical modalities, and topical therapies before nonsteroidal 
antiinflammatory drugs (NSAID). The relative efficacy of 
NSAID versus simple analgesics is being debated .^ In addition 
NSAID can produce toxicity in the gastrointestinal tract®"® and 
botli NSAID and acetaminophen can produce renal toxicity" '® 
tliat may offset tlieir beneficial effect. The American and 
Canadian guidelines do not discuss the use of opioid analgesics 
in any detail.
In contrast, the role of opioids in chronic treatment of can­
cer associated pain has been well established, with adequate 
pain control being achievable in up to 85-95% of patients, 
without umiianageable or intolerable side effects and witliout 
significant risk of addiction'® '''. However, application of tliese 
principles to the treatment of patients with unrelieved pain of 
non-cancer origin has been hampered by concerns over regu­
latory sanctions and the possibility that opioid side effects or
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psychologie dependence will reduce patients’ functional abil­
ity rather than improve it through reduction in pain'®. There is 
a growing literature on the effectiveness of opioid analgesics 
in nonmalignant pain'® '® and recently, controlled clinical tri­
als have been completed indicating the effectiveness of con­
trolled release morphine'^ and controlled release codeine®"-®'. 
This has led to the development of guidelines for the use of 
opioids in patients with pain of non-cancer origin®®-®®.
However, few studies have looked specifically at the role 
of opioids in treating pain associated with OA despite its pre­
sumed nociceptive origin in multiple anatomic sites including 
capsule, ligaments, and insertions, and noncorpuscular type 4 
nerve endings in the fibrous capsule, synovium, articular fat 
pads, and arterioles®'’-®®. Recent demonstrations of the effica­
cy of intraarticular morphine in relieving pain after knee 
surgery, tlirough an action on mu-opioid receptors®® ®®, furtJier 
support the rationale for trials of opioids in patients with joint 
pain.
While codeine is commonly used for tlie treatment of OA 
pain, usually in combination with acetaminophen or acetyl- 
salicylic acid (ASA), there are no controlled studies demon­
strating its benefits. Such studies are needed to balance clini­
cal benefits against concerns over use in patients with non- 
cancer pain. Regular administration of controlled release opi­
oids results in improved compliance and pain control in 
patients with cancer pain®®. The availability of a controlled 
release formulation of codeine with phamiacokinetics sup­
portive of 12 hourly dosing®" suggested that it may be of sim­
ilar value in treatment of patients with OA pain. A previous 
study in patients with cancer pain revealed a dose-response 
relationship in the range of 200-600 mg/day®®. To decrease 
tlie risk of opioid toxicity in patients with a lower level of 
prior exposure to opioids, we conducted a randomized place­
bo controlled trial of patients with OA. Patients began con­
trolled release codeine at a daily dose of 100 mg with provi­
sion for titration to a maximum of 400 mg/day.
MATERIALS AND METHODS
Patient selection. Four Canadian sites participated after obtaining approval 
from an independent research ethics board. Patients with primary OA who 
were male or nonpregnant female and over tlie age of 35 years were eligible. 
Patients were required to have OA symptoms, including pain, stiffness, and 
disability, requiring the use of acetaminophen, antiinflammatory agents, or 
opioid analgesics for the previous 3 montlis or longer. Patients were required 
to provide written informed consent, and were given a copy of tiieir signed 
consent. In all instances, patients had radiographic confimiation of minimum 
Grade II OA severity of a knee or hip joint, as defined by the standard atlas 
of radiographs*®. Grade II OA changes require the presence of an osteophyte 
and joint space narrowing. Individuals with more advanced radiographic 
grades were also eligible provided tliat imminent joint replacement surgery 
Would not prevent study completion. Patients were required to. discontinue 
tlicir prestudy analgesics, and experience a flare in their hip and/or knee pain 
during a 2-7 day washout period. A flare was defined as an increase in pain 
to a minimum report of moderate pain on a 5 point Likert scale (none, mild, 
moderate, severe, and excruciating pain).
Patients were excluded if they had a known allergy to codeine, other opi­
oids, or acetaminophen, and if a liistory of previous opioid abuse, character­
ized by compulsive drug use, an intense desire for the drug, and an over­
whelming craving for its continued availability, or if manipulation of a previ­
ous physician or the medical system for the puiposcs of obtaining additional 
drug was suspected. In addition, patients were ineligible if they had secondary 
causes of OA, or if they had received systemic or intraarticular corticosteroids 
in the past 2 months or intraarticular viscosupplementation in the past 6 
months. Finally, patients with Grade 4 severity and awaiting replacement 
surgery were also ineligible.
Trial design. Medication at the 4 centers was dispensed according to a ran­
domized, balanced, double blind parallel group assignment. Patients were 
allocated to either controlled release codeine (Codeine Contin®, Purdue 
Frederick, Pickering, Ontario, Canada) administered 12 hourly, or identical 
appearing placebo, also given 12 hourly. Use of additional antiinflammatory 
or analgesic medication, other than acetaminophen 650 mg up to 3 limes daily 
for control of pain not managed by controlled release codeine or placebo, was 
not permitted. Acetaminophen use was recorded in a patient diary. Treatment 
was initiated at a dose of 100 mg of controlled release codeine per day (or 
identical placebo), and the dose was escalated weekly, provided there was 
ongoing pain and a lack of limiting side effects, up to a maximum of 400 mg 
per day (200 mg ql2h). Tlie treatment period after tlie washout phase was 4 
weeks, with weekly clinical evaluations and daily completion of a diary by 
the patients.
Two primary measures of efficacy were established a priori. These mea­
sures were the daily Western Ontario and McMaster University Osteoarthritis 
(WOMAC) pain visual analog scale (VAS) and tlie daily overall Pain 
Intensity scores over the previous week. Tlie WOMAC is a validated, multi­
dimensional, self-administered questionnaire capable of measuring clinically 
important symptoms in patients witli OA of the hip and/or knee, that has been 
validated in botli VAS and Likert versions**-*®. Tlie WOMAC pain VAS con­
sists of 5 questions on OA pain, including walking on a flat surface, going up 
or down stairs, at night in bed, at rest, and standing. The VAS version used in 
tills study is a 100 mm scale, anchored by “no pain” at the zero mrn anchor 
and “extreme pain” at the 100 mm anchor. The overall pain intensity over the 
previous week was assessed by asking the patient: “What was your average 
pain over the last week?"
Secondary measures included: weekly WOMAC Stiffness and Physical 
Function scales; daily 100 mm VAS average pain scale; 7 item questionnaire : 
on sleep (4 items using 100 mni VAS scale: 1. trouble falling asleep; 2. need 
medications to fall asleep; 3. awakening by pain at night; and 4. awakening 
by pain in the morning); weekly nondirected adverse events questionnaire; 
and the Drug Liking Index completed at study tennination. Tlie Drug Liking 
Index is a 9 point Likert scale where 1 = “I dislike the drug effect very much” 
and 9 = “I like the drug effect veiy much”*^ . Patients were instructed to use 
this scale to assess the central nervous system effects of tlie drug, independent 
of its analgesic effects on their OA. Patient and physician global assessment 
of clinical effectiveness (a change score using a 7 point scale, where 0 = 
“markedly worse” and 7 = “markedly improved”) was recorded at study ter­
mination.
Sample size and statistical evaluation. Sample size was determined for both 
primary outcomes. For tlie WOMAC pain VAS scale, the maximum score 
obtainable is 500 mm from five 100 mm scales. A previous study evaluating 
2 NSAID showed a standard deviation (SD) of 107 mm, and a mean pain 
scale score of 241"". In order to detect a 100 mm difference between 2 tliera- 
pies, a sample size of 25 patients per treatment arm is needed, when the power 
is set at 80% and the alpha is set at 0.05 (2 tailed). Allowing for a 25% 
dropout rate mandated a total study sample size of 68.
Altliough the WOMAC index has been used in a large number of clinical 
trials', it has not previously been used in an efficacy trial of an opioid anal­
gesic. In addition to the multi-item pain measurement afforded by the 
WOMAC index, a second primary outcome measure based on a single glob­
al VAS pain scale was also used. Assessments of pain on a 100 mm VAS scale 
in studies in OA of the knee have shown an overall median SD of 23 mm"' 
and it has previously been shown using a Delphi approach that a difference of 
15 mm between treatments is clinically important"*. Assuming a 20 mm dif­
ference between controlled release codeine and placebo to be a clinically 
important difference, and with alpha set at 0.05 (2 tailed) and power set at
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80%, a (Otai o f  39 patients per group w ould  be required. A gain  assum ing a 
25% dropout rate, a m inim um  o f  104 patients across tlie study sites w as ca l­
culated to be required.
Data were entered and analyzed in SAS v.6.12. For continuous and ordi­
nal data, analysis was undertaken using means, SD, and analysis of covari­
ance using baseline data as the covariate; baseline comparisons were made 
using the t test. Since rescue analgesic use was not assessed at baseline, analy­
sis of variance was used for comparing tteatments. Categorical variables were 
also compared using Fisher’s exact test and tlie Wilcoxon test (Drug Liking 
Index). Differences across treatment visits were examined using repeated 
measures analysis of variance of tlie change from baseline scores and tlie dif­
ferences between treatments al each visit were assessed by analysis of covari­
ance. For descriptive purposes, values have been expressed as change from 
baseline and percentage change from baseline.
RESULTS
A total of 103 patients were enrolled, with 66 providing com­
plete information across all measurement points. Fifty-one 
patients were initially randomized to controlled release 
codeine, and 52 to placebo. Of the patients completing the 
study 31 had been randomized to controlled release codeine 
and 35 to placebo. Seven patients in each group had previ­
ously used codeine on a longterm basis (a mean of 2.3 and 1.9 
yrs in the controlled release codeine and placebo groups, 
respectively). As shown in Table 1, tire proportion of patients 
who completed the study did not differ between treatments.
The mean initial and final controlled release codeine doses 
were 50 mg (SD 0.0) at baseline and 159 mg (SD 52) 12 
hourly at the 4 week final assessment. The mean age of the 
completed patients was 61.6 (SD 11.2) years witli a minimum 
of 39 years and a maximum of 81 years. Tlrere were 25 men 
(13 codeine, 12 placebo) and 41 women (18 codeine, 23
Table 2. Demographic and baseline data.
Table 1. Patient disposition.
CR Codeine Placebo
_____'------
Total
Completion status
Completed 31 35 66Incomplete* 20 17 37Total enrolled 51 52 103
IReason for non-completionAdverse event 15 4 191Unrelated illness 1 0Inadequate pain control 1 5 6 !Patient noncompliant 1 1 2 'Patient witlidrawal I 1 2 !Protocol violation 0 1 i  jOther reasons 1 5 6 /
Rate of non-completion by treatment, p = 0.54. Fisher’s exact lest. 
CR: controlled release.
placebo). Hip pain was reported by 32 patients, 58 patients 
reported knee pain, and 24 patients reported pain of the knee 
and hip. On average, patients were 94.7 kg in weight. As 
shown in Table 2, there were no statistically significant dif­
ferences between the treatment groups at baseline. There were 
also no differences in demograpliic and baseline characteris­
tics (age, sex, duration of OA, perceived benefit of current 
analgesic, initial pain intensity) between patients who com­
pleted the study and tliose who did not.
All variables in this efficacy analysis favored controlled 
release codeine over placebo, as shown in Table 3. Using 
mean baseline values as tlie denominator, and mean values for 
tlic last week in the study (Week 4), percentage improvement
Characteristic
Completers 
CR Codeine, 
Mean (SD)
Completers 
Placebo, 
Mean (SD)
Non- • 
Completers, 
Mean (SD)
Completers 
CR Codeine vs 
Placebo (p)
Age 60.1 (11.4) 63.0 (10.9) 63.1 (8.9) 0.29
Sex 18F:I3M 23F:12M 23F:14M 0.61
Duration of OA (yrs) 11.8(8.0) 9.5 (7.0) 9.9 (7,3) 0.22
Weight (kg) 94.5 (23.5) 94.8 (19.0) 94.6(21.0) 0.96
Height (cm) 168.6 (10.5) 164.9 (10.3) 165.5 (10.7) 0.15
Knee OA 28 30 20 CC: 16 PL 0.71
Hip OA 13 19 5 CC: 12 PL 0.34
Baseline pain VAS (1-100 mm) 58.2 (18.9) 53.2 (24.5) 61.3 (19.8) 0.35
Pain at rest 24 27 29
(% Yes) 77.4 77.1 76.1 0.8
Perceived benefit of current analgesic 1.7 1.8 1.6
(0.7) (0.8) (0.9) 0.84
Baseline WOMAC VAS pain scale 263.5 252.4 278.7
(0-500 mm) (99.7) (129.8) (133.2) 0.69
Baseline WOMAC VAS stiffness scale (0-200 mm) 126.5 (40.1) 106.2 (47,7) 131.4(45.2) .0.07
Baseline WOMAC VAS function scale 900.5 844.9 867.7
(0-1700 mm) (357.3) (405.3) (398.4) 0.56
Baseline acetaminophen 9.5 11.1 11.2
(tablets used) (8.5) (10.3) (9.9) 0.51
CR: controlled release.
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Table 3. Response characteristics (completers), mean (SD).
Outcome
Controlled Release Codeine, 
n = 31
Baseline Week 4 Difference Baseline
Placebo, 
n = 35 
Week 4 Difference
P
Codeine 
vs Placebo
WOMAC VAS pain 
(VAS, 0-500 mm) 263.5 (99.7) 145.4(101.3) 118.0(106.3) 252.4(120.8) 221.3(118.7) 31.1 (92.0) 0.0004
Weekly pain intensity 
(VAS, 0-100 nun) 65.4 (20.4) 29.4 (20.9) 36.0 (27.6) 57.4 (26.7) 47.8 (25.6) 8.9 (22.2) 0.0001
Pain over 24 h
(VAS, 0-100 mm) 58.2(18.9) 32.5 (21.4) 25.7 (23.3) 53.2 (24.5) 47,7 (24.7) 5.4 (20.3) 0.0001
WOMAC stiffness 
(VAS, 0-200 mm) 126.5 (40.1) 66.2 (46.3) 60.3 (51.1) 106.2 (47.7) 87.1 (52.8) 18.1 (40.7) 0.0030
WOMAC physical function 
(VAS, 0-1700 mm) 900.5 (357.3) 456.2 (316.2) 444.2(400.8) 844.9 (405.3) 687.5 (415.5) 143.5 (284.7) 0.0007
Trouble falling asleep 
(VAS, O-KX) mm) 40.7 (37.2) II.2 (21.2) 29.5 (37.5) 38.2 (34.5) 23.8 (25.5) 14.4 (34.7) 0.0220
Need medications to sleep 
(VAS, 0-100 mm) 34.5 (41.2) 9.3 (21.9) 25.3 (36.4) 24.9 (33.1) 22.3 (30.3) 2.6 (27.0) 0.0039
Pain on awakening 
(VAS, 0-100 mm) 36.8 (34.9) 21.5 (27.6) 28.1 (33.7) 39.5 (35.7) 30.9 (31.1) 9.0 (28.3) 0.0231
Rescue acetaminophen administration by week 
(Baseline is Week 1) 8.9 (7.2) 4.2 (5.8) 4.7 9.9 (8.0) 9.2 (8.1) 0.7 0.0051
was calculated for the major outcome variables. For the 
WOMAC pain VAS there was an improvement of 44.8% in 
the controlled release codeine group compared with 12.3% 
taking placebo (p = 0.0004). For the WOMAC stiffness scale 
the improvements were 47.7% and 17.0%, respectively (p = 
0.0030). On the WOMAC physical function scale, the 
improvements were 49.3% and 17.0%, respectively (p = 
0.0007).
Improvements in pain (vs placebo) seen on the WOMAC 
pain VAS increased with duration of treatment from week to 
week, starting at a mean improvement of 7.9 mm at Week 1, 
followed by 26.8 mm at Week 2,53.6 mm at Week 3, and 75.9 
mm at Week 4. Similar improvements in pain were also seen 
from the weekly VAS pain score, starting with an improve­
ment of 3.3 mm at Week 1, 1.4 nun at Week 2, 16.2 nun at 
Week 3, and finally 18.4 mm at Week 4.
Figures 1 and 2 show the change from baseline at each 
week of the study for the WOMAC pain VAS and the weekly 
pain VAS score, respectively. There was a significant week by 
drug interaction for both the WOMAC pain VAS score (p = 
0.0195) and the weekly pain score (p = 0.0005), reflecting the 
improvement in scores over the 4 weeks of the study with 
controlled release codeine, and lack of change over time with 
placebo. The differences between treatments for the WOMAC 
pain score and the weekly pain scale, respectively, were sig­
nificant at Week 2 (p = 0.0438; 0.1677), Week 3 (p = 0.0023; 
0.0001), and Week 4 (p = 0.0004; 0.(X)01), and overall (p = 
0.0030; 0.0009). The mean doses of controlled release 
codeine in Weeks 1, 2, 3, and 4 of the study were 50.0 ± 0.0, 
96.0 ± 13.1, 131.5 ± 38.2, and 158.9 ± 51.9 mg ql2h, respec­
tively, indicating a dose-response relationship for the effect of 
controlled release codeine.
Change from Baseline in WOMAC Pain Subscale
^CR Codeine Placebo
Weeki Week 2 Weeks Week 4
Figure I. Mean change from baseline for the WOMAC Pain VAS scale at 
each week, with increasing dose from Weeks I to 4.
Change from Baseline in Weekly Pain VAS
^CR Codeine BPlacebo |
Week 1 Week 2 Week 3 Week 4
Figure 2. Change from baseline for the weekly VAS pain scale at each week, 
with increasing dose from Weeks I to 4.
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Variables related to sleep all showed superiority of con­
trolled release codeine over placebo, with less need for med­
ication (improvements of 73.3% and 10.4%, respectively; p = 
0.0039), less pain on awakening (improvements of 76.4% and 
22.8%, respectively; p = 0.0231), and less trouble falling 
asleep (improvements of 72.5% and 37.7%, respectively; p = 
0.0220).
The need for supplemental acetaminophen was also less in 
the controlled release codeine group (4.2 ± 5.8 rescue admin­
istrations/day) than during placebo treatment (9.2 ±8.1 rescue 
administrations/day; p = 0.(X)5).
Table 4 shows tlie global assessment scores. The patient 
clinical effectiveness evaluation was measured at study com­
pletion, and was rated at 2.1 ± 0.9 points (moderately effec­
tive) in the controlled release codeine group and 0.9 ± 1.0 
(less than slightly effective) in the placebo group (p = 0.0001). 
Similarly, the investigators rated clinical effectiveness as 
being superior in tlie controlled release codeine group com­
pared witli placebo (1.9 ± 0.9.and 0.9 ± 1.0, respectively; p =
0.0001). The results of the Drug Liking Index showed a sig­
nificant preference for codeine over placebo (p = 0.0011).
For all patients randomized to treatment, a significantly 
larger proportion (p < 0.01) of controlled release codeine 
patients experienced tlie following side effects than in the 
placebo group: constipation (49%, 11%), somnolence (39%, 
10%), dizziness (33%, 8%), and overall (82%, 58%). For nau­
sea, tlie proportions did not differ significantly (p = 0.091) by 
treatment group. Fifteen patients in the controlled release 
codeine group discontinued treabnent due to adverse events 
compared with 4 patients treated with placebo. Among patients 
who completed the 4 week treatment period, only constipation, 
somnolence, and dizziness were found significantly more fre­
quently on controlled release codeine (p < 0.05). The propor­
tions of completed patients experiencing side effects overall 
were 80.7% and 62.9% for controlled release codeine and 
placebo, respectively (p = 0.173). The percentage of all com­
pleted controlled release codeine patients who experienced 
severe constipation, somnolence, dizziness, or nausea was 
7.8%, 7.8%, 3.9%, and 0%, respectively. The percentage of all 
randomized controlled release codeine patients who experi­
enced severe constipation, somnolence, dizziness, or nausea 
was 25.5%, 15.7%, 11.8%, and 3.9%, respectively.
Our objective was to investigate the efficacy of controlled
Table 4. Global assessments, mean (SD).
Outcome
CR Codeine, 
(n = 31)
Placebo, 
(n = 35)
P
Clinical effectiveness
physician assessment 1.9 (0.9) 0.9 (1.0) 0.0001
Clinical effectiveness
patient assessment 2.1 (0.9) 0.9 (1.0) 0.0001
Drug Liking Index 6.4 (2.0) 5.0 (1.6) 0.0011
CR: controlled release.
release codeine and the primary analysis was limited to com 
pleted patients. To confirm the applicability of the results to 
patients who did not fully complete the study, 4 of the key 
outcome variables, WOMAC pain, daily VAS pain 
WOMAC function, and WOMAC stiffness were subjected 
to an intent-to-treat analysis in which the mean scores from 
each patient’s last week of treatment were used. The mean 
WOMAC pain scores for controlled release codeine (n -  48) 
and placebo (n = 46) were 164.2 ± 97.0 and 242.3 ± 112.2 (p 
= 0.0001); mean daily VAS pain scores were 37.5 ± 20.4 and 
52.9 ± 24.9 (p = 0.0003). The mean WOMAC function 
scores for controlled release codeine (n = 47) and placebo (n 
= 46) were 551.3 ± 333.1 and 804.2 ± 448.2 (p = 0.0005) and 
mean WOMAC stiffness scores were 76.6 ± 48.6 and 101 7 
± 57.5 (p = 0.0073).
DISCUSSION
All tlie outcome variables in tliis study indicated the superior­
ity of controlled release codeine over placebo in the treatment 
of pain due to OA of the hip and knee over a 4 week period. 
Although supplemental opioid containing preparations appear 
to be widely used clinically, in patients with OA, there are few 
objective studies demonstrating their effectiveness. For the 
WOMAC pain VAS scale, the primary outcome measure 
related to pain control, the decrease in score from baseline 
was 118 mm (45%) after 4 weeks’ treatment. On the other 
dimensions of the WOMAC index, decreases of 66 ram (48%) 
and 444 mm (49%) were found for joint stiffness and physical 
function, respectively. These improvements in effect are at 
least as large as those seen after similar duration of treatment 
with the NSAID meclofenamate"", tenoxicam"®, and 
diclofenac""-"®. The trial duration was shorter than that often 
used in tlie evaluation of NSAID and longer term controlled 
trials will be needed. Recent data from a retrospective study"" 
of a cohort of more than 600 rheumatology clinic patients sug­
gests that longterm benefit of opioid treatment may be expect­
ed in controlled trials. Ytterberg, et a/"" found 21% of clinic 
patients had used opioids for more than 3 months and 24% 
had used opioids for less than 3 months. In both groups, 
patients reported significant pain relief tliat had been main­
tained for up to 3 years.
A possible criticism of our study is that patients were not 
asked to guess whetlier they had received active treatment or 
placebo. Botli the experience of prominent opioid side effects 
and tlie relief of pain represent a way in which the identity of 
tlie assigned treatment can become evident to patients in anal­
gesic trials, particularly tliose involving opioids.
In our study, patients were withdrawn from NSAID prior to 
initiation of study drugs. However, recent controlled studies 
have also shown tliat opioids can produce furtlier reduction in 
pain even in patients treated with maxhnal doses of NSAID. 
In a double blind placebo controlled study, controlled release 
oxycodone at a dose of 20 mg ql2h produced a 36% decrease 
in pain intensity, measured on an ordinal scale, in a population
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in which a majority of the patients were maintained on tiieir 
prestudy dose of NSAID"®. Similarly, in another study in 
which all patients received optimal doses of NSAID the addi­
tion of oxycodone resulted in a 43% reduction in ordinal pain 
score"® and the reduction in pain achieved with controlled 
release oxycodone was the same as that achieved with the 
same daily dose of oxycodone administered in combination 
with acetaminophen.
Although both codeine and oxycodone are usually admin­
istered in fixed dose combination witli acetaminophen or 
ASA, results such as these question the value of using such 
combinations in patients already treated with NSAID. Several 
studies in postoperative pain have documented that the anal­
gesia produced by non-opioid/opioid combinations is essen­
tially equivalent to the added effects of tlie components"®. 
Similarly, in patients with OA awaiting Iiip joint surgery tlie 
addition of 30 mg codeine to 200 mg ibuprofen provided sig­
nificantly greater analgesia"®. It is therefore likely that patients 
already treated with maximal doses of NSAID will not realize 
any benefit from added acetaminophen or ASA in combina­
tion with codeine or oxycodone and may experience greater 
risk of toxicity. In addition, single entity opioid formulations 
have the advantage of availability of 12 hourly controlled 
release formulations and no restriction on the ability to titrate 
the dose to optimal effect due to the maximum recommended 
doses of acetaminophen or ASA.
In addition to a beneficial effect of controlled release 
codeine in reducing O A pain, patients in this study also report­
ed improvements in quality of sleep and physical function, 
important determinants of quality of life in, patients witli 
chronic musculoskeletal disease. Since lack of adequate sleep 
can exacerbate pain, improvement of sleep quality is an 
important goal of pain management"". The improvement in 
sleep quality found in tills study may be attributable to the 
prolonged duration of action of the controlled release formu­
lation as evidenced by tlie lower level of pain on awakening. 
In addition, the reduced use of medication to get to sleep indi­
cates that the better pain control achievable with around-tlie- 
clock dosing may have facilitated tlie onset of sleep. Previous 
studies have shown a close association between measure­
ments of pain and disability®®. The finding of a similar degree 
of. improvement in botli the pain and physical function 
"WOMAC scales in the controlled release codeine group is 
tlierefore not surprising. Similar improvements in physical 
function, assessed using the Pain Disability Index, were also 
found in a placebo controlled trial of controlled release 
codeine in patients with clironic nonmalignant pain of mixed 
etiology®". These observations confirm tlie important effect 
that adequate relief of pain can have on quality of life of 
patients with OA.
Tliere were also significant improvements in joint stiffness 
in the patients treated with controlled release codeine. While 
a number of factors, such as muscle tone and conditioning, 
contribute to joint stiffness, its relationship to joint inflanuua-
tion raises the possibility that the effect of codeine on joint 
stiffness may involve a peripheral opioid mechanism. Opioid 
receptors located on peripheral terminals of primary afferent 
sensory neurones are upregulated in inflamed tissue, and the 
action of opioid agonists on these receptors inhibifs the 
release of excitatory proinflammatory mediators®"®'. 
Inflammatory cells such as lymphocytes, macrophages, and 
mast cells contain endogenous opioid peptides that may play 
a role in modulating both hyperalgesia and inflammation®®. 
Inliibition of neuropeptide release represents a peripheral 
mechanism by which opioids could reduce inflammation 
induced hyperalgesia and provide a possible explanation for 
the direct antiinflammatory effect of opioids observed in ani­
mal models of arthritis®®. These observations, togetlier witli 
tlie demonstration of an effect of codeine on both pain and 
joint stiffness in patients with OA, suggest that additional 
studies of opioids are needed in conditions, such as rheuma­
toid artliritis, with a more prominent inflammatory component 
and hyperalgesia in the form of joint tenderness.
A major consideration in tlie evaluation of opioid analgesic 
therapy for chronic nonmalignant pain is the perception that 
patients with chronic pain receiving opioid analgesics are at 
high risk of iatrogenic addiction. This can have significant 
influence on clinicians’ willingness to treat chronic nonmalig­
nant pain with opioids because of failure to distinguish phys­
ical dependence from psychological dependence. Physical 
dependence is characterized by tlie occurrence of an absti­
nence syndrome following abrupt cessation of an opioid ago­
nist or following tlie administration of an opioid antagonist. 
Addiction, on tlie other hand, is a psychological and behav­
ioral syndrome characterized by an intense desire for tlie opi­
oid, along witli evidence of compulsive drug use and acquisi­
tion of opioids by manipulation of the medical system or from 
a nonmedical source'®. Except in individuals who have a his­
tory of substance abuse, addiction is not a common observa­
tion in patients who take opioids to control pain'®. The poten­
tial for abuse was assessed in this study using a Drug Liking 
Index®", which showed a slightly higher score on codeine 
compared with placebo, altliough we did not observe unusual 
requests for additional codeine. Although patients were 
instructed to rate their liking for tlie drug based only on its 
effects otlier tlian analgesia, there is a possibility that some 
patients’ assessments are influenced by the pain relief they 
receive. In a crossover study requiring treatment for 9 weeks 
with morphine or placebo'", there was a nonsignificant but 
higher Drug Liking Index score witli placebo, suggesting tliat 
tlie risk of addiction in patients with chronic nonmalignant 
pain treated with opioids is very low.
This double blind randomized controlled study demon­
strates the superiority of controlled release codeine over 
placebo in the treatment of pain due to OA of the hip or knee. 
This benefit was observed across all outcome measures 
including improvements in joint stiffness, quality of sleep, 
and physical function, as well as measures of OA pain. In
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addition, there was a progressive increase in efficacy as the 
dose of controlled release codeine was increased at weekly 
intervals over the 4 weeks of the study. A high proportion of 
patients in both treatment groups reported typical opioid side 
effects such as constipation, somnolence, dizziness, and nau­
sea. It is possible that a more gradual dose escalation would 
have resulted in fewer patients discontinuing codeine due to 
adverse events.
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EFFICACY AND SAFETY OF DIACEREIN IN OSTEOARTHRITIS 
OF THE KNEE
A Double-Blind, Placebo-Controlled Trial
JEAN-PIERRE PELLETIER, MICHAEL Y ARON, BOULOS HARAOUI, PATRICK COHEN, 
MENAHEM A. NAHIR, DENIS CHOQUETTE, IRINA WIGLER, ITZHAK A. ROSNER, 
A N D R É D. BEAULIEU, and The DIACEREIN STUDY GROUP
Objective. To evaluate the efficacy and safety of 
diacerein, a drug with interieukin-l/3-inhibitory activity 
in vitro, in patients with knee osteoarthritis (OA).
Methods. A total of 484 patients fulfilling the 
American College of Rheumatology criteria for knee OA 
were enrolled in tliis 16-week, randomized, double- 
blind, placebo-controlled, parallel study group with 3 
diacerein dosages of 50 mg/day, 100 mg/day, and ISO 
mg/day (administered twice daily).
Results. In the intent-to-treat population, 100 
mg/day diacerein (50 mg twice daily) was significantly 
superior (P < 0.05) to placebo using the primary 
criterion (visual analog scale [VAS] assessment of pain 
on movement). Significant improvement (P < 0.05) was 
also observed for the secondary criteria, which included 
the Western Ontario and McMaster Universities OA 
Index (WOMAC), the WOMAC subscores, and the VAS 
assessment of handicap. In patients treated with diac­
erein dosages of SO mg/day and 150 mg/day, favorable 
but not significant results were observed for the primary 
criterion. The best daily dosage of diacerein, calculated
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from the effect on the VAS assessment of pain on 
movement, was 90.1 mg. In the per-protocol population, 
the analysis of the primary criterion showed significant 
dose-dependent differences (P < 0.05) between each of 
the 3 diacerein dosages and the placebo. No differences 
were observed among the 3 diacerein groups. A signifi­
cantly higher incidence (P < 0.05) of adverse events 
(AEs), as well as a higher rate of dropoout due to AEs, 
was observed in patients treated with 150 mg/day diac­
erein versus those treated with placebo, 50 mg/day 
diacerein, or 100 mg/day diacerein. Mild-to-moderate 
transient changes in bowel habits were the most fre­
quent AEs, increasing with the dosage.
Conclusion, Diacerein, a drug for the treatment of 
OA, was shown to be an effective treatment for symp­
toms in patients with knee OA. Taking into account both 
efficacy and safety, the optimal daily dosage of diacerein 
for patients with knee OA is 100 mg/day (50 mg twice 
daily).
Diacerein is a drug with interleukin-1 (IE-1)- 
inhibitory activity developed for the treatment of osteo­
arthritis (OA) (1). In animals, oral administration of 
diacerein resulted in antiinflammatory activity as mani­
fested by an inhibition of edema induced by the injection 
of carrageenan into the footpad (2). Diacerein inhibited 
adjuvant arthritis induced in rats by the injection of 
Mycobacterium tuberculosis (1). It also exhibited analge­
sic effects and antipyretic activities in animal models (1). 
Diacerein has no inhibitory effect on phospholipase A 2, 
cyclooj^genase (COX), or lipooxygenase in vitro; on the 
contrary, diacerein stimulates prostaglandin Eg synthesis 
in human chondrocyte cultures (3). Both diacerein and 
its active metabolite rhein are powerful inhibitors in 
vitro of the synthesis o f cytokines (3-5), mainly IL-lp,
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and metalloproteases (collagenase and stromelysin) 
(6,7) that are involved in cartilage degradation. The 
IL-lj3~inliibitory activity of diacerein has been shown in 
vitro to be related to the inhibition of cytokine synthesis 
per se in synovium and chondrocytes, as well as to a 
reduction in the level of IL-1 receptor bioactivity (4,5) in 
these cells. The capacity of diacerein to reduce the 
structural changes of OA has been shown in several in 
vivo experimental models of surgically or mechanically 
induced OA, such as the dog, sheep, guinea pig, and 
rabbit models (8-11).
Several double-blind, randomized, controlled 
clinical trials (12-17) have demonstrated a beneficial 
effect of diacerein on the clinical signs or symptoms of 
OA, comparable with that of nonsteroidal antiinflamma­
tory drugs (NSAIDs). Diacerein is a slow-acting agent 
with symptomatic effects appearing 4 weeks after begin­
ning treatment; most interesting are the results of a 
study conducted in patients with hip O A  which indicated 
that, in these patients, diacerein’s effect was additive 
with that of NSAIDs (12). In several studies, sustained 
pain relief was observed for several weeks after discon­
tinuation of diacerein, suggesting the presence of a 
carryover effect o f the drug (13,15,17).
According to previous studies of the drug’s pro­
file, the riskibenefit ratio of diacerein for the OA patient 
is better than that of NSAIDs (18). This also seems to be 
the case with respect to the administration of diacerein 
to elderly patients who frequently have multiple illnesses 
and are predisposed to gastrointestinal (GI) tract com­
plications due to long-term administration of NSAIDs 
(19).
The purpose o f this double-blind, placebo- 
controlled, phase II dose-range study was to assess the 
optimal daily dosage of diacerein to be given to patients 
with knee OA,
PATIENTS AND METHODS
Patients. Outpatients of either sex, ages 40-80 years, 
with tibiofemoral OA (grades I-III of the Kellgren/Lawrence [K/L] classification [20]), fulfilling the American College of 
Rheumatology criteria for knee OA (21), and with pain 
present most days of the prior month were recruited for the study. Radiographic evidence of knee OA was defined by the 
presence of osteophytes in at least 1 tibiofemoral compartment 
(the radiographs having been obtained <6 months prior to enrollment and with at. least 2 views, posteroanterior and lateral). For study enrollment, there had to be evidence of 
knee pain on movement scored by the patients at >35 mm on a 100-mm visual analog scale (VAS). Patients were not re­
tained for the study if they had serious concomitant medical 
illness, secondary OA, radiographic grade IV by the K/L
classification, or knee surgery planned within the following 6 
months. Patients were not to have been treated with any drug 
supposed to be structure modifying in OA, nor were they to 
have been treated with any intraarticular injection of cortico­steroids for at least 3 montlis before the study.
Before entering the trial, patients underwent washout periods of 7 days for any NSAIDs or 12 hours for analgesics. During the trial, acetaminophen intake (500-mg tablets) was [permitted in cases of persistent pain, and the dose and 
duration were recorded. Patients were enrolled in 15 centers in Canada and 10 centers in Israel. Two committed clinical 
research organizations, one in Israel (More Research Appli­
cation) and the other in Canada (Integrated Research Incor­poration), were in charge of overseeing the study, which 
included verifying both the investigators’ professional qualifi­
cations and the meeting of selection criteria by patients, as well as monitoring the 7 scheduled visits.
Study design. This study was a prospective, multi­center, randomized, double-blind, placebo-controlled, parallel, 4-arm trial of 16-week duration. This duration was chosen according to the results observed in several studies, which demonstrated a delay of action by diacerein on the signs and symptoms of OA (>45 days) (12-15), and also to gain more 
information about diacerein’s safety profile.
The study was conducted in accordance with the Helsinki Declaration (1964) and its revision (1975), and was 
approved by the institutional review boards of all Israeli and Canadian study sites. Patients entered the study after fulfilling the inclusion and exclusion criteria and signing an informed- consent form.
Drug administration. Patients were randomly assigned to 4 treatment groups. The centralized allocation schedule was prepared using a blocked randomization technique (blocking 
factor 8). The treatments were divided between the 2 countries (treatments 1-500 in Israel and 600-1,000 in Canada) and then 
allocated to each center. One group received placebo (1 
capsule twice daily), the second group received 50 mg diac­erein (25 mg twice daily), the third group received 100 mg 
diacerein (50 mg twice daily), and the last group received 150 
mg diacerein (75 mg twice daily).Evaluation of efficacy. The primary efficacy parameter 
was the patient’s assessment of pain on movement (for the 48 
hours prior to the visit) using a 100-mm VAS ranging from 0 = no pain to 100 = unbearable pain. The main secondary efficacy criteria included the following: 1) the Western Ontario and McMaster Universities OA Index (WOMAC) version VA 3,0 (22,23) (for Israeli patients, the WOMAC was translated into 
Ilebrew and the translation was validated [24]); 2) the VAS of 
handicap (100-mm VAS ranging from 0 = no impairment to 100 = unbearable impairment) assessed by asking the patient 
“What is your main problem associated with your osteoarthri­tis?” This scale was shown to be correlated with other func­tional disability scales in rheumatology (25,26) and was used in 
a previous clinical trial with diacerein (13); and 3) the patient 
and physician overall assessments expressed at the end of the treatment period on a 100-mm VAS (efficacy, ranging from 0 = very poor to 100 == excellent). The other secondary efficacy criteria included the following: 1) knee joint swelling according to a 0-3-grade scale (0 = absent, 1 = detectable 
without loss of bone contour, 2 = loss of bone contour, and 3 = important synovial thickening or synovial effusion); 2) duration
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Figure 1. Flow chart of the disposition of the patients in the study.
of morning stiffness, in minutes; and 3) joint mobility mea­
sured by flexion and extension in degrees, assessed with a goniometer. All variables were assessed at baseline and at weeks 2, 4, 8, 12, and 16, or at the time of premature withdrawal.
Evaluation of safety. All adverse events (AEs) re­ported by the patients during the study treatment were re­
corded on the Case Report Form (CRF) and classified in terms of type, time of onset, severity (mild, moderate, or severe), duration, and outcome. The physician asked the patient “How did you tolerate the test medication?” and recorded the response. All the information concerning ex­pected AEs was described on the informed-consent form. The 
physician was asked to express an opinion regarding the relationship of the AE to the study treatments.Laboratory tests were performed at baseline and at weeks 4 and 16 (or at the time of premature withdrawal), 
including blood cell count, erythrocyte sedimentation rate, serum chemistries (electrolytes, liver enzymes, total bilirubin, uric acid, and creatinine), and urinalysis (using reagent sticks).
The global tolerance to the study treatment was as­sessed by the patient and the investigator at weeks 2-16 with a 
scoring system using a 5-point scale ("very good,” “good,” “moderate,” “bad,” and “very bad”).Compliance. Medication compliance and concomitant 
treatment such as acetaminophen were recorded on the CRF. 
Capsule counts were performed at each visit (weeks 2-16).Statistical analysis. Sample size estimates, perfonned 
to detect a pre-post difference in VAS assessment of pain on 
movement of 10 mm, indicated that 100 patients were required 
for each treatment group with the level of significance (1-tailed test) set at P <  0.05 and a power of 90%. The comparisons 
between groups allowed the use of the 1-tailed statistical tests because of the constant superiority of diacerein treatment over placebo shown in previous studies (12-14). With an anticipated 
dropout rate of 20%, the sample size was increased to 125 patients per arm.
Three populations were analyzed in the study, 1 for 
safety and 2 for efficacy. The safety population was defined as all patients who were randomly assigned and who received study medication at least once. The 2 efficacy populations were
the intent-to-treat population (ITT), which consisted of all 
patients who were part of the safety population and for whom 
we had at least 1 postbaseline measure of the primary efficacy 
criterion (VAS assessment of pain on movement); and the 
per-protocol population (PP), which consisted of all patients who completed the 16-week study.
All demographic and assessment variables were com­pared at baseline using an analysis of variance (2-tailed at the 
5% significance level) for continuous variables and chi-square tests for categorical variables.
The primary efficacy criterion, VAS assessment of pain 
on movement, was first analyzed using the normalized area 
under the curve (AUC) for the difference from baseline scores 
(scores at baseline visit) from baseline to week 16 using the 
trapezoidal rule (27). A secondary analysis for this criterion 
was based on the average (AVE) of the score differences from baseline at each visit.
The last observation carried forward (LOCF) method 
and the Linear interpolation method were used to estimate 
missing values. The main analysis was based on comparison of 
the placebo group with each of the treatment groups, using the Dunnett 1-tailed test to detect significant differences between 
the treatment groups and the placebo group. When significant 
differences were detected, a quadratic polynomial (28) was 
fitted and used to determine the best dosage (i.e., the dosage 
value that optimizes the quadratic function).
The main analysis of the secondary parameters was 
based on the Dunnett 1-tailed test to detect significant differ­
ences between the treatment groups and the placebo group. 
The AUC and AVE were used as response variables for all 
criteria except global efficacy assessment, which used raw score assessments at each visit.
All analyses were performed in SAS 6.12 (SAS Insti­
tute, Cary, NC) under HP-UX version 10.20 (Hewlett- 
Packard, McMinnville, OR). The level of significance was set 
at F < 0.05 (1-tailed test) for comparison with placebo and P <
0.05 (2-tailed test) for pairwise comparisons resulting from the 
overall treatment analyses. There were no adjustments for 
multiple comparisons other than the implicit adjustments used 
by the Dunnett test.
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Table 1. Patient demographics and baseline characteristics*
Placebo 
(n =  124)
50 mg/day 
diacerein 
(n = 126)
100 mg/day 
diacerein 
(n =  110)
150 mg/day 
diacerein 
(n =  120)
Age, years 64.5 ± 8.65 62.95 ±  8.41 64.22 ±  8.02 62.27 ±  10.18Men, % 21.0 16.7 24.5 20.0
Women, % 79.0 83.3 75.5 80.0Height, cm 160.94 ±  9.24 159.48 ± 8.66 161.54 ±  8.42 160.71 ±  7.58
Weight, kg 80.45 ±  14.48 80.55 ±  15.56 82.78 ±  17.52 80.62 ± 16.61
BMI, kg/m^ 31.05 ±  5.35 31.63 ±  5.50 31.73 ±  6.21 30.99 ± 5.88
Disease duration 8.0 ± 7.41 7.8 ±  7.18 8.1 ±  6.42 7.8 ±  6.99
Pain, VAS, mm 70.54 ±  19.05 67.27 ±  17.69 73.56 ±  16.74 69.85 ±  18.77
WOMAC, mm 180.79 ±  61.68 168.72 ±  59.48 181.92 ± 54.45 175.72 ±  59.66
Handicap, VAS, mmj 
Joint mobility, degrees
69.48 ±  20.52 65.73 ±  21.51 73.29 ± 17.41 68.22 ±  20.09
Extension 4.33 ±  5.08 4.45 ±  5.66 4.79 ±  5.19 4.98 ±  5.74
Flexion 110.24 ±  21.95 110.40 ±  24.76 109.45 ±  23.05 109.28 ±  23.30
Morning stiffness, minutes 21.48 ±  21.91 24.01 ±  50.60 17.15 ±  19.11 17.58 ±  19.71
* Except where otherwise indicated, values are the mean ±  SD. BMI 
and McMaster Universities Osteoarthritis Index, 
t  P = 0.0353 by analysis of variance between the groups.
body mass index; VAS = visual analog scale; WOMAC =  Western Ontario
RESULTS
Patient characteristics. A  total of 484 patients 
enrolled in the study (Figure 1) by 42 Israeli and 
Canadian investigators were randomly assigned as fol­
lows: 125 (25.8%) received the placebo, 126 (26.0%) 
received 50 mg/day diacerein. 111 (22.9%) received 100 
mg/day diacerein, and 122 (25.2%) received 150 mg/day 
diacerein.
The patients were primarily white (92.4%) 
women (79.6%), with a mean ±  SD age of 63.5 ±  8.9 
years. The mean ±  SD body mass index was 31.3 ±  5.7 
kg/m^, and the mean ±  SD time from diagnosis of OA  
(disease duration) was 7.9 ±  7.0 years. No major differ­
ences were observed among the 4 groups at baseline, 
except for VAS assessment of handicap (the largest 
observed difference was between the 50 mg/day and 100 
mg/day diacerein groups) (Table 1).
Of the 484 randomly assigned patients, 4 (1 in the
placebo group, 1 in the 100 mg/day diacerein group, and 
2 in the 150 mg/day diacerein group) did not have 
postbaseline VAS assessment o f pain on movement, and 
were therefore excluded from the efficacy analyses.
A  total of 166 patients (34.3%) withdrew from 
the study: 36.0%, 34.1%, 27.9%, and 38.5% in the 
placebo, 50 mg/day diacerein, 100 mg/day diacerein, and 
150 mg/day diacerein groups, respectively (Figure 1). 
The reasons for discontinuation were mainly the lack of 
efficag  of the study treatment for the patients receiving 
the placebo or 50 mg/day diacerein and the occurrence 
of AEs for patients receiving 150 mg/day diacerein 
(Table 2).
A  total of 318 patients (65.7%) completed the 
study: 80 of 125 (64.0%) in the placebo group, 83 of 126 
(65.9%) in the 50 mg/day diacerein group, 80 of 111 
(72.1%) in the 100 mg/day diacerein group, and 75 of 
122 (61.5%) hi the 150 m^day diacerein group (Figure
Table 2. Reasons for discontinuation of treatment*
Reason for treatment discontinuation
Treatment
No. of randomly 
assigned patients
Adverse
events Lack of efficacy Other
No. of patients 
completing study
Placebo 125 14 (11.2) 23 (18.4) 8 (6.4) 80 (64.0)
Diacerein
50 mg/day 126 16 (12.7) 21 (16.7) 6 (4.8) 83 (65.9)
100 mg/day 111 11 (9.9) 12(10.8) 8(7.2) 80 (72.1)
150 mg/day 122 23 (18.9) 16 (13.1) 8 (6.6) 75 (61.5)
Total 484 64 (13.2) 72 (14.9) 30 (6.2) 318 (65.7)
Values are the number (%).
EFFIC AC Y A N D  SAFETY OF D IA C E R E IN  IN  KNEE O A 2343
Table 3. Differences in clinical assessment criteria from baseline to week 24 in each of the groups in the 
intent-to-treat population*
50 mg/day 100 mg/day 150 mg/day
Placebo diacerein diacerein diacerein
(n = 124) (n = 126) (n — 110) (n = 120)
Pain, VAS, mm -10 .9  ±  19.3 -1 5 .6  ±  21.0 -18 .3  ±  19.3t -14.3 ±  23.7
WOMAC, mm -16 .7  ±  51.9 -27 .4  ±  52.7 -36 .7  ±  52.3t -29.1 ±  46.7
Pain -33.9  ±  90.5 -5 0 .3  ±  94.8 -5 8 .8  ±  92.5t -50.5 ±  88.1
Stiffness -10.3  ±  42.4 -1 7 .7  ±  43.4 -27.3 ±  42.3t -21.4 ±  37.0
Physical -8 5 .8  ±  304.4 -139.3 ±  301.4 -193.3 ±  318.0t -143.3 ±  278.8
Handicap, VAS, mm -9 .9  ±  20.1 -1 2 .3  ±  22.7 -18 .5  ±  2 2 .lt -12 .8  ±  21.7
Global efficacy assessment, mm
Investigator 41.4 ±  32.4 -4 8 .6  ±  33.6 -48 .8  ±  29.7 48.1 ±  32.7
Patient 42.4 ±  33.1 -4 9 .2  ±  33.6 -51 .4  ±  29.3 50.0 ±  32.3
* Values are the mean ±  SD. See Table 1 for definitions, 
t  P <  0.05 versus placebo group.
1). Therefore, for the efficacy analyses, the ITT popula­
tion consisted of 480 patients and the PP population 
consisted of 318 patients. All 484 randomly assigned 
patients were involved in the safety analysis.
Efficacy. The results o f the analysis of the pri­
mary efficacy criterion, VAS assessment of pain on 
movement, showed the diacerein treatment to be supe­
rior to the placebo, irrespective of the diacerein dosage 
and of the population analyzed (Tables 3 and 4). For this 
criterion, a statistically significant difference (p <  0.05) 
was shown between the 100 mg/day diacerein and pla­
cebo groups for the ITT population (Table 3 and Figure
2). There were also statistically significant differences 
for the secondary criteria (mainly the WOMAC, 
WOMAC subscores, and VAS assessment of handicap) 
between the 100 mg/day diacerein and placebo groups. 
A  trend toward improvement was shown in the other 2 
diacerein groups, but tliis trend was not significant for 
the primary and secondary criteria.
In the PP population analysis, a significant differ­
ence was observed for VAS assessment of pain on 
movement between each of the 3 diacerein dosages and 
the placebo group, and improvement of pain was greater 
when the diacerein dosage was increased (Table 4). No 
statistically significant differences were found among the 
3 diacerein groups. As was the case in the ITT analysis, 
significant results in favor of the 100 mg/day diacerein 
group versus the placebo group were shown for the 
secondary criteria (normalized WOMAC, WOMAC  
subscores [stiffness and physical function], and VAS 
assessment of handicap). The same significant trend was 
observed in the 150 mg/day diacerein group for the 
normalized WOMAC and the WOMAC stiffness sub­
score. Similar results were observed when using the 
AVE analyses for the ITT and PP populations.
Physicians' and patients’ global assessm ent 
showed greater improvement in the 3 diacerein groups 
versus the placebo group. However, a significant level
Table 4. Differences in clinical assessment criteria from baseline to week 24 in each of the groups in the 
per-protocol population*
50 mg/day 100 mg/day 150 mg/day
Placebo diacerein diacerein diacerein
(n =  80) (n =  83) (n = 80) (n = 75)
Pain, VAS, mm -1 4 .2  ± 19.2 -2 0 .4  ±  18.8t -2 3 .2  ±  18.2t -24.7 ±  18.8t
WOMAC, mm -2 9 .8  ±  46.4 -4 0 .0  ±  48.5 -50.5  ±  46.7t -46.6 ± 42.5t
Pain -56.5  ±  83.5 -7 3 .3  ±  86.6 -83.5  ±  83.4 -81.1 ± 80.5
Stiffness -17 .1  ±  40.4 -2 5 .5  ±  42.0 -35.9  ±  39 .lt -3 3 .2 ± 3 3 .9 t
Physical -168.5 ±257.9 -211.5 ± 270.2 -276.5 ±  274.lt -239.1 ± 262.8
Handicap, VAS, mm -14.1 ±  18.2 -1 5 .8  ±  22.6 -22.6  ±  19.9t -18.8 ±  19.9
Global efficacy assessment, mm
Investigator 52.3 ±  30.1 623 ±  28.3t 58.9 ±  25.0 60.5 ±  30.3
Patient 52.9 ±  30.9 62.7 ± 28.lt 61.1 ±  24.6 61.0 ±29 .3
* Values are the mean ±  SD. See Table 1 for definitions, 
t  P  <  0.05 versus placebo group.
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Figure 2. Mean change over time of pain on movement (assessed by visual analog scale) by treatment group for the intent-to-treat (ITT) population. 
The analysis was performed for the 480 patients who entered the ITT population. Panels A-D represent the area under the curve (A U C ) of the pain 
over time, and normalized values of A U C  are presented under the curve. A  significant difference (P < 0.05) was found for the A U C  o f  pain between 
the 100 mg/day diacerein group (C) and the placebo group (A). Favorable trends versus placebo were observed for the 50 mg/day diacerein group 
(B) and the 150 mg/day diacerein group (D), but these trends were not significant (NS).
was reached only in the 50 mg/day diacerein group in the 
PP population (Table 4).
According to the analysis plan, and in view of the 
significant results observed for the primary efficacy 
parameter for the ITT and PP populations, a quadratic 
model was fitted to estimate the most effective dosage of 
diacerein. The results indicated a significant fit for the 
ITT {P =  0.0255) (Figure 3) and PP {P =  0.0007) 
(Figure 4) analyses. The best diacerein dosages were 
estimated to be 90.1 mg/day (ITT population) and 145.3 
mg/day (PP population).
An exploratory analysis, based on VAS assess­
ment of pain on movement and performed to determine 
the onset of action of the 100 mg/day diacerein treat­
ment, indicated that differences from placebo were
statistically significant by week 4 in the ITT and PP 
populations {P =  0.0338 and P =  0.017, respectively).
Safety. A total o f 327 of the 484 randomly 
assigned patients (67.6%) presented with AEs (Table 5). 
The proportions of patients who experienced AEs were 
comparable among the placebo (59.2%), 50 mg/day 
diacerein (65.1%), and 100 mg/day diacerein (64.0%) 
groups, while a higher proportion (82.0%) was observed 
in the 150 mg/day diacerein group. A  significantly higher 
frequency of AEs was observed for the 150 mg/day 
diacerein group versus the placebo {P <  0.001), 50 
mg/day diacerein {P =  0.004), and 100 mg/day diacerein 
{P =  0.003) groups.
A total of 64 patients (13.2%) discontinued the 
study due to AEs: 14 of 125 (11.2%), 16 of 126 (12.7%),
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11 of 111 (9.9%), and 23 of 122 (18.9%) in the placebo, 
50 mg/day diacerein, 100 mg/day diacerein, and 150 
mg/day diacerein groups, respectively (Table 2). The 
main AE was generally mild-to-moderate diarrhea, 
which occurred in 28.3% of the patients (13.6%, 17.5%, 
29.7%, and 53.3% in the placebo, 50 mg/day diacerein, 
100 mg/day diacerein, and 150 mg/day diacerein groups, 
respectively). Diarrhea was considered “severe” in 13 
patients in the 150 mg/day diacerein group and in only 2, 
1, and 2 patients in the placebo, 50 mg/day diacerein, 
and 100 mg/day diacerein groups, respectively. With­
drawals due to diarrhea were reported for 12 patients in 
the 150 mg/day diacerein group compared with 3 pa­
tients in each of tlie other 3 groups. No serious or severe 
AEs regarding the upper GI tract occurred during the 
study.
No clinically relevant differences were obsei'ved 
between any of the diacerein groups and the placebo 
group with regard to vital signs and laboratory analysis 
(blood and urine). A  larger number of patients assessed 
safety across visits as “good” and “very good” in the 50 
and 100 mg/day diacerein groups (86-97%  and 77-87%, 
respectively) than did so in the 150 mg/day diacerein 
group (63.5-84%). Similar results were observed for the 
investigators’ assessment.
DISCUSSION
The results of this dose-finding study confirm 
previous findings (12-17) that diacerein is an effective
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Figure 3. Shape and location of the dose-response curve for visual 
analog scale (VAS) assessment of pain on movement in the intent-to- 
treat population (area under the curve [AUC]). Tlie values indicated 
on the curve correspond to the mean ±  SEM values of the AUC of 
pain on movement (VAS assessment in mm) for each of the tested 
treatment groups. A  significant difference was found between the 100 
mg/day diacerein group and the placebo group (P <  0.05). A  signifi­
cant fit for the quadratic polynomial model was found (P ~  0.0255), 
and the best diacerein dosage was estimated to be 90.1 mg/day.
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Figure 4. Shape and location of the dose-response curve for visual 
analog scale (VAS) assessment of pain on movement in the per- 
protocol population (area under the curve [AUC]). The values indi­
cated on the curve correspond to the mean ±  SEM values of the AUC  
of pain on movement (VAS assessment in mm) for each o f the tested 
treatment groups. A significant difference was found between the 
placebo group and each of the 3 diacerein groups (P <  0.05). A  
significant fit for the quadratic polynomial model was found (P =  
0.0007), and the best diacerein dosage was estimated to be 145.3 
mg/day.
treatment for the signs and symptoms of knee OA, and 
that based on the results from O T  analysis, the optimal 
daily dosage is 100 mg/day (50 mg twice daily).
Diacerein is a drug for the symptomatic treat­
ment of OA tliat has no inhibitory effects on prostaglan­
din synthesis. This may explain why diacerein is safe for 
tlie upper GI system, as evidenced by the absence of 
upper GI complaints and findings in clinical trials.
The results of this phase II study indicate that 
with regard to efficacy, the treatment with diacerein, 
judged by the primary criterion of VAS assessment of 
pain on movement, was superior to placebo in all 3 
treatment groups, irrespective of the population ana­
lyzed (ITT or PP). In the ITT population, a significant 
difference was found for VAS assessment of pain only 
for patients receiving 100 mg/day diacerein, while im­
provement detected in the 2 other diacerein groups was 
not found to be significant. Moreover, the between- 
group difference in the improvement of pain level 
assessed with the WOMAC pain subscore (walking on a 
flat surface, going up or down stairs, at night while in 
bed, sitting or lying, and standing upright) was also 
found to be statistically significant in the 100 mg/day 
diacerein group for the ITT population. In the PP 
population, the WOMAC pain subscore showed a favor­
able trend and approached, but did not quite reach,
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Table S, Adverse events'^
Placebo 
(n = 125)
50 mg/day 
diacerein 
(n =  126)
100 mg/day 
diacerein 
(n =  111)
150 mg/day 
diacerein 
(n =  122)
Total 
(n = 484)
Diarrhea 13.6 17.5 29.7t 53.31 28.3
Abdominal pain 12.0 16.7 18.0 25.4t 18.0
Soft stools 4.8 8.7 9.0 11.5 8.5
Headache 8.8 5.6 8.1 9.8 8.1
Nausea 4.0 7.1 9.0 11.5§ 7.9
Musculoskeletal pain 8.811 6.4 0.9 3.3 5.0
Weariness 2.4 5.6 1.8 6.6 4.1
Dyspepsia 3.2 2.4 6.3 4.9 4.1
* Values are Ihe percentage of patients experiencing the event. Only events that occurred in >5% of any 
group are shown, 
t  P <  0.01 versus placebo, 
i  P <  0.001 versus placebo.
§ P <  0.05 versus placebo.
HP <  0.01 versus 100 nig/day diacerein.
significance for the 100 mg/day diacerein group. This can 
be explained by the number of patients who withdrew 
from the study prematurely, dramatically decreasing the 
power of the study.
The large number of withdrawals in the 150 
mg/day diacerein group (mainly at the beginning of the 
treatment period) was due to a high incidence of AEs 
that was probably related to tlie treatment, and may 
explain the absence of a dose-effect relationship in the 
ITT population. Because of the delay of action of 
diacerein’s effect, the LOCF procedure used in the 
present analysis disadvantaged the 150 mg/day diacerein 
group by carrying forward high values for VAS assess­
ments of pain, close to those at baseline. This hypothesis 
is supported by the results obtained in the PP popula­
tion, where statistically significant differences were 
shown for the 3 groups receiving diacerein. Further­
more, the shape and location of the dose-response curve 
in the PP population indicated that the VAS assessment 
of pain significantly decreased in a dose-dependent 
manner. The efficacy of treatment with diacerein was 
also supported by the analysis of the secondary end­
points (WOMAC, WOMAC subscores, and VAS assess­
ment of handicap), which showed statistically significant 
differences compared with placebo for the group receiv­
ing 100 mg/day diacerein in the ITT population. Accord­
ing to the shape and location of the dose-response 
curves, the best daily dosage of diacerein was very close 
to 100 mg/day (FIT population) (calculation from the 
quadratic fit yielded 90.1 mg/day; P = 0.0255).
The analysis of the onset of the beneficial effect 
of diacerein showed a delay of action, with a statistically 
significant effect starting from week 4, particularly in the
group receiving 100 mg/day diacerein, in both the ITT 
{P — 0.034) and PP (P =  0.017) populations. These 
results are in accord with the findings of previous clinical 
studies (12,14,15). Moreover, unlike the case with 
NSAIDs, sustained pain relief lasting 1-2 months was 
observed after discontinuation of diacerein, showing a 
carryover effect of this treatment (13,15,17). This could 
obviously represent a significant advantage of diacerein 
over NSAID treatment in patients who must stop taking 
their medication for several consecutive days.
Regarding the safety data globally, the number of 
patients reporting AEs was found to differ significantly 
among the 4 groups (P <  0.001). This difference was due 
to the 150 mg/day diacerein group, in which the number 
of AEs was significantly higher (P <  0.01) compared 
with the placebo, 50 m^day diacerein, and 100 mg/day 
diacerein groups (1.7-fold, 1.5-fold, and 1.6-fold, respec­
tively). Furthermore, the AEs occurring in the group 
receiving 150 mg/day diacerein were more likely to be 
judged to be “related” to the study treatment. As 
expected from the results of previous clinical trials, 
changes in bowel habits (diarrhea, soft stools, and 
abdominal pain) were the most frequently reported 
symptoms in the diacerein-treated groups, with a clear 
dose-effect relationship. These side effects were gener­
ally classified as “mild” by the patients.
The first possible explanation for this kind of side 
effect with diacerein is that it is a drug class effect (29). 
Another possible, although quite hypothetical, explana­
tion is that since diacerein has been shown to be capable 
of inducing prostaglandin synthesis, it may be that a local 
increase in prostaglandins can lead to an increase in gut 
motility and thus to diarrhea (30). No severe or serious
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AEs concerning the upper GI tract, such as gastric or 
duodenal ulcers, were reported during the trial. These 
findings are reassiuing and are consistent with those of 
postmarketing surveillance (since 1994) in several coun­
tries (including France) where diacerein is available, as 
well as with the results o f previous clinical trials.
Diacerein is therefore a safe alternative to 
NSAIDs for the treatment of OA. In a 2-month, double­
blind, 2 x 2  factorial plan study including 288 patients 
with hip OA, 100 mg/day diacerein was compared with a 
placebo, an NSAID (20 mg/day tenoxicam), and a 
combination of the same dosages of diacerein and 
tenoxicam (12). The improvement of pain on movement 
and aigofimctional Lequesne index showed a significant 
difference versus placebo for the tenoxicam and combi­
nation groups after 2 weeks of treatment. Similar im­
provement was observed for the diacerein group, be­
coming significant after 6 weeks of treatment. No 
differences were observed among the tenoxicam, com­
bination treatment, and diacerein groups. In a second 
double-bhnd study (17), 95 patients with knee or hip OA  
were given either 100 mg/day diacerein or 750 mg/day 
naproxen for 2 months. Similar significant pain improve­
ment was found in both treatment groups.
The results observed in recent clinical trials in the 
treatment of OA involving NSAIDs showed that the 
magnitude of pain improvement in patients (versus 
placebo, assessed with a VAS) was comparable with that 
observed with 100 mg/day diacerein ( - 7 .4  mm to -1 0 .0  
mm), as follows: 15 mg/day meloxicam, -6 .1  mm (31); 
200 mg/day nimesuHde, -6 .0  mm (32); and 200 m^day 
celecoxib, - 7 .6  mm to -1 2 ,2  mm (33). One should, 
however, exercise caution in making this comparison, 
since the assessments of pain were not necessarily 
equivalent among studies (different pain condition as­
sessments). These data nevertheless provide some valu­
able comparative information with regard to diacerein’s 
effect.
In terms of safety, NSAIDs are known to have 
deleterious effects on the gastric mucosa, including 
complications such as peptic ulcers, gastritis, perfora­
tion, and gastric hemorrhage; these effects are related to 
their inhibitory action on COX, with a consequent 
reduction in prostaglandin synthesis. The new genera­
tion of NSAIDs, such as the COX-2 inhibitors, seems to 
have fewer upper GI tract side effects (34,35). However, 
further clinical trials are being conducted to fully assess 
the safety profile of these drugs. Diacerein, an inhibitor 
of IL-1 production, has a mode of action which differs in 
many ways from that of NSAIDs. Given that this drug
has no inhibitory effects on COX, it offers a safe and 
effective treatment for the symptoms of OA.
Based on its chnical efficacy for the signs and 
symptoms of OA, its structure modification potential, 
and its safety profile, diacerein constitutes a novel 
approach to the treatment of O A . It can be envisioned as 
a treatment for the short- and long-term management of 
this disease.
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Continuing Medical Education-Driven Skills 
Acquisition and Impact on Improved Patient 
Outcomes in Family Practice Setting
Nicliolas Bellamy, MD, MS, FRCP(Glas), FRCP(Edin). FRCPC, FACP, FAFRM,
Laurence D. Goldstein, BSc, and Rory A. Tekanoff, PEng(Dipl), APMR
A bstract
Background: An abundance o f educational theory, design, and deliveiy o f  continuing m ed­
ical education (CME) learning interventions, including their impact on learners, are described 
in the health and social sciences literature. However, establishing a direct correlation between 
the acquisition o f  new skills by learners and patient outcomes as a result o f  a planned CME  
learning intervention has been difficult to demonstrate.
Methods: The learning intervention described here tested the impact o f  an injection skills- 
acquisition program fo r  fam ily  physicians treating osteoarthritis o f  the knee by measuring 
patient outcomes using the pain and function subscales o f  the Western Ontario and M cM aster 
(WOMAC) 3.0 osteoarthritis index, a standardized and fu lly  validated patient-centered out­
come measurement. It ivay hypothesized that patients o f  fam ily physicians who participated  
in this skills-acquisition CM E program would benefit from  treatment administered by their 
physician during the time between injection skills acquisition to 6 weeks post-injection. Inclusion 
o f a validated health status measure administered pre- and post-injection in addition to more 
traditional faculty  and participant program evaluations was deemed necessary to test this 
hypothesis. Rheumatology, orthopedic surgery, and fam ily medicine specialists fi-om across 
Canada were invited to contribute to the planning, curriculum elaboration, and delivery o f  
the viscosupplement injectorpreceptorship (VIP) program. Thirty-nine orthopedic and rheuma­
tology specialists agreed to serve as expert faculty and participated in training 474 Canadian 
fam ily and general practitioners over 8 months. The learning intervention involved a review  
o f pertinent literature by a local preceptor and a summary o f recommendations o f  the p lan­
ning committee, fo llow ed by demonstration o f  injector skills and then supervised practice with 
patients, who received hylan G-F 20 (Synvisc'^, Ridgefield, NJ) usually in the offices o f  the 
fam ily physicians. The pain and function subscales o f the WOMAC 3.0 questionnaire were 
se lf  administered to each patient in their physician's office, prior to receiving their jo in t injec­
tion and again at or near 6-weeks post-injection. Data were analyzed in the Department o f  
Epidemiology and Biostatistics dt The University o f Western Ontario, London, ON.
Results: Clinically important statistically significant improvements in pain and physical fu n c ­
tion were noted in patients who received viscosupplementation treatment from family physicians 
who had recently acquired the necessary injection skills. Approximately three-quarters o f  the
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patients experienced a reduction in pain and an improvement in physical function of at least 
20%.
Implications: These results suggest a positive relationship between acquisition o f a new skill 
by learners and improved patient outcomes as a result of this planned CME learning inter­
vention.
Key Words: Continuing medical education (CM E), family physicians, injection, measure­
ment devices, patient outcomes, skills acquisition, validation, viscosupplementation, WOMBAT, 
WOMAC
An environmental scan o f  the continuing m edical 
education (CME), rheumatology, and orthopedic 
literature and input from expert preceptors from  
across Canada revealed there is no standardized 
country-wide undergraduate or postgraduate cur­
riculum or other well-defined educational process 
for acquiring joint injection sk ills! For most fam ­
ily physicians, these skills seem  to be acquired on  
a rheumatology or orthopaedic rotation as an 
undergraduate, intern, or resident, or from a co l­
league while in practice. A  needs assessment con­
ducted among 44 fam ily physicians in south­
western Ontario indicated that 59% were interested 
in acquiring knowledge about joint injection, o f  
which half expressed particular interest in v isco ­
supplementation. This article reports the devel­
opment o f a knowledge- and skills-based CME  
program. The impact o f  the program on partici­
pating family practitioners and on the patients 
they subsequently treated with their newly acquired 
skill was also evaluated.
Methods
A curriculum-elaboration m eeting was organized, 
involving seven medical specialists in orthopedic 
surgery, rheumatology, and family medicine; these 
specialists also foraied a steering committee. This 
group was to provide professional input in the 
development o f a curriculum for injection train­
ing o f family physicians and elaborate the scope  
and dimension o f a suitable learning interven­
tion, including an instruction manual and partic­
ipant workbook along with other relevant CME  
materials, A 1-day meeting was held to define tar­
get audience needs, training group size, faculty 
qualifications, training locations for physician  
instruction, patient qualifiers, evaluative mecha­
nisms, and incentives. It was also agreed that v is­
cosupplementation with hylan GF 20 (Synvisc™ , 
Ridgefield, NJ), an injectable form o f osteoartliri- 
tis therapy, would be used in the training o f fam ­
ily  physicians.
A  viscosupplem ent injector preceptorship  
(VIP) program skills acquisition manual (SAM ) 
was developed with input and review from the 
steering committee. The SAM  was to serve as 
both a guide for expert faculty and a resource for 
participants: it included inform ation on basic 
anatomy o f the knee, diagnosis o f  knee osteoarthri­
tis, treatment guidelines for knee osteoartliritis, and 
patient selection criteria for viscosupplem enta­
tion with SynviscTM, Sections addressing mode of  
action, clinical and adverse effects, warnings and 
contra-indications to Synvisc™  treatment, and 
practical pointers were also included. Issues con­
cerning use of injectable corticosteroids were also 
addressed for the same areas as for viscosupple­
mentation. The remainder o f tlie manual provided 
practical tips for giving injections and for the pre­
vention and management o f  adverse reactions, 
and troubleshooting guidelines. The manual also 
included samples o f all evaluative mechanisms 
(pre- and post-injection pain and function sub­
scales o f  the Western Ontario and M cM aster 
[W OM AC] 3.0 questionnaire, faculty expert 
preceptor-program evaluation, and participant-
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preceptor program evaluation questionnaires) and 
an extensive reference list o f  peer-reviewed liter­
ature. The WOMAC index is w idely used, and is 
a valid, reliable, and responsive self-administered 
tridimensional health status measure for knee and 
hip osteoartliritis studies, available in visual ana­
logue and adjectival formats in over 30 different 
languages.^
Faculty trainers (expert preceptors) were con­
tacted by a third party (KARMA® Clinical Rela­
tions Canada Inc.) to participate in the program. 
Faculty id en tifica tion  w as b ased  on market 
research and intelligence provided by the sup­
porting pharmaceutical and device manufacturers, 
and used the follow ing criteria;
• Specialist or fam ily physicians who have 
particular skills in injection techniques, pri­
marily in the knee;
• Physicians who possess advanced knowl­
edge o f principles o f  viscosupplementation 
and its mode o f action and success rates, and 
have used viscosupplementation in the past 
month;
• Physicians who have successful experience 
with Synvisc™ ;
• Physicians who are local experts in osteo­
arthritis o f the knee as evaluated by local 
family practitioners; and
• Physicians who are interested in CME and 
in teaching other physicians and healtli care 
professionals.
Forty potential expert preceptors were con­
tacted by telephone and interviewed to determine 
tlieir suitability, interest, and availability to par­
ticipate in the learning intervention; 39 agreed to 
participate. Each subsequently met with mem­
bers o f the steering committee either personally or 
by conference call to discuss the program. Each 
received a SAM  prior to fo llow -up contact to 
familiarize themselves with the instruction mate­
rials that participants would receive before their 
training session.
Participants (fam ily practitioners) were iden­
tified and contacted by representatives o f the phar­
maceutical and device manufacturers, and were 
invited to attend the VIP sessions by the follow ­
ing criteria, evaluated in a personal interview:
• The family practitioner expressed an avid 
interest in acquiring joinl-injection tech­
niques to the representative;
• V iscosupplem enation was not currently 
.. . . used for osteoarthritis therapy in the fam­
ily  practitioner’s practice, primarily due to 
lack o f expertise in joint injection;
• The fam ily  practitioner w as w illin g  to 
devote 4 hours to participating in a training 
session;
• The practitioner could provide a patient 
with osteoarthritis o f die knee(s) w ho was 
amenable to joint injection;
• The practitioner would participate in the 
evaluation process (pre- and post-injection 
WOMAC 3.0 questionnaires); and
• The family practitioner would continue self­
directed use o f  the injection skill to main­
tain competency.
Representatives then organized a training ses­
sion for tliree to five family practitioners and a local 
expert preceptor; this is an effective format to 
enhance learning.^ Each session was conducted in 
the clinical practice o f  die participants, which, 
although variable, always was one o f the follow ­
ing: the preceptor’s offices or group-practice clinic; 
die expert preceptor’s private practice, or a hos­
pital. A  typical training session consisted o f a 
small-group interactive learning session followed  
by live patient injection-technique demonstration 
and practice, all taking place over approximately 
4 hours. Each fam ily physician was required to 
bring one patient with osteoarthritis o f the knee(s) 
and the patient’s x-rays to the training session. Prior 
to injection, participants supervised the adminis­
tration o f pre-injection WOMAC 3.0 question­
naires to their patients and die expert preceptor re­
ex a m in ed  ea ch  p a tie n t  and c o n fir m e d  the
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osteoartliritis diagnosis and suitability for visco- 
supplementation therapy. The practical work began 
when the expert preceptor determined that the 
group felt ready to begin injecting. Each family 
practitioner injected their own patient under the 
supervision o f the expert preceptor, while being 
scrutinized by their peers. Since a full course o f  
Synvisc™  requires three intra-articular injections 
administered 1 w eek apart, the preceptor was 
available to the family practitioner should difficulty 
be encountered during subsequent injections. In 
only 9 o f 445 (2%) cases did a family practitioner 
contact the expert preceptor for additional train­
ing or to request that the expert preceptor perform 
the follow-up injections on their patient. An aver­
age o f  four fam ily practitioners participated in 
each training session, with 96 individual sessions 
completed in 6 months across Canada.
A  second objective o f  this study was to vali­
date a patient global assessment question for future 
incorporation into a modified WOMAC 3.0 index, 
that w e have provisionally termed the Western 
Ontario Measurement Battery (WOMBAT 3.0). If 
successfully validated, the WOMBAT 3.0 would  
contain the W OM AC pain and physical function 
subscales, and a patient global assessment o f knee 
osteoartliritis subscale. In contrast to the WOMAC  
3.0, the W OMBAT 3.0 would not contain a stiff­
ness subscale. This modification was to accom­
modate recommendations made at the OMER- 
ACT 111 Conference'* and in the Ostearthritis 
Research Society guidelines document^ in which  
pain, function, and patient global assessment (but 
not stiffness) were established by international 
consensus as core set clinical variables for future 
osteoarthritis studies. The WOMAC 3.0 and the 
patient global assessment question were prepared 
in adjectival (Likert) format, in both English and 
French for Canada, and combined in a single ques­
tionnaire, hereafter referred to as the W OM AC/ 
PGA questionnaire.
Data were coded, entered, and analyzed in 
the Department o f Epidemiology and Biostatistics 
at the University o f Western Ontario using the 
S AS program.^ Descriptive statistics were used to
characterize responses to the tliree questionnaires. 
Tlie statistical significance o f  the treatment effect 
was evaluated using both parametric (Students / 
test) and nonparametric (W ilcoxon Signed Rank 
test) methods. Previous comparisons o f tliese two  
approaches using the W O M AC Index has not 
shown important differences in levels o f signifi­
cance or data interpretation.
In order to validate the patient global assess­
m ent question, the approach captured by the 
OMERACT Filter was used."' The OMERACT  
Filter for selecting outcom e measures p laces  
emphasis on those that fulfill criteria for truth 
(validity), sensitivity (responsiveness + reliability), 
and feasibility. Validity was assessed by testing 
convergent construct validity between patient 
global assessment scores and WOMAC pain and 
function subscale scores. Sensitivity was evaluated 
by comparing post-injection and pre-injection 
patient global assessment scores: feasibility was 
evaluated by observing i f  completed WOMAC  
questioimaires were accompanied by completed 
patient global assessm ent questions.
Results
Only 445 five patients received injections, since  
29 o f  the 474 physicians were unable to supply a 
patient but had not stated this in the interview  
selection process (completion rate =  94%). O f the 
890 potentially available W OMAC/PGA ques­
tionnaires, 602 were returned sometime after the 
first injection: o f these, there were 163 complete 
pairs (f.e., preaccompanied by post) that were 
used in the analyses reported. O f the remainder, 
115 had only a pre- and 25 only a post-injection 
assessment, 18 contained data from different knees 
at the two assessment points, and in 118 (59 pairs), 
the post-injection assessm ent was made less than 
21 or more than 84 days after the pre-injection 
questionnaire was completed. Although all post­
injection assessments should have been completed 
at 6 weeks, there was considerable variation in 
when post-injection assessments were made (Fig­
ure 1). We elected to restrict the data analysis to
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Figure 1 Time to completion of post-injection 
WOMAC 3.0.
subjects who had completed their post-injection 
assessments between 3 and 12 weeks. Three weeks 
is the first week after completion of the series of 
three injections, and 12 weeks is the point used in 
several published studies to evaluate the early 
response to Synvisc™.
Data from 163 subjects were used in tlie analy­
sis. Pre- and post-injection WOMAC scores and 
associated change scores for tlie two subscales 
are presented in Table 1. These improvements 
were clinically important and statistically signif­
icant for both WOMAC 3.0 subscales (pain -  
physical function at p < .001, by both parametric 
and nonparametric analyses). Notwithstanding 
the current lack of responder criteria for osteoarthri­
tis knee studies, patients were classed as respon­
ders if they fit either of the following two defin­
itions: 20% or more reduction in pain and 20% or 
more reduction in pain as well as 20% or more 
improvement in physical function. Seventy-four 
percent of participants were responders by the 
first definition and 73% by the second.
More tlian 94% of family practitioners agreed 
or strongly agreed that the VTP program was prac­
tical and relevant, met their objectives and expec­
tations, was credible and well organized, that time 
and interaction were adequate, that the preceptor 
was knowledgeable, and that they now felt com­
fortable with tlie procedure and would consider vis­
cosupplementation as a treatment option for 
osteoarthritis knee patients in their practice (Table
2). Almost 100% of preceptors agreed or strongly 
agreed that the program was practical and relevant, 
met their objectives and expectations, was credi­
ble and well organized, that time and interaction 
were adequate, and that they would participate, in 
future VIP programs.
With respect to the validation of the patient 
global assessment question, tliere was a strong 
positive correlation between patient global assess­
ment scores and WOMAC pain and function 
scores. For pre-injection, pain had an r = 0.59 
and function had an r = 0.62 at p  < .001; post­
injection pain had an r -  0.79 and function had an 
r = 0.77 atp < .001 ; the change score for pain had 
an r = 0.69 and function, an r = 0.71 at p < .001.
Table 1 Clinical Profiles Pre- and Post-Injection with Synvisc^^^
Variable n Mean SD Min. Max.
Pre-injection - WOMAC pain 163 10.55 3.45 1 20
WOMAC function 163 37.36 11.67 8 68
Global assessment 157 2.94 0.79 1 4
Post-injection WOMAC pain 161 6.04 4.5 0 20
WOMAC function 163 23.18 14.36 0 66
Global assessment 161 1.71 1.14 0 4
Pre- to post-difference WOMAC pain 161 4.50* 4.16 -11 18
WOMAC function 163 14.18* 14.32 -37.69 54
Global assessment 156 1.21* 1.19 -3 4
p  <  .001. by Student’s t-test and Wilcoxon Signed Rank test.
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Table 2 VIP Program Evaluation Summary
Ranking Neutral (%) Agree (%) Strongly Agree (%)
Practice relevancy EP - 26.0 74.0
FP 0.6 29.2 69.6
Met course objectives BP - 26.0 74.0
FP 1.9 26.1 71.4
Met personal expectations EP - 32.0 68.0
FP 2.5 27.5 69.4
Credible EP - 42.0 58.0
FP 3.1 31.7 64.6
Well organized EP 5.0 37.0 58.0
FP 1.9 27.3 69.6
Adequate time for learning EP - 26.0 74.0
FP 2.5 25.8 70.4
Adequate interaction with expert and peers EP - 21.0 79.0
FP 0 20.1 78.6
Participate as expert again EP - 21.0 79.0
FP - - -
Learning objectives met EP - - —
FP 0.6 25.0 73.7
Knowledgeable and skilled expert preceptor EP - - -
FP 0,6 13.8 84.9
Comfortable with repeating procedure EP - - -
FP 4.6 28.7 65.7
Will use viscosupplement in practice EP - - -
FP - 38.3 60.7
EP =  expert preceptor, FP = family practitioner.
Pre-injection and post-injection patient global 
assessment scores and the associated change 
scores relating to responsiveness are illustrated in 
Table 1.
The improvements noted were clinically 
important and statistically significant (p < .001 by 
both parametric and nonparametric analyses). 
With respect to feasibility, ah completed WOMAC 
questionnaires were accompanied by completed 
patient global assessment questions.
Discussion
The majority of previous CME studies have 
assessed the consequence of tlie CME intervention
at the level of the motivation, knowledge, or inten­
tion to change behavior by tire learner.^'- While 
these are useful endpoints from an educational 
standpoint, tlrey leave unanswered tire more impor­
tant question of.whether the CME program had a 
meaningful and beneficial impact on the health sta­
tus of patients subsequently treated by those who 
participated. This tendency to measure more- 
proximal endpoints is understandable, since the 
measurement of clinical consequence is botlr com­
plex and costly. Furthermore, it is difficult to 
directly attribute alterations in the health status of 
patients to the learning intervention: this may 
have deterred some previous investigators from 
pursuing the more important distal endpoints. 
Clearly, attendees at CME events are to some
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extent self-selected by motivation, need, and ambi­
tion, and such individuals are not readily ran­
domized by whether they do or do not attend the 
CME event.’ ’^’'* Moreover, once attendees return 
to their practices, it is no longer possible to ran­
dom ize their patients and exam ine differential 
effects o f being treated by their own physician with 
versus without the recently acquired skill.
In this study, not only the experience o f the pre­
ceptors and learners but also the changing health 
status o f those patients whom they treated im m e­
diately after acquiring the skills necessary to per­
form viscosupplementation were evaluated. The 
preceptors were clearly satisfied with the educa­
tional experience even prior to observing a bene­
ficial effect on the patients they subsequently  
injected. It is noteworthy that, follow ing review  
o f the SAM and completion o f  a supervised injec­
tion o f  Synvisc™ , almost all family practitioners 
felt comfortable about viscosupplementation and 
would consider its use in future management o f  
osteoarthritis knee patients. For the fam ily prac­
titioners, this represented a relatively small time 
commitment to acquire a skill o f general value in 
the management o f osteoarthritis and delivery o f  
intra-articular therapy. It also permitted skills  
acquisition to occur in a clinical environment sup­
portive for both the family practitioner and par­
ticipating patients. The preceptors w ere often  
teaching in locations remote from their practices 
and on patients they had not previously met or 
examined. That the preceptors were also satisfied  
with their involvement in the VIP programs and 
would participate in future programs underscores 
tlie success o f the intervention.
This is particularly remarkable given the inher­
ent difficulty of maintaining consistency in deliv­
ering a learning intervention at multiple sites in 
different geographic areas witli regional variations 
in health care systems, and involving faculty and 
learners with different medical specialty back­
grounds. The uniformly high level o f satisfaction 
expressed by faculty and learners can be attributed 
to the planning, design, and delivery approaches 
employed in this intervention. Variations o f several
adult learning principles and other approaches 
described in the literature were adopted and 
a p p l i e d , a n d  may be summarized as follows:
1. A  multi-stakeholder approach, receiving 
input and validation by faculty and learn­
ers at each stage o f  the developm ent and 
delivery processes;
2. M ultiple learning devices versus reliance 
- —  on a single educational event;
3. Delivery in or close lo the community in 
which the learners practice;
4. Learners in volv in g  their ow n  patients 
rather than artificial models;
5. Small learning groups: and
6. Self-assessm ent and immediate feedback 
to facu lty  and learners from their own 
observations o f patient outcomes provided 
by tlieir administration of the pre- and post- 
injection W OMAC 3.0 questionnaires.
In assessing patient outcomes, it is important 
to use measures tliat are vahcL reliable, and respon­
sive. The W O M AC osteoarthritis index is one 
such measure, and has been extensively used in 
over 50 countries throughout the world.” ^  In this 
study, clinically important improvements were 
noted in W OM AC pain and function scores. Fur­
thermore, while there is currently no internation­
ally accepted definition of responder criteria for 
osteoarthritis knee studies, a outpoint used in 
rheumatoid artliritis studies-' was borrowed and 
three-quarters o f patients were observed to expe­
rience a clinically meaningful response m  both pain 
and function follow ing viscosupplementation.
Furthermore, the patient global assessment 
question used in this study was shown to  be valid, 
sensitive to change, and feasible, thus fulfilling the 
requirements o f the OMERACT filter. It is there­
fore proposed that the patient global assessment
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be used to supplement the standard W OM AC 3.0  
index to create a W OM AC 4.0, or that it replaces 
the stiffness subscale in die W OM AC 3.0 to cre­
ate a modified index termed the WOMBAT 3.0 tliat 
meets OMERACT/OARSI guidelines.
Potential limitations o f the study merit con­
sideration. In general, bias may occur as control 
over experimental conditions diminishes. Clinical 
benefit was observed among patients treated by 
participants in the VIP program. Since die program 
was delivered as a package, die relative contri­
bution o f its different components cannot be dis­
cerned. However, die combination o f die SAM  and 
the experienced preceptors provided optimum  
conditions for small-group learning and for prac­
ticing a newly acquired skill. This was an open 
study in which expectation bias both by the fam­
ily practitioner and patient could modulate the 
response, potentially in a favorable direction. For 
example, the family practitioner could have pre­
sented the possible benefits to patients in an enthu­
siastic way, and patients who elected to participate 
might be self-selected on tiiat basis. However, 
double-bhnd randomized placebo-controlled trials 
o f Synvisc™ have demonstrated the intrinsic effi­
cacy of viscosupplementation,^ which has been 
substantiated in controlled trials o f  nonsteroidal 
class agents^ as well as in open studies,^^ indicating 
that w hile the response may be modulated by 
expectation in som e patients, it does not account 
for the improvement in healtli status observed.
Som e procedures required for tliis study were 
more commonly used in chnical trials based in aca­
demic centers. The requirements for patient selec­
tion were detailed in the SAM , w hile the verifi­
cation o f a diagnosis o f knee osteoarthritis was 
performed by the expert preceptor based on a per­
sonal interview and examination o f the knee and 
accompanying radiographs. O f tlie 445 patients 
w ho participated, com plete W O M A C /patient 
global assessment data within the 3- to 12-week  
period were available on 163, although som e data 
were available on 380 patients. These protocol 
violations and losses to follow-up are likely attrib­
utable to the absence o f a clinical research orga­
nization monitoring the data acquisition, a con­
tingency strongly recommended for future family 
practitioner-based studies o f this type.
The use of a self-administered outcome mea­
sure (WOMAC 3.0) in tliis study obviated any fam­
ily practitioner-associated positive reporting. While 
tlie global question in tlie W OMBAT is new, this 
question is valid, responsive, and feasible, and 
may be used in future osteoartliritis knee studies 
either within the WOMBAT 3.0 or as a supple­
mentary question witliin a W OMAC 4.0 index.
Conclusion
H ie VIP program was successful in training fam­
ily practitioners to apply a safe and effective intra- 
articular therapy in patients with knee osteoarthri­
tis. The m ost important design  elem ent w as 
longitudinal evaluation o f those patients who were 
recipients of a family practitioner’s newly acquired 
skill. The clinically important and statistically 
significant improvements in health status that 
occurred following Synvisc™  injection under­
score the true value o f the VIP program and estab- 
hsh a link between improved patient outcomes and 
a newly acquired learner skill when CME pro­
fessionals apply several essentials o f adult learn­
ing theory and incorporate a standardized validated 
health-status measure in design and delivery o f a 
CME enterprise. In an environment o f multi-stake­
holder demand for evidence o f effective use o f  
health care resources, including CME resources, 
the use o f patient outcomes as a measure cannot 
be ignored. CME professionals need to consider 
this trend and exam ine cost-effective ways o f  
incorporating these measures into the design and 
delivery of future CME endeavors.
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patients with knee osteoarthritis (Part 1 of 2): clinical results
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Summary
Objective: First, to assess the clinical effectiveness of hylan G-F 20 in an appropriate care treatment regimen (as defined by the American 
College of Rheumatology (ACR) 1995 guidelines) as measured by validated disease-specific outcomes and health-related quality of life 
endpoints for patients with osteoarthritis (OA) of the knee. Second, to utilize the measures of effectiveness and costs in an economic 
evaluation (see accompanying manuscript).
Design: A total of 255 patients with OA of the knee were enrolled by rheumatologists or orthopedic surgeons into a prospective, randomized, 
open-label, 1-year, multi-centred trial, conducted in Canada. Patients were randomized to 'Appropriate care with hylan G-F 20’ (AC+H) or 
'Appropriate care without hylan G-F 20’ (AC). Data were collected at clinic visits (baseline, 12 months) and by telephone (1, 2, 4, 6, 8, 10, 
and 12 months).
Results: The AC+H group was superior to the AC group for all primary (% reduction in mean Western Ontario and fvtcfi^aster Universities 
Osteoarthritis Index (WOMAC) pain scale: 38% vs 13%, P=0.0001) and secondary effectiveness outcome measures. These differences 
were all statistically significant and exceeded the 20% difference between groups set a priori by the investigators as the minimum clinically 
important difference. Health-related quality of life improvements in the AC+H group were statistically superior for the WOMAC pain, stiffness 
and physical function (all P<0.0001), the SF-36 aggregate physical component (P<0.0001) and the Health Utilities Index Mark 3 (HU13) 
overall health utility score (P<0.0001). Safety (adverse events and patient global assessments of side effects) differences favoured the 
AC+H group.
Conclusion: The data presented here indicate that the provision to patients with knee OA of viscosupplementation with hylan G-F 20 within 
an appropriate care treatment regimen provides benefits in the knee, overall health and health related quality of life at reduced levels of 
co-therapy and systemic adverse reactions. ©  2002 OsteoArthritis Research Society International. Published by Elsevier Science Ltd. All 
rights reserved.
Key words: Hylan G-F 20, Osteoarthritis, Knee, Effectiveness, Health-related quality of life. Randomized controlled trial.
Abbreviations: ACR, American College of Rheumatology; OA, osteoarthritis; AC+H, Appropriate care with hylan G-F 20; AC, Appropriate care without hylan G-F 20; WOMAC, Western Ontario and McMaster Universities Osteoarthritis index; HU13, Health Utilities Index; NSAIDS, 
nonsteroidal anti-inflammatory drugs; FDA, Food and Drug Administration; RCT, randomized controlled trial; CRO, contract research organiz­
ation; HRQOL, health-related quality of life; SF-36, Short Form 36; ITT, intent-to-treat; ANCOVA, analysis of covariance; GI, gastrointestinal.
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Introduction
Osteoarthritis (OA) Is a common, degenerative musculo­
skeletal condition which consistently challenges the prac­
tising ciinician and adds substantiai burden to health care 
budgets'* The increased prevalence of OA with aging, 
coupled to the demographics of aging populations, make 
OA a high priority healtti care problem^. OA is a leading 
cause of severe activity limitations and disability, with 
indirect costs to society, which can far exceed its direct 
medical costs'*.Guidelines for managing the symptoms of knee OA are 
available from various sources^. The goal of therapy is to 
control pain and maintain function. Weight control, physical 
therapy and simple analgesics such as acetaminophen, are 
suggested as first-line tools for patient management to 
minimize the need for higher risk treatments such as 
non-steroidal antiinflammatory drugs (NSAIDs) or surgery. 
NSAIDs continue to be a widely used medical therapy in 
response to patient demands for symptomatic improve­
ment, In the United States alone, there are an estimated 
56 000 hospitalizations and 8800 deaths each year among 
OA patients, attributed to NSAID treatment®.
Viscosupplementation is a new therapy for the treatment 
of knee OA based on the replacement of synovial fluid by 
intraarticular injection of viscoelastic solutions containing 
hyaluronan or its derivatives^. Hylan G-F 20 (Synvisc® 
Genzyme Corporation, Cambridge MA U.S.A.) is one of the 
viscosupplementation products approved for marketing in Canada since 1992 and the United States since 1997 after 
public review of the data by a Food and Drug Administration (FDA) advisory panel®. A recent systematic review of the 
randomized controlled trial (RCT) data on viscosupplemen­tation concluded, that despite mixed results, the overall data support the efficacy of viscosuppiementation®. While 
some physicians continue to question the efficacy of hylan G-F 20, the reality Is that hyian G-F 20 is an approved treatment in Canada, the U.S.A., and most other countries. Furthermore, the recently revised guidelines published by 
the American College of Rheumatology (ACR) now include viscosupplementation in the treatment paradigm for knee 
OA, thus establishing it as a standard therapy'*®.
Considering the limited resources available for health care, it is important to consider how incorporating the new 
technology affects patient outcomes and health care expenditures. A randomized, controlled trial of health out­
comes was specifically designed to determine the incre­
m ental effectiveness, cost-effectiveness and cost-utility of 
making viscosupplementation with hylan G-F 20 available 
as part of an appropriate care paradigm for treating patients with knee OA. The study utilized a pragmatic design to maintain a real world scenario, and therefore measured effectiveness rather than efficacy'*'*“'*'*, That is, rather than asking the question of whether the treatment is efficacious compared to placebo, the trial sought to determine whether 
the treatment was effective under real world conditions. 
The Canadian Guidelines for Economic Evaluation of Pharmaceuticals state: 'Ideally, pharmacoeconomic studies should report on drug effectiveness rather than efficacy’*®. For this reason the trial design minimized protocol-driven 
interventions and the comparator arm did not include placebo injections. Effectiveness includes all aspects of a 
treatment that add or detract from its success, including efficacy, patient compliance and satisfaction, safety, and positive or negative interactions with other concurrent 
treatments.
The availability of a safe and effective local therapy for managing a localized condition such as knee OA might 
offer important health care benefits. The clinical results and health-related quality of life (HRQOL) outcomes for this trial are reported here, with the economic results separately 
reported in an accompanying manuscript'*®.
Materials and methods
STUDY MANAGEMENT
The study was funded jointly by Biomatrix, Inc and Rhône-Poulenc Rorer Canada Inc. Innovus Research Inc., 
an independent contract research organization (CRO), was contracted to manage the study. An independent Steering 
Committee was assembled with the responsibility to design the study, develop the analysis plan, resolve methodologi­cal issues that arose throughout the study, and interpret and disseminate study results. The Committee consisted of 
five academics, one representative from each of the two sponsoring companies and one representative from the CRO. The Steering Committee was deliberately structured to be dominated by the five independent academics on the Committee. The Steering Committee actively dealt with all scientific questions that arose throughout the course of the study, and did so blinded to implications. The contractual 
arrangement gave the investigators unrestricted rights to publish the study results.
PATIENTS
Patients were enrolled between April and December 1997, at 14 sites across Canada (10 rheumatologists, four 
orthopedic surgeons). The study protocol and informed consent form were approved by the relevant Ethics Committees for the sites, informed consent was obtained 
from each patient.Patients with age greater than 40 years, were required to 
have a primary diagnosis of radiologically verified OA in the study knee (knee most symptomatic or with the most 
predominant musculoskeletal problem), to be symptomatic 
[visual analogue scale total pain score greater than 175 mm of 500 mm on the Western Ontario and McMaster 
Universities Osteoarthritis Index (WOMAC) pain scale] despite prior treatment with acetaminophen or NSAIDS at 
any point prior to the study, to be ambulatory and willing to participate and sign informed consent. Patients with Grade 
IV'**' radiologic changes according to the clinical investi­
gators were excluded. Other exclusion criteria included patients with inflammatory arthropathies, a tense effusion in 
the study knee at baseline, chondrocalcinosis or those with a severe varus or valgus deformity in the study knee. In 
addition, patients were excluded If they had received a steroid Injection in the study knee during the prior 3 months, 
if they had prior viscosuppiementatlon therapy, if they had 
isolated patellofemoral OA or any uncontrolled morbidity, particularly morbidity in any joint which would impede measurements in the study knee.
TRIAL DESIGN
This was a multicentre, 1-year, prospective, randomized, open-label study. Patients were randomized to either ‘appropriate care with hylan G-F 20’ (AC + H) or to ‘appro­priate care without hylan G-F 20’ (AC). The AC group only
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differed in that intraartlcuiar injections of hylan G-F 20 or 
other viscosupplementation products were not allowed. 
Appropriate care was the preferred management strategy 
of a treating physician who was encouraged to follow the Guidelines for the Medical Management of Osteoarthritis of the Knee proposed by the ACR®. Appropriate care could include medications such as analgesics, NSAIDs, corticos­
teroid injections, supportive measures such as education and counseling, weight loss, joint rest, application of heat or 
ice, and use of devices, physical therapy, arthroscopy, and 
total joint replacement.Hylan G-F 20 is administered as a series of 3 intra- 
articular injections at intervals of 1 week. The contralateral 
knee could also be treated with hylan G-F 20, and patients could receive subsequent treatments to either or both knees as required.
Computer-generated randomization was designed to 
be balanced (1:1 allocation ratio) within each site. Randomization within site was blocked, but the block size 
was randomly assigned as blocks of 2 or 4, with the additional constraint that blocking was balanced for the first 12 patients. Additional patients exceeding the first block of 12, were randomly allocated in blocks of 2. The allocation 
scheme was concealed from all clinical sites. Central 
randomization was used whereby the site telephoned the CRO, provided the patient’s initials, and received 
the patient’s identification (ID) number and treatment allocation.Patients were assessed at the site during the baseline visit and the 12-month termination visit. Patients random­
ized to AC + H returned to the site for 2 consecutive weeks after baseline for the remaining hylan G-F 20 injections. These were the only site visits required by the protocol. Structured telephone interviews of the patients in both 
treatment groups were conducted by the CRO at months 1, 
2, 4, 6. 8, 10, and 12. The 12-month termination visit was 
included for patient assessment by the investigator and for 
measuring change since baseline. Patients returned to the physician as required for clinical deterioration, treatment of adverse events, change in medication, or additional 
treatment with hyian G-F 20 if required.Patient demographics, appropriate care treatment for 
knee OA, treatment for overall OA, concomitant medi­cations. and patient self-administered questionnaires were collected at the baseline visit. The same information was 
collected during the telephone interviews, with the addition 
of pill counts performed by the patient, medication dosage and duration, adverse events, health care resources, and whether the health care resource was related to OA. The 
patients kept a diary to keep track of this information, and 
their content was provided to the telephone interviewer at each telephone interview. During the telephone interviews, 
the patient referred to the self-administered questionnaire and provided his/her answers to the telephone interviewer. To blind the patient to his/her previous answers to the same questions, s/he was instructed not to record the answers, 
and the questionnaire was laminated with plastic to make if 
difficult if someone tried to do so. Although the question­naires were completed originally at the baseline visit and 
then during telephone interviews, a study comparing the completion of the WOMAC Likert 3.0 questionnaire at the physician's office to completion over ttie telephone found that differences between the modes of administration did 
not reach statistical significance*®. Information collected 
during the telephone interviews (with the exception of the questionnaires) was compared to the patient's medical 
chart during monitoring visits and differences were
resolved. The investigator reviewed the adverse events for possible attribution to study interventions.
OUTCOMES
The primary measure of effectiveness was the mean change in the WOMAC Likert 3.0 pain score in the study 
knee from baseline to termination. The WOMAC is a self-administered disease-specific HRQOL instrument that asked the patient questions concerning his/her study 
knee*®. The WOMAC Likert 3.0 provides scores for three 
subscales: pain, stiffness, and physical functioning, and an aggregate total score.
There were also measures of secondary effectiveness. Two of the secondary effectiveness measures were the percent of patients improved at termination since baseline using different combinations of the WOMAC Likert 3.0 
subscales as follows: (1) at least 20% improvement since baseline in the WOMAC pain score in the study knee; (2) at 
least 20% improvement since baseline in the WOMAC pain score in the study knee and either 20% improvement in function score or stiffness score. A 20% difference between 
treatment groups for the primary and secondary measures of effectiveness was established a priori by the Steering 
Committee as the minimum clinically important difference, in part based on previous research^®. Other secondary effectiveness measures were the patient global assess­ment of effectiveness for (1) OA in study knee; (2) OA in all joints, and (3) overall health.
HRQOL was measured using three instruments: disease-specific HRQOL using the WOMAC; general 
HRQOL using the Short Form 36 (SF-36)^*, and preference-based HRQOL using the Health Utilities index Mark 3 (HU13)^ .^ The SF-36 provides two composite scales: aggregate physical component and aggregate 
mental component. The HUI3 provides an overall multi­attribute utility score (min: -0.36, death: 0, max: 1). The 
overall utility score is the preference or wortti assigned to a 
particular health status on an interval scale where 0 repre­sents death and 1 represents perfect health. States worse 
than death can take on negative scores.
Safety was measured in two ways during the course of 
the study. The first method was by asking patients to report adverse events during each telephone interview and then having the clinical site review the adverse events. The second method of measuring safety was by asking patients to complete global assessments of side effects. Global 
assessments were measured in two ways: throughout the 
study at baseline and at each telephone interview recall­ing the past 4 weeks; and once during the 12-month termination visit recalling the time period since the baseline 
visit
STATISTICS
The sample size was calculated to detect a 20% differ­
ence between treatment groups in the primary effective­
ness measure. Using a power of 90% and a=0.05, the required sample size was 94 patients per group, for a total 
of 188 patients. The final total sample size required was 252 patients, to accommodate a 20% predicted dropout 
rate over 1 year and to accommodate stratification by site (15 sites).
All patients enrolled in the study were included in the intent-to-treat (ITT) group for all analyses. However, if a patient in the AC group violated the protocol by receiving hylan G-F 20 treatment, the patient was treated as a
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dropout at that point, and all data collected after that time were not included in the analyses. These patients were 
classified as crossovers, and their data following the hylan G-F 20 treatment were imputed as was done for all drop­
outs. This was necessary to ensure the analysis was consistent with a comparison of appropriate care in a world with hyian G-F 20 to appropriate care in a world without 
hylan G-F 20.Two models were used for the statistical analyses, and 
results for the first model are provided. The first model adjusted for design variables (baseline value of the variable 
being analysed, site, blocking by site, BMI, Baseline WOMAC aggregate score), and the second model adjusted for design variables and potentially clinically important 
differences (as judged by the clinical principal investi­gator while blinded to treatment allocation) between the 
treatment groups at baseline.An analysis of covariance (ANCOVA) was used for the primary effectiveness analysis and the HRQOL analysis. A 
generalized linear model was performed for analysis of patients improved. A logistic analysis was undertaken for the patient global assessment of side effects and effective­ness. A nested analysis that incorporates the number of 
events per patient was used to compare the number of gastrointestinal (GI) adverse events.The hot deck method^® was utilized to impute data for 
the primary and secondary effectiveness of patient improved. Dropout patients were matched with a patient 
who completed the study. The matched patient was ran­domly selected from the group of patients who matched the 
dropout patient on criteria deemed most relevant in predict­ing primary effectiveness. The Last Observation Carried 
Forward (LOCF) imputation technique was performed to 
compare to the hot deck method.
Results
PATIENT CHARACTERISTICS
A total of 255 patients were enrolled, 127 patients randomized to AC + H and 128 to AC (Fig. 1). The central 
randomization process was audited to ensure that the randomization schedule was implemented properly. There 
were more dropout patients in the AC group (21) than the 
AC+H group (3) (P=0.001). Of the 21 patients who dropped out of the AC group, the main two reasons were 
that the patients wanted hylan G-F 20 (eight patients) and that the patients were unwilling to continue (eight patients). 
As shown in Fig. 1, eight patients randomized to AC 
received hyian G-F 20 (protocol violators/crossovers), and one patient in the AC+H group did not receive hyian G-F 20 (protocol violator/crossover). The patient changed their mind after being randomized to receive hyian G-F 20. Eighteen of the 24 patients (75%) who dropped out, did so before Month 4. Of the 24 patients who dropped out, four 
continued to have data collected during the remainder of 
the study, however, the data were not used In the analyses. Because these four patients violated the protocol by receiv­
ing hylan G-F 20 treatment despite being randomized to AC without hylan G-F 20, their data after the hylan G-F 20 
injection were not included in the analyses.Demographic and OA status data are presented in Table
I. Greater than 79% of patients in both groups had received previous acetaminophen and NSAID treatment for OA in their knee(s). Although Grade IV OA in the study knee as determined at the sites by the investigators at enrollment
was an exclusion criterion, 20% of patients in the AC+H group and 33% of patients in AC had grade IV OA as 
subsequently determined by central radiologic grading. Greater than 84% of patients in both groups had OA in the 
other knee, and greater than 68% of patients in both groups had other joints affected.
KNEE OA TREATMENT
Table II lists knee OA and overall OA treatment. All patients except one in the AC+H group had at least one course of hyian G-F 20 in their study knee, and 53 (42%) had at least 1 course in their other knee. Forty-eight 
patients (38%) in the AC+H group received a second 
course in the study knee, three patients (2%) received a third course in their study knee, and 20 patients (16%) 
received a second course in their other knee (data not shown in Table II). There were more patients in the AC group who reported corticosteroid injection(s) in the study knee (89 vs 18) or the other knee (35 vs 8) (both P<0.0001). There were more corticosteroid injections in the AC group in the study knee (149 vs 27) and the other knee 
(51 vs 14). There were more patients In the AC group taking NSAIDs for any knee (P=0.0062), and other medications for any knee (P=0.0216). Other medications included medications such as antiinflammatories, neuralgia therapy, 
opioid analgesics and vitamins. There were seven arthro­scopies and four total knee replacements in the AC group compared to one arthroscopy and two total knee replace­ments in the AC + H group. Despite these reductions in the use of medication for the study knee, there was no signifi­cant difference between the groups in the utilization of 
concomitant medications for overall OA (Table II).The other treatments, not listed in Table II, that were used most often in both groups were exercise, physio­therapy, walking, water exercises, and assistive devices 
such as bandages, canes, knee braces, bath bars, and 
orthotics. There were too many details to provide the other treatments and assistive devices results in Table II. 
However, the cost results summarized in the accompany­ing economic manuscript indicate that the annual cost per 
patient for other therapy was $5 in the AC+H group versus $16 in the AC group. The annual cost per patient for 
assistive devices was $237 in the AC + H group versus $305 in the AC group*®.
EFFECTIVENESS
Table 111 provides the primary and secondary effective­ness results. The AC+H group was superior to the AC 
group for all primary and secondary effectiveness measures. These differences were all statistically signifi­
cant and exceeded the 20% minimum clinicaiiy important difference. The AC+H group experienced a 25% greater 
improvement in the WOMAC pain score in the study knee 
from baseline to termination (P=0.0001). The AC+H group had a larger percent of patients who improved by at least 20% (P=0.0001). The primary and secondary effectiveness analyses yielded similar results for model 2 (data not 
shown). Imputation using LOCF did not change the results. The AC+H group experienced 26% greater improvement in the WOMAC pain score, and a 30% greater improvement 
in percent of patients who improved by at least 20% in WOMAC pain. The AC + H group also did better on the patient global assessments of etfectiveness for OA in the
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Crossovers 
n= 8
Not Reported 
n= 1
Non-Crossovers
n=12
Crossovers 
n= 1
Non-Dropouts 
n= 124
Non-Dropouts
n=107
Non-Crossovers
n=2
Appropriate Care 
n=128
Screening Failures 
n=32
Not included in 
effectiveness analysis n=l
Patients Screened 
n=287
Appropriate Care + hylan G-F 20 
n=127
Patients Randomized 
n=255
Dropouts 
n— 21
Did not reach effectiveness 
endpoint
Dropouts
n=3
Did not reach effectiveness 
endpoint
Fig. 1. Trial profile.
study knee, as well as OA in all joints and overall health (P<0.05).
Figure 2 displays the mean WOMAC pain score at each time point during the study year. The patients in the AC+H group had a greater reduction in the WOMAC pain score over the full study year compared to the AC group 
(P=0.0001).
HEALTH-RELATED QUALITY OF LIFE
Table IV provides the baseline, Month 12, change, and 
change as a % of baseline for the three HRQOL outcome 
measures. For ail three WOMAC subscales, the SF-36 aggregate physical component, and the HUI3 overall health utility score, the AC+H group was statistically significantly superior (P<0.0001). For all cases in the WOMAC and 
SF-36, the difference between groups was greater than 20% except for the SF-36 aggregate physical component 
where the difference between groups was 19%.
SAFETY AND TOLERABILITY
Adverse events were reported by 96% of patients (1114 
events) in the AC+H group and 90% of patients (1026) in 
the AC group (not compared statistically). There was one 
serious adverse event in the AC group (patient presented to 
the emergency room with a gastro-duodenal ulcer) listed by 
the investigator as remotely related to appropriate care,
Intraarticular injection of hylan G-F 20 is occasionally 
accompanied by pain, swelling, or effusion In the treated 
knee. A local adverse event was defined during the analysis 
as any emergent signs or symptoms occurring In the knee. 
The local adverse events were subdivided into those occur­
ring within 46 hours of a hylan G-F 20 injection and those 
occurring at any other time. There were 82 local adverse 
events (in 38 patients) that occurred within 48 hours of a 
hylan G-F 20 injection in the AC + H group. Of these 82 local adverse events, one was reported as related to osteoarthri­
tis, nine were reported as not related to hylan G-F 20, 15
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Table 1Demographic information and osteoarthritis status
Demographics, f (percent of n)* AC+H
(n=127)
AC
(n=128)
Age in years, mean ( s .d .) 62.6 (9.4) 63,5(10.5)
Sex
Female 86 (68%) 93 (73%)
Body mass index (kg/m^), mean ( s .d .) 32.1 (8.0) 32.9 (7.2)
OA status
Duration (years) of OA symptoms
Study knee, mean ( s .d .) 9.0 (9.5) 9.9 (9.7)
Other knee, mean (s .d .) 7.4 (8.8) 8.3 (9.3)
Previous therapy for OA of the knee(s)
Acetaminophen 100 (79%) 109 (85%)
NSAIDs 120 (94%) 110(86%)
Prior surgery, study knee 40 (31%) 39 (30%)
Prior surgery, other knee 27 (21%) 23(18% )
Radiology grading within 1 year (central grading )
Not reported 0 (0%) 1 (1%)
Grade 0 4 (3%) 4 (3%)
Grade i 17(13% ) 11 (9%)
Grade II 32 (25%) 33 (26%)
Grade 111 49 (39%) 37 (29%)
Grade IV 25 (20%) 42 (33%)
OA at baseline
Other knee affected 109 (86%) 108 (84%)
Any other joints affected 95 (75%) 87 (68%)
Patient global assessment of OA in study knee at baseline
Not reported 0 (0%) 1 (1%)
Very good 0 (0%) 0 (0%)
Good 2 (2%) 1 (1%)
Fair 44 (35%) 31 (24%)
Poor 58 (46%) 57 (45%)
Very poor 23(18% ) 38 (30%)
Patients global assessment of OA in all joints at baseline
Not reported 1 (1%) 2 (2%)
Very good 1 (1%) 2 (2%)
Good 9 (7%) 5 (4%)
Fair 54 (43%) 44 (34%)
Poor 47 (37%) 49 (38%)
Very poor 15(12%) 26 (20%)
WOMAC pain subscale score (0-20), mean ( s .d .) 11.4 (2.7) 11.9(2.9)
*f is frequency, n is sample size. Not all percentages sum to 100 due to rounding.
tRadioiogy grading is based on central grading, which may have differed from the site investigator’s 
determination for patient eligibility.
OA=osteoarthritis: WOMAC=Western Ontario and McMaster Universities Osteoarthritis Index; AC+H = 
Appropriate Care + hylan G-F 20; AC=Appropriate Care.
were reported as remotely, possibly or probably related to 
hylan G-F 20, and 57 related to the injection procedure.The occurrence of GI adverse events was lower in the 
AC+H group for total GI events (109 vs 140 events, P=0.0439), and GI events attributed to AC (25 vs 62 
events, P=0.0001), and for total severe GI events (26 vs 53, P=0.0033), and severe GI events attributed to AC (5 vs 22, P=0.0024). Medications taken for side effects of OA 
treatment were collected. Thirty-nine patients in the AC group were taking medications for the gastrointestinal tract compared to 21 patients in the AC + H group (P=0,0057).
For the globai assessments of side effects for the time period since baseline, 62% (79/127) of AC+H patients experienced no side effects compared to 41% (52/128) of AC patients (P=0.0100). The global assessments of side effects (combined mild, moderate or severe) performed at baseline and months 1, 2, 4, 6, 8, 10 and 12 are illustrated 
In Fig. 3. Fewer patients in the AC+H group (52%; 64/124)
experienced side effects at Month 12 than patients in the 
AC group (68%; 73/107) (P=0.0116).
Discussion
This report details the clinical results of a prospective, 
randomized, effectiveness/health outcomes trial evaluating the incremental value of making a new treatment modality, viscosuppiementatlon with hyian G-F 20, available for the treatment of patients with knee OA. All of the clinical outcomes measured provided consistent results favoring 
the group receiving AC+H. The difference between the groups was clinicaiiy important and statistically significant using a disease-specific instrument (WOMAC 3.0), a 
generic HRQOL instrument (SF-36), a preference based HRQOL instrument (HUI3) and global evaluations by the patient of OA in the study knee, overall OA, and overall
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Table IIKnee osteoarthritis treatment and overail osteoarthritis treatment
Treatment, f (percent of n)* AC+H
(n=127)
AC
(n=128)
P-value
Number of patients reporting hylan G-F 20 course(s)
Study knee 126(99%) 6 (5%)
Other knee 53 (42%) 0 (0%)Number of patients reporting corticosteroid Injection(s)
Study knee 18 (14%) 89 (70%) <0.0001
Other knee 8 (6%) 35 (27%) <0.0001
Number of patients reporting arthroscopy
Study knee 1 (1%) 5 (4%)
Other knee 0 (0%) 2 (2%)
Number of patients reporting total knee replacement (TKR)
Study knee 1 (1%) 3 (2%)
Other knee 1 (1%) 1 (1%)
Number of patients reporting medication for any knee
Analgesic (oral) 84 (66%) 96 (75%) 0.1158
NSAID (oral) 82 (65%) 101 (79%) 0.0062
Alternative ttierapy 41 (32%) 44 (34%) 0.5501
Analgesic (topical) 20(16% ) 24(19% ) 0.6996
Other 13(10%) 25 (20%) 0.0216
Number of patients reporting medications for overall osteoarthritisf
Musculoskeletal 16(13%) 15(12%)
CNS 15 (12%) 12(9% )
Minerals and vitamins 1 (1%) 1 (1%)
Anti-infectives 1 (1%) 0 (0%)
Other 5 (4%) 10(8% )
*f is frequency, n is sample size.
tP"Value results from Model 1 adjusting for design variables.
j i f  a patient was taking the same medication for knee osteoarthritis and osteoarthritis in other joints, it was 
included in knee osteoarthritis.
NSAIDs= non-steroidal antiinflammatory drugs; CNS=centra I nervous system: AC+H = Appropriate Care+ 
hylan G-F 20; AC=Appropriate Care,
Table IIIPrimary effectiveness and secondary effectiveness results
AC + H AC [(A C +H )- P-vaiue*
(n=127) (n=128) (AC)]
Primary effectiveness n=127 n = 127
Change from baseline to termination in WOMAC pain, mean (s.d.) -4 .4  (3.9) -1 .8  (3.8) -2 .6 0.0001
Change as a % of baseline, mean (s.d.) -38 .4  (34.4) -13 .3  (39.9) -25 .07 <0.0001
Secondary effectiveness f (percent of n )t n=127 n=127
Patients Improved at termination since baseline;
WOMAC pain 87 (69%) 51 (40%) 29% 0.0001
WOMAC pain and either stiffness or physical functioning 79 (62%) 45 (35%) 27% 0.0001
Patients global assessment of change since baseline
(improved slightly, moderately, or markedly):
OA in study knee 93 (73%) 35 (27%) 46% <0.0001
OA in all joints 48 (38%) 22 (17%) 21% 0.0011
Overall health 48 (38%) 21 (16%) 22% 0.0010
Patients global assessment at month 12 over the past 4 weeks
(fair, good, or very good): f?=124 n = 107
OA in study knee 94 (76%) 46 (43%) 33% <0.0001
OA in all joints 88 (71%) 45 (42%) 29% <0.0001
Overall health 118(95%) 91 (85%) 10% 0.0115
*P-value results from Model 1 adjusting for design variables. The results were similar for model 2 adjusting for design variables and 
potentially clinically important differences at baseline, 
f f  is frequency, n is sample size. The sample size is indicated in the table heading unless otherwise indicated in the table. 
OA-osteoarthritis; WOMAC=Western Ontario and McMaster Universities Osteoarthritis Index; AC+H=Appropriate Care+hylan G-F 20; 
AC=Appropriate Care.
health. These data do not address the continuing debate they clearly demonstrate that making viscosupplementation
regarding the reiative contribution of the intraarticular pro- available as part of an AC treatment regimen results incedure and the material injected into the knee. However, ciinically important improvement to patients with knee OA.
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Table IVMean change since baseline in WOMAC, SF-36 and HUi
Baseline Month 12 Change 
(month 1 2 -  
baseline)*
Change as a % 
of baseline
P-valuef for 
comparison 
at month 12
W OMACt subscales, mean ( s .d .) 
Pain (min; 0; max: 20)
AC + H
AC
(AC+H) "(AC)
n=^27 
11.35 (2.71) 
n=127 
11.94 (2.89)
n=127 
6.94 (3.97) 
n=127 
10.10(4.24)
-4.41 (3.88) 
-1 .83  (3.83)
-38.41 (34.39)
-13 .34  (39.86) 
-25.07
<0.0001
Stiffness (min: 0; max: 8) 
AC+H
AC
(AC+H)-(AC)
n=127
5.06(1.51)
n=127
5.10(1.42)
n=124 
3.22(1.74) 
n=107 
4.31 (1.56)
-1 .83  (1.73) 
-0.71 (1.57)
-34 .74  (35.00)
-10 .42  (37.42) 
-24.32
<0.0001
Physical function (min: 0; max: 68) 
AC+H
AC
(AC+H)-(AC)
n=127 
39.54 (9,27) 
n=127 
40.20 (9.26)
n=124 
24.26(12.95) 
n=107 
33.87 (13.88)
-15.04(12.29) 
-5 .85  (11.18)
-37 .82  (31.44)
-14 .52  (30.39) 
-23.30
<0.0001
SF-36§, mean ( s .d .)
Aggregate physical component (min: 2; max: 76) 
AC + H
AC
(AC+H)-(AC)
n=127 
28.33 (6.60) 
n=126 
28.18(7.78)
n=124 
33.24(10.16) 
n=107 
27.78 (8.90)
4.88 (9.78) 
-0 .40  (7.22)
20.31 (37.43)
1.07 (29.10) 
19.24
<0.0001
Aggregate mental component (min: -2 ; max: 81) 
AC+H
AC
(AC+H)-(AC)
n=127 
51.74 (11.83) 
n=126 
49.91 (11.82)
n -124  
55.29(10.45) 
n=107 
52.65 (11.56)
3.32 (12.06) 
1.55(10.55)
11.53 (33.80)
5.40 (23.11) 
6.13
0.0939
HUI3|j (min: -0.36; max 1), mean (so.) 
AC + H
AC
(A C + H )-(A C )
n=123 
0.50 (0.22) 
/7=126 
0.46 (0.24)
n=122 
0.63 (0.25) 
n=107 
0.51 (0.28)
0.13 (0.23)
0.03 (0.22) 
0.10
n/a
n/a
<0.0001
*Due to differences in sample size from baseline to month 12 computation of change (Month 1 2 -Baseline) was calculated for patients with 
both baseline and termination values.
tP-value results from Model 1 adjusting for design variabies. The results were similar for model 2 adjusting for design variables and 
potentially clinically important differences at baseline 
$The higher the score, the worse the problem 
§The higher the score, the better the health perception 
||The higher the score, the better the overall health utility
n/a denotes not applicable. Because HUI3 is an interval scale, percent improvements are not useful and indeed distort the magnitude of 
change.
WOMAC = Western Ontario and McMaster Universities Osteoarthritis Index; AC+H=Appropriate Care+hylan G-F 20; AC =Appropriate 
Care; SF-36 =Short Form 36; HUI3=Health Utilities Index 3.
The data reported that inclusion of hyian G-F 20 in an 
appropriate care treatment regimen resulted in a meaning­ful decrease in the utilization of other treatments for knee 
OA. These decreases were statistically significant with respect to the utilization of steroid injections, oral NSAID 
therapy and ‘other’ medications for knee OA. Patients in the AC+H group also received fewer arthroscopies and 
fewer total knee replacements, but the difference was not 
compared statistically.
Overall the safety data collected and analysed In this trial 
confirm that patients treated in different ways are likely to
experience different patterns of side effects. Patients in the 
AC+H group experienced some discomfort associated with 
the intraarticular procedure. The 15 local adverse events categorized as remotely, possibly or probably attributed to hylan G-F 20 out of a total of approximately 700 hyian G-F 
20 injections represents a rate of approximately 2% , similar to that observed in other trials '^*. However, the hyian G-F 
20 treated patients also had a clinicaiiy meaningful 
decrease in both the number and severity of Gi side effects 
related to appropriate care and the need for medication to treat GI side effects. Furthermore based on the patients'
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global evaluation of side effects, it would appear that the 
patients in the AC+H group judged themselves to have 
experienced additional benefits by virtue of having en­countered fewer side effects. These data suggest that a 
management strategy, which includes hylan G-F 20 may 
result In Important safety gains, principally by reducing Gl events and the necessity for their treatment with Gl medi­cations. It should be noted that COX-2 selective inhibitors were not available during the trial.Although viscosupplementation with hylan G-F 20 is a 
local treatment which was only used to treat knee OA in this trial, the AC + H group experienced significantly better 
improvements in global evaluations measuring overall OA, and overall health, and In HRQOL instruments which reflect the health status of the whole patient. This Is particularly surprising considering that in the AC+H group 66% of 
patients had OA In some joint other than the knee and 49% of patients scored their OAin all joints as poor or very poor at baseline (Table I). These ‘whole patient’ improvements probably reflect the fact that for the patients in this trial the knee was their most symptomatic musculoskeletal prob­lem, and was therefore a major determinant of their pain, 
disability and HRQOL. It Is not uncommon In OA patients for one or two joints to be the primary source of the 
patient’s disability^®. Similar improvements In HRQOL are observed after surgical treatments for knee OA such as knee replacement^®.In keeping with the study's pragmatic design, the X-ray 
grade used to determine study Inclusion was that scored by the investigator entering the patient, and based on their best clinical judgement and the radiologist report. The 
investigator was not asked to provide a grade, but to determine that the patient had OA that was not Grade IV. 
Hence one radiologist will possibly provide a different rating than the impression of 14 investigators who were not asked to provide a grade. Because the authors were sensitive to 
potential differences between investigators and to the prevalence of ‘borderline’ scores, central grading was per­
formed by a trained radiologist. This was done after the patients were entered and used only in the analyses. Patients judged to have Grade IV X-ray by central scoring 
were not asked to leave the trial.Grade IV OA of the study knee was an exclusion 
criterion, because those patients would be more likely to receive surgery, and the intention was to avoid having 
surgery dominate the cost results. Despite this exclusion 
criterion, approximately 20-30% of patients in the study 
were judged by a central radiologist to have grade IV OA. It is not surprising that the grading provided by the site investigators and central radiologist differed for some 
patients, as the difference between grade level III and IV Is 
subtle. The effectiveness of hylan G-F 20 is not expected to 
differ significantly for the two grade levels^^. Patients with grade IV OA are also indicative of real world practice. To address the Imbalance in X-ray grades between the two treatment groups, the analyses adjusted for Grade IV OA as a covariate; however, this did not change any results.
The demographics of aging populations make OA a particularly challenging medical and socioeconomic prob­lem^ ®. There is therefore a growing pool of patients with symptomatic knee OA who must be managed for many years, and in whom it is desirable to delay knee 
replacement for as long as possible. Currently the only 
treatments widely available for such patients are prescrip­
tion NSAIDS or analgesics, intraarticular steroid injections, topical agents, and arthroscopic lavage and debridement. All of these available modalities have drawbacks or signifi­
cant side effects. The data presented here indicate that the provision to patients with knee OA of viscosupplementation 
with hylan G-F 20 within an appropriate care treatment regimen provides benefits in the knee, overall health and 
health related quality of life at reduced levels of co-therapy and systemic adverse reactions.
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Summary
Objective: Viscosuppiementation with hylan G-F 20 has recently become registered for treatment of patients with osteoarthritis (OA) of the 
knee in most parts of the world. The cost effectiveness and cost utility of this new therapeutic modality were determined as part of a Canadian 
prospective, randomized, 1-year, open-label, multicentered trial.
Design: A total of 255 patients were randomized to 'Appropriate care with hylan G-F 20’ (AC+H) or 'Appropriate care without hylan G-F 20’ 
(AC). Costs (1999 Canadian dollars) were collected from the societal viewpoint and included ail costs related to OA of the knee and OA in 
all joints. Patients completed a number of outcomes questionnaires including the Western Ontario and McIVIaster Universities Osteoarthritis 
index (WOMAC) and the Health Utilities Index Mark 3 (HUI3). Data were collected at clinic visits (baseline, 12 months) and by telephone 
(1, 2, 4, 6, 8, 10, and 12 months).
Results: The AC+H group over the year had higher costs ($2125-$1415=$710, P<0.05), more patients improved (69% -40% =29% , 
P=0.0001), greater increases in HUI3 (0.13-0.03=0.10, P<0.0001) and increased quality-adjusted life years (QALYs) (0.071, P<0.05). The 
incremental cost-effectiveness ratio was $2505/patient improved. The incremental cost-utility ratio was $10 000/QALY gained. Sensitivity 
analyses and a second cost perspective gave similar results.
Conclusion: The cost-utility ratio is below the suggested Canadian adoption threshold. The results provide strong evidence for adoption of 
treatment with hylan G-F 20 in the patients and settings studied in the trial. ©  2002 OsteoArthritis Research Society International. Published 
by Elsevier Science Ltd. All rights reserved.
Key words: Hylan G-F 20, Osteoarthritis, Knee, Economics, Cost and cost analysis. Health-related quality of life.
Introduction
Hylan G-F 20 (Synvisc® Genzyme Corporation, Cambridge, MA, U.S.A.) is a high-molecular weight viscosupplemen-
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tatlon product for injection into the intraarticular space of the knee as a synovial fluid replacement. The product has molecular weight and viscosity similar to the synovial fluid 
found in healthy knees'*. Hylan G-F 20 has been recently approved for the treatment of patients with osteoarthritis 
(OA) of the knee in most countries in the world. Accordingly,
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the question we sought to answer in this research project was, given that this is an approved and used treatment, 
how effective and cost effective is it in the real world compared to appropriate care without its availability? That 
is, we sought to compare a world with hylan G-F 20 to a 
world without hylan G-F 20.Health-related quality of life (HRQOL), effectiveness, cost-effectiveness and cost-utility are studied and reported here. The clinical and safety results of this study are reported In the accompanying manuscript^. The study was conducted following the Canadian guidelines for health economic studies®, which in turn are consistent in most respects with similar guidelines in other countries'*"^. This is a pragmatic trial. To enhance the real world generaliz- 
ability of the results the study was conducted in multiple sites, with both rheumatologists and orthopedic surgeons, 
the study was 1 year in length, the inclusion/exclusion criteria were liberal, and the .study was not blinded. The comparator was deliberately selected as appropriate care, 
not usual care. It was felt that usual care might contain some inappropriate care, and demonstrating that a new 
treatment is effective and cost-effective compared to in­appropriate care is not particularly useful. Appropriate 
care is the preferred management strategy of specialists, rheumatologists or orthopedic surgeons, encouraged to 
follow the treatment guidelines published by the American College of Rheumatology^ and instructed to treat conservatively.The study was funded jointly by Biomatrix, Inc and Rhône-Poulenc Rorer Canada Inc. Innovus Research Inc.. 
an independent contract research organization (CRO), was 
contracted to manage the study. An independent Steering 
Committee was assembled with the responsibility to design the study, develop the analysis plan, and disseminate study results. The Committee consisted of five academics, one representative from each of the two sponsoring companies and one representative from the CRO. The Steering Com­
mittee was deliberately structured to be dominated by the five independent academics on the Committee. The Steer­ing Committee was very active and, in fact, dealt with all scientific questions that arose throughout the course of the study, and did so blinded to implications. The contractual arrangement gave the investigators unrestricted rights to 
publish the study results.There are several audiences for the study. Clinicians will 
be interested in the findings of clinical effectiveness and of HRQOL. Many clinicians will also be interested in the 
findings of the cost-effectiveness and cost-utility analyses, particularly clinicians interested in the efficient use of lim­
ited resources and those involved in establishing treatment guideiines. Third-party payers, formulary managers, and 
fiscal administrators will be interested in all of the findings but particularly the results of the cost-effectiveness and 
cost-utility analyses.
years of age, to have a primary diagnosis of radiologically 
verified OA in the study knee (knee most symptomatic or 
with the most predominant musculoskeletal problem), excluding grade IV; to be symptomatic (total pain score greater than 175 mm on the five 100 mm visual analogue 
pain questions in the Western Ontario McMaster University Osteoarthritis Index (WOMAC)® despite prior treatment 
with acetaminophen or non-steroidal antiinflammatory drugs (NSAIDS) at any point prior to the study, and to be ambulatory.Protocol-driven costs and outcomes were minimized by limiting study-induced clinic visits. Patients were assessed at the site during the baseline visit and the 12-month termination visit. Patients randomized to AC + H returned to 
the site for 2 consecutive weeks after baseline for the remaining hylan G-F 20 injections. Other visits could occur 
on an ‘as needed’ basis for clinical deterioration, treatment of adverse events, change in medication, or additional 
treatment with hylan G-F 20 if required; however, no other visits were required by the protocol.Structured telephone interviews of the patients in both treatment groups were conducted by the CRO at 1, 2,4. 6, 8, 10, and 12 months. The 12-month termination visit was 
included for patient assessment by the investigator and for measuring change since baseline. At the baseline visit 
the following data were collected: patient demographics, appropriate care treatment for knee OA, treatment for overall OA, concomitant medications, and patient self- administered questionnaires (WOMAC Likert 3.0)® 4-week recall, the Short-Form 36 (SF-36)® 4-week recall, and the 
Health Utilities Index 3 (HUIS)"*® 4-week recall. Except for 
patient demographics, the same information was collected at each telephone interview, with the addition of pill counts, adverse events, health care resources (e.g., physician visits, physiotlierapy, hospitalizations), any patient expenses (e.g., travel), and lost time from work or usual activities due to OA treatment or OA symptoms. At each 
telephone Interview the information was collected for the time period since the last interview, except for the patient self-administered questionnaires at months 4, 6, 8 and 12 where the recall period was 4 weeks. During the telephone interviews, the patient referred to the self-administered 
questionnaire and provided his/her answers to the tel­
ephone interviewer. To blind the patient to his/her previous answers to the same questions, s/he was instructed not to record the answers, and the questionnaire was laminated with plastic to make it difficult if someone tried to do so. 
Information collected during the telephone interviews (with the exception of the questionnaires) was compared with the patient’s medical chart during monitoring visits and differences were resolved. The investigator reviewed 
the adverse events for possible attribution to study interventions.
Methods
STUDY DESIGN
This was a muiticenter, 1-year, prospective, randomized, 
open-label, parallel design trial of appropriate care with hylan G-F 20 (AC + H) compared to appropriate care with­
out hylan G-F 20 (AC) in the treatment of patients with symptomatic OA of the knee. Patients were recruited from 14 sites across Canada, 10 rheumatologists and four 
orthopedic surgeons. Patients had to be older than 40
OUTCOME MEASURES
The WOMAC Likert 3.0 is a disease-specific HRQOL instrument that asks the patient questions concerning the 
study knee, it produces an aggregate total score and scores for three subscales: pain, stiffness and physical 
functioning.The outcome measure for the cost-effectiveness analy­sis (CEA) was patients improved. In the design of the study 
the Steering Committee provided two definitions of an improved patient. The primary definition was a patient whose WOMAC pain score at month 12 was reduced by
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Fig. 1. The types of costs that were included In the societal and health care system perspectives.
20% or more compared with baseline. The secondary definition was a patient who not only reduced their pain score by 20% or greater but also reduced either their 
stiffness or their physical functioning score by 20% or more as well. The design also specified that the percentage of patients improved In the, AC+H group would have to exceed the percentage in the AC group by at least 20% for the results to be clinically important.
The HUI3 is a generic, preference-weighted health status instrument that asks the patient questions about 
their overall health status and HRQOL. Specifically, the 
HUI3 measures health status using the following eight attributes: vision, hearing, speech, ambulation, dexterity, 
emotion, cognition and pain/discomfort. The patient is clas­sified on each attribute into a level varying from normal to 
severely impaired. The scoring formula for the instrument is based on community preferences as measured by the standard gamble method and thus represents a von Neumann-Morgenstern utility'**. The instrument provides an overall utility score (min: -0.36; max: 1) on the conven­tional health utility scale where dead=0.00 and perfect 
health=1.00. States worse than death can take on negative 
scores.The outcome measure for the cost-utility analysis (CUA) is the number of quality-adjusted life years (QALY) gained. 
The overall utility score from the HUI3 is used as the quality 
adjustment factor for calculating QALYs gained. Note that the cost-effectiveness analysis focuses on the study knee  effectiveness, whereas the cost-utility analysis focuses on 
patient effectiveness.
PERSPECTIVES
Figure 1 shows the categories of costs that are included in the different perspectives. Some costs, such as medi­cations and hylan G-F 20. fall in more than one perspective, 
depending upon the patient’s drug plan. A comprehensive societal perspective was adopted as the primary perspec­tive for the economic analyses. In this perspective all costs 
are counted. Lost time was captured for both the patient and for the unpaid family caregiver, and was categorized into lost work time (for those In paid employment) and lost 
usual activity time (for those not In paid employment). In the 
base case analysis only lost work time was included. In a 
sensitivity analysis, ail lost time was included. The health care system (HCS) consists of the two major payers in 
Ontario, Ministry of Health and private medical plans. This perspective was adopted as the secondary perspective.
RESOURCE UTILIZATION AND COSTING
At each telephone interview patients reported health 
care received, and indicated which they thought were related to OA (i.e., due to OA In any joint, the treatment of OA in any joint, or the treatment of adverse events related to the treatment of OA). The patient’s data were compared 
with the patient’s chart at the investigator’s office, and 
discrepancies were resolved. The physician or the research coordinator at the site reviewed the Items and could override the patient’s attribution to OA. To improve
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Fig. 2. A typical patient profile for the HUI3 score showing the area-under-the-curve calculation for quality-adjusted life years (QALY). The 
baseline HUI3 score is shown on the y-axis; however, it is not used to calculate the QALY
consistency across sites, the three clinicians (JPR, PT, NB) 
from the Steering Committee reviewed the attribution of all resources, while blinded to treatment allocation. They could override the site’s attribution to OA. Only costs related to OA were included in the analysis. The following protocol 
driven items were not included in the costs; screening visit, 
X-ray at screening, lab test at baseline, and termination 
visit.Costs are reported in 1999 Canadian dollars ($Can). Costs not available in 1999 dollars were adjusted to 1999 
using the health and personal care component of the consumer price index**^ . Costs are from ttie province of 
Ontario, Canada’s largest province.The market price of hylan G-F 20 in Canada during the study was $339 including tax per course of three injections. Medications were priced according to the Best Available Price for drugs listed on the Ontario Drug Benefit Formu­
lary, or the brand name price from a pharmacy wholesaler’s catalogue*® *'*. Prices for outpatient resources were obtained from a variety of appropriate sources; e.g., fees for physician services and laboratory and procedures*®, arid cost of other health care professionals*®. A standard 
cost ($165.55) for a generic emergency room (ER) visit was used for all ER visits in the study*®. The reason for 
hospitalization (e.g. total knee replacement) was coded into an international classification of disease ninth revision 
clinical modification (ICD9-CM) code. The mean cost for patients hospitalized for that ICD9-CM code for the same length of stay was employed*^. Patient lost productivity was valued at the Canadian average industrial wage rate ($121.59 per day) for time lost from employment and 
non-work time losses*®.
STATISTICS
The sample size for the study was calculated based on 
the primary effectiveness measure for the clinical results, mean change in WOMAC pain score in study knee, as described in the accompanying paper^. The sample size was not calculated on the basis of the cost-effectiveness or cost-utility ratio because well-established methods to do so 
did not exist at the time the study was designed.
All patients randomized were included in the analysis. 
Missing data were imputed, so that a full data set was available for the statistical analyses. The hot deck method was used to impute data*®. A patient with missing data was matched to a small group of ‘similar’ patients with complete data, from which one was selected randomly. Data points missing in the index patient were filled in from the matched 
patient. Consistent with the comparison of a world with hylan G-F 20 to a world without hylan G-F 20. the few patients in the AC group who violated the protocol by receiving hylan G-F 20 treatment were treated as drop-outs at that point .^ That is, their data from that point forward were imputed. Just like any other drop-out.The WOMAC and HUI3 questionnaires specified a recall period of 4 weeks, except for the questionnaires at months 1 and 2 in which the recall period was the time since the previous visit. The HUI3 overall utility score represents the mean score for that patient over the recall time period. A typical patient profile is shown in Fig. 2. Note, the horizontal segments in Fig. 2 represent measured scores while the sloping segments represent linear interpolation. The QALY for each patient is calculated by taking the area under the 
curve for the patient’s utility, using years as the unit for time.
Because all patients were not in the study for exactly 365 days, their costs and QALYs were converted to an 
equivalent annual figure [annualized cost or QALY=(total cost or QALY for time in study/number of days on study)X365.25 days]. Because the time horizon for the 
analysis was 1 year, discounting of future costs and consequences was not necessary.
The base case analysis is the primary analysis. The following one-way sensitivity analyses were performed to test the robustness of the results;
• Effectiveness: for the CEA, the incremental effectiveness (difference in proportion of patients improved) was varied to its upper and lower 90% confidence bounds. Similarly, for the CUA, the incremental effectiveness (QALYs gained) was varied to its upper and lower 90% confi­dence bounds.• Cost: for the CEA and CUA, the incremental cost was 
varied to its upper and lower 90% confidence bounds.
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Table IDemographic information and osteoarthritis status, f (percent ofn)*
AC+H  
(n = 127)
AC
(n=128)
Age, mean ( s .d .) years 62.6 (9.4) 63.5 (10.5)
Sex, female 86 (68%) 93 (73%)
Work status
Full-time 30 (24%) 19 (15%)
Part-time 11 (9%) 16 (13%)
Sick leave 1 (1%) 2 (2%)
Not in paid employment 84 (66%) 90 (70%)
Not specified 1 (1%) 1 (1%)
Prescription drug plan coverage
No plan 15 (12%) 15 (12%)
Employer or private 53 (41%) 39 (31%)
Government 47 (37%) 64 (50%)
Government+(private or employer) 11 (9%) 8 (6%)
Not specified 1 (1%) 2 (2%)
Duration (years) of OA symptoms
Study knee, mean ( s .d .) 9.0 (9.5) 9.9 (9.7)
Other knee, mean ( s .d .) 7.4 (8.8) 8.3 (9.3)
OA at baseline
Other knee affected 109 (86%) 108 (84%)
Other joints affected 86 (68%) 78 (61%)
*f Is frequency, n is sample size. Not all percentages sum to 100 
due to rounding.
OA=osteoarthritis; AC+H = Appropriate Care + hylan G-F 20; 
AC=Appropriate Care.
Time loss: the CEA and CUA were re-done using a more liberal costing of time loss that costed all time loss whether work or usual major activity {including leisure). In the base case only time loss from work was costed.
Results
PATIENTS
One hundred and twenty-seven patients were random­ized to receive AC + H and 128 to receive AC. The demographic and OA status of the patients are displayed in Table I. The patients had a mean age of 63 years, with the 
preponderance of them being unemployed women with OA In both knees, and covered by a drug plan. The two groups were well balanced.
COSTS
The mean annual OA-related cost per patient from the societal perspective by type of cost is shown in Table II. There were too many different kinds of costs to show unit costs within type (e.g. 20 types of injections, 80 types of 
outpatient resources, 30 types of assistive devices). The total annual cost per patient in a world without hyian G-F 20 (AC group) was $1415. The total in a world with hyian G-F 20 was $2125, an excess of $710. The 95% confidence
Table IIIdean annual OA-related cost per patient from the societal perspective
AC+H
(n=127) (n
AC 
= 128)
Mean
difference
([AC+H]-
AC)
hylan G-F 20 676.01 (370.89) 0.00 (0.00) 676.01
Knee OA appropriate care treatment
Injections (e.g. corticosteriods) 4.05 (10.42) 18.45 (17.31) -14 .40
Medications (e.g. NSAIDs) 200.63 (242.95) 370.10 (529.13) -169.48
Other therapy (e.g. physiotherapy) 237.32 (831.22) 305.10 (669.22) -67 .78
Assistive devices (e.g. cane) 5.38 (11.61) 16.38 (54.58) -11.00
Procedures (arthroscopy) 1.70 (19.19) 18.12 (118.65) -16 .42
Subtotal (knee treatment) 449.08 728.15 -279.08
Concomitant medications
OAin other joints (e.g. NSAIDs) 16.91 (67.62) 17.81 (72.06) -0 .9 0
Adverse events due to OA treatment (e.g. antacid, analgesics) 53.88 (179.05) 50.08 (123.68) 3.80
Subtotal (concomitant meds) 70.79 67.89 2.90
Outpatient resources (e.g. physician visits) 245.72 (399.96) 134.02 (135.11) 111.70
Hospitalization 194.53 (1012.28) 101.57 (752.54) 92.96
Time loss from work
by patient
Due to OA 229.13 (942.26) 190.37 (1085.09) 38.76
Due to OA treatment 53.49 (150.86) 37.95 (180.66) 15.54
by caregiver
Due to OA 0.37 (4.15) 0.06 (0.69) 0.31
Due to OA treatment 35.30 (350.30) 6.56 (26.32) 28.74
Subtotal (time loss) 318.29 234.94 83.35
Out-of-pocket expenses (e.g. transportation) 170.30 (250.09) 148.00 (215.23) 22.30
Total cost 2124.71 (2528.35) 1414.58 (2032.74) 710.13
All costs are in 1999 Canadian dollars. Mean ( s .d .).
OA=ost6oarfhritls; A C +H =Appropriate Care+hylan G-F 20; AC=Approprlate Care; NSAIDs=non-steroidal antiinflammatory drugs.
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Interval for the difference in mean total costs was a lower 
bound of $147 and an upper bound of $1273. Thus, the 
cost difference between groups was statistically significant at the 5% level (95% confidence interval did not include 0). 
From a HCS perspective, the total annual OA-related cost was also greater in the AC + H group, and by alnnost the same amount. The difference was $705 which was also statistically significant at the 5% level (data not shown).The major contributor to the societal incremental cost of 
$710 was the cost of the hylan G-F 20 itself, $676. This was the average cost of hylan G-F 20 per patient over the year in the AC + H group. The actual cost of the product for a 
treatment of three injections was $339, but because many patients had the other knee done as well, and some had 
additional treatments throughout the year, the average cost was $676. The second major contributor to the incremental 
cost of $710 was a savings in other treatment costs for the knee OA of $279 (Table II, knee OA appropriate care 
treatment). The third major contributor was the $112 extra 
for outpatient visits, primarily the visits to receive injections of hylan G-F 20. At $93 hospitalizations were the next 
largest contributor. In the base case analysis there were a total of five hospitalizations attributable to OA in the AC + H 
group and three in the AC group. The five in the AC + H group were: total knee replacement in study knee, total 
knee replacement in other knee, total hip replacement, triple ankle fusion, and tibia osteotomy. The three in the AC group were: total knee replacement in study knee, total knee replacement in other knee, and bunionectomy. Inter­estingly, there were two additional total knee replacements 
in the study knee that were not counted in the base case analysis because they occurred after the two patients in question had violated protocol by receiving hylan G-F 20. The fifth largest contributor to the cost difference was the additional cost of lost work time for the AC + H group at $83, 
which could be due to the visits needed for the hylan G-F 20 injections. Out of pocket expenses were also slightly 
higher possibly for the same reason, i.e., travel costs for 
visits.
CONSEQUENCES
The percent of patients improved at 12 months using the 
primary definition of improvement was 69% In the AC + H group and 40% in the AC group for an increment of 29%. Using the secondary definition of improvement the results were 62% and 35% for an increment of 27%. Both increments were statistically significant (P=0.0001) and exceeded the clinically important difference of 20% 
established a priori as part of the research design.
The improvement in mean utility from baseline to termin­ation as measured by the HUI3 was 0.13 in the AC + H group compared to 0.03 in the AC group, for a difference of0.10 units of utility (P<0.0001). Figure 3 displays the 
change in mean utility score from baseline to each inter­view for tx)th treatment groups. Both groups improved 
sharply for the first 2 months and then tailed off. However, the AC + H group improved more and tailed off less, thus giving a substantial area between the two curves. The area between the two curves over the 12 months represents the difference in QALYs between the two groups. The patients 
in the AC+H group gained 0.071 QALYs compared to the patients in the AC group. The 95% confidence interval for 
the difference in QALYs was a lower bound of 0.017 and an upper bound of 0.126. The difference between groups was 
statistically significant at the 5% level (95% confidence 
interval did not include 0).
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Fig, 3. Difference between treatment groups in mean change from 
tiaseline in Health Utilities Index 3 utility score. HUI3 = Health 
Utilities Index 3; QALYs =quality-adjusted life years.
BASE CASE ANALYSIS
The base case CEA and CUA are shown in the first row of Table III. The AC+H group was more costly and more 
effective. The incremental cost per patient over 1 year was $710 and $705 from the societal and HCS perspective, respectively. The incremental effectiveness was an increase of 0.2834 proportion of patients improved. The C/E ratio was $2505 or $2488 per patient improved, from the societal and HCS perspective, respectively. For the CUA the incremental effectiveness was 0.071 QALYs 
per patient. The C/U ratio was $10 000 or $9930 per QALY gained, from the societal and HCS perspective, respectively.
SENSITIVITY ANALYSES
Table III displays the results of the sensitivity analyses for the CEA and CUA. There are five sensitivity analyses: effectiveness high, effectiveness low, costs high, costs low, 
and alternative definition of lost time. To help interpret these results the CUA sensitivity analyses are plotted on a 
cost-effectiveness graph in Fig. 4. Note that the slope of the line through the point is the cost per QALY of that point. Thus, lower slopes are more cost-effective, and vice versa. To enhance the interpretation we have also plotted on Fig. 
4 the decision thresholds suggested by Laupacis e t al.^°: 
cost per QALY between $0 and $20 000=strong evidence for adoption: between $20 000 and $100 000=moderate evidence for adoption; and above $100 000=weak evi­dence for adoption. Figure 4 demonstrates that the results 
are robust; four of the five sensitivity analyses fall in the 
decision sector 'strong evidence for adoption’ while the fifth falls in the adjacent sector ‘moderate evidence for adoption".
Discussion
Although the trial was powered only for the primary 
clinical outcome (change in mean WOMAC pain score), the outcomes for the economic evaluation (gain in percent of patients improved, gain in QALYs, and cost difference) also achieved statistical significance at the 5% level. Thus the findings are particularly robust, especially for a prospective 
economic evaluation study.
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T ab le  litCost-effectiveness and cost-utility analyses: base case and sensitivity analyses from the societal and health care system perspectives
Annual cost 
difference
Difference in 
proportion of 
patients
Cost per patient QALYs
improved* gainedf
Cost per QALY 
gained#:
Societal HCS Improved Societal HCS Societal HCS
Number of patients (AC + H/AC)§ 127/128 127/128 127/127 127/128 127/128 127/128 127/128 127/128
Base-case analysis $710 $705 0.2834 $2505 $2488 0.071 $10 000 $9930
Sensitivity analyses on outcomes)!
High $710 $705 0.3820 $1859 $1846 0.117 $6068 $6026
Low $710 $705 0.1848 $3842 $3815 0.025 $28,400 $28,200
Sensitivity anaiyses on costsjj
High $1183 $1008 0.2834 $4174 $3557 0.071 $16,662 $14,197
Low $238 $402 0.2834 $840 $1418 0.071 $3352 $5662
Sensitivity analysis using alternative
costing for time loss** $938 n /a ft 0.2834 $3310 n /a ft 0.071 $13,211 n /a ft
All costs are in 1999 Canadian dollars.
*The cost per patient improved ^ incremental cost ([AC+H]-AC)/incremental effectiveness ([AC+H]-AC). 
fQALY gained is adjusted for baseline differences.
TThe cost per QALY gained ^ incremental cost ([AC+H]-AC)/lncremental QALY ([AC+H]-AC).
§The mean cost per patient and QALYs gained were calculated from 128 patients; ttie proportion of patients improved was calculated from 
127 patients.
IlHigh represents the upper 90% Cl for the difference between groups, and Low represents the lower 90% Cl for the difference between 
groups.
**The base-case analysis included time loss from work. The sensitivity analysis included time loss from usual major activities also. 
t tA  ratio will not be calculated as the cost of time loss was not included in the HCS perspective costs.
QALY equality-adjusted life year; HCS=health care system; AC+H=Appropriate Care+hylan G-F 20; AC=Appropriate Care; 
Cl-confidence interval.
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Fig. 4. Base-case (Base) and sensitivity analysis (1A-3) results for the cost-utility analysis from the societal perspective. Sensitivity analyses 
assume: 1A, upper 90% Cl for difference in QALYs gained between groups; 1B. lower 90% Cl for difference in QALYs gained between 
groups; 2A, upper 90% Cl for difference In total costs between groups; 2B, lower 90% Cl for difference in total cost between groups; 3, annual 
cost of time loss from work or usual major activity for all patients and caregivers. Cl=confidence interval; QALY=quality-adjusted life year;
$Can-Canadian dollars.
The cost findings are relatively easy to interpret. The use of hylan G-F 20 reduced the need for and the cost of other 
treatments for OA, but not enough to offset the increased costs due to the price of the product and due to the
costs associated with the extra physician visits required to administer the treatment.The patient outcome findings are also straightforward. The patients in the AC + H group were better off, and
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statistically significantly so, by both the disease specific measure (WOMAC), and by the health utility measure 
(HU13). The important outcomes for the economic analysis were the incremental proportion of patients improved in the AC+H group compared to the AC group (29%) and the incremental QALYs gained in the AC + H group compared to the AC group (0.071). The former outcome, 29%, exceeded 
the a priori threshold for clinical importance which had been set at 20%. However, no threshold had been established a priori for an important increment in QALYs.
is a mean gain of 0.071 QALYs per patient important? One way to address this question, is to return to the theory 
on which the HUÎ3 instrument is based, von Neumann- Morgenstern utility theory and the standard gamble measurement. On the basis of this theory a direct interpret­ation is that a gain of 0.071 QALYs over a year Is equivalent 
to a reduction In mortality rate of 0.071. That is, providing 
an ongoing improvement in quality of life of this magnitude (0.071 QALY per year) is equivalent to finding a group of healthy individuals (no HUI3 disabilities) who are at high risk (50%) of immediate sudden death and providing them 
with an absolute risk reduction in mortality of 7.1% (i.e., reducing their risk to 42.9%). If the group of individuals has 
compromised quality of life like patients with knee OA. the 
interpretation is even more dramatic. According to von Neumann-Morgenstern utility theory a patient like those at baseline in the AC+H group with a utility score of 0.50 and no risk of immediate death would be willing to take a risk of immediate death of 12.4%, 0.124=1.000-(0.500/ (0.500+0.071)), to achieve an ongoing improvement in 
quality of life of 0.071. Thus, there is little question that a QALY gain of this magnitude is important. Moreover, any QALY gain can be important depending on the cost required to produce the gain and on the overall context of 
the gain^\The cost-effectiveness finding is that the incremental 
cost per patient improved over 1 year is $2505 (societal) and $2488 (HCS). That is, an expenditure of approximately 
$2500 will purchase an improved patient for a year. Is this good value for money? There is no absolute answer. 
Decision-makers responsible for allocating resources will have to weigh this opportunity against other choices. If the 
other choices are not expressed in the same metric, 
improved patients, the comparison becomes difficult. This highlights the advantage of cost-utility analysis.
The finding of the cost-utility analysis is that the incre­mental cost per QALY gained is $10 000 (societal) and $9930 (HCS). That is, an expenditure of approximately 
$10 000 will purchase a gain of 1 QALY. is this good value 
for money? There are several ways to approach the ques­
tion. One approach is to compare the results to other studies using a league table in which studies are ranked from best to worst according to their cost per QALY gained. Current methodological advice is that indiscriminate com­
parisons of this type can be misleading, and that league tables should be restricted to high-quality studies that use 
comparable scientific methods, and possibly further restricted to interventions targeted at one condition (e.g., 
musculo-skeletal problems)^^.Chapman e t al. from Harvard University undertook a comprehensive literature review of cost-utility studies 
1976-1997 and categorized them into ‘Panel-worthy’ or not, and further subdivided the list by disease categories one of which is muscuio-skeletaF^. ‘Panel-worthy’ studies 
are those that met a minimum standard of methodological quality established by Chapman e t al. based on the recom­
mendations of the Panel on Cost-Effectiveness in Health
Table IVCost!QALY League Table (1998 US dollars)
Cost/QALY
gained
Treatment and comparator
Cost-saving Total hip arthroplasty vs no total hip arthroplasty 
in white 60-year-oid women with hip osteoarthritis 
in American College of Rheumatology function 
class ill (significant functional limitation, but not 
dependent)^^
$5500 Total hip arthroplasty vs no total hip arthroplasty
in white men >85 years old with hip osteoarthritis 
in American College of Rheumatology function 
class III (significant functional limitation, but not 
dependent)^^
$6500 Appropriate Care+hylan G-F 20 vs Appropriate
Care for knee osteoarthritis, health care system 
perspective (this study)
$6600 Appropriate Care+hyian G-F 20 vs Appropriate
Care for knee osteoarthritis, societal perspective 
(this study)
$7500 Total hip arthroplasty vs no hip arthroplasty for all
patients, 3 year foilow-up^^
$11 000 Prophylaxis for NSAID-associated gastric ulcers
with low-dose misoprostol (100 meg four times 
daily) for elderly (>60 years old) vs no 
prophylaxis for all NSAID users in rheumatoid 
arthritis patients on NSAIDs^^
$12 000 Prophylaxis for NSAID-associated gastric ulcers
with low-dose misoprostol (100 meg four times 
daily) for ail vs prophylaxis for elderly (>60 years 
old) in rheumatoid arthritis patients on NSAIDs^^
and Medicine '^ .^ There has been only one ‘Panel-worthy’ study in the field of musculo-skeletal diseases, a cost- effectiveness analysis of total hip arthroplasty for OA of the hip, published in 1996 by Chang e ta l . In addition, there is a relevant ‘Panel-worthy’ study in the digestive system category, a cost-utility analysis of the use of misoprostol prophylaxis for rheumatoid arthritis patients receiving NSAIDs drugs, published by Gabriel e t al. in 1994. These two studies contain four cost-utility ratios. The four ratios are included in our league table (Table iV).
In addition we have included, for comparison, one rel­evant Canadian study^^. Although it did not meet the 
criteria for ‘Panel-worthy’, we believe it can be usefully interpreted. One shortcoming of the study, lack of discount­
ing, we have corrected in the data shown here using a 
discount rate of 5% per year. Another shortcoming, lack of incremental costing (they did not measure the costs that 
would have occurred without hip replacement) was con­servative. On the positive side, the study was Canadian and, thus, is more directly cbmparable to our hylan G-F 20 study. The study prespectively measured costs (from the 
perspective of the health care system) and time trade-off utilities for total hip arthroplasty over 1 year, and modeled 
the analysis for 2 additional years for a total analytic 
horizon of 3 years.For consistency with the Harvard table of ‘Panel-worthy’ studies, all entries in the league table (Table IV) have been adjusted to 1998 US dollars. The two Canadian ratios were 
first adjusted to 1998 Canadian dollars, using the Health Care component of the Canadian Consumer Price Index^ ®, and then converted to US dollars using the mean exchange rate for 1998,1.4831^^. As shown in the league table, hylan G-F 20 provides ‘value for money’, from either perspective, that is not as good as total hip arthroplasty for 60-year-old
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US women as studied by Chang et al., but is similar to total hip arthroplasty for >85-year-oid US men studied by Chang 
e t al. or for Canadians studied by Laupacis e t al.^^, and Is better than misoprostol prophylaxis for rheumatoid arthritis 
patients taking NSAIDs.A second approach to answering the question of value for money is to compare the results to some external 
standard. For example, Laupacis e t al.^° suggest that if a new therapy is more effective and more costly than the 
existing one and costs less than $20 000/QALY gained, there exists strong evidence for adoption of the new therapy. Similarly, $20 000 to $100 000/QALY gained pro­vides moderate evidence for adoption, and over $100 000/ QALY gained provides weak evidence for adoption. These costs are in 1990 Canadian dollars, and the thresholds in 
1999 dollars may be larger. Thus, the cost-utility results for the use of hyian G-F 20 in the knee fail in the category of 
strong evidence in favour of adoption.
STUDY STRENGTHS
The study was designed according to rigorous standards put forth in guidelines for economic evaluations. Ail of the 
participating investigators had a high degree of experience treating patients with hyian G-F 20, therefore it was poss­ible to measure effectiveness, or 'real world' clinical effects, 
the outcome required for an economic evaluation. Hylan G-F 20 was compared to an appropriate comparator in that 
current practice guideiines were employed rather than placebo. The study was open-label and therefore physi­
cians could practice according to their normal routine. Both treatment groups had equal access to the full repertoire of appropriate care. It was possible to limit the amount of 
protocol-driven costs by employing telephone interviews to collect data. Costs included indirect and direct costs, and overhead costs were included. The study time horizon was 1 year, which enabled measurement of downstream costs 
and consequences associated with subsequent courses of hyian G-F 20, adverse events, and treatment failure.
STUDY LIMITATIONS
One of the limitations was that the study was open-label 
and patients or physicians may have been biased in favour of hylan G-F 20 treatment which in turn could have affected 
outcomes and costs. On the other hand, many in the AC group also received a knee injection (corticosteroid), and ail 
patients in both groups received appropriate care. The ongoing telephone interviews may have influenced the 
patient assessments. The patients might have improved 
because of the attention they received, or they might have felt worse because they focused more on their symptoms 
when answering symptom questionnaires. However, the potential telephone interview biases would have been simi­lar in both groups, therefore it is unlikely there was a 
differential from this source.
GENERALIZABILITY
The study applies to patients treated by rheumatologists and orthopedic surgeons in Canada. The results are not 
directly applicable in other countries. Readers in other 
countries have to decide which aspects of the study apply, and which aspects need to be modified, it is generally felt that clinical findings travel fairly well. One would expect
similar findings in the patient outcomes—WOMAC scores, SF-36 scores and HUI3 scores. Moreover, although the 
HU13 is scored based on preferences from a Canadian population, there is considerable evidence that preference 
scores from the general public are independent of country (for example, see Johnson et a/.^° and Gales et a/.^ ®). On the other hand, because the health care systems differ among countries, the utilization of health care resources may differ. Moreover, the prices of health care resources 
including hylan G-F 20 differ in different countries. Thus, the costs can not be assumed to apply in other countries. Those interested in other countries will have to modify the study results appropriately^® or use this study as a proto­type from which to conduct a study in their own country.
Conclusions
This study demonstrates that hyian G-F 20, when used in conjunction with appropriate care, provides an improve­ment in outcomes that is both clinically important and 
statistically significant. Total costs are higher when hyian G-F 20 is selected as a treatment option for patients with 
OA of the knee, but the cost per QALY gained is well below 
the suggested Canadian threshold for adoption.
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Appendix
AC+H=Appropriate care with hylan G-F 20 
AC=Appropriate care without hyian G-F 20 
WOMAC=Western Ontario and McMaster Universities Osteoarthritis index HUI3=Heaith Utilities Index 3 QALYs=quality-adjusted life years 
OA=osteoarthritis
HRQOL=Heaith-related quality of life CRO=contract research organization 
NSAIDs=non-steroidai antiinflammatory drugs SF-36=Short-Form 36 
HCS=hea!th care system 
$Can=Canadian dollars ER=emergency room
ICD9-CM^international classification of disease ninth revision clinical modification CEA=cost-effectiveness analysis CUA=cost-utility analysis
18
SECTION 6 - Globalisation
The early phase of globalisation of the WOMAC Index occurred 
contemporaneous with two parallel but largely unrelated processes: 1) Guidelines 
development by such groups as the Outcome Measures in Rheumatology Clinical Trials 
(OMERACT) Group and the Osteoarthritis Research Society International (OARSI), and 
2) the sudden demand for alternate-language translations of standardised, valid, reliable 
and responsive health status measurement tools to meet an international measurement 
need in OA for the evaluation of cyclo-oxygenase-2 (COX-2) inhibitor class compounds. 
These developments eventuated in the early to mid-1990’s, and both the guidelines 
development by OMERACT and OARSI, and subsequently by regulatory agencies, as 
well as the ongoing need for standardised measures in clinical research environments 
continue to drive the globalisation of the WOMAC Index.
The guidelines for the testing of SADOA, derive from the recommendations of a 
WHO/ILAR Working Party, meeting in association with the newly formed Osteoarthritis 
Research Society. The resulting guidelines addressed various aspects of clinical trial 
design for this class of intervention (19). The guidelines identified five domains (pain, 
function, consumption of analgesics and/or NSAIDs, physical examination and quality of 
life) (19), These guidelines were particularly important since they recognised the 
importance of measuring physical function and quality of life, as well as pain, and 
provided support for use of the WOMAC Index in SADOA class trials (20), (see 
commentary by Professor J Edmonds in Summary and Conclusions on page 77 of The 
Journal of Rheumatology 1994; Supplement 41) (19).
The OMERACT III meeting held in Cairns, Australia, is of particular importance 
since it used evidence-driven, consensus-based decision-making to specify domains of 
measurement for future OA clinical trials of knee, hip and hand OA. The process 
involved the presentation of data on existing measurement alternatives (21), followed by 
discussions and polling sessions (22). The end result, with participation of academics, 
rheumatologists, measurement experts, pharmaceutical and device manufacturers and 
representative of regulatory ageneies, was > 90% agreement on pain, physical function 
and patient global assessment, as core set clinical measures for all future OA knee, hip 
and hand studies (22). The OMERACT III consensus stopped short o f specifying specific 
instruments for measuring the three eore clinical domains, and, by agreement, this was 
postponed until the OARSI Task Force meeting scheduled for a few weeks later in 
Washington DC.
The OARSI Task Force Guidelines for the design and conduct of clinical trials in 
patients with OA also involved multiple stakeholders from different disciplines, and used 
a similar process to that employed by OMERACT to achieve evidence-driven, consensus- 
based deeisions regarding clinieal trials methods and outcome measurement 
procedures(23). The OARSI ratified the OMERACT core clinical set specification of 
outcome measurement domains, and also specified outcome measurement techniques and 
instruments, which included recognition of the WOMAC Index (23). Appendices to the 
main OARSI document dealt with special measurement topics including Appendix II, 
which described issues relating to clinieal assessment techniques (23).
Most recently, an ostensibly North American consensus group called the Initiative 
on Methods, Measurement and Pain Assessment in Clinical Trials (IMMPACT) Group
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have developed evidence-based consensus around outeome measurement domains (24) 
and instruments (25) for clinical trials in patients with chronic pain. The latter 
publication also recognizes the relevance of the WOMAC Index for trials involving 
patients with OA.
The OMERACT and OARSI guidelines, in particular, resulted in a rapid increase 
in demand for the WOMAC Index, not only in its original language form o f English for 
Canada, but also in multiple other languages, and in both the 5-point Likert and 100 mm 
visual analogue scaling formats. The development of the alternate-language translations 
of the WOMAC 3.1 Index was undertaken under my copyright, by Health Outcomes 
Group in Palo Alto California, using their standard operating procedures (SOP). In 
summary, the SOP involved the following seven steps: a) tandem forward translation to 
target language (fluently bilingual translators), b) reconciliation of any differences 
between target language translations, c) tandem backward translation to English (fluently 
bilingual translators), d) reconciliation of any differences between source (English) and 
backward translations, e) agreement on a proposed forward translation, f) linguistic 
validation on-site in a small group of relevant individuals, and g) finalisation of the 
alternate-language form. The time frame for the WOMAC 3.1 Index was standardised at 
48-hours, and patients were directed to think about a specific joint (either a hip or knee, 
depending on the study). In order to address diversity in the use of language, the 
instructions to patients were enhanced and some question stems expanded to include 
more prepositions and common language. The WOMAC 3.1 Index, thereafter, became 
the standard form of the WOMAC Index.
The rigorous development and validation of the original WOMAC Index, the 
state-of-the-art SOP by which the WOMAC alternate-language translations were created, 
the immediate availability o f over 60 alternate translations of the WOMAC 3.1 Index in 
the end-users preferred scaling format (Likert or VA), and the capacity of the WOMAC 
Index to meet many of the requirements of recently introduced measurement guidelines, 
aligned with those of regulatory bodies or recognised by those bodies, undoubtedly 
contributed to the rapid globalisation of the WOMAC Index (26).
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Guidelines for Testing Slow Acting Drugs 
in Osteoarthritis
MICHEL LEQUESNE, KENNETH BRANDT, NICHOLAS BELLAMY, ROLAND MOSKOWITZ 
CHARLES JOEL MENKES, and JEAN-PIERRE PELLETIER
ABSTRACT. New compounds appear to improve symptoms o f  osteoarthritis (OA), and others are putative chon- 
droprotective agents. We suggest experimental designs for studying the effects o f  these agents in 
subjects with hip and knee OA. The course o f  the articular cartilage lesion is the primaiy outcome 
measure to be assessed in putative chondroprotective agent trials. Serial radiographic studies sug­
gest that the annual rate of joint space narrowing in patients with hip or knee OA is about 0.25  
mm. Other approaches to quantitation o f  cartilage loss, e .g ., radiographic measurement o f tlie area 
o f joint space, ultrasonography, magnetic resonance imaging and fiberoptic arthroscopy (for knee 
OA) are under investigation. ( /  Rheumatol 7994;(suppl 41)21:65-73)
Key Indexing Terms:
OSTEOARTHRITIS 
CHONDROPROTECTIVE DRUGS
Two classes of slow acting drugs for the treatment of osteo­
arthritis (OA) — SADOA — will be considered: (1) Sympto­
matic Slow Acting Drugs for Treatment of Osteoarthritis 
(SYS ADO A) and (2) Disease Modifying OA Drugs 
(DM0AD), sometimes inappropriately called chondroprotec­
tive agents. Both classes may be administred by the oral, 
parenteral, or intraarticular route.
Symptomatic slow acting drugs for treatment of osteoarthri­
tis (SYSADOA). Recently, some drugs that are neither rapidly 
acting analgesics nor nonsteroidal antiinflammatory drugs 
(NSAID), nor chondroprotective (disease modifying) agents, 
but have a slow onset of action, have been alleged to improve 
OA symptoms. Their onset of action occurs only after a 
peroid of weeks, and symptomatic relief may continue for 
a considerable period after cessation of treatment. Some of 
these agents are administered orally or parenterally (e.g., 
chondroitin sulfate*, glucosamine sulfate^, diacerrhein^); 
others (e.g., hyaluronic acid^ "*^  orgotein^) are administered 
by intraarticular injection. Although these agents have been 
studied in controlled clinical trials, additional studies are 
necessary to demonstrate whetlier any are efficacious.
To ascertain its efficacy, a SYSADOA should, in general, 
be compared against placebo, analgesics, or an NSAID of
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SLOW ACTING DRUGS IN OA 
TRIAL METHODOLOGY
proven efficacy, using classical tecliniques in a trial o f moder­
ate length, i.e., several months to 1 year. Target populations 
might include subjects with either early or advanced OA. 
Outcome measures should, as in trials of NSAID, assess the 
effect of treatment on joint pain, function, and quality of life.
Disease modifying antiosteoarthritis drugs (DMOAD). The 
term chondroprotection introduces the concept that some 
drugs may slow the rate of articular cartilage degeneration, 
and/or enhance the rate of cartilage repair. Conversely, the 
term chondroaggression has been applied to suggest tliat some 
drugs (NSAID) may accelerate the rate of cartilage degener­
ation or inhibit cartilage repair. Both concepts derive 
primarily from results obtained with animal models and in 
vitro experiments, rather than from validated observations 
in humans.
Our present knowledge suggests that some abnormalities 
in OA cartilage may be reversible (e.g., proteoglycan deple­
tion) and others irreversible (e.g., damage to the collagen 
network). These principles must be taken into account when 
clinical trials of DMOAD are designed and primary outcome 
measures are established.
Data from well designed clinical studies do not now exist 
to support the contention that any drug is chondroprotective,
i.e., prevents, retards, or reverses cartilage lesions in 
humans. However, the search for agents capable of prevent­
ing OA progression and/or reversing established OA is 
strongly encouraged.
Patient groups suitable for study of a DMOAD. Depending 
upon tire objective of treatment, the following groups of 
patients may be used to evaluate the efficacy of a DMOAD 
(Table 1).
Group 1. To assess the ability of the drug to prevent OA 
in an at-risk joint, subjects with an injury known to be as­
sociated with development of OA in a high proportion of
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T able 1. R equ irem en ts f o r  c lin ica l tr ia ls  o f  SA D O A
Trials  o f  S Y S A D O A Trials o f  D M O A D
Aim
Study population
Main assessment criteria
Duration o f trial 
Difficulty in recruitment
Improvement o f  symptoms
Patients with painful OA o f  hip, 
knee, and (? hand)
Pain scales
Algofunctional indices 
Consumption o f  analgesics and/or 
NSAID  
Physical examination 
Quality o f life scale
3 -1 2  months 
Minimal
Slowing, arrest, or reversal o f  
articular cartilage lesions
1. Patients with painful idiopathic 
hip or knee OA without 
complete loss o f  articular 
cartilage (Grade II-III Kellgren- 
Lawrence, Grade I by 
chondroscopy)
2. Patients with OA of the hand
Prevention o f  articular cartilage lesions
1. Victims o f  mechanical joint 
derangement*
2. Subjects with vocational or avocational 
risk for OA**
Status o f  articular cartilage, based on radiography (joint space) or fiberoptic 
arthroscopy (knee) or, possibly MRI, ultrasonography, fiberoptic 
arthroscopy. Rate o f  change monitored on serial images o f the affected 
joint.
Time interval between trauma or exposure 
and onset o f  OA  
2 -4  years Many years
Minor. Requires symptomatic Maximal. Requires asymptomatic subjects
patients with incomplete undergoing longterm treatment o f  only
narrowing o f  joint space on theoretical benefit,
radiograph
* e .g ., anterior cruciate ligament rupture, meniscectom y, meniscus tear. 
** e .g ., football, judo, dance, rugby.
cases, e.g., anterior cruciate ligament rupture, would be 
suitable.
Group 2. To assess the ability of the drug to retard the 
progression of established OA, patients with symptomatic 
idiopathic OA of knee or hip with incomplete loss of joint 
space, or early hand OA, would be suitable.
Group 3. To assess the ability of the drug to repair damaged 
cartilage (disease reversal), patients with OA at any stage 
would be suitable.
Patients in Group 2 are the most likely targets for study. 
Outcome measures in studies of DMOAD. For studies of these 
groups, outcome measures must be clearly defined, as 
follows.
Anatomical assessment of disease progression. Current 
metliodologies continue to undergo validity and reliability 
testing. In prospective studies conducted over 3 years, meas­
urements of the joint space, using special calipers on plain 
radiographs of the hip or knee of patients with OA, showed 
a mean rate of loss of about 0.25 mm -^’ to 0.30 mm® per 
year, with a coefficient of variation (intraobserver reprodu­
cibility) of about 8-10%. Measurement of a relevant area 
of the joint space may be more useful tlian measurement of 
the width at a given point®-*®. Other techniques, such as 
microfocal radiography, ultrasonography*•, magnetic 
resonance imaging (MRI), and computerized tomography, 
are under consideration. For evaluation of the knee joint, 
artliroscopy (currently the gold standard for pathologic find­
ings) should be considered. Use of a small bore fiberoptic 
arthroscope is less invasive than standard surgical artliro-
scopy, and use of the needle arthroscope for serial evalua­
tion of a patient is ethically acceptable.
Biochemical/immunochemical markers. Biochemical or im­
munochemical measurement of the concentration in synovi­
al fluid, serum, or urine of indicators of degenerative and/or 
reparative responses in joint tissues is possible. However, 
while levels of these variables may reflect the magnitude of 
a biologic response in OA, none has been shown to reflect 
the adequacy of such responses within joint tissues. Before 
such measurements can be recommended for clinical use, 
further reliability and validity testing are required* .^
Since no reference drugs are available for use as standards 
for testing DMOAD, a placebo control group should be used. 
Assessment of the efficacy of a DMOAD will require years, 
rather than weeks or months.
Experimental prerequisites (DMOAD). The results of in vitro, 
ex vivo, or in vivo studies of the effects of drugs on cultures 
of articular cartilage or chondrocytes from animal models 
do not necessarily predict tlie results of clinical trials in 
humans with OA. It is essential, nonetlieless, that evidence 
of a beneficial effect of a prospective DMOAD be obtained 
in vivo in animal models before trials in humans are 
undertaken.
Although, tlieoretically, a drug that is ineffective in vitro 
could be efficacious in vivo, and vice versa, it is reasonable 
to require that a potential DMOAD demonstrate activity in 
vitro and then in vivo in animal models of OA before a clini­
cal trial in humans.
The most widely used in vitro methods for assessing the
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effects of drugs on cartilage involve measurement of levels 
of degradative enzymes or the biosynthetic activity of the 
chondrocyte in cell cultures or organ cultures of animal or 
human OA cartilage*  ^*'*. The most widely used animal 
models of experimental OA involve anterior cruciate liga­
ment transection in the dog (the Pond-Nuki model), partial 
medial meniscectomy in the rabbit (the Moskowitz model), 
and standardized contusion of the patella in the rabbit (the 
Mazier es model). Models using intraarticular injection of 
iodoacetate or papain have also been employed'5.
Among the many issues requiring consideration, determi­
nation of tiie dose o f the DMOAD to be tested in vivo is one 
of the most difficult. This determination must be based upon 
the results of toxicology studies, which are essential before 
implementation of a clinical trial.
Demonstration that a candidate DMOAD possesses desir­
able properties in vitro (e.g., enhancement of chondrocyte 
proliferation, synthesis of type H collagen and proteoglycans, 
reduction of enzymatic degradation of the matrix) is of un­
certain significance and does not necessarily represent chon­
droprotection. An effective DMOAD will, by definition, 
preserve or improve the morphology of hyaline articular car­
tilage in the OA joint.
Many in vitro or ex vivo studies of potential DMOAD have 
been conducted using normal articular cartilage. While im­
portant, this is only a first step, since the metabolic effect 
of a drug on OA cartilage may be different from its effect 
on normal cartilage.
Moreover, efficacy of a DMOAD should be demonstra­
ble in at least 2 well established animal models of experimen­
tal OA, involving animals of 2 different species. Further­
more, consistency of in vitro and in vivo findings should be 
demonstrated.
It is desirable not only that results of in vivo testing in 
different experimental models of OA are consistent, but that 
the observations are confirmed by more than one investigator.
Unfortunately, to date, among those NSAID or SADOA 
that have shown a chondroprotective effect in vitro or in vivo 
in animals, none has proved chondroprotective in well con­
trolled clinical trials in humans with OA.
Trials of SYSADOA in human OA. Aim. As with a rapidly 
acting drug, the aim is to reduce the severity of symptoms 
of OA in humans, and trials should be conducted in accor­
dance with WHO/EULAR recommendations.
Criteria for assessment of efficacy. SYSADOA trials should 
take into account (1) the lag in the onset of improvement 
(induction-response interval) (2) the duration of the residu­
al effect on symptoms after cessation of treatment; (3) 
changes in the requirement for analgesics or NSAID during 
the first weeks of treatment and later; (4) changes in joint 
mobility: while measurements of mobility are insensitive in 
short term studies, they may be of interest in trials of longer 
duration.
The investigator should choose a reasonable number of as­
sessment measures (generally 5 to 8). One of these should 
be designated the primary outcome measure. The following 
should be considered: (1) Visual analog scale (VAS) for pain. 
This may be applied separately to different types of pain 
(e.g., nocturnal, weight bearing); (2) Functional indices. Two 
have been specifically designed and validated for OA: the 
severity, or algofunctional, indices for hip and knee OA"* 
and the WOMAC Osteoarthritis Index for the same 
joints'718; (3) Doyle Index*® in its complete form or limit­
ed to specific joints of interest, e.g., hips, knees, or hand 
joints; (4) Loss of joint mobility (range of motion), although 
the reproducibility of this measure is not good^ ®; (5) Walk­
ing time over 20 or 50 meters, or the time to go up and down 
a standard flight of stairs (applicable to hip and knee OA). 
In a multicenter trial, however, the stairs may not be suffi­
ciently standardized; (6) Level of consumption of analges­
ics and/or NSAID; (7) Number of flares over time (especi­
ally with effusion in patients with OA of the knee); (8) 
Patient’s overall (global) judgement of efficacy; (9) Investi­
gator’s overall (global) judgement of efficacy; and (10) Qual­
ity of life scale. A simple QOL scale is needed tliat is relia­
ble, valid, and sufficiently sensitive to detect clinically ira 
portant change in trials of SYSADOA.
As a criterion of efficacy, one of the above outcome meas­
ures must be chosen as primary a priori. This will help in 
calculating the sample size and will serve for primary statisti­
cal analysis. Moreover, although clinical endpoint measures 
have been validated in numerous short and moderate term 
trials, this is not yet the case for longterm trials (2-3 years). 
Good candidates are the algofunctional indices of OA severity 
(i.e., WOMAC and Lequesne’s indices, and their compo­
nents), and various other measures of pain, stiffness, and 
physical disability.
Physical and psychosocial adaptation may influence some 
of these endpoint measures, especially in longterm studies, 
and should be taken into consideration. However, the effect 
of tjiis possible source o f bias should be eliminated by the 
randomization process in randopiized controlled trials.
Assessment of side effects. The occurrence of adverse reac­
tions should be assessed by traditional methods. Followup 
must be continued for 2 to 3 months after completion of treat­
ment, since the effect of SYSADOA is often longlasting.
Types of patients and eligibility criteria. OA of the hip and 
tibiofemoral OA are the best models. Patellofemoral joint 
OA, if this is the only, or the most prominent, site of OA 
in the knee, should be excluded, since it represents an entity 
distinct from tibiofemoral OA and symptoms are highly 
variable.
The diagnosis of OA must be confirmed according to 
defined criteria. Those quoted by the WHO/EULAR guide­
lines of 1986 were set up by Lequesne®*, those of Altman, 
et al (American College of Rheumatology) have recently been 
validated®®'®'*. Patients with chondrocalcinosis and other
Lequesne, et al: Testing slow  acting OA drugs 6 7
causes of secondary OA should be excluded. Exclusions for 
age, concomitant disease, and other variables should be 
appropriate.
The hip or knee joint should be painful daily, or at least 
on more than half of the days of the previous 2 months. Pain 
severity should be sufficient to permit detection of change 
(for example, 35 mm on a 100 mm VAS). The severity 
index‘d should usually be between 3 and 12 points.
Since the assessments will monitor only change in 
symptoms, the stage of OA is immaterial. However, patients 
with very far advanced OA (e.g., Kellgren-Lawrence Stage 
ÏV) should be excluded, as should those awaiting arthro­
plasty. Informed consent must be given by every patient. 
Design and duration of the trial. The trial should be con­
trolled, randomized, double blinded, and parallel in design. 
Since no reference SYSADOA exists, placebo should be used 
for the comparison group, with use of a rescue analgesic, 
if necessary. The duration of the trial should be at least 4-6  
months. If a placebo group is not employed, a control group 
taking NSAID could be used alternatively. When feasible, 
both a placebo control group and an NS AID/analgesic group 
should be included in initial studies of these agents. 
Concurrent treatment. Physiotherapy and occupational ther­
apy may be continued if the patient has already been on a 
stable program and continues on the program throughout the 
trial. Intraarticular injections of any type should be prohibited 
for 3 months before the onset and throughout the trial.
An important consideration is the concomitant use of anal­
gesics and NSAID. In most trials of SYSADOA, continued 
use of analgesics and/or NSAID has been permitted and tlie 
rate of consumption has been used as an outcome measure. 
However, some investigators prefer not to use reduction in 
NSAID intake as a primary criterion, and some even pro­
hibit NSAID use during the study, using only a rescue anal­
gesic, as needed. If that approach is used, the patient should 
be asked to terminate analgesic treatment at a sufficient 
interval before each assessment to wash out any analgesic 
effect. This method would focus the assessment on the effect 
of the SYSADOA.
Statistical analysis. The number of patients required must 
be calculated in advance. Withdrawals represent an impor­
tant problem in moderate and longterm studies. An intentlon- 
to-treat design is preferable, with the final observation 
providing the endpoint for analysis. The method based on 
survival curves can solve the problem if outcome is cate­
gorized only as “ success” or “ failure.”
Labelling. The label chondroprotective agent is not warranted 
for a SYSADOA unless it can be shown to predictably 
decrease the rate of cartilage loss. Similarly, the designa­
tion “ antiosteoarthrotic substance” should be avoided unless 
the agent has been shown to retard progression of OA.
Trials of DMOAD (chondroprotective agents)
Definition of chondroprotection and objective of the trials.
DMOAD (chondroprotective) therapy in OA, by definition, 
prevents, retards, or reverses the articular cartilage lesions 
in the disease in vivo in humans. To satisfy this definition, 
morphologic evidence of prevention, stabilization, or slowing 
of destructive lesions in the articular cartilage of the involved 
joint is required.
Criteria for assessment of efficacy. The primary outcome 
measure is the rate of articular cartilage loss over years, 
determined by radiography or some other method^. 
Radiographic measurement of the rate of joint space nar­
rowing (JSN). (I) Measurement at the point of maximal nar­
rowing. In patients with hip or knee OA, the rate of JSN 
may be measured on serial high quality radiographs of the 
pelvis or the knees taken in the standing position. Ideally, 
measurements should be made with a special caliper with 
2 sharp points and a stabilizing screw. A magnifying glass 
with 0.1 mm graduation is used to measure the distance 
between the 2 sharp points. The joint space at tlie site of max­
imal narrowing may be measured with a precision of 0.1 
mm^. With this manual technique, in a controlled, prospec­
tive, randomized, 3 year double blind trial comparing 
glycosaminoglycan peptide complex (Rumalon) and place­
bo in 42 patients with hip OA, Lequesne, et al^  found a 
mean rate of JSN of 0.22 mm/year, with a very large inter­
patient variation: 95% Cl =  0 to 0.82 mm/year (Figure 1). 
Tran, ei a/*,, using computerized image analysis^, found a 
mean loss of 0.30 mm/year.
Using the manual technique in a prospective study of 
patients with femorotibial OA, Lequesne, et al found a mean 
rate of medial compartment JSN of 0.24 mm/year^ (Figure 
2) in patients followed for nearly 4 years. In contrast, in a 
recent abstract, Kirwan, et aP^  reported that measurement 
of joint space width directly with a ruler on the radiograph 
showed a loss of 15% (=  0.6 mm/year) in one group and 
of 4% (=  0.2 mm/year) in another group of patients with 
knee OA. The marked discrepancy in the rate of JSN in these 
2 studies is unexplained. (2) Measurement of the area of the
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joint space. Investigators have examined the possible advan­
tages of measuring the area of the joint space on digitized 
radiographic images of the joint^ -^ '^ -^ -^^ .^ The technique has 
good reproducibility and may be preferable to direct meas­
urement of the joint space since it encompasses the entire 
relevant area of tlie joint space, some part of which generally 
remains available for measurement over years. However log­
ically, measurement of the JS area is less sensitive to change 
tlian that of the JS narrowest point as argued by Buckland- 
Wright in a remarkable review^®.
Obviously, the rate of progression of JSN in an individu­
al patient, determined from the specific reduction of joint 
space on serial examinations, must take into account the sen­
sitivity of the method employed (coefficient of variation 
8-10%)^-’. (3) Validation of the joint space measurement 
method. In view of the length of the trial necessary to evaluate 
a DMOAD, tlie observation that serial radiographs may show 
progressive loss of joint space over years suggests that this 
measurement may provide a global view of articular cartilage 
thickness. It should be noted, however, that whether radio- 
graphic measurement of the joint space accurately reflects 
the thickness of cartilage in the knee or hip has not been con­
firmed by correlation with measurements on anatomical 
specimens. On the other hand, while newer techniques, such 
as ultrasonography” , MRI, or arthroscopy^^ may provide 
reasonably accurate and sensitive measurements of articu­
lar cartilage thickness or lesions, they have not been 
employed in prospective longterm studies to determine an 
annual rate of cartilage loss, (4) Microfocal radiography. This 
technique, advocated by Buckland-Wright^®- -^ '^, provides 
higher resolution than conventional radiography, but the 
equipment is expensive and not generally available. The tech­
nique is, therefore, not well suited to a multiregional trial. 
(5) Measurements in patients with bilateral disease. In cases 
with asymptomatic contralateral involvement, progression 
of JSN should be measured bilaterally.
Other imaging techniques. In addition to the radiographic 
techniques described above, other imaging methods, e.g 
ultrasonography and MRI, show promise for assessing the 
thickness of articular cartilage, but these remain to be vali­
dated in cohort followup studies.
Needle arthroscopy (Chondroscopy). This modified needle 
arthroscopic technique, currently useful only for the knee, 
is being validated for quantification of cartilage lesions^ .^Jz. 
It may be more sensitive than radiographic techniques and 
permit trials of shorter duration. The main limitations of this 
technique arc inconsistency in assessing and mapping the 
chondral lesions and the ethical problem of repeated studies 
in patients who improve symptomatically with treatment. 
However, Ayral, et al have recently scored the lesions with 
an acceptable reproducibility, provided the chondroscopy is 
performed by the same well trained investigator^ .^
Biochemical œid immunochemical markers ofOA. Serologic 
markers of cartilage breakdown or repair have not been 
shown to be of value in quantifying the progression of car­
tilage breakdown or the adequacy of cartilage repair in 
OA'2.
Clinical assessment. Tests for efficacy and safety of DMOAD. 
Since stabilization or improvement in the status of articular 
cartilage in an O A joint would be inconsequential unless ac­
companied by improvement in algofunctional status, a 
DMOAD should be assessed also by the clinical outcome 
measures for evaluation of a SYSADOA described above, 
measures of importance since symptoms and radiographs 
often did not correlate^ .^^ .^
Eligibility and exclusion criteria. Two types of individuals 
are potentially suitable for DMOAD trials; (1) those at risk 
for future OA because of previous trauma, malformation, 
or occupation, in whom preventive treatment can be under­
taken; (2) those witli symptomatic<hip and knee OA, in whom 
maintenance of radiographic joint space width over several 
years will be the primary assessment criterion ..Consequent­
ly, JSN at the onset of the trial should be incomplete.
Patients under 50 years of age should be excluded, since 
OA tends to progress slowly in younger individuals.
Patients witli complete congenital dysplasia and disloca­
tion of the hip, OA secondary to acetabular protrusion, osteo­
necrosis, previous articular fracture, or significant genu 
varum should also be excluded, since the course of the dis­
ease is often more rapid in these conditions.
OA of tlie iiiterphalangeal joints of the hand could be used 
as an alternative model. Outcome measurements would 
include assessment of the course in affected joints (despite 
obvious imaging difficulties’^ -^ ) and the development of 
OA in previously unaffected joints.
As a general principle, in trials involving patients with hip
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OA or knee OA it is important also to evaluate other sites 
of potential or actual involvement, e.g., interphalangeal 
joints.
Design and duration of the trial In all cases, the trial should 
be controlled, randomized, double blinded. A parallel design 
should be used and, until a reference drug is identified, should 
include a placebo group. It should be conducted over an 
appropriate number of years in well characterized patient 
groups that are as homogeneous as possible with respect to 
disease characteristics.
In trials of agents in which the aim is prevention of OA, 
analysis of the results is based on survival curves. Only one 
outcome criterion is relevant: development or absence of OA 
at a specified location, as determined by periodic radio- 
graphic or other imaging techniques. The curve might look 
like tire theoretical one in Figure 3.
However, a trial aimed at demonstrating a prophylactic 
effect is rather hypothetical and would be difficult to imple­
ment. The duration of the trial would be unknown, since the 
rate of occurrence of OA is extremely variable (and is often 
measured in decades, even in subjects predisposed to OA, 
e.g., those witli cruciate ligament transection). Furthermore, 
recruitment of a sufficient number of subjects who would 
be prepared to be followed over years on a treatment of 
uncertain value would be difficult, particularly if none is sym­
ptomatic and 50% are assigned to the placebo group.
In trials of agents in which the aim is the stabilization or 
repair of established OA, given that the rate of articular car­
tilage loss is usually slow (Figures 1, 2), the duration of the 
trial should be no less than 2 to 3 years.
Concomitant therapy. Concomitant treatment that is poten­
tially chondroprotective or chondroaggressive should obvi­
ously be prohibited during a study involving a putative 
DMOAD. In a longterm trial it is desirable to permit only 
analgesics. NSAID should be used only if essential, for short 
periods, as a rescue medication.
The change in consumption of analgesics, reflecting the 
level of joint pain, may be a useful secondary clinical as­
sessment measure, if analgesic use is strictly monitored.
Intraarticular injection of the target joint should be 
prohibited.
Statistical analysis and calculation of sample size. Statisti­
cal analyses can be employed using techniques suitable for 
comparing the experimental and control groups. If radio- 
graphic evidence of JSN is employed as tlie primary outcome 
measure, the sample size calculation should be based on 
studies that have measured the rate of joint space loss^.^ 
For example, in patients with OA of the hip, the mean loss 
over a 3 year period was 0.66 mm, with a large SD of ±
0.93 mm®. Consequently, to obtain a difference between the 
treated group and the placebo group of 0,5 mm in joint space 
loss over a 3 year period, with type I error -  0.05 and type 
II error =  0.10 in a 2-tailed test, it would be necessary that 
163 patients per group complete 3 years in the study, and, 
for a gain of 0.33 mm within 3 years, 86 patients per group. 
The coefficient of variation of tlie measurement (8-10%) was 
taken into account in our calculation.
In order not to lose any information from patients who 
withdraw from treatment, an analysis based on survival 
curves should be performed. This offers tlie considerable ad­
vantage of accounting for all patients who are enrolled. Those 
who withdraw due to inefficacy or adverse reactions can be 
analyzed separately or together. A theoretical example of 
such a curve is shown in Figure 4.
Labelling. Unless evidence of true protection of human OA 
cartilage has been demonstrated, the designation “ chon- 
droprotectiye drug” should not be used.
Conclusion. Although a number of putative SYSADOA and 
DMOAD are already available for clinical use in certain 
countries, it is essential that such agents undergo further 
rigorous evaluation. In this article, which was written under 
the authority of the International League of Associations for 
Rheumatology (ILAR), we have tried to summarize tlie rele­
vant methodology for study of both classes of SADOA.
Two important issues remain unresolved: (1) For clinical 
assessments, what is the best primary criterion of efficacy 
(i.e., outcome measure)? Will the principal outcome meas­
ures prove to be satisfactory in longterm trials? And, especi­
ally in trials of SYSADOA, should concomitant treatment 
with an NSAID be permitted, so that possible redqction of 
NSAID intake may serve as an outcome measure? It would
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Fig. 3. Theoretical example of a positive effect on a survival curve regarding 
the prevention of OA by a putative DMOAD in at-risk subjects.
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Fig. 4. Theoretical survival curve showing a positive result of a DMOAD 
candidate to reduce the rate of patients with OA with worsening of their 
established OA image.
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seem desirable that some trials of SYSADOA are conducted 
with the concomitant NSAID treatment' and others without 
it. (2) With regard to studies of DMOAD, several methods 
for measuring articular cartilage loss over years are under 
evaluation. Presently, radiographic measurement of the rate 
of JSN is the simplest among these, and in longterm followup 
of patients with hip and knee OA has shown a consistent rate 
of loss. However, correlations of joint space width with 
actual measurements of cartilage thickness are not currently 
available.
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Outcome Measurement in Osteoarthritis Clinical Trials
NICHOLAS BELLAMY
ABSTRACT. The clinical assessment o f outcome in osteoarthritis (OA) clinical trials is highly dependent on the 
use of valid, reliable, and responsive measurement techniques. Despite several decades of clinical 
studies, and a half-century o f development in clinical metrology, we still lack international stan­
dards of measurement for OA trials. There have, nevertheless, been several very encouraging 
developments. In particular, the Osteoarthritis Research Society and the 5th WHO/ILAR Task Force 
have discussed issues o f standardization. The Western Ontario and McMaster Universities Osteo­
arthritis Index and Lequesne Index have been proposed as important outcome measures. Finally, data 
have recently been published on observer variability, variance estimation, and sample size determina­
tion for OA trials. {J Rheumatol /995,(suppl 43)22:49-51)
N. Bellamy
Key Indexing Terms: 
OSTEOARTHRITIS OUTCOME MEASUREMENT CLINICAL TRIALS
The use of valid, reliable, and responsive measures is 
essential for the successful detection of clinically important 
alterations in health status in osteoarthritis (OA) clinical trials. 
During the last 50 years of musculoskeletal clinical metrol­
ogy, numerous ad hoc methods of measurement have been 
employed. In contrast, several validated instruments, largely 
based on patients with rheumatoid arthritis (RA), e.g.. Health 
Assessment Questionniare (HAQ) and Arthritis Impact Meas­
urement Scales (AIMS), have been applied in OA studies. 
In addition, the Ritchie Index has been modified (i.e., Doyle 
Index) for use in patients with OA. Most recently there have 
emerged 2 purpose-built instruments for use in OA studies 
[i.e.. The Western Ontario and McMaster Universities Osteo­
arthritis Index (WOMAC) and the Lequesne Index].
Despite these developments, there has been relatively little 
standardization in outcome measurement in OA studies. Two 
recent reviews of published clinical trials suggest that there 
has been a high degree of variability not only in the varia­
bles selected but also in the instruments and scales employed 
for measurement. Measures of pain, patient global assess­
ment, physician global assessment, and stiffness have been 
used in >  50% of nonsteroidal antiinflammatory drug 
(NSAID) trials'. However, despite the clinical importance 
of physical disability, validated questionnaires have been in­
frequently employed in its measurement. While the 1985 
EULAR guidelines^ for OA clinical trials recommend 
measurement of physical disability by questionnaire, no 
specific mention of a similar measurement is made in the 
1988 US Food and Drug Administration (FDA) guidelines^ 
In contrast, walk time is cited in both tlie EULAR and FDA 
guidelines, yet this measure seemed to lack responsiveness
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in the aforementioned clinical trials that were reviewed. Cur­
rent FDA and EULAR guidelines differ in their listings of 
preferred outcome measures (Table 1). With few exceptions, 
insufficient detail is given in either set of guidelines regard­
ing instruments, scales, or recording methods. The guide­
lines are not in agreement, one with the other, and both con­
tain redundancies.
Most recently a set of guidelines for outcome measure­
ment in trials of so-called slow acting drugs in OA (SADOA) 
has been proposed (Table 1)^ . These guidelines contain 9 
disease specific measures and one generic (quality of life) 
health status measure. They include measures of pain, phys­
ical function, physician and patient global assessments similar 
to the core measures developed by the Outcome Measures 
in Rheumatoid Arthritis Clinical Trials (OMERACT) group 
for use in RA trials. The relative merits of different articu­
lar indices (e.g., graded versus binary) have not been studied 
in OA, and, therefore, the role of the Doyle Index (partial 
or complete) remains to be defined. Overall, this proposal 
forms an excellent basis around which to discuss future instru­
mentation in SADOA trials.
Pari pçssu with attempts to develop guidelines for trials, 
there have been significant developments in the basic clini­
cal metrology of OA. For example, it appears that patients 
with OA may rate their pain qualitatively in a different 
fashion than those with fibromyalgia or RA. Furthermore, 
pain varies and distinct circadian (acrophase =  19:20) and 
circaseptan (acrophase =  Sunday) patterns of pain in patients 
with knee OA have been reported®. This suggests that the 
specific instrument used to measure pain in OA needs care­
ful consideration, as does the time at which the measurement 
is made.
Our own mdex, the WOMAC Osteoarthritis Index, has been 
subject to 2 major validation studies and 16 additional investi­
gations. We have compared Likert and visual analog versions 
of the; index, blind versus informed presentations, parametric 
versus nonparametric forms of analysis, signal versus aggre­
gate methods of measurement, the time frame dependency
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T able 1. G u idelin es f o r  OA c lin ica l tr ia ls
FDAb
1. Swelling
2. Redness
3. Tenderness on pressure
4. Pain at rest or on motion
5. Range of motion
6. Walking or stair climbing time
7. Investigator’s opinion of the patient’s condition on tlie day of 
assessment
8. Patient’s opinion of his/her condition on the day of assessment 
EULART
1. Index of severity of hip and knee disease (Lequesne, 1982)
2. Investigator’s overall opinion
3. Pain on visual analogue scale
4. Patient’s overall opinion
5. Walking time (if knee, stair climb is recommended)
s a d o a T-
1. Visual analogue scale of pain
2. Functional indices (e.g., WOMAC or Lequesne)
3. Doyle Index
4. Loss of mobility
5. Walking or stair climbing time
6. Consumption of analgesics and/or NSAID
7. Number of flares over time, especially effusion in OX knee
8. Patient's overall judgment of efficacy
9. Investigator’s overall judgment of efficacy
10. Quality of life scale
of the response, and the importance of different index items, 
as well as the relative importance of scores on the 3 sub­
scales to individual patients. We have also compared the rela­
tive statistical efficiency of WOMAC against the Lequesne, 
HAQ, AIMS, and Doyle indices, and against the 50 foot walk 
time, intermalleolar straddle (hip), intercondylar distance 
(hip), and range of movement (knee). These investigations 
suggest that WOMAC is, in general, slightly greater in 
statistical efficiency than otlier outcome measurement proce­
dures. Most recently, we compared a computerized version 
of WOMAC against the original paper version, and have 
shown high levels of correlation between the 2 versions. 
WOMAC has been requested for translation into French, 
German, Italian, Spanish, Dutch, and Swedish, and valida­
tion of these foreign language translations is pending. To 
date, WOMAC has been requested for use by over 100 differ­
ent investigators in 14 different countries.
In general, sample size calculation for clinical trials is 
based on a single variable. If this variable is pain, then tlie 
trial becomes a test of comparative analgesia. However, 
researchers are often interested in other outcomes. Our own 
research in this area, based on an analysis of NSAID trials 
and a series of studies examining variables for sample size 
calculation, suggests that sample size requirements differ 
depending on tlie variable employed®-®. Thus, with stan­
dardized observers and techniques, and assuming a 2-tailed 
a0.05 and BO.l, the sample size estimates (per group) for
a double blind randomized controlled parallel trial compar­
ing 2 NSAID were as follows: Investigator’s opinion of the 
patient’s condition on the day of assessment = 25; patient’s 
opinion of his/her condition on the day of assessment = 26; 
range of motion measurements =  29-31 ; pain on movement 
=  41; pain on visual analog scale = 47; tenderness on pres­
sure = 76; 50 foot walk time = 94; and pain at rest =119 .  
Such differences in sample size requirements need to be 
acknowledged and accommodated in future trials. This in 
itself creates logistic problems. For example, the use of mul­
tiple variables may necessitate a statistical correction for mul­
tiple comparisons. Alternatively, weighting and aggregating 
information from multiple variables into a single value avoids 
the aforementioned correction, but is itself problematic. 
Nevertheless, the future success of OA trials depends on ad­
dressing, rather than ignoring, tlicsc issues. An alternative 
approach to aggregation is the development of response 
criteria, i.e., a combination of change values exceeding a 
specified magnitude on one or more predefined variables.
This approach has been attempted by RA but not by OA 
researchers. Once a core set of variables is declared, the de­
velopment of response criteria will naturally follow.
Much research to date has been based on disease specific 
measures, and yet there is an increasing interest in generic 
measures. Such measures offer an opportunity to compare 
different disease states and are a prerequisite for certain types 
of economic analysis. The use of measures such as the SF36 
(The Medical Outcomes Study 36-Item Short-form Health Sur­
vey) and the Health Utilities Index (HUI) in OA studies has yet 
to be established, as has tlie sample size consequences of their 
inclusion. A recent presentation at the OMERACT II Con­
ference, in Ottawa, suggested that in a total joint arthroplasty 
study, the SF36 was more responsive as a generic measure, 
but WOMAC was superior as a disease specific measure.
In essence, both measures are excellent, but examine different 
aspects of the response to treatment.
Further research is required to rationalize the conceptual 1
basis for measurement in OA studies. A framework that en- |
compasses the symptomatology of OA and its consequences I
is illustrated in Figure 1. In essence the cellular and biochem­
ical pathology of OA may result in a number of consequences 
that may be detected by imaging techniques such as plain 
radiographs, MRI, or chondroscopy. Ultimately, the disease 
may be clinically manifest and result in joint tenderness 
(Doyle Index), perfomiance decrements (range of movement,
50 foot walk time) and the cardinal features of pain, stiff­
ness, and physical dysfunction (WOMAC Osteoarthritis 
Index). If sufficiently severe, these and other associated 
effects may result in a decline in quality of life or overall 
health status (SF36 or HUI). In making global assessments, 
the patient and physician may independently take into account 
a variety of clhiical consequences of OA. The physician may, 
in addition, consider the severity of disease detected by ancil­
lary tests (e.g., radiographs, MRI, chondroscopy). By using
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GENERIC HEALTH STATUS MEASURE 
e.g, SF36
PROCESS MEASURES 
(e.g. Radiographs, Chondroscopy, MRI)
ASSESSMENT
PHYSICIAN
GLOBAL
ASSESSMENT
GLOBAL
PATIENT
MEASURES OF THE  
CLINICAL EFFECT 
OF DISEASE
"e.g. Doyle Index" 
Range of Motion 
Walk Time
- e.g. WOMAC " 
OSTEOARTHRITIS  
INDEX
DISEASE
SPECIFIC
MEASURE
Fig. 1. A conceptual frainework for outcome measurement in clinical trials 
o f OA o f  Uie hip and/or knee.
a conceptual framework w e can define not on ly  what change  
is occurring, but w h ere it occurs w ith in  the dim ensionality  
o f  the sym p tom ato logy  o f  the d isease .
In sum m ary, future needs in ou tcom e m easurem ent can  
be m et by the sim ultaneous pursuit o f  severa l goals: (1 ) The  
encouragem ent o f  d ia logue betw een  various a gen cies that 
have develop ed  gu id elin es to estab lish  a truly international 
standard for studies having sim ilar g o a ls . (2) T h e  preferen­
tial use o f  valid , reliab le, and responsive ou tco m e m easures * 
for future O A studies. (3) The routine incorporation o f  m eas­
ures o f  physical disab ility  in the o u tcom e m easurem ent ; 
process. For hip and knee studies this w o u ld  entail the use ? 
o f  the W O M A C  or L equesne ind ices, and for  generalized  
O A  trials the H A Q  or A IM S indices. (4) T he further refine- : 
ment o f  parameters used in sample size calculation. (5) Evalu- ; 
ation o f  the ro le  o f  generic  health status m easures such as : 
the SF 36 and H U I in O A  clin ical trials. (6) O A  researchers 
should fo llow  tire exam ple o f  tlie O M E R A C T  group in RA  
and develop a core set o f  m easures for O A  c lin ica l trials and ; 
a set o f  response criteria to adjudicate tire su ccess versus ■ 
failure o f  therapy in individual patients.
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Osteoarthritis Clinical Trials: Candidate Variables and 
Clinimetric Properties
N IC H O L A S B E L L A M Y
ABSTRACT. O utcome assessm ent in osteoarthritis (O A ) clin ical trials requires the use o f  valid, reliable, and 
responsive m easurem ent techniques. Clinical assessm ent procedures exam ine patient relevant 
issues, w hile im aging procedures and b iologic marker assays probe different aspects o f  the under­
lying d isease process. At present, there is no international agreement on w hich standardized proce­
dures should be used in future studies or which dom ains should be included. N evertheless, sign ifi­
cant progress has been made in recent years toward attaining that goal and there are numerous m ea­
surement procedures, differing in their conceptual and clinimetric properties, from  which to select a 
core set. The fo llow in g  review  provides a description o f  candidate variables that merit consideration  
in reaching international harmonization on outcom e measures for future O A clin ical trials. 
U  Rheumatol /997;24:768-78)
Key Indexing Terms: 
OSTEOARTHRITIS CLINICAL TRIALS OUTCOM E
Osteoarthritis (O A ) is o ften  considered  to be either o f  
know n (secondary) or unknow n (prim ary or idiopathic) ori­
gin. L ike m ost other organs, the c lin ica l repertoire o f  the  
m uscu loskeletal sy stem  is relatively  restricted. T he m ajor 
features o f  osteoarthritic in vo lv em en t o f  a jo in t are pain, 
tenderness, sw ellin g , crepitus, and dysfunction . H eat occurs 
occasionally , w h ile  redness is rare, ex cep t in cases o f  ero­
siv e  arthritis and in the early stages o f  nodal O A  in so m e  
patients.
The c lin ica l m etrology o f  O A  is co m p lex  because, like  
conditions such as rheum atoid arthritis (R A ), ankylosing  
spondylitis, and fibrom yalgia , there are fe w  constants in the 
c lin ica l presentation. Furthermore, O A  m ay be sym ptom atic  
or asym ptom atic, and the associated  radiographs either nor­
m al or abnorm al. Indeed, the association  b etw een  clin ical 
and radiographic features is often  lo o se , and there m ay be  
disparity betw een  radiographic and arthroscopic aspects o f  
the d isease . F inally , the b iochem istry  o f  O A  is co m p lex  and, 
desp ite  considerable progress, current understanding is 
incom plete, there be ing  no sero log ic  test for O A  and no b io ­
lo g ic  marker un iversa lly  acknow ledged  as a marker o f  “d is­
ease  activ ity” or o f  prognostic  value.
For m étro log ie  purposes, it is n ecessary  to  subcategorize  
O A. O nly prim ary form s o f  the disorder w ill be further co n ­
sidered here, sin ce  patients w ith secondary form s o f  O A  are 
usually  exclu d ed  from  m ost c lin ica l trials. H ow ever, it m ust 
be acknow ledged  that ultim ately the e tim o g y  o f  all form s o f  
O A  m ay be know n, and that the disorder cu n en tly  termed  
“primary O A ” is probably a heterogeneous group o f  d is­
orders varying in etio logy . From  a m étrologie  standpoint,
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primary O A  can be d iv ided  into 7 categories: hip, knee, 
hand, and other form s o f  loca lized  O A , and generalized, 
apophyseal, and ero siv e  O A . I d iscuss hip, knee, hand, and 
generalized O A  sin ce  trials o f  ph arm acological agents are 
usually conducted in th ese  areas. T he im portance of, for 
exam ple, shoulder or ank le O A , or the pain and disability 
that m ay result from  apophyseal or erosive  O A  should not 
be underestim ated. H ow ever, the hands, hips, and knees are 
the m ost frequent target areas for primary O A  and m ay be 
involved  in a loca lized  or generalized  fashion. Furthermore, 
m any m easures suitable for assessing  knee or hip O A  are not 
appropriate for hand O A  and are inadequate by them selves 
to  assess patients w ith  generalized  O A . T his d ifficu lty  o f  
m easuring different c lin ica l configurations o f  the disease, 
from  a m étrologie standpoint, differentiates O A  from  RA.
CLINICAL VARIABLES
B efore considering candidate variables for  ou tcom e mea­
surem ent in future O A  trials, it is  necessary to consider a 
conceptual fram ework for conducting m easurem ent in such 
stu d ies’. A lthough lin k ages betw een the d ifferent conse­
quences o f  d isease  m ay be rather lo ose , it is, pragmatically 
speaking, reasonable to  consider a series o f  consequences 
arising from  the underlying cellu lar pathology. In particular, 
c lin ica l pathology leads to various c lin ica l m anifestations, 
and thereafter to a series o f  c lin ica l outcom es (impairment, 
disability, handicap, even  death). C onceptually , one can 
consider the ex isten ce  o f  corresponding m easurem ent strata. 
D epend ing on the d isea se  and the dim ension o f  interest, one 
could  use (or d evelop ) one or several appropriate instru­
m ents to probe each o f  the strata, or as m any as are relevant 
g iven  the research qu estion  and the know n or predicted 
pharm acodynam ic properties o f  the test com pounds. Since 
the fram ework is presented as a hierarchical structure, it 
w ould be necessary to m onitor all strata betw een  the lowest
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and highest stratum selected  for inclusion . Indeed, it m ight 
be reasonable in so m e  studies to m onitor all c lin ica l strata, 
since not only betw een-drug within-strata com parisons are 
relevant, but so  are com parisons o f  the exten t to w h ich  the 
treatm ent e ffects penetrate the hierarchical structure o f  d is­
ease  consequ en ce. M onitoring all strata, for exam ple, m ight 
allow  differentiation o f  a system ic corticosteroid  from  a 
non stero id a l an tiin flam m atory  type drug (N S A ID ).  
Sim ilarly, a drug that im proved functional status m erely  by  
elevatin g  m ood (and having little or no e ffect on low er stra­
ta) w ould  have a different “therapeutic im pact profile” from  
a drug w h ose e ffects w ere entirely m ediated through its ab il­
ity directly to affect the basic inflam m atory process and any 
potentially reversib le consequ en ces. T im s, instead o f  ca te­
gorizing outcom e m easures in order o f  alphabetic priority, 
degree o f  observer dependency or independency, prim ary or 
secondary outcom e m easurem ent status, or even  random  
order, the m easurem ent process could  be described in term s 
o f  the strata m onitored and the instrum ent(s) se lec ted  to 
m onitor effects w ith in  each corresponding stratum. Such  
organization w ou ld  a llow  a better understanding o f  w here  
tire primary outcom e m easure(s) fit(s) into the overa ll m ea­
surem ent fram ework. From the above construct, a num ber  
o f  candidate variables and m easurem ent procedures for  
evaluating patients can be developed . T h ese  are identified  in  
Table 1 and d iscu ssed  in the fo llo w in g  paragraphs.
Pain . T he pain literature is ex ten sive  and diverse^. A lthough  
not develop ed  sp ec ifica lly  for or validated ex c lu s iv e ly  in 
patients w ith O A , the perform ance characteristics o f  both  
Likert and visual analog scales (V A S) have been evaluated  
in patients w ith OA^. Variations o f  these basic sca les , such  
as the pain faces scale^, continuous chrom atic analog sca le ‘s, 
as w ell as the M cG ill Pain Q uestionnaire^ and B ehavioural 
O bservation Techniques'-^, have not usually  been used  in 
eva lu ative  trials in O A . A s a result, their applicability  and  
perfonnance characteristics rem ain uncertain.
E xperience w ith  both 5 point Likert and 10 cm  h orizon­
tal VA S in O A  trials indicates they are both valid , reliable, 
and responsive techniques for assessing  pain®~'°. S in ce  pain  
is a personal experience, pain sca les should  be com pleted  by  
patients and not by independent assessors.
Stijfness. B ecau se  stiffness is generally o f  shorter duration  
in O A  than untreated R A , it is often  assjumed to  lack im por­
tance. H ow ever, patients asked to rate the absolute im por­
tance o f  stiffness ind icate tliat it is o f  m oderate im portance” . 
Furthermore, patients asked to rate the relative im portance  
o f  stiffn ess (cf. pain and physical function) assign  im por­
tance scores o f  21%  in knee'^ and 25%  in hand O A . G iven  
its relatively short duration, it is preferable to a ssess sev er i­
ty rather than duration in patients w ith O A  (cf. patients w ith  
R A ). Valid, reliable, and responsive techniques based on 5 
point Likert and 10 cm  VAS have been develop ed  for this 
purpose®"’®.
5 0  f o o t  w a lk  tim e. T his m easure is on ly  applicable to the
study o f  lower extrem ity  involvem ent and is, therefore, 
inappropriate for assessm ent o f  hand O A  or in iso lation  for  
the assessm ent o f  generalized  O A. Even in the study o f  hip  
O A  or knee OA patients, this m easure has o ften  been poor­
ly responsive'^. D esp ite  being valid and reliable, it is qu es­
tionable whether the 5 0  foot walk tim e is relevant or n e c es­
sary®"'®.
A scen t time. Like the 5 0  foot w alk tim e, this test is on ly  
applicable to low er extrem ity  assessm ent. T here is no d e fi­
nition o f  a standard set o f  stairs on w hich to p erfon n  the test, 
although the sam e set cou ld  be used for serial assessm en ts  
o f  individuals. Perform ance on this test m ay depend on a 
num ber o f  factors in c lu d in g  p h y sica l c o n d itio n in g .  
Furthermore, com orb id ities such as cardiovascular d isease , 
neuropathy, and cerebellar dysfunction m ay result in this 
form  o f  assessm ent b e in g  hazardous, particularly i f  the stairs 
are steep. I do not feel this m easure is relevant for eva lu a­
tive  research in c lin ica l trials.
K nee range o f  m otion  (R O M ). T his m easure is o n ly  app lic­
able to the study o f  knee involvem ent. R estricted  knee  
RO M , how ever, m ay reflect a num ber o f  factors, so m e relat­
ed to the state o f  the articular cartilage, otliers to the jo in t  
capsu le or adjacent m u scle  and ligam entous structures. 
During flex ion  the relative relationship betw een  the axes o f  
the fem ur and tibia ch ange such that the traditional m ech an­
ical lon g  arm gon io m eter  is not an ideal instrum ent. 
N evertheless, reliable determ inations o f  knee R O M  can be  
m ade by appropriately trained assessors®"'®. In general, the 
m easure has detected statistically  significant d ifferences  
b etw een  active treatm ents and either p lacebos or N S A ID -  
free w ashout periods'®. D isparity may ex ist betw een  the  
num ber o f  degrees o f  m ovem ent o f  the knee and its fun c­
tional capacity; k n o w led g e  o f  knee RO M  m ay therefore lack  
clin ical relevance.
In ten n a lleo la r  s tra d d le . A  m easure o f  hip abduction, the  
interm alleolar straddle is  reliable w hen determ ined by  
trained assessors®"'®. Its responsiveness has been proved in  
N S A ID  trials'®. H ow ever, like oflter m easures o f  jo in t  
geom etry, its relevance in  pham iacodynam ic studies is qu es­
tionable and its use not recom m ended.
In terco n d y la r d istance. A  m ultiplanar m easure o f  com p o site  
hip (abduction/extem al rotation) and knee (flex io n ) m o v e ­
m ent, this m easurem ent can be perform ed reliably by  
trained assessors®"'®. It has been show n capable o f  d etecting  
statistically  significant d ifferences in one N S A ID  trial 
reviewed'®. Tlie relevan ce o f  the intercondylar d istan ce is  
questionable for pharm acodynam ic studies and its u se  is not 
recom m ended.
M easurem ent o f  jo in t geom etry by ROM  techniques g en ­
erally requires assessor training, and like other perform ance  
based m easures (e .g ., 5 0  fo o t w alk  tim e and ascent tim e) the  
functional consequence o f  m easured im provem ents or dete­
riorations is variable and d ifficu lt to quantitate. H ow ever, as
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Table 1. Candidate variables for OA outcome assessment.
Variables Knee
Potential Applicability
Hip Hand Generalized
Clinical 
Pain scales
VA + + + +
Likert + + + +
Stiffness
Severity + + + +
Duration + H- + +
Redness - - ? -
Physical performance
Grip strength - - + -
50' walk time -r + - 7
Ascent time ? ? - ?
Knee ROM + - - -
Intermalleolar straddle - + - -
Intercondylar distance - + - —
Swelling
Arthrocircametry ? - ? —
Graded + - 7 -
Heal til status instruments
WOMAC + + - -
Lequesne + + - -
Dreiser, et al (hand) - - + -
Bellamy, et al (hand) - - + -
HAQ + + + +
AIMS + + + +
AIM S2 + + + +
FSI + + + +
Health related quality o f  life
SF-36 ? ? ? 7
EuroQol ? ? ? ?
NHP 7 7 ? ?
HUI ? ? 7 7
Imaging 
Plain radiographs
Nonmicrofocal + + + ?
Microfocal + + + 7
MRI ? ? ? -
Scintigraphy ? ? ? 7
Ultrasound ? ? ? 7
Arthroscopy + ? ? ?
Biological markers
Aggrecan (SFAGN) ? - -
846 epitope in aggrecan (SF846) ? - —
Stromelysin-I (SFSLN) ? - - -
Collagenase (SFCLN) ? - - -
Tissue inhibitor o f  metalloproteinase (SFTEMP) ? - - ~
Procollagen II C-propeptide (SFPCIIC) ? - - -
Serum keratin sulfate (SKS) ? .? ? ?
+ • A ppropriate , not appropriate , ?: uncertain applicability
m easures o f  c lin ica l interm ediaries (w ith  the p ossib le  ex cep ­
tion o f  the intercondylar distance), they are satisfactory. 
D o y le  Index. Several aiticular ind ices have been  develop ed  
for the assessm ent o f  patients w ith  R A . In that disorder, 
issu es o f  jo in t se lection , grading o f  tenderness and sw ellin g , 
w eighting  and aggregation procedures, and the use  o f  
reduced jo in t counts have been tlioroughly addressed. B y  
com parison, the D o y le  Index (a m odification  o f  the R itchie
Index) has received  scant attention, and alternative m ethods 
o f  perform ing jo in t counts in O A  have not been  explored. 
For exam ple, signal jo in ts, reduced jo in t counts, grading and 
w eighting/aggregation  issu es , all deserve further considera­
tion'''.
T h e m ost obvious application for an articular index is in 
the assessm ent o f  patients w itli generalized  O A . It is not 
clear, how ever, w hether it is  necessary to se lect and grade
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Tabic 2. Concentrations o f molecular markers o f  cartilage matrix turnover assayed in joint fluid and serum, with 
calculations o f specificity and sensitivity for discrimination between presence and absence o f knee joint pathol­
ogy. Joint pathology in this context includes diagnosed injury to cruciate ligament and/or meniscus in the pres­
ence or absence of osteoarthritic joint changes detected by arthroscopy or radiography. (Reprinted with permis­
sion from Lohmander S: A cta  O rth op  S ca a d  /P95.(suppl 266)66:84-7.)
VoF SFAGN*’ SF846" SFSLN" SFCLN' SFTIMP* SFPCIIC« SKS"
Joint pathology (n) 2352 2119 385 1037 614 1028 428 758
Median 5 66 0.6 21 0.6 15 3.4 293
10th percentile 0.5 30 0.4 2.7 0 5 0.9 196
90tli percentile 50 204 1.0 137 8.1 55 10.1 426
Reference (n) 118 88 9 77 26 77 49 137
Median 1 70 0.3 4.7 0,1 5 1.7 277
10th percentile 0.2 32 0.2 0.4 0 1.9 0.8 196
90tli percentile 1.9 102 0.4 23.4 0.4 12 6.1 422
Specificity %* 83 83 82 83 84 84 83 84
Sensitivity %* 75 59 91 69 76 78 59 57
* Total volume of joint fluid aspirated (ml).
 ^Synovial fluid aggrecan fragments detected by Alcian blue precipitation (pg/ml).
Synovial fluid 846 epitope in aggrecan detected by immunoassay (pg/m l).
 ^Synovial fluid stromelysin-1 (MMP-3) protein detected by immunoassay (nM).
" Synovial fluid collagenase (MM P-1) protein detected by immunoassay (nM).
f Synovial fluid tissup inhibitor o f  metalloproteinase (TIMP-1 ) protein detected by immunoassay (nM).
* Synovial fluid procollagen II C-propeptide detected by immunoassay (ng/nil).
'■ Serum keratan sulfaté'(SD4-epitope) detected by immunoassay (ng/ml).
* Specificity and sensitivity are calculated as sensitivity = (a/(a+c)) and specificity = (d/(b-t-d)), where tlie arbi­
trary cutoff point was set equal to the 80th percentile o f  the values for the reference group and where
Disease 
Present Absent
a b
c d
Test positive 
Test negative
tlie degree o f  tenderness in involved  jo in ts , or w hether a 
sim p le  count o f  the number o f  tender jo in ts w ould  su ffice . 
Indeed, the w eighting  system  developed  by Lansbury'® m ay  
b e  m ore relevant to O A  tlian RA patients, g iven  that the 
areas used in that w eighting system  m ore clearly approxi­
m ate the cartilage area than that o f  the sy n o v ia l m em brane. 
Such counts also  m ay be applicable to studies o f  hand O A . 
H ow ever, tlie relevance o f  using the index in patients w h o se  
d isease  is lim ited  to the hips or knees (particularly m onoar­
ticular O A ) is questionable, espec ia lly  if  the jo in t is sim ply  
graded as be ing  either tender or nontender.
T he assessm ent o f  sw ellin g  in O A  is contentious, since it 
m ay be o f  bony or soft tissue origin. Furthermore, ach iev ing  
adequate reliability  in grading sw ellin g  m ay prove problem ­
atic. S in ce  no pharm acologic agents have been d evelop ed  
that reverse the bony changes, it m ay not be appropriate to 
grade bony sw ellin g  at present. H ow ever, evaluation o f  the. 
D o y le  Index, and various m odifications, m ay be warranted  
sin ce  the assessm ent can be perfonned by trained assessors 
in a reliab le fash ion and the index is capable o f  detecting  
change in c lin ica l trials®"'®. Possib ly  the applicability  o f  the
electronic dolorim eter in patients witli O A could  b e  evaluat­
ed'®.
R edness. A lthough the assessm ent o f  redness is m entioned  
in the U S  F ood  and D rug Adm inistration (F D A ) gu id elin es  
for outcom e m easurem ent, redness is found to be infrequent 
except in erosive  arthritis®. In tlie early stage o f  nodal O A , 
erosive  O A , and certain form s o f  secondary O A , redness 
son ietim es occurs. H ow ever, even in these patients the  
assessm ent o f  redness probably adds little to the assessm ent 
process.
G rip  strength . Grip strength is m ost com m on ly  assessed  
using a pneum atic dynam om eter (i.e ., m odified  sp h ygm o­
m anom eter c u ff coupled  to a standard manometer)'®. T his 
m ethod has been applied infrequently in O A  c lin ica l trials, 
p ossib ly  because o f  the relative infrequency w ith w h ich  the 
O A  hand has been the focu s o f  study'®. T he determ ination- 
can be perform ed reliably by trained assessors®"'®. In these  
studies it is necessary to consider whether grip strength  
should  be determ ined w ith or witliout inclusion  o f  counter­
pressure from  the thum b. F irst carpom etacarpal jo in t
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invo lvem ent m ay be m ore readily assessed  w ith a pinch 
meter. Grip strength determ ination m ay be im portant in 
hand O A  stu d ies and so m e  g en era lized  O A  stu d ies. 
H ow ever, the functional consequ en ce o f  grip strength decre­
m ents is variable and m ay reduce the value o f  this m easure­
m ent.
A rth rocircam etry . A lthough em ployed  in several studies, the 
m easurem ent o f  jo in t circum ference in centim eters has not 
proven a popular technique for eva lu ative  research o f  
antirheum atic drugs'®. For the m easurem ent o f  sm all hand 
jo in ts, je w e lle r ’s rings or a flex ib le  p lastic tape can be 
e m p lo y ed ’®. In O A , so ft tissue changes and e ffu sio n s m ight 
im prove w ith treatm ent (cf. bony proliferation). E ven  in R A  
c lin ica l trials, w here experience w ith arthrocircam etry is 
m uch greater, there is little current enthusiasm  for its routine  
incorporation®"'®-'®. A s a result, I w ould  not recom m end the 
use o f  arthrocircam etry in O A  clin ical trials.
A n a lg esic  counts. In those studies in w h ich  pain is  an end­
point, a m easurem ent o f  supplem entary analgesic  use is usu­
ally essen tia l to account for the potential e ffec ts  o f  this 
im portant co-in tervention . M etliods occa sio n a lly  used to 
correct pain scores for analgesic  consum ption are generally  
unsatisfactory. In short tenn  studies, drug diaries m ay be a 
suitable m etliod. H ow ever, in longer term trials, direct anal­
g esic  counts o f  the quantity consum ed m ay be m ore appro­
priate. T he u se  o f  pill container system s em p loy in g  a 
m icrochip in the lid (to record opening and c lo s in g  o f  the 
container) requires further evaluation.
G lo b a l a ssessm en ts . A  variety o f  types o f  g lobal a ssess­
m ents m ay be m ade by either patient or physician . T he fo l­
low ing  ph ysician  global assessm ents have been em ployed: 
overall a ssessm ent o f  ph ysica l disability, investigator’s sub­
jec tiv e  op in ion  o f  each general condition , ph ysician  esti­
m ate o f  d isea se  activity, and ph ysician ’s global assessm ent 
o f  d isease  activity®"'®-'®. In contrast, the fo llo w in g  patient 
global a ssessm ents have been  em ployed: patient’s overall 
assessm ent o f  pain, patient’s overall assessm ent o f  physical 
disability, patient’s estim ate o f  d isease  activity, patient’s 
opin ion  o f  general condition , patient’s g lobal assessm ent o f  
disease activity®"'®-'®. G iven  the precedent set by R A  clin ical 
trials gu id elin es, and the frequent use o f  g lobal assessm ents  
in routine c lin ica l practice, it is appropriate to retain global 
assessm ents as candidate variables for outcom e assessm ent 
in O A  c lin ica l trials.
H ealth  s ta tu s  instrum ents. H ealth status instrum ents can be 
divided  into those that are d isease sp ec ific  and those that are 
generic. T his is a som ew hat artificial d iv ision , but it serves 
to d ifferentiate instrum ents w ith a relatively sp ec ific  appli­
cation from  th ose  used to assess arthritis overall or arthritis 
affecting m any different jo in ts. That is  not to say tliat all 
generic instrum ents m easure the sam e aspects o f  health or 
that any is a com prehensive m easure o f  patient quality o f  
life . In general, financial w e ll being, personal security, reli­
g ious freedom , and nutritional adequacy are not assessed  
H ow ever, the majority o f  generic instruments, to a variable 
extent, m easure health related quality o f  life.
D isea se  sp ec ific  m easures. Several m easures have now  been  
develop ed  sp ecifica lly  to a ssess  the effect o f  O A  in particu­
lar joints.
W estern O n tario  a n d  M c M a s te r  U n iversities O steo a rth ritis  
(W O M A C ) Index. T he W O M A C  Index is a tridim ensional, 
disease  sp ec ific , self-adm inistered , health status measure'®. 
It probes c lin ica lly  im portant, patient relevant sym ptom s in 
the areas o f  pain, stiffness, and physical function in patients 
with O A  o f  the hip and/or knee. T h e  index con sists o f  24 
questions (5 pain, 2 stiffn ess, 17 physical function) and can 
be com pleted in less than 5 m inutes. It is availab le in both 
Likert (W O M A C  L K 3.0 ) and VAS (W O M A C  V A 3.0) for­
m ats. W O M A C  is a valid , reliable, and responsive m easure  
that can detect c lin ica lly  im portant changes in health status 
after a variety o f  interventions (pharm acologic, surgical, 
physiotherapy, e tc .). It has been translated in to  m ost 
European languages and has been  requested for use by more 
tlian 130 researchers in 14 different countries. It has been  
recom m ended recently as a m easure for assessing  future 
slo w  acting drugs in O A  (S A D O A ) clin ical trials'®. T lie  fo l­
lo w in g  properties o f  the W O M A C  instrum ent have  been  
exam ined: Likert versus V A S, prior score availability, tim e 
fram e dependency, s in g le  versus aggregate m easurem ent, 
parametric versus nonparam etric analysis, relative e ffic ien ­
cy , w e ig h tin g  and agg reg a tio n , com p u teriza tion  o f  
W O M A C  V A 3.0, and back  translation and validation o f  for­
eign language translations. A  u ser’s guide is available for the 
W O M A C  Index®®.
L equ esne a lg o fu n c tio n a l ind ices. Two O A  algofunctional 
ind ices have been d evelop ed  by Lequesne, one applicable to 
the hip, the other to the knee®'-®®. T he ind ices contain 3 com ­
ponents: pain or d iscom fort, m axim um  distance w alked, and 
activities o f  daily liv ing . (A  sexual function question  includ­
ed  in the hip in d ex  is  not considered  n ecessary  for 
antirheum atic drug stu d ies.) T lie  2  indices are identical with 
respect to 4  o f  the 5 pain item s and distance w alked, but dif­
fer in the sitting pain and activ ities o f  daily liv ing  items. 
P oints are allocated according to response such that higher  
values indicate greater severity. The ind ices are recom ­
m ended as m easures for O A  trials in the 1985 European  
L eague A gainst R heu m atism  (E U L A R ) G uidelin es for 
antirheum atic dm g research®® and in the recent SA D O A  
guidelines'®. T he reliability, validity, and responsiveness o f 
the L equesne a lgofunctional ind ices have been established. 
A lthough conceptually  d ifferent from  the W O M A C  Index, 
the relative statistical e ffic ie n c y  o f  the W O M A C  and 
L equesne ind ices is very similar^®. The fo llow in g  clin im et­
ric issues o f  the L equesne Index require som e clarification: 
(1) h ow  the question inventory w as selected; (2 ) whether the 
index can be self-adm inistered  or requires an interviewer;
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(3 ) what determ ines the score assign ed  for the different 
degrees o f  d ifficu lty  ly ing betw een  the extrem es o f  0  and 2;
(4 ) what tim e fram e is used; (5) w hat conceptual and m ath­
em atical princip les are used to aggregate pain, m axim um  
distance w alked, and activ ities o f  daily  liv in g  into a sin g le  
number; (6) can the break points for m axim um  distance  
walked be m ade m utually exc lu siv e ; (7 ) can item  (a) in the 
pain com ponent be m odified  to rem ove an am biguity that 
relates to situations in w hich pain occu rs w ithout m ovem ent 
but also  in certain positions. A  generally  availab le u ser’s 
guide w ould  be usefu l.
D re ise r  a lgo fu n ction a l index. T his ind ex  applicable to O A  
hand studies contains 10 item s; 9 probe function and one  
explores the extent that a patient m ay be reluctant to accept 
a handshake®". T his last question m ay be considered a pain  
related rather than a function  related question. T his is a rel­
atively  new  index, and there has not been  broad experience  
in its use. H ow ever, like the L equesn e A lgofun ctional Index, 
it represents an im portant contribution to c lin ical m easure­
m ent. T he D reiser Index is p h ysician  adm inistered, respons­
es to each o f  the 10 questions be ing  rated on 4  point verbal 
scales. Internal and external consisten cy , sensitiv ity  and  
specificity , intraobserver reproducibility, responsiveness in 
placeb o  contro lled  trials, and e a se  o f  u se  have  been  
assessed®".
A n ovel tr id im en sion a l OA h a n d  index. Our ow n  research  
group is  currently d evelop in g  a trid im ensional se lf-adm in is­
tered questionnaire probing pain, stiffness , and physical 
function in O A  hand patients®®. T he develop m en t strategy 
has fo llo w ed  very c lo se ly  that used  for the W O M A C  Index. 
Tire item  inventory w as generated from  a com bination  o f  
c losed  ended questions (derived from  an exam ination o f  
otlier ind ices and interview s w ith  orthopedic surgeons, 
physiotherapists, and rheum atologists) and open ended  
questions. R esp onses to both types o f  questions w ere eva lu ­
ated by interview ing 50  patients w ith  hand O A . From  that 
study, item s o f  h igh prevalence, h igh  frequency o f  recur­
rence, and m oderate to extrem e im portance to patients w ere  
se lected  for incorporation into a test instrum ent. B oth Likert 
(5 point) and VAS (10  cm  horizontal) form s o f  the instru­
m ent have been prepared. Data on the reliability  and c o n ­
struct valid ity o f  both form ats have  been  obtained on 50  
patients w ith hand O A . T he respon siven ess o f  the sca le  has 
yet to be determ ined. It is anticipated that tlie final index  
w ill b e  available in Sum m er 1997 . L ike the W O M A C  Index, 
the new  hand index can be self-adm inistered and w ill be  
availab le in both Likert and V A S form ats. A lthough index  
data w ill usually  be analyzed on a sca le  by sca le  basis, w e  
have used a d ev ice  term ed the PA R IS Sectogram  to derive  
w eights for investigators w h o w ish  to aggregate the 3 sub­
com ponents into a sin g le  score.
H ealth  A ssessm en t Q u estionn aire . D evelop ed  by Fries and 
co-w orkers at Stanford U niversity, the H ealth A ssessm ent  
Q uestionnaire (H A Q ) has been  w e ll validated and is used
widely®®. The H AQ  is se lf-adm inistered, w ithout any addi­
tional instructions, and the 2 d im ension s o f  pain and d is­
ability can be com pleted  in 5 - 8  m inutes. T he disability  
dim ension has 8 categories: dressing and groom in g, arising, 
eating, walking, hygiene, reach, grip, and activ ities (each  
containing 2 or 3 item s). T he instrum ent is valid , reliable, 
and responsive in a variety o f  different conditions and situ ­
ations. It is particularly su itab le for the assessm ent o f  gener­
alized O A. Our ow n experien ce  statistically  com paring the 
W O M A C  (pain and functional su bsca les) and the H A Q  
instrum ents in O A kn ee patients, is that, overall, the 
W O M A C  may offer a sligh t advantage®®. For this reason w e  
have tended to use the W O M A C  for O A  hip and knee stud­
ies , and considered the H A Q  useful in the assessm ent o f  
generalized OA. T he H A Q  has been translated into several 
different languages. A  u ser ’s guide is availab le. O ne o f  the 
advantages o f  the H A Q  instrum ent is its brevity and its s im ­
plicity.
A rth ritis  Im pact M easu rem en t S ca le  (AIM S). T h e  A IM S, 
developed  by M eenan and co-w orkers in B oston , has, like  
the H A Q , been ex ten siv e ly  validated®®. It is a m ultid im en­
sional, self-adm inistered instrum ent using 4 6  item s to probe 
9 separate dim ensions o f  m obility, ph ysica l activity, dexter­
ity, socia l role, socia l activity, activ ities o f  daily  liv ing , pain, 
depression, and anxiety. T he instn im ent is valid , reliable, 
and responsive and has been used in a variety o f  c lin ica l set­
tings. Our ow n  ex p erien ce  statistica lly  com paring the  
W O M A C  Index and the A IM S has been that the W O M A C  
(pain and functional su bsca les) m ay overa ll o ffer  slight 
advantage®®. For this reason w e  have  tended to em ploy the 
W O M A C  in O A  hip and knee studies, the A IM S , like the 
H A Q , being an ex ce llen t ch o ice  for studies o f  generalized  
O A . M eenan, et a l  have recently revised  and expanded the 
A IM S instrument, producing a new  questionnaire, AIMS2®^. 
N ine different types o f  m odification  have been m ade to the 
original AIM S instrum ent. R eliab ility  and valid ity  determ i­
nations have been perform ed. A lthough a relatively  long  
questionnaire, A IM S 2 is a sophisticated  instrum ent w h ose  
strength lies in its com preh en siven ess and its se lf-ad m in is­
tration. The new  u ser ’s gu ide w ill be invaluable to those  
adm inistering and scoring tlie A IM S and A IM S 2 instru­
m ents. T he on ly  lim itation o f  the A IM S instrum ent is the 
tim e for com pletion and the tim e requirem ents for scoring  
and analysis. It m ay not be necessary to use  a ll subscales in  
all studies.
F unctional S ta tus In dex  (FSI). T he FSI w as developed  by  
Jette and D eniston as part o f  the P ilot Geriatric Arthritis 
Project®®. It m easures the degree o f  dependence, pain, and 
difficu lty experienced in perform ing daily activ ities. There  
are 2 form s o f  tlie FSI. T he original contains 4 5  item s spread 
across 3 d im ensions, and takes 6 0 -9 0  rain to administer. 
T he revised version  contains 18 item s grouped in 5 d im en­
sions (gross m obility, hand activ ities, personal care, hom e  
chores and interpersonal activ ity). T he shortened version
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takes 2 0 -3 0  m in to adm inister. T he instrum ent is in terview ­
er adm inistered (cf. H A Q , A IM S, W O M A C ). T he validity, 
reliability, and respon siven ess o f  the instrum ent have been  
established, although it has not com m on ly  been  used in 
pharm acodynam ic studies. M uch o f  the early validation  
work w as perform ed on RA rather than O A  subjects accord­
ing to a recent rev iew  o f  the instrum ent. T he FSI m ay be  
app licab le in a ssess in g  patients w ith  g en era lized  O A , 
although generally  the H A Q  or A IM S instrum ents have  
been m ore frequently em ployed .
H ealth  re la ted  q u a lity  o f  life m easures. A  variety o f  instru­
m ents have been develop ed  to probe various aspects o f  
health related quality o f  life . Four instrum ents that m ay be 
applicable to O A  c lin ica l trials are: Sh ort-F om i (SF ) 36  
H ealth  Status Q uestionnaire® ', EuroQoP®, the H ealth  
U tilities Index®®, and the N ottingham  H ealth Profile®".
S F -3 6  H ea lth  s ta tu s  question n a ire . T his questionnaire, 
d evelop ed  from  the Rand C orporation’s insurance experi­
ment, is in the form  o f  a self-adm inistered  questionnaire  
containing 3 6  items®'. It takes about 5 m in to com plete  and 
m easures 3 m ajor health attributes (functional status, w e ll 
being, overall health) and 8 health concepts: (1 ) lim itations  
in physical activ ities because o f  health problem s; (2 ) lim ita­
tions in soc ia l activ ities because  o f  ph ysica l or em otion al 
problem s; (3) lim itations in  usual role activ ities becau se  o f  
ph ysica l health problem s; (4) bod ily  pain; (5 ) general m en­
tal health; (6) lim itations in usual role activ ities because o f  
em otional problem s; (7) vitality; and (8) general health per­
ceptions. T he questionnaire has been constructed for adm in­
istration by telephone or by a trained interview er. In a recent 
evaluation o f  patients undergoing total jo in t artliroplasty. 
Bom bardier, e t a l  show ed that the W O M A C  O A  Index and 
the SF -36 provide com plem entary data®®, the form er being a 
superior d isea se -sp ec ific  instrum ent and the latter a superior 
generic instrum ent. U sed  together, these 2  h igh perform ance  
ind ices m ay be valuable.
E u ro p ea n  Q u a lity  o f  L ife  (E u ro Q o l)  Q u es tio n n a ire . 
E uroQ ol is a self-adm inistered questionnaire that c la ssifie s  
the patient into  o n e  o f  24 3  health states®®. It co n sists o f  a 5 
part questionnaire probing deficits in m obility , self-care, 
m ain w orking activity, socia l relationships, pain and m ood, 
and a VA S on  w h ich  patients rate their o w n  health status. It 
is su itable for use  as a postal questionnaire, and does not 
require interview er administration. It is recom m ended  for  
use w ith other m ore detailed generic m easures, such as the 
SF -36. There is relatively little experience w ith the EuroQ ol 
in pharm acodynam ic evaluations o f  antirheum atic drugs. 
H ealth  U tilities Index. T he H ealth U tilities Index w as d ev e l­
oped to provide a com prehensive description o f  health sta­
tus in cancer patients®®. T he system  m easures 8 attributes; 
v ision , hearing, speech , physical m obility, dexterity, co g n i­
tion, pain and discom fort, and em otion . T h e index is se lf­
adm inistered and provides a sing le , overall sum m ary score.
It has been adm inistered by face  to face interview  and also  
by telephone. There has been lim ited experien ce w ith the 
H ealth U tilities Index in pharm acodynam ic evaluations o f  
antirheum atic drugs in O A .
N ottin gham  H ealth  P rofile . T he N ottingham  H ealth Profile  
sca le  contains 38 item s that can be grouped into 6 sections- 
physical m obility, pain, sleep , socia l isolation , em otional 
reactions, and energy level®". It is self-adm inistered. Section  
scores m ay be presented as a profile  or an overall score ca l­
culated. E xperience w ith the N ottingham  H ealth P rofile  in 
pharm acodynam ic evaluations o f  antirheum atic drugs in O A  
is lim ited at the present tim e.
Experience w ith the m easurem ent o f  health related qual­
ity o f  life  in antirheum atic drug studies, particularly in O A , 
is extrem ely lim ited. It is, therefore, difficult, at the present 
tim e, to recom m end one instrum ent over another. T he e x p e ­
rience o f  Bom bardier, e t aP^ su ggests that the SF -36 , w hen  
used in com bination w ith the W O M A C  Index, provides 
com plem entary data, and that this may, therefore, be the pre­
ferred com bination for knee, and possib ly  for hip studies. 
N o inform ation is availab le on  patients w ith hand O A , and 
w e are not aware o f  eva lu ation s perform ed sp ec ifica lly  in 
patients with generalized  O A . W e require com parative stud­
ies o f  generic instrum ents in O A  clin ical trials and an ex a m ­
ination o f  the extent to w h ich  other factors, such as so c ia l 
and  em otional w e ll being , he lp lessn ess, and com orbid ities, 
m ight m odulate the relationsh ip  betw een d isea se -sp ec ific  
instrum ents and health related quality o f  life  instrum ents. A t 
present my preference is to  u se  the S F -36  until com parative  
data becom e available.
IMAGING TECHNIQUES
A  “chondroprotective drug” has been defined  as an agent 
that can retard, arrest, or reverse tire degenerative process o f  
O A  in human hyaline cartilage'". To date, no  pharm acolog­
ic agents have m et this criterion. Tlrere has been debate as to 
how  this phenom enon can b e  identified, and w hether plain  
radiographs are adequate or w hether alternative techniques, 
such as arthroscopy or m agnetic resonance im aging (M RI), 
m ight be required. Indeed, the term “d isease m od ify in g” 
m ight be preferable to “chondroprotective,” sin ce  path olog­
ic  changes also occur in  the subchondral bone, synovial 
m em brane, and adjacent tissues.
P la in  rad iograph s. T he literature o f  the rad iology o f  OA  
jo in ts has expanded rapidly in recent years®®"®". Various 
m ethods have been described for taking the radiographs and 
a number o f  different scoring system s have been developed . 
A lthough som ew hat lack ing in sophistication , the K ellgren  
and L aw rence grading system  can detect deterioration, 
albeit over a long  period o f  time®® "®. Newer, non-m icrofocal 
tech n iq u es, d escr ib ed  by  Dougados®^ and B uck lan d- 
Wright"®, based on sp ec ific  v iew s o f  the knee, can identify  
change over tim e. T he advantage o f the D ou gados m ethod is 
its sim plicity, w h ile  the Buckland-W right m ethod relies on a
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high ly  standardized procedure that requires radiographer  
training. T he m icrofocal m ethods described by B uckland- 
W right add a further leve l o f  sophistication , but m ay not be  
generally  availab le for m ulticenter studies"®""®. T he m icro- 
foca l techniques offer the advantage o f  h igh spatial reso lu ­
tion and high m agnification , and have been used  to exp lore  
osteoartlrritic involvem ent o f  the hand and knee.
It is som ew hat d isconcerting that plain radiographs o f  the 
knee m ay not accurately predict the state o f  the articular car­
tilage as determ ined by artlrroscopy"'-"®. N evertlie less, for  
purposes o f  random ized controlled trials, the aforem en­
tioned techniques are capable o f  detecting progressive  jo in t 
sp ace narrowing. D ifferent m ethods have been  described for 
m easuring changes in jo in t space w idth or categorizing  var­
ious degrees o f  narrowing.
MRI. T lie  w idespread use o f  M RI, for eva lu ative studies in 
O A , is constrained by cost and availability. Furtliermore, 
there is on ly  m oderate concordance betw een  articular carti­
la g e  le s io n s  seen  w ith  M R I and th o se  o b serv ed  by  
arthroscopy®®. P ilch, et a l  have identified  errors in ex istin g  
3-D  com puter softw are used to perform  volum etric  studies  
o f  O A  cartilage®^. For clin ical research purposes, M R I tech­
n o lo g y  requires further developm ent and validation . 
R a d io n u clea r scanning. D ieppe, e t a l have confirm ed the 
value o f  scintigraphy in predicting subsequent lo ss  o f  jo in t  
space in OA®®. H ow ever, the role o f  scintigraphy in ou tcom e  
assessm ent in O A  c lin ica l trials rem ains in doubt. M ethods  
o f  quantitating the scintiscan have not been  su ffic ien tly  
refined, and the technique only exam ines subchondral bone  
and not the state o f  tlie adjacent cartilage. It seem s likely, 
therefore, that radionuclide scanning w ill not be used  for  
outcom e assessm ent other than in predicting future radio- 
graphic change.
U ltrason ograph y. M yers, e t a l  have show n in v itro  that h igh  
frequency ultrasonic im aging provides accurate and repro­
ducib le m easurem ents o f  the th ickness and subsurface char­
acteristics o f  hum an cartilage®®. H ow ever, the capacity  o f  
this tech nology  to detect chondroprotective e ffects has not 
been proved and rem ains in doubt. V alidity and resp o n siv e ­
ness, w ithin the context o f  antirheum atic c lin ica l trials in  
O A , h a v e  yet to be determ ined.
A rth roscopy. A lthough an invasive  procedure, consideration  
has been g iven  recently to tlie applicability o f  n eed le  arthro­
scop ic  techniques in the evaluation o f  osteoarthritic carti­
lage in c lin ica l trials. Ayral and co-w orkers have develop ed  
a new  m ethod for scoring chondroscopy and a ssessed  its 
valid ity  and reliability®". A t the present tim e, how ever, tlie  
applicability  o f  tliis technique, particularly in m ulticenter  
trials o f  potential chondrom odulating agents in  O À , has yet 
to b e  determ ined.
B IO L O G IC  M A R K E R S
T he destruction o f  jo in t cartilage in O A in v o lv es the degra­
dation o f  matrix m odules, w hich are then released into jo in t
fluid, blood, and urine, w here they may be d etected  by b io ­
chem ical or im m unological assays®''. Such b io lo g ic  markers 
m ight be o f  use in outcom e m easurem ent but the valid ity, 
reliability, and responsiveness o f  these markers have yet to 
be determ ined. Lohm ander recently published an analysis o f  
the sensitiv ity  and sp ecific ity  o f  b io log ic  m arkers by co m ­
paring patients with jo in t pathology in the presen ce  or 
absence o f  O A  changes as detennined by arthroscopy or 
radiography (Table 2). In general, the sp ec ific itie s  are high, 
and the sensitiv ities m oderate to high. W hen used  in co m b i­
nations o f  2  or m ore markers (in the sam e sam p le), sp ec i­
fic ity  and sensitiv ity  m ay im prove. For exam ple, the co m b i­
nation o f  assays o f  strom elysin , co llagen ase , and tissue  
inhibitor o f  m etalloproteinase in jo in t flu id  resu lts in a 
sp ec ific ity  o f  93%  and a sensitiv ity  o f  90% . A t present there 
is insu fficien t relevant inform ation on either sy n o v ia l fluid  
(SF ) or serum to be able to recom m end one m easure or co m ­
bination o f  m easures over alternatives. Indeed, it is  not cer­
tain at this stage whetlier any o f  the aforem entioned markers 
w ill prove suitable to assess change over tim e. Furtlier work  
is required in this im portant area o f  m olecular b io logy .
F U T U R E  P E R S P E C T IV E
Future d ecision s regarding outcom e m easurem ent sh ould  be 
based  partly on prior experien ce and partly on recent d ev e l­
opm ents. F ew  form al preferences have been  ex p ressed  to 
date regarding clin ical outcom e m easures for O A  trials other 
tlian those encom passed in the F D A  G uidelines (1988)® ', the 
EULAR®®, and the S A D O A  G uidelines'" (Table 3 ). T he  
F D A  guidelines are not as exp lic it about ou tcom e m easure­
m ent in O A  c lin ica l trials as they are regarding R A  and A S  
trials. T he G uidelines do not clearly sp ec ify  “prim ary e ffi­
ca cy  variables,” but su ggest that “efficacy  evalu ation  o f  
other m anifestations o f  d isease , even  tliough they  m ay not 
be  shared by all patients, should be carried out w ith  respect 
to change in sw ellin g , redness, tenderness on pressure, pain  
at rest or on m otion, change in range o f  m otion , and w alk ­
in g  or stair clim bing. In addition, tlie in vestig a to r’s and 
patient’s opinion o f  the patient’s condition on the day o f  
assessm ent are recom m ended.” In contrast, tlie E U L A R  
gu id elin es recom m end the fo llow in g  e fficacy  m easures: 
index o f  severity o f  hip and knee d isease (L equesn e a lgo ­
functional ind ices), investigator’s overall op in io n , pain  
V A S, patient’s overall op in ion , and w alking tim e ( i f  knee, 
stair clim bing is recom m ended). The S A D O A  G uidelin es  
recom m end the use o f  a pain scale, functional ind ices  
(L equesne or W O M A C ), D o y le  Index, lo ss o f  m obility, 
w alk ing or stair clim bing tim e, global assessm ent o f  e ffic a ­
cy  by patient, global assessm ent o f  e fficacy  by physician , 
num ber o f  flares, analgesic consum ption, sim p lified  quality  
o f  life  instrument.
A  rev iew  o f  prior N S A ID  clin ical trials in O A  ind icates a 
preference for m easures o f  pain, patient g lobal assessm ent, 
and physician global assessm ent. H ow ever, functional dis-
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Table 3. Guidelines for OA clinical trials.
EULAR::*
1.
2 .
3.
4.
5.
FDA^ "
1 .
2 .
3.
4.
5.
6.
7.
8 .
SADOA*^
1.
2 .
3.
4.
5.
6 .
7.
8 .
9.
10.
hidex o f  severity of hip and knee disease (Lequesne)
Investigator’s overall opinion
Pain on VAS
Patient’s overall opinion
Walking time (if knee, stair climb recommended)
Swelling
Redness
Tenderness on pressure 
Pain at rest or on motion 
Range o f motion 
Walking or stair climbing time
Investigator’s opinion of the patient’s condition on the day o f assessment 
Patient’s opinion o f his/her condition on the day o f assessment
VAS
Functional indices (WOMAC or Lequesne)
D oyle Index
Loss o f  mobility
Walking or stair climbing time
Consumption of analgesics and/or NSAID
Number o f  flares over time, especially effusion in OA knee
Patient’s overall judgment o f efficacy
Investigator’s overall judgment o f efficacy
Quality o f  life scale
(Reprinted with permission from: Bellamy N: Instruments to assess osteoarthritis 
needs (editorial). Ann Rheum Dis /P 95;54;692-3 .)
current status and future
ability, the 2nd m ost important consequ en ce  o f  O A , w hich  
is  am enable to m easurem ent and has a c lin ica l im portance  
and patient relevan ce  greater than that o f  m easures o f  jo in t 
geom etry or ph ysica l perform ance tests, has been assessed  
w ith relative infrequency. M y current preference for c lin ical 
outcom e m easures is illustrated in Table 4 . In particular, I 
favor m easures o f  pain, function, patient g lobal assessm ent, 
physician  g lobal assessm ent, and a generic health status 
m easure. C om parative studies o f  generic health status m ea­
sures w ill be  required before a preferred m easure can be  
identified , but at present the S F -3 6  appears to  be suitable. 
There are currently no international gu idelines for im aging  
procedures or b io lo g ic  marker assays for O A  c lin ica l trials. 
W ith respect to radiographic techniques, standardized m eth­
ods, such as tliose described by Buckland-W right (nonm i­
crofocal) or D ou gados are o f  im m ediate application and do  
not im p ose  the leve l o f  operational constraints required for  
m icrofocal m ethods. Joint space narrowing can be accur­
ately  assessed  by a perspex ruler, or a grid, or by com puter  
assisted  m ethods. A lternatively, the grading system s, based  
on photographic standards, recently published by Altm an, et 
a/®® or Burnett, e t  are superior to the original c la ssifica ­
tion  system  advanced by K ellgren and Lawrence"^. W hile  
M R I tech nology  m ay provide future opportunities, further 
validation  w ork is required, particularly w ith respect to  v o l­
um etric analysis. N eed le  arthroscopy m ay have a role to 
play, but its in vasive  nature and its lim ited  availab ility  make 
it currently unsuitable for w idespread application in m ulti- 
center studies®". T he ideal b io lo g ic  marker has yet to be 
identified , and it w ill require further developm ents in the 
area o f  m olecular b io lo g y  before consensus can be reached  
on standard m easures o f  dem onstrated reliability, validity, 
and responsiveness®®. A  sero log ic  marker w ould  be much 
easier  to use than a SF  marker. A lthough this is a difficult 
area o f  c lin ica l m etrology, progress in recent years has been  
extrem ely  encouraging. International agreem ent on clinical
Table 4. Clinical outcome measurement batteries for OA trials.
Measure Generalized OA Hip OA Knee OA Hand OA
Pain HAQ orA IM S, AIM S2 WOMAC W OMAC Bellamy, et al*
Stiffness VA or Likert WOMAC WOMAC Bellamy, et at*
Physical functional (indices) HAQ orA IM S, AIM S2 WOMAC W OMAC Bellamy, et al*
Global assessment MD/patient MD/patient MD/patient MD/patient
General health status/QOL SF-36 SF-36 SF-36 SF-36
* The validation o f this novel tridimensional index is nearing completion.
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outcome measures can be achieved this year. Development 
in imaging techniques and molecular biology is progres­
sively advancing.
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Recommendations for a Core Set of Outcome 
Measures for Future Phase III Clinical Trials in 
Knee, Hip, and Hand Osteoarthritis. 
Consensus Development at OMERACT III
NICHOLAS BELLAMY, JOHN KIRWAN, MAARTEN BOERS, PETER BROOKS, VIBEKE STRAND,
PETER TUGWELL, ROY ALTMAN. KENNETH BRANDT, MAXIME DOUGADOS, and MICHEL LEQUESNE
ABSTRACT. Significant progress has been made in outcome measurement procedures for osteoarthritis (OA) clin­
ical trials, and guidelines have been established by tlie US Food and Drug Administration, European 
League Against Rheumatism, the World Health Organization/International League of Associations 
for Rheumatology, and the Group for the Respect o f Ethics and Excellence in Science. However, 
there remains a need for further international harmonization of measurement procedures used to 
establish beneficial effects in Phase 111 clinical trials. A key objective of the OMERACT III confer­
ence was to establish a core set o f outcome measures for future phase III clinical trials. During the 
conference, using a combination o f discussion and polling procedures, a consensus was reached by 
at least 90% of participants that tlie following 4 domains should be evaluated in future phase III tri­
als of knee, hip, and hand OA: pain, physical function, patient global assessment, and, for studies of 
one year or longer, joint imaging (using standardized metliods for taking and rating radiographs, or 
any demonstrably superior imaging technique). These evidence based preferences, achieved with a 
high degree o f consensus, establish an international standard for future phase in trials and will also 
facilitate metaanalysis and Cociirane Collaborative Project goals. {J Rheumatol /P97;24:799-802)
K ey Indexing Terms: 
OSTEOARTHRITIS ENDPOINTS CORE SET OUTCOME MEASURES
Outcome measurement in clinical trials requires the use of 
valid, reliable, and responsive measurement procedures that 
adequately capture important aspects of the condition. In 
recognition of this requirement, a number of individuals and 
groups have published lists of recommended outcome mea­
sures'"®. In particular, the US Food and Drug Adminis­
tration, European League Against Rheumatism, World 
Health Organization/International League of Associations 
for Rheumatology, and the Group for Respect of Ethics and 
Excellence in Science have published guidelines which in 
part specify domains and in part recognize actual measure­
ment techniques or instruments. While not in complete
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agreement, the existing guidelines nevertheless share 
several important elements, namely, the measurement of 
pain, walk time, patient global assessment, and physician 
global assessment.
To build on experience and current preference but not 
exclude other measures of potential importance in future tri­
als, a process was followed that had 4 basic elements: (1) 
provision of information from the literature; (2) lectures fol­
lowed by discussion periods; (3) breakout groups; (4) 
polling procedures.
THE PROCESS
Prior to OMERACT III, participants were asked to complete 
an initial questionnaire to identify candidate variables. From 
return questionnaires, a second questionnaire was then con­
structed incorporating additional suggestions. The question­
naire was extensive and identified 4 site specific forms of 
osteoarthritis (OA) (knee, hip, hand, and generalized), 2 
types of studies (symptom modifying OA diugs and struc­
ture modifying OA drugs), 3 levels of measurement (clini­
cal, imaging, and biologic markers) and various domains 
and measurement techniques. Participants were asked to 
rank in order of importance their preferences for outcome 
measurement for each clinical situation and drug class. This 
proved excessively demanding and only 15 questionnaires 
were returned. Prior to OMERACT III each participant also 
received position papers that outlined the dimensionality of
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the measurement problem and provided up-to-date informa­
tion in areas of clinical, imaging, and biologic markers.
During OMERACT III, participants attended presenta­
tions addressing the different measurement areas and, where 
available, data were presented on the clinimetric properties 
of different instruments and comparisons of measurement 
techniques. Time was allowed during question period for 
clarification and for alternative viewpoints. Participants 
then completed an exercise in which they were asked to 
assign 100 points to reflect their measurement preferences 
in each of 4 types of OA trials (knee, hip, hand, generalized). 
Participants next separated into 3 clinical and one combined 
imaging/biologic markers group. Feedback was available 
from the voting profiles within each of the breakout groups. 
The breakout groups provided an opportunity to discuss 
contentious issues more fully and bring back recommenda­
tions to the group as a whole. Following these deliberations 
as well as other informal discussions, a final questionnaire 
was designed to allow participants to vote for inclusion of 
domains in a core set and to express use preferences for 
types of instruments. However, questions regarding specific 
instruments, while permitting flexibility, were not generated 
from prior voting procedures and a decision was made not 
to include recommendations regarding specific instruments 
for research applications.
THE CONSENSUS
Participants were provided opportunity to recommend a 
measure for inclusion in (a) the core set (i.e., mandatoi-y in 
future Phase III clinical trials in knee, hip, and hand OA 
studies); (b) the research agenda (i.e., worthy of further for­
mal evaluation and possible future inclusion in the core set); 
or (c) inclusion in neither the core set nor the research 
agenda. The summary results are shown in Table 1.
After presentation of these data a number of issues were 
raised.
1. Whether generalized OA was a distinct and definable 
entity for clinical trials purposes. (Resolution — to exclude 
further consideration of generalized OA.)
2. Whether the rate of onset of therapeutic effect (fast versus 
slow) determined the need for different types of clinical 
measures. (Resolution — time of onset determines when to 
measure rather than what to measure.)
3. Whether different measures were required for an anal­
gesic study versus a nonsteroidal antiinflammatory drug 
(NSAID) study. (Resolution — the domains are the same 
but the measurement techniques might vary.)
4. Whether clinical measures should be different for system 
modifying versus structure modifying OA drug studies. 
(Resolution — the clinical core domains are the same.)
5. It was assumed that biologic markers would be important 
in the future, but confirmatory evidence is lacking for the 
evaluative and predictive value of any single marker.
6. It was acknowledged that data existed on the value of 
measures of health related quality of life (generic and utility 
measures), but tliat no one measure had yet been identified 
as superior to all others for clinical trial purposes. Tlie 
importance of such measures in health related quality of life 
determination, eross study and cross disease comparisons, 
and in pharmacoeconomic comparisons was generally 
acknowledged. As a result, while not in the core set, it was 
decided to strongly recommend the incorporation of health 
related quality of life measures in future Phase III trials of at 
least 6 months’ duration. Over the next 3 to 5 years it should 
be possible to evaluate the role of such measures in clinical 
trials.
7. It was emphasized that no measure was excluded from 
use in future clinical trials by decisions made at OMERACT
III. Indeed, in some studies the primary outcome might not 
be one cited in tlie core set (e.g., the effect of a future drug 
on time to surgery). However, such studies would be 
required to also include assessments of domains cited in the 
core set in the measurement battery.
8. There was debate whether stiffness should be incorpor­
ated, whether pain and stiffness were part of the same 
domain, whether patients understood the concept of stiff­
Table I. Preferences for core set of efficacy domains in future Phase III hip, knee, and hand OA trials.
Domain In Core In Research Agenda In Neither Number Voting
(% Voting Yes) (% Voting Yes) (% Voting Yes)
Pain 100 0 0 75
Piiysical function 97 1 1 76
Imaging* 92 7 1 76
(in studies of I yr or longer)
Patient global assessment 91 1 1 75
Physician global assessment 52 21 27 73
Generic quality of life/utility 36 58 6 69
Stiffness 14 61 25 72
Other** 13 69 19 16
Inflammation 8 70 22 74
♦ Standardized techniques for taking and scoring radiographs or demonstrably superior imaging techniques. 
** Includes tenderness, performance based measures, time to surgery, number of flares, biologic markers.
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ness, and whether current techniques accurately assessed it. 
(Resolution — when stiffness is to be assessed in hip and/or 
knee studies it should be measured using the WOMAC or 
Algofunctional Severity Indices.)
9. There was debate on the value of physician global assess­
ment in OA trials (as there had been at OMERACT I regard­
ing its use in rheumatoid arthritis trials). Only 52% of par­
ticipants felt it should be included in the core set for OA and 
as a result it was not included. It was acknowledged, how­
ever, that it was important to about half the participants and 
its continued use was acceptable.
In drawing up the core set, 3 assumptions were proposed: 
(1) to be included there needed to be evidence for reliabili­
ty, validity, and responsiveness; (2) it was not necessary to 
specify exact instruments, but only to agree on the major 
domains to be included; (3) there is a difference between 
consensus and unanimity. However, a 51/49% split seemed 
insufficient, since 49% of participants would be in disagree­
ment. Similarly, a 60/40% split would not be decisive. 
Common sense suggests if 90% or more participants agreed 
on a core set, one could claim a consensus, albeit without 
unanimity. As a result the core set recommended by OMER­
ACT III was based on a consensus of > 90% and included 
the following measures:
• Pain
• Physical function
• Patient global assessment
• Imaging in studies > 1 year (As an efficacy measure in 
structure modifying OA drug studies, but also as a safety 
measure in pure system modifying OA drug studies of > 1 
year duration)
These are illustrated in Figure 1, in which the inner core 
defines the core set for OA. The middle core identifies 
health related quality of life measures (optional, but strongly 
recommended) and physician global assessment (optional, 
depending on perceived importance to the investigator). The 
outer core contains measures of stiffness (by WOMAC and 
Algofunctional Severity Indices), biologic markers, mea­
sures of inflammation, and other assessments (e.g., perfor­
mance based measures, flares, time to surgery, analgesic 
consumption), all of which are optional measures. This con­
cept places highly patient relevant measures at the center, 
while measures less relevant to patients are at the periphery. 
It should be noted that only domains cited in the inner core 
(i.e., core set) will be obligatory in outcome measurement in 
future Phase 111 trials. Any instrument used should be of 
adequate reliability, validity, and responsiveness. For imag­
ing, the preferred technique currently is radiographic and
QOL/UnUTY
90%}
i i e i
MD GLOBAL
% voting for inclusion in core set Placement Consequence
>90% INNER CORE ----- ► "CORE SET"
>36% -< 90% MIDDLE CORE QOLAJTILITY( Strongly Recommended)
8% - < 36% OUTER CORE OPTIONAL
Figure 1. Osteoarthritis core concept.
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requires standardized methods for both taking and scoring 
films. The terai imaging was selected specifically to allow 
for future developments of technically superior methods.
CONCLUSION
These evidence based preferences were achieved through a 
high degree of consensus. They allow international harmo­
nization of outcome measurement procedures in OA clinical 
trials. However, they also offer 4 additional advantages: (1) 
they do not exclude other measures being used in addition to 
the core set; (2) they are flexible and allow over time for the 
inward and outward migration of measures as developments 
occur in clinical, imaging, and molecular disciplines; (3) 
they create a foundation on which other organizations and 
consensus conferences can build, particularly with respect 
to the specification of exact instruments for use in specific 
situations; and (4) they will facilitate metaanalyses and 
Cochrane Collaborative Project goals®.
In summary, participants at OMERACT Iff agreed (> 
90%) on a core set of 4 domains for outcome measurement 
in future Phase Iff clinical trials of hip, knee, and hand OA. 
The 4 domains identified were pain, physical function.
patient global assessment, and, for studies of at least one 
year, joint imaging.
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A. Introduction
There have been many recent advances in 
understanding the pathophysiology and evolution 
of osteoarth ritis (OA). These advances have led to 
im provem ent in diagnosis and therapy , and have 
prom pted a re-evaluation of the m ethodology and 
metrology involved in the perform ance of clinical 
tria ls in  OA. Recently, a combined com m ittee of 
the W orld H ealth O rganization (WHO) and 
In ternational League of A ssociations for R heum a­
tologists (ILAR) has defined two classes of 
sym ptomatic therapy based on the onset and 
duration  of the response to trea tm ent [1], and has 
proposed a th ird  classification for agents th a t  may 
alte r the disease process. In addition, a workshop 
sponsored by the WHO and the American Academy 
of O rthopedic Surgeons (AAOS) has reviewed 
methods to assess progression of OA of th e  hip and 
knee [2]. A t the  request of the U. S. Food and Drug 
A dm inistration , an independent com m ittee has 
developed a set of guiding principles for the 
developm ent of new drugs for OA [3]. Sub­
sequently , the European Group for the Respect of 
E thics and Excellence in Science (GREES), 
th rough  a subcommittee, has made recom m en­
dations regarding the methods to be used for 
reg istra tion  of drugs for OA [4]. M ost recently , the 
Outcome M easures in A rthritis C linical T rials 
(OMERACT) group has recommended a core set of 
m easures to be used in OA clinical tria ls [5].
The O steoarthritis Research Society also estab­
lished a Task Force to address the issue of clin ical 
tr ia l guidelines for OA. Through a series of 
m eetings, a d raft m anuscript was developed. The 
in ten t of the Task Force was to bring together th e  
ideas on the conduct of clinical tria ls generated by 
the re levan t active working groups, and to  add 
sufficient detail to be of help to any party  involved 
in  the  design of clinical trials. The Task Force was 
composed of academic and clinical physicians, 
researchers in  the pharm aceutical industry  and 
members of GREES. Representatives of regulatory  
agencies were invited to attend all meetings.
On M ay 26 and 27,1996, a W orkshop attended by 
representatives of the basic and clinical sciences, 
the pharm aceutical industry , GREES, and reg u la t­
ory agencies was held in W ashington, D. C. to  
discuss the working document of the Task Force. 
The present document resulted from the W orkshop 
and reflects a consensus of the partic ipan ts (See 
Appendix I).
I t  can be expected th a t the m etrology and 
methodology of clinical tria ls of drugs for OA will 
change in the future , as they have in the past [6, 7]. 
The following recommendations for the design of
clin ical trials in patients with OA are made with 
the understanding th a t they will require modifi­
cation as new inform ation becomes available. 
Investigators, regulatory and sponsoring agencies 
should be aware of the likelihood of such changes. 
Investigators and sponsors will need to incorpor­
a te  new methodologies into their protocol design, 
and regulatory agencies will require flexibility to 
adap t to the newer technologies and m ethod­
ologies. Indeed, as pa rt of the advancem ent of 
science, it  is expected th a t OA protocols will 
contain  both validated measures and investiga­
tional outcome measures still requiring validation. 
The following are recommendations, or guidelines, 
no t rigid rules for the conduct of clinical tria ls in 
OA. Many of the recommendations are supported 
by published clinical research. However, some 
recommendations have yet to be validated and are 
based on the best judgm ent of the Task Force and 
the  participants of the Workshop.
B. Objectives for treatm ent o f OA
M edications for OA may affect symptoms and/o r 
modify structure (joint pathology). Dem onstration 
of these benefits will depend upon the tria l design 
and outcome param eters selected. Trial design will 
depend on the mechanism of action of the drug and 
the expected response.
For trials related to symptoms, some m easure of 
jo in t pain will usually be the prim ary outcome 
variable. Factors th a t  are considered in tr ia l 
design include, bu t are not limited to, the 
pharmacodynamics of the drug, time to clinical 
response , duration of benefit after discontinuation 
of treatm ent, route of adm inistration , frequency 
and severity of adverse events, effects on pain, 
effects on inflammation and effects on other 
symptoms and signs of the disease. In  contrast to  
a p rio r consensus publication [1], the m ajority of 
the  members of the Task Force and partic ipants in 
the Workshop felt th a t  there is no advantage in  
creating  a separate class for those agents th a t  
produce a rapid symptom response from those w ith 
a slow er onset of benefit. M edications used to  tre a t 
symptoms have generally included analgesics and 
nonsteroidal anti-inflammatory drugs (NSAIDs). 
Examples of agents th a t may prove to be of benefit 
w ith a particularly prolonged onset to  pain  relief 
include in tra-articu lar (lA) hyaluronic acid, o ral 
glucosamine, chondroitin sulfate and diacerrhein. 
F o r the purpose of th is report, the term symptom 
modifying drugs for OA will be used for both rapid  
and slow onset agents.
A drug may have effects on joint structure/func­
tion  independent of its effects on symptoms.
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Studies of drugs th a t are expected to modify the 
pathologic process of OA should m easure outcome 
param eters th a t  reflect an  a lte ra tio n  of jo in t 
structu re . Such drugs may (1) prevent the 
developm ent of OA, and/or (2) prevent, retard , 
reverse , or stabilize the progression of established 
OA by altering  the underlying pathologic pro- 
cess(es). A drug th a t affects the pathology of OA 
may have no direct effect on jo in t symptoms. 
Symptomatic improvement may occur only after a 
prolonged period of adm inistration. Demon­
stra tio n  of symptomatic im provem ent is not 
required  if no claim, is made for this outcome. 
Indeed , the GREES group have clearly separated 
those drugs th a t  may a lte r the stru c tu re  w ithout 
an  affect on symptoms from those th a t modify 
stru c tu re  and do effect symptoms [4]. W hether 
re la ted  to symptoms, function or some other 
variable , the prim ary outcome m easure should be 
clinically  relevant.
Drugs w ith a potential for stru c tu re  modification 
have been labeled as 'chondroprotective', disease 
modifying drugs for OA (DMOADs), ‘anatom y 
modifying agents’, ‘modifiers of m orphology’, etc. 
T here is no uniformity of opinion concerning the 
term  th a t best reflects the action  of these agents. 
F o r the purposes of this report, and to provide 
consistency in  the literatu re [4], the term  structu re  
modifying drugs will be used. To date , no agent has 
been proved to  have structu re modifying proper­
ties in  hum ans. It should be pointed out th a t  a 
symptom modifying drug may prove to have 
stru c tu re  modifying properties (favorable or dele­
terious), ju s t as a structure modifying drug may 
have symptom modifying properties.
C. L evels o f clin ical t r ia ls  fo r  OA
Preclin ical studies are helpful in  assessing 
p o ten tia l modes of action and the dose range for 
Ijeneflt/toxicity , and may sho rten  the duration  of 
clin ical testing of a potential s tru c tu re  modifying 
drug. A lthough they are not essential, studies th a t 
dem onstrate efficacy in anim al models of OA will 
streng then  the rationale for clinical tria ls  of 
s tru c tu re  modifying drugs in hum ans.
M edications undergoing clinical investigation 
are  allocated to different levels of development as 
described below [8].
C.l. PHASE 1 TRIALS
Phase 1 tria ls are directed principally a t 
dem onstrating pharm acokinetics and safety. They 
may also contain a dose-finding component. 
E scalating dose tria ls are desirable for in itia l
evaluation  of drug safety. M echanism  based 
pharm acological evaluations, including those a t 
the site of action (i.e., in jo in t tissues), are 
common. Initially , the presence of comorbid 
conditions should be minimized; la te r studies may 
ta rg e t special populations, such as individuals 
tak in g  concom itant medication. Phase 1 tria ls  may 
be performed in norm al volunteers or in a patien t 
population appropriate for the targe t indication. 
Double-blind, placebo-controlled, single and mul­
tip le  dose Phase 1 tria ls  are desirable for the in itia l 
evaluation  of drug safety. Evaluation of efficacy is 
n o t the prim ary purpose of Phase 1 trials. A Phase 
1 tr ia l cannot adequately address the benefits of 
s tru c tu re  modifying drugs.
C.2. p h a s e  2 TRIALS
The goals of Phase 2 trials are to  define an  ideal 
effective dose range and regimen (Phase 2 tria ls 
m ust take into account both drug activ ity  and 
toxicity) and to provide sufficient patien t exposure 
to dem onstrate safety in order to justify  pro­
gression to Phase 3 trials (See Below). The 
d ura tion  of the study and num ber of patien ts 
studied should be based on the m echanism  of 
action  of the drug, duration of action of the  drug, 
outcom e variable being assessed, variability  of the 
outcom e param eters, and the intended pa tien t 
population. Dose ranging in these and subsequent 
studies should identify the minimal effective dose 
and  dose-response profile, and may define the 
maximum tolera ted  dose of the drug in patien ts 
w ith OA.
C.2J. Symptom modifying drugs
Phase 2 studies of symptom modifying drugs for 
OA should be placebo controlled, randomized and 
double-blind. Efficacy can often be dem onstrated 
w ith in  days. Longer studies (weeks) are needed to 
dem onstrate slow onset or persistent benefit. Even 
longer studies are required for safety. In studies of 
long-duration , rescue analgesia may be necessary. 
A sho rt-acting analgesic is suggested w ith a 
su itab le washout employed prior to efficacy 
assessment.
C.2.2. Structure modifying drugs
As an  alternative to dem onstrating effects on 
jo in t structure , dose-ranging studies in  Phase 2 
tria ls  of a s tructu re  modifying drug may utilize 
o ther measures of mechanism-based drug activity. 
Because these are measures of physiology and not 
efficacy endpoints, multiple dose regim ens may be
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needed in  la te  Phase 2 (2b) or Phase 3 tria ls. The 
duration  of Phase 2 studies for a struc tu re  modi­
fying drug will also depend on its mode of action.
C.3. PHASE 3 t r i a l s
Phase 3 tria ls  are intended to convincingly 
dem onstrate efficacy and safety of the optim al 
regim en and  dose(s) of the test agent. R eplication 
of pivotal studies (studies of prim ary im portance 
for reg istra tio n  of drugs) for dem onstration of 
efficacy is recommended. There should be only one 
ta rg e t jo in t in a single trial. These studies are 
designed to clearly define the dose/regimen of the  
test d rug to  be recommended for clinical use, 
fu rther define toxicity, and compare the tes t drug 
w ith a reference drug and/or placebo. Sample size 
and study du ra tion  should be calculated to assu re 
th a t subjects will be followed for a sufficient time 
period to detect a clinically relevant, as well as a 
s ta tis tica lly  significant, difference between tre a t­
m ent and control groups with respect to efficacy— 
outcome param eters (see S ta tistical M ethods). 
Sufficient d a ta  m ust be supplied to the appropriate 
regula tory  agency(ies) to satisfy safety concerns. 
The num ber of patients and length of tim e to assess 
safety should follow the recom m endation for 
chronic diseases of the Guidelines for Industry  [9].
C.3.1. Symptom modifying drugs
Phase 3 tria ls  of drugs w ith a rapid  onset of 
effect can be as sho rt as 4 weeks. At times, sho rter 
tria ls are  appropriate. Longer tria ls may be needed 
to evaluate  efficacy for drugs w ith a  slower onset 
of action. In  studies of long-duration , rescue 
analgesia may be necessary. A sho rt-acting 
analgesic is suggested w ith a suitable w ashout 
p rio r to assessm ent of efficacy. A Phase 3 double 
blind study may be followed by a long-term 
double-blind study or open-label extension to 
evaluate safety.
C.3.2. Structure modifying drugs
There a re  no proven structu re modifying drugs. 
Hence, the ex ten t of testing needed to dem onstrate 
this effect is n o t established. The duration  of the  
tria l should be predetermined, and i t  is rec­
ommended th a t it  be a t least 1 year. The duration  
will depend on the mode of action of the drug , the 
an ticipated  response rate , the prim ary outcome 
variable and  the length of time needed to show a 
difference in comparison with a control (i.e., 
placebo) group. S tructural changes are required as 
prim ary endpoints. The size of the study popu­
lation be should be ideally calculated on the basis 
of preliminary data from Phase 2 trials in the  
particular population to be studied (see Statistical 
Section).
C.4. phase 4 TRIALS
Phase 4 studies are performed after the agent has 
been approved for clinical use by the regulatory  
agency. These studies may be used to suppo rt 
clinical observations leading to expanded indi­
cations. They also perm it exploration of uncom ­
mon adverse events th a t can be discovered only in  
studies w ith a large sample size. It also provides 
supportive evidence of long-term benefit. Some 
Phase 4 tria ls  may be open label. To date. Phase 4 
tria ls have been published only for symptom 
modifying drugs.
C.5. r e g u l a t o r y  i s s u e s
When evaluating  OA medications, it  is advisable 
(when applicable) for the sponsor to schedule a 
pre-investigational new-drug m eeting w ith the 
appropriate regulatory  agency to define the 
preclinical and clinical requirem ents prior to 
in itia tion  of Phase 1 trials. The sponsor should 
m aintain com m unication with the regulatory 
agency as the drug progresses th rough Phase 2 and 
Phase 3 studies.
D. E nterin g  p atien ts in OA trials
This section addresses several aspects of the 
study design, including the protocol, admission 
criteria , selection of the study population and the 
definition of w hat is to be studied. Baseline 
assessment should provide inform ation on jo in t 
localization (site), etiology (primary, secondary), 
severity of symptoms, s tructu ra l abnorm ality in  
the joint, concom itant therapy and comorbidity [4].
D .l. o v e r v i e w  o f  t h e  p r o t o c o l
The study p rotocol should be divided into 
sections th a t  encompass background information , 
ra tiona le for th e  study, the question(s) being 
asked, size and site(s) of the study, method of 
patien t selection (including inclusion and exclu­
sion criteria), the method of procedure, clearly 
defined prim ary and secondary outcome variables, 
specific m easures to  be performed a t each visit, 
drug dispensing format, method of reporting 
adverse events, s ta tis tica l analysis and regulatory 
issues (including drug accountability , in stitu tional 
requirem ents, etc.).
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I t  is desirable to include a table (or flow sheet) 
th a t  outlines the m ethod of procedure , inform ation 
from selected references (e.g., disease classifi­
cation , radiographic criteria), the informed con­
sent statem ent, protocol worksheets, drug 
accountability  forms, the data collection forms, 
etc.
The protocol should carefully define the investi­
gators, th e ir study sites, the m ethod of randomiz­
ation , pa tien t m onitoring procedures, technical 
aspects of im aging techniques, labo ratory  tests, 
m ethods of docum enting adverse events, methods 
of blinding and m ethod of docum enting medication 
in take for each p a tien t (active drug, placebo, 
rescue analgesia), and the method of m aintaining 
the m edication log for each partic ipating  center.
D.2. DEMOGRAPHICS
Demographics recorded in the protocol should 
include identifying inform ation , such as the 
p a tien t’s name, address and telephone number, 
w hich should be kept confidential. The p a tien t’s 
name should be coded by letters/num bers for data  
processing and futu re reference.
As a minimum , sociodemographic and clinical 
d ata  collected a t the time of enrollm ent into the 
study should include age (date of birth), sex, race , 
height, weight, m arita l status and years of formal 
education.
D.3. d i a g n o s i s
C riteria  for diagnosis of OA should be clearly 
stated. P atien ts should fulfill validated criteria  for 
the classification of OA, such as those published by 
the A m erican College of Rheumatology (ACR) 
[10-12]. The disease should be classified as prim ary 
or secondary. Study populations should be as 
homogenous as possible w ith regard  to the 
presence of idiopathic (primary) or secondary OA 
[10]. If patien ts w ith secondary OA are studied, the 
underlying condition should be specified and 
should be the same in all patien ts (e.g., post-trau­
m atic a rth ritis , m echanical derangem ent of the 
knee). It is suggested th a t in studies of patients 
w ith idiopathic OA, exclusions for secondary OA 
of the study jo in t include septic arthritis, 
inflammatory jo in t disease, gout, P aget’s disease of 
bone, recu rren t pseudogout, a rticu lar fracture , 
m ajor dysplasias or congenital abnorm ality , 
ochronosis, acromegaly, hemachromatosis, 
W ilson’s disease and prim ary osteochondrom atosis
[4].
D.4. r a d i o g r a p h s
The radiographic severity of OA in each patien t 
should be quantified and documented using either 
aggregate radiographic criteria  (e.g., Kellgren and 
Lawrence scale [13, 14]) or grading of specific 
radiographic features [15-17]. This estim ate of 
anatom ic a lte ra tio n  on images should be acquired 
w ithin 3 m onths after entry. The range of grades 
used for entry  criteria , as well as varia tions in 
grade among trea tm en t and placebo (or control) 
groups should be com parable and sim ilar. These 
radiographic entry  crite ria  should also be appro­
priate for the specific study design. Fo r example, a 
cohort th a t  included advanced severity m ight be 
appropriate in studies of a symptom modifying 
drug while a cohort limited to minimal severity 
would be more appropriate for studies of a 
s tructure modifying drug in tended to re tard  
progression.
D.5. STUDY p o p u l a t i o n
The source of the patien t population (e.g., 
clinic-based, community-based, hospital-based) 
should be defined in the protocol. Considerable 
controversy exists regarding the use of broad vs 
narrow  p a tien t eligibility criterion. Broad patien t 
eligibility allows for generalizable application of 
positive results; however, because of the larger 
am ount of varia tion , broad patien t eligibility 
increases the sample size of the study population 
required to  dem onstrate clinical and statistically  
significant differences, and may m ask the presence 
of subsets receiving benefit (unless extensive 
stratifica tion  is performed). A t the W orkshop, the 
consensus was th a t patien t eligibility should define 
specific populations and that, where appropriate , 
stratifica tion  of subgroups should be employed 
within studies for secondary endpoints of interest.
Examples of high-risk groups th a t m ight be 
considered for inclusion in studies of structure 
modifying drugs include obese women with 
un ilatera l radiographic knee OA [18], and men or j
women who have undergone meniscectomy [19, 20]. |
Examples of variables to be considered for |
stratification  of the source population m ight I
include prio r su rg ical in tervention of the  index |
joint, and high- vs low-risk groups. Examples of ]
subjects who m ight be considered for exclusion I
m ight encompass either low- or high-risk popu- |
lations, such as young age (<45  years old) and Î
those w ith pro trusio  acetabuli, concentric femoral j
head m igration , extensive surgery of the reference j
joint, excessive varus/valgus deformity, concomi- j
tan t rheum atic illness (e.g. fibromyalgia), and those »
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involved w ith litigation/com pensation re la ted  to 
the reference joint.
D.5.1. Symptom modifying drugs
For studies of symptomatic response , the level of 
symptoms a t baseline should be of sufficient 
severity to perm it detection of change, i.e., not too 
mild. A fter w ashout (see Section E.5.), inclusion 
crite ria  for symptomatic response should include 
the following:
•  Pain  of a t least mild intensity: e.g., 100 mm 
visual analog scale (VAS) recording of 
> 25 mm; or five point categorical (Likert) 
scale grade > 1  (where 0 is no pain  and 4 is 
extrem e pain);
•  Definite radiographic changes of OA, using an 
established scale and atlas, e. g., K ellgren 
and Law rence radiographic grade > 2  for 
tibiofem oral OA (i.e., presence of a definite 
osteophyte); modified Croft scale > 2  for hip 
OA [13, 14, 21, 22].
D.5.2. Structure modifying drugs
For studies of structure modifying drugs, as 
discussed above, special subpopulations of sub­
jects who are a t high risk for developm ent of OA 
or rapidly progressive OA may be advantageous (as 
above). In  addition , the following should be 
considered:
•  K ellgren and Lawrence radiographic entry 
criteria: prevention studies: grades 0 or 1 (i.e., 
absence of a definite osteophyte); disease 
re tardation /reversal studies: grades 2 or 3 (i.e., 
sufficient rem aining in terbone distance to 
perm it detection of worsening/progression);
•  C urren t or previous pain  in the index jo in t 
is no t essential. However, changes in  pain  
may be examined as a secondary outcome 
m easure
Prelim inary data suggest th a t  some m olecular 
m arkers in  serum  may predict radiographic 
progression of established OA [23, 24]. Analysis of 
m olecular m arkers may select subpopulations who 
a re  most likely to  show progression in  OA.
D.6. i n c l u s i o n s / e x c l u s i o n s
Inclusion crite ria  should be clearly defined and 
should specify the population to  be studied by age, 
sex, d iagnostic criteria , jo in t w ith OA, degree of 
symptoms, and radiographic grade.
Exclusion criteria should sim ilarly be clearly  
defined w ith regard to  degree of symptoms, 
radiographic grade, concom itant disease, p rio r 
peptic ulcer disease (if a drug is perceived to  have 
gastro in testinal effects), concom itant m edications, 
pregnancy/contraception , lA depocorticosteroid or 
hyaluronic acid injection , tidal lavage, secondary 
OA (listed above).
Opinion varies concerning the proximity to  the  
beginning of a study for adm inistering lA  
m edication into the reference joint. All agreed th a t 
there  should be a sufficient interval between the  
time of the injection and the beginning of the study 
to elim inate the confounding effects of th e  
injection on jo in t pain. The consensus of the 
partic ipan ts a t the W orkshop was th a t a minimum 
of 3 months should elapse between the time of the 
lA  injection and the tr ia l (e.g., lA corticosteroids). 
This in terval may be longer for specific types of lA 
therapy  (e.g., lA  hyaluronan), but sufficient 
evidence is not available to provide more definitive 
guidance a t this time. The investigato r should 
consider stratification  of patients receiving p rio r 
lA  therajly adm inistered w ithin a year of the  
study.
A dditional exclusions are significant in jury  to 
th e  affected jo in t w ith in  6 months of tr ia l sta rt; 
arthroscopy of the affected jo in t w ithin 1 year; 
disease of spine or o ther lower extrem ity jo in ts of 
sufficient degree to affect assessment of the ta rg e t 
jo in t, use of assistive devices other than  a cane 
(walking stick) or knee brace, concom itant 
rheum atic disease (e.g., fibromyalgia), or poor 
general hea lth  in terfering  with com pliance or 
assessment.
As w ith any investigational drug, women of 
childbearing potential should be screened for 
pregnancy , and if p regnant, should be excluded 
from the trial.
D.7. OA HISTORY
The OA history is used to characterize the study 
population and should include the location and 
num ber of symptomatic OA joints; p resence of 
hand  OA (e.g., H eberden’s nodes in  patients w ith  
hip or knee OA); duration  of symptoms; du ra tion  of 
the diagnosis of OA; h isto ry  of prior m edications 
for OA; surgical procedures performed on the study 
jo in t (including arthroscopy), w ith the date of the  
most recent procedure; use of assistive devices, 
such as canes, crutches, knee braces (in studies of 
lower extrem ity OA); history of prior lA  (e.g. 
depocorticosteroid or hyaluronan) injection , w ith  
date of most recent in jection (see above).
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D-8. HISTORY ( o t h e r )
O ther baseline history th a t may be of value 
includes smoking history , horm onal sta tu s  in 
postm enopausal women, concom itant chronic dis­
ease, and concom itant medications, e.g., estrogens, 
anti-inflam m atory drugs.
D.9. STUDY JOINT
Protocols should be limited to  the evaluation  of 
a single jo in t site (e.g., knee, hip) or in the case of 
hand OA, either both hands or the sym ptomatic 
hand  (preferably the dom inant hand).
D.9.1. Symptom modifying drugs
A lthough d ata  may be collected for both righ t 
and left jo in ts (e.g. knee, hip), for symptom studies 
only one should be the prim ary jo in t evaluated 
(except for hands as above). This is most often the 
signal (more symptomatic) side. Changes in the 
con tra la te ra l jo in t should be considered as a 
secondary outcome variable.
D.9.2. Structure modifying drugs
For studies of a structu re  modifying drug , the 
more involved side of a single jo in t site (e.g., hip, 
knee) should be studied as the prim ary outcome 
variable. In  these cases, changes in  the co n tra la t­
eral jo in t can serve as a  secondary outcome 
variable. However, changes in  the con tra la te ra l 
jo in t, which may not yet be sym ptomatic or have 
definite OA, may be selected as the prim ary 
outcom e variable (e.g. Chingford data) [18].
For studies of both symptom and stru c tu re  
modifying drugs, additional jo in t sites may be 
evaluated as secondary outcome variables.
D.IO. PHYSICAL e x a m in a t io n  OF THE INDEX JOINT
Baseline inform ation about the index jo in t helps 
characterize the study population and provides 
reference data for assessing how variables of 
in tere st have changed during the  course of 
treatm ent. Evidence of inflam m ation (e.g., jo in t 
effusion), jo in t deformity, and jo in t contractures 
should be noted. For large joints, loss of range of 
m otion and presence of severe valgus/varus 
deformity may be useful as exclusion criteria. 
A lthough it  is im portant to record the presence of 
clinical signs of inflammation, including synovial 
effusion, these should not be used as a prim ary 
outcom e measure in tria ls of s truc tu re  modifying 
drugs.
D .ll. FUNCTION
M easuring the degree of functional im pairm ent 
can identify the severity of disease in th e  study 
population. F unctional im pairm ent should be 
defined using a segregated , validated m ultidim en­
sional index (SMI) such as the W estern O ntario  
and M cM asters U niversities (WOMAC) [25] OA 
index for hip and knee OA, or an aggregated 
m ultidim ensional index (AMI) such as th e  Algo­
functional Index (AFI) for hip or knee [26]. A t this 
time, although the AFI has been validated , 
separate pain , stiffness and physical function  
subsections have no t been validated for indepen­
dent application.
D.12. g e n e r a l  p h y s i c a l  e x a m i n a t i o n
A general physical exam ination should  be 
performed a t  the onset of the study and again  a t 
the end of the study.
D.13. i n f o r m e d  c o n s e n t
Guidelines for inform ation to be contained in  the 
Informed Consent statem ent should be in  accord­
ance w ith the D eclaration of Helsinki [27]. P a tien t 
partic ipation  requires understanding, and  com­
pletion of an informed consent document th a t has 
been approved by the  appropriate in stitu tio n a l i 
review board.
E, Conduct o f th e study
This section deals w ith the procedures used 
during th e  study, exclusive of individual outcom e 
variables.
E.l. s t u d y  d e s i g n
Studies should generally be single jo in t, con­
trolled , randomized, double-blind, and p a ra lle l in 
design. Occasionally, crossover studies or o ther 
designs may be appropriate.
The study should include a screening and 
baseline visit. The two visits allow th e  collection 
of more reliable baseline data, assure th a t  the 
patien ts fulfill entry  criteria and may be used to  
help reduce noncompliance (Taintness-of-heart 
te s t’ [28]), collect biological specimens, etc. For 
trea tm ent group assignment, patients should be 
randomized in  the order in which they are  enrolled 
into the study, to receive treatm ent according to a 
random ization schedule specifically designed to  
meet study objectives.
At each visit, v ita l signs (blood pressure , pulse,
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and weight) should be recorded and a report of 
adverse experiences (see below) obtained.
In order to minimize unw anted sources of 
va ria tion  in patien t assessment, to the ex ten t 
possible, the same examiner should examine the  
same p a tien t a t each visit, a t the same time of day 
(and preferably also on the same day of the week) 
th roughout the duration of the trial.
E.2, PRIMARY STUDY OUTCOME
Efficacy studies of OA drugs should preferably 
identify a single clearly defined prim ary outcome 
variable. The choice of this variable will depend 
upon the  na tu re  of the desired drug effect and the  
objective of the study.
An alternative approach m ight involve the use 
of several prim ary outcome variables. W ith th is  
la tte r  approach , adjustm ents to the significance 
level are  required for m ultiple analyses performed. 
(See Outcome M easures below.)
E.3. SECONDARY STUDY OUTCOMES
The inclusion of one or more secondary outcome 
variables will strengthen  the study design. Collec­
tion  of inform ation for the secondary outcom e 
variables should no t interfere w ith collection of 
data  for the prim ary outcome variable.
E.4. e x a m in e r
The method used for tra in ing  and m asking of the 
exam iner and  m asking of the patien t m ust be 
specified. Both a blinded investigato r (to assess the 
p a tien t for efficacy and adverse events) and an 
unblinded investigato r may be needed to adm inis­
te r th e  test medication and m onitor toxicity in  
some studies.
E.5. WASHOUT r e q u i r e m e n t s
E.5.1, Symptom modifying drugs
All symptom-oriented studies require discontinu­
ation  of prior analgesic and anti-infiammatory 
m edications, including topical agents, p rior to  
in itia tin g  treatm ent w ith the test drug in  order to  
perm it an evaluation  of unmodified pain severity. 
The tim e of w ithdraw al should be the time required  
for the  clinical effect to disappear (e.g., 5 half-lives 
of the drug). D uring the w ashout period, subjects 
may use acetam inophen (or paracetam ol) as rescue 
analgesia (up to  4 g/day in the U.S. and up to 
3 g/day in  Europe). This must be discontinued in
sufficient time for the clinical effects of the rescue 
drug to disappear.
W orsening of symptoms during the w ashout 
period—although not necessarily a requisite for 
subject inclusion into the tria l—should be docu­
mented.
E.5.2. Structure modifying drugs
A w ashout period is not required in tr ia ls  of a 
s truc tu re  modifying drug. If however, the effect of 
the drug on symptoms is to be tested, then the use 
of a w ashout period should be considered.
E.6. a d m i n i s t r a t i o n  o f  s t u d y  m e d i c a t i o n
Control agents may include placebo or active 
(e.g., analgesic or NSAID) agents. Use of placebo 
may be influenced by ethical and regulatory  
agency considerations. Active control agents offer 
the advantage of dem onstrating improved efficacy 
over existing therapies, bu t may require large 
num bers of subjects.
E.6.I. Topical
Topical test m edications should be dispensed in 
containers which are  identical in appearance to 
those containing the comparison agent (drug or 
placebo). The com parison agent should mimic the 
te s t m edication in  appearance, odor and local 
effects on the skin. Clear instructions regarding 
use m ust be provided to  the patient both orally and 
in  w ritten  form and  m ust be contained in  the 
Informed Consent. Compliance should be m oni­
tored by weighing the re tu rned  tubes or m easuring 
the re tu rned  liquid. Placebo responses are particu ­
larly  frequent w ith th is  technique of drug delivery, 
so placebo controlled tria ls are particu larly  
im portant, as are carefully defined, homogeneous 
study populations.
E.6.2. Oral
O ral test m edications should be form ulated to 
provide an  appearance identical to th a t  of the 
comparison drug (placebo or other). If th is is not 
feasible, a ‘double dummy’ technique (two non­
identical active agents, each w ith an identical 
m atching placebo) should be used.
Preferably , m edication should be dispensed in 
b lister packs w ith the label clearly stating  the day 
and time of adm inistration. Compliance should be 
m onitored by counting returned unused medi­
cations or by use of medication vials w ith 
computerized caps.
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C oncom itant m edication (e.g., rescue analgesia 
and NSAIDs in studies of structu re  modifying 
drugs) may be dispensed in bottles. The pills should 
be counted a t  each visit. Analgesic drugs w ith a 
sho rt half-life should not be taken  from the evening 
prior to  the day of the evaluation if pain is to be 
evaluated.
E.6.3. Parenteral medication
P aren te ra l m edication should be form ulated to 
provide an  appearance identical to th a t  of the 
com parison drug. If th is is not possible, the 
p aren te ra l m edication should be dispensed by a 
person o ther th an  the  blinded investigato r (e.g., by 
an unblinded investigator) and the in jectable 
agent should be concealed from both the  p a tien t 
and the blinded evaluator.
E.6.4. I  A  Medication
lA  study m edication should be form ulated to 
provide an  appearance identical to  th a t  of the 
com parison drug. If this is not possible, the 
m edication should be injected by a physician o ther 
th an  th e  blinded investigator (e.g., unblinded 
investigato r). The volume of control (carrier) 
in jected  should equal the volume of the test agent. 
The jo in t should be aspirated to remove any 
existing effusion as completely as possible prior to 
in s tilla tio n  of the drug, and the volume of fluid 
removed should be recorded. The in jectable should 
be concealed from both the patien t and the blinded 
evaluator. Placebo responses are particu larly  
frequent w ith this technique of drug delivery, so 
placebo controlled tria ls are particu larly  im port­
ant, as is the use of carefully defined homogeneous 
study populations.
E.7. COMPLIANCE AND SUBJECT RETENTION
I t  is essential for studies of structure modifying 
drugs, th a t  strategies be employed to maximize and 
docum ent patien t compliance. For example, con­
tac t m ight be m aintained with patients a t  4-8 week 
in terva ls by telephone. The method of communi­
ca tion  and  time spent w ith patien ts should be 
standard ized as much as possible w ithout jeopar­
dizing th e  relationship w ith the patient.
B .8 . SOCIOECONOMIC m e a s u r e s
Sponsors should consider performing pharm a­
coeconomic analyses in ail OA clinical tria ls 
[29, 30].
E.9. USE OF CONCOMITANT MEDICATIONS
E.9.1. Symptom modifying drugs
It is im practical to  expect patients to pa rtic ipa te  
in a long-term tr ia l w ithout some potential for use 
of rescue m edications for pain. For long-term 
trials, use of concom itant m edication should be 
perm itted on a lim ited basis. An example may be 
the use of acetam inophen (or paracetam ol) for 
escape analgesia (up to 4 gm/day in the U.S. and  up 
to 3 gm/day in  Europe). Any escape m edication 
m ust be d iscontinued in sufficient time for the 
clinical effects of the agent to disappear prio r to 
the assessment. Protocol design should include a 
record of the consum ption of analgesics, NSAIDs, 
and IA injections. However, the use of such 
inform ation as an  outcome in clinical tria ls  has not 
been validated.
lA  depocorticosteroids should not be perm itted 
in studies of symptom modifying drugs, except as 
p a r t of the  protocol design.
E.9.2. Structure modifying drugs
Concom itant therapy may interfere w ith the 
evaluation of outcom e measures and should ideally 
be excluded. However, in long-term studies, it  is 
neither eth ical nor practical to exclude all 
concom itant treatm ents. In all trials, concom itant 
therapies (drugs o r o ther interventions) th a t  are 
likely to affect jo in t structure should be excluded, 
and rescue therapy  should be standardized , 
carefully recorded and monitored. As noted above, 
partic ipants may use acetaminophen (or parace ta­
mol) for escape analgesia (up to 4 g/day in the U.S. 
and up to 3 g/day in  Europe). Analgesics and 
NSAIDs m ust be discontinued prior to the 
assessm ent in  sufficient time for the clinical effects 
of the rescue m edication to disappear.
The consum ption of analgesics, NSAIDs, and lA 
injections should be documented a t each visit. 
However, m ethods need to be developed to 
effectively control for these confounding variables 
in  the analysis and the use of this info rm ation has 
no t been validated  as an outcome variable.
E.IO. CONCOMITANT NON-MEDICINAL THERAPY j
Concom itant treatm ent w ith physical and/or j
occupational therapy  should be either standard- |
ized or ad justed  for in  the analysis to ensu re th a t J
the effects of exercise programs on disease ;
progression do no t bias the outcome of the study. |
Inform ation on w eight change (reduction or gain), j
changes in  use of ambulatory suppo rt (cane, |
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crutches, walker), and in troduction  of, or changes 
in, physical or occupational therapy during the 
study should be incorporated  into the study design.
E .ll .  L A BO RATO RY T E ST S
For m ost m ulticenter studies, routine laboratory 
tests (complete blood count, urinalysis, serum 
chem istry determ inations) should be performed in 
a cen tral laboratory.
R outine synovial fluid analyses should be 
performed a t each site, and should include an 
exam ination for cells and crystals.
For studies routinely  perform ing arthrocentesis 
w ith in jection of an  IA agent, culture of the 
synovial fluid should be performed as clinically 
indicated.
E.12. A D V E R S E  E V E N T S
Adverse, events should be ascertained in an 
open-ended m anner, ra th e r th an  by checklist. They 
should be recorded a t each v isit and between visits, 
as app ropriate. The date of onset, severity, a 
judgm ent w ith  respect to  the relationship between 
the adverse event and th e  test agent, treatm ent and 
the duration , and resolution  of the adverse event 
should all be recorded.
Serious adverse events should be reported to 
regulatory  au thorities immediately.
E-13. PROTOCOL V IO L A T IO N
Reasons for term ination  of a subject from the 
study due to protocol vio lation m ust be specified in 
the protocol. In take of rescue m edications (other 
th an  those specifically prescribed), use of oral or 
topical agents, or devices targeted  tow ard pain 
relief during the course of the study should be 
prohibited. Inform ation on the use of such agents 
should be obtained a t each visit and recorded, and 
the patien t should be w arned about such co-inter­
ventions. P a tien ts in repeated violation of the 
protocol may need to be dropped from the study.
Screening for protocol violations by performing 
blood or u rine  analyses for salicylates or related 
agents is no t considered useful.
E.14. C A SE  R E PO R T  FO RM S A N D  S U P P L IE S
Investigato rs m ust m aintain  adequate records 
showing the receipt, dispensing, re turn , or other 
disposition of the investigational drug, including 
the date , quantity , batch  or code number, and 
identification of subjects who received the study 
drug. Investigato rs m ust m aintain  completed case
report forms and inform ative source documents. 
Case report forms m ust be kept in locked cabinets 
to m aintain security. T here are no special 
requirem ents for OA trials.
F . O u tco m e  m e a s u re s  o f OA
Instrum ents used to m easure outcome in clinical 
tria ls of OA should be valid, reliable and 
responsive to change , when such m easures exist. 
C linical tria ls in  OA should use published 
instrum ents th a t have been used in  other studies, 
thus perm itting com parison of results across tria ls 
of different therapeu tic  interventions. Clinical 
tria ls in OA should include a core set of validated 
m easures [5] (Appendix II):
•  Pain
• Physical function
• P atien t global assessm ent
• Imaging (for studies > 1  year in duration)
Additional m easures th a t  a re  recommended in­
clude the following:
•  Quality of life/u tility  (strongly recommended)
• Physician global assessm ent
Optional m easures for tria ls in OA include the 
following:
•  Signs of inflam m ation
• Biologic m arkers
•  Stiffness
•  Perform ance based m easures of function
• Presence of ‘flares’
•  Time to su rgery
•  Analgesic consum ption
The item s listed below perta in  mostly to phase 3 
trials. These m easures should be recorded a t 
baseline and serially  a t  appropriate intervals.
F.l. SY M PT O M  M O D IF Y IN G  D R U G S
For studies of drugs designed to affect symptoms, 
the prim ary outcom e variab le should usually be 
jo in t pain reported  by the patien t. M easurem ent 
should be serially  recorded a t  appropriate in ter­
vals, a t least m onthly. However, th is is dependent 
upon the ta rg e t jo in t and study design.
F .L l. Pain
The degree of jo in t pain  in  the index joint(s) 
should be graded. P ain  should be recorded on a 
five-point L ikert scale (e.g., none, mild, moderate, 
severe, very severe) or on a 100 mm VAS. Single 
questions about pain  can be used but the activity
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causing pain should be specified; e.g., weight 
bearing , resting, nocturnal, post exercise, s ta ir 
climbing. A lternatively , a validated pain  instru ­
m ent can be used (e.g., WOMAC pain  subscale 
[24]). O ther pain indices include the  H ealth 
Assessm ent Q uestionaire (HAQ) [31] and A rthritis 
Im pact M easurem ent Scale (AIMS) [32].
F .l.5. Joint examination
M easures of range of motion, in term alleo lear 
distance, knee in terbone distance , heel to  bu ttock  
measurements, knee circumference, etc. have been 
validated to variable degrees [42]. The usefulness 
of these measures in  clinical tria ls rem ains unclear 
and their inclusion is optional.
F .l.2. Function
The AFI [25] and the function subscale of the 
WOMAC [24] have . been validated  and are 
recommended for studies of OA of th e  hip and 
knee. O ther indices w hich have been used include 
the HAQ disability index [28], and AIMS [33]. 
D isability  indices specifically designed to m easure 
hand  function are under developm ent [34, 35].
F .l.6. Performance-based measures
Performance-based m easures which include such 
items as grip strength , time to w alk a specified 
distance (e.g., 6 or 15 m, 50 ft), distance w alked in 
a specified time (e.g., 6 min)., have been studied  to 
a variable degree. Some composite m easu res exist 
[43]. The usefulness of these m easures in  clinical 
tria ls remains unclear and their inclusion  is 
optional.
F .l.3. Global status
F.l.S.a. Patient assessment o f global status. The 
p a tien t’s assessment of h is/her global s ta tu s  should 
be m easured using a L ikert or VAS scale. The 
optim al m ethod by which th is should be m easured 
is no t well established. However, a standard  
question should be asked, e.g., ‘C onsidering all the 
ways your OA (joint site) affects you, how are you 
doing (time frame)?’
F.l.S.b. Physician assessment o f global status. A 
m easure of the physician assessm ent of global 
sta tu s  m ay be required by some regulatory  
agencies. There is no generally accepted method 
for m easurem ent of th is variable. A question such 
as ‘Considering all inform ation , how is the 
p a tien t’s OA [joint site] today?’ should be used 
w ith a VAS or L ikert scale.
F.1.4. Quality of life scales
M easurem ent of health-related  quality  of life 
and u tility  based measures a t app ropriate intervals 
is strongly recommended; although , these are not 
a p a r t of the core set of measures. Examples of 
h ea lth  re la ted  quality of life instrum ents include 
the M edical Outcomes Study, 36 question sho rt 
form (SF-36) [36], Sickness Im pact Profile (SIP) 
[37], N ottingham  H ealth  Profile (NHP) [38], and 
EuroQ ol [39]. Examples of u tility  instrum ents 
include the  Time Trade Off, the S tandard  Gamble 
and Techniques and Feeling Therm om eter and the 
H ealth  U tilities Index (HUI) [40, 41].
F .l .7. Inflammation
Clinim etric properties of methods designed to 
m easure inflam m ation have not been well eluci­
dated. The usefulness of these m easures in  clinical 
tria ls remains uncertain .
F .l.8. Response criteria
There is no definition of a minimum clinically 
im portant response for the above m easures. 
Available inform ation does not allow se ttin g  of 
predeterm ined limits for improvement. This is 
particu larly  true  for the composite indices. A t this 
time, the Task Force recommends th a t  each 
protocol predefine a significant response , based 
upon statistically  significant im provem ent in  a 
carefully defined prim ary efficacy variab le  (see the 
statistical section below). At this time, th e  Task 
Force does no t recommend using an  individual 
response criterion  such as has been recom m ended 
in  rheum atoid a rth ritis  [44].
F.2. STRUCTURE MODIFYING DRUGS
For studies of potential structu re  modifying 
drugs, the prim ary outcome variable should  be a 
m easure of jo in t morphology; e.g., im aging (see 
below) or direct visualization, i.e., arthroscopy. As 
stated  above, time to jo in t replacem ent su rgery  is 
not recommended as a prim ary outcome variab le 
due to its dependence on factors u n re la ted  to 
disease progression. Clinical follow-up of patien ts 
partic ipating  in tria ls of structure modifying drugs 
should be a t intervals of 3 months or less.
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F.2.L Radiography
The primary radiographic evaluation should be 
of a single joint (knee, hip, hand). Outcome should  
assess the effect of the drug on joint structure. 
Although assessm ent should include both cartilage  
and bone, the primary radiographic outcom e 
variable for studies o f progression of the hip and 
knee should be minimum joint space width (JSW), 
since this measure is more sensitive than global 
scoring [45*49]. Osteophytes and other bone  
changes should be assessed as secondary outcom e 
variables either by measurement or by grading, 
using published atlases [13-17]. In contrast, for 
studies o f prevention, the primary radiographic 
outcome variables should include osteophytes, 
since th is feature is m ost strongly associated w ith  
knee pain, is a basic component of the A OR 
classification criteria, and is the hallm ark of the  
K ellgren-Law rence scale of the knee. Outcome 
variables for hand OA should be based on  
published atlases agreed upon by the study group 
in advance.
Obtaining reproducible X-rays on successive  
visits is  a prerequisite for reliable assessm ent o f  
progression of OA. The sources of variability in  
joint space width measurement are numerous 
(patient positioning, radiographic procedure, 
measurement process, etc.), protocols have been  
proposed for hip and knee joints [50-52]. It is 
essential to standardize radiographic technique  
based on published, validated data (Appendix III). 
The m ethod should define the radio-anatom ic 
position of the joint, beam alignment, and should  
define the anatom ic landmarks for measurements. 
Positioning of the patient should also be based on  
validated published methods, but in all cases, 
w eight bearing (standing) anteroposterior view s  
should be used in  studies involving the hip or knee. 
Repositioning o f the jo in t can be facilitated  by use  
of foot maps drawn at the time of the in itia l 
exam ination. Correction for radiographic m agnifi­
cation has been shown to improve accuracy and 
precision o f measurem ents [48,53]. Techniques 
that improve the precision of measurements might 
lead to studies requiring smaller sample sizes.
Quality assurance should include training  
sessions for technologists at the onset of the study  
as w ell as for any technologists recruited during 
the study. Radiographic quality, including patient 
positioning, exposure, labeling, etc., should be 
monitored throughout the study. Even minor 
changes in  technique may significantly alter the 
precision o f m easures of jo int anatomy and hence  
conclusions about treatm ent response. It is, 
therefore, critical that the technique be identical
at all centers involved in a m ulti-institutional 
study and remain consistent throughout the study.
The number of readers, method of blinding and 
the method of m anual measurement should be 
agreed upon in advance by the study group. 
Quality control o f the readings should include an 
in itia l training session  and periodic assessm ents o f  
performance. V alidated methods for computerized  
reading of digitized radiographs can decrease 
observer-based error. Enhanced anatom ical detail 
provided by m icrofocal m agnification radiography 
can further improve precision and accuracy of 
measurements [48, 54].
F.2.2. Magnetic resonance imaging (M RI)
MRI is uniquely capable of visualizing all 
components of the jo in t sim ultaneously, and 
therefore offers an opportunity to asses the jo in t as 
an organ. MRI is capable of quantifying a number 
of morphological and com positional parameters of 
articular tissues relevant to OA. Recently devel­
oped techniques for noninvasively quantifying  
cartilage volume, th ickness and water content, 
particularly in early disease, show promise as 
potential outcome m easures for future therapeutic  
studies (Appendix IV). W hile some cross-sectional 
measures have been validated, their performance 
in  longitudinal studies has yet to be determined.
F.2.3. Other im aging modalities
Computed tomography, ultrasonography and  
scintigraphy have not been adequately validated  
and cannot be recommended for use in long-term  
studies.
F.2.4. Arthroscopy
Arthroscopy can directly visualize cartilage and 
other lA  structures, including fibrocartilagenous 
menisci, synovium, ligam ents and chondrophytes. 
Attempts to quantify th is information have  
followed two strategies. The first transforms 
information from each cartilage lesion into a 
numeric score, w eighted m ainly by depth and size 
of the lesion. W hen several lesions are found, as 
occurs frequently in  OA, a composite score is 
derived from the scores of individual lesions. The 
second approach calls for the arthroscopist to  
globally assess cartilage degeneration in a 
compartraent-by-compartment fashion, recording  
each impression on a VAS. Both strategies are 
being employed in  the two systems currently  
under evaluation, w ith  intra- and inter-observer 
reliability determined for both [55,56], and
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sensitivity  to change (utilizing videotaped records 
from two points in time) has been shown for the 
French system [51].
O ther systems yet to be devised may prove 
superior for assessment of particu lar aspects of 
OA, examining biomechanical charac teristics of 
cartilage (which m ight be shown better by a probe) 
or features of the accompanying synovitis. The 
precision and sensitivity to change of any system 
employed in an OA outcomes tria l should be 
determ ined by a study group before the system is 
implemented. M anagem ent of arthroscopic data  by 
videotaping each procedure provides an im­
m utable record th a t can be reviewed by a blinded 
evaluator. However, video records do no t convey 
certa in  impressions obtained in  real time, such as 
three-dim ensional perception and tactile  feedback 
from probing the cartilage. Regardless of the 
recording technique , a system atic uniform  m ethod 
of collecting arthroscopic data is essential, and 
should be specifically delineated in any protocol. 
D iscussion of the technical aspects of th e  
arthroscopic procedure is beyond the purview of 
th is report. However, the size and type of 
instrum ent used and conditions under which the 
procedure is performed should be uniform  for all 
investigato rs in  any particu lar study.
F.2.5. Molecular markers
M olecular m arkers have no t been validated  as 
outcom e m easures in clinical tria ls  of OA 
(Appendix V). However, m olecular m arkers have 
th e  poten tial of offering a unique way of assessing 
d rug effects on specific disease mechanisms, and  
modes of action of drugs in phase 1 clinical tria ls  
[57-59]. The field is developing rapidly. For these 
reasons, tria ls  should include collections of body 
fluid samples. S tandardization of m ethods for 
collection and storage is im portant.
G. S ta tistica l m ethods
There are specific statistical tasks in the design, 
im plem entation and analysis components of a 
clinical tria l. General textbooks cover a broad 
range of topics regarding statistics in  clinical tr ia l 
research  [60, 61].
G.l. D E S IG N
The predom inant activity of the sta tis tician  is 
w orking w ith the researcher in  developing the  
protocol. The protocol m ust clearly list the 
prim ary and secondary study objectives. W here
appropriate , these objectives should be rephrased 
as null versus a lternative hypothesis to be tested.
All protocols should specify the outcome 
measure(s) to be used for evaluating the study 
treatm ents and should contain sample size calcu- ! 
lations for all prim ary outcomes, ind icating  the ; 
required num ber of patients to achieve prestated ï 
power and significance levels, or a ca lcu lation  of 
the power provided w ith a prestated sam ple size. - 
Sample size calculations are based on the  choice of  ^
experim ental design (e.g. parallel groups, factorial 
design, more th an  one treatm ent group vs control) 
and require th a t explicit assum ptions be made 
regarding the variance(s) in  outcomes among study 
subjects and the desired magnitude of change(s) in 
the outcome variable(s) during the study period; 
these assum ptions should be stated  explicitly in  
the protocol. Phase 3 studies should require a 5% 
or lesser level of significance and 80% or greater 
power to detect a protocol defined minimal 
clinically  m eaningful difference in the expected 
outcome between the treatm ent and  control 
groups. These assumptions should, when possible, 
be based on available clinical/epidem iological 
data.
Random ization is a method for assigning 
patients to a te s t or control treatm ent th a t  is free 
of selection bias. The method for random ization 
should be specified in the protocol. Two general 
designs exist for randomization of patien ts to 
treatm ents: fixed randomization and adaptive 
random ization. Fixed randomization schemes may 
be completely random  or may be constrained so as 
to ensure balance in the num ber allocated  to 
various trea tm ent groups (random ization in  blocks 
of fixed size, stratified  random sampling). Ran­
domization in  blocks should be considered if 
p a tien t enrollm ent is likely to continue over an 
extended period of time, or if the study population 
can be expected to  change over the course of 
treatm ent. S tratification should be considered 
when patients are recruited from m any sites. 
Adaptive random ization schemes should be con- | 
sidered when investigators require th a t  balance be I 
achieved on m ultiple factors. i
G.2. IM PLE M E NT A T IO N  ;
S ta tistica l quality control procedures are essen- î 
tia l to ensure the validity of the data  collection | 
and  com puter en try  methods. Key data  variables j 
should be run  through checking program s to 
ensure, a t a minimum , th a t the data are  w ith in  the 
permissible range of possible values, th a t  missing 
data  are flagged, th a t  patients meet inclusion and 
exclusion criteria , and that p atien ts’ data  fbruis ,
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are obtained in  a timely fashion, as per protocol. 
Double en try  of all keyed data  is preferred. A 
random sam ple of data  coded on data entry forms 
should be checked against original sources (e.g. 
forms from laboratories and/or the  medical 
record).
Once study eligibility  is validated , subjects are 
enrolled (and possibly stratified on baseline 
factors), assigned a study identification and 
thereby random ized to treatm ent following the 
predeterm ined random ization plan.
G.3. A N A L Y S IS
Generally , com parisons among treatm ent groups 
should be made as an  ‘in tent-to-treat’ analysis; th a t 
is, (1) p atien ts  should be counted in  the trea tm ent 
group to w hich they were randomly assigned, (2) 
the denom inator for a treatm ent should be all 
patien ts assigned to  th a t treatm ent, and (3) all 
events (w hether believed to be re la ted  to the 
disease process under treatm ent or not) should be 
counted in  the comparison(s) of prim ary interest.
An in ten t-to -trea t analysis can lead to an 
underestim ate of the true treatm ent effect, es­
pecially if com pliance is low, there are many 
treatm ent crossovers, or the denom inator includes 
many patien ts who could not be followed for the 
outcome of in terest. Secondary analyses m ight 
then be carried  ou t on completers (those staying on 
the program  to study end), controlling for 
compliance levels. In  general, analyses focused on 
an individual p a tien t’s longitudinal response, 
using com posite (multidimensional) outcomes, 
should be encouraged. The outcome dimensions 
could include symptoms and/or s tructu ra l 
m easurem ents.
Some analy tic  m ethods used to compare trea t­
m ents in  tria ls  are as follows:
G.3,1. Comparison of proportions
This m ethod is valid  provided th a t patien ts are 
subject to  th e  sam e length  of follow-up and the loss 
of follow-up is low, and occurs for the same 
reasons, across trea tm ent groups. S tatistical 
evaluation of th e  difference in proportions can 
be perform ed using F isher’s exact tests or chi- 
square te s t for larger samples. Examples include 
proportion who are ‘pain free’ and proportions 
experiencing serious adverse medical events. An 
example w ith respect to structu re modifying drugs 
might include proportions developing jo in t space 
narrowing.
G.3.2. Lifetable analysis
This approach provides a means for dealing with 
varying duration  of follow-up to achieve the 
prim ary endpoint and for dealing with cases where 
the prim ary endpoint does not occur by the end of 
the study (‘censored d a ta ’). S tatistical comparisons 
of lifetable ra tes are often performed using a ‘log 
rank ’ test. Examples include: time un til pain 
resolves, time u n til norm alization of a laboratory 
param eter.
G.3.3. Comparison of means
This method is valid, subject to the same 
conditions required  for com paring proportions (see 
above). S ta tistical evaluation  of the difference in 
means can be perform ed using a two-sample (-test 
or the standard  norm al d istribution for larger 
samples. Example: com paring average change in 
pain over the study period.
G.3.4. Descriptive methods
These are useful for assessing the baseline 
com parability of th e  treatm ent groups, and for 
secondary analyses assessing compliance issues. 
Descriptive sta tis tics often include means, s tan ­
dard deviations, and percents of subjects in 
different s tra ta  (e.g. gender).
G.4. A D J U S T M E N T  PR O C E D U R E S
To be valid, evaluation  of treatm ent effects m ust 
be performed on trea tm en t groups th a t are 
comparable w ith respect to th e ir baseline charac­
teristics. S ta tis tical adjustm ent for one or more 
sources of va ria tio n  is often performed by using 
regression models. M ultiple linear regression 
models are used for quantitative outcomes, 
m ultiple logistic regression models are used for 
binary outcomes, and Cox proportional hazards 
models are used to ad ju st ra tes calculated from 
lifetables. These m ethods are especially useful if 
the random ization scheme failed or if randomiz­
ation was not used in  allocating patients to 
treatm ent groups.
G.5. IN T E R IM  A N A L Y SIS
The concept of in terim  analysis is th a t patients 
assigned to the inferior treatm ent should be 
removed from it  as soon as the choice is clear. 
These methods provide statistically  valid P-values 
by accounting for the m ultiple looks of the 
outcome data during the study period. The scheme
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for in terim  analyses should su it the p articu la r 
tria l. The procedure of O’Brien and Flem ing is one 
sta tistica lly  valid  m ethod for ad justing the 
P-value.
G.6. R E P E A T E D  M E A S U R E S  A N A L Y S E S
These m ethods are useful for quantifying the 
trend  and tem po of outcomes repeatedly assessed 
during th e  course of a tr ia l and during the  
extended follow-up period. S ta tistical evaluation  
of the difference in summary statistics (e.g. trend , 
or slope) can be performed using the analysis of 
variance for repeated measures. Comparisons 
across trea tm en t groups are valid provided th a t 
pa tien ts are  followed for the same length of time 
and there  is no differential loss to follow-up.
H. Sum m ary
H .l. SY M PT O M  M O D IF Y IN G  D R U G S
The prim ary outcome variable is a specific 
aspect of jo in t pain , although a ‘signal’ symptom or 
some m easure of function may also be studied. 
T rials of drugs w ith a rap id  onset of effect can be 
as sho rt as 1-4 weeks bu t may be as long as 12 
weeks. Longer tria ls (up to 2 years) may be needed 
to evaluate  longer-term  toxicity , determ ine opti­
m al long-term  dosing regimens, or establish 
long-term benefit. Supplem ental escape analgesia 
should be minimized, m onitored and discontinued 
prior to evaluation  of efficacy.
Some agents th a t provide symptom relief may 
not provide benefit u n til weeks after in itia tion  of 
therapy. U nder these circum stances, tria ls  will 
vary from 3-12 m onths in length. If the agent is 
adm inistered in  courses, episodic readm inistration 
of the  drug may be needed in long-term trials. 
Longer tria ls  (up to 2 years) may be required to  
exclude toxicity  or establish long-term benefit.
efficacy of a drug in  th is category. In these studies, 
it may be necessary  to  permit concom itant use of 
drugs for relief of symptoms (NSAIDs, analgesics). 
The confounding effects of glucocorticoids and 
NSAIDs in these tria ls  is not yet understood and 
very restric ted  use of lA  depocorticosteroids is 
recommended.
D em onstration of structu re modification will 
require the use of d irect measures of jo in t anatomy , 
such as radiography , particu larly  m easurem ent of 
the radiographic jo in t space. As stated  above, the 
p lain  radiograph is presently the m ost repro­
ducible and readily  available method for assess­
m ent of disease modification. Studies are needed to 
validate su rrogate m arkers of disease activity , 
since they may help sho rten  Phase 2 structu re  
modifying drug trials. As an a lternative  to 
radiography , some tria ls  may utilize arthroscopy.
As we approach th e  beginning of the  twenty-first 
century , concepts of clinical tria ls  of OA drugs are 
changing. M ethodology and techniques for the 
evaluation of new  agents for OA have been refined 
dram atically over the  last decade. We look forward 
to  the future w ith excitem ent as we an tic ipate  the 
development of new agents th a t  may a lte r the 
symptoms and course of OA. The above recommen­
dations are in tended  to  help us ascertain  which of 
these new agents are effective.
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H.2. ST R U C T U R E  M O D IF Y IN G  D R U G S
These drugs are in tended to prevent, retard , 
stabilize or reverse development of the morpho­
logic changes of OA. A lthough th is has been called 
‘chondroprotection’, the term  is m isleading and 
should be avoided, because all structu res of the 
jo in t are involved in OA, no t a rticu la r cartilage 
alone. The benefits of disease modifying therapy 
may no t be apparen t un til years after the onset of 
trea tm ent. The selection of high-risk groups may 
sho rten  th e  time of investigation. Improvement in 
symptoms (i.e., jo in t pain) is no t a requisite for the
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Appendix II 
Clinical a ssessm en t techniques  
N icholas B ellam y  
Core se t m easures
The core set of outcome measures for OA clinical 
tria ls  developed a t OMERACT III, contain three 
clin ical measures; pain, physical function and 
pa tien t global assessm ent w ith imaging for studies 
of 1 year or longer [1].
P A IN
P ain  is usually m easured on a ra ting  scale 
(L ikert or VAS) which grades perceived pain 
severity in one or several situations (e.g., noctu r­
nal, s ta ir  climbing, walking, rest, global) [2]. The 
pain  subscale of the  WOMAC OA Index has been 
validated  for use in patien ts w ith hip and/or knee 
OA [3-6]. WOMAC is available in both L ikert and 
10 cm VA scaled form ats and in  a large num ber of 
a lte rn a te  language translations. A lthough not 
recommended for use as a distinct pain scale, the 
AFI have been validated for use in hip and knee 
studies where the goal is to provide a weighted 
clin ical severity score in which scores for 
pain/discom fort, stiffness, maximum distance 
w alked and activities of daily living are summated 
in to  a single value [7, 8]. A sim ilar approach can be 
used w ith the WOMAC in  situations where a 
composite score (based on pain, stiffness and 
physical function) is required , using weights 
derived from the P a tien t Assessment of the 
Relative Im portance of Symptoms (PARIS) Sec- 
togram  [6]. The H ealth  Assessment Q uestionnaire 
(HAQ) [9] pain scale or the AIMS [10] or AIMS2 
[11] may be of lim ited value for studies focusing on 
a single joint, because they are appropriated for 
studies m easuring pain  severity in both the upper 
and lower extremities. Options for OA hand studies 
are  lim ited but early experience with the pain 
subscale of an instrum ent term ed the A ustralian/ 
C anadian (AUSCAN) O steoarthritis Hand Index 
has been favorable [12].
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P H Y SIC A L  F U N C T IO N
Physical function/disability  is usually m easured 
on a ra tin g  scale (Likert, VAS) which grades the 
perceived severity  or degree of disability in one or 
more ac tiv ities of daily living (e.g., s ta ir climbing, 
w alking, etc) [13]. The physical function subscale 
of the WOMAC index has been validated for use in 
patien ts w ith  h ip  and/or knee OA [3]. The index is 
available in  bo th  L ikert and 10 cm VAS scaled 
form ats and  in  a  large num ber of a lte rn a te  
language transla tions. A lthough not recommended 
as a d istinc t physical function scale, the AFI 
have been validated  for use in  hip and knee 
studies, w here the goal is to provide a weighted 
clinical severity  score in which scores for 
pain/discom fort, stiffness, maximum distance 
w alked and activ ities of daily living are summated 
in to  a single score [7, 8]. A sim ilar approach can be 
used w ith the  WOMAC by weighting and aggregat­
ing the pain , stiffness and physical function 
subscales using PARIS Sectogram  weights [6]. An 
AFI developed by Dreiser and colleagues contains 
10 questions directed a t functional disability in the 
hand [14]. E arly  experience w ith the  function 
subscale of the  AUSCAN O steoarthritis Hand 
Index has been favorable [12]. In studies m easuring 
physical d isability  in both the upper and lower 
extrem ities, th e  physical function subscale of the 
HAQ [9] or AIM S [10] (or AIMS2) [11] instrum ents 
is app ropriate.
formats th a t have been used successfully in past 
studies or should develop and validate new 
standardized questions.
N on -core se t m easures
H E ALTH -RELATED Q U A L IT Y  OF LIFE (h RQOl )  A N D  
U T IL IT Y  (U T ) M E A SU R E S
HRQOL and/or UT measures are increasingly 
being considered as very im portant components of 
the m easurem ent b a tte ry  for studies of 6 m onths or 
longer. They no t only allow m easurem ent of the 
p a tien t’s quality  of life or the utility  of their hea lth  
state , bu t also facilita te  pharmacoeconomic and 
cispsB-disease com parisons of outcome. There is 
relatively little  experience to date w ith these 
instrum ents (e.g., SF-36 [16], EuroQol [17], N otting­
ham H ealth  Profile [18], H ealth  U tilities Index [19], 
S tandard  Gamble [20], Time Trade Off [21], 
Category Scaling [22]) in  OA trials. However, 
because of th e ir po ten tial importance, use of 
HRQOL and/or U T measures is highly rec­
ommended in P hase 3 tria ls of 6 m onths or 
longer. I t  is expected th a t there will be improve­
m ent in our know ledge of the performance of one 
or more of these instrum ents, their role in Phase 3 
clinical tria ls  and  the relative im pact th a t  
in terventions have on different measures will 
evolve over the  nex t few years. Comparing 
different m easures in  the same tria l would be 
particu larly  useful.
P A T IE N T  GLOBAL A S S E S S M E N T
The p a tien t’s perception of the clinical severity 
of th e ir OA is usually assessed by a d irect question, 
e.g., ‘C onsidering all the ways your OA affects you, 
how would you ra te  your condition today?’ 
Suitable response scales could include the follow­
ing; L ikert—very poor, poor, fair, good, very good; 
or 10 cm horizontal VAS anchored to very poor 
(left hand  end) and very good (right hand  end). 
A lternatively , o r in addition , a t the end of the 
study a change in  score could be derived using a 
sim ilar question, e.g., ‘Considering all th e  ways 
you r OA -has affected you, how do you feel now 
com pared w ith  the beginning of the  study?’ 
Responses could be made on a L ikert scale, e.g., 
‘m uch b e tte r’, ‘b e tte r’, ‘no change’, ‘worse’, ‘much 
worse’. T here is currently no standard  question 
and no s tan d a rd  response format [15]. It should be 
noted th a t depending on the research hypothesis, 
there are  several ways of ph rasing the global 
question, e.g., m usculoskeletal condition , OA in 
the study knee , overall health , etc. Investigato rs 
should be guided by questions and response
P H Y S IC IA N  G LO BAL A S S E S S M E N T
The physician’s perception of his or her p a tien t’s 
OA can be based on a number of different 
variables, e.g., symptoms, signs, imaging, and, 
possibly, in  the fu ture , biologic m arkers. I t  is 
im portant to specify in the question or in 
accompanying instruction s which variables should 
be considered in m aking the assessment. Usually, 
this will be based on symptoms, and since the 
clinical encounter w ill likely be quite brief, the 
question should be phrased with respect to the day 
of assessment, e.g., ‘Considering all the ways OA 
affects you r patien t, how would you ra te  his o r her 
condition today?’ Suitab le  response scales could 
include the following: L ikert—very poor, poor, 
fair, good, very good; or 10 cm horizontal VAS 
anchored to  very poor (left hand end) and very 
good (right hand  end). A lternatively , or, in  
addition, a t end of study a change score can be 
derived using a sim ilar question, e.g., ‘Considering 
all the ways OA has affected your patient, how do 
you ra te  th e ir condition now compared w ith the
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beginning of the study?’ Responses could be made 
on a L ikert scale, e.g., m uch better , better, no 
change, worse, much. T here is currently  no 
standard  question and no standa rd  response 
format [15]. Investigato rs should be guided by 
questions and response form ats th a t have been 
used successfully in  past studies or should develop 
and validate  new standard ized questions. I t  should 
be noted th a t  depending on the research hypoth­
esis, there  are several ways of ph rasing the global 
question, e.g., m usculoskeletal condition, OA in 
study knee, overall hea lth , etc.
PE R F O R M A N C E -B A S E D  M E A S U R E S
M any perform ance based m easures are avail­
able, some of which a re  of dem onstrated reliability , 
validity and responsiveness [15,23]. Although 
providing num erical estim ates of performance, the 
clinical consequence to individual patien ts of any 
change for the  b e tte r or worse on such measures 
lacks clarity. As a consequence , while sometimes 
useful in certain  types of studies, they are not 
included in  the core set. M easu res th a t have been 
employed include: w alking distance , walk time, 
grip streng th  [23]. I t  is im portan t w ith these 
measures to use standa rd  techniques and to tra in  
assessors to acceptable levels of inter-observer 
reliability  [15].
E X A M IN A T IO N  B A S E D  M E A S U R E S
The clinical exam ination provides an  opportu­
nity to detect swelling (bony, soft tissue , effusion), 
crepitus, heat, range of movement, deformity, 
ligam entous laxity, range of movement (goniome­
ter, p lurim eter, in term alleo lar straddle, in ter­
condylar distance , heel to  bu ttock  test) [15, 23]. 
These assessm ents require standard  methods 
applied by tra in ed  assessors [15]. In general, as 
w ith perform ance-based m easures, changes for the 
better or worse occurring on these examination- 
based m easures lack  defined levels of clinical 
im portance to individual patients. They may be 
useful in some types of study bu t are not in  the core 
set.
M IS C E L L A N E O U S
‘Stiffness’ is a sense of resistance or decreased 
ease during active m ovem ent of the  joint. Some, 
but no t all, patients have difficulty differentiating 
between pain and stiffness. W hen stiffness is 
m easured in clinical tria ls, i t  is preferable to use 
the WOMAC [3-6] or API [7, 8] (depending on 
w hether a segr egated or aggregated stiffness score
is required) for hip and knee studies. The 
assessment of stiffness may be useful in  some types 
of studies but has n o t been validated  as an outcome 
in OA and is no t in  the core set.
‘Inflamm ation’ has  no t been extensively studied 
in OA clinical tria ls . As a result, the validity , 
reliability  and responsiveness of inflammatory- 
based measures rem ain  in  doubt. They may be 
useful in some types of study bu t are no t validated 
in  OA and are no t in  the core set.
‘Number of “F la res’” and the occurrence of 
disease ‘flares’ in OA lacks precise definition and 
as a resu lt is difficult to  reliably identify. This 
variable has no t been included in the core set.
‘Time to su rgery’ is influenced by a large number 
of factors, independent of the study intervention , 
e.g., the dynamics of scheduling operating time. 
A lthough th is va riab le  may be useful in some 
studies it has no t been validated  as an outcome in 
OA and is no t included in the core set.
‘Analgesic consum ption’ is an  im portan t source 
of cointervention; however, the precision with 
which analgesic consum ption can be monitored, 
particularly  in long-term  studies, is suboptimal.
R E S P O N S E  CR IT E R IA
Response c rite ria  may apply to groups of 
patients or individuals. The definition of a 
minimum clinically im portan t difference between 
two groups of p atien ts exposed to different 
interventions, depends on a num ber of factors 
relating to p a tien t characteristics, disease fea­
tures, the na tu re  of the in terventions, and the 
prim ary outcome m easu re selected. It is difficult to 
determine estim ates of minimum clinically im port­
an t differences for OA clin ical studies [16], A t the 
present time th ere  are  no standa rd  crite ria  for 
defining the success, o r failure , of treatm ent in 
individual OA p atien ts in  a clinical tria l.
Sum m ary
The core set of outcom e m easures for OA clinical 
tria ls requires m easu rem ent of pain , physical 
function , pa tien t global assessment, and imaging 
procedures for studies of 1 year or longer. 
Depending on the  research  hypothesis, one of 
several existing va lidated  m easures can  be selected 
for evaluating change in  each of the four domains.
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A ppendix III 
R adiographic im aging  tech n iq ues
J. C hristopher B uckland-W right, 
W illiam  W. S co tt Jr, Charles P eterfy
The reproducibility of the  radiographic technique 
is dependent on contro l of a num ber of technical 
issues. The discussion below presents a few 
methods th a t a ttem pt to standardize m any of the 
relevant techniques. O ther m ethodologies exist. 
Such standard ization is essential in  o rder to 
reliably assess sequential changes in  jo in t an a t­
omy. The m ost consistent results will be obtained 
by carefully adhering to standardized radiographic 
procedures, based on published , validated data. 
Quality control of personnel and procedures is 
essential for m ulticen ter or com parative studies. 
The m ethods described below require no special 
facilities o ther th an  fluoroscopy.
Hip jo in t
P A T IE N T  PO SIT IO N
A nteroposterior radiographs are obtained w ith 
the patien t standing. W eight bearing compresses 
the jo in t space to its most narrow  configuration 
[I, 2]. The feet are positioned in in te rna l ro ta tio n  
w ith the toes subtending an angle of 15 +  5° [3]. A 
foot map, used to facilitate repositioning a t 
successive visits may improve m easurem ent repro­
ducibility. However, a foot map alone does not 
assure identical repositioning as the body can
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torque abou t the knee. Reproducibility requires 
m ultipoint control.
X -R A Y  BEAM  A L IG N M E N T
W ith a focus to film distance of 100 cm, th e  X-ray 
beam m ust be horizontal and perpendicular to the 
film. W hen the X-ray beam is centered on the 
superior aspect of the symphysis pubis to  rad io ­
graph both hips together. There is less accuracy 
and precision in the jo in t space w idth m easu re­
ment th an  when the central ray of the X-ray beam 
is aligned w ith the center of each femoral head 
[3-5].
R A D IO G R A P H IC  M A G N IF IC A T IO N
In view of the  variable distance between hip 
jo in t and film among individuals, variable radio- 
graphic m agnification can occur. A m etal sphere of 
known size (10 ram), mounted in  a sem i-radiolucent 
m aterial and taped to  the skin over the  g reater 
trochanter can be used to correct for radiographic 
m agnification a t the joint. This is needed only if 
significant w eight change has occurred betw een 
visits to a lter this distance. An increase in the 
number of study patients may be needed w ithout 
correction for radiographic m agnification.
K nee joint: tibio fem oral com partm en t
S T A N D IN G  FU LLY  E X T E N D E D  V IE W  [6-9]
Patient position
Separate anteroposterior radiographs of each 
knee are obtained w ith the patien t standing  and 
the w eight equally distributed to both  feet. The 
knee m ust be in full extension, w ith the back of the  
knee as near as possible to the vertical cassette. 
W ith the  aid of fluoroscopy, the lower limb is 
ro tated  so th a t the tib ial spines appear cen trally  
placed re la tive  to  the femoral notch. A foot map 
may be used to facilitate repositioning a t  succes­
sive visits.
X-ray beam alignment
The central ray o f the X-ray beam is centered on 
the jo in t space and inclined downward to ensure  
that the medial tibial plateau is parallel to the  
X-ray beam.
Correction for radiographic magnification
It is only necessary to correct for radiographic 
m agnification if the distance between the back of 
the knee and the vertical cassette is altered in  
subsequent exam inations (see above).
S T A N D IN G  PARTIALLY FL E X E D  V IE W  [3, 10, 11] 
Patient position
Separate anteroposterior radiographs of each 
knee are obtained w ith the p a tien t standing. Each 
knee is flexed un til the tib ial p lateau is ho rizontal 
rela tive to the floor, and therefore parallel to  the 
cen tral X-ray beam which is oriented perpendicu­
lar to the X-ray film. The degree of flexion varies 
among individuals due to  differences in the angle 
of inclination of the tib ia l plateau. The precise 
inclination  is obtained w ith the aid of fluoroscopy. 
W ith the heel fixed, the foot is in ternally  or 
externally ro tated  u n til the  tib ial spines appear 
centrally  placed relative to the femoral notch. A 
foot map may be used to facilita te  jo in t reposition­
ing a t successive visits; patien ts are provided w ith 
hand supports to  ensure th e ir stability.
X-ray beam alignment
W ith a focus to film distance of 100 cm, the X-ray 
beam, m ust be horizontal to the floor, perpendicu­
la r to the film, and aligned w ith the center of the 
joint.
Radiographic magnification
Correction for the effect of radiographic magnifi­
cation includes a m etal sphere of known size 
(5 mm) taped above the head of the fibula. The 
dimension of this ball is used to determ ine the 
degree of radiographic m agnification a t the  joint. 
This is only needed if there is varia tion in knee to 
film distance between visits.
Published studies may guide the calculation of 
num bers needed for a structu re  modifying drug 
tr ia l [12,13].
W rist and hand joints
P A T IE N T  P O SIT IO N
Dorsopalmar radiographs of the wrist and hand 
are obtained with the fingers held together and in  
line with the axis of the wrist and forearm, since  
spreading the fingers may alter joint alignm ent 
and lead to an incorrect assessm ent of jo int space
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loss. A hand  map may be used to facilita te  precise 
reposition ing  a t  successive visits.
X -R A Y  B EA M  A L IG N M E N T
The tube is positioned a t a focus to film distance 
of 100 cm. The cen tral ray of the X-ray beam  is 
centered  vertically  a t the head of the  th ird  
m etacarpal bone.
Landm arks for m easurem ent
J O IN T  S P A C E  W ID T H  OR IN T E R B O N E  D IS T A N C E
Jo in t space narrow ing correlates w ith cartilage 
th ickness in  OA [13]. Because cartilage loss in OA 
is no t uniform  across the jo in t [14], minimum jo in t 
space w idth is the appropriate m easurem ent [15].
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Appendix IV 
M agnetic resonan ce im aging  
C harles Peterfy
MRI is a  relatively  new imaging technique, bu t its 
u tility  for evaluating  structu ra l derangem ents of 
d iarth rodia l jo in ts, such as meniscal tears, cruci­
ate ligam ent rup tu res  and bone injuries is already 
well-established in  clinical practice. Recent tech­
niques show promise for serial quantification of 
the volume, th ickness, geometry and composition 
of a rticu la r cartilage [1]. These techniques are so 
new, however, th a t only a few have been validated 
cross-sectionally and  none has been assessed 
longitudinally.
P ossib le u ses o f MRI
MRI is uniquely suited for monitoring s tru c tu ra l 
changes in  OA, for i t  is capable of directly 
examining all com ponents of the jo in t sim ul­
taneously. In addition  to delineating anatomy , 
however, MRI shows promise for quantification of 
com positional and functional param eters of a r ticu ­
la r tissues.
M E A S U R IN G  CARTILAG E M ORPHOLOGY
Fat-suppressed , T l-weighted three-dim ensional 
(3D) grad ien t echo im aging can delineate a rticu la r
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cartilage morphology in the knee [2-6]. and fingers 
[7, 8]. In a recen t study of 48 knees [4, 5], th is 
technique dem onstrated a sensitiv ity  of 86% and 
specificity of 97% for identifying cartilage defects 
which were visible on arthroscopy. The surface 
topography of individual cartilage plates as well as 
contact-areas between opposing a r ticu la r surfaces 
can be mapped [9]. A ccurate m easurem ent of 
cartilage th ickness requires spatia l resolution 
better than  10% of th a t thickness (e.g., 200 pm 
in-plane resolution for a 2-mm th ick  cartilage). 
This is possible w ith conventional MRI, but 
generally beyond w hat is performed during rou tine 
clinical imaging. Considerably less resolution is 
required to quantify cartilage volume in  the knee 
[3] or the m etacarpophalangeal [7]. V alidation of 
the longitudinal reproducibility  of cartilage vol­
ume m easurem ent and its sensitivity  to  volume 
changes will no t be available for several years.
M E A S U R IN G  CARTILAG E Q U A L IT Y
MRI may be able to probe the composition of 
a rticu lar cartilage. Areas of m atrix  loss and 
increased w ater content in  the cartilage may cause 
focal signal in tensity  a lterations and it  may be 
possible to map the fractional w ater conten t of 
normal and abnorm al cartilage [10]. This tech­
nique, however, must aw ait fu rth e r optim ization 
and validation. O ther param eters of a rticu la r 
cartilage in tegrity , such as w ater diffusivity 
[11,12], proteoglycan conten t [18,14], collagen 
content and organization [15,16] and compressive 
stiffness, may be m easurable in  the future. Should 
these advancem ents occur, MRI may replace 
radiography as the standard  im aging method.
E V A L U A T IN G  OTHER A R TIC U L A R  T IS S U E S  IN  OA
MRI also provides inform ation about the 
severity of synovial inflammation, the in tegrity  of 
lA ligam ents and menisci, the sta tu s  of peria rticu ­
la r muscles and tendons, the presence of sub a rtic­
ular bone m arrow edema, and the morphology of 
the a rticu la r bones (including the  size, num ber and 
location of osteophytes and subchondral cysts) 
[17, 18].
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A ppendix V
M ethods for co llec tio n  and storage o f body  
fluid sam ples
S tefan  L ohm ander
M ost of the published studies on m arkers have 
focused on analyzing cartilage-derived products; 
however, m arkers of th e  m etabolism  of o ther jo in t 
tissues, such as m eniscus, synovium and bone 
should also be considered. In  addition , m arkers of 
genetic susceptibility , and cellular activity  or 
o ther processes th a t  m ight be re levant to the 
pathogenesis of OA should also be given consider­
ation. The following represents an update and 
sum m ary of the previously published guidelines for 
sam ple collection and sto rage [1].
however, time of collection m ust be recorded. 
Specimens should be chilled to  4°C and clarified in 
a clinical centrifuge w ith in  4 h. Approximately 
25 ml should be aliquoted into a 50 ml polypropy­
lene tube with a screw cap. The specimen should 
be clearly labeled and stored frozen (see below).
BLO OD
Approximately 25 ml blood should be taken  from 
the an tecubital vein after fasting, and collected in  
either plain , heparin  or EDTA tubes. The choice of 
tubes is dictated by th e  effect either may have on 
the m arker assays eventually  chosen. For example, 
some heparin  sam ples may contain interfering 
substances in assays for carbohydrate epitopes on 
chondroitin sulfate or k e ra tan  sulfate. The samples 
should be kept a t 4°C un til plasm a (or serum) can 
be prepared by centrifugation in  a clinical 
centrifuge, preferably w ithin 4 h. The clarified 
plasma (or serum) should be aliquoted into 
‘Eppendorf-type’ tubes (1 ml per tube). The tubes 
should be clearly  labeled and stored frozen (see 
below). A lthough th e  collection of serum  may be 
simpler, it was argued  th a t plasma samples could 
be preferred for some m arker assays, and may also 
be a source of DNA for analysis of genetic 
susceptibility. If analysis of genetic m aterial is 
planned as a  specific targe t, p reparation and frozen 
storage of buffy coa t is recommended.
Sam ple co llection
Three biological fluids are potential sources for 
m arkers in OA studies: urine , blood and synovial 
fluid. G uidelines for collecting these samples 
should minimize m anipulations a t the site of 
collection. W hile th is probably does not p resent 
difficulties w ith u rine  and blood, some special 
problem s are noted below for synovial fluids. In 
general, samples should be processed so th a t they 
may be frozen a t the  collection site in  small 
screw-cap tubes designed for storage. A dditional 
m anipulations, involving dilution, aliquoting, 
sto rage and shipping of collected specimens to 
labo ra tories perform ing the m arker assays would 
be best accom plished by a referral center w ith 
appropriate facilities and trained  personnel. Due 
to  th e  possibility of circad ian  variations in  m arker 
levels, care should be taken  to collect samples a t 
the same time of the  day in  longitudinal studies.
U R IN E
Specimens should be obtained as the second void 
in the morning; spot sam pling would be acceptable;
S Y N O V IA L  F L U ID
Synovial fluid should, if a t  all possible, be 
collected undilu ted , i.e. w ithout lavage. In  cases 
w ithout jo in t sw elling and exudate , synovial fluid 
volumes will be small. Up to 10 aliquots of 1 ml 
should be d istribu ted  into 1.5-2.0 ml ‘Eppendorf- 
type’ tubes. Any rem aining larger volumes can be 
stored in  larger size aliquots. The tubes should 
contain EDTA in appropriate amounts to prevent 
fibrin clot form ation. The tubes should be suitable 
for centrifugation in  a h igher speed centrifuge, 
such as a microfuge. The higher speeds are 
required to rem ove cells and debris from the 
samples w hich are frequently very viscous. 
Samples should be kept a t 4°C and centrifuged 
w ithin 4 h. C larified supernatan ts should be 
transferred  into appropriate sized (2 or 20 ml) 
polypropylene tubes w ith screw caps. The 
specimens should be clearly labeled and stored 
frozen, preferably a t —70°C, prior to shipm ent to a 
referral center. A recom m endation for sample 
centered inform ation th a t should always be 
available , to com plem ent the core clinical data , is 
included (Table I).
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T a b le  I.Sample centered data to be collected with all specimens 
U r in e
F ir s t  or  s u b s e q u e n t  a .m . v o id , o r  o t h e r  t im e  o f  ‘s p o t ’ 
sa m p le
S eru m
S ite  o f  v e n e p u n c tu r e
( if  n o t  a n te c u b ita l  v e in ,  w h e r e )
S y n o v ia l  f lu id
T o ta l v o lu m e  w ith d r a w n
L a v a g e  u s e d  (y e s /n o )— i f  y e s , v o lu m e
F o r  a l l
D a te  a n d  t im e  sa m p le  w a s  ta k e n  
H a v e  g u id e l in e s  fo r  h a n d lin g  a n d  s t o r a g e  b e e n  
a d h e r e d  to
( i f  n o , p r o v id e  d e ta i ls )
A t  w h a t  te m p e r a tu r e  h a v e  sa m p le s  b e e n  s to r e d
Referral co llection  cen ters
The collection center should have defined 
protocols for thawing , diluting, aliquoting, coding 
(consider bar coding), freezing and  sto ring the 
specimens received. Accompanying clinical and 
chemical data , required by the clinical protocol 
and any accessory inform ation , would be encoded 
into a data  bank system. This center would also 
distribute appropriate sample sets to labo ratories 
conducting the  m arker assays. R esults of the 
assays would be sent to  th is center and entered 
into the  data  bank. For synovial fluid samples, 
volumes will often be small, and a minimum set of 
aliquots could be prepared based upon a 1 ml 
volume. A m easured volume, e.g. 1 ml, should be 
diluted w ith four volumes of physiological saline
supplemented w ith either EDTA or heparin 
depending upon the original choice. A liquots of 
250 pi should then  be distributed in to  small 
volume, coded polypropylene tubes w ith 0-rings 
and screw caps. This dilution and sampling 
protocol will yield around 20 identical samples for 
each original synovial fluid sample. For synovial 
fluid samples w ith larger volumes, we recommend 
preparing a t least one such set of 20 identical 
standards, and then  sto ring the rem ainder of the 
1:4 diluted samples in larger aliquots (5 or 10 ml) in 
appropriate tulles for long-term storage. All 
storage should be a t -70°C.
F reezing and shipping
Freezing and thaw ing of samples should be 
minimized, as some m arkers may loose antigenicity  
in the process. S torage a t -70“C is p referable if 
such freezer capabilities are available a t th e  site of 
sample collection. In th is case, the sam ples can be 
stored for long periods of time. If  this option is not 
available , samples can be stored a t -20°C in a 
freezer which does no t have an  autom atic defrost 
cycle. Samples collected during a week should then 
be sent on dry ice to a referral collection center.
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Abstract
Objective. T o provide recoininendations for the core outcom e domains that should be considered by investigators conducting clin ical trials 
o f  the efficacy and effectiveness o f  treatments for chronic pain. D evelopm ent o f a core set o f  ou tcom e domains would facilitate com parison  
and pooling  o f  data, encourage m ore com plete reporting o f  outcom es, sim plify the preparation and review  o f  research proposals and 
manuscripts, and allow  clin icians to make informed d ecisions regarding the risks and benefits o f  treatment.Methods. Under tlie auspices o f  the Initiative on  M ethods, M easurem ent, and Pain A ssessm ent in Clinical Trials (IM M PA C T), 27  
specialists from academ ia, governm ental agencies, and tlie pharmaceutical industry participated in  a consensus m eeting and identified core  
outcom e dom ains that should be considered in clin ica l trials o f  treatments for chronic pain.Conclusions. There was a  consensus that chronic pain clin ical trials should assess outcom es representing six core domains: (1 ) pain, (2) 
physical functioning, (3 ) em otional functioning, (4) participant ratings o f  im provement and satisfaction witli treatment, (5) sym ptom s and
* Corresponding author. Tel.: + 1-206-616-2626; fax: + 1 -206-543-2958 .
E-mail address: turkdc@u.washington.edu (D C. Turk).
0304-3959(520.00 ©  2003 International Association for the Study o f  Pain. Published by Elsevier B .V . A ll rights reserved. 
doi;10.10l6/j.pain.2003.08.001
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adverse events, (6) participant disposition (e.g. adherence to the treatment regim en and reasons for premature withdrawal from  tlie trial). 
Although consideration should be given to the assessm ent o f each o f  these domains, tliere may be exceptions to tlie general recom m endation  
to include all o f  tliese domains in chronic pain trials. W hen tliis occurs, the rationale for not including domains should be provided. It is not 
tlie intention o f  tliese recom m endations tliat assessm ent o f  the core dom ains should be considered a requirement for approval o f product 
applications by regulatory agencies or that a treatment must demonstrate statistically significant effects for all o f  the relevant core dom ains to 
establish ev id en ce o f  its efficacy.
©  2003  International A ssociation for tlie Study o f  Pain. Published by Elsevier B .V . A ll rights reserved.
K ey w o rd s :  Chronic pain; Clinical trials; Assessment; Outcomes; Quality o f  life; Physical functioning; Emotional functioning; Adverse events; Global ratings
1. Introduction
Variability among clinical trials in outcome assessments 
has impeded evaluations of the efficacy and effectiveness of 
treatments for chronic pain, and the use of different outcome 
domains precludes meaningful comparisons among studies. 
One way to facilitate such evaluations would be through the 
use of a standard set of outcome domains. Although 
investigators may wish to augment a core set of domains 
with others that are specific to die situation or treatment 
being studied, use of a core set of outcome variables among 
studies would permit comparisons among different samples, 
treatments, and settings.
Development of a core set of outcome domains and 
measurement procedures would facilitate comparison and 
pooling of data while leaving investigators free to augment 
die core set with others of their choice. In addition, a core set 
of domains would encourage more complete investigation 
and reporting of relevant outcomes, so that investigators do 
not simply present a single outcome while ignoring others. 
Another advantage is that it would encourage development 
of cooperative multicenter projects, in which different 
centers agree to assess the core domains, in addition to any 
measures selected to evaluate specific research questions. A 
standard set of outcome domains would simplify die process 
of designing and reviewing research proposals, manuscripts, 
and published articles. Finally, published results of clinical 
trials with common outcome domains will allow clinicians to 
make more informed clinical decisions for each patient 
regarding the optimal treatment, especially with respect to its 
risks and benefits. Once core outcome domains for clinical 
trials are identified, the next step would be to select measures 
that meet appropriate psychometric standards (i.e. reliability, 
validity, responsiveness, appropriate, normative data).
To address the identification of core outcome domains, 
the Initiative on Methods, Measurement, and Pain Assess­
ment in Clinical Trials (IMMPACT, additional information 
concerning IMMPACT and its meetings can be found at 
immpact.org) convened a meeting to develop consensus 
recommendations for chronic pain clinical trials. There was 
agreement that the identification of specific measures would 
occur at a subsequent meeting. Other initiatives provide 
precedents for this undertaking, including Outcome 
Measures in Rheumatoid Arthritis Clinical Trials (OMER­
ACT; Bellamy et al, 1997) and World Health Organization/
International League of Associations for Rheumatology 
(WHO/ILARS; Brooks and Hochberg, 2001) in rheumatol­
ogy, European Organization for Research and Treatment of 
Cancer (EORTC, Aaronson et al, 1993) and the Research 
Network of the European Association of Palliative Care 
(Caraceni et al, 2002) in oncology, and an international 
consortium of back pain researchers (Deyo et al.. 1998). 
Although these other disease-specific initiatives were used 
to inform the discussion, the objective of the IMMPACT 
meeting was to develop a consensus on outcome domains 
that would transcend specific chronic pain syndromes. Our 
goal in this paper is to present the consensus recommen­
dations from the first IMMPACT meeting for a core set of 
outcome domains that should be considered for all clinical 
trials of treatments for chronic pain.
2. Methods
2.1. Sponsorship
Abbott Laboratories, AstraZeneca, Elan Pharmaceuti­
cals, Endo Pharmaceuticals Inc., GlaxoSmithKline, Novar­
tis Pharmaceuticals, Ortho-McNeil Pharmaceutical Inc., 
Pfizer, and Purdue Pharma provided unrestricted edu­
cational grants to the University of Rochester Office of 
Professional Education to support a meeting and manuscript 
preparation.
2.2. Procedure
A  meeting consisting of 27 people representing acade­
mia, governmental agencies, and the pharmaceutical 
industry was held on November 1 -2,2002. The participants 
attending the meeting were selected to represent health care 
disciplines that cover chronic pain broadly defined and 
included anesthesiology, biostatistics, clinical pharma­
cology, epidemiology, geriatrics, internal medicine, neurol­
ogy, nursing, oncology, pediatric pain, physical medicine 
and rehabilitation, psychology, and rheumatology; all have 
research, clinical, or administrative expertise relevant to 
evaluating chronic pain treatment outcomes. In addition, 
representatives from the pharmaceutical industry who are 
engaged in chronic pain clinical trials and an attorney were 
included to provide specific expertise.
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The process of the consensus meeting was semi­
structured, with the first two authors leading discussions. 
Prior to the meeting, all participants were provided copies of 
a recent edited volume on pain assessment (Turk and 
Melzack, 2001), as well as four published clinical trials tliat 
are representative of chronic pain trials. Outcomes included 
in these studies were used to illustrate the diversity of 
domains examined in recent trials. The list of various 
domains generated by the participants was discussed and 
consensus was reached based on the results of the discussion 
and a formal vote.
The first two authors facilitated the consensus meeting 
and prepared the first draft of this paper. They were 
responsible for revising the manuscript and integrating the 
comments of the other authors. All authors reviewed the 
final draft and endorsed its publication.
3. General issues
To demonstrate the benefits of treatment, investigators 
must decide the appropriate endpoints for establishing both 
the statistical significance and the clinical importance of the 
effects of treatment. In a clinical trial of a treatment for 
chronic pain, pain reduction and safety are necessary 
outcome variables but they may not be sufficient for a 
comprehensive evaluation of the overall benefit or harm 
of treatment (Dionne and Witter, 2(X)3). The complexity of 
cliroiiic pain and its negative impact on diverse aspects of 
function is well established (e.g. Melzack and Wall, 1982). 
Thus, evaluation of the effectiveness of any treatment for 
chronic pain requires consideration of the assessment of 
multiple outcome domains to adequately characterize the 
impact of the intervention. Adverse events resulting firom 
the treatment might outweigh the benefits of pain reduction, 
and pain reduction alone does not guarantee that physical or 
emotional functioning will improve.
The domains of importance in a clinical trial should 
match Hie purpose of the study, measure positive and 
negative outcomes of treatment, and be appropriate for the 
chronic pain syndrome studied and the specific character­
istics of tlie sample (e.g. geriatric participants). Central 
issues involve the identification of outcome domains that are 
clinically meaningful and for which there are measures that 
are responsive and provide a comprehensive yet efficient 
evaluation of treatment response (Bellamy et al,, 1997; 
Revicki and Ehreth, 1997).
4. Core outcome domains for chronic pain clinical trials
The authors recommend that each of the six core 
outcome domains listed in Table 1 should be considered 
in the design of all clinical trials of the efficacy and 
effectiveness of treatments for clironic pain. If one or more 
of these domains is not included in such a chronic pain
Table 1
Core domains for ciinical trials o f  chronic pain treatment efficacy and 
effectiveness
Pain
Physical functioning 
Emotional functioning 
Participant ratings o f global improvement 
Symptoms and adverse events
Participant disposition (including adherence to the treatment regimen and 
reasons for premature withdrawal from the trial)
clinical trial, the reasons for the exclusion should be justified 
a priori. Importantly, it is not the intention of these 
recommendations that assessment of these core domains 
should be considered a requirement for the approval of 
product applications by regulatory agencies or that a 
treatment must demonstrate statistically significant effects 
for all of the core domains to establish evidence of its 
efficacy. Rather, these recommendations are presented in an 
effort to promote collection and publication of standardized 
outcomes, which will allow for improved evidence-based 
comparisons and meta-analyses of chronic pain treatments. 
As noted above, there will be clinical trials in which these 
core assessment domains wUl require modification, for 
example, clinical trials in individuals with mild pain (in 
whom the impact of treatment on physical function and 
emotional distress may be less relevant than it is in patients 
with moderate or severe pain), single-dose studies in 
participants with a chronic pain syndrome, and clinical 
trials in the cognitively impaired and in infants and children.
Oiu* recommendations are most applicable to clinical 
trials of treatments for chronic pain designed to evaluate 
efficacy or effectiveness, for example, what are termed 
Phase III and IV trials within the regulatory context (United 
States Department of Health and Human Services, 1997). 
These recommendations are made with die assumption that 
clinical trials will be conducted according to the principles 
of good clinical practice presented in the E6 Good Clinical 
Practice Consolidated Guidance of the International Con­
ference on Harmonisation of Technical Requirements for 
Registration of Pharmaceuticals for Human Use (United 
States Department of Health and Human Services, 1996).
4.1. Pain
There are several dimensions of pain that can be assessed 
in a clinical trial (e.g. intensity, location, specific descriptors 
and qualities). Most chronic pain clinical trials will also 
assess pain history, but these variables are more likely to be 
considered baseline characteristics or covariâtes.
It has often been assumed that chronic pain is highly 
associated witli alterations in emotional and physical 
functioning and that reduction in pain will inevitably lead 
to improvement in function and satisfaction with treatment. 
This is not necessarily tlie case, and in many studies, pain 
and functioning are only modestly related. Moreover,
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changes in pain severity may have only a variable 
relationship with participants’ ratings of improvement and 
satisfaction (Dougados et al., 2002; i-arrar et a l, 2001; 
Dawson et al., 2002). Such data indicate that even though 
pain is typically considered the primary outcome in 
evaluating pain treatments, it is important to consider 
other outcomes in clinical trials.
4.2. Physical functioning
In addition to relieving clinical symptoms and prolong­
ing survival, the objectives of health care intervention 
include improvement of functioning (Revicki et a l, 2000). 
Thus, Üiere is a need to assess multiple domains of 
functioning, including behavior, mood, and satisfaction 
(Ware, 1984; Revicki, 1993). Quality o f life (QOL) is a 
term that refers to how a person feels and how he or she 
functions in daily life. Concerns with the all-encompassing 
nature of QOL in the evaluation of treatment outcomes 
have led a number of investigators to use a more 
circumscribed construct, health-related quality o f life 
(HRQOL). HRQOL refers to those domains that are 
specifically related to health and that can be potentially 
influenced by the healthcare system (Varni et al, 1999; 
Seid et a l , 2000). HRQOL outcomes are especially 
important for evaluating the impact of treatment on chronic 
diseases for which cure is not possible and therapy may be 
prolonged. Moreover, especially when treatment extends 
over long periods, it is critical to examine whether the 
benefits of symptom reduction are compromised by 
reductions in QOL resulting from adverse effects of 
treatment.
Several authors have argued that the assessment of QOL 
and HRQOL is problematic because of tlie lack of clear 
definitions and shared theoretical frameworks, which makes 
it difficult to determine whether a given scale is a valid 
measure (Faden and LePlege, 1992; Celia and Bonomi, 
1995). The consensus of the authors is that two central 
components of existing HRQOL instruments, physical 
functioning and emotional functioning, are core domains 
that should be considered in all clinical trials of chronic pain 
treatments. This recommendation is supported by the results 
of studies in which exploratory and confirmatory factor 
analyses were used to identify the variables needed to 
comprehensively assess chronic pain participants, which 
suggested that three relatively independent domains—pain 
severity, physical functioning, and emotional functioning— 
are required to capture the multidiniensionality of the pain 
experience (Mikail et al, 1993; De Gagné et a l. 1995; 
Holroyd et al, 1999).
Measures of physical functioning evaluate diverse 
aspects of a participant’s life, including the ability to 
carry out such daily activities as household chores, 
walking, work, travel, and self-care, as well as strength 
and endurance. A major decision to be made in assessing 
the impact of a treatment on physical functioning involves
whether a generic or a disease-specific measure will be 
used (Stucki et al, 1995; Gruxatt et al., 2001). Disease- 
specific measures are designed to evaluate the impact of a 
specific condition (e.g. ability to wear clothing in 
participants with postherpetic neuralgia). Such specific 
effects of a disorder may not be assessed by a generic 
measure, and disease-specific measures may therefore be 
more likely to reveal clinically important improvement or 
deterioration in function that is a consequence of treatment. 
In addition, responses on disease-specific measures wiU 
generally not reflect the effects of co-morbid conditions on 
physical functioning, which may confound the interpret­
ation of change occurring over tlie course of a trial when 
generic measures are used. Generic measures, however, 
make it possible to compare the physical functioning 
associated with a given disorder and its treatment with 
those of different conditions (Dworkin et al, 2001). Thus, 
the use of disease-specific and generic measures in 
combination facilitates the achievement of both sets of 
objectives (Patrick and Deyo, 1989).
Different levels of analysis can be used to conceptu­
alize the core outcome domain of physical functioning. 
For example, activities of daily living such as performing 
self-care behaviors (e.g. bathing and dressing) can be 
distinguished from social-role functioning. The consensus 
of die meeting was that these two levels of activities 
should be differentiated with activities of daily living 
being more fundamental than engaging in social activi­
ties. Consequently, tliere was agreement that the effect of 
the treatment on the ability of the participant to perform 
specific physical tasks or the reduction in the interference 
of the pain in the participant’s ability to engage in 
routine, daily physical activities should be treated as a 
core domain, whereas the impact of treatment on 
alteration in social functioning was considered a sup­
plemental domain.
4.3. Erno tional functioning
The results of numerous studies suggest that chronic pain 
is often associated with emotional distress, particularly 
depression, anxiety, anger, and irritability (e.g. Fernandez 
and Turk, 1995; Banks and Kerns. 1996; Robinson and 
Riley. 1999). Emotional functioning as reflected in 
emotional distress, is not intended to be synonymous with 
a psychiatric diagnosis or disorder, but is rather meant to 
refer to distressed mood more generally. The consensus of 
the participants was tliat the assessment of emotional 
functioning should be considered a core outcome in chronic 
pain clinical trials. Although it is difficult to interpret 
changes in emotional functioning because of the many 
factors that contribute, this domain is central in people’s 
assessments of their well-being and satisfaction with life 
and the authors recommend that it should be considered a 
core outcome domain in clinical trials of treatments for 
chronic pain.
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4.4. Participant ratings o f global improvement 
and satisfaction with treatment
Assessments of individual outcome domains such as pain 
and physical and emotional functioning may not adequately 
characterize the participant’s expectations about the treat­
ment, overall assessment of treatment, and the mean­
ingfulness to the participant of any improvement (or 
worsening). Global evaluations by participants in clinical 
trials of tlie benefits of treatment reflect not only the 
magnitude of the changes in these outcomes and feelings 
about treatment delivery, but also the personal importance 
that these outcomes have for participants. Such perceptions 
of the importance of treatment-associated changes often 
differ considerably from those of health care professionals 
(Lipton and Stewart, 1999), and the value and significance 
of therapeutic changes differ greatly among participants and 
are important determinants of their treatment satisfaction.
The use of participants’ overall evaluation of treatment in 
clinical trials is controversial. A substantial amount of 
confusion about this group of outcomes is generated by 
vastly different meaning applied to terms such as ‘patient 
satisfaction’ and ‘impression of change’. In addition, many 
such assessments are based on rating a single item, and it is 
not possible to establish the internal consistency of one 
rating. In addition, global impressions of improvement may 
fail to detect important changes (e.g. Just et al., 1999). 
Furthermore, the judgment of change requires participants 
to assess both their present and initial state and then perform 
what may be an unreliable mental subtraction; because 
participants may be unable to recall their initial state, their 
ratings may be based on an ‘implicit theory’ of change 
beginning with their present state and working backward 
(Ross, 1989). However, if a treatment is associated with 
severe adverse effects, the participant may not need to 
remember baseline pain to rate satisfaction with treatment. 
In addition to problems of memory recall, participants’ 
global impressions may be influenced by systematic biases 
such as the desire to please health care providers (e.g. 
demand characteristics). Participants’ efforts to comply with 
their perceptions of provider expectations might also 
contribute to global judgments beyond the actual balancing 
of perceived benefits against accompanying negative 
effects. Despite the necessity for care in the use of 
participant global assessments, the results of recent research 
provide support for their validity (e.g. Fischer et al., 1999; 
Collins et al.. 2001; Farrar et al., 2001).
Ultimately, participants decide whether the positive 
attributes of a treatment outweigh its negative aspects, and 
this is an important determinant of whether they adhere to 
and continue with treatment. Willingness to continue with 
the treatment regimen may be viewed as a gross indication 
of participant satisfaction. A more systematic approach is to 
ask participants to rate their degree of satisfaction. Such 
ratings permit a range of satisfaction beyond the dichot- 
omous behavior of withdrawal from a protocol. Participant
ratings of improvement and satisfaction with treatment 
provide unique information in outcomes assessment in 
clinical trials because they may allow an integration of the 
benefits of treatment and adverse events and other costs 
from within tlie participant’s personal perspective. The 
authors therefore recommend that at least one rating of 
global improvement should be considered for inclusion in 
all chronic pain clinical trials, but must be carefully 
constructed to capture the relevant data.
4.5. Symptoms and adverse events
Many participants will experience symptoms and adverse 
events associated with their illness and pharmacologic 
treatment. The huportance of monitoring adverse events 
has long been recognized as an essential component of all 
therapeutic clinical trials (Anderson and Testa, 1994). 
Therapies, such as the dmgs that relieve pain, have a variety 
of effects, and these cannot only cause discomfort but also 
may potentially impair physical and emotional function and 
exacerbate co-morbid symptoms, which tliereby may 
potentially offset the therapeutic benefit (Croog et al.. 
1986). Max and Task a (1991) have noted that common 
analgesic adverse events (e.g. gastrointestinal distress, 
sedation, depression) can limit the dosage that can be 
realistically prescribed. Moreover, side effect burden plays 
an important role in treatment adherence (Anderson et al., 
1999). Participants may view adverse events as sufficiently 
noxious to discontinue treatment or limit dosage, and the 
overall benefit of treatment may therefore be reduced. A 
major challenge in developing analgesic drugs is determin­
ing an optimal dosage (i.e. one that minimizes adverse events 
and maximizes pain relief and functional improvement).
The onset of new diseases and initiation of new treatments 
during a clinical trial complicates assessments of symptoms 
and adverse events. When initiated during a trial, concomi­
tant treatments (e.g. drugs, physical therapy, psychological 
therapy, nerve blocks) are often protocol violations. 
Participant disease is a baseline characteristic or covariate 
when present at the beginning of a trial but is an adverse event 
when it emerges or worsens. The risk of addiction has 
attracted considerable attention in the evaluation of analgesic 
drugs. Addiction is a neurobiologie disease, and if it occurs 
during a trial it should be considered an adverse event but 
when it is present at the beginning of a trial it is a baseline 
characteristic. As a caution, we note tliat addiction is not the 
same as physical dependence or tolerance. Physical depen­
dence is a pharmacologic consequence of a drug character­
ized by the occurrence of a withdrawal syndrome following 
abrupt discontinuation of the substance or the administration 
of an antagonist. Tolerance refers to a physiologic state in 
which increased dosages of a substance are required to 
sustained a desired effect.
Assessment of the percentages of participants experien­
cing adverse events based on passive capture is standard in 
clinical trials; however, assessments of their severity and
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importance to participants are much less common, although 
this may provide valuable information (Katz, 2002). The 
authors recommend that the prospective assessment of 
symptoms present at the onset of a trial and symptoms and 
adverse events that emerge during the trial is a core outcome 
domain that should be included in all chronic pain clinical 
trials, and that the strategy used to assess these events 
should include participant ratings of their presence, severity, 
change, and importance.
4.6. Participant disposition
Following tlie recommendations of the CONSORT 
statement (Consolidated Standards of Reporting Trials 
guidelines, CONSORT; Begg et al., 1996; Moher et al., 
2001), all participants screened for a clinical trial should be 
carefully described with respect to the proportion who are 
ultimately enrolled, and why those who were not enrolled 
were not. Detailed information should be provided regard­
ing the extent and reasons for treatment non-adherence, 
prohibited concomitant medications and all other protocol 
deviations that may impact the interpretation of the trial 
results, treatment modification, premature participant with­
drawal from tlie trial, and loss to follow-up. Investigators 
should report the number of witlidrawals related to each of 
the symptoms and adverse events identified in each of the 
treatment groups. This detailed characterization of partici­
pant disposition is tlie sixth core domain that should be 
assessed in all clinical trials of chronic pain treatment.
To be effective, a treatment must have a beneficial effect 
on tlie symptom or disease being treated and the participant 
must adhere to the treatment regimen (Turk and Rudy,
1991). The most potent analgesic may demonstrate less than 
its potential benefit if participants in a clinical trial fall to 
use the medication in the manner prescribed, are unable 
to tolerate a fully effective dose, or drop out of the trial due 
to unacceptable adverse events or inadequate pain relief. 
Furthermore, the benefit of the treatment being studied may 
be obscured if participants receive any treatments that are 
not allowed in tlie protocol.
The dosage and duration of aU treatments received by 
participants during the clinical trial must be recorded, not 
only the treatment being investigated, but also all 
concomitant treatments. Treatments initiated during the 
trial often reflect inadequate pain relief or the presence of 
distressing or uncontrolled adverse events (the use of 
rescue medications and changes in concomitant medi­
cation use may be justifiable as pain outcome measures 
when specified in the protocol). Assessments of the use of 
rescue and prohibited medications and alterations in 
prescribed treatment due to adverse events and symptoms 
must be considered in evaluating the results of chronic 
pain clinical trials.
To evaluate whether side effects or other factors have 
compromised the double-blind in a clinical trial, it is 
important to assess subjects’ and investigators’ guesses of
Table 2
Supplemental domains for chronic pain clinical trials
Role functioning (i.e. work and educational activities)
IntcriDersonal functioning (i.e. relationships and activities with family, 
friends, and others)
Pharmacoeconomic measures and health care utilization 
B iological markers (e.g. assessments based on quantitative sensory testing, 
imaging, genetic markers, pharmacogenomics, and punch skin biopsy) 
Coping
Clinician or surrogate ratings o f  global improvement 
Neuropsychological assessments o f  cognitive and motor function 
Suffering and otlier end-of-life issues
which treatment was administered. The reasons for the 
specific guesses should also be assessed, because these can 
have different implications for interpretation of the results, 
for example, unblinding occurring because of the effective­
ness of the active treatment or because of its side effects 
(Moscucci et al, 1987).
5. Supplemental outcome domains
There are many other outcome domains that can be 
considered in the design of pain clinical trials depending on 
the specific research question. Supplemental assessment 
domains may be included in a clinical trial without a 
hypothesis that they will change and without the trial having 
adequate power to test the hypothesis that they will respond 
to treatment, 'fable 2 contains a list of eight supplemental 
outcome domains that might be considered in the design of 
chronic pain clinical trials.
6. Conclusions
The core outcome domains specified in these IMMPACT 
consensus recommendations—pain, physical functioning, 
emotional functioning, participant ratings of global 
improvement and satisfaction with treatment, symptoms 
and adverse events, and participant disposition—are 
generally consistent with the recommendations for artliritis 
clinical trials from OMERACT-III (Bellamy et al, 1997) 
and WHO/ILARS (Brooks and Hochberg. 2001). Pain, 
physical function, participant global assessment, and 
imaging studies are the core outcome domains specified in 
the OMERACT guidelines, and the first three of these 
domains are included in the present recommendations.
The objective of die first IMMPACT consensus meeting 
was to establish recommendations for clinical trials of 
chronic pain treatment. Imaging studies were not considered 
because they have limited relevance to die assessment of 
outcome in many chronic pain syndromes. In addition to the 
three domains that overlap with the OMERACT guidelines, 
the authors consider emotional functioning a core outcome 
domain because of its well-established and clinically 
important relationships wifli chronic pain. Symptoms and
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adverse events have been included as a core domain to 
emphasize that comprehensive assessment of the health 
burdens that often accompany treatment is necessary to 
achieve tlie key purpose of clinical trials—assessment of the 
risk-benefit balance. The recommendation tliat participant 
disposition is a core outcome domain is consistent with the 
CONSORT guidelines (Begg et al. 1996; Moher et al. 
2001), although we have emphasized that reports of 
participant disposition should be accompanied by detailed 
explanations of withdrawals, non-adherence, and protocol 
violations.
A legitimate concern for any clinical trial is participant 
burden. Assessment of the six,core domains will inevitably 
require more effort from participants than simply assessing 
pain reduction as the sole end-point of importance. 
However, it is important to emphasize that there are 
reasonably brief measures available that are capable of 
capturing the domains described above. Attention toward 
identifying measures that have demonstrated appropriate 
psychometric properties with the least participant burden 
will be the focus of the second IMMPACT consensus 
recommendations. Those who are designing clinical trials 
for chronic pain will need to balance the importance of 
assessing the core domains against the added participant 
burden.
The authors believe that investigators designing and 
conducting clinical trials of chronic pain treatment efficacy 
and effectiveness should consider each of the six core 
domains listed in Table 1 and discussed in this paper. It is 
important to emphasize, however, that we are not 
suggesting that positive results must be obtained for all 
of the core domains for the treatment to be deemed 
efficacious. Also we would like to emphasize the word 
considered. These core domains should be considered and 
are not mandatory because it is possible that there are 
specific trials for which one or more of these domains 
might not be relevant. In such instances, our recommen­
dation is that investigators should acknowledge that they 
have considered each outcome domain and provide tlie 
rationale when they decide not to include assessment of a 
particular domain. Of course, tliere are many supplemental 
outcome domains that can be included in a chronic pain 
clinical trial (see Table 2), and we expect that the core 
outcome domains will be supplemented by assessment of 
additional domains that are required to evaluate a specific 
treatment (or that tlie investigator wishes to include for 
exploratory purposes).
Numerous outcome measures related to the rec­
ommended core domains have appeared in tlie research 
literature (e.g. Benzon et al., 1994; McDowell and 
Newell, 1996; Turk mid Melzack, 2001). Selection of 
specific measures of each of the core and supplemental 
outcome domains from the many available should be 
based on reliability, validity, responsiveness to change, 
feasibility and practicality within the clinical trial setting 
(e.g. participant and investigator burden, need for special
training), availability of normative data and linguistically 
and culturally validated versions, mode of administration, 
and appropriateness to study objectives and the partici­
pant population and treatment being investigated (Dwor­
kin et al., 2001). Future IMMPACT recommendations 
wül focus on identifying specific measures within the six 
core outcome domains that have the most favorable 
characteristics and tlie widest range of applicability, 
methods for determining the clinical importance to 
patients of changes in these measures, and strategies 
for selecting primary endpoints and combining multiple 
endpoints in assessments of treatment efficacy and 
effectiveness. The use of standard outcome assessments 
has the potential to greatly enhance the validity, 
comparability, and clinical applicability of clinical trials 
of chronic pain treatments.
Academic, health care, and pharmaceutical industry 
investigators who conduct clinical trials, the government 
and private organizations that provide funding for many 
such studies, and the government regulatory agencies that 
review this research and ultimately approve new therapies 
for the public all share a commitment to identifying 
treatments for chronic pain that are more effective and 
have fewer adverse effects than those currently available. 
These different groups, however, sometimes have different 
goals, contrasting ideologies, and separate constituencies 
with particular interests in clinical trials. Although unsyste­
matic efforts to bring these different individuals together 
have occurred in various medical specialties, much more 
can and should be done to enhance mutual understanding 
and promote creativity in the development and investigation 
of improved treatment approaches (Klein et ai., 2002). The 
authors hope tliat IMMPACT and the recommendations 
made in this paper will provide an example of the value of 
such collaborative efforts among academia, government, 
and industry. The ultimate goal of such efforts should be to 
advance the science of chronic pain clinical trials and 
thereby provide improved treatments for patients suffering 
from chronic pain.
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1. Introduction
Many patients with chronic pain do not obtain adequate 
relief or experience unacceptable side effects from existing 
treatments. Moreover, even when clinical trials report 
positive outcomes, the long-term benefits of these treat­
ments have not been demonstrated. Efforts to develop 
treatments that provide improved outcomes are therefore a 
priority for pain research. Because variability in outcome 
measures across clinical trials hinders evaluations of the 
efficacy and effectiveness of treatments, the Initiative on 
Methods, Measurement, and Pain Assessment in Clinical 
Trials (IMMPACT) has recently recommended that 6 core 
outcome domains should be considered when designing 
chronic pain clinical trials. These 6 core outcome domains 
were: (1) pain; (2) physical functioning; (3) emotional 
functioning; (4) participant ratings of improvement and 
satisfaction with treatment; (5) symptoms and adverse 
events; and (6) participant disposition (Turk et al., 2003).
The benefits of adopting these core outcome domains in 
clinical research on chronic pain would be augmented by tire 
identification of optimal measures for assessing them. Such 
core outcome measures could be supplemented by measures 
specific to the situation or treatment being studied. Use of a 
standard set of outcome measures for chronic pain clinical 
trials would facilitate tire process of developing research 
protocols, encourage development of multi-center projects 
in which all participating facilities agree to include these 
measures, provide a basis for determining the treatment 
outcomes that constitute clinically important differences, 
permit pooling of data from different studies, and provide a 
basis for meaningful comparisons among treatments of tire 
clinical importance of their outcomes, particularly through 
systematic reviews (Jadad, 1998; Jadad and Cepeda, 2000).
IMMPACT-II was convened to develop consensus 
recommendations for specific measures of each of the 
IMMPACT core outcome domains. Although there have 
been recent attempts to recommend outcome measures for 
specific clrronic pain conditions—including osteoartlrritis 
(Bellamy et al., 1997), low back pain (Deyo et ai., 1998), 
and neuropathic pain (Cruccu et al., 2004)—tire only 
previous attempt to identify specific treatment outcome 
measures applicable to diverse chronic pain conditions was 
published over fifteen years ago (Williams, 1988). The 
objective of the present article is to present consensus 
recommendations for specific measures of each of tlie 
IMMPACT core outcome domains.
2. Consensus meeting procedure
The IMMPACT-II meeting was held on April 11-12, 
2003 and included 35 participants from academia,
governmental agencies, a self-help organization, and the 
pharmaceutical industry. The participants were selected on 
the basis of their research, clinical, or administrative 
expertise relevant to the design and evaluation of chronic 
pain treatment outcomes. Literature reviews of measures of 
the IMMPACT core outcome domains were commissioned 
specifically for the IMMPACT-II meeting and distributed to 
participants prior to the meeting. These reviews focused on 
measures that could be used in trials of all chronic pain 
conditions and did not examine measures that were specific 
to certain types of chronic pain. These background literature 
reviews and the slide presentations delivered at the meeting 
are available on the IMMPACT-II page at www.immpac- 
t.org/meetings.html. They should be consulted for detailed 
reviews and discussions of the measures that were 
considered, the evidence on which the present recommen­
dations are based, and the reasons for selection or rejection 
of specific measures.
Among the criteria used in evaluating potential core 
outcome measures were: (1) appropriateness of the 
measure’s content and conceptual model; (2) reliability; 
(3) validity; (4) responsiveness; (5) interpretability; (6) 
precision of scores; (7) respondent and administrator 
acceptability; (8) respondent and administiator burden and 
feasibility; (9) availability and equivalence of alternate 
forms and methods of administration (e.g. self-report, 
interviewer); and (10) availability and equivalence of 
versions for different cultures and languages (Fitzpatrick 
et al., 1998; Scientific Advisory Committee of the Medical 
Outcomes Trust, 2002). Responsiveness has been defined 
and assessed in numerous ways, but it most often refers to 
the ability of a measure to detect changes over time (Guyatt 
et al., 1987; Terwee et al., 2003). With respect to chnical 
trials, responsiveness has also referred to the ability of a 
measure to distinguish between treatments, in particular, 
between an active/experimental treatment and a placebo/ 
conti'ol treatment. Although Hays and Hadorn (1992) have 
noted that responsiveness is a component of validity, the 
authors considered responsiveness a separate attribute of 
outcome measures because of its pivotal role in clinical 
trials.
In evaluating the extent to which the various measures 
reviewed in the background presentations fulfilled these 
criteria, appropriateness of content, reliability, validity, 
responsiveness, and participant burden were given die 
greatest weight. In particular, measures for which published 
information on these specific criteria were lacking were not 
recommended, and when such information was available for 
two or more relevant measures, recommendations were 
primarily based on comparisons of these five attributes. It is 
important to emphasize that even though basic information 
on reliability and validity is usually available for measures
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that have been used in studies of patients witli chronic pain, 
information on other important attributes of tliese measures 
is often lacking. The absence of data relevant to a measure’s 
responsiveness, for example, must therefore be carefully 
distinguished from the availability of data that demonstrate 
its lack of responsiveness. Unfortunately, die absence of 
evidence is much more common than clear evidence of 
limitations for most of the criteria considered in evaluating 
outcome measures for chronic pain clinical trials.
Reliability, validity, and responsiveness can be condition 
or context specific and are not invariant properties of a 
measure. Although the authors considered evidence of the 
generalizability of these attributes to diverse chronic pain 
syndromes, in circumstances in which such data are lacking, 
it is important to evaluate the applicability of the measure to 
the chronic pain syndrome being investigated.
3. Core outcome measures for chronic pain clinical trials
The core outcome measures listed in Table 1 should be 
considered in the design of all clinical trials of die efficacy 
and effectiveness of treatments for any type of chronic pain. 
It is not the intention of these recommendations that use of 
these measures should be considered a requirement for 
approval of applications by regulatory agencies or that 
treatments must demonstrate statistically significant or 
clinically important benefits with all of these measures to 
establish evidence of efficacy or effectiveness. There may be 
circumstances in which use of some or aU of these core 
outcome measures will not be appropriate, for example, in 
clinical trials in cognitively impaired individuals or in 
infants. As was true of the IMMPACT recommendations for 
core outcome domains (Turk et al., 2003), the present
Table 1
Recommended core outcom e measures for clinical trials o f  chronic pain 
treatment efficacy and effectiveness
Pain
11-point (0 -10 ) numerical rating scale o f pain intensity 
Usage o f rescue analgesics
Categorical rating o f  pain intensity (none, mild, moderate, severe) in 
circumstances in which numerical ratings may be problematic 
Physical functioning (either one o f  two measures)
M ultidimensional Pain Inventory Interference Scale 
Brief Pain Inventory interference items 
Emotional functioning (at least one o f two measures)
Beck Depression Inventory 
Profile o f  M ood States 
Participant ratings o f  global improvement and satisfaction with treatment 
Patient Global Impression o f  Change 
Symptoms and adverse events 
Passive capture o f  spontaneously reported adverse events and symptoms 
and use o f open-ended prompts 
Participant disposition
Detailed information regarding participant recruitment and progress 
tlirough the trial, including all information specified in the CONSORT  
guidelines
recommendations are most applicable to clinical trials to 
determine the efficacy or effectiveness of treatments 
for chronic pain and are made with the assumption that 
these trials will be conducted in accord with tlie principles 
of good clinical practice (International Conference on 
Harmonisation, 1996a; United States Department of Health 
and Human Services, 1997).
3.1. Pain
There are various aspects of pain Üiat can change as a 
result of treatment, and the results of reviews of the 
literature on pain assessment in adults (Jensen, 2003; Jensen 
and Karoly, 2001) support the recommendation that 
measures of pain intensity, the use of rescue treatments, 
pain quality, and the temporal components of pain should be 
considered when assessing pain outcomes. Self-report 
measures provide the ‘gold standard* in assessing pain 
outcomes because they reflect the inherently subjective 
nature of pain, but tlrey should be supplemented by careful 
assessments of the use of rescue treatments. Depending on 
the specific objectives of the chnical trial, other approaches 
to assessing pain can be considered, for example, overt 
expressions of pain and distress (‘pain behaviors’; Keefe 
et al., 2001) and surrogate endpoints such as imaging 
measures.
3.1.1. Pain intensity
For most clinical trials of chronic pain treatments, a 
measure of pain intensity will provide the primary outcome 
measure. Each of the commonly used methods of rating pain 
intensity, including visual analogue scales (VAS), numeri­
cal rating scales (NRS), and verbal rating scales (VRS) are 
reliable and vahd, and no one scale consistently demon­
strates greater responsiveness in detecting improvements 
associated with pain treatment (Jensen and Karoly, 2001). 
However, there are important differences among VAS, 
NRS, and VRS measures of pain intensity with respect to 
lost data from patients faihng to complete the measure 
correctly, patient preference, ease of data recording, and 
ability to administer the measure by telephone or with 
electronic diaries. VRS and NRS measures tend to be 
preferred over VAS measures by patients. Furthermore, 
VAS measures usually demonstrate greater amounts of 
missing and incomplete data than NRS measures, presum­
ably because NRS measures are less abstract and easier to 
understand. Greater difficulty completing VAS measures is 
associated witli increased age and opioid intake (Jensen and 
Karoly, 2001). Cognitive impairment has been shown to be 
associated with inability to complete NRS ratings of pain 
intensity (Jensen and Karoly, 2001). Patients who are unable 
to complete NRS ratings may be able to complete VRS pain 
ratings. There will, of course, be circumstances when self- 
reports of pain wiU be impossible and in these instances 
alternatives (e.g. observations of behavior, surrogate 
ratings) will have to be considered.
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On the basis of a review of the literature on pain 
measures prepared for the IMMPACT-II consensus meeting 
(Jensen, 2003) and discussions among the participants, an 
11-point (i.e. 0-10) NRS measure of pain intensity is 
recommended as a core outcome measure in clinical trials of 
chronic pain treatments. In order to facilitate consistency 
among studies, the authors recommend that the specific 
format of this rating should include presentation of tlie 
numbers from 0 to 10, with 0 meaning ‘No pain’ and ‘10’ 
meaning ‘Pain as bad as you can imagine,’ accompanied by 
the instructions “Please rate your pain by indicating the 
number that best describes your pain on average in the last 
24 h” (Cleeland and Ryan, 1994). Depending on the specific 
aims and design of the clinical trial, pain during tlie 
past week can also be assessed using this scale, as could pain 
‘at its worst’ or pain ‘at its least’.
Investigators should also routinely consider including a 
VRS measure of pain intensity (none, mild, moderate, 
severe) as an additional pain outcome measure. Doing so 
makes it possible to compare the results of a clinical trial 
with the many studies, especially of acute pain, that have 
used such VRS measures. In addition, use of a VRS measure 
of pain intensity should limit the amount of missing data 
that results from some study participants having difficulty 
completing the primary NRS measure.
There are clinical conditions for which reliable, valid, 
and responsive measures of pain intensity that do not use an 
NRS are routinely used (e.g. the Western Ontario and 
McMaster Universities Osteoarthritis Index [WOMAC] 
VAS ratings in studies of patients with osteoarthritis; 
Bellamy et al., 1988). These circumstances should be 
distinguished from those for which no such measures exist 
and NRS ratings of pain intensity are recommended. When 
other measures of pain intensity are used, it may be useful to 
also administer NRS ratings to compare with other diseases 
or treatments.
In addition to analyzing and reporting absolute changes 
in pam intensity, it is recommended that the percentages 
of patients obtaining reductions in pain intensity from 
baseline of at least 30% be reported when an NRS (or 
VAS) has been used in a chronic pain chnical trial. This 
recommendation is primarily based on the results of an 
analysis of the relationships between changes in pain 
intensity and patient reports of overall improvement in 
ten clinical trials of chronic pain in patients with diverse 
diagnoses (Farrar et al., 2001). Importantly, these 
relationships were consistent across age, sex, treatment 
group (different dosages of pregabalin/placebo), the five 
clinical conditions, and whether study results demon­
strated separation from placebo or not (Farrar et al., 
2001). To permit comparisons with previous studies and 
meta-analyses, investigators may also wish to report the 
percentages of patients obtaining reductions in pain 
intensity from baseline of at least 50% (McQuay and 
Moore, 1998).
3.1.2. Rescue analgesics and concomitant pain treatments
The use of all pain-related treatments during the course 
of a clinical trial should be assessed, including rescue 
analgesics and any other concomitant pain treatments. This 
is a straightforward task in single-dose analgesic trials that 
prohibit the concurrent use of other medications, but it is 
more difficult in chronic pain clinical trials that allow 
concurrent use of pain medications and other treatments for 
pain (e.g. physical therapy) for weeks or months. Some 
chronic pain trials have allowed previously used pain 
medications to be continued throughout the trial, and 
dosage stabilization is often required before patients are 
allowed to enroll in such trials. However, when changes in 
the use of concomitant pain treatments are permitted, 
they can be considered as an outcome measure (e.g. 
Kieburtz et al., 1998).
Providing patients with access to rescue analgesics may 
make it easier to include a placebo group in treatment 
efficacy studies, since patients not obtaining adequate pain 
relief are provided with an analgesic. However, adminis­
tration of rescue treatment complicates the interpretation of 
differences in pain ratings between patients taking placebo 
and active treatments because of the reduction in pain 
expected to occur in patients receiving rescue treatment. 
The use of rescue medications is affected by botli patient 
and provider beliefs. Patients use rescue medications to 
achieve varying levels of pain relief, but also for other 
reasons, including improving sleep or reducing anxiety, 
preventing increased pain resulting from increased activity, 
and treating pain (e.g. headache) tliat may be unrelated to 
the clinical trial. When recording treatments used for pain 
during the clinical trial, it may tlierefore be desirable to 
distinguish analgesics used for relief of the disorder being 
studied from all other uses.
Rescue medication consumption has been used as an 
outcome measure in clinical trials, with assessments 
including amount used and time-to-use (e.g. Chrubasik 
et al., 2003; Eisenberg et al., 2001). Scales have been 
developed that allow quantification of medication use in 
chronic pain patients based on dosage and medication class 
(Steedman et al., 1992), and composite measures have been 
proposed that combine rescue medication usage and pain 
intensity ratings into a single score (Lehmann, 1990; 
Silverman et al., 1993). Although these may be used to 
compare different treatment groups in clinical trials, the 
psychometric properties of such composite measures are not 
well established.
Despite the complex issues involved in the interpretation 
of rescue medication usage in a clinical trial, patients in a 
placebo group can be expected to take more of a rescue 
treatment than patients administered an efficacious investi­
gational treatment. When considered together with pain 
intensity ratings, the amount of rescue treatment used by 
patients tlierefore can provide an important supplemental 
measure of the efficacy of the treatment being evaluated. 
For these reasons, assessments of rescue treatments are
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recommended as a core outcome in trials where rescue 
interventions are available and permitted.
3.1.3. Pain quality and temporal aspects o f pain
Pain has different sensory and affective qualities in 
addition to its intensity, and various measures of these 
components of pain can be used to more fully describe a 
patient’s pain experience (Price et ah, 1987). The efficacy of 
pain treatments may differ for various pain qualities. 
Measures of the affective and sensory qualities of pain 
may therefore identify treatments that are efficacious for 
certain aspects of pain but not for overall pain intensity. 
Assessment of pain qualities at baseline also makes it 
possible to determine whether certain patterns of pain 
characteristics moderate the effects of treatment.
Whereas pain intensity reflects the overall magnitude of 
tlie pain, pain affect can be viewed as reflecting tlie distress 
caused by the pain. Assessment of pain affect or 
unpleasantness is supported by the evidence that the 
affective component of pain can be empirically distin­
guished from pain intensity and may be differentially 
responsive to treatments (Jensen, 2003; Price, 1999). As 
with pain intensity, pain affect can be assessed with VAS, 
NRS, and VRS items having different anchors, for example, 
‘not unpleasant’ and ‘most unpleasant feeling possible’.
The Short-Form McGill Pain Questionnaire (SF-MPQ; 
Melzack, 1987) assesses 15 specific sensory and affective 
pain descriptors and provides a total score and sensory and 
affective subscale scores. This questionnaire is reliable and 
well-validated, and its sensory and affective subscales have 
demonstrated responsiveness in recent chronic pain clinical 
trials (e.g. Dworkin et al., 2003; Rowbotham et al., 1998). 
Because it assesses both specific sensoiy pain qualities and 
the affective component of pain, the SF-MPQ is rec­
ommended for inclusion in clinical trials as a secondary 
outcome measure to evaluate the effects of pain treatment on 
both sensory and affective qualities of pain.
Measures of the temporal aspects of pain—including 
variability in intensity; time to onset of meaningful pain 
relief; durability of pain relief; and frequency, duration, and 
intensity of pain episodes—have not received adequate 
attention in pain research. The available evidence indicates 
that measures of pain frequency have validity and represent 
a distinct dimension of pain (Jensen and Karoly, 2001). 
Frequency of ‘breakthrough’ pain (periods of severe pain 
superimposed on ongoing pain) is an important temporal 
aspect of pain that has been used as an outcome measure in 
clinical trials (e.g. Farrar et al., 1998). When appropriate, 
investigators should consider administering measures of the 
temporal aspects of pain as secondary outcome measures in 
clinical trials. The temporal dimensions that should be 
considered include patients’ reports of the time to onset of 
meaningful pain relief and its durability as well as the 
frequency and intensity of episodes of breakthrough pain.
3.2. Physical functioning
Chronic pain interferes with daily activities, and it has 
been assumed that relief of pain is accompanied by 
improvement in function. However, many studies have 
demonstrated that pain intensity and physical functioning 
are only modestly associated (Turk, 2002), which supports 
the importance of including measures of functioning in 
chronic pain clinical trials. Measures of physical function­
ing typically assess multiple aspects of function, including 
activities of daily living. Disturbed sleep is prevalent in 
people with chronic pain, and its assessment is also 
important in clrronic pain trials. Individuals with chronic 
pain consider both increased ability to function and 
improved sleep important treatment objectives (Casarett 
et al., 2001).
There are two broad types of measures of physical 
functioning and, more generally, health-related quality of 
life (HRQOL). Generic measures provide information about 
physical functioning and treatment benefits that can be 
compared across different conditions and studies; disease- 
specific measures assess problems associated with specific 
conditions that may not be assessed by generic measures 
and may also be more responsive to tlie effects of treatment 
(e.g. Dworkin et ai., 2001; Guyatt et al., 1993). Because 
each of these approaches has strengtlis, use of both disease- 
specific measures, when available, and generic measures of 
physical functioning should be considered in designing 
chronic pain clinical trials.
On the basis of reviews of the literature on generic and 
pain-related measures of physical functioning prepared for 
the IMMPACT-II consensus meeting (Haythomthwaite, 
2003; Stucki and Cieza, 2003) and discussions among the 
participants, use of a disease-specific measure of physical 
functioning is recommended in chronic pain clinical trials 
when a suitable and well-accepted one is available. 
Examples of such disease-specific measures of physical 
functioning are the WOMAC (Bellamy et al., 1988) and the 
Roland and Morris Back Pain Disability Scale (Roland and 
Morris, 1983). However, disease-specific measures of 
physical functioning have not been developed and validated 
for many chronic pain conditions. In clinical trials 
examining such disorders, use of either the Multidimen­
sional Pain Inventory (MPI; Kerns et al., 1985) Interference 
Scale or the Brief Pain Inventory (BPI; Cleeland and Ryan, 
1994; Cleeland et al., 1996) pain interference items (i.e. 
general activity, mood, walking ability, work, relations with 
other people, sleep, enjoyment of life) is recommended. The 
MPI and BPI interference scales both provide reliable and 
valid measures of the interference of pain with physical 
functioning that have been translated into many languages 
and studied in diverse chronic pain conditions in multiple 
countries.
The MPI and BPI measures of physical functioning have 
distinct advantages and disadvantages, and use of both may 
be considered when doing so would not impose an undue
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burden on participants (a total of 16 items, 9 for the MPI and 
7 for the BPI). The MPI Interference Scale does not assess 
sleep, and if this measure of physical functioning is 
administered, then use of a reliable and valid measure of 
tlie impact of pain on sleep is recommended. The BPI does 
include an item assessing pain interference with sleep, but 
also includes ratings of mood, social relations, and 
enjoyment of life. These three items may constitute a 
separate factor measuring affective state that is relatively 
independent of tlie remaining items (Cleeland et ah, 1996). 
Few clinical trials, however, have examined BPI factors 
separ ately and so administration and analysis of only the 
three BPI activity items (general activity, walking ability, 
normal work) as a measure of physical functioning cannot 
be recommended until more data become available.
Regardless of whether a disease-specific measure of 
physical functioning or the MPI or BPI interference scale is 
used in a clinical trial, administration of a generic measure 
of physical functioning should be considered to obtain data 
tliat will allow comparisons with other disorders and that 
could be used in cost-effectiveness analyses (Thompson, 
2002; Turk, 2002). The SF-36 Health Survey (Ware and 
Sherboume, 1992) is tlie most commonly used generic 
measure of HRQOL and it has been used in studies of 
diverse medical and psychiatric disorders and in numerous 
clinical trials. The authors recommend the SF-36 as a 
generic measure of physical functioning because of the large 
amount of data available that pemiit comparisons among 
different disorders and treatments. The development of new 
HRQOL measures is an active area of research and tliese 
may offer improvements over the SF-36 and ultimately 
replace it (e.g. Chwastiak and Von Korff, 2003; Rogers 
et ah, 2000).
In many chronic pain conditions, increased activity is 
accompanied by increased pain. Some patients limit their 
physical functioning because of pain, and their response to 
decreased pain may be to increase their activity until pain 
increases to its tolerated intensity. Other patients wiU tolerate 
increased pain to maintain a desired level of function and their 
response to decreased pain may be to report less pain as long as 
their level of function remains satisfactory. Although both 
situations represent true relief of pain, pain relief is reflected in 
increased activity with little change in pain intensity in the 
first, and in decreased pain intensity with little change in 
activity in the second. This issue has been addressed in some 
studies by examining combined measures of activity level and 
pain intensity to assess outcome (Malec et ah, 1981 ; Peters and 
Large, 1990), but additional research on such composite 
measures is needed.
3.3. Emotional functioning
Chronic pain is often accompanied by symptoms of 
psychological distress and psychiatric disorders, including 
depression, anxiety, and anger (Fernandez, 2002). On tlie 
basis of a review of the literature of measures of emotional
functioning prepared for the IMMPACT-II consensus 
meeting (Kerns, 2003) and discussions among the partici­
pants, the Beck Depression hiventory (BDI; Beck et ah, 
1961) and the Profile of Mood States (POMS; McNair et al., 
1971) are recommended as core outcome measures of 
emotional functioning in chronic pain clinical trials. Both 
the BDI and POMS have well-established reliability and 
validity in the assessment of symptoms of depression and 
emotional distress, and they have been used in numerous 
clinical trials in psychiatry and in an increasing number of 
chronic pain clinical trials (Kerns, 2003). In research in 
psychiatry and in chronic pain, the BDI provides a well- 
accepted measure of the level of depressed mood in a 
sample and its response to treatment.
The POMS assesses six mood states—tension-anxiety, 
depress ion-fiejection, anger-hostility, vigor-activity, fati- 
gue-inertia, and confusion-bewilderment—and also pro­
vides a summary measure of total mood disturbance. 
Although the discriminant validity of the POMS scales in 
patients with chronic pain has not been adequately 
documented, the POMS has scales for the three most 
important dimensions of emotional functioning in chronic 
pain patients (depression, anxiety, anger) and also assesses 
three other dimensions that are very relevant to chronic pain 
and its treatment, including a positive mood scale of vigor- 
activity. Moreover, the POMS has demonstrated beneficial 
effects of treatment in some (but not all) recent chronic pain 
trials (e.g. Rowbotham et al., 1998). For these reasons, 
administration of both the BDI and the POMS is 
recommended in cluronic pain clinical trials to assess the 
major aspects of the emotional functioning outcome 
domain.
The assessment of emotional functioning in patients 
with chronic pain presents a challenge because various 
symptoms of depression—such as decreased libido, 
appetite or weight changes, fatigue, and memory and 
concentration deficits—are also conuuonly believed to be 
consequences of clironic pain and the medications used for 
its treatment (Gallagher and Verma, 2(X)4). It is unclear 
whether the presence of such symptoms in patients with 
chronic pain (and other medical disorders) should never­
theless be considered evidence of depressed mood, or 
whether the assessment of mood in these patients should 
emphasize symptoms that are less likely to be secondary to 
physical disorders (Wilson et al., 2001). Because the 
evidence indicates that measures of emotional functioning 
are adequately reliable, valid, and responsive when used in 
the medically ill (Kerns, 2003), the authors recommend 
that the principal analyses of the BDI and POMS in chronic 
pain clinical trials use the original versions without 
adjustment for presumed confounding by somatic symp­
toms. Depending on the specific objective of the clinical 
trial, supplemental analyses could be conducted to 
separately examine non-somatic and somatic aspects of 
emotional functioning.
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3.4. P a r tic ip a n t ra tin g s o f  g lo b a l im p ro vem en t  
an d  sa tisfa c tio n  w ith  trea tm en t
Global ratings of improvement and satisfaction in a 
clinical trial provide an opportunity for participants to 
aggregate all of the components of their experience—pain 
relief, improvement in physical and emotional functioning, 
side effects, convenience—into one overall measure of their 
perception of the advantages and disadvantages of tlie 
treatment tliey received. Such measures reflect the ‘dis- 
disparate values and preferences of individual patients’ (Gill 
and Feinstein, 1994) and in so doing provide an important 
measure of pain treatment outcome (Collins et al., 2001). 
Moreover, global ratings by patients of tlieir improvement 
and satisfaction with treatment can be used to investigate 
participants’ judgments of the clinical importance of 
changes in other outcome measures (Farrar et al., 2001; 
Fischer et al., 1999).
Many different approaches have been used to assess 
participants’ overall evaluation of their treatment in clinical 
trials. On the basis of a review of the literature of measures 
of global outcome prepared for the IMMPACT-II consensus 
meeting (Farrar, 2003) and discussions among the partici­
pants, tlie Patient Global Impression of Change scale (PGIC; 
Guy, 1976) is recommended for use in chronic pain clinical 
trials as a core outcome measure of global improvement 
with treatment. This measure is a single-item rating by 
participants of their improvement witli treatment during a 
clinical trial on a 7-point scale that ranges from ‘very much 
improved’ to ‘very much worse’ with ‘no change’ as the 
mid-point.
There has been widespread use of the PGIC in recent 
chronic pain clinical trials (e.g. Dunkl et al., 2000; Farrar 
et al., 2001), and the data provide a responsive and readily 
interpretable measure of participants’ assessments of the 
clinical importance of their improvement or worsening over 
the course of a clinical trial. Impression of change scores 
using different verbal outcome categories have also been 
used to determine the minimally important changes in 
quality of life measures (e.g. Guyatt et al., 2002; Hagg et al., 
2003). Although these measures appear to have validity, 
additional research is necessary to determine the relative 
extent to which ratings on the PGIC and similar measures 
reflect reduced pain, improvement in functioning, side effect 
burden, or other variables and whether this varies for 
different samples and treatments.
Other approaches to the global assessment of treatment 
response that have been used less frequently tlian the PGIC 
in chronic pain trials include ratings of participant 
satisfaction with treatment, prospectively conducted global 
ratings of disease state from which changes from baseline 
can be calculated, and global ratings of specific outcome 
domains, for example, global ratings of improvement in 
physical functioning or in overall side-effect burden 
(Middell et al., 2001). Single-item ratings of treatment 
outcome have both advantages and disadvantages when
compared to multiple-item scales (Sloan et ah, 2002), and 
additional research will be important to determine the 
optimal method for obtaining global ratings from patients.
3.5 . Sym ptom s a n d  a d v erse  even ts
The assessment, analysis, and reporting of adverse 
events is an essential component of all clinical trials. 
Within the context of pharmacologic investigations, 
adverse events have been defined as “any untoward medical 
occurrence in a patient or clinical investigation participant 
administered a pharmaceutical product and which does not 
necessarily have to have a causal relationship with this 
treatment” (International Conference on Harmonisation, 
1995b, p. 2-3). Such events are unintended signs, 
symptoms, laboratory abnormalities, or diseases associated 
in a temporal manner with the use of a medication.
Clinical trial protocols should define the method of 
assessment and the rationale for that approach. In selecting 
the approach used for ascertaining adverse events and the 
methods used for recording and coding the terms used to 
describe these events (e.g. Medical Dictionary for Regulat­
ory Activities, Brown, 2003), consideration should be given 
to the type and purpose of tiie trial, whether international 
regulatory requirements dictate certain approaches (Inter­
national Conference on Harmonisation, 1995a,b, 1996b), 
the phase of development or post-marketing, and the total 
safety experience with the product.
On the basis of a review of the literature on the assessment 
of symptoms and adverse events prepared for the 
IMMPACT-II consensus meeting (Katz, 2003) and discus­
sions among tlie participants, the authors recommend that, at 
a minimum, passive capture of spontaneously reported 
events and the use of open-ended prompts should be used 
in chronic pain chnical trials to assess adverse events. In 
describing the results of clinical trials, the incidence of 
individual adverse events and serious adverse events should 
be reported for each treatment group, including the 
percentages of participants who experienced treatment 
emergent adverse events of particular significance or with 
an incidence greater than placebo. It is also very important to 
evaluate and report tlie severity of adverse events as this may 
differ among treatments that have a comparable incidence of 
adverse events (Edwards et al., 1999).
Active capture using structured interviews or question­
naires to assess specific symptoms and adverse events that 
are relevant to the disorder or treatment being studied will 
often be more sensitive and more informative than passive 
capture or general inquiries (e.g. Anderson and Testa, 1994; 
Edwards et al., 1999). Depending on the objectives of a 
chronic pain clinical trial, active capture of selected 
symptoms and adverse events can be conducted at periodic 
intervals throughout the trial, including baseline and the 
conclusion of the trial, ideally by tlie same investigator.
It is important to recognize that tlie frequency, duration, 
intensity, distress, importance to the patient, impact on daily
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function, and investigator and patient causal attributions can 
be assessed for symptoms and adverse events (e.g. Anderson 
et al., 1999; Portenoy et al, 1994; Wolfe et al., 2000). Such 
assessments provide information about tlie clinical import­
ance of safety and tolerability outcomes.
The authors recommend tliat methods for active capture 
of symptoms and adverse events relevant to clironic pain 
and its treatment be vigorously explored. In developing 
comprehensive strategies to assess these events, consider­
ation should be given to including participant ratings of 
frequency, severity, importance, and associated distress. In 
such research, it will be important to evaluate whether the 
use of these methods increases the reported incidence of 
clinically insignificant events that have no implications for 
tolerability, safety, and patient satisfaction with treatment.
3.6. Participant disposition
On the basis of a review of the literature on the 
assessment of participant disposition in clinical trials 
prepared for the IMMPACT-II consensus meeting (Turk, 
2003) and discussions among the participants, the authors 
recommend tliat chronic pain clinical trials should collect 
and report comprehensive information on participant 
disposition, including detailed information regarding the 
recruitment of participants and their progression through the 
trial. Information on participant disposition is essential for 
the adequate evaluation of the results of a clinical trial and 
for interpreting the trial's conclusions regarding efficacy 
and safety.
Although the CONSORT (Consolidated Standards of 
Reporting Trials) guidelines (Altman et al., 2001; Begg 
et a l, 1996; Moheret a l, 2001) were developed to serve as a 
guide to reporting results of clinical trials, they also provide 
a valuable enumeration of the core elements of information 
on participant disposition that should be recorded when 
conducting trials (Goudas et al, 2001), including the 
numbers of participants who withdraw and are lost to 
follow-up as well as the reasons for withdrawal and loss. 
The following additional information can be valuable in 
interpreting tlie results of a clinical trial and should be 
collected and reported when doing so is feasible; (1) the 
recruitment process and the percentages of participants 
enrolled from each recruitment method; (2) the number of 
candidate participants who were excluded from partici­
pation and the reasons why; (3) the number of candidates 
who chose not to enter the trial and the reasons why; (4) the 
use of prohibited concomitant medications and all other 
protocol deviations that may impact the interpretation of the 
trial results; (5) tlie number and reasons for withdrawal from 
each treatment group, including deaths and patients lost to 
follow up; and (6) the types, rates, and reasons for non­
adherence with treatment in each treatment group.
Dosages and duration of all treatments received by 
participants during the clinical trial should be recorded, 
including assessments of the use of rescue, concomitant.
and prohibited medications and all alterations in prescribed 
treatment. Detailed information describing the extent to 
which each participant adhered to the protocol will make it 
possible for data analyses to be conducted tliat specifically 
examine efficacy in patients who adhered to the protocol. 
Such efficacy evaluable or per protocol analyses can 
sometimes be valuable in interpreting the results of 
intention-to-treat analyses, altliough the benefits of compar­
ing randomized groups are lost. Although an important 
component of patient disposition, withdrawal from a 
clinical trial due to lack of treatment effectiveness can 
also be considered an endpoint (European Agency for the 
Evaluation of Medicinal Products, 2002; International 
Conference on Harmonisation, 2001).
Although reasons for withdrawal are usually provided in 
reports of clinical trials, this information is often 
inadequate. For example, ‘drop out due to adverse events’ 
may be given as a reason for withdrawal, but this is not 
informative without tabulation of the specific adverse events 
associated with the withdrawals. Similarly, ‘withdrawal of 
consent’ is commonly given as a reason for withdrawals, but 
this is impossible to interpret witliout description of the 
reasons why patients withdrew consent.
There are several factors that may compromise die 
integrity of the double-blind used in a clinical trial (Even 
et al., 2000). Participants’ and investigators’ guesses of 
which treatment was administered should therefore be 
assessed, and the reasons for the specific guesses (e.g. 
medication side effects or pain relief) should also be 
collected to assist in intepreting any unblinding that may 
have occurred (Moscucci et a l, 1987; Turner et al., 2002).
4. Conclusions
The authors recommend that tire core outcome measures 
listed in the table should be considered when designing 
clinical trials of chronic pain treatments. It must be 
emphasized, however, that the autlrors are not suggesting 
that the inclusion of these measures in a trial should be 
considered a requirement for pubhcation in a scientific 
journal or by regulatory agencies. Furtlrermore, these 
recommendations are not meant to imply that positive 
results must be obtained for all of these outcome measures 
for a treatment to be deemed efficacious and safe.
Pain intensity and impairments in physical and emotional 
functioning are associated in patients with chronic pain, and 
improvement in pain has been associated with improvement 
in functioning and reports of overall benefit in some but not 
all clinical trials. There are many circumstances, however, 
in which improvement is found for measures of one or two 
of the core outcome domains but not others. There are 
undoubtedly many explanations for such results, including 
the generally modest relationships among the core outcome 
domains (Turk et al, 2003). Moreover, tlie statistical power 
of clinical trials is typically determined for the primary
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endpoint, and it can therefore be expected that inadequate 
power may sometimes explain results for secondary 
outcome measures tliat are not statistically significant. 
Conversely, positive results for secondary outcomes in 
chronic pain trials such as physical and emotional 
functioning would not necessarily provide convincing 
evidence of efficacy or adequate demonstration within 
regulatory contexts to support additional efficacy claims.
It is important to emphasize that there will be clinical 
conditions or treatments for which one Or more of these core 
outcome measures will not be relevant and should therefore 
not be included in a clinical trial. Fuffire research may also 
identify other measures of these core domains that will be 
shown to have psychometric properties that are superior to 
the specific measures recommended in this article. The 
autliors also expect that the recommended measures will 
typically be supplemented by other measures that are 
included for exploratory purposes or to evaluate treatment- 
or disease-specific issues (Turk and Melzack, 2001). 
Regardless of which measures are ultimately used, the 
reasons for selecting each of the specific measures that have 
been included in a clinical trial should be provided.
There are many decisions that must be made in 
administering outcome measures in chronic pain trials. 
For example, whether ratings of pain or the other measiues 
discussed in this article are made using retrospective or 
serial assessments is a very important issue that may have 
imphcations for the ability of a measure to detect change 
(Fischer et ah, 1999). These and other decisions will depend 
on the design of the trial, the resources available, and other 
considerations that are beyond the scope of this article.
In recommending specific core outcome measures, the 
authors acknowledge the important limitations of existing 
measures and the pressing need to develop improved 
methods for assessing chronic pain outcomes. For this 
reason, forthcoming IMMPACT recommendations will 
provide guidelines for developing improved measures of 
chronic pain outcomes and will identify the types of studies 
that are required to successfully develop such measures. 
Additional IMMPACT meetings will focus on methods to 
identify the chnical importance of changes in chronic pain 
outcome measures, and on approaches for combining 
multiple outcome measures to evaluate treatment efficacy 
and effectiveness. The use of standard outcome assessments 
has the potential to greatly enhance the vafidity, compar- 
abihty, and clinical applicability of clinical trials of chronic 
pain treatments.
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Editorial
WOMAC: A 20-Year Experiential Review 
of a Patient-Centered Self-Reported Health 
Status Questionnaire
A key element in clinical research and clinical practice in mus­
culoskeletal medicine is the evaluation of the therapeutic beneiit 
of interventions used either singularly or in combination. In both 
clinical research and clinical practice environments, reliability, 
validity, and responsiveness are essential attributes of health sta­
tus measurement tools, and in the latter brevity, simplicity, and 
ease of scoring are regarded with high importance’-^ .
Prior to 1981, measurement procedures for quantifying 
pain, stiffness, and physical disability in hip and knee 
osteoarthritis (OA) in rheumatology were diverse and lacked 
standardization in content, format, and scaling^. Further, 
health status questionnaires were available in very few lan­
guages, most often having been developed in English and 
translated into a few European languages.
The challenge in 1981 was to build a standardized disease- 
specific patient-relevant self-reported health status question­
naire for hip and knee OA. In 1982, I had the opportunity in 
the course of completing an MSc thesis to describe the devel­
opment of a health status questionnaire termed the Western 
Ontario and McMaster (WOMAC) Osteoarthritis Index! 
Twenty years later, the WOMAC Index has been extensively 
validated and has been translated and linguistically validated 
in over 60 altemative-language forms. In the majority of alter- 
native-language forms it is available in both Likert (LK) and 
visual analog (VA) scaling formats. There are several hundred 
citations (full manuscripts, abstracts, reviews) to the use of 
WOMAC in validation studies, comparative studies against 
other health status measures, and in its application in various 
clinical research and clinical practice settings^.
Tlie idea for the WOMAC index evolved from a brief dis­
cussion with Professor Watson Buchanan, a conversation in 
which I sought his advice in selecting a thesis topic that would 
address an unmet need in clinical measurement. While devel­
opment of the idea took only 12 months, the validation and 
implementation was to consume much of the next 15 years. 
Between 1996 and 1999 the Index underwent significant 
refinement, a process that has been consolidated between 
1999 and the present, and has resulted in the 3.1 series of 
WOMAC questionnaires. The WOMAC LK3.1 and WOMAC 
VA3.1 versions of the Index are now extensively used, partic­
ularly in assessing efficacy in pharmaceutical and biotechnol­
ogy environments.
'ITie success of the WOMAC index is in large part related 
to 6 factors: (1) Extensive patient involvement in the devel­
opment of the item inventory®. This is perhaps the most 
important since it is an approach that reduces the potential 
influence of paternalism, and anchors the item content into 
aspects of the disease experience that are relevant to patients, 
and to which they can therefore relate. (2) The conduct of 
numerous studies evaluating different clinimeiric properties 
of the Index, including analyses evaluating valichty, reliabili­
ty, and responsiveness, comparative studies assessing LK ver­
sus VA scaling, blind versus informed presentation, tracking 
signal items versus complete index usage, parametric versus 
non-parametric analyses and time frame variations®. (3) The 
development and linguistic validation of numerous altema­
tive-language forms of WOMAC VA3.1 and WOMAC LK3.1 
using a standard operating procedure based on tandem for­
ward and backward translation processes and subsequent lin­
guistic validation®. (4) Continued research and development 
into content and administration issues including the applica­
tion of WOMAC in telephone interviews’ as well as mouse 
driven cursor and touch screen electronic data capture for- 
mats*' .^ (5) The incorporation of WOMAC into Osteoarthritis 
Research Society International (OARSI) clinical trials guide­
lines as an index relevant to outcome measurement in 0A'°; 
and (6) the provision of the WOMAC Index, in the required 
scaling format, alternative-language form, and administration 
format for academic, commercial, and clinical applications, 
and ongoing user support.
The development of WOMAC has not been without its 
challenges. Trans-cultural adaptation of the WOMAC 3.1 
Index has been a complex process for which Health Outcomes 
Group, Palo Alto, California, USA, have taken primary 
responsibility and in which they have applied their standard 
operating procedures to develop linguistically valid alterna- 
tive-language forms of extremely high quality. The prepon­
derance of instruments developed in either North America or 
Europe might be viewed with concern given the global nature 
of OA and diversity of lifestyles. It is gratifying, therefore, 
that the performance of the WOMAC Index has been main­
tained in its global applications. Tims, while potentially 
reflecting a restricted view of global diversity, the Index nev­
ertheless appears to tap into the commonalities that exist in the
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dimensionality of the symptomatology of OA. That notwith­
standing, it is clear that the impact of environmental chal­
lenges involved in, for example, stair climbing and trans­
portation are different in different parts of the world, and 
bathing and toileting habits are quite varied. The index con­
structor therefore is faced with the dilemma of whether to 
modify the item content and risk comparing apples with 
oranges or making minor accommodations in order to main­
tain a standard question battery. In the case of the WOMAC 
Index, the latter strategy has been followed, and allows a 
small degree of flexibility in interpretation. In terms of lai'ge 
multinational clinical trials I believe this is the preferred solu­
tion. However, it is possible that at a national level, for clini­
cal practice applications, modification of the item inventory 
either at an individual question or group of questions (module) 
level might provide additional advantage.
We have assessed the performance of items self-selected 
by individual patients, a so-called signal strategy, but have 
been concerned by the inconsistency with which patients 
adhere to the selected signal with the passage of time. Our rec­
ommendation at the present time, therefore, is to use the entire 
Index, rather than the signal form.
Scaling format selection is a challenge for any instrument 
developer, trade-offs often being involved. Likert and VA 
scales are both commonly used in health status questionnaires. 
Likert scaling provides a simple and easing scoring system, 
while the more demanding VA scale may be slightly more sen­
sitive. For this reason we have created parallel forms of the 
WOMAC 3.1, making available both LK and VA formats for 
most language forms. In the alternative-language forms, it has 
been interesting to note that even for the standard scales, word 
usage is different in different countries. For example, words 
such as “moderate” and “extreme” may be deemed appropri­
ate in one context, but not in another. As a result the equiva­
lent words may be “average” or “very severe,” respectively, in 
some cultures.
I have been interested to note over the last several years 
that in some cases the WOMAC Index appears to have passed 
from one user to another and occasionally in that process the 
instrument has been altered in a variety of ways. Sometimes 
the modifications seem quite minor, such as crowding the 
questions on to one or 2 pages. On other occasions, more rad­
ical alterations of the Index have been made such as rescaling 
the instrument, using Health Assessment Questionnaire-style 
scaling or using a 5 centimeter instead of 10 centimeter visu­
al analog scale on a paper version of the instrument. From 
time to time I have been sent versions of the instrument that 
are incomplete, usually the result of the provider not having 
photocopied the entire instrument when passing it. on to a 
friend or colleague. I have also encountered versions in which 
additional questions have been added but for which there is no 
apparent evidence of subsequent revalidation. Tlie concern 
here is that some modifications may degrade instrument per­
formance, or at the very least erode the level of standardiza­
tion previously achieved. For this reason, and because the 
Index, even in English, exists in a number of different forms 
having different applications, I prefer to provide the most 
appropriate form of the Index directly to end users in order to 
better meet their specific measurement needs.
In comparative analyses against other disease-specific and 
generic health status measures, the WOMAC Index has fre­
quently been superior in performance”’’!  Two Rasch analy­
ses using an item response theory approach to index construc­
tion seem to generally uphold the current structure, although 
this now populai" approach might suggest some modification. 
However, the consequence of such modification on respon­
siveness has yet to be determined’®’’®. Recommendations both 
for shortening the Index”  and for lengthening the Index’® 
have been made, the former to reduce responder burden, the 
latter to encompass other, potentially younger and more ath­
letic, individuals in orthopedic environments. A role for the 
WOMAC Index in predicting future health status’^  and health 
resource utilization^® has been suggested, but remains to be 
clarified. Similarly, an application of the WOMAC Index in 
the assessment of lower limb involvement in rheumatoid 
arthritis has been suggested, but remains to be verified^’.
It is important to consider whether the development of the 
WOMAC Index is static or dynamic. The answer is most cer­
tainly that it. is and remains distinctly dynamic. Tlie develop­
mental form of the WOMAC had 5 subscales (pain, stiffness, 
physical function, social function, emotional function), the 
first 3 of which were retained in the original form of the 
WOMAC and probed the symptom experience of OA in the 
“hips/and or knees.” The WOMAC 3.0 focused on an investi­
gator selected study joint. During that phase of development 
we also experimented with strategic variations such as using 
sepai'ate WOMAC indices for the study knee and the con­
tralateral knee, and using separate WOMAC pain and stiffness 
subscales for the left and right knees but a common WOMAC 
physical function subscale. We have experimented with set­
ting the time frame at 24 h, 48 h (WOMAC 3.1), past. 7 days 
(WOMAC 3.1W), and past month (WOMAC 3.1M), and have 
created alternative-language forms and a signal version 
(WOMAC 3.IS). The development of the alternative-lan­
guage translations has resulted in enhancements to the instruc­
tions to patients, the subscale introductory comments, the 
question stems, and to the WOMAC User Guide. We have 
looked at short-forming the Index (WOMAC 3.1SF), initial 
analyses siiggesting the prefened short form may be in part 
dependent on clinical setting, geographic environment, and 
analytic strategy^ .^ Opportunities for electronic data capture 
by computer-assisted technology have resulted in programs 
looking at alternatives to patient in-office self-completion on 
paper®. We are currently engaged in an initiative to assess the 
added value, from an effectiveness and cost-effectiveness 
standpoint, of providing quantitative WOMAC data to practi­
tioners in a routine clinical care setting. We are also examin­
ing an expansion of the current WOMAC inventory
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(WOMAC 3.1ER) to accommodate some potential opportuni­
ties that may exist in the study of purported structure-modify­
ing OA drugs. WOMAC data have been used in developing a 
definition of minimum perceptible clinical improvement^®, 
and together with data from other instruments in developing 
the OARSI Responder Criteria®^ ’. We are further evaluating a 
weighting and aggregation system for the WOMAC Index 
using a device called the Patient Assessment of the Relative 
Importance of Symptoms (PARIS) Sectogram®, and examin­
ing the relationship between WOMAC scores and scores from 
several generic health-related quality of life measures in 
patients with and without comorbidity. We are cuirently rede­
veloping the WOMAC website at www.womac.org to 
enhance information flow with new and established WOMAC 
users. An additional consequence of the WOMAC develop­
ment has been the advantage provided by that experience, in 
the rapid development of a comparable index, termed the 
Australian/Canadian (AUSCAN 3.0) Index^ ®’®®, for OA hand 
studies, details of which can be located at www.auscan.org. 
All these activities are indicative of a dynamic longterm com­
mitment to advance and refine patient-centered outcome mea­
surement in OA, for application in clinical research and clini­
cal practice environments.
The last 20 years’ development of the WOMAC has not 
been simply the application of classical measurement theory 
to symptom quantification. It has also involved an extensive 
collaboration with colleagues in musculoskeletal medicine 
and other health disciplines, and the interest and commitment 
of many patients with knee and/or hip OA. I am most grateful 
to all those who have given their time and resources to support 
this international initiative. The principal challenges now are 
to make a good measure even better, to maintain its relevancy 
in a changing multicultural world, to broaden its application in 
clinical practice environments, particularly considering issues 
such as individual response, shared goal setting, and personal 
and environmental modulators of outcome, to meet, emerging 
needs in structure modifying environments, and to take advan­
tage of emerging technological opportunities.
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SECTION 7 - Flexible Delivery
The traditional method of administration of the WOMAC Index is by patient self­
completion of the paper version. However, envisioning developments in electronic data 
capture (EDC) in research environments and applications o f the WOMAC Index in 
clinical practice, population or community-based research studies, or decision-making in 
health care management, alternative delivery platforms for the WOMAC Index were 
explored.
Early work with a mouse-driven cursor application on a NeXT computer, and 
subsequently modified for use on a personal computer, was successful in developing the 
concept of EDC with the WOMAC Index, and validating an e-version of the WOMAC 
VA3.0 Index (27). The software was not completely debugged, and because of the 
emergence of more readily available touch-screen technology, we halted further 
development on this particular application. Nevertheless, the study was successful in 
demonstrating that valid WOMAC e-data, comparable to paper-based WOMAC data, 
could be acquired by patient self-completion at a computer terminal and transmitted to a 
remote location in another city (27).
In preparation for a pharmaco-economic evaluation of hylan G-F 20 in knee OA 
(17,18), a comparative study was undertaken comparing telephone versus onsite 
completion of the WOMAC LK3.0 Index (28). The purpose of the study was to explore 
whether valid WOMAC data could be obtained by a telephone interviewer, thus 
obviating the need for a patient to visit the doctor’s office to self-complete the WOMAC 
LK3.0 Index (28). The study demonstrated that the method was both feasible and valid, 
and facilitated the delivery of the WOMAC Index by telephone in the aforementioned 
pharmaco-economic evaluation o f hylan G-F 20 (17,18).
By late 1999, touch screen technology was evolving, but software was still not 
commercially available to support EDC of WOMAC data by touch-screen, and hardware 
was less than ideal for the application. A collaborative project, with colleagues in 
Switzerland, was initiated to build a touch-screen computer and write computer code for 
software to support patient self-completion of the e-WOMAC Index on a laptop computer 
(29). The study employed an 11-point numerical rating scale German for Switzerland 
version of the Index (WOMAC NRS 3,0) (29). The study demonstrated that the method 
was feasible, and e-WOMAC data comparable to paper-based WOMAC data were 
obtained, thus demonstrating the validity of this method of data capture using touch­
screen technology. The responsiveness of this version of the e-WOMAC Index was not 
evaluated.
A further collaborative project, with colleagues in Switzerland, based on the 
German for Switzerland 5-point Likert version of the WOMAC Index was initiated, and 
utilised a commercially available touch-screen laptop computer and new purpose-built 
software to support patient self-completion o f the e-WOMAC Index (30). The study 
demonstrated that the method was feasible, and e-WOMAC data comparable to paper- 
based WOMAC data were obtained, thus demonstrating the validity of this method of 
data capture using touch-screen technology (30). Furthermore, the responsiveness of the 
e-WOMAC LK 3.0 Index was evaluated in a longitudinal study, and found not to differ 
from that of the paper version (30).
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Having worked with different versions of the WOMAC Index scaled on 5-point 
Likert, 11-point numerical and 100 mm visual analogue scaling formats, a study was 
undertaken to explore the relative responsiveness of different scaling formats (31). The 
study did not involve the WOMAC Index, but employed instead single global pain 
questions scaled in different formats, as well as the McGill Pain Questionnaire (MPQ). 
The patterns of joint involvement with OA varied between patients and were not confined 
to the hip or knee joints. The observations were consistent with our previous experience 
with the WOMAC Index, that the standardised response mean, a measure of 
responsiveness, was greater for the VA than the Likert scale. A similar analysis 
conducted by our group in patients with rheumatoid arthritis showed a similar scale- 
dependent pattern, as did a subsequent experience with a WOMAC-like Index, called the 
Australian/Canadian (AUSCAN) Hand Osteoarthritis Index, also originated by the author 
of this thesis. The 100 mm VA scale generally, therefore, appears to be more responsive 
than the 5-point Likert scaled equivalent (31).
Based on postal surveys conducted in the late 1990s in Canada (32) and Australia 
(33), responding clinical rheumatologists in both countries placed value for routine 
clinical care applications, not only on an assessment technique’s validity, reliability and 
responsiveness, but also on its simplicity, quick completion and easy scoring. Accepting 
the limitation of the survey method, this requirement did not appear specific to OA, and 
likely represented a general trend, that might, in part, explain the relatively low level of 
uptake in routine clinical practice o f health status questionnaires used relatively 
frequently in clinical research environments in studies of rheumatoid arthritis, 
osteoarthritis, ankylosing spondylitis and fibromyalgia (32,33).
In order to explore the opportunities for, and consequences of, shortening the item 
inventory o f the WOMAC Index, a study was initiated, in collaboration with colleagues 
in France, on the longest of the WOMAC Index subscales, namely the physical function 
subscale (34). The investigation, using the WOMAC LK 3.0 Index in French for Canada, 
in 1218 outpatients, resulted in the cautious proposal of an 8-item short form of the 
normally 17-item long function subscale (34). The need for further studies, o f different 
language translations and scaling formats, in different countries, clinical environments 
and interventions was acknowledged (34). Nevertheless, this study provided preliminary 
insight into opportunities for short-forming, in order to meet clinical practice user needs 
for simplicity and quick completion, in health status assessment questionnaires.
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Validation Study of a Computerized Version of the 
Western Ontario and McMaster Universities VA3.0 
Osteoarthritis Index
NICHOLAS BELLAMY, JANE CAMPBELL, JOHN STEVENS, LAWRENCE PILCH, CINDY STEWART, 
and ZAHID MAHMOOD
ABSTRACT. Objective. To study tlie validity and feasibility of a computerized version of the Western Ontario and 
McMaster Universities (WOMAC) Osteoarthritis Index.
Methods. Thirty patients with osteoartliritis (OA) o f the knee completed botli a paper and a com­
puterized version of WOMAC in random order. The visual analog scaled version of WOMAC,
VA3.0, was used. We studied criterion validity by comparing the paper and computerized versions.
Results. AU patients completed the computerized version without undue difficulty. Criterion validi­
ty, based on aggregated subscale scores, was excellent: Pain, ICC = 0.89, Stiffness, ICC = 0.87, 
Physical Function, ICC = 0.95,
Conclusion. Tlie computerized version o f WOMAC VA3.0 is a valid alternative to the paper ver­
sion. (J Rheumatol 7997,•24:2413-5)
Key Indexing Terms:
WOMAC OSTEOARTHRITIS INDEX  
OUTCOME MEASUREMENT
VALIDITY
OSTEOARTHRITIS CLINICAL TRIALS
Initially developed in 1982’, the Western Ontario and 
McMaster Universities (WOMAC) Osteoarthritis Index has 
been the subject of 2 major validation studies^ *®. The index 
takes the form of a self-administered questionnaire of 24 
questions categorized in 3 subscales (Pain, Stiffness, 
Physical Function). In addition to verifying the adequacy of 
the reliability, validity (face, content, construct), and respon­
siveness of the index, we examined several of its basic prop­
erties including the effects of (1) Likert (LK) versus visual 
analog scale (VAS) formatting^®; (2) blind versus informed 
presentation'*; (3) time frame dependency of scores®; (4) 
parametric versus nonparametric forms of analysis^®; (5) 
signal versus aggregate methods of measurement®’^ ; and (6) 
weighting and aggregation issues®. Originally developed in 
English, the index has now been translated into several alter­
native languages for use in more than 25 countries. Recently 
tlie WOMAC Index has been recommended as a suitable
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clinical measure for assessing outcomes in Phase III clinical 
trials in hip and knee osteoarthritis (OA)®. Given its general 
usage, particularly in multicenter clinical trials, we evaluat­
ed a computerized version of WOMAC. The purpose of the 
study was 2-fold: (1) to validate the computerized format 
(WOMAC-C) against the original paper format (WOMAC- 
P), and (2) to assess the feasibility of patients completing 
WOMAC-C and subsequently transmitting scores by 
modem from London to a central computer in Toronto.
MATERIALS AND METHODS
Thirty consecutive consenting outpatients considered to have primary OA 
of the knee were enrolled in tlie study. Inclusion criteria included: sympto­
matic primary OA of at least one knee for at least 3 months; age 45-80 
years; American Rheumatism Association (ARA) functional class I-III'®; 
radiographic evidence of narrowing of joint space, sclerosis, marginal lip­
ping. bone cysts or osteophyte formation, with a minimum Grade 2 and 
maximum Grade 3 severity'*. Exclusion criteria included: inability to com­
prehend English, ARA functional class IV, prior joint replacement surgery 
on the study knee. Tlie following disease and demographic variables were 
recorded: age, sex, disease duration, ARA functional class, radiographic 
class assessed by comparison against radiographs in the A tla s  o f  S ta n d a rd  
Radiographs'^ .^ Patients completed the 2 versions of WOMAC in random 
order. There was an interval of about 10 min between completion of the 2 
versions. Patients did not have access to their prior scores when complet­
ing tlie 2nd version, and since tlie WOMAC contains 24 questions (answers 
being made on VAS), it was not considered likely tliat they could remem­
ber tlieir initial scores.
For tliis study tlie paper version (WOMAC-P) was the VAS version of 
WOMAC (syn; WOMAC VA3.0). Patients self-assessed their pain, stiff­
ness, and physical function over the preceding 48 h with respect to their 
study knee. WOMAC-C was developed as part of a computerized mea­
surement process for longterm studies of the effects of antirheumatic drugs 
on cartilage. Tlie software was developed by L. Pilch and ran on a NeXT 
computer. The WOMAC questionnaire was displayed on the color monitor
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ill a format very similar to that of the original paper version. Patients were 
instructed to indicate their scores directly on the screen for each of the 24 
WOMAC items using a mouse to move the cursor. An assistant (JC) was 
present to demonstrate how to use the mouse. Tlic VAS were horizontally 
oriented with the same terminal descriptor format as the paper version. Tlie 
cursor was in tire form of a short box with a central vertical indicator mark­
er, The marker could be set anywhere between tlie tenninal descriptors by 
mouse manipulation. Patients were given the opportunity to review their 
cursor placements and revise them if they considered it necessary. The cor­
responding numerical values between 0 and 100 were automatically gener­
ated for each VAS from the exact cursor placements but were not revealed 
to the patient. Instead, they were stored in London and downloaded each 
night to the central computer in Toronto.
Statistical analysis was performed using SPSS/PC'^. Descriptive analy­
ses were conducted on the demographic variables. Mean aggregated 
WOMAC-C and WOMAC-P subscale scores were compared by paired t 
tests. Intraclass correlation coefficients (ICC) were calculated between the 
paper and tlie computerized aggregated WOMAC subscale scores' ,^
RESULTS
Thirty patients completed both versions of the question­
naire. There were 19 women and 11 men with a mean age of
64.8 years (range 46-77). Mean disease duration was 10.8 
years (range 4 mo-25 yrs). ARA functional class was grad­
ed as Class 2 in 25 patients and Class 3 in 5 patients. The 
mean and standard deviation (SD) of WOMAC scores for 
the (P) and (C) formats as well as the mean difference and 
SD of the difference between the 2 fonnats are shown in 
Table 1. Statistically significant differences were observed 
between aggregate pain (p = 0.04) and physical function 
(p = < 0.(X)1) subscale scores using tlie 2 versions of the 
questionnaire, but not on the stiffness subscale (p = 0.44). 
The pattern of response even for a single individual was 
quite variable, responses on WOMAC-C being higher than 
WOMAC-P on some items but lower on others. In all, there 
were 720 comparisons (i.e., 24 items and 30 paiieuts). In 
56% of instances WOMAC-P scores were greater than 
WOMAC-C. In 39%, WOMAC-P scores were less than 
WOMAC-C scores, and in 5% they were identical. In com­
parisons where a difference was detected, the magnitude of 
the mean difference was greater when WOMAC-P was 
higher than when WOMAC-C was higher (Pain 16.3 vs 8.9;
Stiffness 13.6 vs 11.5; Function 12.2 vs 8.8; Overall 12.8 vs 
9.4). The percentage differences between WOMAC-C and 
WOMAC-P mean scores were as follows; Pain 8.1%, 
Stiffness 3.5%, and Physical Function 8.9%. Wlien consid­
ered with respect to the corresponding scale lengths (Pain 
500 ram. Stiffness 2(X) mm. Physical Function 1700 mm), 
the percentage differences in mean scores, i.e., [(WOMAC- 
P -  WOMAC-C/scale length) x 100], were as follows: Pain 
3.5%, Stiffness 1.7%, Physical Function 4.1%. The frequen­
cy of zero scores was extremely low and similar in the 2 
forms of the index (WOMAC-C: Pain 0.01%; Stiffness 0%; 
Function 0.02%; WOMAC-P: Pain 0%; Stiffness 0%; 
Function 0.02%. Criterion validity (assessed using ICC), 
based on aggregate subscale scores between the 2 forms, 
was excellent (Table 1). No order effects were observed.
Following some simple instructions, no patients had any 
significant difficulty completing the task, although the 
majority had no prior experience working with computers. 
All completed the task in 10-15 minutes. Automatic scoring 
on site, storage, and remote transmission of data to Toronto 
were successfully achieved for all patients.
DISCUSSION
The use of valid, reliable, and responsive measures is quin­
tessential to the efficient and successful completion of clin­
ical trials. The WOMAC Osteoarthritis Index, like several 
other musculoskeletal indices*'*, has been rigorously validat­
ed in several settings. Its use by several groups of investiga­
tors and its incorporation in recent Osteoarthritis Research 
Society guidelines aie indicative of its widespread use in 
multicenter trials. In such trials the ability to transmit raw 
data to a central or mainframe computer is of considerable 
importance. If, in addition, the time consuming task of gath­
ering data from case report forms and/or measuring VAS 
scores from raw data sheets can be automated, there is fur­
ther efficiency. Tiree questions arise: (1) Is the method 
valid?; (2) What is tlie feasibility of this approach?; (3) Can 
the data be irretrievably lost? With respect to this study, we 
observed excellent correlation, assessed by ICC, between
Table 1. Descriptive statistics for WOMAC-P and WOMAC-C based on aggregated subscale scores.
WOMAC Subscale Mean SD Mean
Difference
SD of 
Difference
t test 
p value
ICC
Pain
WOMAC-P 216.2 101.2
WOMAC-C 198.7 96.0 17.5 41.4 0.04 0.89
Stiffness
WOMAC-P 95.2 46.8
WOMAC-C 91.9 41.8 3.3 . 22.8 0.44 0.87
Physical Function
WOMAC-P 777.5 357.4
WOMAC-C 708.6 329.9 68.9 91.0 < 0.001 0.95
SD: standard deviation;
ICC: intraclass correlation coefficient.
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WOMAC-C and WOMAC-P scores, suggesting that 
WOMAC-C is valid and can be used as an alternative to 
WOMAC-P for clinical trial purposes. We have, in addition, 
examined agreement, both descriptively and comparatively. 
The differences in mean scores on the pain and physical 
function subscales observed between the 2 formats are 
numerically small and clinically unimportant (i.e., < 10%). 
However, the slight differences in pain and physical func­
tion scores indicate that the 2 forms should not be inter­
changed during the course of a single trial. The observed 
difference between WOMAC-P and WOMAC-C scores is 
accounted for by the fact that WOMAC-C scores were lower 
(vs WOMAC-P scores) in a greater percentage of responses 
and also the magnitude of those differences was greater. The 
reason for computer scores being slightly lower is specula­
tive. It may relate to the near vertical orientation of the com­
puter screen vs the horizontal placement of the paper ques­
tionnaire. Tlie use of a mouse rather than a pen may alter the 
patient’s perception of the VAS. Finally, tlie cursor is broad­
er than the pen marker. Possibly patients line up on the right 
hand end of the cursor rather than centering it on the intend­
ed placement. We evaluated the possibility of a floor effect 
by comparing the percentage of patients with zero scores. 
However, these are rare and did not differ between the 2 
forms of the WOMAC. Each of these possibilities, while 
plausible, does not explain how all individuals answered 
higher on some questions but lower on others (vs WOMAC­
PI. The feasibility of having patients of varying age, sex, 
computer literacy, and background complete WOMAC-C 
has been confirmed in this study. However, we have not 
studied the extremes of age or the socioeconomically disad­
vantaged or those less conversant in the English language. 
Nevertlieless, the questionnaire was completed successfully 
by all patients in a short time (10-15 min). Finally, we were 
able to automatically score the exact cursor position on tlie 
VAS, generate an in-house record, and then automatically 
download the data to the central computer in Toronto with­
out loss of information. Since a permanent record (hard 
copy) can also be produced on site before the patient’s 
departure from clinic, the possibility of total data loss can be 
avoided.
In conclusion, we compared a computerized version of 
WOMAC against the original paper questionnaire, and 
observed this to be a valid, feasible, and efficient method of 
collecting, recording, and transmitting data. Although we 
have not yet studied the relative sensitivity to change (i.e., 
responsiveness) of WOMAC-C (vs WOMAC-P), this study
has im plications for the conduct o f  future c lin ica l trials in 
OA, particularly those u sin g  m ultiple centers. W e are cur­
rently com pleting co n version  o f  the softw are to run on IBM 
com patib le  com puters. T h is adaptation should  provide  
broader access to researchers w orking in IBM form ats.
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A Comparative Study of Telephone versus Onsite 
Completion of the WOMAC 3.0 Osteoarthritis Index
NICHOLAS BELLAMY, JANE CAMPBELL, JONATHAN HILL, and PHILIP BAND
ABSTRACT, Objective, Outcome assessment in clinical trials using the Western Ontario and McMaster 
University (WOMAC 3.0) Osteoarthritis Index is traditionally achieved through self-administration 
of the Index. However, in other areas of clinical measurement, telephone administration has been 
shown to be a reliable method of acquiring data that are both accurate and complete. To address this 
issue in knee osteoarthritis (OA), we conducted a comparative study of telephone administration by 
interviewer of WOMAC LK3.0 versus onsite self-completion at the hospital.
M ethods. Fifty consenting patients with knee OA were randomized to complete the W OMAC LK3.0 
Index by telephone interview one day, followed by onsite completion the following day, or vice 
versa. Neither patients nor interviewers had access to any prior scores.
Results. The mean age o f the 50 patients was 66.3 years (range 44-82); 34  (68%) were female and 
16 (32%) male. There was excellent agreement between (he mean office and telephone scores, with 
mean differences for the WOMAC LK3.0 pain, stiffness, and function subscale scores and total 
score o f 0.09, 0.12, 0.78, and 0.98, respectively. These differences were well within the respective 
protocol defined equivalence criteria of ± 1.7, ±  0.9, ± 6.4, and ± 9.1, and represented differences 
from office scores of 0.9, 2.6, 2.4, and 2.2%, respectively.
Conclusion. The use o f telephone interviews for the WOMAC LK3,0 Index is a valid method of 
obtaining OA outcome measurements. These observations have important implications for 
designing data acquisition strategies for future OA clinical trials and for longterm observational 
studies. (J Rheumatol 2002;29:783-6)
K ey Indexing Terms: 
OUTCOME ASSESSM ENT  
WOMAC SURVEY
The use of telephone contact to collect information on 
patient outcomes is well founded in the literatme. Tliis 
method has been used in several clinical studies and has 
been foimd to be a valid tool for patient outcome assess­
ment”®. I-Iowever, searching under the MeSH headings 
“telephone,” “survey,” “VAS,” “WOMAC,” “osteo­
artluitis,” and “outcomes,” no published data could be found 
specifically validating the use of data collected by telephone 
in osteoarthritis (OA) outcome studies. The Western Ontario 
and McMaster University (WOMAC) Osteoarthritis Index 
has been in use for 19 years®'®, but to date tlrere has been no 
formal assessment of tlie Index comparing telephone admin-
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istration by interviewer against the usual approach of self­
completion onsite in the clinic or doctor’s office. 
Verification of tire validity of telephone data, in comparison 
to visit-collected data, would be useful for designing data 
acquisition stmtegies for future OA clinical trials, as well as 
for longterm longitudinal studies. This study was under­
taken to validate telephone assessment of tlie WOMAC 
LK3.0 Index by comparing the results of telephone inter­
views versus onsite assessments.
MATERIALS AND METHODS
This was a single center, outpatient study, designed to compare patient 
responses to the WOMAC LK3.0 instrument administered by telephone 
and during an office visit. It was conducted as part of a larger study, 
comparing telephone vs office administration of 3 visual analog measures 
of pain and function (TPQ-VAS) and a 5 point Likert scaled patient global 
assessment (PGA) question whose performance we are evaluating. In each 
case, the WOMAC LK3.0 was the first questionnaire completed, since we 
wished to avoid reactivity on WOMAC LIC3.0 scores. The WOMAC 
LK3.0 is a tridimensional joint targeted, patient centered questionnaire 
containing 5 pain, 2 stiffness, and 17 physical function questions, responses 
to which are scaled on 5 point (none, mild, moderate, severe, extreme) 
adjectival scales resulting in subscale score sizes of 0-20 for pain, 0-8 for 
stiffness, 0-68 for physical function, and 0-96 for total score. Male and 
female outpatients from the investigator’s practice were initially contacted 
by one of the following methods: ( 1) by letter requesting their participation 
in the study; (2) by telephone call; or (3) during their visit to an outpatient 
clinic. Screening procedures included a review of the inclusion criteria. 
Patients meeting the following criteria were eligible for entry into the
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study: over 35 years of age, inclusive; radiographic evidence of knee OA^ ; 
ability to understand English; and willingness to participate in the study 
according to the protocol. Because of the noninvasive nature of this study, 
there were no explicit exclusion criteria. Patients who wished to enroll 
received a blank copy of the WOMAC LK3.0 questionnaire for reference 
during the telephone interview. The first 50 patients from the investigator’s 
patient population who consented to participate were selected for study. 
After enrolling in the study, patients were randomized to one of 2 groups. 
Group 1 completed questionnaires by telephone on Day I, followed on Day 
2 by questionnaire completion in the office. Group 2 completed question­
naires in the office on Day 1, followed by telephone completion on Day 2, 
All interviews, whether by telephone or in the office, were supervised by 
an evaluator trained in the administration and evaluation of the WOMAC 
LK3.0 Index. At the beginning of the study, patients were asked to select 
the knee with the worst OA symptoms. This was then designated their 
study knee. The WOMAC LK3.0 questionnaire contained written instruc­
tions for completion of the form. Patients were instructed to rate the 
severity of the pain, stiffness, and physical disability they had experienced 
in their study knee over the previous 4 weeks. The WOMAC LK3.0 was 
self-administered in the office. During the telephone assessment, the eval­
uator read each WOMAC LK3.0 question, and then recorded the patient’s 
response on the blank questionnaire. Neither the patient nor the evaluator 
had access to any prior WOMAC LK3.0 scores.
Patients were free to withdraw from the study at any time. However, 
because of the short duration and noninvasive nature of the trial, no explicit 
provisions for removal of patients from assessment were included in the 
study protocol. This study did not involve drug administration or other 
invasive procedures, and patients were not requested to make any changes 
to their existing treatment regimen prior to or during the assessment period. 
Prior and concomitant therapies were not expected to have a material effect 
OH the results because o f  the short retest interval, and therefore concomi­
tant therapies were neither recorded nor controlled.
Statistical issues. As noted, this study was conducted within the framework 
of a larger study. As a consequence, sample size calculations were 
performed to estimate the minimum sample size required to establish with 
95% confidence that TPQ-VAS telephone values did not differ by more 
than 15 mm from office administered values. Statistical analyses for equiv­
alence were performed using analysis of variance (ANOVA) (alpha = 0.05) 
to establish the upper and lower limits of the relevant confidence interval*®. 
Twenty percent has been used in the arthritis literature as a threshold value 
for declaring a clinically important difference*', and earlier studies have 
established standard deviations for VAS measures of pain of about 15 
mm*^ '*^ . Equivalence was to be inferred if the 95% confidence limits for the 
differences between the office and telephone scores were within ± 20% of 
the mean office scores. Based on these assumptions, a sample size of 50 
patients was determined to be adequate for the required statistical power. 
This sample size was also considered adequate for evaluating similar issues 
for the WOMAC LK3.0 and the PGA (i.e., equivalence was to be inferred 
if the 95% confidence limits for the differences between the office and tele­
phone scores were within ± 20% of the mean office scores).
After completion of the questionnaire stage of the stndy, data were 
entered from the patient questionnaires into a database and subjected to 
quality assurance procedures that were double verified, providing 100% 
verification for the key OA outcome measurements. There was no a priori 
reason to suspect that performing the assessment in the office first would 
influence the outcome of the subsequent telephone interview and vice 
versa. However, because of this, it was necessary to ensure that results from 
the office visit and the telephone interview were consistent, regardless of 
order of presentation.
For each outcome measure, ANOVA statistics were computed for the 
telephone and office scores, classifying them with respect to those obtained 
first and those obtained second. The first and second office scores and the 
first and second telephone scores were to be pooled if p values for a given 
outcome measure were greater than 0.05. Comparisons were made using
the pooled error estimate obtained from the ANOVA. Scores for outcome 
measures that satisfied the pooling criterion were pooled and evaluated for 
equivalence as follows. WOMAC LK3.0 data were treated as continuous 
normally distributed data for the purposes of the analyses. Difference 
scores for each WOMAC LK3.0 component were calculated on a by­
patient basis by subtracting the value determined on the telephone from the 
corresponding office visit value. These differences were then subjected to 
statistical analysis based on the principles advanced by Bland and 
Altman*®, and using the SAS program PROC Means.
RESULTS
An initial cohort of 50 patients was selected for the study. 
One patient, who did not have a knee radiograph on file to 
provide radiographic evidence of OA, was subsequently 
dropped from the study. One otlier patient, randomized to 
telephone assessment on Day 1, was assessed on Day 2 at 
her home instead of in tlie office and was also dropped from 
the study. Data from tliese patients were not included in the 
database. Two additional patients were recruited to achieve 
tlie desired study cohort of 50 patients. Of the final 50 
patients, 22 were randomized to Group 1 (telephone first) 
and 28 were randomized to Group 2 (office first).
In violation of the protocol, 5 patients did not complete 
questionnaires on consecutive days. Four of these patients 
completed tlie second assessment on Day 3, rather than Day
2. One patient completed the second assessment on Day 5 
instead of Day 2. However, because patients were rating tlie 
condition of their study knee over a 4 week timeframe, tliese 
deviations were not considered to be serious violations. 
Furtlier, any effect of tliese more extensive intervals would 
be expected to decrease ratiier tlian increase observed levels 
of agreement. Therefore, the scores for these patients were 
included in tlie analysis.
The mean age of tlie 50 randomized patients was 66.3 
yeais (range 44 to 82). Of these 50 patients, 34 (68%) were 
female and 16 (32%) male. The severity of tlie patients’ OA 
ranged from Grade I to IV, as graded by Kellgren-Lawrence 
radiographs®: Grade I 20%, Grade II 38%, Grade III 40%, 
Grade IV 2%.
The significance of tlie effect of order (first or second) on 
assessment method (office or telephone interview) was 
analyzed by ANOVA. Tlie results aie provided in Table 1. The 
results indicate there were no statistically significant differ­
ences attributed to the order of questionnaire administration 
for any of tlie outcome measures. Tliis means tliat office and 
telephone scores from tliose patients randomized to the tele- 
phone-first questiomiaire were statistically equivalent to tlie 
corresponding office and telephone scores for patients in the 
office-first gioup. Therefore, tlie results from tlie 2 groups of 
patients were combined for the analysis of success criteria.
As described above, tlie WOMAC LK3.0 telephone and 
office visit metiiods were considered equivalent if the 
combined 2 sided 95% Cl for tlie differences between 
metiiods were witliin + 20% of the mean office scores. 
Altliough all patients were symptomatic, tliis study included 
patients with a wide range of OA symptoms. As a result.
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Table 1. Analysis o f  sequence effects.
Outcome Measure Mean Office Scores (SD) Mean Telephone Scores (SD)
First, Second, P First, Second, P
n = 28 n = 22 n = 22 11 = 28
WOMAC Pain 9.H (3.17) 8.16(3.15) 0,424 8.15(3.19) 8.96 (2.77) 0.491
WOMAC Stiffness 5.00 (1.70) 3.95 (1.68) 0.120 3.91 (1.72) 4.82 (1.72) 0.174
WOMAC Function 34.71 (11.46) 28.96 (12.37) 0.212 27.65(11.53) 34.36 (10.52) 0.147
WOMAC Total 48.82(14.70) 41.07(16.41) 0,205 39.71 (15,52) 48.14(14.05) 0.168
zero scores on some, but never on all outcome measures, did 
occur for tlie outcome measures of specific patients. The 
primary success criteria evaluated in tliis study were 
analyzed by subtracting tlie telephone score from the cone- 
sponding office visit score for each WOMAC component. 
The differences were tlien subjected to a statistical analysis 
using tlie SAS program PROC Means. The results of this 
analysis are provided in Table 2. There was excellent agree­
ment between the mean office and telephone scores, witli 
mean differences for die WOMAC LK3.0 pain, stiffness, 
function, and total scores of 0.09, 0.12, 0.78, and 0.98, 
respectively. These differences are also well witliin tlie 
protocol-defined equivalence criteria of ± 1.7, ± 0.9, ± 6.4, 
and ±9.1, respectively, for pain, stiffness, physical function, 
and total WOMAC LK3.0 scores, and represent differences 
from office scores of 0.9, 2.6, 2,4, and 2.2%, respectively.
The exact time taken to complete tlie questiomiaires was 
not measured. However, completion times estimated by 
evaluators were between 5 and 10 minutes.
DISCUSSION
Telephone contact to collect infonnation on patient outcomes 
has been used extensively in clinical studies and has been 
found to be a valid tool for patient outcome assessment. The 
ability to use telephone contacts to obtain OA patient healtli 
assessments would be of great benefit to those patients for 
whom office visits can be both difficult and inconvenient.
Tliis smdy was designed to validate tlie use of WOMAC 
LK3.0 telephone interviews as a measure of OA study
outcome by comparing the results of telephone versus office 
visit assessments. The WOMAC LK3.0 demonstrated excel­
lent agreement between the mean office and telephone 
scores, witli mean differences for the WOMAC LK3.0 
outcome measures ranging from 0.09 to 0.98. The 95% Cl 
were well witliin established equivalence criteria of ± 20% 
of the mean office scores for the respective outcome 
measures. The telephone administered WOMAC can there­
fore be considered as validated by the criteria established in 
the protocol. Tins dernonstratioii of clinical and statistical 
equivalence provides the first evidence that the use of tele­
phone interviews using the WOMAC LK3.0 Index is a valid 
niediod of obtaining OA outcome measurements.
In recognizirig tlie following potential limitations, it is 
acknowledged tliat the results of this study are directly 
generalizable only to individuals and groups having similar 
characteristics to tins group of patients. We have not specif­
ically addressed issues peculiar to lire elderly, those not 
fluent in English, institutionalized patients, those not under 
medical care, or those of low education or socioeconomic 
status. Furthermore, tlie study population was not consti­
tuted to permit such an analysis. It is notable that 
Bombardier, et al have successfully administered the 
WOMAC Index to OA patients seen by family physicians, 
supporting the contention that tliis method of administration 
is feasible in a community based setting*'*. Witli respect to 
memory effects, we have experience witli varying die time­
frame of die WOMAC Index*® and the interval between pain 
assessments*® *"^, as well as performing repeated assessments
Table 2. WOMAC LK3.0 outcome measures: analysis of differences between telephone and office assessments 
(n = 50).
WOMAC
Pain
WOMAC
Stiffness
WOMAC
Function
WOMAC
Total
Mean office scores (SD) 8.69 (3,16) 4.54(1.75) 32.18(12,09) 45.41 (15.80)
Mean telephone scores (SD) 8.61 (2.96) 4.42(1.76) 31.41 (11.47) 44.43 (15.16)
Mean difference 0.09 0.12 0.78 0.98
SD, difference 1,83 0.92 3.43 4.05
Paired t, difference 0.33 0.92 1.60 1.71
Prob > T, difference 0.74 0.36 0.12 0,09
Lower 95%, difference -0.44 -0.14 -0.20 -0.17
Upper 95%, difference 
Protocol defined equivalence 
criteria ± 20% of mean
0.61 0.38 1.75 2.13
office score ±1.74 ±0.91 ±6.44 ±9.08
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of health status on the same patients without time/patient 
interactions^^. WMle the potential for memory effects 
deserves recognition, our experience in dissecting circadian 
rhythm!city in knee OA^ ®, hand OA^ ®, and rheumatoid 
artiuitis^° strongly suggests that patients can detect even 
small changes in symptom intensity, and memory effects are 
negligible or absent.
We did not collect quantitative data on patient and inter­
viewer experience evaluations, or tlie costs and time of 
administration. The costs of conducting telephone inter­
views aie mostly attributable to the costs of reciuiting, 
training, and retaining interviewers and charges for tele­
phone service and line usage. The former does not impose a 
liigh skill requirement, wliile the latter offers opportunities 
to negotiate favorable rates if long distance or liigh volume 
usage is contemplated. Offsetting this is die greater conve­
nience and cost savings to die padent of not having to leave 
home, and the opportunity to collect community based 
radier tiian specialist based information.
It should be noted diat die administration mode-depen­
dent differences detected are very small and in magnitude 
fall below die values of published definitions of minimum 
perceptible clinical improvement^^ minimum clinically 
important difference^^, and responder criteria for OA clinical 
trials^. Tills suggests that die WOMAC Index is capable of 
detecting meaningful alterations in healdi status, when 
administered by telephone. It is worth reiterating that in diis 
study patients were provided widi a blank copy of the 
WOMAC Index for reference during die telephone interview.
These issues notwithstanding, we believe our findings 
can be applied to designing data acquisition strategies for 
futuie OA clinical trials and longtenn observational studies. 
From a research and regulatory perspective, it facilitates the 
completeness and speed of data acquisition and tiansfer, and 
from tlie patient’s perspective allows an accurate assessment 
of OA starns witiiout the inconvenience and physical 
demands associated witli office visits.
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Clinical evaluation of the WOMAC 3.0 OA Index in numeric rating scale 
format using a computerized touch screen version
R. Theiier*, J. Splelberger*, H. A. Bischofff, N. Bellamy^, J. Huber* and S. Kroesen*
"Division o f Rheumatology, Cantonal Hospital Aarau, Switzerland; tDivision of Rheumatology, Immunology 
and Allergy, the Robert B. Brigham Arthritis and Musculoskeletal Clinical Research Centre, Brigham and 
Women's Hospital, Boston, U.S.A.; tCentre of National Research on Disability and Rehabilitation Medicine 
(CONROD), Department of Medicine C Floor, Clinical Sciences Building, Royal Brisbane Hospital, Brisbane, 
Australia
Summary
Background: The Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index is a previously described self-administered 
questionnaire covering three domains: pain, stiffness and function. It has been validated in patients with osteoarthritis (OA) of the hip or knee 
in a paper-based format.
Aim: To validate the WOMAC 3.0 using a numerical rating scale in a computerized touch screen format allowing immediate evaluation of the 
questionnaire. In the computed version cartoons, written and audio instruments were included in order facilitate application.
Methods: Fifty patients, demographicaliy balanced, with radiographtcally proven primary hip or knee OA completed the classical paper and 
the new computerized WOMAC version. Subjects were randomized either to paper format or computerized format first to balance possible 
order effects.
Results: The intra-class correlation coefficients for pain, stiffness and function values were 0.915, 0.745 and 0.940, respectively. The 
Spearman correlation coefficients for pain, stiffness and function were 0.88, 0.77 and 0.87, respectively.
Conclusion: These data indicate that the computerized WOMAC OA index 3.0 is comparabie to the paper WOMAC in aii three dimensions. 
The computerized version would allow physicians to get an immediate result and if present a direct comparison with a previous exam. 
©  2002 OsteoArthritis Research Society International. Published by Elsevier Science Ltd. All rights reserved.
Key words: Patient self-assessment, Electronic WOMAC 3.0, Electronic data capturing (EDC). QÜALITOUCH method.
Introduction
The Western Ontario and McMaster Universities (WOMAC) 
Osteoarthritis index was developed for standardized assessment of osteoarthritis (OA) symptoms In hip and/or knee joints\ It is composed of 24 questions covering three dimensions: pain (five questions), stiffness (two questions) and function (17 questions). The WOMAC OA Index has been extensively tested for validity, reliability, feasibility and 
responsiveness for measuring changes after different OA 
interventions^’^ .Consensus was reached at the third conference on 
outcome measures in rheumatoid arthritis clinical trials (OMERACT ill). An OA research society (OARSI) task 
force dealing with outcome measurement in OA clinic trials decided that the WOMAC OA index as a disease specific questionnaire is recommended for core set assessment in 
OA clinical trials for knee and hip OA"^ .in the present study we used a simplified computer touch 
screen format that could be applied in senior citizens or non-computer skilled individuals by offering a multimedia
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presentation: cartoon, written and spoken (Fig. 1). We 
hypothesized that this method is a reliable way for assess­ing the WOMAC if compared with the original paper ver­sion. The scaling of the computerized WOMAC In a previous study^ was a visual analog scale, in contrast we 
used the same questionnaire but answered a numeric rating scale format.
The development of a computer version of the WOMAC 
index application was of research and clinical interest, This application could improve the quality of data collection in clinical trials by computer-based direct data harvesting. In addition it could simplify Its use both in the research setting and in daily clinical practice.
Materials and methods
Fifty consecutive seen outpatients with radiographically 
proven primary OA were invited to complete both a paper format and a computerized touch screen format of the WOMAC OA Index. The demographics of these patients can be seen In Table I. The following inclusion criteria were employed: symptomatic OA at least in one joint of the lower 
limb with symptoms lasting for at least 3 months and ability to comprehend the German language. Exclusion criterion 
was prior joint replacement on the study joint.
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Wi« stark sind Ihra Schrnerzari tMwrm Srtzeri odar 
Uegerr ? ^
kèine
Scâierzen extremeISchmerzen
Fig. 1. The screen display of the question 4. Translation: Wie stark sind Ihre Schmerzen b»einn Sitzen Oder Liegen?=How much pain do you 
have in sitting or lying. Keine Schmerzen=no pain. Extreme Schmerzen=extreme pain. Zurück=back. Wiederholen=repeat question.
LIberspringen-next.
Patients either completed the paper form first or the 
computerized version first. The mean time interval between completing the computerized version and the paper format of the WOMAC OA Index was 16 min. Patients were not able to see their prior scores. The German paper version of WOMAC 3.0 OA Index using a numeric rating scale format, which has been validated, was used®. For the computer­
ized version audio and visual cues were presented on a 
34.3 cm diameter screen. The questions were answered by touching one of the squares of the numeric rating scale on the computer screen. By using five buttons on screen the 
patient could get help and was able to move one question forward or backward. It was not possible to leave one 
question unanswered. Furthermore the help function self activated after 15 s inactivity and presented the next poss­
ible steps to the patient. The software was developed by a 
private programming company, as was the purpose built touch screen computer. This data capturing method was 
called the QUALITOUCH method.
Table I
Démographie: vaiidation WOMAC NR 3.0
Male 
Female 
Age (range)
Knee right 
Knee left 
Hip right 
Hip left
Knee both side 
Hip both sides 
Mean time difference 
between completing the forms
29 patients 
21 patients 
61 (34-79) years 
12 joints 
10 joints
8 joints
9 joints 
5 joints 
5 joints 
15 min
The numeric rating scale scores 0 (best) and 10 (worst) 
health. Therefore,the maximal aggregated score for pain, stiffness and function was 50, 20 and 170, respectively.A block randomization with a block size of four was used 
for creating the two groups. Descriptive statistics included the mean of the aggregated scores, the standard deviation and the mean difference between the scores of the paper and computerized version. Agreement was assessed using 
intraciass correlation of Spearman's rank correlation coefficient.
Results
Fifty patients completed both versions of the question­
naire. There were 21 female and 29 male with a mean age of 50.5 years (range 34-79). Age and gender was balanced between the groups. The means and standard deviations 
(s.D.) of WOMAC scores for the (P) and (0) formats as well as the mean difference and s .d . of the difference between 
the two formats are shown (Table II). No statistically signifi­cant differences were observed for aggregate pain (P=0.9), stiffness (P=0.6) and physical function (P=0.9) subscale 
sores using the two versions of the questionnaire.The relative (%) differences in mean scores based on 
scale length ((WOMAC-C-WOMAC-P/scale length]*100), were 0.07 for pain, 2.18 for stiffness and 0.42 for physical 
function. A tendency towards zero scores was observed in the three different sections of the WOMAC index. Criterion 
validity, assessed and based on aggregate subscale 
scores between the two formats, was excellent (Table II). No order effects were observed.
Following standardized instructions, no patient had sig­nificant difficulty completing the task, although majority had
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Table IIDescriptive statistics for WOMAC-P and WOMAC-C based on aggregated subscale scores
WOMAC
subscale
Mean
score
S.D. Mean
score
difference
S.D, of
difference
f-test P value ICC
Pain
WOMAC-P 15.64 10.3 0.04 4.28 0.98 0.91
WOMAC-C 15.68 10.4
Stiffness
WOMAC-P 8.28 5.4 0.48 3.76 0.65 0.74
WOMAC-C 7.80 5.0
Function
WOMAC-P 53.8 36.8 0.78 12.42 0.91 0.94
WOMAC-C 54.5 35.9
S.D.: standard deviation. 
ICC: intra class correlation.
no prior experience in working with the computer. Ail 
completed the tasks in 10-15 min.
Discussion
The WOMAC questionnaire is a frequently used out­come measure in patients with lower limb OA. To our knowledge this Is the first published report about a touch 
screen version of the WOMAC questionnaire. The present 
study shows that the touch screen format is reliable if 
compared with the original paper version.In this computerized WOMAC format the questions are shown in a cartoon, written and spoken. This QUALITOUCH method could improve and facilitate the patient's understanding. The questions are answered by touching the screen directly. Thereby neither keyboard nor 
mouse is necessary for working with this computer. This may be important if non-computer skilled persons or senior 
citizens are using the computerized version of the WOMAC 
questionnaire.Future applications are seen in the establishment of 
regional, national or international databases of OA patients 
by connecting the computer to an internet application. In daily clinical practice patients could be asked to do the 
WOMAC index on the portable computer while waiting for e.g. a physiotherapy assessment. The immediate evalu­ation with a graphical display could be used as a patient education tool in the process of rehabilitation, especially if it 
is used in a longitudinal perspective to track the long-term 
outcome, in addition the computer version might be a tool for future quality management projects e.g. in orthopedic 
surgery.In conclusion, the computerized version of the WOMAC seems to be a valid and feasible instrument for outcome measurement in clinical OA trials.
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Summary
Background'. The Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index is a self-administered validated questionnaire 
for patients with osteoarthritis (OA) of the hip or knee. The electronic touch screen version of the WOMAC (e-WOMAC) has been previously 
shown to be highly correlated with the original paper format. However, whether the e-WOMAC would be suitable for monitoring the effects of 
drug treatment is unknown.
Aim: To validate the longitudinal use of the e-WOMAC questionnaire and its ability to detect changes in WOMAC-scores induced by drug 
treatment in outpatient care.
Methods: Fifty-three outpatients, men and women (mean age: 64 years; SD ±  9.5), with symptomatic osteoarthritis of hip or knee were 
included in an open label study with rofecoxib. At three visits over 3 weeks, responsiveness of the WOMAC 3.1 regarding the three subscales, 
pain, stiffness and function, were compared for the original paper format and the computer touch screen format (QUALITOUCH®) using 
a Likert scale. WOMAC scores were transformed to the 0-100 scale. ANOVA for repeated measures was used for analysis and effect sizes 
by subscale were compared for both formats.
Results: Responsiveness for all three subscales was similar between formats. In both formats, pain and stiffness were significantly reduced 
with rofecoxib as early as 7 days, while functional ability was significantly increased (P < 0.01 for all aggregate subscale scores) with 
continuing improvement until the end of study. The effect sizes by subscale between Day 1 and 21 were not statistically different between the 
paper and the electronic version of the questionnaire and showed similar clinically meaningful improvements in WOMAC scores over 3 weeks.
Conclusion: In this longitudinal intervention study, the e-WOMAC OA index 3.1 showed similar responsiveness in detecting clinically 
meaningful changes than the original paper format.© 2004 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
Key words: Patient self-assessment, Electronic WOMAC 3.1, Electronic data capturing (EDC), QUALITOUCH method, Rofecoxib.
Introduction
The Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index was developed for standardized as­sessment of osteoarthritis (OA) symptoms in hip and/or knee joints\ The WOMAC OA Index covers the domains of pain, stiffness and function in 5, 2 and 17 questions, respectively. This index has been extensively validated for measuring changes after different interventions in patients with OA^  and is the most widely recommended disease-
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specific questionnaire for core set assessment in clinical trials for knee and hip OA established by the Osteoarthritis Society Task Force, as proposed at the third conference on outcome measures in rheumatoid arthritis clinical trials (OMERACT III)®.In daily clinical practice the WOMAC questionnaire is a suitable tool for optimizing patient monitoring as the data are directly provided by the patient and are very re­producible. However, the paper format does not allow for an immediate display of results. The e-WOMAC was designed to improve patient monitoring by its simple design and provides the opportunity to discuss results with the patients or the team that takes care of the patients in a timely fashion, as results are available immediately and can be shared electronically'^ . Another advantage of the e-WOMAC may be its presentation format, where each question Is displayed as text and a situational cartoon, and are verbalized over the loudspeaker (QUALITOUCH®
912
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^^Stéîfiikéit
Wie stark 1st Ittre . 
Gejanksteifheit nach clem 
ersten Aufwachen am  ^
Morgen?
leichle mSssige slorke extreme'
'  mi
Fig. 1. (a) QUALITOUCH® multimedia 3-D interactive interface- 
questions answered by touching one of the squares of the Likert 
scale on the computer screen, (b) Screen display of the electronic 
touch screen featuring question 6 of the WOMAC 3.1 OA Index and 
the Likert scale. Translation: Steifigkeit =  stiffness. Wie star1< ist 
Ihre Gelenksteifigkeit nach dem ersten Aufwachen am Mor­
gen? = how important is the stiffness of your joints after the first 
awakening in the morning. Keine = none. Leichte =  mild. Massi- 
ge =  moderate. Starke = severe. Extreme =  extreme. Frage wie- 
derholen =  repeat question. Befragung abbrechen =  stop 
interview. Hilfe =  help. Vorherige Frage =  previous question.
Nachste Frage =  next question.
method). This may be appreciated especially by the older patients. The electronic formats of the WOMAC-lndex 3.0 have been previously validated®" .^Of special clinical and scientific interest is the ability of a questionnaire to detect and monitor improvement or worsening of the clinical situation based on an intervention. We therefore compared the responsiveness of the original paper format and the computer touch screen format to rofecoxib treatment in patients with symptomatic hip or knee OA over a course of 3 weeks. The aim of this study was to validate the longitudinal responsiveness of the e-WOMAC questionnaire.
Patients and methods
Three sites that participated in the previously published SVIS-Study, with 136 recruited patients and 22 sites in total®, participated in this ancillary e-WOMAC protocol and 53 eligible consecutive outpatients were recruited and included in the evaluation. The SVIS-study was a pro­spective open label 3 weeks multicenter study to document the effect of rofecoxib in patients with painful radiograph­ically proven primary OA of the knee or the hip according to ACR criteria who were dissatisfied with their prior NSAID treatment (because of either non-responsiveness to or adverse events from previous NSAID-therapy, including celecoxib). At inclusion the patients stopped their previous NSAID therapy and started therapy with rofecoxib 25 mg once daily on the following day (to) for 3 weeks, after which the final visit took place (f^ ), with an interim visit on day 7 (h)".Because the core study was a clinical trial with drug intervention, conducted according to GCP guidelines and the e-WOMAC is not yet a validated format of the questionnaire acceptable to regulatory authorities, we had to renounce to block randomize the patients for the paper vs the electronic format of the questionnaire. However, all patients gave their separate written informed consent before their participation in this ancillary study. At all three visits, the patients filled in the paper format of the WOMAC first, followed by the electronic format.The validated German paper format of the WOMAC 3.1 with a Likert scale was used The electronic format of the WOMAC was identical to the German questionnaire with an identical Likert scale in a computerized touch screen format, which has been previously shown to have very good agreement with the original paper format in its numeric rating scale format®. The OUALITOUCH® data capture method was developed to facilitate patient assessment. The OUALITOUCH® computer program offers a multimedia 3-D interactive interface: the questions are displayed on a 34.3 cm diameter screen as a text and a situational cartoon and are verbalized over the loudspeaker. The questions are answered by touching one of the squares of the Likert scale on the computer screen [Fig. 1 (a)]. By using five buttons on screen the patient could exit the question­naire, get help, have the question repeated or move only one question fonvard or backward [Fig. 1 (b)]. It is therefore possible to leave out one question and move to the next. Furthermore, the help function self activates after 15 s of inactivity and presents the next possible steps to the patient. Patients are not able to see their prior scores.
STATISTICS
Descriptive statistics included the mean of the aggre­gated scores, the standard deviation and the mean dif­ference between the scores of the paper and computerized
Table I 
Patient demographics
Male (n =  32) Female (n =  21) Total (n =  53)
Age in years 
(mean ±  SD)
63.2 ±  10.3 65.7 ±  8.1 64.2 ±  9.5
Height in cm 
(mean ±  SD)
175.5 ±  5.3 162.0 ±  6.8 170.1 ±  8.9
Weight in kg 
(mean ±  SD)
86 ±  15.3 75.7 ±  17.3 81.9 ±  16.8
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Table IIComparative table of the effect of rofecoxib by format (paper vs electronic) and by WOtvlAC standardized subscale score over time,mean +  SD
Subscale Format to (a Effect size fg vs to
Pain Paper 39 .7+14.5 33.7 +  15.7 28.6 +  14.8 0.76
e-WOMAC 42.3+15.2 34.6 ±15.6 29.2 +  14.6 0.88*
Stiffness Paper 43.4+18.9 36.5 +  15.7 31.1 ±  20.0 0.63
e-WOMAC 46.1 +  22.2 38.6 +  18.1 33.4 +  20.8 0.59*
Function Paper 44.1 +  14.0 38.4 +  15.4 32 .8+16 .2 0.75
e-WOMAC 43.8+  14.3 38.9 +  16.2 32.0 +  16.2 0.77*
‘Difference between paper vs electronic format scores statistically not significant.
format. To detect possible format (paper vs computer), time 
(to =  baseline vs h = visit 1 at day 7 vs /a = visit 3 at day 21), scale (pain vs stiffness, vs function) or gender (male vs female) related effects, a variance analysis by "repeated measures ANOVA” was performed. In addition, the standardized mean difference was used to measure the effect size by WOMAC subscale between to and ^ (effect size -  [{mean score fg -  mean score fo)/{pooled SD}] and tested for significance of the paper vs the electronic format. All statistical tests were performed at a significance level of0.01 or lower to correct for multiple testing. Normality of the distribution was tested by Kolmogorov-Smirnov. All statis­tical analyses were performed with SAS® StatView® 5.01.
Results
PATIENTS
All consecutive 53 patients recruited in the three participating study centers were included in the analysis and completed both formats of the questionnaire in all three visits. The detailed patient characteristics are shown in Table I. Age and gender were balanced. Forty-three patients (81%) had primary unilateral knee osteoarthritis, 5 (9%) primary bilateral knee OA, 4 (8%) primary idiopathic hip OA and 1 (2%) had secondary hip OA after congenital hip dysplasia. The time needed to answer all questions in the electronic format of the WOMAC 3.1 was12.9 ± 2.7 min vs 12.5 ± 3.5 min for the paper format (not significant).
WOMAC-SCORES
WOMAC baseline scores by subscale were not signifi­cantly different by format (electronic or paper) and the effect size by subscale between to and (2 was not significantly different by format (Table II). The overall effect size between to and ^ was 0.71 for the paper version and 0.74 for the electronic version and was statistically not signifi­cant. Therefore, the responsiveness by subscale was not significantly different between the electronic and the paper
versions of the WOMAC. At visit 1 (h — day 7) pain and stiffness were significantly reduced with rofecoxib, while function was significantly increased (P < 0.01, Table III). The mean magnitude of the effect of rofecoxib was continuously increasing over time in all three subscales and in both formats. Comparing baseline (fo) to visit 2 (day 21), pain decreased by 30%, stiffness by 28% and function increased by 26% irrespective of whether the paper or the electronic format of the WOMAC 3.1 was used (Fig. 2). While the format (paper vs electronic) might have had some influence on the stiffness scale and on the total WOMAC Index, the format X time interaction of WOMAC 3.1 scores between the paper and the electronic formats at to (baseline), h (day 7) and ^ (day 21) were not significantly different for pain (P = 0.22), stiffness (P = 0.895), func­tional ability (P = 0.542) and for the total WOMAC Index (P = 0.508), indicating that the pattern of changes in WOMAC scores and subscores over time did not differ by format (Fig. 3). The time X format X scale interaction was not significant, indicating that the pattern of changes of the WOMAC scores was the same for both formats and all scales (Table IV). Gender had no influence on the results.
Discussion
This is the first longitudinal study documenting repeated measures with electronic data capturing through patient self-assessment. Electronic data capturing has become increasingly popular for data acquisition in clinical trials. However, the data collected usually refers to laboratory or diagnostic examination values or to patient history and data entry is usually performed by medical or paramedical personnel. In daily clinical care, there is little experience with patient self-assessment using standardized question­naires and almost no related validated tools exist. One study documents the initial evaluation of an electronic format of the Short Form 36, concluding that electronic data collection is acceptable to patients and feasible in a clinical setting while providing comparable responses to those of the paper format, improving data capture and being immediately available^ ®.
Table IIIEffect of time (to, ti, W, format (paper vs electronic) and time X  format interaction on the WOMAC subscaies and the WOMAC Index
to, fT fi. fa* fo. fa* Format** Time X  format*
Pain subscale 
Stiffness subscale 
Function subscale 
WOMAC 3.1 Index
-6.86 (P =  0.0002) 
-7.73 (P =  0.0003) 
5.32 (P =  0.0018) 
-6.64 (P <  0.0001)
-5.27 (P =  0.0041) 
-4.77 (P =  0.0243) 
6.25 (P =  0.0003) 
-5.43 (P =  0.0008)
-12.14 (P <  0.0001) 
-12.5 (P <  0.0001) 
11.58 (P <  0.0001) 
-12.07 (P <  0.0001)
-1 .33  (P =  0.0119) 
-2 .73  (P =  0.0078) 
0.26 (P =  0.5770) 
-1.27 (P =  0.0049)
P =  0.22 
P =  0.895 
P =  0.542 
P =  0.508
"Significant if P <  0.0033. “ Significant if P < 0.01.
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Fig. 2. Evolution of WOMAC 3.1 subscales with rofecoxib one tablet 
once daily over 3 weeks, paper vs electronic evaluation.
Patient self-assessment by electronic data capturing presents numerous advantages in clinical care: the data collection is standardized and the impact of potential external influences, which may vary in nature from visit to visit, is limited; the data may be coliected anonymously across departments, hospitals and medical practices allow­ing for constant optimization of patient management techniques by detecting outliers regarding treatment
success. When performed in the waiting-room, self-assess­ment makes the best use of the patient’s and the physician’s time and is a valuable contribution to the patient-physician interaction, especially in the decision­making process of treatment adaptations. In contrast with paper questionnaires which are archived in the patient’s file, electronic data allow for easy treatment effect monitoring at a glance. With the e-WOMAC, the patient’s progress is documented for the three subscales: pain, stiffness and function. Multiple assessments over time are displayed on one page displaying the change over time in an easy to read graph. The e-WOMAC data collection by patient self- assessment with a QUALITOUCH® touch screen interface has been shown to have very good agreement in all three subscales with the original paper format of the question­naire®. In another study, the patient preference for the electronic vs the paper format of the questionnaire was documented: although 54% of the patients had no experience with computers at all, only 9% preferred the paper format, 91% either preferring the computer format (51%) or being indifferent (38%). Ninety-four percent of the patients declared that the 3-D environment presented (text, sound and cartoon) was helpfuF.This study shows that e-WOMAC is responsive to treatment over time with regard to pain, stiffness and function. In addition, no significant difference was found while comparing the degree of responsiveness by subscale between the electronic and the paper format of the
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Fig. 3. Changes in mean WOMAC subscales and in WOMAC Index (±95%  confidence intervals), by visit at /b (baseline), (day 7) and fg 
(day 21), paper vs computer fomriat, with rofecoxib one tablet once daily.
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Table IVWOMAC Index: levels of significance with repeated measures ANOVA with one, two or three factors
Effect P value interpretation
Time* <0.0001 Rofecoxib significantly
(to. hi tz) improved WOMAC score over time
Format* (paper 0.0049 Format had an Influence
vs e-WOMAC) on WOMAC score
Scale* (pain vs 0.0183 Subscale had no influence
stiffness vs function) on WOMAC score
Time x  format* 0.5077 Changes of WOMAC scores 
over time were the same 
for both formats
Time X scale* 0.7229 Changes of WOMAC scores 
over time were the same 
for all WOMAC subscales
Time X format X scale* 0.7703 Patterns of change in 
WOMAC scores over time 
did not differ by version 
and scale
‘Significant if P <  0.01.
questionnaire. This suggests that the e-WOMAC is as responsive as the original paper format. As the main endpoints of the SVIS study were to document the effects of rofecoxib on Quality of Life (measured by the SF-12) and disease specific symptoms (measured by the WOMAC paper questionnaire) and because at the time of the initiation of the SVIS study the e-WOMAC was not completely validated, we renounced to randomize for the two formats (paper and electronic) and asked all patients to fill in the paper format of the questionnaire consistently before they filled in the electronic format, accepting thereby a systematic error in the validation procedure. As a single parameter, the format seemed to have an influence on the WOMAC score, the significance being driven by the two questions related to pain (Table V). In this study, the overall effect size between to and fg reached 0.71 when measured with the paper version of the WOMAC and 0.74 with the electronic version. An effect size between 0.2 and 0.5 is considered as small but clinically meaningful, while a large effect size is estimated at being 1.0 or more” . Therefore the observed effect size of rofecoxib between to and ^ should be considered not only statistically significant but also clinically relevant. In contrast the difference in effect size of 0.03 observed between the paper and the electronic version of the WOMAC is statistically non-significant and should be considered as clinically irrelevant. This holds true for all three subscaies of the WOMAC, the largest observed difference in effect size between formats being 0.12. Furthermore, the paper and the electronic formats of the WOMAC have proven to be very similar for the monitoring of treatment effects and under the premises that the choice for the paper or the electronic format is made upfront and carried out throughout the timecourse of the observation,
Table VInfluence of the version in relation with the section of thequestionnaire
Questions addressing Number of questions Significance level
Pain 5 0.012
Stiffness 2 0.0078
Function 17 0.577
‘Significant if P < 0.01.
both formats can be considered as equivalent. In the meantime, another study with correct block randomization has demonstrated the patient's preference for the electronic format and the perfect interchangeability of the paper and the electronic formats .^In patients with symptomatic OA at the hip or knee treated with rofecoxib, the paper and the electronic format of the WOMAC 3.1 showed similar effect sizes and were equally suitable for the longitudinal monitoring of the effects of drug treatment and the detection of clinically meaningful changes. The future successful use of the e-WOMAC by the OUALITOUCH® method in medical care will depend on its integration in the daily processes of patient management at the primary care physician level.
References
1. Bellamy N, Buchanan WW. A preliminary evaluation ofthe dimensionality and clinical importance of pain and disability in osteoarthritis of the hip and knee. Clin Rheumatol 1986;5(2):231~-41.2. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J,Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy In patients with osteoarthritis of the hip or knee. J Rheumatol 1988;15(12):1833-40.3. Bellamy N, Kirwan J, Boers M, Brooks P, Strand V,Tugweli P, et at. Recommendations for a core set of outcome measures for future phase 111 clinical trials in knee, hip, and hand osteoarthritis. Consensus de­velopment at OMERACT ill. J Rheumatol 1997;24(4): 799-802.4. Pincus T, Sokka T. Quantitative measures for assess­ing rheumatoid arthritis in clinical trials and clinical care. Best Pract Res Clin Rheumatol 20Q3;17(5); 753-81.5. Theiier R, Bischoff HA, Good M, Uebelhart D. Rofecoxibimproves quality of life in patients with hip or knee osteoarthritis. Swiss Med Wkly 2002; 132(39-40): 566-73.6. Theiier R, Splelberger J, Bischoff HA, Bellamy N,Huber J, Kroesen S. Clinical evaluation of the WOMAC 3.0 OA Index in numeric rating scale format using a computerized touch screen version. Osteoar­thritis Cartilage 2002;10(6):479-81.7. Bischoff-Ferrari HA, VonDechend M, Bellamy N, TheiierR. Validation and patient acceptance of a computer touch screen version of the WOMAC 3.1 Osteoarthritis index. Ann Rheum Dis July 1 2004; PMID:15231508.8. Stuck! G, Meier D, Stuck! S, Michel BA, Tyndall AG,Dick W, et al. [Evaluation of a German version of WOMAC (Western Ontario and McMaster Uni­versities) Arthrosis Index]. Z Rheumatol 1996;55(1): 40-9.9. Bellamy N. Personal communication of the Germanversion of the WOMAC 3.1 with Likert scale.10. Wilson AS, Kitas GD, Carruthers DM, Reay C, Skan J,Harris S, et al. Computerized information-gathering in specialist rheumatology clinics: an initial evaluation of an electronic version of the Short Form 36. Rheuma­tology (Oxford) 2002;41(3):268-73.11. Cohen J. Statistical Power Analysis for the BehavioralSciences. 2nd edn. Hillsdale, NJ: L. Erlbaum Asso­ciates; 1988: p. xxi, 567.
Current M edka t Research and Opinion. Vol. 15. No. 2, 1999. 113-119 
O  1999 LibraPharm Limited J
Comparative Study of Self-rating Pain Scales in 
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Sum m ary
Although progress has been made in the clinical metrology of pain in osteoarthritis, much ^ r th er  work remains. The preferred methods of measurement remain debatable.In this longitudinal, open study, a comparison o f eight self-rating pain scales has been conducted. A total o f333 patients entered the four-week study after completing a 3-7  day NSAID-free washout period. Patients were assigned to treatment with oxaprozin 1200 mg p.o. once daily with titration permitted between 600mg and 1800 mg. Rescue analgesia with acetaminophen (paracetamol) 325 mg (maximum 2600mg) was allowed. At the end of the washout and the treatment period, patients completed eight self-administered pain scales.All pain measures detected clinically important and statistically significant improvements in pain. The pain scales differed in their degree of responsiveness. The Likert and visual analogue scales and their primary variations (continuous chromatic analogue and numerical scales) were more responsive than more complex measures. A positive correlation between initial pain rating and subsequent pain relief was confirmed in this study.'We conclude that, while pain is a subjective sensory phenomenon, its perceived severity can be evaluated using a variety of self-administered pain scales, all of which are capable of detecting improvements in health status following effective pharmacological 
intervention.
I n t r o d u c t i o n .  available contain pain questions or even
d istin c t p a in  subscales. It is debatable 
Pain is an entirely subjective p h en o m en o n  w h eth er it is preferable to  measure pain as
and is the quintessential sym ptom  of m ost a global entity or to m easure pain in each
m usculoskeletal conditions. The m ethods of several distinct situations (e.g. night pain,
used to assess pain are m any an d  varied , pain w ith activity, pain at rest), and then
W ith th e  exception  of th e  b eh a v io u ra l create a pain subscale which respects the
observation techniques,-m ost m ethods.a re  - Totality .of. pain. =The-clinimetric problem  is 
based on  p a tien t~ se lf-rep o rt q u e s tio n -  ’ fu rther'com plicated by the Tact fh a fp a in
naires*. M any of the  m ost soph isticated  m ay be different in different joints at the
h e a lth  sta tu s q u e s tio n n a ire s  c u rre n tly  sam e point in time, and, in a single joint.
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and may fluctuate with time, sometimes, 
bu t not always, in a rhythmic circadian or 
circaseptan pattern^  In selecting a pain 
scale for longitudinal monitoring of patients 
w ith osteoarthritis (OA), there are at least 
two im portant issues:
1, For clinical practice and clinical trials 
purposes, there are differences in the 
responsiveness (syn: sen s itiv ity  to 
change) of different pain scales, and
2. In clinical trials, should pain be used 
as a stratification variable because of a 
purported relationship between current 
pain severity and the m agnitude of the 
subsequent pain relief achieved with 
treatm ent?
Although a few comparative studies of pain 
rating scales in musculoskeletal diseases 
have been conducted, the diversity of scales 
is now greater, and, therefore, it is timely 
to reappraise this important issue, based on 
th e  principal types of scales em ployed 
currently in  the evaluation of OA patients.
Patients and M ethods
The study was conducted as a longitudinal 
open  study in clinical practice settings 
including general practitioners, rh eu m ­
atologists and  internists. P atien ts w ere 
req u ired  to fulfil Am erican C ollege of 
Rheumatology criteria for the diagnosis of 
OA*, be aged 18-75 years, ambulatory, able 
a n d  w illin g  to  com plete  th e  s tu d y  
questionnaires, able and willing to  give 
inform ed consent, and be eligible to  be 
t re a te d  w ith  a n o n -s te ro id a l a n t i ­
inflammatory class agent for at least four 
weeks. Patients w ere  excluded for the 
following reasons:
1. Pregnant or nursing mothers
2. Applying for, or receiving, disability or
w orkm en's com pensation benefits
3. C u rrently  engaged in disability-related 
litigation
4. Allergy to aspirin or o ther NSAIDs
5. A llerg y  to , o r in to le ra n c e  of, 
acetam inophen
6. A c tiv e  g a s tr i t is  c u r re n tly ,  o r 
docum ented peptic ulcer disease in  the 
last six m onths
7. Upper gastrointestinal bleeding in the 
last tw o years
8. Uncontrolled hypertension, respiratory, 
r e n a l ,  h e p a tic ,  g a s tro in te s t in a l ,  
haematological, endocrine or any other 
disease w hich , in  the opinion of the 
investigator, m ight affect the evaluation 
of the  study m edication
9. U ncontrolled cardiac disease
10. Previously entered  in  the protocol
11. Recipient of any investigational drug 30 
days before study entry
12. Requiring concom itant trea tm ent w ith 
narcotic analgesics
13. S ystem ic o r in tra -a r t ic u la r  s tero id  
injections o r soft tissue injection of a 
steroid in the last m onth
14. N ot practising  a reliable m eth o d  of 
contraception
15. C o n c o m ita n t t r e a tm e n t  w ith  
anticoagulant or lithium
16. Any inflam m atory disease other than  
rheum ato id  or osteoarthritis
17. E v id en ce  of c h o n d ro ca lc in o s is  on  
available radiograph
Consenting patients completed a 3-7-day 
N SA ID -free w a sh o u t p erio d  an d  w ere  
thereafter placed on oxaprozin {Daypro*^ *'^ ) 
1200 mg p.o. once daily. Bidirectional dose 
titration  of betw een  600 mg and 1800 mg 
per day was perm itted  during the  active 
trea tm ent phase. The medication was taken 
as a single dose except at the 1800 mg dose, 
w here the m edication was split betw een 
1200 m g in the m orning and 600 mg in  the 
evening. All m edications w ere taken w ith 
food. The planned active treatm ent phase
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was four w eeks. During the w ashout phase 
and a c t iv e  trea tm en t p eriod , rescu e  
analgesia w ith acetaminophen (paracetamol) 
325 mg (m axim um  eight tablets a day in  
divided dosage) was permitted. Comphance 
to study m edication was assessed by pill 
cou n tin g . Patients w ere asked to avoid  
an a lgesia  for eight hours prior to th e  
baseline assessm ent.
In addition  to collecting dem ographic 
and disease data, patients com pleted the  
fo llo w in g  self-adm inistered pain  rating  
scales at th e  end of the washout period and 
again at th e  end of the study: McGill pain 
q u estion n aire (M PQ )\ five-point Likert 
scale*, 10 cm  horizontal visual analogue  
scale*, ladder scale (reversed)*, numerical 
ratin g  s c a l e ’, co n tin u o u s  ch ro m a tic  
analogue scale®, Moll pain faces scale’ and 
Champion pain faces scale®. Both English 
and French-Canadian versions of the pain  
scales w ere available since the study was 
run in various centres across Canada. The 
sample size  w as considered sufficient to  
provide a broad experience with the various 
p a in  s c a le s .  S tudy su b jects  w ere  
characterised using descriptive statistics. 
The m ean and standard deviation (SD) of 
the baseline scores, termination scores and  
change scores w ere calculated. The static 
and change scores have been docum ented  
to facilitate the calculation of sample size 
for future clinical studies based on the  
param eters observed in this study. The 
relative responsiveness of the instruments 
w a s co m p a r e d  u sin g  f -v a lu e s ’ and  
standardised response means (SRMs)*°. The 
f iv e -p o in t  L ikert sca le  w as se le c te d  
arb itra r ily  as th e  an ch or for all RE 
com parisons. Within-group changes w ere 
assessed using the Student's f-test based on  
a per p r o to c o l  an a ly sis . F in a lly , th e  
relationship betw een the initial pain rating 
and the subsequent pain response (pain 
relief) w a s  d eterm in ed  using P earson  
correlation coefficients. Since the efficacy 
of oxaprozin in OA had been previously
established**"**, w e  w ere in terested  in  
comparing the responsiveness of different 
pain scales, and, therefore, performed a per 
protocol (efficacy) analysis rather than an  
intention to treat (effectiveness) analysis.
Results
Of the 333 OA patients w ho entered the  
study, 119 were excluded from analysis for 
the following reasons:
1. Age > 75 years (14)
2. Compliance < 80%  (28)
3. Use of other analgesics (5)
4. Assessments com pleted outside study  
duration w indow  of ± 5 half-lives (i.e. 
10 days) (72)
Response data from  214 patients w ere  
analysed, of w hom  61 % w ere females and 
92% were Caucasian. The m ean age of 
participants w as 60 years (range 3 5 -8 3  
years, SD = 11) and m ean disease duration  
w as seven years (range 0 .1 -4 0  years, 
SD = 7). The m ean joint count was 5 (range 
1-41, SD = 7). M ean pain scores and SD at 
baseline and term ination, change (relief) 
scores, SD, p-values and effect sizes are 
shown in Table 1. Clinically important and  
statistically significant treatm ent effects 
w ere recorded by all eight pain scales, 
including the different components of the  
MPQ. Pain m easures have been ranked  
according to the hierarchy of effect sizes. 
Statistical p-values w ere similar for m ost 
measures. In contrast, /-values and SRMs 
were different for different measures (Table 
1). The most com m only chosen words at 
baseline and termination in the English and 
French-Canadian version of the MPQ are 
illustrated in Table 2. The hierarchy of 
w ords chosen w as slightly different in , 
English versus French-Canadian centres 
and differed at termination versus baseline.
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Table 1. M ean p a in  scores at b aselin e , term in a tio n  and re lie f score ordered by e ffec t
size
M ea su re B a s e l in e T e r m in a tio n C h an ge (re lie f) sc o re SR M
M e a n SD M e a n SD M ean SD p -v a lu e
VA 5 9 .7 1 2 1 .7 8 3 5 .4 5 2 4 .1 7 2 4 .7 3 2 5 .5 9 0 .0 0 0 1 0 .9 7
C CAS 5 .7 7 1 .93 3 .6 6 2 .2 7 2 .1 6 2 .31 0 .0 0 0 1 0 .9 4N u m er ica l 5 .8 6 2 .0 0 3 .7 0 2 .2 5 2 .1 7 2 .3 8 0 .0 0 0 1 0 .9 1L ikert 3 .3 8 0 .7 2 2 .6 0 0 .8 5 0 .7 9 0 .9 4 0 .0 0 0 1 0 .8 4P a in  faces 1 ® 3 .3 9 1-44 1 .99 1 .6 0 1 .43 1 .8 4 0 .0 0 0 1 0 .7 8M PQ  (total) 2 4 .5 0 1 2 .7 8 1 6 .1 4 1 2 -4 4 8 .7 9 1 1 .8 7 0 .0 0 0 1 0 .7 4
M P Q  (PPI) 2 .7 0 0 .9 0 1 .9 9 0 .9 2 0 .71 1 .0 2 0 .0 0 0 1 0 .7 0M P Q  (sen so ry ) 1 5 .4 9 7 .5 2 1 0 .7 8 7 .3 0 5 .1 7 7 .4 0 0 .0 0 0 1 0.70
P a in  faces 2 ’ 4 .4 7 1 .1 9 3 .3 7 1 .6 4 1.11 1 .5 9 0 .0 0 0 1 0 .7 0
M P Q  (NW C) 1 0 .3 9 4 .8 3 7 .6 3 5 .3 8 2 .8 7 4 .4 0 0 .0 0 0 1 0 .6 5
R ev er sed  la d d e r 5 .4 0 2 .0 4 4 .0 3 2 .5 5 1 .38 2 .7 9 0 .0 0 0 1 0 .5 0
M P Q  (m isc .) 5 .0 3 3 .2 0 4 .2 8 2 .9 9 1 .45 3 .2 8 0 .0 0 0 1 0 .4 4
M PQ  (ev a lu a tiv e ) 2 .4 9 1.21 2 .0 2 1 .1 3 0 .5 5 1 .4 2 0 .0 0 0 1 0 .3 9
M P Q  (a ffec tiv e ) 3 .8 6 2 .7 9 3 .2 9 2 .6 7 0 .91 2 .8 0 0 .0 0 2 0 0 .3 3
Key: SRM, standardised response m ean; VA, visual an alogue; CCAS, continuous clnom atic analogue scale, 
MPQ, McGill pain questionnaire; PPI, present pain in tensity; NWC, number of words chosen; Mise, 
misceUancdus
Table 2. W ords ch o se n  b y p a tie n ts  from  th e  M cGill pain questionnaire to  describe  
th e ir  p ain  b y  language o f  th e  questionnaire
E n g lish  F ren chBaseline n = Word 183% Termination n = 183 Word % Baseline n = 31 Word % Termination » -  31 Word %
Nagging 52 Aching 35 Elancement 52 Fatigante 39Aching 51 Tender 35 Fatigante 42 Elancement 26Throbbing 49 Tiring 34 Désagréable 35 Engourdissement 26Shooting 40 Annoying 31 Enervante 29 Enervante 23Sharp 38 Nagging 30 Engourdissement 29 Desagreable 19Tiring 37 Burning 20 Serrement 29 Harcelante 19Tender 36 Shooting 19 Chaleur 26 Chaleur 16Burning 30 Throbbing 18 Déprimante 26 Déprimante 10Exhausting 30 Sharp 18 Harcelante 26 Serrement 10Miserable 28 Miserable 18 - - - —Stabbing 25 Penetrating 16 — - — —Gnawing 25 Gnawing 15 - - -Penetrating 25 Stabbing 12 - - - —Annoying 25 Exhausting 10 - - — —
Statistically significant correlations w ere 
observed  b e tw e e n  b a se lin e  scores and 
subsequent pain relief scores (Table 3).
D iscussion
The m easurement of pain in clinical trials 
requires th e  use o f va lid , reliab le  and 
responsive a ssessm en t tech n iq u es. The 
clinimetric properties of scales used in the
stu d y  have been  previously evaluated*. 
Previous comparative studies of pain scales 
h a v e  suggested high levels of correlation 
b etw een  scores’ However, correlation  
coefficients are an expression of the degree 
of association, not measures of agreement, 
nor do they address issues of the relative 
responsiveness of different scales. Data  
derived from a study of auranofin in RA 
suggested that, w hile scale sensitivity wa% 
comparable for different measures, the p- 
va lu e for the 10 cm VA scale {p = 0.01) was
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Table 3. Correlations of in itia l pain rating and pain relief
Pain  sc a le r p -v a lu e
M PQ (ev a lu a tiv e ) 0 .6 6 0 .0 0 0 1
M PQ (m is c e lla n e o u s) 0 .5 8 0 .0 0 0 1
M PQ (a ffec tiv e )  
P ain  fa c e s  1®
0 .5 6 0 .0 0 0 1
0 .5 5 0 .0 0 0 1
M PQ (p r e se n t  p a in  in te n s ity ) 0 .5 4 0 .0 0 0 1
M PQ (se n so r y ) 0 .5 2 0 .0 0 0 1
L ik en 0 .5 0 0 .0 0 0 1
M PQ (to ta l score) 0 .5 0 0 .0 0 0 1
V isual a n a lo g u e  sc a le 0 .4 9 0 .0 0 0 1
N u m e r ic a l p o in t 0.48 0 .0 0 0 1
L adder 0 .4 8 0 .0 0 0 1
C o n t in u o u s  c h ro m a tic  a n a lo g u e  sc a le 0 .4 3 0 .0 0 0 1
Pain  fa c e s  2 ’ 0 .3 4 0 .0 2 9 7
M PQ (n u m b e r  of w o r d s  c h o s e n ) 0 .3 2 0 .0 0 0 1
MPQ, McGill pain questionnaire
T
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less than that for the MPQ (p -  0 ,0 2 ), and  
both were smaller than for the pain  ladder 
scale {p = 0.09)*. Previous stu d ies h ave  
e ith er  fo cu sed  on  p a t ie n ts  w ith  
osteoarthritis’, or m ixed m usculoskeletal 
disorders**, or have compared relatively few  
pain measures in RA*. By comparison, w e  
have assessed a large number of different 
scales in a single w ell-defined disorder. We 
have observed that all measures detected  
c lin ica lly  im p o rta n t and s ta t is t ic a l ly  
significant im provem ents in pain during  
treatm ent w ith oxaprozin. The clin ica l 
efficacy of D ayp ro’®'* in OA h a s b e e n  
p rev iou sly  esta b lish ed  in r a n d o m ise d  
clinical trials**"** using a variety of pain  
scales. We can now  confirm that efficacy, 
regard less of th e  ty p e  of p a in  sc a le  
employed. Pain scales, however, do differ 
in their degree of responsiveness. It is of 
note that the two basic approaches to pain  
measurement (VA and Likert scales) and  
th e ir  prim ary v a r ia tio n  (CCAS an d  
numerical scales) w ere more responsive  
than more complex measures. In particular, 
w e w ere not able to  d em on strate  an y  
statistical superiority of the MPQ over other 
indices. The MPQ is a more com plex index  
which does indeed provide qualitative, as 
w ell as quantitative information, regarding 
the patient's pain. It is of note that French- 
and E nglish -speak in g  C anadians u sed
different words from one another, and this 
is probably culturally based, since there is 
n o  evidence that the disease is differently 
expressed in different parts of Canada. For 
clinical trials purposes, the most responsive 
pain measure w ould afford a reduction in  
sam ple size. It appears, therefore, that the 
VA and Likert scales frequently used are 
in d e e d  ap p rop ria te  for th is p u rp ose. 
However, the CCAS is difficult to produce 
in comparison w ith  other measures and 
m ay n o t be quite as practical, and the  
com plexities of p a in  faces scales, w hile  
offering advantages in special subgroups 
(e.g. children), m ay not be accompanied by 
su p er io r  r e sp o n s iv e n e ss . In contrast, 
n um erica l rating scales m ay be useful, 
particularly in transcultural adaptations of 
pain questionnaires given the commonality 
of numerical (cf. linguistic) expression in  
different countries.
By comparison, in  chnical practice, the 
key requirements of a measurement are 
simplicity, brevity, rapid completion and 
ease of scoring** *®. The LK and numerical 
scales are likely to be the most useful in  
this setting. Q uantitative m easurem ent, 
using standardised self-reported health- 
status m easures, is perform ed relatively  
infrequently in rheum atology outpatient 
practice, according to  surveys conducted 
r e c e n tly  in  Canada** and Australia'®.
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Studies, exam ining the contribution of 
serial quantitative clinical m easurem ent to 
c lin ic a l d ec is io n  m ak in g  and p a tien t  
outcom e, are urgently required to define 
the role of quantitative m easurem ent in 
routine practice.
The positive correlation betw een initial 
pain rating and subsequent pain response, 
as measured using a subtraction technique 
(r = 0.62) originally noted by Huskisson” , 
and confirmed in this study, suggests that 
patients with more severe pain may achieve 
greater overall reductions in  pain than  
those w ith mild pain. It should, however, 
be noted that, despite being statistically 
significant, the strength of association does 
vary quite markedly for different pain scales 
(0 .3 2 -0 .6 6 ) .  These ob serva tion s have  
im portant im plications for clinical trials 
w here initial pain rating m ight be used as 
a stratification variable, and for som e pain 
sca les m ay have m ore re lev a n ce  than  
demographic-based stratification variables 
such as age and gender or disease-based  
v a r ia b les  su ch  as d isea se  d u ra tio n . 
Although the occurrence of ceiling effects 
cannot be excluded by this analysis, these 
observations provide a basis for optimism  
w h en  treating OA patients w ith efficacious 
n on -stero id a l anti-in flam m atory drugs 
such as oxaprozin, since there appears to 
be a positive relationship betw een  current 
pain severity and the degree of pain release 
subsequently achieved.
W e co n c lu d e  th at, w h ile  p a in  is a 
su b je c tiv e  sen so ry  p h e n o m e n o n , its  
perceived severity can be evaluated using 
a variety of self-administered pain scales, 
a ll o f w h ich  are capable of d etectin g  
clinically important, statistically significant 
im provem ents in health status following 
effective pharm acological in tervention . 
Simple scaling methods seem  to be as, or 
m o re , responsive than m ore com plex  
m ethods. Such scales can be incorporated 
in to  s in g le - ite m  or m u lt i- ite m  p ain  
questionnaires depending on w hether a
single global estimate is required or a m ulti­
faceted  s itu a tion a lly  based estim a te  is 
needed, and are equally applicable in the  
clinical research or clinical practice setting.
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Quantitative Rheumatology: A Survey of Outcome 
Measurement Procedures in Routine Rheumatology 
Outpatient Practice in Canada
NICHOLAS BELLAMY. S HAIL A KALONI, JANET POPE, KEITH COULTER, and JANE CAMPBELL
ABSTRACT. Objective. To assess the extent to w hich quantitative clin ical m easurement is perform ed by rheuma­
tologists in the longitudinal fo llow up  o f  patients w ith rheumatoid arthritis (R A ), osteoarthritis (OA), 
ankylosing spondylitis (A S), and fibrom yalgia (FM ) in routine outpatient practice in Canada. Methods. A  cross sectional postal survey w as conducted using an 18 item  self-adntinistered ques­
tionnaire sent to Canadian R heum atology A ssociation  members.Results. R heum atologists (response rate 85% ) w ere more likely to longitudinally fo llow  patients 
with RA  and AS than those with O A  or FM . Tliere was a high degree o f  variability in the metliods 
used to monitor patients longitudinally. M any m easures used in clin ical research w ere used infre­
quently in routine clinical practice. In general, the major heal tit status m easures surveyed w ere not 
used in clin ical monitoring. There was a high level o f  agreement (>80% ) tliat tlie characteristics 
required o f  an outcom e measure for use in clin ical practice should include sim plicity, brevity, ease 
o f  scoring, reliability, validity, and sensitivity to change.Conclusion. H ie  majority o f  Canadian rheum atologists perform outcom e m easurem ent during tlie 
longitudinal follow up o f  their outpatients w itli R A , A S , O A , and FM . H ow ever, the process lacks 
standardization. H igh performance health status m easures, developed for clin ical research, have not 
been w idely  adopted in rheum atology practices. There is agreement on tlie characteristics required 
by Canadian rheumatologists for m easurem ent procedures used in routine clin ical care. Quantitative 
m easurem ent in clin ical practice using standardized procedures is an attainable, but as yet, unreal­
ized opportunity. (J Rheumatol 1998 ;25:8 5 2 -8 )
Key Indexing Terms: 
O U TC O M E M E A SU R EM E N T C LIN IC A L PRACTICE RHEUM ATIC D ISEASES
There has been steady progress in the development of 
measurement techniques for clinical research purposes*. 
Accepted methodologies have been established for the 
development and validation of new measurement proce­
dures. This evolution has resulted in the availability of a 
wide variety of outcome measurement alternatives for 
musculoskeletal clinical trials. One consequence of tliis 
development has been a lack of adequate standardization, 
different measures often being used in different studies*. 
Even regarding primary outcomes, international agreement 
has been reached only recently on core sets of measures for 
future Phase III clinical trials in rheumatoid arthritis (RA)^, 
and hip, knee, and hand osteoarthritis (OA) .^ Various groups
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are working toward developing consensus on core sets for 
ankylosing spondylitis (AS) and fibromyalgia (FM) studies. 
In contrast, there have been no published studies and few 
recommendations regarding outcome measures for routine 
clinical care in rheumatology. Furthermore, few techniques 
have been developed for specific application in the clinical 
practice setting. In view of these developments, we 
surveyed monitoring practices used by Canadian rheumatol­
ogists in the longitudinal followup of patients with RA, OA 
(hip, hand, knee, generalized), AS, and FM in routine clin­
ical care. Our purpose was to describe current monitoring 
practices, to determine the required characteristics of instru­
ments suitable for use in clinical practice, and to gauge the 
extent to which several major health status instruments are 
currently being used in the clinical care setting.
MATERIALS AND METHODS
An 18 item (178 subcomponent) questionnaii'e was developed, pre-tested, 
revised, formatted, and distributed by post to Canadian rheumatologists. 
The survey was termed the Outcome Measurement In Rheumatology 
Routine Outpatient Practice (OMIRROP) Survey. The sample was ascer­
tained from the 1995 Canadian Rheum atology A ssociation (CRA) 
Directory. We excluded any identified CRA registrant who was not a clin­
ical rheumatologist (e.g., imm unologist), or who was a pediatric rheunia-
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toiogisi, or who was not currently residing in Canada. Two hundred fifty 
eligible practising rheumatologists were surveyed. Participants were ques­
tioned specifically regarding their measurement practices in the longitu­
dinal followup (serial assessments over time) o f  their adult outpatients with 
RA, OA, AS, and FM. Because o f tlie large number o f  outcom e measures 
currently available, it was not possible to include all in the questionnaire. 
However, the majority were incorporated. For the purpose o f the survey, an 
outpatient was defined as a non-hospitalized (i.e., ambulatory) patient seen 
eitlier in private clinical practice or in tlie outpatient clinic o f  a health care 
facility. Second and third mailings o f  the OMIRROP questionnaire were 
made to non-respondents at intervals o f about one month, with a personal 
letter accompanying the third mailing to m axim ize the response rate.
Tlie analysis was based mainly on descriptive statistics. To identify 
measurement procedures routinely used by a high percentage o f  respon­
dents. we separately identified those outcom e measures that were used 
“A lways” or “Usually” by > 70% of respondents. W hile this was an arbi­
trary division, it nevertlieless defines tliose measures tliat might be consid­
ered part o f  usual care.
RESULTSResponse data. Responses were obtained from 213 rheuma­
tologists (response rate 85%). The mean year of graduation 
from medical school of respondents was 1972 (range 
1942-1990) (non-respondents: mean 1975, range 1947- 
1990; p = NS), and the mean year of starting practice in 
rheumatology of respondents was 1980 (range 1952-1995). 
The type of practice of respondents was as follows: full time 
private practice 41%, full time university 34%, part time 
university 24%. Tlie majority of respondents (84%) had 
experience participating in at least one prior clinical 
research project, in which they had been required to make or 
supervise clinical measurements on study subjects. 
Respondents were more likely to longitudinally follow 
patients with RA (100%) and AS (96%) than patients with
knee OA (74%), generalized OA (72%), hip OA (71%), 
hand OA (58%), or FM (51%).
Basic measurement procedures. To assess the use of basic 
measurement procedures, participants were asked to 
respond to a number of questions in the following format. 
“How often do you serially use the following assessment 
techniques for longitudinally monitoring the efficacy of 
antirheumatic drug therapy in your adult {specify disease) 
outpatient practice?” Responses to this question were sepa­
rately obtained with respect to RA (Table 1), generalized 
OA (Table 2), hip OA, knee OA, and hand OA (Table 3), AS 
(Table 4), and FM (Table 5). For RA, participants also were 
questioned regarding monitoring practices in the separate 
situations of nonsteroidal antiinflammatory drug (NSAID), 
disease modifying antirheumatic drug (DMARD), and 
steroid therapy (Table 1).
Usage patterns for RA, OA, AS, and FM varied for 
different outcome measures (Tables 1-5). Those used 
Usually or Always by >70% are identified by an asterisk and 
those used by <20% have been relegated to a footnote 
(Tables 1-5). Measures have been ranked according to the 
prevalence of Always/Usually usage (Tables 1,2,4,5).
Health status instruments. No major health status instru­
ment evaluated was used frequently in routine clinical prac­
tice. The American College of Rheumatology (ACR) 
Functional Classification* was used most frequently (RA 
49%, AS 30%, OA 24%, FM 15%), followed by the Healdi 
Assessment Questionnaire (HAQ)^ (RA 16%, AS 11%, OA 
9%, FM 9%), the Functional Status Index® (RA 12%, AS 
9%, OA 7%, FM 7%), and the Fibromyalgia Impact 
Questionnaire’ (FM 8%). For all other instruments, i.e..
Table 1. Responses to the questions: (A) How often do you serially use tlie following assessment techniques for longitudinally monitoring tlie efficacy o f  
antirheumatic drug therapy in your adult RA outpatient practice? (B) In what situation do you use tlie aforementioned assessment techniques in RA? (please 
only answer for tliose techniques tliat you do use).
A B
Assessm ent Technique N ev Occ Usl A lw Monitoring 
NSAID Therapy
Monitoring 
DM ARD Therapy
Monitoring 
Steroid Tlierapy
Duration o f  morning stiffness* 2 5 31 62 82 94 80
Physician global assessment (same/better/worse)* 7 6 31 56 81 91 81
Patient global assessment (same/better/worse)* 6 8 37 49 80 88 76
Number o f  swollen joints* 3 13 38 46 71 89 72
Number o f tender joints* 5 13 40 42 73 87 73
Number o f involved joints* 10 15 37 38 59 77 60
Physician global assessment (none/niild/moderate/severe) 21 13 34 32 68 76 66
Number o f damaged joints 12 29 34 25 40 68 48
Severity o f  morning stiffness 23 20 27 30 60 69 60
Patient global assessment (nonc/mild/moderate/severe) 29 20 26 25 44 71 61
Grip strength 19 34 26 21 53 64 53
Pain scale (adjectival) 46 19 25 10 64 67 59
ARA joint count 53 20 13 14 41 54 39
Nev: Never, Occ: Occasionally, Usl: Usually, Alw: Always.
*Used by > 70% o f respondents Usually or A lways.
NB: Used by < 20% o f respondents Usually or Always: Pain scale (VAS), Physician global assessment (VAS), Patient global assessment (VAS), 28 joint count. 
Som e other form o f joint count (specify), Walk time, Ritchie articular index. Som e other form o f pain scale (specify).
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Table 2. Responses to the question; How often do you serially use tlie following assessment techniques for longi­
tudinally monitoring the efficacy o f  antirheumatic drug therapy in adult outpatients with generalized OA?
Assessm ent Technique Never Occasionally Usually Always
Patient global assessment (same/better/worse)* 14 6 40 40
Physician global assessment (same/better/worse)* 15 5 40 40
Number o f involved joints 24 15 32 29
Physician global assessment (none/mild/moderate/severe) 30 9 31 30
Number o f  swollen joints 25 16 31 28
Patient global assessment (none/mild/moderate/severe) 31 10 29 30
Number o f  damaged joints 24 20 30 26
Number o f  tender joints 26 21 27 26
Pain scale (adjectival) 39 11 30 20
Duration o f  morning stiffness 28 24 28 20
Severity o f morning stiffness 45 22 19 14
Grip strength 44 31 13 12
*Used by >  70% o f respondents Usually or Always.
NB: Used by <  20% o f respondents Usually or Always: Pain scale (VAS), Patient global assessment (VAS), Walk 
time. Physician global assessment (VAS), ARA joint count, Som e other form o f pain scale (specify). Som e other 
form o f joint count (specify), 28 joint count, D oyle articular index.
Table 3. Responses to the question: How often do you serially use the following assessment techniques for longitudinally monitoring tlie efficacy o f  
antirheumatic drug tlierapy in your adult OA outpatient practice in patients witli (A ) Hand OA, (B) Knee OA, and (C) Hip OA?
Assessm ent Technique Nev
(A) Hand OA  
Occ Usl A lw N ev
(B) Knee OA  
Occ U sl A lw  Nev
(C) Hip OA  
Occ U sl A lw
Functional capacity*
Pain scale (VAS or adjectival) 
Duration o f  morning stiffness 
Severity o f  morning stiffness 
Patient global assessment* 
Physician global assessment* 
Number o f  involved joints 
Number o f  tender joints 
Number o f  swollen joints 
Grip strength
Sw elling (present/absent)* 
Crepitus (present/absent)* 
Tenderness (present/absent)* 
Knee ROM^ (by goniometry) 
Tenderness (graded)
Hip ROM (by goniometry)
13 5 41 41 10 2  37 51 9 4 37 50
37 15 28 20 27 14 33 26 27 II 31 31
27 24 30 19 27 27 28 18 29 24 28 19
42 26 20 12 42 23 23 12 39 25 23 13
18 7 34  41 —  —  —  _ _ _ _ _
19 8 34 39 —  —  —  _ _ _ _ _
23 11 34 32 —  —  —  _  _  _  _  _
24 15 33 28 —  —  —  _ _ _ _ _
27 14 32  27 —  —  —  _ _ _ _ _
34 27 22  17 —  —  —  _  _  _  _  _
—  —  —  —  8 5 35 52 —  —  —  -—-
—  —  —  —  10 9 31 50  —  _  _  _
—  —  —  —  II 10 37 42 —  _  _  _
_  _  _  _  36 21 22 21 —  —  —  —
—  —  —  _  41 23 21 15 _  _  _  _
_  _  _  —  —  —  —  —  43 15 23 19
Nev: Never, Occ: Occasionally, Usl: Usually, Alw: Always, ROM: range o f motion.
*Used by > 70% of respondents Usually or Always.
NB: Used by < 20% o f respondents Usually or Always: Hand —  D oyle Index; Knee —  Walk time. Ascent time; Hip ■
distance. Walk time. Ascent time.
■ Intercondylar distance, Intermaileolar
Arthritis Impact Measurement Scales (AIMS)®, AIMS2^, 
Rapid Assessment of Disease Activity in Rheumatology 
(RADAR)***, Western Ontario and McMaster Universities 
Osteoartlrritis Index (WOMAC)*’, Lequesne Indices of 
Clinical Severity” , Dougados Functional Index*®, McGill 
Pain Questionnaire**, Health Utilities Index*®, Nottingham 
Health Profile*®, Medical Outcome Survey Short Form-36” , 
European Quality of Life Index*®, Index of Wellbeing” , and 
Sickness Impact Profile’**, the reported frequency of usage 
was between 0 and 4%.
Data recording. Respondents differed in the procedures
tliey usually followed for recording scores derived by the 
above instruments. The following methods were used: 
written notes in the patient’s chart (34%), dictated notes in 
the patient’s chart (31%), not recorded (21%), recorded on 
rough notes (6%), recorded on a flow sheet (4%), other 
(4%). When serially documenting the distribution of joint 
involvement in RA for longitudinal followup, a homunculus 
or mannikin was used Usually or Always by 63% of respon­
dents (Always 36%, Usually 27%, Occasionally 21%, 
Never 16%).
Characteristics of a measure for use in adult outpatient
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Table 4. Responses lo the question: How often do you serially use the 
following assessment techniques for longitudinally monitoring the efficacy  
of antirheumatic drug therapy in your adult AS outpatient practice?
Assessment Technique Never Occasionally Usually Always
Schober test (or modification)* 5 14 34 47
Chest expansion* 4 18 35 43
Wall to occiput distance 10 22 34 34
Finger to floor distance 20 19 27 34
Sacroiliac joint tenderness 22 24 24 30
Finger to fibula distance 48 19 13 20
Chin to sternum distance 49 22 15 14
*Used by > 70% o f respondents Usually or Always.
NB: Used by <  20% o f  respondents Usually or Always: Occiput to C7 
distance, Tragus to wall distance, Dougados Articular Index.
Table S. Responses to tlie question: How often do you serially use tlie 
following assessment techniques for longitudinally monitoring the efficacy  
of antirheumatic drug therapy in your adult FM outpatient practice?
Assessm ent Technique Never Occasionally Usually Always
Quality o f  sleep* 11 11 28 50
Fatigue* 13 13 29 45
No. tender points 17 15 29 39
Skinfold tenderness 47 25 19 9
*Uscd by 5  70% o f respondents Usually or Always.
NB: Used by < 20% o f  respondents Usually or Always: Reactive hyper­
emia, Dolorimeter scores.
practice. Respondents were asked to rate the importance of 
various characteristics, relevant to the use of measurement 
techniques in routine clinical practice, according to the 
following scale: “Very Important,” “Quite Important,” 
“Somewhat Important,” “Quite Unimportant,” “Not 
Important At All” (Table 6). Over 80% of respondents iden­
tified the same 6 characteristics of a measure for use in 
routine practice as being Very Important. The remaining 
respondents (with one exception) rated the same 6 charac­
teristics as Quite Important (12-17%) or Somewhat 
Important (1-3%). The 6 characteristics were as follows: 
Simplicity, Quick Completion, Easy Scoring, Reliability,
Validity, and Responsiveness. In general, use of a measure 
in prior clinical research studies or recommendation by the 
ACR for research purposes was regarded with higher levels 
of importance than recommendation for research use by the 
Food and Drug Administration (FDA), International League 
of Associations for Rheumatology (ILAR), World Health 
Organization (WHO), or European League of Associations 
for Rheumatology (EULAR).
Information recorded in the patient notes at outpatient 
visits. Change in arthritis status, response to treatment, 
current drug profile, and recent drug side effects were 
recorded by 100% of respondents, while change in overall 
health (93%) was almost always recorded. For drug moni­
toring, blood count (92%), biochemistry (89%), urinalysis 
(84%), and for inflammatory disease erythrocyte sedimenta­
tion rate (82%) were frequently recorded. Blood pressure 
(69%), pulse rate (38%), respiratory rate (11%), and weight 
(44%) were recorded less frequently.
Familiarity with basic measurement methods. Eighty-six 
percent of respondents thought Likert-type (i.e.. 
Descriptive, Adjectival) scales were easy to use. A slightly 
smaller percentage (77%) felt that visual analog scales 
(VAS) were easy to use. Less than half tlie respondents 
(43%) felt comfortable using health status questionnaires, 
which required several items to be added together to give a 
final score. More respondents expressed adequate famil­
iarity with the sphygmomanometric measurement of grip 
strength (94%) and the use of the goniometer (84%) than the 
dolorimeter (45%).
DISCUSSION
Quantitation of the clinical effects of interventions has 
become a standard procedure in clinical research. The 
methods used are based on valid, reliable, and responsive 
measurement techniques. The data produced are a required 
part of tlie licensing process for new antirheumatic drugs, 
similar procedures being used in tlie assessment of new 
orthopedic surgical techniques, the evaluation of physio­
therapy modalities, and in health economics evaluations. 
Quantitative clinical measurement in routine clinical care
Table 6. Responses to the question; Consider measurements you use, or would like to use, in your clinical adult 
outpatient practice. How important would you generally rate the following characteristics?
Characteristic
Very
Important
Quite
Important
Somewhat
Important
Quite
Unimportant
Not 
Important At 
All
Previously used in clinical research 
studies
25 31 23 12 9
Recommended for research by ACR 16 22 30 17 15
Recommended for research by FDA 6 12 34 24 24
Recommended for research by ILAR 4 13 35 23 25
Recommended for research by WHO 3 12 34 27 24
Recommended for research by EULAR 2 15 35 22 26
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offers several advantages: (1) it provides information 
regarding the severity of the patient’s disease, and places the 
patient on the spectrum of disease; (2) it provides informa­
tion to both physician and patient regarding the necessity to 
initiate, continue, modify, or terminate a particular therapy;
(3) it provides information to disability insurers regarding 
the severity of disease and the outcome of treatment 
programs; (4) it provides information to litigators regarding 
the patient’s health status and may provide some insight into 
attribution issues; and (5) it allows health care agencies to 
understand the clinical effect of their expenditures and, 
therefore, the appropriateness of ongoing payment for clin­
ical interventions’*.
Response profile. Surveys have 2 potential limitations. First, 
if tlie response rate is low, the results may not be generaliz- 
able. However, in this survey, the response rate was 
extremely high (85%), and in as much as practice patterns 
may be a function of year of graduation” , there was no 
significant difference between respondents and non-respon­
dents. We believe, tlierefore, that our observations are 
generalizable to practice patterns in Canadian rheuma­
tology. Second, surveys based on self-administered ques­
tionnaires provide information on what respondents say 
they do, and this may differ from what they actually do in 
practice. While this is an inherent weakness of survey tech­
niques in general, a direct chart audit might not provide 
entirely accurate data with respect to the focus of this 
survey, since 21% of respondents indicated they did not 
record the information at all, while a further 10% made no 
formal record in the patient’s chart. We feel tliat the postal 
survey methodology used provides reasonable insight into 
which outcome measures are currently used in routine care. 
Rheumatoid arthritis. The measurement procedures most 
frequently used to longitudinally monitor RA outpatients 
were similar to those currently recommended by the ACR 
for Phase III clinical research studies (i.e., number of tender 
joints, number of swollen joints, pain, function, patient 
global assessment, and physician global assessment)’. 
Separate counts of tender and swollen joints (or, alterna­
tively, involved or damaged joints) were preferred over 
graded joint counts, e.g., Ritchie Index’®. However, despite 
being the major symptoms of RA, pain was routinely 
measured by less than 70% of respondents, and functional 
capacity was routinely assessed by less than 50% of respon­
dents, the latter being more often assessed using the ACR 
Functional Classification'* than the more responsive HAQ®. 
Comparative (same, better, worse) global scales were 
slightly more popular than Likert global scales, but both 
were distinctly more popular titan global VAS. It is notable 
that the duration of morning stiffness was an extremely 
popular measure in clinical practice, yet it is not included in 
tlie ACR core set’. This may represent the fact that acade­
mics still debate the cause and nature of joint stiffness, 
whether patients can differentiate stiffness from pain, and
whether it can be accurately quantitated given the difficulty 
of defining the point of first awakening (or getting out of 
bed) and the time of resolution (i.e., first noticeable 
improvement, or time when patient is as limber as they will 
be for the rest of the day). From a clinical care standpoint, 
however, the duration of morning stiffness is a very useful 
measure, since it varies as a function of disease activity and 
response to treatment. It is of note that performance based 
measures of physical function are not included in the ACR 
core set’, and neither were they routinely used by the 
respondents to this survey.
The pattern of usage of different measures was similar 
for measuring the response to DMARD, NSAID, and corti­
costeroids. However, there was a trend toward the more 
frequent usage of outcome measures in assessing the 
response to DMARD therapy. This is not surprising, given 
the symptom modifying potential of all 3 classes of drugs, 
but also an expectation of substantial longterm benefits on 
joint structure and function from DMARD therapy. Finally, 
despite the availability of several well validated measures of 
quality of life, such measures were rarely used by respon­
dents to the survey, and neither are they included in the ACR 
core set’.
Osteoarthritis. Current clinical measurement procedures 
recommended by the Osteoarthritis Research Society 
(OARS), for hand, hip, and knee studies® include pain, phys­
ical function, and patient global assessment. In addition, 
physician global assessment is recommended and the 
measurement of quality of life highly recommended. The 
OARS guidelines®, and the Outcome Measures in Arthritis 
Clinical Trials III recommendations’'* that preceded them, 
were published after the OMIRROP survey was conducted. 
In addition, because of space limitations, physical function 
measurement questions were not included in the generalized 
OA section, and global assessment questions were not 
included in the hip or knee sections.
In generalized OA, patient and physician global assess­
ments were tlie only measures used Always or Usually by 
>70% of respondents, and comparative scales (same, better, 
worse) were slightly more popular than Likert scales. For 
pain measurement in generalized OA, Likert scales were 
used more often than VAS. With the exception of the ACR 
Functional Classification**, health status questionnaires and 
health related quality of life questionnaires were rarely used. 
Simple counts of tender, swollen, damaged, or involved 
joints were most frequently employed, while the Doyle 
Index’® (a graded count based on the Ritchie Index’®) was 
rarely used. Grip strengtli and walk time were not usually 
measured in routine clinical care.
Despite being the principal symptom of hand, hip, and 
knee OA, pain was routinely measured by <70% of respon­
dents. Nevertlieless, measures of functional capacity were 
the most popular outcomes followed. Global assessments 
were surveyed only for hand OA and were used routinely by
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>70% of respondents. Since global assessments were used 
routinely in generalized OA and hand OA, but the question 
was not asked for hip and knee OA, we speculate that the 
patient and physician global assessments may also be a 
popular method of monitoring patients with hip and knee 
OA. With 2 exceptions, all other types of measurement 
procedures were infrequently employed. The reasons for 
this were not surveyed but the measurement of stiffness is 
contentious, and joint counts are not particularly useful in 
regional conditions. Although the vast majority of respon­
dents were familiar with the use of the modified sphygmo­
manometer and the goniometer, they did not use these 
instruments in longitudinal monitoring. In contrast, the 
assessment of joint swelling and crepitus are part of the 
routine examination of the musculoskeletal system, and it is 
not surprising that they form part of routine clinical moni­
toring.
Ankylosing spondylitis. There is currently no agreement on 
a core set of outcome measures for future AS clinical trials, 
although a working group recently has proposed a prelimi­
nary set’®. The AS section of the OMIRROP survey ques­
tionnaire focused on examination based measures only. 
Since restricted lumbar spinal movement and chest expan­
sion form part of the diagnostic criteria for AS” , it is not 
surprising that they are also commonly used in outcome 
measurement. Many of the examination techniques used to 
assess AS patients need to be performed in a standardized 
fashion and both intraobserver and intrapatient variability 
taken into account*. Paradoxically, respondents to this 
survey were more likely to use the ACR Functional 
Classification'* to rate patients With AS than to use the 
purpose-built Dougados Functional Index” . It should be 
noted that we did not specifically question rheumatologists 
regarding their use of the HAQ for the Spondylo­
arthropathies’® or the Bath Ankylosing Spondylitis 
Functional Index (BASF!)” .
Fibromyalgia. There is no international agreement on 
outcome measurement procedures for future Phase III FM 
studies’. The OMIRROP survey probed 6 outcome 
measures used in previous FM studies, but did not survey 
the use of pain or global measures. Given that nonrestora­
tive sleep and chronic fatigue are key symptoms of FM®”, it 
is not surprising that they were the outcome measures most 
frequently employed by survey respondents. The number of 
tender points forms part of the diagnosis of FM®”, and 
almost 70% of respondents used them in longitudinal moni­
toring. The dolorimeter was rarely used, and this may be 
partly explained by the fact that 55% of respondents did not 
feel sufficiently familiar with its use. Neither the ACR 
Functional Classification"* nor the HAQ® was developed 
specifically for use in patients with FM, and yet both were 
used more frequently than the purpose-built FM Impact 
Questionnaire’.
It should be noted that quality of life measures were
rarely used by respondents in monitoring patients with RA, 
OA, AS, or FM. Since there is still debate on the content and 
conceptual basis of health related quality of life question­
naires, concern that comorbidities may affect the score, and 
recognition that antirheumatic treatment may be successful 
but not alter the score, it is not surprising that practitioners 
have not yet adopted these measures for routine usage.
We conclude that most Canadian rheumatologists 
perform outcome assessment in their longitudinal followup 
of patients with RA, AS, OA, and FM. The usual method 
employed fay the majority of respondents was to a large 
extent based on overall impressions rather than ratings 
derived from precise scores generated on a number of sepa­
rate component measures. They agree on the qualities they 
require in an outcome assessment technique (quick comple­
tion, simplicity, easy scoring, validity, reliability, respon­
siveness) for use in routine outpatient care. The reason for 
the observed lack of standardization in the methods 
currently used is speculative. We suspect that it may be, in 
part, due to the following: (1) the lack, until recently, of 
international agreement on core sets of outcome measures;
(2) a lack of familiarity with the format, administration, 
scoring, and interpretation of newer health status instru­
ments; (3) the logistic constraints of performing some 
measurement procedures in a busy outpatient clinic setting;
(4) the lack of any requirement to perfonn formalized serial 
measurements; (5) an absence of clinical research exam­
ining whether the availability of quantitative data makes a 
significant and favorable difference in clinical decision 
making, resource utilization, economic aspects of health 
care delivery, and, most importantly, in patient outcome; 
and (6) tlie lack of emphasis on formalized measurement in 
many rheumatology training programs. As a result, a 
rheumatologist may be more likely to measure the blood 
pressure, pulse rate, respiratory rate, and weight titan to 
administer a generic or disease specific health status instru­
ment or measure the patient’s quality of life.
There is an opportunity to perform quantitative outcome 
measurement in rheumatology. To achieve tliis goal 3 
requirements need to be met: (I) rheumatologists need to 
become familiar with the newer generic and disease specific 
self-administered health status questionnaires, (2) instm- 
ment developers need to address tlie measurement needs of 
rheumatologists and their patients in the routine outpatient 
clinical care setting, and (3) the benefits of practising quan­
titative clinical rheumatology need to be assessed from a 
number of standpoints (physician decision making, quality 
of care, resource utilization, health economics, and indi­
vidual patient outcomes).
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A Survey of Outcome Measurement Procedures in 
Routine Rheumatology Outpatient Practice in Australia
NICHOLAS BELLAMY, KENNETH D. MUIRDEN, PETER M. BROOKS, DAVID BARRACLOUGH,
MICHELLE M. TELLUS, and JANE CAMPBELL
ABSTRACT. Objective. To assess the extent to which quantitative clin ical measurem ent is perform ed by rheuma­
tologists in the longitudinal fo llow up o f  patients with rheumatoid artluJtis (R A ), osteoartluitis (OA), 
ankylosing spondylitis (A S), and fibrom yalgia (FM ) in routine outpatient practice in Australia.Methods. A cross sectional postal survey w as conducted using an 18-item  self-adm inistered ques­
tionnaire sent to Australian Rheum atology A ssociation  (A R A ) members.Results. R heum atologists (response rate =  76% , com pletion rate =  72% ) w ere m ore likely  to longi­
tudinally fo llo w  patients with RA and A S than tliose with OA or FM . There w as a high degree o f  
variability in the m ethods used to m onitor patients longitudinally. M any m easures used in clinical 
research w ere used  infrequently in routine clin ical practice. In general, the m ajor health status 
measures surveyed w ere not used in clinical m onitoring. There was a high lev e l o f  agreement (>
80% ) that the characteristics required o f  an outcom e measure for use in c lin ica l practice should  
include sim plicity, brevity, ease o f  scoring, reliability, validity, and sensitiv ity  to change.Conclusion. The majority o f  Australian rheum atologists perform outcom e m easurem ent during the 
longitudinal fo llow up  o f  their outpatients w ith R A , A S , OA, and FM . H ow ever, tire process lacks 
standardization. H igh perform ance health status m easures developed for clin ical research have not 
been w idely adopted in rheum atology practices. Tliere is agreement on tlie characteristics required 
by Australian rheum atologists for m easurem ent procedures used  in  routine ch n ica l care.
Quantitative measurem ent in chnical practice using standardized procedures is an attainable, but as 
yet, unrealized opportunity. (J Rheum atol 1999;26 :1593-9 )
Key Indexing Terms: 
OUTCOM E M E A SU R EM E N T CLINICAL PRACTICE r h e u m a t i c  d i s e a s e s
In recent years, there has been steady progress in the devel­
opment of measurement teclmiques for clinical research 
purposes’. Accepted methodologies have been established 
for tlie development and validation of new measurement 
procedures. This evolution has resulted in the availability of 
a wide variety of outcome measurement alternatives for 
musculoskeletal clinical trials. One consequence of this 
development has been a lack of adequate standardization, 
different measures often being used in different studies’. 
Even with respect to primary outcomes, international agree-
Froni the Department o f  Medicine, The University o f Western Ontario, 
London, Canada, The University o f Melbourne, Afelboume, The 
University o f New South Wales, Sydney, and University o f Queensland, 
Brisbane, Australia.
Supported in part by'the Arthritis Foutidation o f  Victoria arul the 
University o f Melbourne through the H&L Hccht Visiting Professorship. 
N. Belldmy, MD, MSc, FRCP(Glas), FRCP{Edin), FRCPC, FACP, 
Professor o f Rehabilitation Medicine, Department o f  Medicine,
University o f  Queensland; K.D. Muirden, MD, BS, FRACP, Department 
of Medicine, University o f Melbourne; D. Barraclough, MB, BS, FRACP; 
M.M. Tellus, MB, BS, FRACP, Royal Melbourne Hospital, University of 
Melbourne; P.M. Brooks, MD, FRACP, Executive Dean, Health Sciences, 
University o f  Queensland, Brisbane, Australia; J. Campbell, BA,
Research Assistant, Department of Medicine, University o f Western 
Ontario.
Address reprint requests lo Prof. N. Bellamy, University o f Queensland, 
Department o f  Medicine, Floor C, Clinical Sciences Building, Royal 
Brisbane Hospital, Herston, Queensland 4029, Australia.
Submitted February 20, 1998 revision accepted September 1, 1998.
ment has been reached only recently on core sets of 
measures for future Phase III clinical trials in rheumatoid 
artliritis (RA)’, and hip, knee and hand osteoarthritis (OA)® 
and ankylosing spondylitis (AS)".
While publications on measurement in routine clinical 
care are numerous®’’", no surveys of practice habits of 
rheumatologists in conducting outcome measurement in 
routine clinical care have been published. Indeed, few tech­
niques have been developed for specific application in the 
clinical practice setting’®*’®. We therefore surveyed moni­
toring practices used by Australian rheumatologists in longi­
tudinal followup o f patients with RA, OA (hip, hand, knee, 
and generahzed), AS, and FM in routine clinical care. Our 
purpose was to describe current monitoring practices, deter­
mine required characteristics of instruments suitable for use 
in clinical practice, and gauge the extent to which several 
major healdi status instruments are cunently being used in 
the clinical care setting. This survey was directed at moni­
toring patients and did not enquire whether rheumatologists 
acquired information for prognostic purposes.
MATERIALS AND METHODS
An 18 item (178 subcom ponent) questionnaire was developed, pretested, 
revised, formatted, and tlien m ailed  in  Australia to Australian rheumatolo­
gists. The survey w as term ed the O utcom e Measurement In Rlieumatology 
Routine Outpatient Practice (O M IR RO P) Survey. Ttie sample was ascer­
tained from the 1995 A ustralian  Rheum atology A ssociation (A R A ) 
Directory. Any ARA registrant identified who was not a clinical rficuma-
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tologist (e.g., an imm unologist), or who was a pediatric rheumatologist, or 
not currently residing in Australia was excluded. A total o f  197 eligible  
practicing rheumatologists was identified. Participants were questioned 
specifically regarding their measurement practices in the longitudinal 
followup (serial assessments over time) o f  their adult outpatients with RA, 
OA, AS, and 17M. Because o f  the large number o f outcom e measures 
currently available, it was not possible to include all o f  th em  in the ques­
tionnaire. However, the majority were incorporated. For the purpose o f  the 
survey, an outpatient was defined as a nonhospitalized (i.e., ambulatory) 
patient seen in either private clinical practice or in the outpatient clinic o f a 
health care facility. Second and third mailings o f the OMIRROP question­
naire were made to nonrespondents at intervals o f about one month, with a 
personal letter accompanying the third mailing to m axim ize the response 
rate.
Analysis was based mainly on descriptive statistics. To identify 
measurement procedures that were routinely used by a high percentage o f 
respondents, w e separately identified those outcom e measures used 
“Always” or “Usually” by > 70% o f  respondents. W hile tliis is an arbitrary 
division, nevertheless, it defines those measures that might be considered 
part o f  usual care.
RESULTS
Response data. Responses were obtained from 142 rheuma­
tologists (response rate = 72%). The mean year of gradua­
tion from medical school of respondents was 1972 (range 
1939-1986) (nonrespondent: mean = 1971, range
1949-1986, p = NS), and the mean year of starting practice 
in rheumatology of respondents was 1981 (range 
1948-1995). The type of practice of respondents was as 
follows: Visiting Medical Officer (Non-Teaching Hospital) 
= 64%, Full Time Hospital = 24%, Visiting Medical Officer 
(Teaching Hospital) = 12%. The majority of respondents 
(93%) had experience participating in at least one prior clin­
ical research project, in which they had been required to
make or supervise clinical measurements on study subjects. 
Respondents were more likely to longitudinally follow 
patients with RA (99%) and AS (96%) than patients with 
knee OA (62%), hip OA (60%), generalized OA (58%), 
hand OA (49%), or FM (46%).
Basic measurement procedures. To assess the use of basic 
measurement procedures, participants were asked to 
respond to a number of questions in tlie following format: 
“How often do you serially use the following assessment 
techniques for longitudinally monitoring the efficacy of 
antirheumatic drug therapy in your adult (specify disease) 
outpatient practice?” Responses to this question were sepa­
rately obtained with respect to RA (Table 1), generalized 
OA (Table 2), hip OA, knee OA and hand OA (Table 3), AS 
(Table 4), and FM (Table 5). For RA, participants were 
questioned also regarding monitoring practices in the sepa­
rate situations of nonsteroidal tlierapy, disease modifying 
antirheumatic drug (DMARD) therapy, and steroid therapy 
(Table 1).
Usage patterns for RA, OA, AS, and FM varied for 
different outcome measures (Tables 1-5). Those used 
“Usually” or “Always” by > 70% are identified by an 
asterisk and those used by < 20% have been relegated to a 
footnote (Tables 1-5). Measures have been ranked 
according to the prevalence of “Always’V“Usually” usage 
(Tables 1. 2, 4, 5).
Health status instruments. No major health status instru­
ment evaluated was used frequently in routine clinical prac­
tice. The reported frequency of usage for the American 
College of Rheumatology Functional Classification (FIQ)', 
Health Assessment Questionnaire (HAQ)*, Functional
Table I .  Responses to tiie questions: (A) How often do you serially use the following assessment techniques for longitudinally monitoring tlie efficacy of 
antirhcumatic drug therapy in your adult rheumatoid arthritis outpatient practice? (B) In what situation do you use the aforementioned assessment techniques 
in rheumatoid artliritis (please only answer for those techniques tliat you do use).
B
Assessem ent Technique Nev Occ Usl Alw M onitoring
N SA ID
Therapy
Monitoring . 
DM ARD  
Therapy
Monitoring
Steroid
Therapy
Duration o f  morning stiffness*^ 2 4 41 54 70 87 77
Physician global assessment (same/better/worse) * I 5 4 28 62 73 85 78
Patient global assessment (same/better/worse)** 5 5 31 58 69 83 76
Severity o f  morning stiffness 21 10 32 37 65 78 71
Physician global assessment (none/mild/moderate/severe) 23 13 23 41 62 74 65
No. o f swollen joints 19 20 42 19 60 80 68
N o. o f  involved joints 24 15 43 18 55 67 61
Patient global assessment (none/mild/moderate/severe)* 33 10 25 33 42 75 69
No. o f  tender joints 21 26 37 16 54 76 64
Pain scale (adjectival) 40 11 31 18 57 70 63
No. o f  damaged joints 31 27 34 8 38 59 52
Grip strengtli 38 30 20 12 43 59 52
Nev: Never; Occ; Occasionally; Usl: Usually; Alw: Always; NSAID: nonsteroidal antiinflanunatory drug; DM ARD; disease modifying antirheumatic drug. 
^Due to rounding percentage does not add to 100. *Used by > 70% o f the respondents Usually or Always.
NB: Used by < 20% o f  respondents Usually or Always: Pain scale (VAS), Physician global assessment (VAS). Som e other form of joint count (specify). Patient 
global assessment (VAS), Walk time, Ritchie articular index, ARA joint count, 28 joint count. Som e otiter fonn o f  pain scale (specify).
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T able 2. Responses to the question; How often do you serially use the following assessment techniques for longi­
tudinally monitoring the efficacy o f antirheumatic drug therapy in adult outpatients with generalized 
osleoartliritis?
Assessm ent Technique Never Occasionally Usually Always
Physician global assessm ent (same/better/worse)* 18 12 38 32
Patient global assessment (same/bettcr/worse) 19 12 36 33
Physician global assessm ent (none/mild/moderate/severe)'^ 38 10 30 23
Pain scale (adjectival)^ 45 8 32 16
Patient global assessm ent (none/mild/moderate/severe) 43 12 24 21
No. o f  involved joints' 41 17 30 11
N o. o f damaged joints' 48 13 29 11
No. o f  swollen joints 45 19 27 9
No. o f  tender joints' 50 20 24 7
Duration o f  morning stiffness 49 24 18 9
Severity o f  morning stiffness 58 16 20 6
*Used by > 70% of respondents Usually or A lways.
^Due to rounding does not add to 100.
NB: Used by < 20% o f respondents Usually or Always; Pain scale (VAS), Grip strengtli, Walk time. Physician 
global assessment (VAS), Patient global assessment (VAS), Som e other form o f  joint count (specify). Som e other 
form o f  pain scale (specify), ARA joint count, 28 joint count, D oyle articular index.
Table 3. Responses to the question: How often do you serially use the following assessment techniques for longitudinally monitoring tlie efficacy o f  
antirheumatic drug tlierapy in your adult osteoarthritis outpatient practice in patients witli (A) Hand OA, (B) Knee OA, and (C) Hip OA?
(A) H AND OA (B) KNEE OA (C) HIP OA
Assessment Technique Ncv Occ Usl Alw Nev Occ Usl A lw Nev Occ Usl A lw
Functional capacity'* 21 10 46 24 15 12 48 26 16 6 50 28
Pain scale (VAS or adjectival)' 44 11 26 19 33 ' 16 30 21 32 15 31 23
Duration o f morning stiffness' 52 23 17 8 46 30 16 7 49 27 17 7
Severity o f  morning stiffness' 57 22 13 9 57 22 15 6 58 23 12 7
Patient global assessment* 18 11 37 34
Physician global assessment' 20 12 36 33
Number o f  involved joints 41 16 33 10
Number o f tender joints 40 20 32 8
Number o f  swollen joints 39 22 29 10
Grip strengtli 51 23 17 9
Swelling (present/absent)* 13 4 47 36
Crepitus (present/absent)'* 18 11 38 34
Tenderness (present/absent)' 22 14 38 28
Knee range o f  motion (by goniometry) 38 27 23 12
Tenderness (graded) 57 18 16 9
Hip range o f  motion (by goniom etry)' 49 26 17 7
Ncv: Never; Occ: Occasionally; Usl: Usually; Alw: Always. ^Due to rounding percentage does not add to 100.
*Used by > 70% o f respondents Usually or Always.
NB: Used by < 20% o f respondents Usually or Always; Hand-Doyle Index; Knee-Walk time, Ascent time; Hip— Intercondylar distance, Intermalleolar 
distance; Walk time. Ascent time.
Status Index! Fibromyalgia Impact Questionnaire!
(FIQ), Arthritis Impact Measurement Scales!, Arthritis 
Impact Measurement Scales 2^ , Rapid Assessment of 
Disease Activity in Rheumatology!, Western Ontario and 
McMaster Universities Osteoarthritis Index!, j^gquesne 
Indices of Clinical Severity!, Dougados Functional Index!, 
McGill Pain Questionnaire!, Health Utilities Index!, 
Nottingham Health Profile!, Short Form-36 (SF-36)!,
European Quality of Life Index!, Index of Wellbeing!, 
Sickness Impact Profile! ^^s between 0% and 10%.
Data recording. Respondents differed in the procedures they 
usually followed for recording scores derived by the afore­
mentioned measurement techniques. The following methods 
were used: written notes in the patient’s chart (48%), 
dictated note in the patient’s chart (16%), not recorded 
(26%), recorded on rough notes (7%), recorded on a flow
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Table 4. Responses to the question: How often do you serially use the 
following assessment techniques for longitudinally monitoring the efficacy  
o f antirheumatic drug therapy in your adult ankylosing spondylitis outpa­
tient practice?
Assessment Technique Never Occasionally Usually Always
Chest expansion* 3 18 43 36
Schober test (or modification)* 9 20 40 31
Finger-to-floor distance 20 23 32 25
Sacroiliac joint tenderness 19 24 37 20
W all-occiput distance 35 23 23 19
*Used by > 70% o f respondents Usually or Always.
NB: Used by < 20% of respondents Usually or Always: Tragus-to-wali 
distance, Finger-to-fibula distance, Chin-to-stemum distance, Occiput-to- 
C7 distance, Dougados articular index.
Table 5. Responses to the question: How often do you serially use the 
following assessment techniques for longitudinally monitoring tlie efficacy  
o f antirheumatic drug therapy in your adult fibromyalgia outpatient prac­
tice?
Assessment Technique Never Occasionally Usually A lways
Quality o f  sleep* 18 8 42' 32
Fatigue' 21 140 43 23
No. o f tender points 38 22 30 10
*Used by > 70% o f respondents U sually or A lways.
'Due to rounding percentage does not add to 100.
NB: Used by <  20% o f respondents Usually or A lways. Skinfold tender­
ness, Reactive hyperemia, Dolorimeter scores.
sheet (3%), other (2%). When serially recording the distrib­
ution of joint involvement in RA for longitudinal folio wup, 
a homunculus or mannikin was used “Usually” or “Always” 
by 14% of respondents (Always 5%, Usually 9%, 
Occasionally 34%, Never 52%).
Characteristics o f  a measure fo r  use in adult outpatient 
practice. Respondents were asked to rate the importance of 
various characteristics, relevant to tlie use of measurement 
techniques in routine clinical practice, according to the
following scale; “Very Important,” “Quite Important ” 
“Somewhat Important,” “Quite Unimportant,” 
Important At All” (Table 6). Over 80% of respondents iden 
tified the same 6 characteristics of a measure for use in 
routine practice as being “Very Important.” The remaining 
respondents (with one exception) rated the same 6 charac­
teristics as “Quite Important” (11-17%), or “Somewhat 
Important” (1-3%). The 6 characteristics were as follows- 
Simplicity, Quick completion. Easy scoring. R eliab ility  
Validity, and Responsiveness. In general, use of a measure 
in prior clinical research studies or recommendation by the 
American College of Rheumatology (ACR) for research 
purposes was regarded with higher levels of importance 
than recommendation for research use by the Food and Daig 
Administration, International League of Associations foi 
Rheumatology, World Health Organization, or European 
League of Associations for Rheumatology.
Information normally recorded in the patient’s notes at most 
outpatient visits. Response to treatment, cunent drug 
profile, recent drug side effects, change in arthritis status, 
and change in overall health were almost always recorded 
(92-99%). For dmg monitoring, blood count, biochemistry, 
urinalysis, and for inflammatory disease erythrocyte sedi­
mentation rate were also frequently recorded (85-96%). 
Blood pressure (48%), body weight (43%), pulse rate 
(22%), and respiratory rate (5%) were recorded less 
frequently.
Familiarity with basic measurement methods. Eighty-six 
percent of respondents were of the opinion that Likert-type 
(i.e., Descriptive, Adjectival) scales were easy to use. A 
slightly smaller percentage (75%) felt that visual analog 
scales (VAS) were easy to use. Less than half the respon­
dents (47%) felt comfortable using health status question­
naires, which required several items to be added togetlier to 
give a final score. More respondents expressed adequate 
familiarity with the use of the goniometer (85%) and the 
sphygmomanometric measurement of grip strength (83%) 
than with the use of the dolorimeter (26%).
Table 6. Responses to the question; Consider measurements that you use, or would like to use, in your clinical 
adult outpatient practice. How important would you generally rate the following characteristics?
Characteristic
Very
Important
Quite
Important
Somewhat
Important
Quite
Unimportant
Not 
Important At 
All
Previously used in clinical research studies 22 28 35 7 8
Recommended for research by ACR* 9 17 38 22 15
Recommended for research by FDA 5 11 36 28 20
Recommended for research by ILAR 3 17 40 23 17
Recommended for research by WHO* 3 12 40 24 20
Recommended for research by EULAR* 3 11 44 22 19
*Due to rounding percentage does not add to 100.
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DISCUSSION
Quantitation of the clinical effects of interventions has 
become a standard procedure in clinical research. The 
methods used are based on valid, reliable, and responsive 
measurement techniques. Tire data produced are a required 
part of the licensing process for new antirheumatic drugs, 
similar procedures being used in the assessment of new 
orthopedic surgical techniques, the evaluation of physio­
therapy modalities, and in health economics evaluations. In 
contrast, quantitative clinical measurement in routine clin­
ical care offers several advantages: (a) it provides informa­
tion regarding the severity of the patient’s disease, places the 
patient on the spectrum of disease, and may be of prognostic 
importance^’!'! '^ ; (b) it provides information to both physi­
cian and patient regarding the necessity to initiate, continue, 
modify, or terminate a particular therapy; (c) it provides 
information to disability insurers regarding the severity of 
disease and the outcome of treatment programs; (d) it 
provides information to litigators regarding the patient’s 
health status and may provide some insight into attribution 
issues; and (e) it allows health care agencies to understand 
the clinical effect of their expenditures and, therefore, the 
appropriateness of ongoing payment for clinical interven- 
tions °^.
Response profile. Surveys have 2 potential limitations. First, 
if the response rate is low, the results may not be generaliz- 
able. However, in this survey, the response rate was high 
(i.e., 72%), and in as much as practice patterns may be a 
function of year of graduation^', there was no significant 
difference between respondents and nonrespondents. We 
believe, therefore, that our observations are generalizable to 
rheumatology practice patterns in Australia. Second, 
surveys based on self-administered questionnaires provide 
information on what respondents say they do, and this may 
differ from what they actually do in practice. While this is 
an inherent weakness of survey techniques in general, a 
direct chart audit might not provide entirely accurate data 
with respect to the focus of this survey, since 26% of respon­
dents indicated that they did not record the information at 
all, while a further 9% made no formal record in the 
patient’s chart. We feel that the postal survey methodology 
used provides reasonable insight into which outcome 
measures are used currently in routine care.
General observations. In general, comparative assessments 
(same, better, worse) were slightly preferred over quantita­
tive measures. VAS were less popular than Likert scales for 
assessing health status. Standard health status measures 
were rarely used. Since there is still debate as to the content 
and conceptual basis of health related quality of life ques­
tionnaires^ ,^ concern that comorbidities may influence the 
score^ ,^ and recognition that antirheumatic treatment may be 
successful but not alter the score '^', it is not surprising that 
practitioners have not yet adopted these measures for 
routine use. Simple binary joint counts were more
frequently used than graded joint counts. Tests of physical 
performance were rarely used.
Rheumatoid arthritis. Current ACR outcome measurement 
guidelines for Phase III clinical research studies recommend 
the assessment of number of tender joints, number of 
swollen joints, pain, function, patient global assessment, and 
physician global assessment^. While, separate counts of 
tender and swollen joints were preferred over graded joint 
counts, in general, specific joint counting procedures were 
employed by < 70% of respondents. Furthermore, despite 
being the major symptom of RA, pain scales were routinely 
employed by less than 70%, and functional capacity-assess­
ments by less than 11%, of respondents, the majority, of 
those using the HAQ (10%). It is of note that the duration of 
morning stiffness was an extremely popular measure in clin­
ical practice, but yet is-not included in the ACR core set (cf, 
physician and patient ■ global assessments)^. In contrast, 
performance based measures are not included in the ACR 
core set^ and were not routinely used by survey respon­
dents.
There was a trend towards the more frequent usage of 
outcome measures in assessing the response to DMARD 
tlierapy. This is not surprising given the symptom-modi­
fying potential of all 3 classes of drugs but an added expec­
tation of substantial longterm benefits on joint structure and 
function from DMARD therapy.
Osteoarthritis. Current clinical measurement procedures, 
recommended by the Osteoarthritis Research Society 
40ARS), for hand, hip, and knee studies^ include pain, phys­
ical function, and patient global assessment. In addition, 
physician global assessment is recommended and the 
measurement of quality of life highly recommended. The 
OARS guidelines^ and the OMERACT III recommenda­
tions^  ^ that preceded them were published after the 
OMIRROP survey was conducted. In addition, because of 
space limitations, physical function measurement questions 
were not included in the generalized OA section, and global 
assessment questions were not included in the hip or knee 
sections.
In generalized OA, the physician global assessment 
predominated and was the only measure used “Always” or 
“Usually” by > 70% of respondents.
Despite being the principal symptom of hand, hip, and 
knee OA, pain was routinely measured by < 70% of respon­
dents. Nevertheless, measurements of functional capacity 
were popular outcome measures. Global assessments were 
surveyed only for hand OA and were used routinely by 
about 70% of respondents. Since global assessments were 
used routinely in generalized OA and hand OA, but the 
question was not asked for hip OA and knee OA, we specu­
late that the patient and physician global assessments may 
also be a popular method of monitoring hip and knee OA 
patients. Although tlie vast majority of respondents were 
familiar witli the use of the modified sphygmomanometer
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and tlie goniometer, they did not use these instruments in 
longitudinal monitoring. Quantitating joint swelling is noto­
riously difficult, while crepitus is not usually considered 
quantifiable and not expected to change with treatment. 
Ankylosing spondylitis. A degree of agreement has been 
reached on a core set of outcome measures for future AS 
clinical trials. The AS section of the OMIRROP survey 
questionnaire focused on examination-based measures only. 
Since restricted lumbar spinal movement and chest expan­
sion form part of the diagnostic criteria for AS, it is not 
surprising that they are commonly used also in outcome 
measurement. It is a paradox that respondents to this survey 
were more likely to use the FSI, HAQ, or the ACR 
Functional Classification in AS patients than the purpose- 
built Dougados Functional Index. It should be noted that we 
did not specifically question rheumatologists regarding their 
use of the HAQ-S^  ^ or the Batli Ankylosing Spondylitis 
Functional Index^ .^
Fibromyalgia. There is currently no .international agreement 
on outcome measurement procedures for future Phase III 
FM studies'. Tlie OMIRROP survey probed 6 outcome 
measures used in previous FM studies, but did not survey 
the use of pain or global measures. Given that non-restora­
tive sleep and chronic fatigue are key symptoms of FM^ ,^ it 
is not surprising that they were the most frequently 
employed outcome measures by survey respondents. The 
number of tender points forms part of the diagnosis of FM^  ^
but only 40% of respondents used them in longitudinal 
monitoring. Tlie dolorimeter was rarely used, and may be 
partly explained by the fact that 74% of respondents did not 
feel sufficiently familiar with its use. While the FSI was not 
developed specifically for use in FM patients, it was used 
more frequently than the puippse-built FIQ.
We conclude from tliis survey that most Australian 
rheumatologists perform outcome assessment in their longi­
tudinal followup of their patients with RA, AS, OA, and 
FM. The usual methods employed by the majority of 
respondents were to a large extent based on overall impres­
sions rather than ratings derived from precise scores gener­
ated on a number of separate component measures. They 
agree on the qualities required of an outcome assessment 
technique for use in routine outpatient care. The observed 
lack of standardization in the methods currently used is 
speculative. We suspect that it may be in part due to the 
following; (a) lack, until recently, of international agreement 
on core sets of outcome measures; (b) lack of familiarity 
with the format, administration, scoring, and interpretation 
■of newer health status instruments; (c) the logistic 
constraints of performing some measurement procedures in 
a busy outpatient clinic setting; (d) the lack of any require­
ment to perform formalized serial measurements; (e) an 
absence of clinical research examining whether the avail­
ability of quantitative data has significant and favorable 
consequences in clinical decision making, resource utiliza­
tion, economic aspects of health care delivery and, most 
importantly, on patient outcome; and (f) the lack of 
emphasis on formalized measurement in many rheuma­
tology training programs. As a result, a rheumatologist may 
be more likely to measure the blood pressure, weight, and 
pulse rate, than to administer a generic or disease-specific 
health status instrument or measure the patient’s quality of 
life.
There is an opportunity to perform quantitative outcome 
measurement in rheumatology. To achieve this goal 4 
requirements need to be met: (a) rheumatologists need to 
become familiar with the newer generic and disease-specific 
self-administered health status questionnaires; (b) instru­
ment developers need to address the measurement needs of 
rheumatologists and their patients in the routine outpatient 
clinical care setting; (c) the consequences of practicing 
quantitative clinical rheumatology need to be assessed from 
a number of standpoints (physician decision making, quality 
of care, resource utilization, health economics, monitoring 
and prognosticating individual patient outcomes); and (d) ^
patient management systems need to be developed that are |
user friendly, affordable, and capable of performing ^
multiple functions (data management, booking, billing, etc.) ^
tliat will reduce workload and enhance decision making for 
practicing rheumatologists and improve the precision and 
efficiency of clinical practice. Perhaps in practical terms this 
last element will be the critical step in the successful imple­
mentation of quantitative rheumatology. Finally, it is not 
that we need to replace existing outcome measures but it is 
necessary to address not only the clinimetric issues of 
validity and responsiveness but also the third element of tlie 
OMERACT Filter, that of feasibility^®. This can only be 
achieved by bridging the gap between the theoretical and the 
practical and understanding the reality of performing quan­
titative measurement in clinical practice.
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Background; The WOMAC {Western Ontario and McMaster Universities) function subscale is widely used 
in clinical trials of hip and knee osteoarthritis. Reducing the number of items of the subscale would enhance 
efficiency and compliance, particularly for use in clinical practice applications.
Ob|eciive: To develop a  short form of tlie W OMAC function subscale based on patients' and experts' 
opinions (WOAAAC function short form).
Merivbds: W OMAC function subscale data (Likert version) were obtained from 1218 outpatients with 
painful hip or knee osteoarthritis. These patients and their rheumatologists selected the five items that they 
considered most in need of improvement. The rheumatologists were asked to select the five items for which 
patients in general a re  the most impaired. Items that were least important to patients and experts, those 
with a  high proportion of missing data, and lliose with a response distribution showing a  floor or ceiling 
response w ere excluded, along with one of a  pair of items with a  correlation coefficient > 0 .7 5 .
Results: The WOMAC function short form included items 1, 2, 3, 6, 7, 8 , 9, and 15 of the long form. The 
short form did not differ substantially from the long form in responsiveness (standardised response m ean of 
0 .84  vO.BO).
Conclusions: A short form of the WOMAC function subscale was developed according to the views of 
patients and rheumatologists, based on the responses of 1218 patients and  399 rheumatologists. The 
clinical relevance and applicability of this WOMAC function subscale short form require further 
evaluation.
O n e  o f  the m ajor u ses o f  h ea lth  m e a su r e m e n t sca les is d etectin g  h ea lth  sta tu s ch a n g e  over tim e, e ith er  in  the  co n tex t o f  c lin ica l trials or ep id em io lo g ica l stu d ies or 
as a stra tegy  for m on itorin g  the o u tc o m e s  a n d  m akin g  
d ec is io n s a b ou t th e  care o f  in d iv id u a l p a tien ts  in  d a ily  clin ical 
practice. In all situ a tio n s , a priority m a y  b e effic ien cy , 
a ch ieved  by the sh ortest p ossib le  questionnaire.*  To date, 
m eth o d s o f  sh o rten in g  q u estio n n a ires h a v e  fo cu sed  on  
approaches that m a in ta in  th e  grea test in tern a l consistency.^  
H ow ever, in  th e  co n tex t o f  h ea lth  m e a su r e m e n t scales  
targeting a rela tively  h e tero g en eo u s d isorder, it  m a y  b e  
ad va n ta g eo u s to sacrifice in ternal c o n sis te n c y  for con ten t  
validity.*
T he W estern  O ntario an d  M cM aster U n iversities  
(W O M AC) osteoarth ritis in d ex  is a valid , reliab le, and  
resp onsive  m easu re in  h ip  and k n e e  osteoarthritis."  ’ This 
in d ex  is se lf  a d m in istered  and in v o lv es 17 item s ad d ressin g  
th e  d egree  o f  d ifficu lty  in  acco m p lish in g  17 activ ities  o f  daily  
life. W h ile  th e  m ea n  im portan ce score o f  th e  17 item s is 
sim ilar at a group  level, there is in ter in d iv id u a l variab ility  in  
the im p ortan ce a ttach ed  by in d iv id u a l p a tien ts  to  particular  
items." * The W OM AC fu n ctio n  su b sca le  is short, an d  ca n  be  
com p leted  quick ly. N everth eless, an  ev e n  sh orter  version  
w o u ld  further en h a n ce  its app licab ility  in  ep id em io lo g ica l 
stu d ies an d  for u se  in  rou tin e  c lin ica l practice.^
O ur a im  in  th is stu d y  w as to sp ec ify  a sh ort form  o f  the  
W OM AC fu n ctio n  su b sca le  ded icated  to all p a tie n ts  w ith  hip  
or k n e e  osteoarth ritis , by  preserving th e  m o st im portant 
item s for p a tien ts  an d  rh eu m a to lo g ists  (W OM AC fun ction  
su b sca le  sh ort form ).
METHODS 
S tudy  p o p u la t io n
W e co n d u cted  a prospective cohort stu d y  o f  four w eek s' 
duration , in v o lv in g  1362 ou tp a tien ts w ith  h ip  or k n ee  
o steoarth ritis as d efin ed  by th e  A m erican  C ollege o f
R lieum atology,^  and  399 private rh eu m a to lo g ists  in  
France. Each rheu m ato log ist w a s  required to in c lu d e  fo u r  
p a tie n ts , three w ith  k n ee  o steoarth ritis and  o n e  w ith  h ip  
o steoarth ritis . To be in clu d ed  in  th e  study , p a tien ts  h ad  to  
ex p erien ce  pa in  from  the osteoarth ritis ( > 3 0  m m  o n  a v isu a l  
a n a lo g u e  sca le (VAS) ranging from  0  to 100 m m ) an d  to  
require treatm en t w ith  a n o n -s te ro id a l a n ti- in fla m m a to ry  
drug (N SA ID ). Inclusion  cou ld  b eg in  w ith  th e  o n se t  o f  
trea tm en t or w ith  a sw itch  from  o n e  N SA ID  to a n o th er . 
P atien ts w ere  exclu d ed  i f  th e y  had  a p rosth esis o n  th e  
a sse sse d  jo in t or i f  th ey  had  b e e n  treated  w ith  in tra -articu lar  
in je ctio n  in  the four w eek s b efore  th e  stu d y  b egan . A ll 
p a tien ts in itia lly  v isited  th e  rh eu m a to lo g ist in  charge o f  the ir  
case, an d  a n  NSAID w a s p rescribed  (th e  drug and  its  d o sa g e  
w ere ch o se n  by the p h ysic ian ). A  fina l v isit to  th e  sa m e  
rh eu m a to lo g is t  w as sch ed u led  four w eek s later.
M e a s u re m e n ts
P atien ts an d  rh eu m ato log ists a sse sse d  the p a tien t's  s ta tu s  
w ith  resp ect to  the osteoarthritis a t th e  b aselin e v isit  an d  at 
w e e k  4 . P atien ts com p leted  th e  F ren ch  C anadian versio n  o f  
th e  W OM AC physical fun ctio n  subscale® (17 item s, fiv e  p o in t  
Likert sc a le  version , total score varying b e tw een  0  a n d  68; 
h ig h  scores in d ica te  a h igh  d egree o f  fu n ction a l im p a irm en t).
P atien ts w ere  a lso  asked  to  se lec t  th e  five item s o f  th e  
W O M AC fun ctio n  subsca le  tha t th e y  considered  m o st  in  n eed  
o f  im p rovem en t.
T he rh eu m ato log ists w ere ask ed  on  on e  occa sio n  to se lect  
the five item s on  the subscale  w h ic h  they con sid er resu lt in 
th e  g rea test im pairm ent in  p a tie n ts  w ith  k n e e  and  h ip  
osteoarth ritis (not the sp ecific  p a tien ts  they had in c lu d ed  in 
th e  stu d y ).
A bbreviations: ICC, inlradoss correlation coefftcieni; SRM, 
standardised response mean; WOMAC , Western O ntario and 
McMaster Universities osieoaribrifis index
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T able 1 B aseline chorocterisU cs o f th e  p a tie n ts
Full WOMAC function 
subscalc' (n = 1218)
Incomplete WOMAC function 
subscalet (n = 144)
Age (years) 66 ,9  (10.4) 69.7 (10.8)
Female sex 854 (70.1%) 59 (41.0%)
Body moss index (kg/m '| 27.6 (4.7) 27.8 (5.0)
Disease duralion (years) 4.5 (5.6) 4.7 (5.9)
Kellgren and Lawrence grade
11 246 (20.2%) 19(13.2%)
III 530 (43.6%) 62 (43.1%)
t v 440 (36.2%) 63 (43.8%)
NSAID intake during lire past 4  weeks 355 (29.2%) 38 (26.4%)
Analgesics]: during lire post 4 weeks 699 (57.5%) 87 (60.4%)
Symplomah'c slow acting drug intakeS
during the past 4 weeks 437 (36.0%) 38 (26.4%)
Poin (0-100 VAS)
Mean (SO) 57.9 (17.0) 57.6 (17.4)
Week 0  to week 4 (SD) -2 3 .3  (22.1) -2 1 .4  (22.4)
Global assessment (0-100 VAS)
Mean (SD) 58.6 (19 .0 ) 59.3 (20.6)
Week 0  to week 4 (SD) -2 3 .1  (24.1) -2 1 .0  (26.6)
WOMAC function score (0-68)
Mean (SD) 29 .7(11 .4 ) -
Week 0  to week 4 (SD) - 7 .8  (9.7) -
Volues are mean (SD) or n (%).
'Patients witfioyi missing data for itie WOMAC function subscole at tfie baseline visit; tfius tliose vdto were invotved 
in tfie derivation process.
fPotients witfi missing data lor tfie WOMAC function sufjscale or who did not complete the questions at all at 
baseline.
jOifier ition NSAID.
SCKondroitin sulphate, diacerheine, o r avocado/soybean unsaponifiables.
NSAID, non-steroidal anti-inflammatory drugs; VAS, visual analogue scale; WOMAC, Western Ontario and 
McMaster Universilies osleoartfiritis index.
To a ssess  th e  te st-r e te st  re liab ility  o f  the resu ltin g  W OM AC  
fu n ctio n  su b sca le  short form , a su b sa m p le  o f  86  p a tie n ts  w a s  
ask ed  to co m p lete  the  full W OM AC fu n ctio n  su b sc a le  aga in , 
4 8  h ou rs a fter the  b aselin e  visit. T h ese p a tie n ts  h a d  b eg u n  
ta k in g  N SA ID s 48  hours after the b a se lin e  v is it  ( th a t  is, a fter  
co m p le tin g  the W OMAC fun ctio n  su b sca le  a se c o n d  tim e).
S fa t isM c a l a n a l y s i s
F irst, w e  com p u ted  descriptive sta tistics o n  c lin ica l a n d  
d em o g ra p h ic  variables. T hen w e  u sed  a four step  proced u re to 
e lim in a te  item s as fo llow s:
•  S tep  i .  W e ranked  th e  17 item s o f  the c o m p le te  W OM AC  
fu n c tio n  su b sca le  from  h ig h est  to  lo w e s t  im p o rta n ce  
accord in g  to the p atien ts' an d  rh eu m a to lo g ists ' op in io n s, 
ex c lu d in g  the  five item s that w ere  least im p o rta n t for b o th  
p a tie n ts  an d  rh eu m ato log ists . The w h o le  sa m p le  w a s th e n  
d iv id ed  in to  tertiles o f  th e  W OM AC fu n c t io n  su b sca le  
score  to in vestig a te  the  p oten tia l im pact o f  th e  level o f  
fu n ctio n a l im pairm ent on  th e  p atien ts' ran k in g .
•  S tep  2. W e ranked the 17 item s by th e  p rop ortion  o f  
m iss in g  data per item . Item s w ith  a h ig h  proportion  o f  
m iss in g  d ata  w ere  exclu d ed .
•  S tep  3. Item s w h o se  d istr ib u tion  o f  a n sw e rs  sh o w e d  a 
floor  or ce ilin g  resp onse  w ere  exclu d ed . T his resp o n se  is 
p resen t w h e n  m o st o f  th e  an sw ers are c lu stered  in  o n ly  a 
fe w  resp o n se  op tion s at o n e ex trem e— that is, w h e n  m o st  
o f  th e  su b jects a ttes t  to  h a v in g  n o  d iff ic u lty  (flo o r  
resp o n se ) or extrem e d ifficu lty  (ceiling  r e sp o n se ) in  th e  
activ ity . For floor response item s, it is im p o ssib le  to detect 
im p ro v em en t, w h ile  for ce ilin g  resp onse  item s, it is n ot 
p o ss ib le  to d istin gu ish  a m on g  various grades o f  d ifficu lty , 
as m o st o f  th e  subjects an sw er the  sam e w a y .
•  S tep  4. W e tested  for p o ten tia lly  red u n d an t item s. In ter­
item  correlation  coeffic ien ts w ere  com p u ted . W h en  the
correlation co effic ie n t w as greater th a n  0 .7 5 , th e  least 
im portant item  o f  th e  pair in the p atien ts' r a n k in g  w as 
exclu d ed .
R esp onsiven ess w a s  a ssessed  by u se  o f  th e  sta n d a rd ised  
resp onse  m ea n  (SR M ) for th e  com plete W O M AC fu n ctio n  
su b sca le  and the W O M AC function  short form . S R M  is the  
m ea n  ch an ge in  score b e tw e e n  the b aselin e an d  th e  f in a l visit 
d ivided  by the  stan d ard  deviation  o f  th e  c h a n g e  in  score. 
T est-re test reliabiUty w a s  assessed  u sin g  th e  in tra c la ss  
correlation co eff ic ie n t (ICC). C onstruct v a lid ity  o f  the  
W OM AC fu n ction  sh o rt form  w as a ssessed  u s in g  the  
correlation  b e tw een  sco res o f  the long and  sh o r t fo rm s, as 
recom m en d ed  w h e n  th e  orig inal scale can n ot b e  co n sid ered  
a gold  standard ( th a t is, the reference m e a su r e m e n t  
in stru m en t).' In tern a l con sistency  w a s a s s e s s e d  u sin g  
C ronbach's a .’
S tatistical an a ly ses in vo lv ed  u se  o f  the  SAS R e le a se  8.2  
statistica l so ftw are p ack age.
RESULTS
In all, 1362 p atien ts w e r e  enrolled in the  study: 1 0 1 9  (75% ) 
w ith  k n ee o steoarth ritis and  343 (25%) w ith  h ip  o ste o a r ­
thritis. At the b a se lin e  v isit, 1218 patients (89% ) co m p le ted  
th e  full WOMAC fu n c tio n  subscale w ith ou t an y  m is s in g  data. 
The derivation p rocess is based  on these  1 2 1 8  p a tie n ts , 
described  in  table 1.
R a n k in g  o f  th e  1 7  i t e m s  o f  th e  c o m p le te  W O M A C  
fu n c t io n  s u b s c a le
P atients and rh eu m a to lo g ists  w ere con sisten t in  r a n k in g  the  
im portance o f  item s (ta b le  2 ). The four m ost im p o r ta n t  item s  
for rh eu m ato log ists w ere  am ong the five m o st im p ortan t  
item s for patients. T h e  five least im portant ite m s  for 
rh eu m ato log ists w ere  a m o n g  the six least im p o r ta n t item s  
for patients. The ran k in g  o f  item  im portan ce w a s  sim ilar
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betw een  p atien ts w ith  h ip  osteoarthritis and th o se  w ith  k n ee  
osteoarthritis (d a ta  n o t sh o w n ), except for " d escen d in g  
stairs" (ranked  s ix th  an d  first, respectively), an d  "putting  
on so ck s/sto ck in g s"  (first and  12th, respectively). As th ese  
item s are rela tively  sp ec ific  to the location  o f  th e  o steo a r ­
thritis (h ip  or k n e e ) , th is d iscrepancy w as exp ected . The  
ranking o f  the  item s' im portan ce w as sim ilar b e tw e e n  m en  
and w o m e n  (data  n o t sh o w n ), except for "going sh op p in g"  
(ranked 10th an d  fourth , respectively) and  "perform ing ligh t 
d om estic d u ties"  (ra n k ed  13th  and seven th , resp ective ly ).
The five lea st im p o rta n t item s for b oth  patients and  exp erts  
were "lying in  bed ,"  " b en d in g  to the floor," " rising from  
bed," " sittin g ,"  " tak in g  o f f  socks/stock ings,"  and  " stan d in g ."
R esults o f  d iv id in g  th e  w h o le  sam ple in to  tertiles o f  the  
WOMAC fu n ctio n  su b sca le  score sh ow ed  exactly  th e  sa m e  
item s b e in g  se lec te d  by p a tien ts  in th e  three subgroups.
Ranking o f  the  17 items by the proportion of missing  
data
Three item s g en era ted  n ota b ly  m ore m issin g  data  th a n  the  
others. T h ese  ite m s m a y  h a v e  b een  interpreted too  literally  
and con sid ered  n o t to  b e  relevant— for exam p le, d o m e stic  
duties m a y  h ave b e e n  interpreted  on ly  as c lean in g  th e  h o u se  
and therefore probab ly  o f  m ore concern to w o m e n , w h ile  
respondents a n sw e r in g  th e  gettin g  in /ou t o f  th e  b ath  
question  m a y  n o t  h a v e  appreciated  that th is q u estio n  can  
alternatively  be co n sid er ed  relevant to getting  in /o u t o f  the  
show er.
The item s e x c lu d e d  w ere  "perform ing heavy d o m e stic  
duties,"  " p erform in g  lig h t d o m estic  duties,"  and  " gettin g  in /  
out o f  the bath ."
Items fo r  w h ich  th e  d is tr ib u tio n  o f a n sw e rs  sh o w e d  a 
Floor o r  c e ilin g  re s p o n s e
Alm ost a ll th e  ite m s o f  the  com p lete W OMAC fu n ctio n  
subscale h ad  a g o o d  d istr ib u tio n  o f  an sw ers am ong  resp o n se  
n o d es. H ow ever, tw o  h a d  a saturation  poin t in  o n e  or tw o  
esp ou se  m o d es: for " b en d in g  to th e  floor" an d  " lying in 
)ed," 74% an d  75% o f  th e  an sw ers, respectively, w ere  "no  
lifficulty" or " slig h t d ifficu lty ."
The item s ex c lu d ed  w ere  "bending to the  floor" and " ly ing  
n bed." B o th  ite m s h a d  already b een  exclu d ed  in  a previous  
tep.
In te r- ite m  c o r r e la t io n
Pairs o f  h ig h ly  correlated  item s (r> 0 .7 5 ) w ere " putting  on  
so c k s /sto ck in g s"  w ith  " tak ing  o ff  socks/stock in gs"  (r =  0 .8 5 )  
and " p erform in g  lig h t d o m e stic  duties"  w ith  "perform in g  
h eavy  d o m e stic  d u ties"  (r — 0 ,7 8 ).
The item s exclu d ed  w ere  " taking o ff  socks/stock in gs,"  and  
"perform ing  h e a sy  d o m e stic  duties."  Both item s had  b een  
e x c lu d ed  in  a prev ious step .
S u m m ary  o f th e  re d u c tio n  p ro c e d u re
T he e ig h t item s o f  the W OM AC function  subscale sh ort form  
derived by th e  a b ove m en tio n ed  m eth od s are sh o w n  in  the  
ap p en d ix . T h ese  item s w ere  th e  eigh t m ost im portant in  th e  
p atien ts' op in io n .
W h en  su m m a ris in g  the d ifferent steps in th e  red u ctio n  
procedure, it can  be se e n  that six  o f the n in e  exclu d ed  item s  
w ere ex c lu d ed  in  a t lea st tw o  step s (tw o  steps for four o f  the  
item s a n d  three for tw o  o f  the  item s).
P e rfo rm a n c e  c h o ra c fe r is lic s
T he W O M AC fu n ctio n  su b sca le  short form  did  n o t d iffer  
su b sta n tia lly  from  th e  co m p le te  WOMAC fu n ction  su b sca le  
eith er  in  resp o n s iv en ess  (SR M  =  0 .84  ( n =  1169) an d  0 .8 0  
(n  =  1048), resp ective ly ) or in  te st-re te st reliab ility  (ICC =  
0 .75  (0 .6 5  to 0 .8 3 ) an d  0 .7 9  (0 .6 9  to 0 .87 ), resp ective ly ).
C onstruct va lid ity  o f  th e  W OM AC fun ction  su b sca le  sh o rt  
form  w a s  e x c e lle n t (r =  0 .95  b e tw een  the lon g  an d  sh ort  
form s). In ternal co n s is te n c y  w a s  good in  the  W OM AC  
fun ctio n  su b sca le  sh ort form  an d  the com p lete W OM AC  
fu n ctio n  su b sca le  (a  =  0 .8 4  and a  =  0 .93 , respectively).
D I S C U S S I O N
U sin g  p a tie n ts ' and  rh eu m a to lo g is ts ' op in ions in  France, and  
based  o n  th e  Likert v ers io n  o f  th e  French C anadian W OM AC  
fu n ctio n  su b sca le , w e  h a v e  specified  a short form  o f  th is  
su b sca le  for p a tie n ts  w ith  h ip  or k n ee  osteoarthritis ( in c lu d ­
ing a broad sp ectru m  o f  d isea se  severity). To address recen t 
reco m m en d a tio n s for sh o rten in g  com p osite  m ea su rem en t  
sc a les,' w e  h a v e  en su red  that th e  original sca le  w as va lid , 
relevant in  th e  co n te x t  o f  h ip  an d  k n ee osteoarth ritis , a n d  
had sa tisfactory  m ea su rem en t properties." *
T he W OM AC fu n ctio n  su b sca le  short form  co n ta in s o n ly  
e ig h t item s. It w a s  derived  by preserving face va lid ity
TaWe 2 The 17 items of the complete WOMAC function subscale ranked in importance by patienb and rheumatologists
Hettt. w# PatiénV tdnkingL 'NrtldfiSS -!
Descending stairs 64.10 73.85 1 1 0.22
Ascending stairs 62.65 47.90 2 5 0.29
Walking on the flat 50.20 28.15 3 8 0.15
Getting in/out of a  car 41.45 51.90 4 4 0.22
Rising from sitting 39.90 66.00 5 3 0.37
Going shopping 34.10 19.30 6 10 0.95
Getting on/off the toilet 33.65 28.95 7 7 0.37
Putting on socks/stockings 30.85 66.80 8 2 0.44
G ettin g  in /o u t  o f  th e  b a th 30.00 45.65 9 6 4 .2 6
P erform ing ligl)t d o m e s tic  du ties 26.65 10.25 10 12 4 .7 7
P erform ing h e a v y  d o m e s tic  du ties 26.30 23.75 11 9 5 .2 9
S ta n d in g 25.70 9.05 12 13 0.22
Taking off so c k s /s to c k in g s 11.95 17.10 13 11 0.59
Sitting 8.40 3.20 14 15 0.37
Rising from  b e d 7.05 5,65 15 14 0.37
B end ing  to floor 4.60 2.00 16 16 0,22
Lying in b e d 2.40 0.40 17 17 0.22
Eocti patient selected ttie five items tfiey considered tfie most important to be improved by treatment; each rheumofologist selected tlie five items for vdrich their 
patients are generally most impaired. Excluded items are in italics.
'Percentage of patients who considered tlils item as one of the five most important. 
fPercentoge of rheumatologists who considered this item as one o( the five most important.
tRank of Hie item based on the percentage of patients who considered tliis item as one of the five most important.
5 Rank of the item based on the percentage of rheumatologists who considered llils item as one of the five most important.
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(p a tien ts' an d  rh eu m a to lo g ists ' o p in io n s)  and  q uality  o f  the  
item s ( fe w  m issin g  data, n o  red u n d an cy , good  d istrib u tion  o f  
th e  a n sw e rs  across resp o n se  m o d e s). P reserving face valid ity  
is im p o rta n t b eca u se  it in creases the  a ccep tan ce o f  the  
in stru m e n t by th o se  w h o  w ill u ltim a te ly  u se  it and thu s  
d ecreases th e  a m o u n t o f  m iss in g  d a ta .’ This short form  h as  
good  resp o n s iv en ess , g o o d  te s t-r e te s t  reliability, and good  
con stru ct va lid ity  for th is sam p le , b ut th e se  param eters  
sh o u ld  b e  v a lid a ted  in  an  in d ep en d e n t sam p le  o f  subjects  
from  the target population .'"  Our red u ction  procedure  
in vo lved  d e le tin g  item s th at w ere  h ig h ly  correlated , and thus 
a lo w er  in tern a l c o n sis te n c y  w a s  ex p ected  for the  short form  
th a n  for the co m p lete  su b sca le  (a n  in ternal C ronbach's a = i 
in d ica tes red u n d a n cy ).
A s th e  W OM AC su b sca le  is d ed ica ted  to p a tien ts w ith  h ip  
or k n ee  osteoarth ritis , ou r  sam p le  reflects th is target 
p o p u la tio n  w e ll. T he proportion  o f  p a tien ts w ith  h ip  and  
k n ee  o steoartlir itis (th ree  quarters k n ee  an d  o n e  quarter h ip ) 
is c lo se  to th e  d istr ib u tion  in  th e  co m m u n ity ."  A s sh o w n  in  
table 1, our sam p le, is s im ilar  to sam p les in c lu d ed  in  trials on  
osteoa rth r itis  treatm en t an d  rep resen ts a large sp ectru m  o f  
d isea se  severity . In c lu sio n  criteria, esp ecia lly  th e  requ irem ent  
for N SA ID  treatm en t, w ere  th e  sa m e  as th o se  in  th e  
v a lid a tio n  stu d y  o f  th e  W OM AC sca le  by B ellam y an d  
associates."  In  our sam p le, th e  sa m e item s w ere  se lected  by  
p a tien ts across the  range o f  osteoarth ritis severity; th e  resu lts  
o f  d iv id in g  th e  sam p le  in to  tertiles o f th e  W OM AC fu n ction  
su b sca le  score sh o w ed  th a t th e  five lea st  im portan t item s to  
p a tien ts ( th o se  to be ex c lu d ed ) w ere  exactly  th e  sa m e in  th e  
three tertiles.
It h as b e e n  assu m ed  that item s for a ssessin g  k n ee  o s te o ­
arthritis m a y  be so m ew h a t d ifferen t from  th o se  required for 
h ip  d isea se . In  fact, w h e n  w e  eva lu ated  the  rank ing o f  the  17 
ite m s o f  th e  com p lete  W OM AC fu n ctio n  su b sca le  according  
to  their im p ortan ce to p a tien ts w ith  h ip  or k n ee  d isea se , th e  
five lea st  im p ortan t item s ( th o se  to  be ex c lu d ed ) w ere th e  
sa m e  for p a tien ts w ith  b o th  types o f  osteoarth ritis .
A ccordin g  to previous reco m m en d a tio n s, w h e n  the orig inal 
sca le  c a n n o t  b e  con sid ered  a gold  standard (th e  reference  
m ea su rem en t in stru m e n t), an  expert b ased  approach  to item  
red u ction  m a y  be preferable to  a sta tistica l approach .' T his 
s itu a tio n  is far m ore lik ely  in  th e  p atien ts' se lf  a sse ssm e n t o f  
sy m p to m s. A n  expert b a sed  approach  h as b een  em p loyed  in  
very fe w  stu d ies  that in vo lved  red u cin g  in d ices, an d  m a in ly  
served  to h e lp  ch o o se  a m o n g  several so lu tio n s provided  by  
sta tistica l m e th o d s .' W e c h o se  th e  o ther route. W e u sed  an  
exp ert b a sed  red u ction  procedure, an d  sta tistica l a n a lyses o f  
th e  q u a lity  o f  th e  item s w ere  secon dary  criteria. To reduce  
in fo r m a tio n  b ias in  the  red u ctio n  process, w e  com b ined  tw o  
types o f  expert: p atient exp erts, w h o  had  exp erien ce  o f  th e  
prob lem s (rep resen tatives o f  th e  target p o p u la tio n ), and  
rh eu m a to lo g is t  experts, u sin g  their k n o w led g e  o f  a broad  
sp ec tru m  o f  the d isease.
The originality  o f  our approach lies in  the large num ber o f  
experts invo lved  in  th e  study. Expert based  approaches usually  
rely o n  th e  authors' o w n  ju d gm en t o f  redundancy an d  
in su ffic ien t face validity, or on  th e  u se  o f  con sensu s m eth od s  
w ith  relatively  sm all panels o f  experts. For in stan ce, G uillem in  
an d  co lleagu es"  u sed  tw o panels w h e n  shorten ing  the arthritis 
im pact m easu rem en t scales 2 (A IM S2); on e o f  19 experts 
(rh eu m ato log ists, rehabilitation specialists, and m eth od o lo ­
g ists) and an oth er o f  12 patients. W liileh ouse  et aP used a panel 
o f  36 experts (orthopaedic surgeons, rheum atologists, nurses, 
physiotherap ists, and research personnel). The large sam ple o f  
patient experts (n  =  1218) and rh eum atologist experts 
(n  =  399, approxim ately 15% o f th e  rheum atologists in  
France) in  our study is a good indicator o f its representativeness  
and o f  the  valid ity o f  the results.
The relevance o f  our red u ction  procedure is reinforced  by 
the o u tcom e o f  the  procedure. The rem ain ing  item s are the 
eig h t m ost im portant in  the patients' op in ion , and m o st of  
the excluded  item s w e r e  exclu d ed  in  at least tw o  step s o f  the 
reduction  procedure. T ak in g  p atien ts' op in ion  in to  acco u n t in 
deriving short form s o f  validated  q u estio n n a ires could  
im prove the clin ical re lev a n ce  o f su ch  m eth o d s.
W h iteh ou se  et aP p rop osed  a seven  item  short form  o f the 
WOMAC fu n ction  su b sca le , but the derivation  process 
involved  on ly  a su b g ro u p  o f  patients w ith  severe  d isease  
(pa tien ts undergoing  h ip  or k n ee arthrop lasty). In this 
con text, the short form  sh o u ld  be d ed icated  to a ssessin g  
the  o u tcom e o f  to ta l jo in t  arthroplasty, as W h iteh o u se  
ind icated . H ow ever, fiv e  item s are shared  b e tw e e n  the 
W h iteh o u se  form  an d  ou r  ow n . The particu lar popu lation  
in  W h itehou se's stu d y  m a y  exp la in  som e o f  th e  d iscrepancies  
b etw een  the  tw o  sh o rt form s— especially  that fact that 
activ ities su ch  as " sittin g"  or "rising from  bed ,"  w h ic h  are 
m ore likely to be im p aired  in  severe d isease , are tw o  o f  the  
seven  item s in clu d ed  in  W h iteh ou se's version  b u t exclu d ed  
from  our version  (b e c a u se  they  w ere ranked 14th  a n d  15th, 
respectively, by th e  p a tie n ts ) .
The a ssessm en t o f  th e  perform ance ch aracteristics o f  the 
WOMAC fun ctio n  su b sc a le  short form , its c lin ica l relevance, 
an d  its acceptability  req u ire further stu d ies in  in d ep en d e n t  
sam ples. Such  stu d ies sh o u ld  in vo lve  d ifferent v ers io n s o f  the 
WOMAC fu n ction  su b sca le , as w e ll  as d ifferen t la n gu age  
translations an d  d ifferen t sca ling  form ats, an d  sh o u ld  be 
con d u cted  in  d ifferen t cou n tries, in  d ifferen t clin ical 
em dronm ents (for ex a m p le , rh eu m ato logy , orth opaed ic  
surgery, ph ysioth erap y , reh ab ilita tion ), and  w ith  d ifferent 
in terventions.
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APPENDIX
P r o p o se d  W OM AC fu n ct ion  su b s c a le  sh ort  form  
(e igh t  items)
•  D e s c e n d in g  sta ir s
•  A sc e n d in g  s ta ir s
•  R is in g  fr o m  s it t in g
•  W a lk in g  o n  fla t
•  G e ttin g  in /o u t  o f  a  car
•  G o in g  sh o p p in g
•  P u ttin g  o n  s o c k s /s to c k in g s
•  G e ttin g  o n /o f f  th e  to ile t
T h e  W O M A C  f u n c t io n  s u b s c a le  g r a d a tio n s  in  th e  L ikert-  
sca le d  F ren ch  C a n a d ia n  3 .0  v e r s io n  are: 0  =  n o n e ,  I =  s lig h t,
2 =  m o d er a te , 3 =  s e v e r e , 4  =  e x tr em e .
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Xhe W OM AC fu n ctio n  su b sca le  short form  co m p rises a 
total o f 32 p ossib le  p o in ts , w ith  0 b ein g  the b est an d  32 b e in g
the w orst.
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SECTION 8 - Responder Criteria and State-Attainment Criteria
The traditional approach to the analysis of data from OA clinical trials has been 
performed at the group level. More recently, attention has focused on individual patient 
reported outcomes. These can be considered as being of two general forms: responder 
criteria in which each patient is classified as a responder or non-responder to treatment, 
based on whether their change in health status exceeds a pre-defined threshold, and state- 
attainment criteria in which patients are classified, not on the basis of change (better, 
same, worse), but on the basis o f when, whether, and/or for how long they achieve a 
certain pre-defined level of low symptom severity. Research in both areas is 
developmental and can be considered proposals, rather than guidelines or requirements. 
Nevertheless, responder criteria and state-attainment criteria represent innovations in the 
analysis of clinical trial outcomes, and may provide a bridge between health outcomes 
assessment strategies in clinical research and clinical practice environments.
Although responder criteria had been proposed by the American College of 
Rlieumatology in 1995 for clinical trials in patients with rheumatoid arthritis, no 
comparable development had occurred for clinical trials in patients with OA. Following 
the development of consensus on core set clinical measures for OA clinical trails (22,23), 
a Task Force of the Osteoarthritis Research Society International engaged in the 
development of response criteria for clinical trials in hip and knee OA (35). This 
initiative, in part based on WOMAC data, resulted in the specification of two sets of 
criteria (Propositions A and B), which were joint and intervention-class specific, and of 
defined levels of sensitivity and specificity (35). The OARS I Response Criteria are based 
on minimum thresholds, for combined absolute and relative change, on one or more of 
the core set clinical variables (pain, function, patient global assessment).
The relationship between changes registered on the WOMAC Index and the same 
patients’ perceived global assessment of their response to therapy was explored in the 
context of data from two identical RCTs involving rofecoxib (36). The analyses 
determined that the Minimum Perceptible Clinical Improvement (MPCI) for the 
WOMAC VA3.0 Index subscales in patients with hip and knee OA, was 9.7 mm (0-100 
scale) for pain, 9.3 mm for function and 10 mm for stiffness (36). The study suggested 
that the MPCI might provide a better assessment of the clinical relevance of the effects of 
therapeutic interventions in OA (36).
The OMERACT V Conference provided an opportunity to further explore issues 
relating to the measurement of change, definitions of patient response and responder 
criteria in OA (37,38). Various definitions o f change were discussed including the 
Minimum Change Potentially Detectable (MCPD), the Minimum Percentage Change 
Potentially Detectable (MPCPD), the MPCI, the Minimum Clinically Important 
Difference (MCID), the minimal change detectable beyond measurement error, OARSI 
responder criteria, and patient perceptions of change (37). Consensus-based estimates, 
acquired through interactive touch-pad polling of delegate opinion, indicated support for 
the following: a) Development of response criteria for individuals with other diseases, b) 
The importance of defining major clinically important improvement for RA, c) The 
importance of validating short-term response/improvement in predicting long- term 
outcome, and d) Defining response criteria for OA in terms of both percent and absolute
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change (38). In essence the OMERACT consensus was supportive of the general 
approach taken by the OARSI Task Force in developing responder criteria for OA 
clinical trials (35,38).
In an attempt to further explore the original OARSI responder criteria 
(Propositions A and B), and potentially simplify the presentation of the OARSI responder 
criteria, a collaborative exercise was undertaken between OMERACT and OARSI (39). 
Six scenarios (Original Propositions A and B, and four new Propositions C-F) were 
evaluated, in what were termed ‘‘elaboration” and “revisit” data sets (39). The majority of 
the pain evaluations and almost all the functional evaluations, in contributing studies, had 
been performed with the WOMAC Index (See Table 1 in Reference 39). The initiative 
resulted in the proposal o f a single international simplified set o f responder criteria for 
OA clinical trials, that were applicable to hip and knee OA, and independent of 
intervention class (39).
In order to further explore the application of responder criteria, two secondary 
analyses (40,41) of the previously published pharmaco-economic evaluation of hylan G-F 
20 (17,18) were undertaken. The first analysis paralleled developments in RA, where 
ACR 20, 50 and 70 levels of response had already been investigated in RA patients. The 
evaluation of the WOMAC 20, 50, 70 response criteria in knee OA patients, based on the 
WOMAC LK3.0 Index, provided preliminary evidence, supporting the capacity of 
WOMAC 20,50 and 70 responder criteria, to detect clinically important, statistically 
significant between-group differences in a pragmatic randomised trial (40). The second 
analysis was performed to assess the performance of the OARSI Responder Criteria 
(Propositions A and B), and the OMERACT-OARSI Response Criteria (Proposition D) 
in knee OA patients (41). The analyses provided support for the capacity of all three 
criteria to detect clinically important statistically significant differences between 
treatment groups, in an RCT of a hylan class intervention (41).
The aforementioned criteria are largely based on a combination of expert opinion 
and statistical techniques. In order to incorporate the patient’s own perspective, a study 
was conducted, through collaboration with colleagues in France, and resulted in 
preliminary definitions for the Minimally Clinically Important Improvement (MCII)(42), 
and the Patient Acceptable Symptom State (PASS) (43) in knee and hip OA. The 
definitions for physical function were entirely based on data captured by the WOMAC 
3.0 Index. The following definitions for MCI! absolute on 0-100 scales (and relative %) 
changes for knee and hip OA respectively, were suggested by the analyses: a) Pain -19.9 
mm (-40.8%) and -15.3 mm (-32.0%); b) patient global assessment-18.3 mm (-39.0%) 
and -15.2 mm (-32.6%); and c) WOMAC physical function -9.1 mm (-26.0%) and -7 .9  
mm (-21.1%) (42).
The Patient Acceptable Symptom State (PASS) is a novel concept, and is the 75^  ^
percentile of the symptom severity score of patients who consider their health state to be 
satisfactory. The following definitions for PASS (threshold values on 0-100 scales) for 
knee and hip OA, respectively, were suggested by the analyses: a) Pain 32.3 mm and 35.0 
mm; b) patient global assessment 32.0 mm and 34.6 mm; and c) WOMAC physical 
function 31.0mm and 34.4 mm (43). The development of state-attainment criteria, in OA, 
is very new, and the analyses provide preliminary information (43). It is acknowledged 
that the concept requires further investigation and the propositions requiring further 
validation (43). Nevertheless, patient involvement in estimating the clinical importance of
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improvement (42) and the acceptability o f different levels of symptom severity (43) is 
innovative, meets the obligations and requirements for consumer involvement in decision 
making and establishes preliminary consumer-based definitions for response and state 
attainment in knee and hip OA.
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Summary
Background: The domains of pain, function and patient’s global assessment are identified as core variables and frequently measured in 
clinical trials of patients with osteoarthritis (OA) of the hip and knee.
Objective: To develop response criteria for OAof hip and knee based on the domains of pain, function and patient’s global assessment.
Methods: A methodology was developed by an interaction of the Osteoarthritis Research Society International Standing Committee on 
Clinical Trials, biostatisticians, pharmaceutical company representatives and health agency representatives. Data from previously conducted 
placetjo-controlled clinical trials were normalized and cailated. Data were subset by location of OA (knee, hip), active agent used in the 
clinical trial (non-steroidal anti-inflammatory drug, other agent) and route of administration (oral, intra-articular). Statistical analysis identified 
response criteria which best discriminate active agent from placebo.
Results: Based on the analysis of data from 14 studies (totaling 1886 patients) and consensus opinion, the optimal responder criteria set 
differed for location of OA, active agent to be used, and route of administration. Because of nearly identical statistical results, two sets of 
responder criteria are proposed: (1) ’high’ pain response or, alternatively, a ’moderate' response for at least two of three domains: pain, 
function and patient's global assessment; (2) 'high’ response for either pain or function or, alternatively, a 'moderate' response for at least 
two of three domains; pain, function and patient's global assessment. The sensitivity (i.e., the percentage of responders in the active group) 
ranged from 52 to 96% and the specificity (i.e., the percentage of nonresponders in the control group) from 47 to 73%.
Conclusion: Based on data from clinical trials, two sets of responder criteria have been developed that can categorize an individual's 
responses to treatment in a clinical trial. These responder criteria require validation in additional datasets. ©  2000 OsteoArthritls Research 
Society International
Key words: Clinical Trials Response Criteria initiative.
Introduction
Presently available therapeutic modalities for osteoarthritis 
(OA) are directed at symptoms, with no device or drug consistently shown to modify structure (joint pathology). Definitions for the design and conduct of clinical trials have been developed by the Osteoarthritis Research Society international (OARSI)  ^ the World Health Organization
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Miami VAMC, 1201 NW 16th Street, Miami, FL 33125, U.S.A. 
Tel.: +1 305-243-5735; Fax: +1 305-243-5655; E-mail:
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(WHO), the international League of Association for Rheu­
matologists (ILAR),  ^ the experts involved in Outcome Measures in Arthritis Clinical Trials (OMERACT),^ and the 
European Group for the Respect of Ethics and Excellence 
in Sciences (GREES) through an Osteoarthritis Sub­committee.’* All recommend a clear separation of the evalu­
ation of the symptoms from the evaluation of the structure (disease) in OA.
In the evaluation of symptoms of OA, several domains can be considered. Examples include pain, function, 
inflammation, range of motion, quality of life, patient’s global opinion, physician’s global opinion, etc. However, discussion at OMERACT III focused on three domains, identified as core variables to be included In all clinical
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studies Involving OA, i.e. pain, function and patient's global 
assessment.Within each of these three domains, several instruments may be considered, such as a simple visual analog scale 
(VAS) or Likert scale. Measurement may also be by a more 
complex instrument, such as the Lequesne Functional 
Severity Index,® the Western Ontario McMasters Univer­sities Osteoarthritis (WOMAC) index,® the Health Assess­ment Questionnaire (HAQ) and the Arthritis impact Measurement Scales (AIMS).’’
While defining a core set of domains to be measured represents an advance in defining and standardizing the 
conduct of OA clinical trials, the analysis and reporting of results continues to be based on average improvement for 
the study population on each of the outcomes measured. Hence, the average improvement experienced by a group 
of treated patients is compared to the average improve­
ment of another group of treated patients (treatment of which may be placebo). In contrast, for rheumatoid arthritis there have been at least two sets of multi-variable response criteria proposed in order to present the results obtained in 
clinical trials for an individual.®'® There are presently no 
such criteria available for OA.Such response criteria in clinical trials offer the following 
advantages:
(1) They permit a single statistical analysis. This takes into account clinically important changes on multiple variables, without the need for correction for multiple 
comparisons, and provides an exact determination for each individual as to whether or not they have 
responded to the study treatment.(2) They facilitate the categorical analysis of groups of 
patients In clinical trials based on definitions of 
responders and non-responders.(3) They allow the comparison of data from different 
clinical trials in OA.
Response criteria may also have application in the cal­
culation of sample size for clinical trials,*® assist in phar- macoeconomic analysis and in data analysis of the Cochrane Collaborative Project,** and facilitate calculation 
in the number needed to treat approach of data analysis.*^ For these reasons, the OARSI Standing Committee on Clinical Trials elected to develop a set of responder criteria for the knee and hip. The committee felt that any such 
criteria should be research-based to the extent that is 
possible.
Methods
BASIC APPROACH
There are several potential approaches to the develop­ment of response criteria. One utilizes data from clinical trials with a statistical strategy that defines the criteria. This 
approach is limited by the quality of the data, but has the 
advantage of being evidence-based. Another approach relies solely on the judgement of experts. The Delphi methodology may help focus the process. This approach is limited because the developed criteria may be statistically unobtainable, but has the advantage that they probably represent clinically relevant goals of management. The 
OARSI Standing Committee on Clinical Trials elected to 
take a third approach, one that takes advantage of the strengths of both strategies, while minimizing the impact of 
their disadvantages.
The Standing Committee on Clinical Trials first set out to 
clearly define the process for the development of response 
criteria. Although the majority of the effort would be by the committee members, different steps of the project would be 
discussed among experts from several fields: rheumatolo­
gists, epidemiologists, biostatisticians, representatives of the pharmaceutical industry and representatives of health regulatory agencies [Food and Drug Administration (FDA) and European Agency for the Evaluation of Medicinal Products (EMEA)].
It was agreed that the data to be processed in the 
analysis would be provided by the pharmaceutical industry, and that these data would be from clinical trials performed under their direction by good clinical practice guidelines. The clinical trial data would be from placebo controlled clinical trials involving an active agent of a minimum 
6 week duration of study. The active agent would not be identified by name, but only by class of agent. In order to maintain the anonymity of the agents, the contributors to this trial are not identified in the text or the acknowledge­
ment. Although not specified in the data collection, all agents have been approved by either the European or US health regulatory agencies.
DATASET COLLECTION
Datasets and protocols from 37 clinical trials were pro­vided by the participating pharmaceutical and biotechnol­
ogy companies. To be eligible, the datasets were to include double-blind, parallel and placebo controlled trials con­
ducted on patients suffering from either hip or knee OA in which at least one of the following clinical variables was 
collected as a primary efficacy variable during the trial: pain 
or function (as an assessment of functional disability), or a global assessment by the patient. Minimal data had to 
include these variables at baseline and after treatment. Studies included In the analysis had to show a benefit 
(positive study) from the study medication/agent when compared to placebo for the primary efficacy variable 
(FfeO.05), The study did not include non-pharmacologic 
modalities.
DEFINITION OF THE OUTCOMES WITHIN EACH DOMAIN
Studies often applied different outcome assessment instruments in the measurement of each of the domains. 
For example, pain may have been measured by the 
five-question subscale of the WOMAC, as a part of the Lequesne Functional Severity Index, or by a single 
question. The following outcomes were chosen for subsequent analyses.
Pain
The pain measurement selected for analysis included 
the following in rank order: (1 ) global measure of pain; if not available, (2) WOMAC pain subscale; if not available, (3) average of the four questions of Lequesne Functional 
Severity Index that focused on pain (I.e. pain at night, pain in the standing position, pain during walking and pain while switching from a sitting to a standing position).
Function
The functional disability measurement selected for analysis included the following in rank order: (1) WOMAC
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functional subscale; if not available, (2) average of the four questions of Lequesne Functional Severity Index that 
focused on functional impairment (i.e. the last four ques­tions of either the hip or knee Lequesne Functional Severity 
Index).Some datasets contained only the total score of the 
Lequesne Functional Severity Index, while others con­tained both the total score and the response to each of the 11 questions. We examined the correlation of the infor­mation contained In the 11 questions of the Lequesne 
functional severity index, and the four specific questions on 
function. This analysis was conducted on available base­
line data from 1748 patients. The following equation was 
able to explain >63% of the variance:
Lequesne's function subscale =-0.22569+0.43204x(Lequesne total)-. 0.00691 X (Lequesne totai)^
This methodology was implemented in one study of 342 
patients.
Patient’s  global assessm ent
The patient’s global assessment measurement was selected for analysis. Because not all data sets contained 
this information, we attempted to explain the variable evaluating ‘patient’s global assessment' by the information contained in the variables evaluating the domains ‘pain’ and 'function'. Analysis of 892 patients' data, from five studies where all three domains were available, revealed 
that pain and function explained no more than 27% of the variance of the patient's global assessment. Hence, studies without a patient's global assessment could not be used In 
the development of the responder index.
2. The ‘tree’ type format.*'* In this format, patients are partitioned into mutually exclusive categories based on the 
outcome measures. The tree selects the most appropriate variable that can differentiate two populations. It does the 
selection in sequential steps, selecting the most appropri­
ate variable at each step. The final tree allows classification of all patients as responder or nonresponder.
3. The American College of Rheumatology rheumatoid arthritis, or ‘ACR-FtA-set’ format.® This technique counts the number of criteria present and if that number exceeds some pre-specified number the patient is classified as a 
responder. This format is easily understood by clinicians and easily applied in practice. This method does not consider the severity of disease activity at baseline. For example, a 50% improvement can be obtained in a patient 
with a pain VAS decreasing from 80 to 40, but also for a patient with a pain VAS decreasing from 6 to 3.It was elected to take advantage of the latter two formats 
with the addition of a minimum response. For example, an 
‘X'% improvement in pain, function or patient’s global assessment from baseline would have to be accompanied 
by a minimum Improvement of ‘Y’ NU (rescaled variable in normalized units, see above), intent-to-treat analysis (ITT) 
with last observation carried forward (LOCF) was used for all studies.
STUDIED POPULATIONS
Data were available to allow the separation of the following subsets: (1) patients with knee OA on an oral 
non-steroidal anti-inflammatory drug (NSAID); (2) patients with knee OAon a non-NSAID anti-OAoral drug; (3) hip OA 
on an oral NSAID; (4) knee OA receiving an intra-articular anti-OA specific non-steroidal agent. Insufficient data were 
available to examine hip OAon a non-NSAID antl-OA drug, intra-articular depocortlcosterolds and intra-articular agents for hip OA.
RESCALING OF THE OUTCOME MEASURES
Studies often utilized instruments with different scales. For example, some studies have used a 10 cm VAS or a 
Likert scale with a variable number of questions. Other 
examples include a 0-8 Interval for the pain questions from the Lequesne functional severity index and the 0-500 interval for the sum of the pain subscale of the WOMAC. When both were present In the same study, a 100 mm VAS 
was used in lieu of a Likert scale. All scales that used anything other than a 0-100 measurement were rescaled to a 0-100 Interval for the purposes of this study, 
henceforth referred to as normalized units or NU.
FORMAT OF THE SET OF CRITERIA
The following three formats were considered:1. The ‘Osteoarthritis Disease Activity Score'.*® This 
format involves a composite index using an equation obtained using multiple regression. The advantage of this 
method is that it develops a single number summarizing the 
clinical symptoms for each single patient at each visit. However, its use is usually based on a discriminate analy­sis comparing high and low disease activity. Such analysis requires an external judgement, which was not available in the different datasets. Therefore, this proposition was 
rejected,
PROPOSED SET OF CRITERIA
Eighteen scenarios defining responders were examined. To illustrate a very conservative scenario, a patient is 
considered as a responder if he/she fulfills the following: ‘an improvement in pain AND in function AND in global assess­ment'. For each proposed scenario, a statistical analysis based on the response criteria capacity to discriminate active and placebo groups was used to evaluate the 
performance of different cut-off points (in both the percent­age of change and the absolute change) for each single variable included in this scenario. However, before this 
analysis, the members of the Standing Committee on Clinical Trials proposed a range for each variable that 
should be explored together with a minimum interval between the different values that should be evaluated (i.e. a minimum interval of 5% or 5 NU). Different definitions of 
response criteria corresponding to different combinations of cut-offs were evaluated. The definition retained (with fixed cut-offs) was the one which maximizes the difference 
between the percentage of responders in the active group 
(‘sensitivity’) and the percentage of responders in the placebo group (‘1-specificity’).
Results
PATIENTS AND STUDY COURSE
The number of studies examined and the screening of 
those studies are illustrated In Fig. 1. The majority of the
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Fig. 1. Flow diagram for numbers of studies and patients.
receiving active drug. The trials examined were relatively recent as reflected by the common use of the WOMAC.
The baseline values In NU and the percent change during the study of the three selected domains are sum­
marized for each of the study subsets In Table II. These data confirm that most of the patients were quite sympto­matic at entry since the mean values of pain, functional 
impairment and patient's global assessment were all over 40 NU. Moreover, the values obtained In the variable 
‘patient's global assessment’ were over 60 NU, higher than the values for ‘pain’ and/or ‘function’. Consistent with the requirement that only positive studies be included, the 
changes from baseline in the ‘active’ group were of greater magnitude than the ‘placebo’ group for all domains. It was 
not possible to determine worsening in the studies of knee intra-articular specific anti-OA drug, as the the change in 
‘function’ and ‘patient's global assessment’ were collected at the end of the study by asking the patients about the level of his/her ‘improvement’.
excluded studies were because of absence of at least one 
of the domains to be examined, mostly the patient’s global assessment. Figure 1 also outlines the number of patients 
involved In the screening process and the numbers derived for each of the subsets to be examined. Although requested, there were no trials available to examine anal­
gesics (narcotic or non-narcotic) in OA. The screening reduced the number of trials from 37 to 14 and the number of patients in those trials from 5512 to 1886. The majority of information was on NSAIDs for knee and hip.The characteristics of the study populations are summa­
rized In Table I. The placebo and active drug groups were 
similar in age, sex and body mass index. The populations were relatively overweight as reflected by a high body mass 
index. In general there were more patients receiving active drug than placebo as several trials had more than one arm
DEVELOPMENT OF SETS OF CRITERIA
There were 18 different response criteria evaluated. 
Each was evaluated for NSAID hip, NSAID knee, anti-OA drug hip, anti-OA drug knee and knee intra-articular specific 
anti-OA drug. Numerous cut-offs on percent change and change in NU were reviewed on each of the 18 response 
criteria for each of the three domains. Each evaluation 
included sensitivity and specificity. Two sets of response criteria were statistically superior and felt to be clinically 
relevant (Figs 2 and 3).The first scenario (proposition A) (Fig. 2) emphasizes the 
domain ‘pain’. A'high' Improvement in pain was sufficient to define a responder. However, using this set of criteria, a patient can be also considered as a responder if an improvement of ‘moderate’ magnitude is observed in two of
Table ICharacteristics of the patients included for the development of the response criteria
Characteristics Selected population
Placebo Active drug
Age (years) (mean+s.o.) 63±10 63±10
Sex (% women) 72 72
Body mass index (kg/m^) (meants.o.) 31+ 7 30 ± 7
Localization
Hip (number) 197 480
Knee (number) 362 847
Route of administration
Oral (number) 460 1232
Intra-articular (number) 99 95
Class of the active drug
NSAIDs (number) 372 977
Specific anti-OA drug (number) 187 350
Domains and outcome assessment instrument 
Pain
Global VAS pain (number, 3 studies) 179 563
WOMAC pain subscale (number, 8 studies) 281 658
4 questions of the algo-functional index (number, 3 studies) 99 95
Function
WOMAC pain subscale: (number, 8 studies) 281 658
4 questions of the algo-functional index (number, 3 studies) 179 574
Patient’s global assessment
Global VAS (number) 228 707
Global Likert scale (number) 232 525
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T a b le  IIBaseline values and changes after therapy (percentage tstandard deviation: standardized units,.0-100 scale) in the three selected domains (pain, function, patient’s global assessment) with regard to osteoarthritis locaiization and category of the active drug
Domains Hip osteoarthritis Knee osteoarthritis Knee osteoarthritis
Knee osteoarthritis 
intra-articular
NSAID study therapy NSAID study therapy specific therapy specific therapy
Placebo
A/=197
Active drug N=480 PlaceboN=175 Active drug N=197 PlaceboN=88 Active drug N=255 PlaceboN=99 Active drug N=95
Pain
Baseline value 64±19 62+21 58 ±22 59 ±22 58±12 59±12 56+20 52±19
Changes during the study -1 4 ± 5 3 -3 4 ± 6 2 -4 + 7 3 -2 3 ± 9 0 -34+ 55 -4 6 ± 4 3 -2 4 ± 4 0 -6 1 ± 2 8Functional impairment
Baseline value 58±17 58±16 56 ±20 56±21 41± 7 4 1 + 8 NA NA
Changes during the study -2 ± 3 8 -2 1 +  4 -7 ± 6 4 -23 ± 5 4 -28+ 45 -34±41 -4 2 ± 1 6 -4 7 ± 1 0
Patient’s  global assessm ent
Baseline value 72±16 72+17 70±18 72+17 61 + 15 61 + 16 NA NA
Changes during the study -2 2 ± 5 9 -4 5 + 4 0 -1 9 ± 4 0 -41 ± 3 9 -3 0 ±  5 -4 1 ± 4 3 -3 9 ± 3 2 -7 9 ± 2 6
Yes .NoYes No
Responder
2 or 3. 2  or 30  or 1 0 or 1
ResponderResponder
Responder
Nonresponder Nonresponder
High improvement In pain High improvement in pain or function
Moderate improvement 
Pain
Function
Patient's global assessm ent
Moderate improvement 
•Pain 
•Function
•Patient's global assessm en t
Fig. 2. OARSI Responder Criteria— Proposition A. Decision tree is 
utilized for each patient. If there is a 'high’ improvement in pain, the 
person is considered a responder. If there is not a 'high' response 
to pain, they must have a ‘moderate’ response to two or three of 
the domains to be labeled a responder.
Fig. 3. OARSI Responder Criteria— Proposition B. Decision tree is 
utilized for each patient. If there is a ‘high’ improvement in pain or 
function, the person is considered a responder. If there is not a 
high’ response to pain, they must have a ’moderate’ response to 
two or three of the domains to be labeled a responder.
the three domains, i.e. pain, function and patient’s global 
assessment.The second scenario (proposition B) (Fig. 3) is similar to 
the first and with nearly identical statistical results. This 
scenario applies equal Importance to ‘pain’ and 'function', 
requiring a ‘high’ response of one OR the other. Alterna­tively, a ‘moderate’ magnitude of response could be 
present in two of the three domains.Optimal cut-offs for the different subgroups were pro­
posed based on statistical analysis (Tables III and IV). The 
proposed cut-offs are different for proposition A and propo­sition B and are different for each intervention and joint.Attempts to develop a single OA response criteria that would include the different subgroups led to important loss of separation of active and placebo groups; ttie loss was only 1-2% in sensitivity, but nearly 15% in specificity.
Considering the first step of the decision tree for both 
sets of response criteria, the different statistical analyses In the different subgroups concluded that an improvement of at least 40% was required (ranging from 40 to 60%) together with an absolute improvement of at least 20 NU 
ranging from 20 to 30. Considering the second step, an 
improvement of lower magnitude was required—a relative
improvement ranging from 15 to 35% and an absolute improvement ranging from 10 to 20 NU. The results con­cerning the performance of the sets of response criteria in 
terms of sensitivity (i.e. percentage of responders in the 
group of patients who received the active drug) and 
1-specificity (i.e. percentage of responders in the group of patients who received the placebo) are summarized in Tables V and Vi.Figure 4 exemplifies how the tables can be used and 
corresponds to the second row of Table III: responder 
criteria for knee OA using an oral NSAID. A major criterion would be a 45% reduction in pain with a minimum decrease 
of 20 NU (i.e. 20 mm on a 100 mm VAS), if that were not achieved, the minor criterion for a responder would be 
someone achieving a change in at least two of the following three domains: a reduction of pain of at least 15% (mini­
mum reduction of 10 NU); improvement in function of at 
least 30% (minimum improvement of 15 NU); and/or an improvement in patient’s global assessment of at least 35% 
(minimum improvement of at least 10 NU).In the NSAIDs trials (hip or knee), the percentage of 
responders is close to what might be expected from prior trials in rheumatic diseases (i.e. 50-60% in the active
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T a b le  IIIOptimal cut-offs to be applied for the OARSI-Responder Criteria—proposition A (see Fig. 2)
Subgroup High improvement 
in pain Pain
Moderate improvement in 
Function Global assessment
Relative
change*
Absolute
change**
Relative
change
Absolute
change
Relative
change
Absolute
change
Relative
change
Absolute
change
Hip NSAIDs 60 20 35 20 20 10 30 10
Knee oral NSAIDs 45 20 15 10 30 15 35 10
Knee oral specific drug 55 30 35 10 15 20 15 15
The three above groups together 55 30 35 15 15 20 15 15
Knee intra-articular specific drug 40 30 35 15 35 10 30 10
"Relative change: percentage of change during the study (final minus baseline over baseline x 100). 
"‘Absolute change: absolute change during the study (final minus baseline on a 0-100 interval scale).
Table IVOptimal cut-offs to be applied for the OARSI-Responder Criteria—proposition B (see Fig. 3)
Subgroup High improvement in 
Pain Function Pain
Moderate improvement
Function Global assessment
Relative
change*
Absolute
change**
Relative
change
Absolute
change
Relative
change
Absolute
change
Relative
change
Absolute
change
Relative
change
Absolute
change
Hip NSAIDs 50 30 50 20 25 15 20 10 20 10
Knee oral NSAIDs 50 20 60 20 30 15 20 20 25 10
Knee oral specific drug 55 30 50 20 30 20 20 20 20 15
The three above groups together 55 30 50 20 30 15 20 20 20 15
Knee Intra-articular specific drug 50 30 60 20 20 20 30 10 30 10
"Relative change: percentage of change during the study (final minus baseline over baseline x 100). 
"‘Absolute change: absolute change during the study (final minus baseline on a 0-100 interval scale).
Table VPercent of study patients meeting OARSI responder criteria—proposition A
Subgroup
High improvement 
in pain
Moderate improvement 
in 2 of the 3: 
pain, function, 
global assessment Total
Percentage responders Percentage responders Percentage responders
Active* Placebo** Active Placebo Active Placebo
Hip NSAIDs 35% 18% 27% 14% 62% 33%
Knee oral NSAIDs 39% 19% 13% 8% 52% 27%
Knee oral specific drug 49% 39% 13% 12% 62% 51%
Knee intra-articular specific drug 44% 18% 48% 29% 92% 47%
‘Active: sensitivity=% responders on active drug. 
“ Placebo; 1—specificity=% responders on placebo.
groups vs 20-30% in the placebo group). These figures are different in both the 'knee systemic specific drug' and the 
‘knee intra-articular specific drug’ in which the percentage of placebo responders was higher (respectively, 51 and 47% in proposition A and 50 and 47% in proposition B).
Discussion
This study combined the efforts of academic researchers, 
biostatisticians, representatives of the pharmaceutical industry and representatives of health agencies to develop 
responder criteria for clinical trials of OA of hip and knee.
The data led the Standing Committee on Clinical Trials to propose two sets of responder criteria, with variation in the 
specific recommendations for hip and knee and for different therapeutic approaches.
The authors are unaware of any previously proposed responder criteria for OA. The proposed responder criteria Include the core set of outcome measures for OA clinical 
trials developed at OMERACT ill; pain, function and patient's global assessment. These outcome measures 
have also been recommended by the OARSI and various health regulatory agencies.There are limitations to this study. Because of variations 
in study design a majority of the screened studies, and
Osteoarthritis and Cartilage Vol. 8 No. 6 401
Table VIPercent of study patients meeting OARSI responder criteria—proposition B
Subgroup
High improvement 
in pain
Moderate improvement 
in 2 of the 3: 
pain, function, 
global assessment Total
Percentage responders Percentage responders Percentage responders
Active* Placebo** Active Placebo Active Placebo
Hip NSAIDs 39% 27% 24% 12% 69% 39%
Knee oral NSAIDs 39% 19% 12% 7% 51% 26%
Knee oral specific drug 52% 40% 9% 10% 61% 50%
Knee intra-articular specific drug 51% 29% 39% 18% 91% 47%
‘Active: sensitivity=% responders on active drug. 
“ Placebo: 1—specificity=% responders on placebo.
Yes No
Sensitivity 52%  
Specificity 73% 2 or 3. 0 or 1
Responder
Active 13% 
Placebo 8%
Responder 
Active 39% 
Placebo 19%
Nonresponder
Active 46% 
Placebo 73%
Pain Reduction 45% ; 20  NU
Improvement 
•Pain 15%; 10 NU 
•Function 30% ; 15 NU 
•Patient's global 35%; 10 NU
Fig, 4. OARSI Responder Criteria— example of proposition A for 
knee oral NSAID subgroup. This decision tree exemplifies the use 
of the algorithm for a patient in a clinical trial that is testing an 
non-steroidal anti-inflammatory drug for osteoarthritis of the knee. 
In this instance a ‘high’ improvement in pain equates to a 45% 
reduction in pain that is also a minimal change of 20 NU or 
normalized units. Twenty normalized units equates to a minimal 
change of 20 mm on a 100 mm scale. If the patient achieves this 
reduction in pain, they are considered a responder. If they do not, 
to be considered a responder the patient must achieve a positive 
result in at least two of the three domains: i.e. pain would need a 
reduction of 15% with a minimal change of 10 mm on a 100 mm 
scale, function would require a 30% improvement for a minimal 
15 mm on a 100 mm scale and the patient's global assessment 
would need a 35% improvement with a minimal 10 mm change on 
a 100 mm scale. This algorithm labeled 52% of the 197 patients on 
an NSAID as responders and 73% of the 175 patients on placebo 
as non-responders.
hence a majority of the patients, had to be excluded from the analysis. Even in studies included In the analysis 
scores had to be generated from existing data that had been collected in different formats. The above studies were of variable duration; the Influence of time of study on the 
response criteria was not addressed.Different information gathering Instruments were used. 
The outcomes from these different instruments may be 
similar but their responsiveness to change may be different. 
There is a question as to whether subscales can be extracted from instruments that were not developed around a subscale structure. There are also limitations imposed by
modeling in order to Input values of real data. Few, if any of 
the studies asked for the patient's global assessment In the 
same way.
The different instruments and even some of the same 
Instruments used different scales, requiring a rescaling to a 
common 0-100 scale in order to normalize values. It is recommended that future studies use a 0-100 Interval. This 
would facilitate analysis and provide uniform and under­standable communication. The 0-100 interval would allow 
the use of the proposed responder criteria, emphasizing minimum change In NU.
The proposed responder criteria utilize a format that requires an absolute change. The technique also Includes a second layer In a simple 'tree' format giving helrarchai 
application of criteria. In order to address severity of disease at baseline, a minimum level of improvement was also required. Whatever the rating scale used, the appli­cation of the proposed set of response criteria Is feasible (for example, a required absolute Improvement of 10% in the variable means an Improvement of at least one grade for a 0-4 Likert scale, 2.4 points for a 0-24 scale, etc.).
It should be pointed out that the use of these responder 
criteria will require a protocol to set minimum entry criteria, since attainment of response by these criteria must remain an achievable target for all participants. Individuals with 
baseline values less than the minimum required absolute 
change can never be designated as responders, even If they are rendered symptom free. Hence, trials using these 
responder criteria should not be used In trials examining milder symptomatic patients. Moreover, since It Is not anticipated that many patients would become symptom 
free, the entry criteria need to be set somewhere above the minimum required to fulfill these responder criteria.
The choice of the different cut-offs was based on statisti­cal analysis for optimization of the discriminant capacity. The results obtained are close to those expected In the field of OA, I.e. a 20-30% placebo response and a 20-30% 
treatment e f f e c t . I t  Is of note that the placebo response 
in intra-articular studies may be as high as 50%.The placebo response for hip and knee with an NSAID varied from those obtained In two other subgroups, In the subgroup 'knee-oral specific OA drug', the placebo effect 
was greater than in the other subgroups. This difference In 
the placebo effect might be explained by the concomitant 
therapy. In NSAIDs trials, acetaminophen was the most commonly permitted rescue medication. In the ‘specific osteoarthrltlc drug’ trials, both acetaminophen and NSAIDs intake was commonly permitted. Considering the subgroup
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‘knee-intra-articular specific OA drug’, both the placebo and the treatment effect were of greater magnitude than in the other subgroups. The higher placebo effect may be explain­
able by knee aspiration at the time of the procedure and 
by a higher placebo effect associated with the route of 
administration.The higher treatment effect for intra-articular therapy Is 
more difficult to Interpret. It Is possible that treatment with an Intra-articular specific OA drug is of greater magnitude 
than any drug given orally. However, in the trials reviewed In this effort, the questions concerning the level of pain, 
functional disability and global assessment were not 
related to the absolute condition of the patient at the end of the study, but to the relative improvement of the patient; 
hence, it was not possible to detect worsening during these trials. The authors feel that the sensitivity and specificity 
obtained in this subgroup should be Interpreted with 
caution.Specific cut-offs are proposed for the responder criteria. 
Additional cut-offs were examined, such as a uniform cut-off for ail subsets. Unfortunately, these alternative cut­
offs showed an Important loss of sensitivity and sensitivityBecause of the lack of available databases, some OA 
conditions were not evaluated, such as hip oral-specific OA 
drugs, analgesics, and hand OA.Two sets of responder criteria were developed In this initiative. The performances of the two sets of criteria in the different evaluated subgroups are similar. One could con­sider that proposition A Is more simple and therefore should be retained. However, the members of the committee, 
together with other participants In this Initiative consider that In some studies changes In functional disability are at 
least as Important as the changes in pain. Hence, proposi­tion B is also included. Finally, these sets of responder 
criteria should be considered as preliminary. Further 
studies are needed in order to validate these proposals in 
other sets of patients and with different drugs.
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Minimal Perceptible Clinical Improvement with the 
Western Ontario and McMaster Universities 
Osteoarthritis Index Questionnaire and Global 
Assessments in Patients with Osteoarthritis
PLLIOTW. EHRICH, GLEUN M. DAVTES, DOUGLAS J. WATSON, JAMES A. BOLOGNESE,
BETH C. SEIDENBERG, and NICHOLAS BELLAMY
ABSTRACT. Objective. To determine the minimal perceptible clinical improvement (MPCI) in patients with 
osteoarthritis (OA) witli the Western Ontario and McMaster Universities Osteoartliritis Index 
(WOMAC) questionnaire, and patient and investigator global assessment of disease status in random­
ized clinical trials for treatment o f OA.
M ethods. Subjects witli OA of the knee or hip were randomized to receive either rofecoxib 12.5 or 25 
mg once daily, ibuprofen 800 mg 3 times daily, or placebo for 6 weeks. The WOMAC and global assess­
ments were completed at baseline and Weeks 2, 4, and 6. A patient global assessment o f response to 
therapy (0 to 4 scale) was used to “anchor” the WOMAC scores. MPCI was defined as tlie difference 
in mean change from baseline in WOMAC (100 mm normalized visual analog scale, VAS) between 
patients with 0 = “None” global response to therapy and patients witli 1 = “Poor” global response to 
therapy.
Results. MPCI was determined to be 9.7, 9.3, and 10.0 ram for tlie WOMAC pain, physical function 
and stiffness subscales, respectively, and «11.1 mm for WOMAC question 1: Pain walking on a flat sur­
face. Tlie MPCI for the investigator was 0.4 with investigator assessment of disease status reported on 
a 0 to 4 Likert scale. Of note, tlie estimated MPCI for the WOMAC and investigator globals were sim­
ilar irrespective of treatment, sex, age, or geographic region.
Conclusion. In tliis analysis, mean changes o f  roughly 9 to 12 mm (100 mm normalized VAS) on 
WOMAC scales were perceptible changes to patients witli hip and knee OA. A mean decrease o f 0.4 in 
global disease status (0 to 4 Likert scale) as assessed by the investigator corresponded to tlie patients’
MPCI. Understanding the minimal perceptible differences may permit a better assessment o f the clini­
cal relevance o f therapeutic interventions in OA. (J Rheumatol 2000;27:2635-41)
Key Indexing Terms: 
OSTEOARTHRITIS 
WOMAC
ROFECOXIB CYCLOOXYGENASE INHIBITORS 
TREATMENT EFFICACY
Therapeutic drug trials for osteoarthritis (OA) often involve a 
number of efficacy measures including both patient and inves­
tigator global assessments of disease status or activity, and 
espouse to therapy. Typically, patient self-assessments will 
include measures of pain and stiffness in affected joint(s), and 
physical function or disability^ These measures must be valid, 
reliable, and responsive to clinically meaningful change in 
order to differentiate between treatments L A commonly used 
OA-specific health status measure is the Western Ontario and
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McMaster Universities Osteoarthritis Index (WOMAC)^; 
results from this questionnaire were studied in tlie context of 
determining minimal perceptible clinical improvement 
(MPCI) in patients witli OA.
Two important concepts when using health status measures 
are the minimal clinically important change (or difference), 
and the minimal perceptible improvement (or difference) to 
tlie patient. The former has received some attention in the lit­
erature '^®. It is important for sample size calculations when 
planning clinical trials, and also provides the clinician witli a 
basis for reference when considering tlie effects of treatment 
in an individual patient. The minimal perceptible difference or 
change is also important; it represents the difference or 
change on the measurement scale associated witli the smallest 
change in health status detectable by tlie patient. It may be less 
than, the same as, or possibly even greater tlian tlie clinically 
meaningful difference or change. To fully understand differ­
ences or changes in health status measures, it is advantageous
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to know both the minima] clinically important difference and 
the minimal perceptible difference.
The minimal clinically important and the minimal 
detectable difference or change on a health status scale can be 
evaluated by several methods. Tliese involve tlie use of distri­
bution based statistical measures (e.g., the standardized effect 
size), or the use of external “benchmarks” or “anchors” as a 
frame of reference (e.g., normative data, disease classes, or 
response on an alternative measure)^ '®-"^ -®. The latter “anchor­
ing” approach is useful to value differences or changes rela­
tive to a metric that can be easily understood by clinicians and 
care givers, and was utilized for this analysis.
This analysis was designed to determine the minimal per­
ceptible difference or change on tlie WOMAC VA 3.1' and on 
an investigator global assessment of disease status measure in 
a population of patients from OA clinical trials, using the 
anchoring method. Since the interventions employed in tlie 
trials were administered following withdrawal of usual thera­
py and a period of disease flare, or worsening, virtually all 
patients stayed the same or improved on both measures with 
treatment. Therefore, we assessed tlie minimal perceptible 
clinical improvement.
MATERIALS AND METHODS
Study population. Data from 2 identical 6 week double blind multiccntcr ran­
domized, placebo controlled, parallel group clinical trials’ comparing tlie 
COX-2 inliibitor rofecoxib (VIOXX®, MK-0966) to ibuprofen in the treat­
ment o f  OA o f  the knee or hip were used in the analysis. One trial was con­
ducted in the United States’  whereas the otlier trial was performed in 26 coun­
tries (Argentina, Brazil, Chile, Costa Rica. Guatemala, Mexico, Peru, 
Venezuela, Canada, New Zealand, Australia, Austria, Belgium, Czech 
Republic, Denmark, France, Germany, Holland, Israel, Italy, Norway. 
Portugal, Spain, Switzerland, Sweden, United Kingdom)'®. Results from the 
2 trials were consistent and data were combined for tlie analysis o f MPCI to 
maximize statistical precision.
Tlie trials employed a prcrandomization washout period during wliich 
current tlierapy for OA was discontinued; during the washout patients had to 
experience worsening o f  disease before being eligible for randomization. 
Patients who were using nonsteroidal antiinflammatory agents (NSAID) to 
treat their OA prior to tlie study were required to have (1) a score < 80 mm at 
tlie prestudy washout visit on the first item o f the WOMAC pain scale (Pain 
walking on a flat surface), (2) at least a 15 mm increase in the pain walking 
score after the washout, and (3) a washout score >  40 mm. In addition each 
patient also had to have an increase o f  I unit in tlie investigator global assess­
ment o f disease status after washout Prior users o f  acetaminophen had to 
have at both the prestudy visit and the visit following washout (1) a score o f  
> 40 mm for pain walking on a flat surface, (2) investigator global assessment 
o f disease status as “fair,” “poor,” or “very poor", and (3) a score >  40 mm on 
the Patient global assessment o f  disease status. Patients who met all entry cri­
teria were randomized to receive, with placebo, rofecoxib 12.5 mg once daily, 
rofecoxib 25 rag once daily, or ibuprofen 800 nig three limes a day. 
Measurements. Patient and investigator assessments o f response to tlierapy 
were made at baseline and at 2, 4, and 6 weeks. Patients completed tlie fol­
lowing; (1) W OM AC VA 3.1 pain (5 items), stiffness (2 items), and physical 
function (17 items) scales (0 -1 0 0  mm VAS for all items; higher scores indi­
cate worse disease status). (2) Patient global assessment o f disease status 
("Considering all tlic ways your arthritis affects you, mark an “x” tlirough tlie 
line for how w ell you are doing”; 0 -1 0 0  mm VAS; higher scores indicate 
worse status. (3) Patient response to therapy (“How would you rate your 
response to (lie study medication you received for arthritis?"; None: no good
at all, ineffective drug; poor: some effect, but unsatisfactory; fair: reasonable 
effect, but could be better; good: satisfactory effect with occasional episodes 
of pain or stiffness; excellent: ideal response, virtually pain free).
Investigators completed tlie following: (I) investigator global assessment 
o f disease status scale ("Make a global assessment o f the patient's disease sta­
tus by marking an "x" in one box below”; 0 = very well, I = well, 2 =  fair 3 
= poor, 4 = very poor). (2) Investigator assessment o f patient response to ther­
apy (“Please rate the therapeutic effect o f the study medication using the fol­
lowing scale”: None: no response, absence o f drug effect; poor: minimal 
response, unacceptable; fair: definite response, but could be better; good: 
good response, but less tlian the best possible anticipated response; excellent: 
the best possible anticipated response, considering the severity and stage ,f 
disease).
Note tliat the response to therapy globals were not measured at baseline 
since these questions refer to study therapy.
Analytic methods. Change scores were calculated by subtracting tlie baseline 
value (al randomization, post washout) for a given metric from tlie value at 
Week 6. Tlie patient and investigator response to tlierapy measures were not 
performed at baseline; tliercforc no change scores were calculated for tfiese 
variables. Missing observations at Week 6 were imputed using tlie last 
observed value prior to Week 6 excluding tlic baseline value.
An “anchoring” metliod was used to assess the clinical interpretation of 
the change from baseline for tlic W OM AC subscale scores, tlie pain walking 
on a flat surface item from the WOMAC, investigator global assessment c i 
disease status, and patient global assessment o f disease status based upon 
responses to the patient response to tlierapy and the investigator assessment 
o f patient response to tlierapy. Mean W OMAC subscale change scores, and 
mean change scores on tlie investigator global assessment o f  disease status 
and tlic patient global assessment o f  disease status were calculated for each 
level o f  the patient global response to therapy. Cumulative distribution func­
tions for the various measures, except for tlic categorical investigator global 
assessment o f disease status, were generated for each patient and investigator 
global response category at the 6 w eek time point.
MPCI, from tlie perspective o f  the patient, was defined as the difference 
in mean change from baseline in W OM AC and global assessment o f disease 
status scores between patients with no response to tlierapy (response score o- 
0: “None, no good at all, ineffective drug") and patients with next liighcr level 
o f response (score 1: “Poor, some effect, but unsatisfactory"). A  one unit dif­
ference at tlie lowest end of the global assessment o f response scale was used 
to define MPCI as it reflects minimum (one unit) and lowest degree of 
improvement tliat could be detected. MPCI, from the perspective o f  the inves­
tigator, was defined in an analogous fashion using the corresponding investi­
gator global assessment o f response to tlierapy scale.
Analysis o f variance (ANOVA) m odels were evaluated to assess tlie rela­
tionship between change scores on tlic WOMAC, tlie investigator global 
assessment of disease status, and tlie patient global assessment o f  disease sta­
tus witli botli tlie patient and investigator global response to therapy mea­
sures. Cliangc scores from the W OM AC scales, the investigator global 
assessment o f disease status, and tlie patient global assessment o f  disease sta­
tus at Week 6 were modeled as a function o f  citlier patient response to tliera- 
py or investigator assessment o f  response to tlierapy, treatment, clinical trial, 
baseline score, age >  65 years, and sex. Pair-wise interactions o f the global 
response to tlierapy witli geograpliic region [Canada/USA, Latin America, 
Europe, and Other (South Africa, Israel, New Zealand, Australia)], treatment 
(placebo, rofecoxib 12.5 mg, rofecoxib 25 mg, ibuprofen), baseline score 
(categorized into tertiles), age > 65, and sex were also included in tlic models 
and assessed at the a =  0.05 level. If interactions were not significant for tlie 
majority o f tlie outcomes, tliey were eliminated from the models. All main 
effects were retained in tlie final models regardless of statistical significance. 
Lcast-square means and differences in least-squarc means were generated 
from the final models for each global response to therapy category.
RESULTS
A total of 1545 patients were enrolled in tlie 2 trials. Data
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from 1501 (97%) to 1531 (99%) patients were used in the 
analyses depending on the particular measure being evaluat­
ed; patients were excluded from analyses for missing data. 
Baseline characteristics of tlie patients (all treatment groups 
combined) are shown in Table 1. Tlie mean age was 62 years. 
The study population was 77% female and 79% white. The 
mean duration of OA was 9.3 years, with a range of < 6  
montlis to 57 years. Tliirteen, 60, and 26% of patients were of 
\merican Rheumatism Association Functional Class I, H, and 
HI, respectively. Twenty-three percent of patients had OA of 
(lie hip, and 77% of the knee. Prior to the sUidy, 90% of 
patients used NSAID for their OA, while 10% used aceta­
minophen. Baseline values for the various assessment mea­
sures (all treatment groups combined) are shown in Table 2. 
Mean baseline scores on tlie WOMAC (0-100 VAS) were 74, 
65, 66, and 64 for pain walking on a flat surface, and the pain, 
stiffness, and physical function scales, respectively. Mean 
baseline score for investigator global assessment of disease 
status (0-4 Likert scale) was 2.9.
The ÀNOVA models suggested that only interactions 
between baseline score (based on tertile categories) and MFCI 
were consistently significant across the various models. As 
such, the interaction term for baseline score was included in 
the model. The interaction was primarily due to differences in 
global response between patients having very severe 
WOMAC or disease status scores at baseline and those hav­
ing less severe scores. The MPCI was consistently associated 
with a greater change from baseline in patients with the worst 
(highest) scores at baseline. On the otlier hand, MPCI for 
patients with the least severe scores at baseline was generally 
smaller in magnitude.
Tabic 1. Baseline characteristics o f  patients. A ll protocols and treatment 
groups combined.
Tabke 2. Baseline values (after washout) o f  efficacy endpoints*, all treatment 
groups combined.
Age, yrs
Mean (SD) 62.4 (9.6)
Range 32-91
Sex (%)
Male 350 (22.7)
Female 1195 (77.3)
Race (%)
White 1217(78.8)
Black 66 (4.3)
Otlicr 262 (17.0)
Duration o f  OA, yrs
Mean (SD) 9.3 (8.0)
Range 0-5 7
ARA Functional Class (%)
I 206(13 .3 )
II 933 (60.4)
HI 406 (26.3)
Study joint (%) '
Hip 355 (23.0)
Knee 1190(77.0)
Prior OA Medication {%)
NSAID 1392 (90.1)
Acetaminophen 153 (9.9)
Pain walking on a flat surface score, 100 mm YAS
Mean (SD) 73 .6 (15 .0 )
Median 75.0
Range 23 -100
WOMAC pain scale score, 100 mm VAS
Mean (SD) 6 5 .0 (17 .3 )
Median 65.4
Range 16-100
WOMAC stiffness scale score, 100 mm VAS
Mean (SD) 65.9 (20.9)
Median 68,5
Range 0 -1 0 0
WOMAC physical function scale score, 100 mm VAS
Mean (SD) 63.9 (18.6)
Median 66.2
Range 7 .2 -99 .9
Patient global assessment o f  disease status, 100 mm VAS
Mean (SD) 69 .6 (1 8 .4 )
Median 71.0
Range 5 -1 0 0
Investigator global assessment o f disease status, 0 -4  Likert
Mean (SD) 2.9 (0.6)
Median 3
Range 1 -4
*Patient and investigator global response to tiierapy not assessed at baseline.
None of the other interaction terms or pairwise compar­
isons including geographic region, age, sex, or treatment 
showed evidence of a consistently significant interaction at 
the 0.05 level across endpoints. In sporadic instances single 
comparisons between subgroup levels were significant, which 
was not unexpected given the large number of comparisons 
performed. Tlie additional interaction terms were therefore 
dropped from the models.
Table 3 shows tlie mean change scores on the efficacy mea­
sures by the patient global response to tiierapy measure at 6 
weeks, adjusted for treatment protocol, age, sex, and tertile of 
baseline score. More negative scores indicate greater 
improvement for all measures. Patients witli global responses 
to therapy of none, poor, fair, good, and excellent had mean 
investigator global disease status change scores of 0.13, 
-0.30, -0.96, -1.61, and -2.10, respectively. WOMAC pain 
walking on a flat surface change scores for patients with none, 
poor, fair, good, and excellent global responses to therapy 
were -3.6, -14.6, -27.8, -46.6, and -59.8, respectively. 
Similar results were seen with the WOMAC pain scale scores, 
and with tlie other measures, although the changes were of 
lesser magnitude compared to the single item of pain walking 
on a flat surface. The minimal perceptible clinical improve­
ment (defined as the difference in mean change scores 
between patients with a “none” response and tliose with a 
“poor” response on the global responses to therapy) was 0.43 
(on a 0-4 Likert scale) for the investigator global disease sta­
tus measure, and 11.1 (on a 100 mm VAS) for the WOMAC
Eliriclt, e t a l:  M A C T A R fo r  OA 2 6 3 7
Table 3. Mean (SE) diange score by patient globaJ response to tJierapy measure, and difference in cliange score means between categories of patient global rcspon- e
to therapy at 6 weeks*. Note MCPl.
Patient Response to Tiierapy at 6 Weeks, 
mean change from baseline
MCPI
Difference Between Categories o f  
Patient Response to Therapy
Measure None to Poor to Fair to Good to
None Poor Fair Good Excellent Poor Fair Good Excellent
Investigator global
disease status 0.13 (0.06) -0 .3 0  (0.06) -0 .9 5  (0.04) -1 .61  (0 .0 4 )-2 .1 0  (0.07) 0.43 (0.08) 0.67 (0.06) 0.65 (0.05) 0.49 (0.07)
Patient global
disease status 5 .0 (1.5) -6 .6  (1.4) -2 1 .0 (1 .0 ) -4 1 .4 (0 .9 )  -5 5 .9 (1 .7 ) 11.7 (2.0) 14.3 (1.7) 20 .5 (1 .2 ) 14.4 (1.8)
W OMAC pain walking
on flat surface -3 .6  (1.6) -1 4 .6  (1.0) -27.8 ( l .I ) -4 6 .6 (1 .0 )  -5 9 .8 (1 .9 ) 11.1 (2.1) 13.1 (1.8) 18.8(1.4) 13.2 (2.0)
WOMAC pain 2.1 (1.4) -7 .5  (1.3) -2 0 .3  (1.0) -3 7 .9 (0 .9 )  -5 2 .0 (1 .6 ) 9.7 (1.9) 12.8 (1.6) 17.6(1 .2) 14.1 (1.7)
W OMAC physical .
functioning 3.7 (1.3) -5 .7  (1.3) -1 5 .0 (1 .0 ) -3 3 .3 (0 .8 )  -4 7 .7  (1.6) 9.3 (1.8) 9.3 (1.5) 18.3(1.1) 14.4 (1.6)
WOMAC stiffness 4 .2 (1.6) -5 .8  (1.5) -1 5 .4 (1 .1 ) -3 4 .8 (1 .0 )  -5 1 .3 (1 .8 ) 10.0 (2.1) 9 .6 (1.7) 19.3(1 .3) 16.5 (1.9)
*Data are adjusted for treatment, protocol age, sex, and tertile o f  baseline score. More negative values reflect greater improvcmenL SE: standard error.
pain walking on a flat surface item. Tlie MPCI was of a simi­
lar magnitude (9-12 mm) on the other 100 mm VAS scales.
The results of the analyses of the WOMAC pain walking on 
a flat surface, by patient global response to therapy, are illus­
trated in Figure 1. Shown are the cumulative distribution func­
tions of change scores at 6 weeks for the patient global assess­
ment of disease status and the various WOMAC subscale 
responses, according to categories of patient global response to 
therapy. Tlie MPCI of roughly 10 mm is seen as tlie difference 
between the median change scores for die “none” and the 
“poor” groups. Tire difference in change scores between other 
adjacent levels of patient global response (e.g., “poor” to 
“fair”) is generally similar, except between “fair” and “good,” 
where tlie difference is sUghtly higher.
Table 4 shows the mean change scores on tlie efficacy mea­
sures by tlie investigator global response to therapy measure 
at 6 weeks, adjusted for heatment protocol, age, sex, and ter­
tile of baseline score. More negative scores indicate greater 
improvement for all measures. Patients rated by the investiga­
tor as having global responses to therapy ratings of none, 
poor, fair, good, and excellent had mean investigator global 
disease status scores of 0.51, 0.02, -0.66, -1.51, and -2.23, 
respectively. WOMAC pain walking scores for patients witli 
none, poor, fair, good, and excellent investigator global 
response to therapy ratings were -1.1, -13.3, -26.2, -42.6, 
and -54,0, respectively. Similar results were seen with the 
WOMAC pain scale scores, and with the other measures, 
altliough tliey were of lesser magnitude compared to tlie sin-
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Figure 1. Change scores for WOMAC pain walking on a flat surface, by patient global response to tiierapy at Week 6.
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Tabic 4. Mean (SE) change score by investigator global response to therapy measure, and difference between change score means between categories of patient
global response to therapy at 6 weeks*. Note MCPL
Patient Response to Tiierapy at 6 Weeks, 
mean change from baseline
Difference Between Categories of 
Patient Response to Therapy
MCPI
Measure
None Poor Fair Good Excellent
None to 
Poor
Poor to 
Fair
Fair to 
Good
Good to 
Excellent
Investigator global disease 0.51 (0.07) 0.02 (0.07) -0 .6 6  (0.07) -1 .5 0  (0.07) -2 .23  (0.07) 0.49 (0.05) 0.68 (0.04) 0.84 (0.03) 0.73 (0.04)
status
Patient global disease status 6.5 (1.8) -4 .6  (1.4) -1 9 .0 (1 .1 ) -3 7 .6 (1 .0 ) ^ 9 .0  (1.3) I l . l  (2.2) 14.4(1.8) 18.6(1.4) 11.4(1 .5)
WOMAC pain walking 
on flat surface -1.1 (1.9) -13 .3  (1.5) -2 6 .2 (1 .2 ) ^ 2 .6  (I.O) -5 4 .0 (1 .4 ) 12.2 (2.4) 12.9(1 .9) 16.4 (1.5) 11.3(1 .6)
WOMAC pain 4.2 (1.6) -6 .6  (1.3) -1 8 .6  (1.1) -3 4 .3  (0.9) -45 .5  (1.3) 10.8 (2.1) 12.0(1 .6) 15.7(1.3) 11.3(1.4)
WOMAC physical 
functioning 4.5 (1.6) -3 .2  (1.3) -14 .5  (1.0) -2 8 .7  (0.9) -4 2 .3 (1 .2 ) 7.6 (2.0) 11.4(1.6) 14.2(1.2) 13.6(1 .4)
WOMAC stiffness 6.3 (1.9) -4 .1  (1.5) -1 5 .6 (1 .2 ) -2 9 .9 (1 .0 ) -43 .2 (1 .4 ) 10.4 (2.3) 11.5 (1.9) 14.3(1.4) 13.3 (1.6)
♦Data are adjusted for treatment, protocol age, sex, and tertile o f baseline score. More negative values reflect greater improvement. SE: standard error.
gle item of pain waiking on a fiat surface. In this analysis, the 
MPCI was 0.49 (on a 0-4 Likert scale) for the investigator 
global disease status measure. Tlie MPCI on the WOMAC 
pain walking on a flat surface item was 12.2 (on a 100 mm 
VAS). The MPCI was of a similar magnitude (7.5-12 mm) on 
the otlier 100 mm VAS scales. Tlie results of the analyses of 
the WOMAC pain walking on a flat surface, by investigator 
global response to therapy, are shown in Figure 2. The cumu­
lative distribution data show a similar pattern to that seen in 
Figure 1.
Results of analyses to explore tlie relationship between 
outcomes at treatment weeks 2 or 4 versus 6 suggested the
MPCI for the WOMAC pain walking on a flat surface item 
and the investigator global assessment of disease status 
remained relatively stable across time.
DISCUSSION
Our results suggest tliat improvements in the range of 8-12 
mm on the WOMAC 100 mm normalized VAS and 0.40-0,50 
units on the investigator global disease status assessment are 
considered minimally perceptible to tlie patient as well as the 
investigator. To our knowledge, tliese are the only published 
data on the MPCI on the WOMAC.
Knowledge of tlie MPCI on these measures, along with
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Figure 2. Change scores for WOMAC pain walking on a flat surface, by investigator global response to tiierapy at 
Week 6.
Ehrich, at a l: M AC TA R  f o r  OA 2 6 3 9
knowledge of the minimal clinically important difference 
(MCID), enables researchers and clinicians to plan and inter­
pret the results of clinical trials that use these assessments. 
Knowledge of the MCID is necessary for sample size calcula­
tions of trials designed to show improved efficacy, and it is 
also useful to clinicians in interpreting the effect of treatment 
in an individual patient.
As would be expected, the mean change from baseline 
observed in the trials used for this analysis exceeded the esti­
mates of MPCI. For example, the mean change from baseline 
for WOMAC pain walking on a flat surface ranged between 
31 and 35 mm for (he active treatment groups^-’® compared 
with tlie MPCI estimate of 11 mm. The mean change from 
baseline witli placebo (19 mm), although significantly small­
er than that observed with active tiierapy (p < 0.001), also 
exceeded MPCI. This result suggests the mean placebo 
response was still perceptible.
Our estimates of minimal perceptible improvement are 
smaller in magnitude than estimates of minimal clinically 
important difference derived from a consensus development 
exercise'*. The consensus exercise found differences of 20 
mm, 15 mm, and 0.8 to represent clinically important differ­
ences in patient global assessment of disease activity (100 mm. 
VAS), global assessment of pain (100 ram VAS), and investi­
gator global assessment of disease activity, respectively. The 
difference is not necessarily an inconsistency but rather may 
highlight tliat what is minimally perceptible to patients may 
still be less than a clinically meaningful improvement.
An understanding of MPCI is potentially useful in estab- 
lisliing equivalence criteria for trials intended to show compa- 
rabihty (i.e., no clinically important difference) between 
active treatments. Such criteria generally specify that the 95% 
confidence interval of the mean difference in improvement 
between comparable treatments should not exceed a prede­
fined clinically important difference'^. Equivalence criteria 
based on what is minimally perceptible, rather tlran potential­
ly larger clinically important differences, provide a more con­
servative or stringent test of equivalence^
Our analysis examined whether tliere were important dif­
ferences in results according to geographic region, treatment 
(including placebo), baseline scores, age, and sex. With the 
exception of baseline scores, the effects were consistent 
across these subgroups. A positive correlation between base­
line score and subsequent response is consistent with a prior 
analysis of pain responses in patients with rheumatoid arthri- 
tis'L The results reported above differ from the finding of 
Santanello, et al that the minimal perceptible patient improve­
ment on an asthma symptom score varied by treatment and by 
age. In tliat study, patients treated with placebo ^ d  tliose 
older than the median age had smaller minimal perceptible 
improvement values than those undergoing active therapy and 
younger patients, respectively*'*.
Some caution should be used in the interpretation of the 
“None” categories for the patient and investigator global
response to therapy. The scales did not give the option of 
patients getting “worse”; consequently such patients were 
pooled witli those who had no response to treatment. This 
could result in the minimally perceptible important change 
being less than what was indicated by the “anchoring method” 
used in tliis analysis. The interaction between baseline scores 
and MPCI would suggest tliat there is potentially a threshold 
level of response to treatment that needs to be attained for a 
patient to consider himself or herself improved. For examj 'Ie, 
a 10 mm improvement for a patient with a baseline WOM.ÀC 
pain score of 90 nun may not be perceptible to the patient, 
whereas it would be for the patient witli a baseline of 60 mm.
The “anchoring method” is one of several methods used to 
facilitate clinical interpretation of health status measures. 
Other metliods such as collecting normative data, using tlie 
standard error of tlie measurement to assess change, and 
bench-marking against other diseases have been used to aid in 
clinical interpretation of health status measures. In this study, 
we anchored the change on tlie WOMAC to the patient and 
investigator assessments of global response to therapy, a 
method that seems particularly relevant to the interpretation of 
patient change in tlierapeutic drug trials.
In summary, this analysis showed tliat in tliis population of 
patients from 2 OA clinical trials, minimal perceptible clinical 
improvements were observed to be in the range of 8 to 12 
units with tlie WOMAC VAS pain walking on a flat surface 
item, and tlie WOMAC pain, stiffness, and physical function 
scales, and 0.40 to 0.50 units on an investigator global disease 
status assessment (Likert) scale. Witli tlie exception of base­
line score, tliese results did not vary importantly across a var 
ety of patient subgroups. These results provide a reference for 
the interpretation of changes in tliese measures in future clin­
ical trials of OA.
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Towards a Definition of “Difference” in Osteoarthritis
NICHOLAS BELLAMY, ALISON CARR, MAXIME DOUGADOS, BEV SHEA, and GEORGE WELLS
ABSTRACT. To assess ex isting  information regarding detectable d ifferences in osteoartliritis (O A ), a system atic  
literature search w as conducted up to D ecem ber 1999. Tliirty-three articles w ere considered  
m etliodologically  relevant to lire definition  and categorization o f  detectable differences in  O A . It 
w as determ ined tliat tlie m usculoskeletal literature contains a w ealth o f  inform ation that relates to 
observed  changes, m uch o f  w hich  is  derived from  the clm ical trials literature, but there have been  
relatively few  m eliiod olog ica l studies tliat h ave system atically  evaluated d ie  nature, categorization, 
and relevance o f  the change. Furtliermore, m ost o f  those tliat have been  published take the perspec­
tiv e  o f  an individual or groups o f  experts otlier than that o f  the patient. T liis sum m ary o f  the cu n en t  
literature reveals that the diverse sources o f  inform ation go part w ay towards d evelop ing an under­
standing o f  detectable differences and their impoi-tance in the area o f  O A  research and clin ical prac­
tice. Stakeholders’ interests as w ell as factors that m odulate perceptions o f  hnportance need  to be  
taken under consideration. In particular, th e  patient’s perspective o f  tlie im portance o f  change at an 
individual level requires furtlier evaluation. T his a iea  o f  clin ical research is relatively underdevel­
oped , but there is considerable opportunity for progress. (J Rheum atol 2 0 0 1 ;2 8 :4 2 7 -3 0 )
Key Indexing Terms: 
DISC RIM INATIO N OSTEOA RTH RITIS
M INIM ALLY CLINICALLY IM PORTANT DIFFEREN CE
INTRODUCTION
Health status measurement in osteoarthritis (OA) has 
undergone progressive evolution in the last 60 years', with 
more rapid change in the last 20 years^. Core set domains of 
pain, physical function, patient global assessment, and for 
studies of one year or longer, imaging, were established by 
international consensus at the OMERACT 3 conference^, 
and subsequently ratified by the Osteoarthritis Research 
Society International Task Force on clinical trials'*. The 
latter were published within guidelines for the execution of 
future studies, and contained descriptions of relevant 
measurement techniques. The last 20 years have seen 
progress in the development of general measures of muscu­
loskeletal status [e.g., the Health Assessment 
Questionnaire, Arthritis Impact Measurement Scale 
(AIMS), and AIMS2], generic health related quality of life 
measures (Medical Outcomes Survey Short Form-36, 
EUROQOL, NHP, HUI), and disease- specific measures for
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OA knee and hip disease [Indices of Clinical Severity, 
Western Ontario and McMaster University OA (WOMAC) 
Index, WOMBAT Index] and OA hand disease 
(Algofunctional Index, AUSCAN Index)^. Studies of the 
relative responsiveness of the WOMAC suggest that 
disease-specific measures may offer advantage over generic 
arthritis measures and that disease-specific measures are 
more responsive than generic Health Related Quality of Life 
(HRQOL) measures^. From a conceptual standpoint, the 
combination of the disease-specific OA measure and a 
generic HRQOL measure is advantageous in dissecting the 
impact of interventions on the hierarchy of health states.
There are several approaches to defining detectable 
and/or important differences in health state. A taxonomy for 
responsiveness has recently been proposed by Beaton, et 
which employs a tri-axial classification system according to 
who is being analyzed (individuals or groups), when the 
change is being measured (over time/at what point in time), 
and the type of change being quantified (e.g., observed 
change versus important change)^. The nature of the change 
being quantified may be considered from various stand­
points: (a) minimum change potentially detectable by the 
instrument; (b) minimum change detectable given the 
measurement error; (c) observed change in a given popula­
tion; (d) observed change in those deemed to have improved 
(estimated change), and/or (e) observed change in those 
deemed to have an important change^. The last 2 types of 
changes can be viewed from a number of perspectives, 
including those of the patient, clinician/researcher, payer, 
and/or society®.
To assess existing information regarding detectable
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differences in OA, a systematic literature search was 
conducted in MEDLINE, EMBASE, and Current Contents 
up to December 1999, using text words for OA and minimal 
clinically important difference, minimum observable or 
detectable difference, responsiveness, and improvement 
criteria. In addition, recent conference proceedings and 
journals were searched for additional relevant studies. The 
literature search identified 379 articles. Two independent 
reviewers assessed the titles and abstracts to determine eligi­
bility. A total of 66 articles were considered potentially rele­
vant and were retrieved for closer examination. Of these 66 
articles, 33 were considered methodologically relevant to 
the definition and categorization of detectable differences in 
OA. The included articles were then evaluated to determine 
which concepts of the responsiveness cube were addressed 
in the publication.
The subsequent review noted that the musculoskeletal 
literature contains a wealth of information that relates to 
observed changes, much of which is derived from the clin­
ical trials literature, but there have been relatively few 
méthodologie studies that have systematically evaluated the 
nature, categorization, and relevance/consequence of the 
change^. Further, most of those that have been published 
take the perspective of an individual or group of experts 
other tlran that of the patient. The articles cited in the 
following paragraphs are considered relevant to the issue of 
defining various levels of difference in OA, and are for the 
most part based wholly or partly on the OMERACT/OARSI 
core set clinical measures of pain, function, and patient 
global assessment.
MINIMUM CHANGE POTENTIALLY 
DETECTABLE BY THE INSTRUMENT
The minimum change potentially detectable (MCPD) is a 
function of the subscale structure and scale length of the 
instrument. The smallest detectable difference would be one 
unit, which in the case of a visual analog scale is 1 mm, and 
in the case of a Likert scale is equivalent to the smallest 
numerical difference between adjacent grades defined by 
the scoring system. In the case of the WOMAC LK 3.1 
Index, the scale ranges for the component subscales are as 
follows: pain 0-20, stiffness 0-8, physical function 0-68, 
total WOMAC 0-96®. Given an MCPD of 1 unit, the 
minimum percentage change potentially detectable 
(MPCPD) for the respective elements is as follows: pain 
5%, stiffness 12.5%, physical function 1.5%, total WOMAC 
1%. By comparison the WOMAC VA3.1 uses scale ranges 
as follows: pain 0-500, stiffness 0-200, physical function 
0-1700, and total WOMAC score 0-2400. The MCPD is 1 
mm and the MPCPD values are as follows: pain 0.2%, stiff­
ness 0.5%, physical flmction 0.06%, total WOMAC score 
0.04%. In contrast, the Indices of Clinical Severity'* are 
scored on a 0-24 scale, with an option for differences of 0.5 
in the physical function component to provide an MCPD of
0.5 and an MPCPD of 2%. It should be noted that the 
Indices of Clinical Severity are aggregated multidimen­
sional indices and that the total WOMAC score would 
provide a comparable approach to aggregated measurement, 
albeit using a different weighting system. With the 
AUSCAN LK3.0 OA Hand Index®, the length of the 
subscales are as follows: pain 0-20, stiffness 0-4, physical 
function 0-36, total AUSCAN score 0-60. The MCPD is 1 
unit and the MPCPD values are as follows: pain 5%, stiff­
ness 25%, physical function 2.8%, and AUSCAN total 
index score 1.7%. The Algofunctional Index contains 10 
questions^. The scale range of the Algofunctional Index is 
0-30, providing an MCPD of 1 unit and an MPCPD of 
3.3%.
MINIMAL CHANGE DETECTABLE GIVEN THE 
MEASUREMENT ERROR
The measurement error can be subdivided according to 
several sources including the patient and any independent 
assessor. Circadian variation in pain and function has been 
observed in OA of the knee and hand using patient self- 
report methods and performance based measurement tech­
niques'®-". Estimates of measurement error need to consider 
the volatility of the symptom complex and the way in which 
variations in a specified time frame might influence the 
determinatioiF. As a result there are relatively few published 
studies that adequately address this issue.
OBSERVED CHANGE IN A GIVEN POPULATION
There are several sources for observed change in a given 
population. The majority come from either cohort/observa- 
tional studies or from published clinical trials. Such studies 
need to be interpreted in the light of inclusion/exclusion 
criteria, the nature of the intervention, and the duration of 
the study. Relatively few clinical trial reports contain an 
exact description of the method of deriving the minimum 
clinically important difference sought and which was used 
in a sample sized calculatioiF.
OBSERVED CHANGE IN THOSE DEEMED TO 
HAVE IMPROVED
The determination of change can be made by the patient, 
clinician/researcher, payer, or society®. It is to be anticipated 
that the perception of change might be different between 
different reference groups. In a recently published study 
evaluating minimum clinically perceptible improvement 
(MCPI) in OA patients, the MCPI for the WOMAC pain, 
function, and stiffness subscales (0-100 mm) were 9.7, 9.3, 
and 10 mm, respectively, while the MPCI for the investi­
gator global assessment of disease status (0-4) was 0.42'^,
OBSERVED CHANGE IN THOSE DEEMED TO 
HAVE AN IMPORTANT CHANGE
The perceived importance of change may be different for
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different stakeholders. In a group of studies published in The 
Journal ofRheumatology^^'^^, a 3 round Delphi exercise was 
used to define minimum clinically important differences 
(MCID) for clinical trial purposes for a number of outcome 
measures used in prior OA clinical trialsT The median 
MCID for a comparative study of 2 nonsteroidal antiinflam- 
matoiy drugs in a double-blind randomized control parallel 
trial, in the perception of 6 academic rheumatologists expe­
rienced in OA clinical trials and based on actual data from 
60 patients, were as follows: Doyle Index 5.5, Physicians 
Overall Assessment of Pain (visual analog scale, VAS) = 15, 
Physicians Overall Assessment of Pain (Likert Scale, LK) =
0.78, Physicians Overall Assessment of Morning Stiffness 
(VAS) = 15, Physicians Overall Assessment of Morning 
Stiffness (LK) = 0.75, Duration of Morning Stiffness (time 
between arising and improvement in stiffness) = 0.23, 
Duration of Morning Stiffness (clock time from awaking to 
when stiffness begins to wear off ) = 20, Duration of 
Morning Stiffness (time between awakening and when 
patient is limber) = 0.3, Grip Strength (FDAmethod) = 37.5, 
Grip Strength (Dictionary of the Rlieumatic Diseases 
Method) = 37.5, Knee Range of Movement = 15, 
Intercondylar Distance = 6.5, Intermalleolar Distance = 8, 
Physicians Overall Assessment of Physical Disability (VAS) 
= 15, Physicians Overall Assessment of Physical Disability 
(LK) = 0.68, Investigators subject of opinion of Patients 
General Condition = 0.90, Physicians Estimate of Disease 
Activity = 0.78, Physicians Global Assessment of Disease 
Activity (VAS) = 15, Physicians Global Assessment of 
Disease Activity (LK) = 0.78, Soft Tissue Swelling = 1.50, 
Patient Pain at Rest (VAS) = 10.5, Patient Pain on 
Movement (VAS) = 17.5, Patient Overall Assessment of 
Pain (VAS) = 15, Patient Overall Assessment of Pain (LK) 
= 0.78, Subjective Pain Evaluation by Patient -  0.78, 
Patient’s Overall Assessment of Morning Stiffness (VAS) = 
17.5, Patient’s Overall Assessment of Morning Stiffness 
(LK) = 0.80, Patient’s Overall Assessment of Physical 
Disability (VAS) = 15, Patient’s Overall Assessment of 
Physical Disability (LK) = 0.8, Lequesne Knee Index = 3, 
Patient Estimate of Disease Activity = I , Patient’s Opinion 
of General Condition = 0.9, Patient’s Global Assessment of 
Disease Activity (VA) = 20, and Patient Global Assessment 
of Disease Activity (LK) = 1.
The recent OARSI Response Criteria Initiative (RCI) has 
permitted the development of response criteria for clinical 
trials in OA based on an analysis of 14 placebo controlled 
clinical trials (totaling 1886 patients). The criteria were 
presented at the OARSI International Conference in Vienna 
and use a tree format to categorize patients as responders or 
nonresponders according to 2 sets of class-specific 
criteria’®. The first set of responder criteria are based on a 
high pain response, or alternatively a lower level of 
response on at least 2 of the 3 domains: pain, function, and 
patient global assessment. In contrast, the second set of
responder criteria are based on a high level of response in 
pain or function, or alternatively, a lower level of response 
on at least 2 of the 3 domains: pain, function, and patient 
global assessment. These 2 different criteria sets accommo­
date the dynamic profiles of different classes of interven­
tions. In both sets of criteria, a response is defined by a 
combination of both absolute and percentage change. As a 
consequence, they are applicable only to those patients 
whose symptom severity is such that they could qualify as a 
responder should their condition improve sufficiently. It is 
anticipated that the OARSI criteria will require further vali­
dation using additional data sets. Doubtless there will be 
further debate regarding the use of absolute and/or 
percentage change, the implications of incorporating initial 
and/or final values, and the implications of dichotomization. 
Nevertheless, the OARSI responder criteria represent an 
initial attempt to address the complex and challenging 
problem of dichotomizing continuous variables, in order to 
define clinically important changes in health status.
An alternative approach is to provide individual clinical 
profiles of OA patients to key informants and require them 
to categorize the patients according to whether they, the key 
informants, regard the change as being clinically important. 
Such a project was completed immediately prior to 
OMERACT 5. The study was based on the WOMAC Index 
and patient global assessments, and employed a 3-round 
Delphi exercise to facilitate consensus building. A report is 
pending.
PATIENTS’ DEFINITIONS OF CHANGE
Most assessments of treatment efficacy within clinical trials, 
and to a lesser extent in clinical practice, are based on clin­
icians’ definitions of clinically important change. Little is 
known about the degree to which clinicians’ and patients’ 
perceptions of clinically important change are concordant, 
but there is evidence from a number of studies that clini­
cians are poor judges of the degree of pain suffered by 
patients, their quality of life, and the relative importance of 
different treatment outcomes"'"^'. Qualitative research with 
patients with rheumatoid arthritis and their clinicians has 
highlighted differences in the ways in wliich patients and 
clinicians constmct and evaluate disease activity, with 
patients focusing on the personal consequences in terms of 
pain and functional limitations and clinicians using biolog­
ical indicators'^. In OA, the criteria by which patients judge 
treatment efficacy appear to focus entirely on pain and func­
tion and are very specific, for example, being able to sit 
through one television program in comfort or being able to 
walk to a particular shop. There is also some suggestion that 
patients make “allowances” for treatments they particularly 
want to work, altering their efficacy criteria when the treat­
ment fails their initial evaluation. These data suggest that 
patients’ assessments of clinically important differences are 
highly individualized and inconsistent across different inter­
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ventions. Quantifying patients’ minimum clinically impor­
tant differences to interpret the results of clinical trials, or as 
the basis of sample size calculations, may therefore be more 
complex than using differences derived mathematically 
from outcome measures or from groups of clinicians. 
Nevertheless, they are important predictors of health service 
use. Demand for medical care and treatment change is 
driven by patients’ perceptions of treatment efficacy, and 
some attempt should be made to include them, particularly 
in clinical practice.
Issues surrounding the determination of the clinical 
importance and consequence of structural conservation have 
received little attention. It will be important to develop 
outcome measurement strategies for longterm studies. The 
issues are subtly different in situations where the progres­
sion of stmctural damage may be prevented, slowed, 
arrested, or reversed. Traditional measures of pain, patient 
global assessment and especially physical function will be 
relevant. So too may be the propensity for interventions to 
reduce the need for total hip replacement surgery '^*, although 
the timing of this endpoint, while clinically relevant, is 
potentially subject to effects that relate more closely to the 
health care system in which treatment is being delivered 
than to actual health status of the individuals concerned.
These diverse sources of information go part way 
towards developing an understanding of detectable differ­
ences and their importance in the area of OA research and 
clinical practice. Stakeholder interests as well as factors that 
modulate perceptions of importance need to be taken into 
consideration. In particular, the patient’s perspective of the 
importance of change at an individual level requires further 
evaluation. This area of clinical research is relatively under­
developed, but there is considerable opportunity for 
progress.
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Summary
Minimal Clinically Important Difference Module; 
Summary Recommendations, and Research Agenda
INTRODUCTION
In preparation for the conference, methodological papers on 
minimal clinically important differences (MCID) and the 
current status and need for MCID on core measures in the 4 
content areas of interest [osteoartliritis (OA), rheumatoid 
artliritis (RA), osteoporosis (OP), and low back pain (LBP)] 
were written and distributed to the conference participants. 
At the conference, these papers were presented in plenary 
and the participants were then divided into 8 breakout 
groups (3 groups each for OA and RA, and one group each 
for OP and LBP) to further consider the issues. 
Questionnaires were distributed to participants in the 
breakout sessions to help focus discussions during these 
sessions. All questionnaires had a similar core set of ques­
tions on MCID, as well as questions that were specific to the 
content area (OA, RA, OP, LBP). Completed questionnaires 
were collected by tlie breakout session leaders at the end of 
the sessions and the infoirnation was entered into a database 
and analyzed. At the closing plenary session of the confer­
ence, the results of the breakout questionnaire and discus­
sions were presented and conference participants voted on 
key issues associated with MCID.
This paper presents results from the questionnaire and 
voting, summarizes the associated discussions, and identi­
fies some areas for further research.
RESPONSES TO BREAKOUT QUESTIONNAIRE 
A total of 136 questionnaires were returned. Most were 
from the larger number of RA and OA sessions (RA 58; OA 
54; OP 19; LBP 5). Tlie specific results presented here 
primarily relate to RA and OP.
Of tlie 30 cells in the “cube” defined by who is the focus 
(groups, individuals), which scores are contrasted (differ­
ences between, changes within, both), and what type of 
change (minimum potentially detectable, minimum actually 
detectable beyond error, observed in the population, 
observed in those estimated to differ/change, observed in 
those estimated to have important difference/change), the 
cell of most interest was the “individual” setting for “within 
change” scores on “important change.”
In the RA breakout sessions, participants discussed the 
classification in the cube of the current RA response criteria 
according to type of change/difference. The response to the 
question, “Where are the RA criteria currently placed in the 
cube,” indicated that the majority of participants believed
that the ACR20 improvement criteria and the EULAR 
response criteria were considering change/difference 
observed in those estimated to have changed or estimated to 
have an important change (ACR20 52%; EULAR 73%). 
Based on the assumption that ACR and EULAR criteria 
have defined response or improvement corresponding to 
MCID, the participants ranked priority areas for further 
research. The percentage of priority rankings (rank 1 or 2) 
for the different areas considered were as follows: defining 
major improvement (25%); studies that focus on defining 
individual response as opposed to group change or differ­
ence (18%); studies that attempt to define MCID for indi­
vidual elements of the core set including functional status 
measures (16%); further validation of ACR/EULAR defini­
tions against independent definitions of response (15%); 
and studies that focus on whetlier thresholds for response 
differ for different core set items (14%). Only 1% gave a 
priority ranking to studies that evaluate whether core set 
items have particular statistically measurable thresholds for 
MCID. An area of study not listed but given a priority 
ranking by 5% under category of other was validating short 
term response criteria in predicting longterm outcome 
received 5% priority ranking.
Tlie issue of major improvement was further explored, 
with 76% indicating that it was important or useful to estab­
lish criterion for a major clinically important improvement 
as well as a minimal clinically important difference. A qual­
itative analysis of participants’ comments in considering 
major improvement indicated the following supporting 
themes: MCID is only a lower bound of improvement 
change; major change comes after determination and under­
standing of MCID; treatment decisions are more often made 
based on major change; and major change is important in 
interpreting trials of 2 active treatments.
In the OA breakout sessions, the adequacy of current esti­
mates for the OA core set of measures (pain, function, and 
patient global assessment) were considered from the 
perspective of the different types of change, namely: (1) 
minimum potentially detectable; (2) minimum actually 
detectable beyond error; (3) observed in the population; (4) 
observed in those estimated to differ/change; and (5) 
observed in those estimated to have important 
difference/change. The current estimates for pain were 
considered at least adequate (“very adequate or adequate ) 
by over 70% of the respondents for type 1, 2, and 3 change-
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Only 42% and 23% considered it at least adequate for the 
categories observed in those estimated to differ/cliange and 
observed in those estimated to have important 
difference/change, respectively. For function, about 70% 
found it at least adequate for all types of change except for 
the category observed in those estimated to have important 
difference/change, which received only 22%. Patient global 
assessment had a similar pattern to pain with a large 
percentage indicating it was at least adequate for type 1, 2, 
and 3 change (over 65%) but a smaller percentage for type 
4 (34%) and type 5 (21%) change.
The small number of participants in the OP and LBP 
breakout groups made it difficult to analyze and interpret 
their individual breakout session results. The information 
obtained in these sessions will be relayed to and considered 
by their respective societies and interest groups as a basis 
for possible further studies.
In all the breakout sessions, the participants were asked 
whether a MCID should be defined in terms of percentage 
change only, absolute change only, or both. The vast 
majority indicated both (85%), with an equal percentage of 
respondents indicating support for percent (7.5%) or 
absolute (7.5%) change only.
RESPONSES TO PLENARY QUESTIONS
Four questions were posed and voted on in the final plenary 
sessions. The questions were designed to confirm discus­
sions that took place among the participants and tlie inter­
pretation of the questionnaire results. The goal was to set a 
broad overview on a research agenda.
Question 1: Do you support the development o f clinical 
response criteria for individuals in other diseases?
Yes 96%
No 1%
Don’t know 3%
The MCID module concentrated on 4 content areas (OA, 
RA, OP, LBP). To address whetlier other areas should 
consider clinical response criteria in this way, a question
was posed to draw on the various expertise of the partici­
pants, as well as the information they were provided with 
and their specific experience at the OMERACT conference. 
The vote by all the conference participants at tlie final 
plenary session resulted in 96% supporting the development 
of clinical response criteria for individuals in other diseases. 
Question 2: Do you agree that it is important to define 
"major” clinical important improvement for RA?
Strongly agree 47%
Agree 33%
Neutral 13%
Disagree 3%
Strongly disagree 2%
Don’t know 1%
The results of the questionnaire for tlie RA breakout
sessions indicated that “major” clinically important
improvement may be an important area of consideration for 
research. This question was posed to and voted on by all the 
conference participants at the final plenary session, with a 
resulting 80% in agreement.
Question 3: Do you agree that it is important to validate 
short term response/improvement criteria in predicting 
longterm outcome?
Strongly agree 61%
Agree 23%
Neutral 8%
Disagree 2%
Strongly disagree 4%
Don’t know 2%
The issue of validating short term response/improvement 
criteria in predicting longterm outcome received an impor­
tant priority ranking but was essentially considered by only 
one breakout session. This question was posed to and voted 
on by all the conference participants, with a resulting 84% 
in agreement.
Question 4: In OA should any response criteria developed 
be defined in terms of..?
Percent change alone 5%
Absolute change alone 4%
Both 91%
Based on the breakout questionnaire, a large majority of 
participants indicated that a MCID should be defined in 
terms of both percentage change and absolute change only. 
This is an important concept in the development and inter­
pretation of MCID and confirmation of this finding was 
sought for OA response criteria. This question was posed to 
and voted on by all the conference participants, with a 
resulting 91% indicating that both absolute and relative 
should be considered. After tlie vote, Maxime Dougados 
presented the recent work and decisions made by OARSI in 
which both percentage and absolute change were used in the 
definition of OA response criteria.
RESEARCH AGENDA OVERVIEW:
1. Develop clinical response criteria for individuals in other 
diseases?
2. Consider botli relative and absolute change in developing 
response criteria.
3. Consider “major” clinically important change in the 
further development of a clinical response criteria.
4. Validate short term response criteria in predicting 
longterm outcome?
5. Consider the patient perspective in developing response 
criteria.
CONCLUSION
Progress has been made in considering changes/differences 
related to clinical outcomes of interest in some of the 
disease areas. Tlirough a multidisciplinary approach at 
OMERACT involving academic investigators, clinicians,
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and regulatory experts, it is anticipated that this work will 
progress further in areas in which it is more established, 
with the possible development of “major” response criteria, 
and be initiated in areas in which it needs more considera­
tion. During the discussions, two important themes evolved 
that were in need of more consideration — taking a patmnt 
perspective of response and validating the longterm clinical 
consequences of short tenn response criteria.
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Summary
Background: The OARSI Standing Committee for Clinical Trials Response Criteria Initiative liad developed two sets of responder criteria to 
present the results of changes after treatment in three symptomatic domains (pain, function, and patient’s global assessment) as a single 
variable for clinical trials (1). For eadi domain, a response was defined by both a relative and an absolute change, with different cut-offs vrith 
regard to the drug, the route of administration and the OA localization.
Objective: To propose a simplified set of responder criteria with a similar cut-off, whatever the drug, the route or the OA localization. 
Methods: Data driven approach;
(1) Two databases were considered
•  The ‘elatxiration' database with which the formal OARSI sets of responder criteria were elaborated and
♦ The ‘revisit’ database.
(2) Six different scenarios were evaluated:
♦ The two formal OARSI sets of criteria
•  Four proposed scenarios of simplified sets of criteria
Data from clinical randomized blinded placebo controlled trials were used to evaluate the performances of the two fomial scenarios with two 
different databases (‘elaboration’ versus 'revisit') and those of the four proposed simplified scenarios within Itie 'revisit’ database The 
placebo effect, active effect, treatment effect, and the required sample arm size to obtain tlie placebo effect and tlie active treatment effect 
observed were the performances evaluated for eadi of the six scenarios. Experts' opinion approach: Results were discussed among the 
participants of the OMERACT VI meeting, who voted to select the definite OMERACT-OARSI set of criteria (one of tfie six evaluated 
scenarios).
•For correspondence and request for reprint: Professor Maxime Dougados. Rheumatology B Department, Cochin Hospital 27 rue du 
faubourg Saint Jacques. 75014 Paris, France. Tel.: +33-1-58-41-25-62; Fax: +33-1-43-54-92-56; E-mail: maxime.dougados© cch.ap-hop- 
paris.fr
' Name of department and institution to whidi the work should be attributed: René Descartes University, AP-HP, Cochin Hospital, 
Rheumatology B Department, 27 me du faubourg Saint Jacques, 75014 Paris. France.
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Results: Data driven approach: Fourteen  tr ia ls  lo tahng  1886 O A  p a tie n ts  and  fitteen s tu d ie s  in v o lv in g  8164 OA patien ts w ere  e v a lu a te d  in the 
'e la b o ra tio n ' a nd  the  're v is it' da ta ba se s  re spective ly .
T h e  v a r ia b ility  o f the  p e rfo rm a n ce s  o b se rve d  in  th e  're v is it' d a ta b a s e  w he n  us ing  th e  d if fe re n t s im p lified  scenarios  w as  s im ila r  to  that 
o b s e rv e d  b e tw e e n  th e  tw o  d a ta ba se s  ( 'e la b o ra tio n ' versus 're v is it ')  w h e n  u s ing  the  fo rm a l s c e n a r io s . The  trea tm ent e ffec t and  th e  requ ired  
sa m p le  a rm  s ize  w ere  s im ila r fo r each  se t o f c r ite r ia . Experts'opinion a p p ro a c /c  A c co rd in g  to  t l ie  experts , t lie s e  tw o  p re v io u s  p e rfo rm a n ce s  
w ere  th e  m o s t im p o rta n t o f an op tim a l se t o f re s p o n d e r c rite ria . T h e y  c h o se  the  se t o f c r ite r ia  c o n s id e r in g  both pain and fu n c tio n  a s  eva lu a tion  
d om a in  a n d  re q u ir in g  an a bso lu te  change  a nd  a  re la tive  ch a n g e  fro m  b a s e lin e  to  d e fine  a re s p o n s e , w ith  s im ila r c u t-o lls  w h a te v e r the  druq 
th e  rou te  o f a d m in is tra tio n  or the  O A  loca liza tio n .
C onclusion: T h is  data  d riven  and  expe rts ' o p in io n  a p p ro a ch  is th e  b as is  fo r  p ropos ing  an o p tim a l s im p lified  set of re s po n d e r c r ite r ia  lo r Q A 
c lin ica l tr ia ls . O th e r s tud ies , us ing  o th e r se ts  o f O A  p a tie n ts , a re  re q u ire d  in o rd e r to  fu r th e r v a lid a te  th is  p roposed O M E R A C T  -  O A R S I set 
o f c rite r ia .
©  2 0 0 4  O s te o A rlh r it is  R esea rch  S oc ie ty  In te rn a tion a l. P u b lish ed  b y  E ls e v ie r L td. A ll r ig h ts  re s e rv e d .
K ey words: O s te o a rth ritis , O u tco m e s, C lin ica l T ria ls  R esp o n se  C rite r ia  In itia tive .
Introduction
The Osteoarthritis Research Society International (OARSI) Standing Committee for Clinical Trials Response Criteria Initiative and the Outcome Measures in Rheumatology 
(OMERACT) committee, in concert with the international rheumatology community, has led to the development of a 
uniform core set of outcome measures for osteoarthritis (OA)*"'*. One of the objectives was to propose a set of 
criteria for measurement based on multiple domains to present the results of changes after treatment in sympto­
matic parameters as a single variable for clinical trials. The symptomatic variables selected by both the OMERACT and OARSI societies were: pain, functional impairment and 
patient’s global assessment.Based on data from clinical trials, two sets of responder criteria (formal OARSI criteria) that can categorize an individual’s response to treatment in a clinical trial have 
been developed^ (Fig. 1).The main characteristics of the proposed sets of criteria 
were the following;
•  They covered three domains; pain, function and patient’s global assessment.•  For each of these domains, a response was defined by both a relative and an absolute change.
•  The cut-offs that defined a relevant change differed 
with regard to:
• OA localization {e.g. hip vs  knee),•  evaluated study drug {e.g. NSAIDs vs  specific 
anti-OA drug),• route of administration {e.g. per os vs intra- 
articular),•  specific domain (pain, function, patient’s global 
assessment).
The choice of the different cut-offs for the formal OARSI 
set of criteria was based on statistical analysis for optimiz­
ation of the discriminant capacity. The preliminary attempts at uniform cut-off of all subsets showed a lesser placebo and active treatment effect of the set of criteria considered relevant by the members of the steering committee.
The main objective of this study was to evaluate the 
perfonnances of the two previous formal OARSI sets of 
criteria and the performances of the modified ones, pro­
posed by the scientific OMERACT committee. The aim of 
the proposed modifications was to simplify the presentation 
of the set of criteria, by evaluating different scenarios whatever the OA localization, whatever the evaluated drug, 
whatever the route of administration, and with similar 
cut-offs for the different domains.
Metliods
PROPOSED SET OF CRITERIA
Six different scenarios were evaluated. The first two scenarios were the two propositions (A and B) of the formal OARSI set of criteria^ (Fig. 1), The four other scenarios (scenarios C to F) were proposed by the OMERACT scientific committee. Their main characteristic was that 
they used a uniform cut-off whatever the OA localization, whatever the study drug and whatever the route of administration, unlike the formal OARSI set of criteria (Fig. 2). Scenarios A, C and E considered pain at the first responder step (high improvement), and scenarios B, D and F considered pain or function (Fig. 3). Scenarios C and D, as the formal OARSI set of criteria did, considered relative change (percentage of change during the study) and absolute change (absolute change during the study) in the variable to define a response, whereas scenarios E and F considered only relative change to define such response.The study approach was both data driven and used an experts’ opinion approach.
DATA DRIVEN APPROACH
Two databases from clinical randomized placebo con­trolled trials were used;
• The initial one used to elaborate the formal set of criteria, known here as the ‘elaboration database’.•  The second one is labeled the ‘revisit database’. Drug companies who had conducted positive randomized placetx) controlled trials In OA of a minimum 4-week duration were invited to revisit their database. The 
definition of ‘positive’ was based on a p value <0.05 for 
the a priori chosen primary criterion of the trial. Only the intention-to-treat analysis trials using the Last 
Observation Carried Forward technique were used. The participating drug companies were invited to provide anonymous information: OA localization, route 
of administration, characteristics of the study drug (analgesic, NSAID, Specific OA drug), study duration, number of patients in ttie placebo group and in the active treatment group, tools used to evaluate pain (e.g. pain VAS, Likert scale, WOMAC pain subscale), 
function {e.g. WOMAC function subscale) and patient's 
global assessment {e.g. VAS, Likert scale)®, and time of collection of these different tools. Because of confi­dentiality, no demographic data, such as age, gender, body mass index, nor baseline values were asked to the drug companies. The drug was not identified by name, but only by class of agent (e.g. NSAIDs,
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Enrolled studies : 15 
( 8164 patients)
Knee OA 
NSAIDs 
5 Studies 
(n = 4893)
Hip OA  
N SA ID s 
3 Studies 
(n =  1199)
Hip/Knee OA 
NSAIDs 
2 Studies 
(n = 819)
Hip OA 
lA  Speeiftc OA 
2 Studies *
(n = 606)
Knee OA  
Systemic Specific OA  
3 Studies 
(n = 647)
Excluded studies ; 0
S creen ed  stu d ies ; 15 
(8164  patien ts)
* 1 study used a non-placebo control group
Fig, 3. F lo w  d iag ram  fo r num bers  o f s tu d ie s  a n d  p a tie n ts .
systemic specific drug, intra-articular specific drug). For each trial and each scenario, a drug company provided the number of patients and the number of responders in each treatment arm. With this information, sensitivity (percentage of patients receiving an active drug labeled as responders according to the proposed set of criteria) and specificity (percentage of patients receiv­ing the placebo treatment labeled as non-responder according to the proposed set of criteria) could be 
calculated for each trial and for each drug class and 
joint location of interest.
The first step of the data driven approach consisted In the evaluation of the performances of the two formal scenarios 
(scenario A and B), using the two databases, for each category of trial studied during the elaboration step {i.e. 
hip OA-NSAIDs trials, knee OA-NSAIDs trials, knee OA-systemic specific drug trials and knee OA-intra- 
articular specific drug trials). In other words, we compared the following performances in the ‘elaboration’ and in the 
‘revisit’ database: placebo effect (percentage of responders 
in the placebo group), active effect (percentage of respond­
ers in the active treatment group), treatment effect (per­
centage of patients improved in the active treatment group 
minus the percentage of patients improved in the placetx) group) and the sample arm size needed to obtain the 
observed placebo and active treatment effects (a=0.05 and 
p-0.20, two tailed test).The second step consisted in the evaluation of the above performances between the six scenarios within the revisit 
database. For each drug and for each OA localization, the number of patients in the active treatment group and in the placebo group, the placetx) effect, the active effect, the treatment effect and the sample arm size needed to obtain the observed placetx) effect and the active treatment effect
were calculated. These evaluations were also calculated whatever the localization and/or whatever the treatment. Moreover, since criteria sets almost always performed optimistically well when evaluated with the same database which was used to hunt for ‘optimum’ scenario, we com­pared the performances of the scenarios C, D, E and F in the elaboration database to the performances of the scenarios A and B in the revisit database.
E xperts’ opinion approach: Based on the data observed and after discussion among the OMERACT VI meeting 
participants, a vote was conducted to select the definite 
OMERACT-OARSI set of criteria (one of the six evaluated scenarios).
Lastly, the sensitivity and the specificity of the selected scenario has been evaluated in the “elaboration" database 
(knee OA-NSAIDs trials, hip OA-NSAIDs trials). The sensitivity was defined by the percentage of NSAlDs-OA 
patients meeting the OMERACT-OARSI criteria. The 
1 -specificity was defined by the percentage of placebo-OA patients meeting the OMERACT-OARSI criteria.
Results
PATIENTS AND STUDIES
In the elaboration database, fourteen trials totaling 1886 patients were evaluated (see Ref. 5 for details). The majority of the information was on. NSAIDs for knee and hip. In the revisit database, fifteen studies involving 8164 OA 
patients were screened (Fig. 3). None of the studies was excluded. A prospective randomized controlled study in which the control group was receiving the usual therapeutic care without true placebo {vs. an intra-articular OA drug) was included in the revisit database. There were no trials
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T ab le I
Characteristics o f the 15 studies included in the ‘revis it' da tabase ' accord ing to agent class
C haracteristics Drug c la s s
NSAIDs S y s te m ic  sp ec ific  
O A  d ru g
In tra  a rtic u la r  sp e c ific  
O A  d ru g
N um b e r o f s tu d ie s 10 3 2
N um b e r o f p a tie n ts A c tive  d rug  g ro u p 5557 3 16 303
P lace b o  or co n tro l g rou p 1354 331 3 03
S tudy du ra tio n (m ean  + /- sd; w eeks) 9.3±3.B 1 05 .3±8 7 .7 3 3 ± 9 .9
P ain e va lu a tio n W O M A C 40% 100% 50%
VAS 60% 0 5 0%
O tfie rs 0 0 0
Function  e v a lu a tio n W O M A C 100% 100% 50%
V AS 0 0 5 0%
O the r 0 0 0
G loba l a s s e s s m e n t e va lu a tion L ike rt 40% 3 3% 0
VAS 30% 6 6% 5 0 %
O th e r 30% 50%
T im e  o f c o lle c tio n  o f th e  o u tc o m e  v a ria b le s F ina l a n d  b ase line 100% 1 00% 100%
O n ly  fina l v is it 0 0 0
"R e v is it*  d a ta  b ase  is  th e  one  th a t p e rm itte d  to  re v is it th e  fo rm a l se ts  o f respo n d er c rite ria  a n d  to  e va lu a te  th e  s im p lifie d  se ts  o f re s p o n d e r 
c rite ria .
W O M A C : W e s te rn  O n ta rio  M c M a s te r U n ive rs it ie s  O s teo a rth ritis  in d e x ; VAS: V isua l A n a lo g ic  S ca le .
available to examine analgesics in OA. The majority of the 
studies concerned NSAIDs in hip and knee OA (10 of 15).The characteristics of study designs are summarized in Table I. The data concerned 647 patients in systemic specific OA drug trials, 606 patients in intra-articular (lA) specific OA drug trials and 6911 patients in NSAIDs trials. For NSAIDs studies, whatever the OA localization, 5557 patients received the active treatment, and 1354 the pia- cebo. Two studies involving hip and/or knee OA without indication of the localization were included only in the “whatever the localization" calculation. To assess pain and functional disability, two tools were most often used: The visual analog scale (VAS) and the Western Ontario 
McMaster Universities Osteoarthritis (WOMAC) index. For global patient’s assessment, the VAS and the Likert scale 
were mostly used.The knee was the only OA localization of the five specific OA drug studies (systemic and intra-articular), while NSAIDs trials were conducted in both knee and hip OA.
DATA DRIVEN APPROACH RESULTS
F orm al s e t  o f  criteria p e r fo rm a n c e s :  co m p a r iso n  
b e tw e e n  e labora tion  d a ta b a s e  a n d  rev is it d a ta b a s e
Results concerning the placebo and the treatment effects are summarized In Table II. For both the propositions A and 
B, the variability in the placebo and the active treatment 
effects were quite high (from 4% to 21% in the placebo group and from 7% to 34% in the active treatment group). 
Based on the observed results (placebo effect and active treatment effect) in the elalxiration database, the calcu­lation of the sample size required in future NSAIDs trials In knee OA was 67 patients per arm with scenario A and 66 
with scenario B.
P e rfo rm a n c e s  o f  th e  6  s c e n a r io s  in th e  rev is it 
d a ta b a s e  acco rd in g  to  d ru g  c la ss , rou te  o f  
adm in istra tion  a n d  O A loca liza tion
The results of the evaluated performance for each scenario are summarized in Table III. The highest active
treatment effect and placebo effect were observed when using scenario F, whatever the drug class and whatever the localization.
NSAIDs in K nee OA. The highest active treatment effect was observed when using scenario F (66.4%), and at variance, the lowest placebo effect was observed when using scenario B (39.1%). The treatment effect was similar whatever the scenario (19.8%, 19.3%. 19.8%, 19.5%, 19.9% and 19.8% for scenarios A. B, C, D, E and F respectively). The sample sizes “required" in future NSAID knee trials using the “revisit" data were 99 patients per arm, scenario A and 105 per arm, scenario B. Using the simpli­fied scenarios, the sample sizes “required” were 98 per arm, scenario C, 101 per arm, scenario D, 97 per arm, scenario E and 98 per arm, scenario F.
NSAIDs in Hip OA. The highest active treatment effect was observed when using scenario F (60.8%), and at variance the lowest placebo effect was observed when using scenario A (28.9%). As observed in knee OA, the treatment effect was similar whatever the scenario (24.7%, 
26.5%, 25.9%, 25.7%, 25.3% and 25.3% for scenarios A, B, C, D, E and F respectively). The sample sizes ‘required' in future NSAID hip trials using the ‘revisit’ data were 62 
patients per arm, scenario A and 55 per arm, scenario B. Using the simplified scenarios, the sample sizes ‘required’ 
were 58 per arm, scenario C, 59 per arm, scenario D and 
61 per arm, scenario E and scenario F.
System ic Specific OA drug in K nee OA. The highest 
active treatment effect was observed when using scenario F (49.4%), and the lowest placebo effect was obsen/ed 
when using scenario B (29.0%). Scenarios A and B showed the highest treatment effect (6.9% and 6.8% respectively) 
and the lowest sample size “required" for future systemic 
specific OA drug trials in knee OA (743 and 745 patients 
per arm respectively, versus 1167, 1095, 4979 and 3824 patients per arm for scenarios C, D, E and F).
Intra-articular specific OA drug in K nee OA. The highest 
active treatment effect was observed when using scenario F (72,9%), and the lowest placebo effect was observed when using scenario B (34.6%). The highest treatment
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effect was observed when using scenario E (28.1%). The lowest sample size ‘required’ tor future intra- articular 
specific OA drug trials in knee OA were observed when 
using the simplified scenarios (51, 52, 48 and 49 patients per arm for scenarios C. D, E and F respectively, versus 73 
and 74 patients per arm for scenarios A and B).
P erfo rm a n ces  o f  th e  s ix  s c e n a r io s  in th e  revisit
d a ta b a s e  w h a te v e r  th e  drug c la s s , th e  rou te  o f 
adm in istra tion  o r  th e  loca liza tion  o f OA
NSAIDs whatever the OA localization. The highest active 
treatment effect was observed when using scenario F (66.0%), and at variance the lowest placebo effect was observed when using scenario A (36.8%). The treatment effect was similar whatever the scenario (21.5%, 21.3%, 21.4%, 21-1%, 21.3% and 21.5% for scenarios A, B, C, D, E and F respectively). The sample size “required" for future NSAIDs trials in OA was also similar whatever the scenario (84, 86, 84, 87, 85 and 83 patients per arm for scenarios A, 
B, C, D, E and F respectively).
W hatever the sys tem ic  drug (i.e. system ic specific OA 
drugs and NSAIDs) an d  whatever the localization. The highest active treatment effect was observed when using scenario F (65.1%), and at variance the lowest placebo effect was observed when using scenario B (21.7%). The treatment effect was similar whatever the scenario (21.5%, 21.7%, 21.3%, 21.1%, 20.1% and 20.3% for scenarios A, B, C, D, E and F respectively). The "required " sample size was also similar whatever the scenario (84, 62, 86, 87, 96 
and 94 patients per arm for scenarios A, B, C, D, E and F 
respectively).
W hatever the drug and whatever the localization. The highest active treatment effect was observed when using scenario F (65.5%), and at variance the lowest placebo effect was observed when using scenario B (35.6%). The treatment effect was similar whatever the scenario (21.5%, 21.9%, 21.7%, 21.3%, 20.4% and 20.6% for scenarios A,B, C, D, E and F respectively). The sample size “required” for future trials in OA was also similar whatever the scenario (84, 81, 82, 85, 93 and 91 patients per arm for 
scenarios A, B, C, D, E and F respectively).
EXPERTS’ OPINION APPROACH RESULTS
Based on the observed results, it was considered that the 
data driven approach did not permit to select a specific set 
of criteria. However, at least two of these performances (treatment effect and required sample size) were similar whatever the scenario (A to F). These results were pre­sented to the participants of the Osteoarthritis session 
of the OMERACl VI conference (Brisbane 2002). After 
discussion and voting, it appears that:
•  The treatment effect and the required sample size were the two major characteristics to take into account in the 
choice of an optimal set of criteria to fje used for clinical 
trials.,  Two other characteristics were also considered as 
Important:
1) The definition of an improvement based not only on a relative change but also on an absolute change (scenarios A, C and E versus scenarios B, D and F)2) The simplicity of the presentation; same cut-offs, set of responder criteria whatever the localization, the study
drug and the route of administration (scenario A. B 
versus C, D, E and F).
Based on this preliminary discussion between experts and after a voting session, scenario D was selected (Fig. 4). It is now labeled the ‘OMERACT-OARSI’ set of responder criteria.
EVALUATION OF THE DIFFERENT SETS OF CRITERIA
Table IV summarizes the results of the procedure permit­ting the evaluation of the different scenarios. This table shows that the treatment effect was similar whatever the evaluated scenario, but for hip OA. both the sensitivity and the specificity (active treatment effect and placebo treatment effect) were higher for the scenario D.
Discussion
This study, which combined the efforts of academic 
researchers, representatives of the pharmaceutical industry and representatives of health agency, proposes a 
simplified set of responder criteria for clinical trials in DA by simplifying the initial OARSI set of criteria using a data driven and experts’ opinion approach. Limitations of this study include (i) the absence of analgesics trials in our analysis of the improvement tretween active drug-treated group and placebo-treated group; (ii) Available trials con­cerned only knee or hip OA and no other OA localization; (iii) The collected data concerned only the core set of criteria. Drug companies provided for each trial, the per­centage of responders in the active treatment group and the percentage of non-responders in the placebo group, according to each scenario. We did not have access to the individual data, neither to the percentage of responders for each domain separately (pain, function, global patient’s assessment). This lack of data did not allow us to estimate if the core set of criteria was less powerful than each domain treated separately, as has been done for rheuma­toid arthritis ;^ (iv) The cut-offs of the simplified scenarios were inspired by the formal ones. However, more specific cut-offs could not be estimated due to the lack ot individual data for the 8164 OA patients.
We observed considerable variability in the results with regard to the study population (elaboration versus revisit database) within the formal sets of criteria. This variability could tie attributed to a variability tietween the patients included in the two databases. However, in both of them, 
most of the trials have been conducted in multicenter 
international trials following a very similar approach con­
cerning the inclusion and exclusion criteria (phase II and phase III trials).
In the elaboration phase of the formal OARSI set of 
criteria, the loss of sensitivity and specificity using identical 
cut-offs, whatever the localization and the study drug, did not allow to propose a simple set of criteria (similar cut-off whatever the OA localization and ttie study drug). The variability of the performances of these formal sets of criteria between the two databases was in contradiction with the results obtained in the elaboration phase and 
prompted us to further evaluate a simplification of the set of responder criteria.
The data driven conclusions are that, whatever the OA localization, the study drug or the route of administration, formal scenarios A and B had the lowest placebo effect, and scenario F had the highest active treatment effect. In
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OMERACT- OARSI set of responder criteria
High improvement in pain or in function >50% 
and absolute change >20
r?
Yes
Response
No
n
Improvement in at least 2 of the 3 following:
• pain >20% and absolute change >10
• function >20% and absolute change >10
• patient’s global assessment >20% and absolute change >10
Yes
Response
93
No
d
No Response
Fig. 4. OMERACT-OARSI Set of responder criteria.
Table IV
Percentage of patients responding when the OMERACT-OARSI and formal proposition A and B critena sets are applied to a validation data
set*
Validation database Criteria set Knee NSAID trial Hip NSAID trial
Sensitivity Specificity Sensitivity Specificity
Elaboration OMERACT-OARSI 59% 40% 72% 44%
Revisit OARSI-Proposition A 59% 39% 54% 29%
Revisit OARSI-Proposition B 58% 39% 58% 26%
* Sample size required per arm alpha=0.05, beta=0.20, two-tailed.Sensilivlty=% responders on active drug (NSAIDs). 1-Speciticity=% 
responders on placebo.
contrast, the treatment effect and the required sample size 
were quite similar whatever tlie scenario, ranging from 
20.4% to 21.9% and from 81 to 93 patients per arm 
respectively.Although the data driven approach did not allow to select any particular scenario, the simplification of the set of criteria 
did not result in a loss of relevant performances. Indeed, a higher active treatment effect and a higher placetx) effect 
were observed when using the simplified scenarios in both databases. Conversely, the treatment effect and the sample size required to obtain the observed placebo and active effects were similar whatever the scenario (whether formal 
or simplified) in the revisit database.
According to the experts, these two performances were the most important for an optimal set of responder criteria. 
Although all the evaluated scenarios provided similar 
results for these perfonnances, the experts’ choice was 
scenario D (Fig. 4), which confirms the Importance of;
1) A format that requires both an absolute change and a relative change.
2) A format that considers both pain and function as important domains; in certain studies, however, 
changes in functional disability are at least as important 
as changes in pain.
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The observed treatment effect whatever the drug and whatever the treatment when using scenario D is 21.3%. This result is close to what is expected in OA. i.e., 20- 
30%®-®.The required sample size with scenario D whatever the drug and whatever the treatment is 85 patients per arm. This is similar to the sample size required when using the previous formal set of criteria.In conclusion, we propose a simplified definition for symptomatic improvement in osteoarthritis. This set of criteria, approved both by the OARSI and the OMERACT committees, is at least as powerful as the previous OARSI 
formal set of criteria and its simplification will probably 
enhance its use in future OA trials.Other studies are required on order to further validate this proposed OMERACT-OARSI set of criteria in other sets of patients suffering from osteoarthritis of different localizations and treated differently, e.g.. with analgesics or non-pharmacological therapies.
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O bjective: A  seco n d a ry  analysis o f  a  previously conducted o n e  y ea r  random ised  controlled trial to 
evaluate the cap a c ity  o f  responder criteria b a sed  on the W O M A C  in d ex  to detect b etw een  treatment 
group d ifferences.
M ethods: 2 5 5  patients w ith knee osteoarthritis w ere  random ised  to "appropriate care with hylan G-F 2 0 "  
(AC+HJ o r  " ap propriate ca re  without hylan G-F 2 0 "  (AC). In the orig inal analysis, tw o definitions o f  
patient resp onse from b ase lin e  to month 1 2  w ere  used: ( 1 ) a t least a  20%  reduction in W O M A C  pain  
score (W O M A C  20P ); (2) a t least a  20%  reduction in W O M A C  pain score  and  a t least a  20%  reduction in 
either W O M A C  (unction o r  stiffriess score (W O M A C  20PFS). For this an alysis , a  responder w a s  identified  
using 50%  an d  70%  minimum clinically im portant response levels to investigate h ow  in creasing  resp onse  
affects the ability to d etect treatment group  differences.
Results: The hylan G-F 2 0  group  had  numerically m ore responders using all patient resp ond er criteria. 
Increasing the resp o n se  level from 20%  to 50%  .detected sim ilar d ifferences betw een  treatm ent groups  
(25% to 29% ). Increasing the resp onse  level to 70% reduced  the differences betw een  treatm ent groups  
(11% to 12%) to a  point w h ere  the differences w ere  not significant after Bonferroni adjustm ent. 
Conclusions: T hese results provide ev id en ce for incorporating resp onse  levels (W O M A C  5 0 )  in clinical 
trials. W hile d ifferences a t  the highest threshold (W O M A C  7 0 )  w ere  not statistically d etectab le , an  
appropriately p o w ered  study m ay b e  ca p a b le  o f  detecting d ifferences even  at this very h igh  level o f  
im provement.
D evelopm ents in standardisation o f  outcom e m easure­m ent procedures for clinical trials in  the treatm ent o f osteoarthritis and rheum atoid artliritis have follow ed  
sim ilar but not identical pathways. W hile m easures o f pain, 
function, and patient global assessm ent have been  selected as 
core set m easures for cUnical trials in  both  o f  th ese  diseases, 
the outcom e m easures in artliritis clinical trials-A nierican  
College o f  R heum atology ( OMERACT -ACR) criteria for 
rheum atoid arthritis' differ from  the OMERACT- 
Osteoarthritis Research Society International (OARSI) cri­
teria for osteoarthritis,^ ’ in that the former also  include  
m easures o f the num ber o f tender and sw ollen  joints, 
physician global assessm ent, and C reactive protein/erythro­
cyte sedim entation rate values. The subsequent developm ent 
of responder criteria for rheum atoid artliritis'' and  osteoar­
thritis trials' * reflects these differences in  core set m easures. 
In addition, ACR responder criteria for rheum atoid artliritis'* 
are based on percentage changes on  tw o or m ore variables, 
w h ile  OMERACT-OARSI responder criteria for osteoarthritis* 
are based on  a com bination o f percentage and absolute  
changes in  on e  or m ore variables. Following the developm ent 
o f the ACR 20  responder criteria for rheum atoid arthritis," 
Inglier threshold requirem ents for response designation  have 
been explored, nam ely ACR 50 and ACR 70 responder 
criteria.*’ Higher response levels have been m ore difficult to 
achieve, and betw een group differences in  rheum atoid  
arthritis clinical trials have (albeit less often) been  detected  
at these  higher thresholds, requiring individual patient 
im provem ents at or above the 50% and 70% levels, 
respectively.''"Notwithstanding the principle of employing a combination 
of percentage and absolute changes of one or more variables
in  OMERACT-OARSI responder criteria for osteoarthritis,* 
and that o f  basing responder criteria on percentage change  
alone in  OMERACT-ACR criteria for rheum atoid arthritis," w e  
undertook secondary analyses o f a published random ised  
controlled trial'" " to evaluate the ability o f  responder criteria 
based on  the W estern Ontario and M cM aster U niversities 
(WOMAC) osteoarthritis index to detect betw een  treatm ent 
differences. W e com pared the results o f  analyses based on  
WOMAC 20, WOMAC 50, and WOMAC 70 responder criteria 
to determ ine w hether the application o f different criteria 
influences data interpretation.
METHODS
D esign
The analyses reported here w ere undertaken u sin g  the data 
collected in a health outcom es trial evaluating v iscosupple- 
m entation w ith  hylan G-F 20 w h en  added to an appropriate 
care treatm ent regim en for patients w ith  kn ee osteoarthritis. 
The detailed design o f  this trial and the primary analyses o f 
the data have been published elsewhere.'" " Briefly, the trial 
w as a m ulticentre, random ised, controlled, open label study  
over one year, w here patients w ere random ised to either  
"appropriate care w ith  hylan G-F 20" (AC+H) or to 
"appropriate care w ithou t hylan G-F 20" (AC). Appropriate 
care for knee osteoarthritis w as defined by the gu idelines for 
the m edical m anagem ent of osteoarthritis proposed by the  
ACR.'* Patients in this study had sym ptom atic knee  
osteoartln itis (o f m ild to m oderate severity) and had received  
previous treatm ent w ith  analgesics. Appropriate care could
AbbreviaHons: ACR, American College of Rheumatology; W OM AC , 
W estern O ntario and  McMaster Universities osteoarthritis index
wwv/.annrheumdis.com
882 B ellam y, Bell, G o ld sm ith , et al
include treatm ent w ith  analgesics, non-steroidal anti-in flam ­
matory drugs (NSAIDs), corticosteroid injections, supportive 
m easures such as education and counselling, w eight loss, 
joint rest, application o f heat or ice, use o f  devices, physical 
therapy, arthroscopy, and total joint replacem ent. Patients 
random ised to the AC-fH group could receive m ore than one  
course o f hylan G-F 20 treatm ent in the study knee (the knee  
that w as m ost sym ptom atic or w ith  the predom inant 
m usculoskeletal problem ) if m edically warranted, and could  
receive bilateral treatm ent if  their contralateral knee was 
affected. Retreatm ent w as provided w h en  persistent pain  
recurred, w ith  a m inim um  o f  four w eeks betw een  courses o f  
hylan G-F 20. Patients w ere assessed by the clinical 
investigator at baseline and at 12 m onths. Follow up  
assessm ents w ere com pleted by telephone at m onths 1, 2, 
4, 6, 8, 10, and 12. The study protocol and inform ed consent 
form w ere approved by the relevant ethics com m ittees for the  
sites. Inform ed consent w as obtained from  each patient.
O u tc o m e  m e a s u r e s
The WOMAC Likert 3.0 is a se lf adm inistered, disease specific  
health related quality o f  life  instrum ent that asks the patients 
questions concerning the study knee. It produces one  
aggregate total score and scores for three sub scales: pain, 
stiffness, and physical functioning. A h igher score for each  
subscale corresponds to a w orse condition. The pain subscale  
includes five questions on  the degree o f pain experienced  
w ith  certain positions and activities (for exam ple, sitting or 
lying), w ith  the subscore varying from 0 to 20. The function  
subscale includes 17 questions on  the degree o f difficulty  
experienced w hile com pleting activities (for exam ple, des­
cending stairs); the sub score varies from 0 to 68. The stiffness 
subscale includes two questions on severity o f  stiffness (that 
is, after first awakening, and later in  the day), w ith  the  
sub score varying from 0 to 8. For every question in the  
WOMAC, patients rate their pain, stiffness, or function using  
five ordinal responses: none, m ild, m oderate, severe, and  
extrem e. The WOMAC w as com pleted in  the office at baseline  
and by telephone at m onths 1, 2, 4, 6, 8, 10, and 12.
T able 1 D em ographic variab les a n d  d ise a se  status at 
b a selin e
g i^ l in e  s p c c X e  ^
Age (years) 62.6 (9.4) 63.5 (10.5)
Body mass index (kg/m ) 32.1 (8.0) 32.9 (7.2)
Duration (years) of OA symptoms
9.9 (9.7)Study knee 9.0 (9.5)
Other knee 7.4 (8.8) 8.3 (9.3)
Sex: female 86 (68%) 93 (73%)
Previous treatment for OA of the knee(s)
Acetaminophen 100 (79%) 109(85%)
NSAIDs 120(94% ) 110(86%)
Previous surgery, study knee 
Previous surgery, otlier knee ,
40 (31%) 39 (30%)
40(31% ) 23 (18%)
Radiology grading witliin 1 year (central
grading*}
1 (1%)Not reported 0(0%)
G rade 0 4(3%) 4(3%)
G rade 1 17(13%) 11 (9%)
Grade II 32 (25%) 33(26%)
Grade III 49 (39%) 37 (295)
Grade tV 25 (205) 42 (33%)
OA at baseline
Otlier knee affected 109(86%) 108(84%)
Otlier joints affected 95 (75%) 87 (68%)
Values ore mean |SD) or n (%).
•Radiology grading is based on cenlrol grading, wliich may hove 
differed from the site investigator's determination for patient eligibility. 
AC, oppropriate care; AC+H, appropriate core + hylan G-F 20; NSAID, 
non-steroidal anli-indammatory drug; OA, osteoarthritis.
In the original study analysis,"  the primary effectiveness 
m easure was the m ean change in the WOMAC pain subscore 
in the study knee from baseline to m onth  12. Secondary 
effectiveness m easures included tw o definitions of a respon­
der that incorporated a m in im um  clinically important 
response level o f  at least 20%. These m easures w ere defined  
as the percentage o f patients improved by m onth  12 
(compared w ith  baseline) u sing different com binations of 
the WOMAC subscales as follows: (1) at least a 20% 
im provem ent from baseline in the WOMAC pain score in 
the study knee (WOMAC 20P); (2) at least a 20% improve­
m ent from baseline in the WOMAC pain score in the study 
knee and at least a 20% im provem ent from baseline in either 
the function score or the stiffness score (WOMAC 20PFS).
A lt e r n a t iv e  p a t ie n t  r e s p o n d e r  c r it e r ia
Alternative patient responder criteria were exam ined in this 
analysis. Recent trials in rheum atoid arthritis have used 
higher threshold levels to define a patient responder, to "raise 
the bar" and define rheum atoid arthritis im provem ents by 
m ore substantial changes in core set m easures.’ W hile the 
20% m inim um  clinically im portant response level used to 
define a patient responder in  our original study w as able to 
discrim inate betw een the AC-fH and AC treatm ent groups, we 
increased the m inim um  clinically im portant response levels 
to 50% and 70%.
These new  criteria incorporate the pain, function , and 
stiffness subscores from the WOMAC, identical to the 
original secondary effectiveness m easures. For the 50% 
m inim um  clinically im portant response level, the definitions 
were: (1) at least a 50% im provem ent from baseline in  the 
WOMAC pain score in  tire study knee (WOMAC 50P); and 
(2) at least a 50% im provem ent from baseline in the WOMAC 
pain score in the study kn ee and  at least a 50% im provem ent 
from  baseline in either the function score or the stiffness 
score (WOMAC 50PFS). Similarly, for the 70% m inim um  
clinically im portant response level, the definitions were: (1) 
at least a 70% im provem ent from  baseline in  the WOMAC 
pain score in the study knee (WOMAC 70P); and (2) at least 
a 70% im provem ent from baseline in  the WOMAC pain score 
in  the study knee and at least a 70% im provem ent from 
baseline in  either the function  score or the stiffness score 
(WOMAC 70PFS). These responder criteria can be collectively  
term ed the WOMAC 20, WOMAC 50, and WOMAC 70 
criteria.
D if f e r e n c e s  b e t w e e n  t r e a t m e n t  g r o u p s
Discrim inant validity, w h ich  has been defined as the ability 
o f a m easure to distinguish clinically im portant differences 
betw een treatm ent groups," w as evaluated using these 
responder criteria. W e hypothesised  that w h en  increasing 
the threshold for defining patient im provem ent, the number 
o f patients classified as responders in  both treatm ent groups 
w ould decrease. However, it is unclear how  this w ou ld  affect
Table 2  W O M A C  scores a t b aselin e
mèasufe'' i A C tb jn  n ' t ) A C (n= ;l27 )t
V /O M A C  pain (0 to 20)t 11.4 (2.7) 11 .9(2 .9)
WOMAC stittness (0 to Bit 5.1 (1.5) 5.1 (1.4)
WOMAC function (0 to 6 8 )t 39.5 (9.3) 40.2 (9.3)
Values are mean (SD).
•One patient in Hie AC group did not have a  baseline WOMAC 
questionnaire completed and was tlius not included in tlie analysis. 
tThe higher tlie score, the worse tlie problem.
AC, appropriate care; AC+H, appropriate care + hylan G-F 20; 
WOMAC, Western Ontario and McMaster Universities osteoarthritis 
index.
www.annrheum dis.com
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the overall treatment group differences for each patient 
improved definition.
In the original study, a 20% difference between treatment 
groups for the primary and secondary effectiveness measures 
was established a priori by the steering committee as the 
minimum clinically important difference based in part on 
previous research.'* In addition, a 20% improvement was the 
minimum clinically important improvement from baseline to 
month 12 for each patient who was classified as a responder.
S ta t is t ica l  m e th o d s
Data from the locked study database were analysed using 
SAS version 8.2. Multivariable logistic analyses were under­
taken for each of the responder criteria that incorporated 
different minimum clinically important response levels. 
Patient were classified responders if they improved according 
to the criteria outlined in the definition from baseline to 
month 12. The hypothesis tested was whether AC+H was 
superior to AC when the responder criteria were applied.
All analyses were adjusted for design variables— that is, 
baseline value of the variable being analysed, site, blocking 
by site, body mass index, and baseline WOMAC total score. 
The type 1 experiment-wise error rate was controlled for by 
distributing a over all six response levels (that is, WOMAC 
20? and 20FFS; WOMAC 50? and 50PFS; WOMAC 70? and 
70PFS) using the Bonferroni adjustment of ot/6 (a  for each 
comparison =  0.05/6 = 0.0083). The original secondary effec­
tiveness measures are provided for comparison with the 
patient improved definitions which incorporate higher 
minimum clinically important response levels.
All patients were included in the intent to treat group for 
all analyses as described earlier.'* The hot deck method was 
used to impute data for all effectiveness measures as 
described earlier.'*
RESULTS
P atients
In the trial, 128 patients were randomised to receive 
appropriate care and 127 patients to receive appropriate care 
with hylan G-F 20. In all, 24 patients dropped out of the 
study (21 in the AC group, three in the AC-KH group). One 
patient in the AC group did not have a baseline WOMAC 
questionnaire completed and thus was not included in the 
analysis. Descriptive statistics comparing demographic vari­
ables, baseline disease characteristics, and baseline outcome 
measures (that is, WOMAC pain, function, and stiffness 
subscores) are given in tables 1 and 2. Overall, treatment 
groups were similar for demographics, disease characteristics.
and osteoarthritis treatments used at baseline. However, 20% 
of patients in the AC+H group and 33% in the AC group had 
grade IV osteoarthritis, as subsequently determined by 
central radiological grading. WOMAC scores for pain, 
stiffness, and function were similar between groups.
Knee o steoarth ritis  treatm ent
All patients except one in the AC+H group had at least one 
course of hylan G-F 20 in their study knee, and 53 (42%) had 
at least one course in their contralateral knee. Forty five 
patients (38%) in the AC+H group received a second course of 
hylan G-F 20 in their study knee, and three received a third 
course in their study knee. Twenty patients (16%) in the 
AC+H group received a second course in their contralateral 
knee. More patients in the AC group than in the AC+H group 
reported corticosteroid injections in the study knee (70% v 
14%) or in the contralateral knee (27% v 6%) (both 
p<0.0001). There were also more patients in the AC group 
taking NSAlDs for any knee (79% v 65%) (p = 0.0062), and 
other drugs (20% v 10%) (for example, opioid analgesics, 
anti-inflammatory agents) for any knee (p =  0.0216). There 
were no significant differences between the groups in the use 
of concomitant drug treatment for overall osteoartluritis. 
Further details of the knee osteoarthritis treatment can be 
found in the original study results.'*
E ffectiveness
The results for the original secondary effectiveness measures 
and new responder criteria are given in table 3. They showed 
that for both the original secondary effectiveness measure 
and the alternative patient responder criteria, the percentage 
of responders was greater in the AC+H group than in the AC 
group. The treatment group differences were significant at 
the 0.0083 level (ot/6 =  0.05/6) for the 20% and 50% minimum  
clinically important response levels (adjusted using 
Bonferroni correction) and exceeded the required 20% 
difference established a priori as the minimum clinically 
important difference between treatment groups (25% to 
29%). When the minimum clinically important response level 
increased to 70%, the treatment group differences were 
approximately one half the size (that is, 11% to 12%) of the 
differences found with the 20% and 50% levels, and did not 
reach statistical significance after Bonferroni correction. 
Withiri each minimum clinically important response level, 
the treatment group differences were similar regardless of 
whether the WOMAC pain scores, or all of the WOMAC pain, 
function, and stiffness scores, were incorporated into the
Table 3 Number (%) of patient responders using WOMAC 20, 50 , and 70  minimum 
clinically important response levels
OrigincJ effectiveness measures
WOMAC 20f>t 87 (69%) 51 (40%) 29% 0.00011
WOMAC 20PfSt 7 9  (62%) 45 (35%) 27% 0.00011
Ahemafive responder criteria
WOMAC 50P 53 (42%) 20(16%) 26% <0.00011
WOMAC 50PFS 43  (34%) 12(9%) 25% < 0 0 0 0 1 $
WOMAC 70P 26(20%) 10(8%) 12% 0.0118
WOMAC 70PFS 20(16%) 6(5%) 11% 0.0100
‘One potieni in the AC group did not hove a baseline WOMAC questionnoire completed and thus was not 
included in the analysis.
tSecondary effectiveness measures from main study.
^Analysis controlled tor the type I experiment wise error rale by distributing a over all response levels using 
Bonferroni adjustment a /6  = 0 .0 5 /6  = 0  0083.
AC, appropriate core; AC+H « appropriate care + fiylon G-F 20.
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defin ition  (for exam ple, 29% for WOMAC 20P, 27% for 
WOMAC 20PFS).
The percentage o f patients classified as responders 
decreased for both treatm ent groups as response levels 
increased from  20% to 70%, and w ith the m ore stringent 
defin ition  incorporating pain, function, and stiffness w ith in  
each response level. Considering the AC+H group, w h en  
m oving from  the low er to the higher response level for pain  
only (that is, WOMAC 20P to WOMAC 70P), the percentage 
o f responders decreased from 69% to 20%. Similarly, w h en  
increasing the response levels w ith  the more stringent criteria 
incorporating pain and either function or stiffness (that is, 
WOMAC 20PFS to WOMAC 70PFS), a sim ilar decrease w as  
observed in  the AC+H group (62% to 16%). For the AC group, 
large decreases were also found w h en  response levels 
increased for the criteria incorporating only pain (40% to 
8%), and the m ore stringent criteria incorporating pain and  
either fun ction  or stiffness (35% to 5%),
W hen com paring the AC+H group and the AC group for all 
responder criteria, the results show  that the percentage o f  
responders in  the AC+H group relative to the AC group w as  
generally greater for criteria that incorporate the higher  
m inim um  clinically  im portant response levels. For exam ple, 
for the WOMAC 70PFS criterion, the percentage o f respon­
ders in  the AC+H group w as approximately three tim es the  
percentage o f  responders in the AC group (that is, 16% v 5%). 
This is in  com parison to the WOMAC 20PFS criterion w here  
the percentage o f responders in the AC+H group w as less 
than  tw ice the percentage o f responders in the AC group 
(that is, 62% V 35%). This pattern w as also observed w ith  the  
criteria incorporating pain (WOMAC 20? to WOMAC 70?).
D I S C U S S I O N
Traditional m eth ods o f carrying out betw een group com par­
isons o f clinical trials data are often based on the analysis o f 
continuous variables. These provide an appreciation o f tire 
m agnitude and  variation o f group effects but do not usually  
translate in to  an understanding o f the degree o f im prove­
m ent experienced by individual patients. In contrast, 
responder criteria, w h ile  being reductionist from  a group 
standpoint, are capable o f categorising individual patients 
according to w h eth er they achieve levels o f  im provem ent at 
or above prespecified response thresholds. Response tluesh- 
olds have generally been established a priori cither to reflect a 
clinically im portant difference at an individual level, or on  
the basis o f  differentiating m ost efficiently betw een an active 
treatm ent and a placebo control.*^ In the case o f the 
effectiveness m easures used in the original study," these  
w ere proposed during protocol developm ent at a tim e w h en  
there w as no precedent to follow , but 20% w as considered by 
the developm ent group to represent a m inim um  clinically 
im portant difference, and one that was o f the sam e order o f  
m agnitude as the previously published ACR 20  criteria* for 
rheum atoid arthritis. The OARSI responder criteria' w ere  
developed during the execution o f the protocol, and the  
OMERACT-OARSI responder criteria* were developed follow ­
ing com pletion  o f the study, but neither were available at 
study in itiation . It is o f  interest therefore that WOMAC 20  
and WOMAC 50 responder criteria, based on pain only or on  
the pain, stiffness, and function subscales, yield statistically  
detectable b etw een  group differences o f the order o f 25% to 
29%, w ith  percentage response at WOMAC 20 being slightly  
higher num erically  than at WOMAC 50. Indeed this approach 
to the analysis provides additional confirm ation o f the 
clinical and statistical superiority of adding hylan G-F 20 to 
appropriate care regim ens in the treatment o f knee osteoar- 
tlrritis. W hile differences at the highest threshold level 
(WOMAC 70) w ere not statistically detectable after 
Bonferroni correction and m ay be more difficult to attain.
an appropriately pow ered study could be capable o f detecting 
differences in patient a tta inm ent rates at even this veiy  high 
level of percentage im provem ent. This approach to dissecting  
the differential therapeutic response can be considered  
com plem entary to other responder criteria and should not 
be considered as replacing more traditional m ethods. 
W hether these obseivations can be generalised to patients 
w ith  either more or less severe sym ptom s requires further 
study.
A potential lim itation of response criteria based on 
percentage change is that the accompan^dng absolute change 
can  differ markedly. Thus a 20% improvement for a patient 
w ith  a baseline score o f 20  norm alised units (NU) (0 -1 0 0  NU 
scale) is 4  units, w hereas a 20% im provem ent for a patient 
w ith  a baseline score o f  75 NU is 15 units. Furthermore, in  a 
com parison o f outcom e m easures in  rheum atoid arthritis 
clinical trials, Anderson et aV’ noted that m easures based on 
continuous data provided better responsiveness than the ACR 
20 or disease activity score. Nevertheless, response criteria 
based on percentage change offer simplicity, som e com par­
ability w ith  OMERACT-ACR criteria for rheum atoid arthritis, 
and an opportunity to review  the number o f patients who  
attain or exceed a prespecified tlireshold. W hile the use of 
responder criteria m ay have a negative impact on  statistical 
pow er for chnical trials applications, it does provide a novel 
approach to outcom e m easurem ent which m ay facilitate the 
use o f quantitative m easurem ent procedures in clinical 
practice applications.
The results o f  this analysis provide evidence for the 
capacity o f WOMAC 20, 50, and 70 responder criteria to 
detect clinically im portant and statistically significant differ­
ences betw een tw o active treatm ent groups in a pragm atic 
random ised trial. In particular w e have observed— as judged 
by each o f the four criteria sets w ith Bonferroni correction 
and by all six criteria sets w ithout correction— that signifi­
cantly more patients in  the AC+H group achieved responder 
status than in the AC group. This approach, based on 
percentage im provem ent in  pain alone or in pain and either 
stiffness or function, allow s reviewers and consum ers to 
discern how  m any patients experienced a clinically im portant 
reduction in sym ptom  severity. Given that the analytical 
strategy is individualised, this approach m ay have hnportant 
im plications for m onitoring patients in routine clinical 
care and facilitatm g evidence based therapeutic decision  
m aking and shared goal setting in various hea lth  care 
environm ents.
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Summary
Objective: Secondary analyses of a previously conducted 1-year randomized controlled trial were performed to a ssess the application of 
responder criteria in patients with knee osteoarthritis (OA) using different sets of responder criteria developed by the Osteoarthritis Research 
Society International (OARSI) (Propositions A and B) for intra-articular drugs and Outcome Measures in Arthritis Clinical Trials 
(OMERACT)-OARSI (Proposition D).
Methods: Two hundred fifty-five pafients with knee OA were randomized to "appropriate care with hylan G-F 20" (AC+H) or “appropriate care 
without hylan G-F 20” (AC). A patient was defined as a responder at month 12 based on change in Western Ontario and McMaster 
Universities Osteoarthritis Index pain and function (0 -1 0 0  normalized scale) and patient global assessm ent of OA in the study knee (at least 
one-category improvement in very poor, poor, fair, good and very good). All propositions incorporate both minimum relative and absolute 
changes.
Results: Results demonstrated that statistically significant differences in responders between treatment groups, in favor of hylan G-F 20, were 
detected for Proposition A (AC + H =  53.5%, AC =  25.2%), Proposition B (AC +  H =  66.7%, AC =  32.3%) and Proposition D 
(AC +  H =  66.9%, AC =  42.5%). The highest effectiveness in both treatment groups was observed with Proposition D, whereas Proposition 
A resulted in the lowest effectiveness in both treatment groups. The treatment group differences always exceeded the required 20% minimum 
clinically important difference between groups established a priori, and were 28,3%, 24.4% and 24.4% for Propositions A, B and D, 
respectively.
Conclusion: This analysis provides evidence for the capacity of OARSI and OMERACT-OARSI responder criteria to detect clinically 
important statistically detectable differences between treatment groups.
© 2004 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
Key words: Effectiveness, Hylan G-F 20, Osteoarthritis, Randomized controlled trial, Responder criteria.
Abbreviations: AC, Appropriate care without hylan G-F 20; AC +  H, Appropriate care with hylan G-F 20; ACR, American College of 
Rheumatology; NSAIDs, Nonsteroidal anti-inflammatory drugs; NU, Normalized units; OA, Osteoarthritis; OARSI, Osteoarthritis Research 
Society International; OMERACT, Outcome Measures in Arthritis Clinical Trials; SD, Standard deviation; WOMAC, Western Ontario and 
McMaster Universities Osteoarthritis Index
Introduction
Several different approaches to developing a definition for a “responder” have been proposed for osteoarthritis (OA)
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clinical studies^"®. A conceptual approach to generally 
categorizing various types of clinical difference has been advanced by Beaton and colleagues®. A systematic approach, based on the statistical analysis of data from several previously completed placebo-controlled clinical 
trials and multistakeholder consensus, has been conducted 
by a working group of the Osteoarthritis Research Society 
International (OARSI), and resulted in the formulation of OARSI responder criteria A and B^ . The original criteria 
were different for different joints and classes of interven­tions, Proposition A placing priority on high levels of pain 
relief, while Proposition B permitted high relief In pain or
104
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better function. Subsequently, the Outcome Measures in 
Arthritis Clinical Trials (OMERACT)—OARSI collaborative 
exercise evaluated six scenarios and developed agreement around Proposition D as a simplified set of responder criteria applicable to different joints and types of interven­tions®. In each of the aforementioned criteria sets, patients 
are categorized as responders based on a combination of absolute and percentage change on one or more OARSI 
core set clinical measures of pain, physical function and patient global assessment®'^®. To assess the application of responder criteria in OA patients, we have performed secondary analyses of a previously published clinical 
study^’^  ^ to evaluate the capacity of responder criteria to 
detect between-treatment differences in a randomized clinical trial. In particular, we have compared the results of analyses based on OARSI Proposition A, OARSI Proposi­
tion B and OMERACT-OARSI Proposition D to ascertain whether the application of different criteria influences data interpretation.
Methods
DESIGN
The analyses reported here were performed using the data collected in a health outcomes trial evaluating viscosupplementation with hylan G-F 20 when added to an appropriate care treatment paradigm for patients with knee OA. The detailed design of this trial and the primary 
analyses of the data have been published elsewhere . 
Briefly, the trial was a multicenter, randomized, controlled, 
open-label study of 1 -year duration, where patients were randomized to either "appropriate care with hylan G-F 20” (AC+H) or “appropriate care without hylan G-F 20" (AC). Appropriate care for knee OA was defined by the Guide­lines for the Medical Management of Osteoarthritis of the Knee proposed by the American College of Rheumatology 
(ACR)^ .^ Patients in this study had symptomatic knee OA 
(mild to moderate severity) and had received prior treatment with analgesics. Appropriate care could include medications such as analgesics, nonsteroidal anti-inflammatory drugs 
(NSAIDs), corticosteroid injections, supportive measures 
such as education and counseling, weight loss, joint rest, application of heat or ice, and use of devices, physical therapy, arthroscopy, and total joint replacement. Patients randomized to the AC+H group could receive more than 
one course of hylan G-F 20 treatment in the study knee (knee most symptomatic or with the most predominant 
musculoskeletal problem) if medically warranted, and could receive bilateral treatment If their contralateral knee was 
affected. Re-treatment was provided when persistent pain recurred, with a minimum of 4 weeks between courses of 
hylan G-F 20. The protocol did not allow hylan G-F 20 treatment for OA in joints other than the kiiee. Patients were 
assessed by the clinical investigator at baseline and 12 months. Follow-up assessments were completed by tele­
phone at months 1, 2, 4, 6, 8, 10 and 12.
OUTCOME MEASURES
The Western Ontario and McMaster Universities (WO­MAC) Osteoarthritis Index Likert 3.0 Is a self-administered, disease-specific health-related quality of life instrument that 
asks the patients questions concerning the study knee. It produces one aggregate total score (minimum; 0; maxi­
mum: 30) and scores for three subscales; pain, stiffness.
and physical functioning. A greater score for each subscale corresponds to a worsening condition. The pain subscale 
includes five questions regarding the degree of pain experi­enced with certain positions and activities (e.g., sitting or 
lying), with a pain sub-score varying from 0 to 20. The function subscale Includes 17 questions regarding the 
degree of difficulty experienced while completing activities (e.g., descending stairs). The function sub-score varies from 0 to 68. The stiffness subscale Includes two questions on severity of stiffness (I.e., after first awakening, and later in the day) with a sub-score varying from 0 to 8. For every question in the WOMAC, patients rate their pain, stiffness, and function using five ordinal responses; none, mild, moderate, severe, and extreme.Patient global assessments were also measured. The questions that were completed by the patient were de­
veloped specifically for the original study, as no standard­
ized questions were available . Patients were asked; “how has the osteoarthritis in your study knee been during the 
past 4 weeks?” This question was also asked for OA in all affected joints, and for overall health. Patients answered these questions using five ordinal responses; very good, good, fair, poor and very poor. The WOMAC and the patient 
global assessments were completed in the office at baseline and by telephone at follow-up assessments.
In the original study analysis^ the primary measure of effectiveness was the mean change in the WOMAC pain sub-score in the study knee from baseline. Secondary effectiveness measures were the percentage of patients improved at termination (compared to baseline) using different combinations of the WOMAC subscales to define 
an improved patient as foilows; (1) at ieast 20% improve­ment from baseline in the WOMAC pain score in the study 
knee; and (2) at least 20% improvement from baseline in the WOMAC pain score in the study knee and at least 20% improvement from baseline in either function score or stiffness score. The next section describes alternative 
response criteria that were developed to provide a more thorough characterization of who in general improves with OA^ '®.
OARSI AND OMERACT RESPONSE CRITERIA
Alternative effectiveness measures were examined in this study. These measures were the percentage of patients improved at termination (month 12) compared to baseline using the three new responder criteria. Two of these criteria 
were developed by the OARSI (Propositions A and B) specifically to the treatment of knee OA with intra-articular 
drugs’'. The third was developed by the OMERACT—OAR- Sf® task force and is a simplified set of criteria (Proposition D) 
that is independent of drug and localization of OA (see Figs, 1—3). According to all propositions, a patient Is defined as 
a responder, if either a'high' response in pain (Proposition A) 
or a high response in pain or function (Propositions B and D) or a ‘moderate’ response in at least two domains (of pain, function, global assessment) is achieved.
The following measures from our study were used to 
generate inputs for determining fulfillment of the criteria, as outlined in Figs. 1-3. Pain and function were measured by the WOMAC pain and function subscales, at month 12 and 
compared to baseline. The pain and function subscales of 
the WOMAC were converted to a 0-100 normalized units (NU) scale to correspond with the specific criteria outlined in 
Propositions A, B and D. Patient global assessment of OA in the study knee was measured using five ordinal 
responses; very good, good, fair, poor, and very poor.
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High Improvement in pain > 40%  and absolute change > 30 NU
Responder
A C+H =47/I27=37.0%  
AC=21/127=16.5%
yNo A C+H =80/127=63,0% 
AC=106/127=83.5%
M odera te  Improvement, in at least 2 o f the following
• Pain > 35 % and absolute change > 15  NU (AC+H=20/80=25.0% , A C=9/I06=8.5% )
•  Function > 35%  and absolute change > 10 NU (A C+H =22/80=27.5% ,AC=I4/106=13.2% )
■ Global assessment" > 30%  and absolute change > 10 NU (A C+H =39/80=48.8% , AC=47/106=44.3%o)
Yes
T
V
Responder
VA C+II=21/I27=16.5%  No 
A C = 11/127=8.7%
All R esponders 
(Proposition A) AC+n=6S/127=53.5%  AC=32/127=25.2%
4
N on-responders
AC +II=59/127=46.5%  
AC=95/127=74.8%
♦Moderate improvement in global assessment in tlicsc results was considered as at least a onc-categoiy, shift 
(improvement) on a 5 point ordinal response scale (i.e. very poor, poor, fair, good and very good);
**Proposition A criteria for kiicc intra-articular specific drug;
NU = Normalized Units;
AC+H = Appropriate Care + Hylan G-P 20;
A C  = Appropriate Caro,
Fig. 1. Percentage of patients fulfilling specific criteria and overall response criteria for Proposition
The problem with such a scale is that calculating 
a percentage change (e.g., at least 30%) or absolute 
change (e.g., at least 10 NU on a 0—100 scale) in the spirit of the propositions is not meaningful since the global scale is discrete with only five categories. The proposition criteria are suited more towards continuous scales, or scales that 
are approximately continuous (e.g., WOMAC). Normalizing the global assessment scale to 100 NU resulted In a 
one-category improvement shift being equivalent to 25 NU, thus never allowing the proposition criteria to be exactly fulfilled (i.e., absolute change of 10 NU required for
all propositions). Thus, given the ordinal nature of the patient global assessment scale, ‘moderate Improvement’ 
was not defined according to the proposition criteria; rather it was operationally defined as at least a one-category Improvement shift in response (e.g., good to very good).
Based on previous research^ , a 20% difference between 
treatment groups for the original measures of effectiveness was established a priori by the steering committee and 
investigators as the minimum clinically important difference. This difference was applied to the new OARSI responder criteria effectiveness measures.
H igh Improveinent in pain (> 50%  and absolute change> 30 NU) OR function 
(> 60%  and absolute change> 20 NU)
Yes 1
Responder
A C+H=50/127=39.4%
AC=18/127=14.2%
V
No A C+H =77/127=60.6% 
j A C=109/127=85.8%V
M oderate  Improvement in at least 2 of tlie following
•  Pain > 20%  and absolute change > 20 NU (AC+H =24/77=31.2% , AC=19/109=17.4% )
• Function > 30% and absolute change > 10 NU (AC+H =26/77=33.8% , A C=21/109=19.3% )
■ Global assessment* > 30%  and absolute change > 10 NU (A C+H =35/77=45.4% , A C=47/109=43.1% )
Yes
T
V
Responder
AC+H=22/127=17.3%
AC=23/127=18.1%
V■ No
All R esponders 
(Proposition B)
N on-responders
AC+H=55/127=43.3%
AC=36/127=67.7%
AC+II=72/127=56.7%  
A C = 41/127=32.3%
♦Moderate improvement in global assessment in those results was considered as at least a ono-dlrectional category shift 
(improvement) on a 5 point ordinal response scale (i.e. very poor, poor, fair, good and very good).
♦♦Proposition B criteria for knee intra-articular specific drug.
NU = Nonnalized Units;
AC+H = Appropriate Caie + Hylan G-P 20;
A C  = Appropriate Care.
Fig. 2. Percentage of patients fulfilling specific criteria and overall response criteria for Proposition B*
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H igh Improvement in pain or in function > 50% and absolute change > 20 NU
Responder
AC+H=58/127=45.7%
A C=23/127=18.1%
A C+H=69/127=54.3% 
A C =104/I27=8I.9%
M o d era te  Improvement in at ieast 2 of tire following
•  Pain >  20%  and absolute change > 10 NU (AC+H=29/69=42.0% , AC=29/104=27.9%)
•  Function > 20% and absolute change > 10 NU (AC+H=30/69=43.5% ,AC=28/104=26.9% )
•  Global assessincnt"> 20%  and absolute change > 10 NU (A C+H =29/69=42 ,0% , A C=44/I04=42.3% )
AC+H =27/127=21.3% 
AC=31/127=24.4%
VNo
All Responders 
(Proposition D) AC+H=85/127=<;6.9%AC=54/127=42,5%
Non-responders
AC+II=42/127=33.I% AC=73/127=57.5%
♦Moderate improvement in global assessment in tliese results was considered as at least a one-category shift 
(improvement) on a 5-point ordinal response scale (i.e. very poor, poor, fair, good and very good).
NU = Normalized Units;
AC+H = Appropriate Care +  Hylan G-F 20;
A C = Appropriate Care.
Fig. 3. Percentage of patients fulfilling specific criteria and overall response criteria for Proposition D.
STATISTICAL METHODS
Data from the locked study database were analyzed using SAS version 8.2. A logistic analysis was performed using the new OARSI responder criteria defined above (Proposi­
tions A, B, and D) with treatment group. A patient was classified as a “responder" if the patient Improved according 
to the criteria outlined in the proposition from baseline to month 12. The hypotheses to be tested were whether AC+H was superior to AC when each of the new OARSI responder criteria were applied, and if treatment group 
differences were significantly different from each other.All analyses were adjusted for design variables (i.e., 
baseline value of the variable being analyzed, site, blocking 
by site, body mass index, and baseline WOMAC total score). The type 1 experiment-wise error rate was controlled for by distributing alpha over all three compar­
isons (i.e., Propositions A, B, and D) using the Bonferroni adjustment of alpha/3 (alpha for each comparison = 0.05/ 3 = 0.0166). The original secondary effectiveness measure (i.e., percentage of patients with at least 20% improvement in the study knee at termination since baseline) was analyzed using a logistic analysis that controlled for the 
above-mentioned design variables. In this analysis, the type 
1 experiment-wise error rate was not adjusted as there was 
one secondary effectiveness measure. The results of the original secondary analysis are provided for comparison to 
the new OARSI responder criteria.Ail patients were included in the intent-to-treat group for all analyses as described earlierk The hot deck method 
was used to impute data for all effectiveness measures as 
described earlierk
Results
PATIENTS
In the trial, 128 patients were randomized to receive appropriate care and 127 patients were randomized to 
receive appropriate care with hylan G-F 20. A total of 24 patients dropped out of the study (21 in the AC group, 3 in 
the AC+H group). One patient in the AC group did not have
a baseline WOMAC questionnaire completed and was thus not included in the analysis. Descriptive statistics comparing 
demographics, baseline disease characteristics and base­line outcome measures (i.e., WOMAC, global assessment) are provided in Tables I and II. Overall, treatment groups 
were similar with respect to demographics, disease charac­
teristics, and OA therapies used at baseline. However, 20% of patients in the AC + H group and 33% of patients in the AC group had grade IV OA, as subsequently determined by central radiologic grading. In addition, 18% of patients in the 
AC+H group and 30% of patients in the AC group had a ‘very poor’ global assessment of OA in the study knee, at 
baseline. Overall WOMAC scores for pain, stiffness and function were similar between groups.
KNEE OA TREATMENT
All patients except one in the AC + H group had at least one course of hylan G-F 20 in their study knee, and 53 (42%) had at least one course in their contralateral knee. Forty-five patients (38%) in the AC+H group received 
a second course of hylan G-F 20 in their study knee, and three received a third course in their study knee. Twenty 
patients (16%) in the AC+H group received a second course In their contralateral knee. There were more patients 
in the AC vs the AC+H group who reported corticosteroid injection(s) in the study knee (89 vs 18) or the other knee 
(35 vs 8) (both P <  0.0001). There were also more patients in the AC group taking NSAIDs for any knee (101 vs 82) 
(P = 0.0062), and other medications (25 vs 13) (P =0.0216) (e.g., opioid analgesics, anti-inflammatories) for 
any knee. There was no significant difference between the groups in the utilization of concomitant medications for 
overall OA. Further details of knee OA treatment can be found in the original study results^
EFFECTIVENESS
The overall results for the original secondary effective­ness measures and the new OARSI responder criteria measures are provided in Table III. Figures 1—3 provide
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Table I
Demographics and disease status a i baseline
Baseline measure AC +  H, 77 =  127 AC, 7 7 =  128
Mean (SD) Mean (SD)
Age (years) 62,6 (9.4) 63.5 (10.5)
Body mass index (kg/m^) 32.1 (8.0) 32.9 (7.2)
Duration (years) of OA symptoms
Study knee 9.0 (9.5) 9.9 (9.7)
Other knee 7.4 (8.8) 8.3 (9.3)
n (%) 77 ( % )
Sex: female 86 (68) 93 (73)
Previous therapy for OA of the knee(s)
Acetaminophen 100 (79) 109 (85)
NSAIDs 120 (94) 110 (86)
Prior surgery, study knee 40 (31) 39 (30)
Prior surgery, other knee 40 (31) 23 (18)
Radiology grading within 1 year (central grading*)
Not reported 0 (0 ) 1 (1)Grade 0 4 (3 ) 4 (3 )
Grade 1 17(13) 11 (9)
Grade II 32 (25) 33 (26)
Grade III 49 (39) 37 (29)
Grade IV 25 (20) 42 (33)
OA at baseline
Other knee affected 109 (86) 108 (84)
Other joints affected 95 (75) 87 (68)
‘Radiology grading is based on centrai grading, which may have 
differed from the site investigator’s determination for patient 
eligibility.
more detail by describing the specific percentage of patients fulfilling the separate criteria within Propositions A, B, and 
D. The results show that for all definitions of improvement, the percentage of responders was greater in the AC + H 
group vs the AC group. Also, the differences were 
statistically significant at the 0.0166 level {cc/3 — 0.05/3) for all definitions of patient improved (adjusted using the Bonferroni correction) (Table III). The Incremental difference between treatment groups always exceeded the required 20% difference established a priori as the minimum clinically important difference between groups. The magni­tude of the. treatment differences was similar across all 
definitions of improvement, varying from 24.4% (Proposi­tions B and D) to 28.3% (Proposition A, and ‘20% improvement In pain' criteria).
Table II
W OMAC and patient global assessment a t baseline
Baseline measure AC +  H, 77 =  127 AG, 77 =  128
Mean (SD) Mean (SD)
VyOMAC pain (0 -2 0 ) 11.4 (2.7) 11.9 (2.9)
VyOMAC stiffness (0-8)* 5.1 (1.5) 5.1 (1.4)
WOMAC function (0-68)* 39.5 (9.3) 40.2 (9.3)
Patient global assessm ent of n (%) n (%)
OA in study knee __________________________________
Not reported 0 (0) 1 (1)
Very good 0 (0) 0 (0)
Good 2 (2) 1 (1)
Fair 44 (35) 31 (24)
Poor 58 (46) 57 (45)
Very poor 23 (18) 38 (30)
‘The higher the score, the worse the problem. One patient in the 
AC group did not have a WOMAC questionnaire completed at 
baseline and was thus not included in the analysis.
When comparing the new OARSI responder criteria, the highest effectiveness in both treatment groups was ob­
served with Proposition D (66.9% vs 42.5%). Conversely, Proposition A resulted in the lowest effectiveness in both 
treatment groups (53.5% vs 25.2%). The difference between treatment groups was similar for all propositions 
(24.4%-28.3%) and was generally similar for the original secondary measures of effectiveness.
Figures 1-3 describe the percentage of patients fulfilling the specific criteria in each of Propositions A, B, and D. in the 
AC + H group, two thirds of the patients fulfilled the criteria of a ‘responder’ by having a ‘high’ improvement in pain (Proposition A) or ‘high’ improvement in pain or function (Propositions B and D). For example, for Proposition D, 
45.7% of the AC+H group were considered responders since they had a ‘high’ improvement response in pain or function, where the overall percentage of responders was 66.9% (i.e., 45.7%/66.9% =  68.3% or two thirds). For the patients in the AC group, two thirds of patients (i.e., 16.5%/ 25.2% = 65.5% or two thirds) In Proposition A fulfilled the 
criteria of responder by having a 'high' improvement in pain, however, less than half of patients in Propositions B and D fulfilled the criteria of responder by having had ‘high' Improvement in pain or function.As the cut-off criteria for ‘moderate’ improvement 
domains (pain, function, global assessment) become more stringent moving from Propositions D to B to A, the 
percentage of responders (i.e., by moderate improvement only) in both treatment groups decreases (AC+H: 21.3%, 
17.3%, 16.5%: AC: 24.4%, 18.1%. 8.7%, respectively). The results also show that for Propositions A and B, the greatest 
percentage of patients fulfilling ‘moderate’ improvement criteria are numerically with the global assessment domain 
(AC + H; 48.8%, 45.4%; AC; 44.3%, 43.1%, respectively). For Proposition D, the percentage of patients fulfilling ‘moderate’ improvement criteria was similar across the domains of pain and function and global assessment for 
the AC+H group, but was higher for global assessment for the AC group.
Discussion
Traditional methods of performing between-group com­
parisons of clinical trials data are frequently based on the 
analysis of continuous variables. These provide an appre­ciation of the magnitude and variation in group effects, but 
do not permit reviewers an understanding of the degree of Improvement experienced by individual patients. In contrast, 
responder criteria, while being reductionist from a group 
standpoint, are capable of categorizing individual patients according to whether they achieve levels of improvement at or above pre-specified response thresholds. These thresh­
olds have been established a priori either to reflect a clinically important difference at an individual level, or on 
the basis of differentiating most efficiently between an active treatment and a placebo control. In the case of the 
effectiveness measures used in the original study\ they 
were proposed during protocol development at a time when there was no precedent to follow, but 20% was considered, by the development group, to represent a minimum clinically 
important difference. This difference was one that was of the 
same order of magnitude as previously published ACR 20 criteria^ ® for rheumatoid arthritis clinical trials. The OARSI 
responder criteria'' were developed during the execution of the protocol, and the OMERACT-OARSI responder crite­
ria® were developed following completion of the study. It is
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Table III
Summary of response criteria: improvement from baseline to month 12
Criteria Treatment group Difference
AC +  H, 77 =  127 
n (%)
AC*, 77 =  127 
n (%)
[(AC+H )-(AC)] 
(%)
P-value
Original effectiveness measures
>  20% improvement in painf
>  20% improvement in pain and either
>  20% improvement in function or stiffnessf
87 (68.5) 
79 (62.2)
51 (40.2) 
45 (35.4)
28.3
26.8
0.0001
0.0001
New OARSI response criteria 
Proposition A (OARS!)
Proposition B (OARSI)
Proposition D (OMERACT-OARSI)
68  (53.5) 
72 (56.7) 
85 (66.9)
32 (25.2) 
41 (32.3) 
54 (42.5)
28.3
24.4
24.4
<0.0001
0.0002
0.0002
'One patient in the AC group did not have a WOMAC questionnaire completed at baseline and w as thus not included in the analysis. 
^Secondary effectiveness measures from main study.
of interest therefore that these different approaches, separated in time and concept, ail yield comparable, statistically detectable between-group differences, in favor 
of AC + H, of 24.4%-28.3%.It is worthy of note that different criteria, while yielding very similar between-group differences (24.4%-28.3%) (Table III), specify quite different percentages of both 
AC+H (53.5%-68.5%) and AC alone (25.2%-42.5%) patients as responders. For this reason, the criteria should not be considered interchangeable, but rather complemen­
tary. The OARSl-OMERACT Proposition D, and the 
WOMAC 20% improvement in pain response criteria, yield very similar by-group percentage response rates and 
similar between-group differences in this study. The generalizabiiity of this observation will require further study. 
This similarity in results may be explained by the re­quirement for those not fulfilling the primary requirement in 
Proposition D, of alternatively experiencing an improvement 
of 20% or greater in pain, function or global assessment. In contrast. Propositions A and B require secondary improve­ments of 30% (Proposition A) or 20% or greater, re­spectively (Proposition B). Thus, the similarity between the 
lowest threshold for pain on Proposition D and WOMAC 
20% improvement in pain criteria are similar In percentage terms, and may explain the comparable yields. However, 
since there is no absolute change required for the WOMAC 20% improvement in pain criteria, whereas in Proposition D 
an improvement of at least 10 NU is required, the two approaches may yield different results with differing re­
sponse distributions, and may therefore differ from study to 
study.Furthermore, the patients in this study had mean baseline scores in or about the midpoint on all three WOMAC 
subscales. Whether these observations can be generalized 
to patients with either more or less severe symptoms will require further study. The pattern of improvement In patient global assessment Is different from that In pain and function. For Propositions A and B. the percentage of responders for moderate improvement in global assessment is greater 
than the percentage of responders for moderate improve­
ment in pain or function (Figs. 1, 2). Hoeksma e ta l . have observed that fewer patients with hip OA were classified as improved with OARSI response criteria as compared to patient’s giobal assessment. This suggested to the inves­tigators that the OARSI response criteria provided a “more 
objective reflection of the actual clinical status of patients 
with OA of the hip". Taken collectively, these observations 
suggest that the wording and scaling of the patient global
assessment question might require further consideration for application in studies employing responder analyses.The results of this analysis provide evidence for the capacity of responder criteria to detect clinically important statistically detectable differences between two active treatment groups in a randomized clinical trial. These observations support those of other investigators who have 
reported their experience on the responsiveness of the OARSI responder c r i t e r i a ^ I n  particular, this approach 
allows reviewers and consumers to discern how many patients experienced a clinically important reduction in the 
severity of their symptoms. Given that the analytic strategy is individualized, this approach may have important implications for monitoring patients in routine clinical care and facilitating evidence-based therapeutic decision mak­
ing, and shared goal setting, in various health care environments.
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Background: In clinical trials, a t the group level, results are  usually reported as m ean an d  standard  
deviation o f the ch a n g e  in score , w hich is not meaningful for m ost readers.
O bjective: To determ ine the m inim al clinically important im provem ent (MCll) o f pain, patient's g lob a l 
assessm ent o f d isea se  activity, an d  functional impairment in patients with knee and hip osteoarthritis (O A ). 
M ethods: A  prospective mufticentre 4 w eek  cohort study involving 1 3 6 2  outpatients with knee or hip O A  
w a s carried out. D ata on  a ssessm en t o f  pain and patient's g lo b a l assessm ent, m easured on  visual 
a n a logu e scales, an d  functional im pairm ent, m easured on  the W estern  O ntario M cM aster Universities 
Osteoarthritis Index (W O M A C ) function subscale, w ere collected  at baseline and final visits.* Patients 
a ssessed  their response to treatment on a  five point Likert sca le  at the final visit. An anchoring m etfiod  
b ased  on the patient's op in ion  w a s used. The MCI! w as estim ated in a  subgroup of 8 1 4  patients (6 0 3  with  
knee O A , 211 with hip O A ).
Results: For knee and hip O A , MCI! for absolute (and relative) ch a n g es  w ere, respectively, (a) — 1 9 .9  mm  
(—40.8% ) and —1 5 .3  mm ( —32.0% ) for pain; (b) - 1 8 , 3  mm (-39 .0% ) and - 1 5 . 2  mm ( — 32.6% ) for 
patient's global assessm ent; (c) —9.1 ( — 26.0% ) and —7 .9  ( -2 1 .1 % )  for W O M AC function su b sca le  
score. The MCI! is affected  by the initial d egree  of severity o f  the symptoms but not by a g e , d ise a se  
duration, or sex.
Conclusion: Using criteria such as MCll in clinical trials w ou ld  provide meaningful information w hich  
would help in interpreting the results b y  expressing them as a  proportion of improved patients.
The choice o f an  outcom e m easure is a major step in the  design o f clinical trials. In evaluating the sym ptom atic  severity o f osteoarthritis (OA) of the low er lim bs, 
scientific groups such as the OMERACT (O utcom e  
M easures in Rheum atology Group),' GREES (Group for the  
Respect o f  Ethics and Excellence in Science),^ and OARSI 
(OsteoArthritis Research Society International)’ have raised  
the im portance o f evaluating at least three dim ensions: pain, 
patient's global assessm ent o f disease status, and functional 
im pairm ent. At the individual level, determ ining the m inim al 
m eaningful change in a score by use o f a structured  
instrum ent is a challenge. Are changes in self reported levels 
of pain o f 10 m m  on  a 0 -100  m m  visual analogue scale 
(VAS) clinically im portant? Does the change reflect m ea n ­
ingful im provem ent for the patient? The concept o f  the 
m inim al clinically important difference (MCID)*"* could help  
in interpreting changes in scores at the individual level. 
However, the MCID, w hich can reflect either an im provem ent 
or a w orsening, has not been used here, because in clinical 
trials w e are always interested in im provem ent and not 
worsening. Furthermore, it has been show n that the MCID 
could be different for improvement and w orsen ing,’’ The 
m inim al clinically important improvement (MCII), defined  
as the sm allest change in m easurem ent that signifies an 
important im provem ent in a patient's sym ptom , seem s more 
appropriate and, in clinical trials, provides readers w ith  
additional inform ation on the effect size by expressing the  
results more m eaningfully (that is, as a percentage o f  
improved patients).
This p rosp ective cohort study aim ed  at e s tim a tin g  the  M C ll 
from  the p atien t's perspective for three m ain  p atien t reported
outcom es used in OA trials: pain, patient's global assessm ent  
o f  disease activity, and functional impairment.
M ATERIALS A N D  M E T H O D S  
S lu d y  d e s ig n
We conducted a prospective 4  week cohort study.
S tu d y  p o p u la t io n
Tlris study involved 1362 outpatients w ith knee or Irip OA, as 
defined by the Am erican College of Rlieum alology,* ” 
included by 399 rheum atologists. Each rheum atologist had  
to recruit four patients, t ln ee  w ith knee OA and one w ith  hip  
OA. To be included in the study, patients had to experience  
pain from OA (S=30 m m  on a VAS varying from 0 to 100), 
require treatm ent w ith  a non-steroidal anti-inflam m atory  
drug (NSAID), and be able to complete questionnaires in  
French. Inclusion could begin w ith the onset o f  treatm ent or 
a sw itch from one NSAID to another. Patients were excluded  
if  they had a prosthesis on  the assessed joint or if  they had  
been given an intra-articular injection in the 4 w eeks before 
the study began. All patients initially visited the rheum atol­
ogist in charge o f their case, and an NSAID w as prescribed 
(the drug and its dosage w as chosen by the physician). A 
final visit to the sam e rheum atologist was scheduled 4 w eeks  
later.
Abbreviations: MCID, minimal clinically important difference; MCll, 
minimal clinically important improvement; NSAID, non-steroidal anti­
inflammatory drug; OA , osteoarthritis; VAS, visual analogue scale; 
WOMAC , W estern O ntario McMaster Universities Osteoarthritis Index
w ww.annrheum dis.com
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Figure 1 As peek of ilie cumulative distribution function used to 
determine tfie MCI! (changes in pain score in patients with knee OA; 
n = 265). Among patients considering their response to treatment as 
good on o  five point Likert scale, 75% experienced a decrease in pain 
between baseline and final visit of > 1 9 .9  mm on a  0 -1 0 0  mm VAS 
(a change between - 1 0 0  mm and —19.9 mm).
M e a s u r e m e n ts
A t th e  b a se lin e  v isit, d em ograp h ic and  d isea se  data w ere  
co llec ted . P atien ts a ssessed  their OA sta tu s at b a se lin e  an d  
f in a l v is it . They a ssessed  th e  fo llo w in g  p a tien t reported  
o u tc o m es; (a) pain  on  m o v em en t during the 4 8  hours b efore  
th e  v isit , m easu red  o n  a 0 -1 0 0  m m  VAS; (&) g lo b a l 
a ss e s sm e n t o f  d isea se  activity m easu red  o n  a 0 -1 0 0  m m  
VAS; a n d  (c) ph ysica l fu n ctio n , m easu red  on  th e  W estern  
O ntario  M cM aster U n iversities O steoarthritis In d ex  
(W O M A C ) fun ctio n  su b sca le  (17  item s, five p o in t Likert 
sca le  for each  item ; Iiigh scores in d ica te  h ig h  d egree  o f  
fu n ctio n a l im pairm ent; total score n orm alised  to a 0 -1 0 0  
score).
At th e  fina l visit, a ran d om  sam p le o f  tw o  thirds o f  th e  
p a tie n ts  (n  =  923) a ssessed  their resp onse  to N SA ID
treatm ent on  a five p o in t Likert scale (n o n e  =  n o  good  at 
all, in effective  drug; poor =  som e effect but unsatisfactory-  
fair =  reason ab le e ffe c t  but could be better; g o o d  =  sa tisfa c­
tory' effect w ith  o cca sio n a l ep isodes o f  pa in  or stiffness- 
ex cellen t =  ideal resp o n se , virtually pain free). T he other  
third o f  the p atien ts a ssessed  their response to trea tm en t on a 
15 poin t Likert sca le  (from  - 7 ,  a very great d ea l w orse , to +7 
a very great deal better, w ith  0, no ch an ge).
S ta t is t ic a l  a n a l y s i s
A ll the an alyses con sid ered  patients w ith  k n ee  an d  h ip  OA 
separately.
The MCII w as d eterm in ed  in  a subgroup o f  8 1 4  patients  
(603 w ith  k n ee and  211 w ith  hip OA) w h o se  a sse ssm e n t of 
resp onse  to trea tm en t w a s m easured  o n  a five p o in t Likert 
sca le  and w h o  had  co m p leted  the final v isit.
A n an ch orin g  m eth o d  based  on  the p atien t's a sse ssm e n t o f  
resp onse  to treatm en t w a s used.
The MCII w a s e s tim a te d  for both th e  a b so lu te  (final 
v a lu e -b a s e lin e  v a lu e) an d  the relative { (fin a l v a lu e -b a s e l in e  
v a lu e)/b a se lin e  v a lu e) ch an ges in  each  p a tie n t reported  
o u tcom e. It w a s e s tim a te d  by con stru ctin g  a curve o f  
cu m u la tive  p ercen tages o f  patients as a fu n c tio n  o f  the  
ch a n g e  in score (for ex a m p le , d ifference in  p a in  score) a m on g  
p atien ts w h o se  fin a l ev a lu ation  o f  resp onse  to trea tm en t w as  
"good , satisfactory  e ffect w ith  occasional ep iso d es o f  pa in  or 
stiffn ess" , b ecau se  w e  w an ted  to focus on  th e  im p rovem en t  
that w as c lin ica lly  im portan t. L ogistic reg ress ion  w a s  u sed  to  
m o d e l the observation s (fig  I ). W e targeted th e  p o in t at the  
fla tten in g  o f  th e  curve at w h ich  m ost subjects sta ted  they had  
im proved. To d eterm in e  th e  change in  score corresp on d ing  to 
this poin t, w e  first lo o k ed  at the tw o param eter lo g ist ic  m odel 
that best fitted  th e  data . T hen  w e determ in ed  th e  square root 
o f  the third derivative o f  this lo g istic  fu n c tio n  that 
corresponded w ith  th e  M CII. One can  d em o n stra te  that th is : 
p o in t corresponds by con stru ction  to the 7 8 .9 th  cen tile  o f the 
ch an ge in  score, an d  th u s w e  propose to d e f in e  th e  MCII as 
the  75th  cen tile  o f  th e  ch an g e  in  score, b ecau se  it is very close  
to the poin t d efin ed  ab ove and easier to derive. T he m odel 
perm itted  us, firstly, to  d eterm in e that th e  target p o in t w as
Table 1 Baseline characlerislics o f patients
Tv. '
' OA (nx60,3)
J # " ; ■ m . ■. ■
Age (years) 67.9 10.2 64.6 10.2
Weight (kg) 75.5 13.8 71.3 12.3
Height (cm) 163.8 8.5 164,7 8.4
Body mass index (kg/m^) 28.1 4.8 26.2 3.8
Disease duration (years) 4.7 5.8 3.3 4.6
Pain score (0-100 mm YAS)
Week 0 59.3 16.2 56.7 16.5
Change (week 0-we$ik 4) -2 4 .9 21.5 -2 0 .0 21.7
Patient glolxal assessment (0-100 trim VAS),
Week 0 59.6 18.3 58.0 19.3
Change (week 0-week 4) -2 4 .7 24.0 -2 0 .6 23,2
WOMAC function score (0-100)
WeekO 42.8 16.1 44.4 16.5
Change (week 0-week 4) -1 1 .6 13.9 -1 0 .4 13.6
No % No %
Female sex 421 69.8 133 63.0
Kellgren & Lawrence grade 15.7It 108 17.9 33
III 268 44.4 1)1 52.9
tv 227 37.7 66 31.4
NSAID* intake during past 4 weeks 178 29.7 69 32.7
Analgesic IreotmenC* 344 57.2 14.1 67.1
Symploniatic slo-w-acting drug intake*” 209 34.8 90 42.9
*Non-sieroida! onfi-indammalory drugs (before Hie stort of llie study); Tolber llian NSAIDs (before lire start of tbe 
study); jrchondroitin sulphate, diacerbein, or avocado/soybeon unsaponifiabies.
Pat ient  r e p o r t e d  o u t c o m e s  in k n e e  a n d  h i p  O A 31
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Figure 2 Patients' assessm ent of tfieir response to treatment.
correctly approached by the 75th centile and, secondly, to 
estimate the 95% confidence intervals.
In a second step, w e stratified the analysis on the baseline 
score of interest (divided into fertiles) to assess whether the 
level of pain, the patient's assessment of disease activity, and 
functional impairment had a modifying effect on the MCII. 
That is we stratified {a) on the baseline pain score to estimate 
the MCII for pain; (b) on the baseline assessment of disease 
activity to estimate the MCII for patient's assessment of 
disease activity; (c) on the baseline WOMAC function score to 
estimate the MCII for functional impairment.
In a third step, to investigate the effect of covariates (other 
than location of OA) on the MCII, we stratified the analysis 
successively by age, disease duration (both disided into 
tertiles), and sex.
Statistical analyses was performed with the SAS Release
8.2 statistical software package and the S plus 4.5 statistical 
software package.
Com pliance w ith  research  eth ics standards
This study was conducted in compliance, with the protocol, 
good clinical practices, and the Declaration of Helsinki 
principles.
RESULTS
A total of 1362 patients were enrolled in the study: I0I9 
(75%) had knee and 343 (25%) hip OA; 913 (67%) were 
female; and the mean (SD) age was 67.2 (10.5) years. A total 
of 914 (90%) patients with knee and 310 (90%) with hip OA 
completed the final visit. Patients lost to follow up were 
excluded from the analysis and did not differ from 
completers in their baseline characteristics. Among the 
completers, 603 patients vvith knee and 211 with hip OA 
assessed their response to treatment on a five point Likert 
scale.
Table 1 shows the descriptive statistics on clinical and 
demographics variables. Figure 2 shows patients' rating of 
response to treatment
Table 2 lists the MCII values for the three patient reported 
outcomes, according to location of OA These values were 
estimated in the 265 patients with knee and the 87 patients 
with hip OA who completed the final visit and assessed their 
response to treatment as "good". For instance, patients with 
knee OA considered themselves clinically improved if the 
decrease in pain exceeded 19.9 nun on the 0-100 mm VAS. 
We used the data from the five point not the 15 point Likert 
scale mentioned in the "Methods" section.
Table 3 shows the estimates of the MCII (for absolute 
change) stratified on the baseline score in patients vvith knee 
or hip OA. The higher the baseline score, the larger the MCII. 
Patients who have a severe symptom need a higher level of 
change to consider themselves clinically improved than those 
with less severe symptoms. For instance, patients with severe 
pain (a high tertile of baseline pain score) considered 
themselves clinically improved if the decrease in pain 
exceeded 36.6 mm on the 0-100 mm VAS. Patients with less 
pain (low tertile of basehne pain score) needed a lower level 
of change ( — 10.8 mm on the VAS) to consider themselves 
chnically improved. The estimates of the MCII for relative 
change also varied across tertiles of the baseline score (dâta 
not shown).
The estimates of the MCII do not vary across age, disease 
duration tertiles, or sex (data not shown).
DISCUSSION
This study dealt with the clinical meaningfulness of changes 
observed for patient reported outcome measures. Because a 
statistically significant difference is mostly a matter of 
sample size, the most difficult issue is whether an observed 
or estimated difference is clinically important." In other 
words, statistical significance is not equivalent to clinical 
significance. Reporting results of a trial using the MCII (that 
is, as a percentage of improved patients) provides readers 
with values which are more easily understood and additional 
information to help them decide whether a treatment should 
be used. This tlueshold also allows for monitoring of 
individual response to treatment over time and adapting 
treatment to individual patients (for example, determining 
whether to start or interrupt a treatment). Furthermore, the 
designation and use of MCII in clinical trials is critical for 
meaningful systematic reviews and combining results from 
different studies in meta analyses " This concept aims at 
complementing, not replacing, information on the effect size, 
because the effect size remains a more powerful approach " 
The MCII is the smallest change in measures that signifies 
an important improvement in a patient's symptom. Thus, the 
MCII can undoubtedly be considered as a treatment target 
from the patient's perspective. It is based on the patient's 
opinion as an external anchor and contrasts changes within
Table 2  M inim al clinically important im provement (MQI) scores accord ing to patients' location o f  O A
• v  "  /  --“s '  ■ # ..•‘a ,
* - ■ A- ikfcâoitAé tb g n g é
P'Hient repo rted  < ? u » c ^ MOI (95% CD MC« (%) (95% CD
Poin (0-100 mm VAS), mm -19 .9  (-21 .6  to 
Patient global assessm ent -18 .3  (-19 .8  to (0-100 mm VAS), mm
WOMAC function score (0-100) -9 .1  ( -  10.5 to
-17.9) -40 .8  I -44 .8  to -  36.1 ) 
-16.7) -3 9 .0  (-4 5  8 to - 3 0  6)
-7 .5) -2 6 .0  (-2 8  6 to - 2 3  3)
-15 .3  ( -1 7  8 to -12.5) 
-15 .2  (-16 .9  t o -13.4)
-7 .9  ( -8  8 to - 5  0)
-32 .0
-32 .6
-21 1
(-38 .5  to -24.0) 
(-38.7 to -25.2)
(—24.8 to — 17.0)
^  MCII was defined os rfie 75tfi centile of tfie cfxange in score omong patienh whose évoluât ion of response lo treatment was "good", for the three potie 
reported oulcornes: pain, as assessed on a visual analogue scale (VAS); globol assessment of disease status, on a VAS, of tfie Western Ontof io McMaster U niver s i t ies  Osteoorifirilis Index (WOMAC) function subscale score
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Table 3  M inimal clinically important im provem ent (MCII) score of absolute ch an ge in patients with knee or 
interm ediate, an d  high b aselin e  score tertiles
hip OA, by low .
Knee OA Hip OA
Baseline score tertile Baseline score tertile
Low Intermediate High low Intermediate Higti
Pain (0-100 mm VAS) - tO .8  -2 7 .4 -3 6 .6 -7 .2 -2 3 .9 -2 9 .7
(-1 2 .7  t o -8 .7 )  ( -2 9 .7  t o -2 4 .6 ) ( -3 8 .3  to -34 .7 ) ( -1 0 .7  to -2 .9} (-2 8 .3  to -18 .0 ) (-3 5 .4  to -2 1 .8 )
(30 to 51.0) (51,1 to 66.2} {>66.2} {30 to 49.3) (49.4 to 65 4) {>65.4)
Patient's global assessment of - 6 .4  -2 4 .6 -4 3 .2 — 4.3 -2 6 .0 -2 9 .9
disease (0-100 mm VAS) ( - 8 .6  t o -3 .8 )  (-2 6 .8  10 -2 2 .1 ) ( -4 6 .8  to -3 8 .7 ) ( - 6 .9  lo — 1.4) ( -2 8 .3  to -23 .3 ) (-3 4 .5  to -2 4 .3 )
{<50.4} {50.5 to 68.7} {>68.7) {<49 ,9) {50.0 to 69.9) (>69.9)
WOMAC funUion score (0-100) - 5 .3  -1 1 .8 -2 0 .4 -2 .6 -1 4 .8 -15 .1
( - 6 .5  t o -3 .8 )  (-1 3 .0 1 0  -1 0 .4 ) (-2 2 .5  to -1 8 .1 ) ( -4 .4  lo —0.5) ( -1 7 .0  to -1 2 .0 ) 1 -18 .9  to -1 0 .0 )
(< 3 5 .3 ) (35.4 to 51.5) {>51.5} {<38.2) (38.3 to 52.9) (>52.9)
Results are shown as mean (95% confidence interval) {tertile}.
Tlie MCII was' defined as the 75lfi cenlile of llie change in score omong patients wfiose evaluation of response to treatment was "good", for three patient reported 
outcomes: pain, as assessed on a  visual analogue scale (VAS); global assessment of disease status, on a  VAS; or tfie Western Ontario McMaster Universities 
Osteoartliritis Index fWOMAC) function subscale score.
patients at the individual level (proportion o f  improved 
patients) instead o f at the group level (m ean change in a 
variable).
Approaches such as investigator defined (expert consen­
sus) or statistically defined m ethods have been used to 
determ ine this threshold.” Despite the absence o f a 
criterion m easure, establishing the m eaning of changes in a 
m easure requires an independent standard. Patient global 
ratings are recom m ended as an external anchor for evaluat­
ing the clinical significance o f individual change.” The large 
sam ple of patients as experts in determ ining im provem ent is 
a good indicator of representativeness.
To determ ine the MCII, the external criterion w as the 
patient's assessm ent o f response to treatm ent as assessed on  
a five point Likert scale. W e defined MCII in the group of  
patients w h ose  evaluation o f response to treatment w as 
"good", because one is always looking for clinically impor­
tant differences. W e did not include patients w hose evalua­
tion o f response to treatm ent was "excellent," because our 
target w as the minimal change im portant from  the patient's 
perspective. But obviously, this choice w as arbitrary and 
affects the results (data not show n). The group o f patients in  
w h om  MCII is determ ined and the wording o f  the item s in 
the questionnaire to assess response to treatm ent should be 
chosen  w ith  the help o f experts; in our study, the group o f 
patients were chosen by the experts NB, CB, DF, MH, DvdH, 
and MD.
In a previous study,” a three round Delphi m ethod  
involving six academ ic rheum atologists experienced in OA 
trials w as used to define the MCID for som e outcom e  
m easures used in  OA trials (not specifically focusing on hip 
or knee OA). The MCID for patient pain on m ovem ent 
(m easured on a 0 -1 0 0  VAS) w as 17.5 m m  and that for 
patient global assessm ent of disease actm ty (m easured on a 
0 -1 0 0  VAS) w as 15 m m . A lthough this m ethod differs from  
that used in our study, the values are very close to our 
estim ates o f  MCII for these patient reported outcom es. The 
only study dealing w ith  m eaningful change for the WOMAC 
dealt w ith  the m inim al clinically perceptible difference not 
the MCID."
Our study has dem onstrated that the MCII varies depend­
ing on the baseline state. Patients w ho have the m ost severe 
sym ptom s have to experience a greater change to consider 
them selves improved. Biddle and colleagues also found this 
effect in their investigation o f low back pain ,” where the 
MCID varied between 3 and 13 depending on the baseline  
range o f scores (on the Roland-Morris Back Pain 
Q uestionnaire,” total score varying from 0 to 24 points, w ith
baseline scores divided into five approximately equal sized 
intervals). However, the precision o f their estim ates m ay have 
been com promised by the small sample size, especially for 
patients w ith  high levels o f disability.
The variation of MCII across tertiles of baseline scores in 
our study cannot been im puted to the size o f the sam ple, as 
confirmed by the narrowness o f the 95% confidence intervals. 
We believe that this variation depending on the baseline  
score may preclude the use o f the crude MCII. The patient's 
initial or previous score should be taken into account w hen  
m aking decisions about im portant change. We propose to use 
three estim ates o f MCII, corresponding to the tertiles o f each 
baseline score, to express the changes in terms of im portant 
im provem ent. This m eets the recom m endation o f Crosby and 
associates” for estim ating MCID in health related quality of 
life criteria: to anchor baseline severity of individual patients.
We believe tins is the first study to investigate the effect of 
several covariates such as age, sex, OA location, and disease  
duration on patient responses. It is interesting to observe that 
these factors do not consistently m odify the estim ates of 
MCII.
In conclusion, use o f  the concept MCII facilitates the 
presentation and interpretation o f results obtained in  clinical 
trials and the transposition o f trial results into practice. 
However, the baseline score should be taken into  account. 
Furfher studies involving different datasets, clinical environ­
m ents, languages, and countries are necessary to validate 
these observations prospectively.
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Background; The patient accep ta b le  sym ptom  state (PASS) is the value beyond which patients can  
consider tliem selves w ell. This con cep t can  help in interpreting results o f clinical trials.
O bjective: To determ ine the PASS estim ate for patients with knee an d  hip osteoarthritis (OA) b y  assessin g  
pain , patient's g lob al assessm ent o f  d ise a se  activity, an d  functional impairment.
M ethods: A  4  w eek  prospective multicentre cohort study o f  1 3 6 2  outpatients with knee or hip O A  w as  
carried out. Data on assessm en t o f  pa in  an d  patient's g lob al assessm ent o f d isease, m easured  on visual 
an a logu e scales, an d  functional im pairm ent, m easured on  the W estern Ontario M cM aster Universities 
Osteoarthritis Index (W O M A C ) function subscale, w ere collected at baseline and final visits. The patients 
a ssessed  their satisfaction with their current state at the final visit. An anchoring m ethod b a se d  on  the 
patient's opinion w a s used.
Results: For patients with knee an d  hip O A , the estim ates o f  PASS w ere, respectively, 3 2 .3  an d  3 5 .0  mm 
for painj 3 2 .0  and  3 4 .6  mm for patient g lob al assessm ent o f  d isea se  activity, and  3 1 .0  and 3 4 .4  points 
for W O M A C  function score. The PASS varied  m oderately across the tertiles of baseline scores but not 
across a g e , d isea se  duration, or sex .
C onclusion: The use o f  PASS in clinical trials would provide m ore meaningful results ex p ressed  a s  a  
proportion of patients in an a ccep tab le  symptom state.
I n clinical trials, at the group level, results are usually  reported as m ean and standard deviation o f the change in score, w h ich  is not m eaningful for m ost readers. The 
im portance o f incorporating patient perspectives in research 
into rheum atic diseases and defining outcom es that arc 
com prehensive and influence clinical decision m aking w as 
em phasised during the OMERACT 6 m eeting.' Previous 
studies have dealt w ith  the concept o f the m inim al clinically  
im portant difference (MCID)'"" or m inim al clinically im por­
tant im provem ent (MCII)' that could help in interpreting 
changes in scores in individual patients, by expressing the 
results as a proportion of improved patients. Another 
potentially clinically relevant concept is the patient accep­
table sym ptom  state (PASS), defined as the value beyond  
w h ich  patients consider them selves w ell. The MCID deals 
w ith  the concept o f improvement (feeling better) and the 
PASS the concept o f wellbeing or rem ission o f  sym ptofns 
(feeling good). Thus, the PASS is undoubtedly a clinically  
relevant outcom e for the patient.
The MCID and PASS concepts are com plem entary. If a 
patient w ith  a high level o f pain (90 m m  on a 0 -1 0 0  m m  
visual analogue scale (VAS)) experiences a decrease in pain  
o f 40 m m , thus reaching 50 m m  on the VAS, one can  
probably recognise a clinically relevant im provem ent (co n ­
cept o f MCID) but not a satisfactory state (concept o f PASS). 
Results could be expressed both as a proportion of improved 
patients and o f patients in a satisfactory state.
This prospective cohort study aimed at determ ining the 
PASS estim ates for three main patient reported outcom es 
used in osteoarthritis (OA) trials^: pain, patient's global 
assessm ent o f disease activity, and functional im pairm ent.
M ATERIALS A N D  M E T H O D S  
S lu d y  d e s ig n
We conducted a 4  w eek prospective cohort study.
Study population
Tills study involved 1362 outpatients w ith knee and hip OA, 
as defined by the Am erican College of Rlicumatology,^ * 
included by 399 rheum atologists in France. Each rheum atol­
ogist had to Include four patients, three w ith knee OA and 
one w ith Irip OA. To be included in the study, patients had to 
experience pain from  OA (> 3 0  m m  on a VAS varying from 0 
to 100), require treatm ent vvith a non-steroidal anti­
inflam m atory drug (NSAID), and be able to com plete  
questionnaires in French. Inclusion could begin w ith  the 
onset, of treatm ent or a sw itch from one NSAID to another. 
Patients were excluded if they had a prosthesis on the 
assessed joint or if  they had been treated by intra-articular 
injection in the 4  w eeks before the study began. All patients 
initially visited the rheum atologist in charge o f the patient, 
and an NSAID was prescribed (the drug and its dosage were  
chosen by the physician). A final visit to the sam e  
rheum atologist w as scheduled 4 weeks later.
Table 1 show s the descriptive statistics on clinical and 
demographics v'ariables.
A bbreviations: IDA, low d isea se  activity; MCID, minimal clinically 
im portant difference; MCll, minimal clinically im portant im provem ent; 
NSAID , non-steroidal anti-inflam m atory d rug; O A , osteoartliritis; PASS, 
patient accep tab le  sym ptom  state; VAS, visual an alogue  scale; 
W O M A C , W estern  O n ta rio  M cM aster Universities O steoartliritis Index
w w w .onnrlieum dis.com Ü
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T ab le  1 B aseline charac te ristics  o f p a tien ts
Knee OA (n = 914) Hip OA (n = 310)
Mean SD Mean SD
Age (years) 67.8 10.2 65.7 10.8
Weigfil (kg) 75,2 14.2 72.2 14.0
Heiglil (cm) 163.6 8.7 164.8 8.2
Body mass index (kg/m^) 28.1 4.7 26.5 4.1
Disease duration (years) 4.8 5.8 3.4 4.8
Poin score (0-100 mm VAS) 
Week 0 58.3 16.9 56.7 17.4
Change (week 0-week 4) -2 4 .5 22.1 - 1 8 .7 21.8
Patient giolxil assessment (0-100 mm VAS) 
Week 0 58.7 19.1 58.6 16.5
Change (week 0-week 4) -2 4 .0 24.6 -1 9 .5 23.5
WOMAC (unction score (0-100) 
W eekO 42.9 16.6 45.9 17.1
Change (week 0-week 4) -1 1 .6 14.4 -1 0 .8 14.1
No (%) No (%)
Female sex 637 (69.7) 189 (61.0)
Kellgren and Lawrence grade 
II 178 (19.5) 57 (18.5)
It! 394 (43.1) 145 (46.9)
IV 342 (37.4) 107 (34.6)
NSAID* intake during past 4 weeks 262 (28.8) 97 (31.3)
Analgesic inlaket 513 (56.3) 209 (67.9)
Symptomatic slow acting drugs intake^ 311 (34.1) 123 (39.8)
*t4oo'sleroidal onti-inflammotory drugs (beFore ll»e start of tlie study); totF>er tfran NSAtDs (t>efore llie start of Hie 
study); tcKondroitin suipftate, diacertiein, or avocado soybean unsaponifiabies.
M e a s u r e m e n ts
The design  o f the trial included a baseline visit to the  
rheum atologist, a 4  week NSAID treatment phase, and a final 
visit at w eek  4. At the baseline visit, demographic and disease  
data (in particular, disease duration) were collected. Patients 
assessed their OA status at baseline and final visit. They 
assessed the follow ing patient reported outcomes; (tt) pain on  
m ovem ent during the 48 hours before the visit, measured on 
a 0 -1 0 0  m m  VAS; {b} global assessm ent o f disease activity, 
m easured on a 0 -1 0 0  m m  VAS; and (c) physical function, 
m easured on the W estern Ontario McMaster Universities 
Osteoarthritis Index (WOMAC) function subscale (17 items, 
five point Likert scale for each item; high scores indicate high  
degree o f functional impairment; total score norm alised to a 
0 -100  score).
At the final visit, patients' opinions of their state was also 
recorded by their answering "Yes" or "No" to "Taking into  
account all the activities you have during your daily life, your 
level o f  pain, and also your functional im pairm ent, do you  
consider that your current state is satisfactory?".
S tatistica l a n a ly s is
All the analyses considered patients w ith knee and hip OA 
separately.
W e used an,anchoring m ethod based on patient satisfac­
tion w ith  the current state. The sam e m ethods as for the 
MCII study (see  com panion paper in this issue’) were used, 
and the PASS was estim ated by constructing a curve of  
cum ulative percentages of patients as a function of the score 
of interest at the final visit am ong patients w ho considered  
their state satisfactory. Logistic regression was used to m odel 
the observations (fig 1). We targeted the point at the 
flattening o f  the curve at which m ost subjects stated they 
had a satisfactory status. This point corresponds to the 78.9th  
centile o f the final score, and thus w e propose to define the 
PASS as the 75th centile o f  the final score (at week 4), 
because it is very close to the point defined above and easier 
to derive. The m odel permitted us to determine that the 
target point w as correctly approached by the 75th centile and 
to estim ate the 95% confidence intervals. We also m odelled
o Patients considering llieir slate at week 4 
os satisfactory (n = 527]
A Patients considering tfieir state at week 4  
as unsatisfactory |n = 387)
1.0
3 r
y
&  0.4
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Figure 1 Aspects of tbe cumulative distribution function used to 
determ ine the PASS (pain scores in patients with knee OA). Among 
patients considering nieir stale as satisfactory, 75% assessed tfieir pain 
score a t final visit below 32 .3  mm on a  0 -1 0 0  mm VAS (wfiich is the 
PASS limit). Among patients considering tfieir state as unsatisfactory, 
only 25% assessed tfieir pain score a t final visit below 32.3 on a  
0 -1 0 0  mm VAS.
the data from patients w h o considered their state u n satis­
factory (fig 1).
In a second step, w e stratified the analysis on the baseline  
score o f  interest (divided into tertiles) to assess w hether the 
baseline scores for level o f pain, patient's assessm ent o f  
disease activity, and functional impairment affected the 
PASS estim ates. That is w e stratified (a) on the baseline pain  
score to estim ate the PASS for pain; (b) on the basehne  
patient's assessm ent o f  d isease activity score to estim ate the
w w w .annrheum dis.com
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Table 2  Patient acceptab le symptom state (PASS) scores accord ing  to location of O A
Pcrfient reported oofcomes
Khee OA Hip OA
PASS (95% Cl) PASS (95% Cl)
Poin (0-100 mm VAS), mm 32.3 (30.1 to 34.7) 35.0 (32.8 to 37.4)
Polienl glolxil assessment (0-100 mm VAS), mm 32.0 (29.5 to 34.8) 34.6 (32.3 to 37.1)
WOMAC function score (0-100) 31.0 (29.4 to 32.9) 34.4 (31.9 lo 37.3)
PASS for patient's assessm ent o f d isease activity; and (c) on  
the baseline WOMAC function score to estim ate the PASS for 
functional im pairm ent.
In a third step, to investigate the effect of covariates (other 
than location o f  OA) on the PASS, w e stratified the analysis 
successively by age, disease duration (both divided into 
tertiles), and sex.
Statistical analyses Was performed w ith  the SAS Release
8.2 statistical software package and the S plus 4.5 statistical 
softw are package.
C om pliance w ith  research  eth ics stand ards
This study w as conducted in  com pliance w ith the protocol, 
good clinical practices, and the Declaration o f Helsinki 
principles.
RESU LTS
A total o f 1362 patients were enrolled in the study: 1019 
(75%) had knee and 343 (25%) hip OA; 913 (67%) were 
fem ale; and the m ean (SD) age w as 67.2 ( 10.5) years. A total 
o f 914 (90%) patients w ith  knee and 310 (90%) with hip OA 
com pleted the final visit. Patients lost to follow up were  
excluded from the analysis and did not differ from  
com pleters in their baseline characteristics.
Am ong the completers, 527/914 (57.7%) patients w ith knee  
and 156/310 (50.2%) w ith hip OA considered their functional 
state at w eek  4 as satisfactory.
Table 2 lists the PASS estim ates for the three patient 
reported outcom es and gives their 95% confidence intervals. 
For instance, patients w ith knee OA considered their state  
satisfactory if their pain score w as less than 32.3 m m  on the  
0 -1 0 0  m m  VAS. The PASS estim ates are similar (scores o f  
approxim ately 33) across location o f OA, whatever the  
patient reported outcom e. These values arc very close to 
those calculated for the 25th centile of the cum ulative  
distribution function for the final score am ong patients w ith  
knee (fig 1) and hip (data not show n) OA w ho considered  
their fu:^ctional state unsatisfactory.
Table 3 show s the estim ates of the PASS stratified on the 
baseline score o f interest. For instance, patients w ith  knee OA 
w ith severe pain (h igh  tertile of baseline pain score) 
considered their state satisfactory if their pain score was 
< 2 7  mm on the 0 -1 0 0  m m  VAS. The PASS estim ate varied 
moderately across tertiles o f baseline scores (the higher the 
baseline score, the higher the PASS), but this trend is clearer 
for functional im pairm ent.
The PASS estim ates did not vary across age or disease 
duration tertiles or sex  (data not show n).
D IS C U S S IO N
In this prospective study w e estim ated the PASS,for the three 
m ain patient reported outcom es used in clinical trials in knee 
and hip OA.
The PASS is the value beyond which patients consider 
them selves well. Thus, it can be considered a clinically 
relevant treatm ent target. It is an absolute value, not a 
change. Describing the num ber o f patients achieving and 
m aintaining such a state for a specified period o f  tim e will 
add useful inform ation for daily practice and aid in the 
interpretation o f trial and longitudinal results.’
This concept is very close to the low  disease activity 
(LDA)‘“ " but applies on ly  to patient reported outcom es (that 
is, sym ptom s). The LDA reflects an interm ediate state 
betw een high disease activity and rem ission that could be 
called LDA or partial rem ission, /hr OMERACT 6 workshop  
focused on this concept for rheumatoid arthritis." LDA was 
defined as a disease activity state deem ed a usefu l treatment 
target by both physiciairs and patients. The defin ition  o f the 
PASS is anchored to the personal experience of the patient 
(satisfaction and adaptation to sym ptom s), although the LDA 
is anchored to both  the patient's experience and the 
physician's clinical experience (treatm ent decision and 
prognosis). In a sym ptom atic disease such as OA, PASS and 
LDA are joined. In a d isease such as rheum atoid artliritis, the 
PASS deals only w ith  patient reported outcom es, although
Table 3  Palienf accep tab le sympfom state (PASS) in patients willi knee 
tertiles
or hip O A , b y  b a selin e  score oF interest d iv ided  info
KihSc' pA . • ? HipQÀ,
Basiîjilnç sCorc tortile
: Lovv> h' . • , totenriedidto
Pain (0-1 (XI mm VAS) 27.0
(24.6 to 29.9) 
(30 to 51.0)
34.5
(32.3 to 37.0) 
(51.1 to 66.2)
36.4
(33.2 lo 40.0) 
{>66.2}
29.4
(26.0 to 33.7) 
(30 to 49.3)
35.2
(32.8 to 37.9) 
[4 9 .4  to 65.4)
43.6
(38.9 to 49.6) 
(>65.4)
Poiient's glolxil assessment 
(0-100 mm VAS)
28.3
(25.5 to 31.6) 
(< 5 0 .4 )
34.3
(32.1 to 36.7) 
(50.5 to 68.7)
34.4
(32.1 to 36.7) 
(>68.7)
30.3
(26.6 to 34.9) 
(« 4 9 .9 )
33.5
(31.0 to 36.5) 
(50.0 to 69.9}
41.2
(37.2 to 45.9) 
{>69.9}
WOMAC function score (0-100) 20.4
(19.1 to 21.8) 
(< 35 .3)
33.0
(31.3 to 34.9) 
(35,4 to 51.5)
43.1
(40.8 to 45.7) 
{>51.5}
20.6
(19.1 to 22.3) 
(« 3 8 .2 )
34.4
(31.9 to 37.4) 
(38.3 to 52.9)
44.2
(41.0 to 48.2) 
(>52.9)
Results are shown as llie PASS (95% con(idence inletvol) (tertile).
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the LDA a lso  e n co m p a sses  factors su ch  as b io log ica l s ig n s o f  
in flam m ation .
The con cep t o f  PASS is b ased  o n  p atien t o p in io n  as an  
external anchor, accord ing to the  OMERACT LDA m o d u le  
recom m en d ation  (th e  o p in io n  based  rather th an  data  based  
approach se em s m ore appropriate in  deriv ing the  LDA 
d efin ition ). The large sam p le  o f  p a tien ts u sed  as exp erts to 
d eterm ine rem ission  in  sy m p to m s in our stu d y  is a good  
indicator o f  th e  rep resen ta tiv en ess.
The PASS w a s d efin ed  as th e  75 th  cen tile  o f  the final score  
in p atien ts w h o  con sid ered  their sta te  sa tisfactory . This 
threshold relies on  the data m o d e llin g  an d  w a s ch o se n  w ith  
the h elp  o f  exp erts (N B , CB, DF, M H, DvdH , M D ). H ow ever, 
these va lu es are very c lo se  to th o se  ca lcu la ted  for th e  2 5 th  
centile o f  th e  cu m u la tiv e  d istr ib u tio n  fu n ctio n  for th e  final 
score a m o n g  p a tien ts  w h o  con sid ered  their fu n ctio n a l sta te  
u nsatisfactory . Thus, b eyon d  th e  PASS lim it w ere  75% o f  the  
patients w h o  con sid ered  their  current sta te  sa tisfa cto ry  and  
only 25% o f  th o se  w h o  did  n ot. O therw ise, the es tim a te s  o f  
the PASS ran ge from  a p p rox im ately  30  to 33 o n  a 0 -1 0 0  p oin t 
scale, w h a tev er  th e  p a tien t reported  o u tco m e. T he re levan ce  
of th ese  resu lts is  rein forced  by resu lts  w h ic h  sh o w e d , in  a 
study o f  p a tien ts  w h o  u se d  in tra v en o u s p a tie n t con tro lled  
analgesia  to se lf  ad m in ister  m o rp h in e  su lfa te  a fter in tra ­
ab dom inal surgery, that o n ly  4% w h o  rated their  pa in  
< 3 0  m m  o n  the  0 -1 0 0  m m  VAS req u ested  ad d ition a l 
analgesia , com p ared  w ith  4 3 -80%  o f  th o se  w ith  p a in  scores  
of 3 1 -7 0  or h ig h er ."  Thus, a p a in  score o f  < 3 1  m m  seem s  
acceptable in  th is co n tex t as w e ll.
In our stu d y  w e  in vestiga ted  th e  effect o f  severa l covariates  
on the PASS estim a tes. T he PASS varied m od era te ly  across 
the tertiles o f  b a se lin e  scores b ut less  m ark ed ly  th an  the  
MCII.’ T hus, the  PASS se em s to be m ore robust than  the  
MCII, w h ich  is a ffected  by th e  in itia l level o f  sy m p to m s, so  
the PASS is the  recom m en d ed  ch o ice . H ow ever, th e  o ther  
factors in v estig a ted  (age, sex , OA loca tio n , an d  d isea se  
duration) did  n o t co n sis te n tly  m o d ify  th e  PASS e stim a te s .
In co n c lu sio n , th is stu d y , d ea lin g  w ith  a co n cep t o f  
em erging u se , provides p relim in ary  in form ation  facilita ting  
the p resen ta tio n  and  in terp reta tion  o f  resu lts o b ta in ed  in  
clin ical trials. Further stu d ies in vo lv in g  d ifferen t d a tasets, 
clinical en v iro n m en ts , la n g u a g es, an d  cou n tr ies, are n e c e s­
sary to va lid a te  th e se  o b servation s.
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SECTION 9 - WOMAC Index: A Global Perspective
In mid-1982, the development of a valid, reliable and responsive international 
standard of measurement for OA clinical trials was just a concept. The difficulty of the 
challenge was unknown, but a high probability of failure was recognised. Developments 
in measurement, in other areas o f rheumatology (particularly rheumatoid arthritis), the 
formation of OMERACT and OARSI, and the emergence of COX-2 class agents largely 
account for the unexpected acceleration of interest in outcome measurement in OA 
clinical trials. The precedent established by some of the early pioneers (John Lansbury, 
Otto Steinbrocker, Douglas Taylor), and more recent proponents (Robert Meenan, James 
Fries, Michel Lequesne) of outcome measurement in the rheumatic diseases, also 
propagated the discipline of musculoskeletal clinical metrology, and, in particular, raised 
awareness of methodological issues in health status questionnaire development. 
Nevertheless, in 1982, outcome measurement was far from being standardised, and the 
approach to outcome measurement in rheumatology clinical trials was highly variable, 
with respect to domains, variables, item specification and scales. Furthermore, there was 
no high-level international consensus on core set domains or preferred instruments, and 
no definition of what constituted a clinically important difference, or a symptom severity 
state acceptable to patients. The health status questionnaires of the time were generally 
available in English, or at best also in a few key European languages, and were not 
necessarily created using standard operating procedures, or culturally/linguistically 
appropriate methods.
The OA measurement environment, some 23 years later, in 2005, is completely 
different. It has been both interesting and a privilege to be an active participant in task 
forces, working groups and parties and consensus groups, that have shaped and 
standardised outcome measurement procedures for OA clinical research in rheumatology. 
These have included OMERACT, OARSI, WHO/ILAR, and IMMPACT.
The WOMAC Index is one o f several assessment methods that have emerged. Its’ 
importance in outcome measurement in diverse clinical research and clinical practice 
environments is best appreciated from reviewing the reference section o f the latest 
version o f the WOMAC User Guide (44). WOMAC User Guide VII is the latest in a 
series of WOMAC User Guides dating back to 1995. Different versions of the WOMAC 
User Guide have been distributed, since 1995, to over 10,000 WOMAC Index users. 
WOMAC User Guide VII contains references to over 1,000 publications (original papers, 
reviews, abstracts, and guidance documents) that draw on the WOMAC Index, and its 
applications, in various clinical research environments including the evaluation of anti­
inflammatory drugs, COX-2 selective and specific agents, viscosupplements, orthopaedic 
surgical procedures, and physical forms of therapy. The Guide also details the more than 
60 alternate-language translations of the WOMAC 3.1 series of questionnaires currently 
available, many available in different scaling formats to meet end-user needs and 
preferences.
The WOMAC Index has been produced in 5-point Likert, 11-point NRS and 100 
mm VA formats, in electronic (e-WOMAC) and traditional paper-based applications, and 
with time frames that have varied as follows; 24-hours (original WOMAC 3.0), 48-hours 
(WOMAC 3.0 and WOMAC 3.1), last week (WOMAC 3.1W), last seven days
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(WOMAC 3.1LSD), since last visit (WOMAC 3.1SLV), last month (WOMAC 3.0M). 
The WOMAC Index has been targeted on a single hip or knee joint (WOMAC 3.0 and 
WOMAC 3.1), on hips and/or knees (original WOMAC 3.0), on both knees together, and 
on both knees separately. In the case o f injectable treatments, a version based on the knee 
to be injected has been developed (WOMAC 3.1 IK). Finally the WOMAC has been 
produced in standard format as well as in signal (WOMAC 3.0S and WOMAC 3 .IS), and 
short-form (SF-WOMAC 3.0) formats. These variations on the standard WOMAC Index 
have been produced to meet the specific needs of end users, and complement the standard 
3.1 series WOMAC Index.
The innovative nature of the WOMAC Index was recognised by the Government 
of Canada in the formal registration o f both the copyright to the source questionnaire and 
awarding the Canadian trademark (CDN No. TMA 545,986) to the author of this thesis 
(Appendix A).
Since 1996, the WOMAC 3.1 Index has been licensed for use in over 56 countries 
to major multinational pharmaceutical, biotechnology companies, academics, 
undergraduate and postgraduate students in various disciplines and to a large number of 
practitioners, particularly in the disciplines of rheumatology, orthopaedic surgery, 
physiotherapy and rehabilitation medicine.
The WOMAC Index is widely used in clinical research studies, and is now 
increasingly used in clinical practice environments. The Index often features as one of the 
most commonly used outcome measures in OA clinical studies reported at international 
rheumatology meetings. The WOMAC Index is identified as a measurement option by 
relevant organisations and regulatory agencies in Europe and the United States of 
America, including the draft guidelines o f the European Medicines Agency 
lEMEAVwww.emea.eu.int). and the United States Food and Drug Administration 
IFDAVwww.fda.gov). The Index has been provided for use in Medical Research Council 
funded studies in the United Kingdom, Canada and Australia, and is one of the key 
clinical outcome measures for the National Institutes of Health Osteoarthritis Initiative 
(NIH-OAI) in the United States of America.
As noted in the preceding sections of this thesis, the WOMAC Index has played 
an important role in the specification of core set measures, and proposals for responder 
criteria and state-attainment criteria in OA(44). As previously noted, there are many 
different versions of the WOMAC Index, adapted for different applications, and which 
vary subtly in phraseology, language, time frame, joint target and platform.
The standard version, which is the WOMAC 3.1 series questionnaire, is joint 
targeted and uses a 48-hour time frame. It is this tri-dimensional, 24-item version, 
whether in 5-point Likert or 100 mm VA format, which has proven particularly popular 
and has met requirements in diverse clinical research and clinical practice requirements at 
a global level. The WOMAC Index development has permitted the detection of clinically 
important statistically significant differences in diverse research environments, and has 
arguably established itself as one of the international standards o f measurement in OA 
clinical trials (44). The ability of the WOMAC Index to meet the measurement needs of a 
broad constituency of global users, by providing a valid, reliable and very responsive 
measure of patient reported outcome, meets the original measurement goals established in 
1982. The influence of the WOMAC Index development, in supporting development of 
international measurement guidelines, core set clinical measures and proposals for
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response criteria and state-attainment criteria, exceeds the original expectation, and has 
been achieved through international collaboration with colleagues in academia, industry, 
regulatory bodies and clinical practice. The success of the WOMAC Index is, in no small 
part, attributable to the original 100 patients with OA, who were interviewed in 1983 and 
1984, and whose careful explanation of the impact of OA on different aspects of their 
everyday life, shaped the content and format of the WOMAC Index. Without their insight 
and perseverance, it would not have been possible to develop a valid measure meeting a 
global need.
Reference:
44. Bellamy, N. WOMAC Osteoarthritis Index -  User Guide VII (Published by N. 
Bellamy, Brisbane, Australia) 2005.
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FOREWORD
The WOMAC Osteoarthritis Index is a tridimensional, self-administered, patient-centered health 
status questiomiaire. Its item inventory has been designed to capture the essential elements of 
pain, stiffness and physical disability in patients with osteoarthritis of the knee and/or hip joints. 
The WOMAC Index has been subject to more than 20 studies examining its basic clmimetric 
properties and has been translated into over 60 different language forms. Its ability to detect 
change in health status has been demonstrated following patient exposure to a variety of different 
interventions: Nonsteroidal Anti-inflammatory Drugs, COX-2 Inhibitors, Analgesics,
Viscosupplements, Physiotherapy, Orthopaedic Surgery.
WOMAC User Guide VII provides updated information on Index development and validation, 
and includes information about recently available alternate-language translations, electronic data 
capture using the WOMAC Index, and recent experience with the hidex in clinical research and 
clinical practice environments. This release of the WOMAC User Guide also contains an 
explanation of the meaning of questions in the WOMAC Index inventory. WOMAC User Guide 
VII provides reflections on recent developments in the area of response status assignment in OA 
based on change criteria (OARSI, OMERACT-OARSI, MPCl, MCII and WOMAC 20 50 70 
responder criteria), and state attainment criteria (MCAS, PASS, and BLISS Index), developed in hip 
and/or knee OA environments. Finally WOMAC User Guide VII contains summaries of two other 
related patient-centered health status measures, the Australian/Canadian (AUSCAN) 
Osteoarthritis Hand Index, and the Osteoarthritis Global Index (OGI).
I gratefully acknowledge the generous collaboration of the many research associates, teclinical 
experts, rheumatologists, orthopaedic surgeons, epidemiologists and biostatisticians who 
facilitated the successful development of the WOMAC Index. I am particularly grateful to my 
colleague, Jane Campbell, who has worked diligently over several years on WOMAC projects.
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WOMAC USER GUIDE VII
OVERVIEW
The WOMAC Osteoarthritis Index is a 
tri-dimensional, disease-specific, self- 
administered, health status measure (1-64). It 
probes clinically-important, patient-relevant 
symptoms in the areas of pain, stiffness and 
physical function in patients witli 
osteoarthritis of the hip and/or knee. The 
index consists of 24 questions (5 pam, 2 
stiffness, 17 physical function) and can be 
completed in less than 5 minutes. It is 
available in Likert (WOMAC LK3-series), 
Visual Analogue (WOMAC VA3-series) and 
Numerical Rating (WOMAC NRS-series) 
scaled formats. WOMAC is valid, reliable, 
and sufficiently sensitive to detect clinically- 
important changes in health status following 
a variety of interventions (pharmacologic, 
surgical, physiotherapy, etc). It has been 
translated into many different languages and 
has been requested for use by more tlicm 500 
researchers in over 50 different countries (65- 
1041). Several different formats of the 
WOMAC Index have been produced 
including the WOMAC Original, 3.0, 3.0S,
3.1, 3.1S, 3.1W, 3.1M and 3.1SLV, 3.1(1K) SF- 
WOMAC and e-WOMAC. Tlie WOMAC 
Index has become a standard measure for 
clinical hials in hip and knee osteoarthritis. 
Several major agencies and organisations, as 
well as individual researchers, have given 
focus to the way in wlaich measurement 
should be conducted and standardised 
techniques and tools from which to choose 
(1042-1073).
CONCEPTUAL BASIS
The conceptualisation of WOMAC 
began in 1981, in my MSc thesis (29), and at a 
time when tliere were no international 
standards of clinical measurement in
osteoarüiritis (OA) clinical trials (4). The need 
for such an instrument arose from a review of 
the clinical trials literature (4). In that review 
of 63 NSAID trials m OA, pain had been 
assessed in 58, patient global assessment m 
51, range of movement in 45, physician global 
assessment in 42, joint stiffness in 35, 
qualitative aspects of sleep in 28, walk time in 
23, activities of daily living in 22, joint 
tenderness in 19, analgesic consumption in 
15, joint swelling in 15, signal joints in 10, 
ascent time in 3, muscle power in 3, hand 
function in 3, radiology in 2, and joint 
temperature in 1. Not only did the variables 
differ, but there was considerable variability 
in tlie scales and instruments employed. 
Apart from physician and patient global 
assessments, pain and stiffness were the only 
otirer two variables monitored in more tlran 
half of the hials. While the second most 
important symptom of OA, physical 
disability, was monitored in only 35% of tire 
studies, measures of physical function 
detected a sigirificairt difference betweerr an 
active treatment phase aird either a washout 
phase or placebo treahnent period in 86% of 
assessable studies. Most of the other 
measures used iir the 63 NSAID trials were 
observer-dependent, i.e., required a 
physiciair or allied healtlr professional to 
make a judgement based on observed 
performance or cliirical examination. Given 
drat such measures are subject to observer 
variability and may lack clinical importance 
to mdividual patients, we elected to focus on 
three observer-iirdependent, patient-relevant 
measures, i.e., pain, stifhress, and physical 
function. An mdex applicable to OA hip and 
knee patients was considered necessary given 
the propensity for OA to affect these two 
anatomic areas, aird dre fact that most
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pharmacologie studies have focused on these 
two joints.
DERIVATION OF THE ITEM 
INVENTORY
In order to construct the item 
inventory of WOMAC, the dimensionality of 
the symptomatology of OA was explored in 
100 patients with hip and/or knee 
involvement (4). The survey questionnaire 
was developed by a peer review process 
involving the opinions of four academic 
rheumatologists and two clinical 
epidemiologists experienced in clinical 
measurement in the rheumatic diseases. 
Initial questions were open-ended and 
probed the clinical importance and 
characteristics of any pain, stiffness, physical, 
social or emotional dysfunction. Once 
spontaneous responses to these questions 
were exhausted, a battery of closed-ended 
questions, derived from (and modified where 
necessary) six existing questionnaires (Health 
Assessment Questionnaire - HAQ, Functional 
Status Index - FSI, Arthritis Impact 
Measurement Scales - AIMS, Pooled Index, 
McMaster/T oronto Assessment Index 
MACTAR, McMaster Health Index 
Questionnaire - MHIQ), was used to 
complete the assessment of each dimension 
and quantitate any sources of discomfort and 
disability. The survey questionnaire was 
administered by face to face interview. The 
following data were recorded:
1) The presence or absence of each of several 
types of discomfort or disability.
2) The frequency with which each type of 
discomfort or disability occurred (daily, 
weekly, fortnightly, monthly or less).
3) The importance of each type of discomfort 
or disability to the patient (0 = none, 1 = 
slight, 2 = moderate, 3 = very, 4 = extreme).
Patients were specifically questioned 
about sources of discomfort and disability 
recently experienced and attributed to OA in 
the hips and/or knees. They were questioned 
regarding the perceived importance of each 
type of discomfort and disability in order to 
assess its clinical relevance. Gender-specific 
questions relating to physical disability (e.g. 
ironing) were avoided and questions phrased 
in more general terms (e.g. light domestic 
duties). Questions relating to sexual disability 
were not included since this has been 
previously noted to inliibit responses to 
subsequent non-sexual questions. Although 
questions relating to social and emotional 
dysfunction were included in the evaluation 
of the dimensionality of the symptomatology 
of OA, and were subsequently included in 
two validation studies of the WOMAC Index, 
they do not form part of the WOMAC 3.1 
Index and will not be considered further. 
The social dimension was deleted because of 
poor construct validity. In contrast, the 
emotional dimension performed extremely 
well but was not included, because at that 
time it seemed redundant without the 
accompanying social dimension. However, 
the recent Initiative on Methods, 
Measurement and Pain Assessment in 
Clinical Trials (IMMPACT) consensus 
included not only recommendation to 
measure pain and function, but also the 
inclusion of measurement of emotional 
function (1058,1072) As a consequence, the 
WOMAC emotional function subscale may 
be reintroduced for clinical trials and clinical 
practice applications in hip and knee 
osteoarthritis which require measurement of 
the emotional domain.
The prevalence (P), mean importance 
score (MIS), and percentage of symptomatic 
patients experiencing daily or weekly 
symptoms (DW) varied between component
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items. The range of values for items retained 
within the WOMAC Index was as follows: 
Pam: P = 56-77%, MIS = 2.51 - 2.63, DW = 94 - 
96%; Stiffness: P = 47 - 73%, MIS = 2.30, 2.52, 
DW = 100%; Physical function: P = 33 - 70%, 
MIS = 2.26 - 2.67, DW = 71 - 100%. No 
association was observed between MIS for 
pain, stiffness or physical function and the 
following variables: age, gender, disease 
duration. The item inventory of the WOMAC 
Index was directly derived from the 
aforementioned study. This development 
strategy ensured that the Index had face and 
content validity and that it probed symptoms 
which occurred commonly, were regarded as 
being of importance to symptomatic 
individuals, and generally were experienced 
on a daily or weekly basis. The fact that the 
symptoms occurred daily or weekly was 
important, since patients can only record 
change on an index if they have had 
opportunity to re-experience events at a time 
when the effects of a new intervention might 
be expected to have occurred. Thus the item 
inventory of the WOMAC Index monitors 
clinically-important events, relevant to 
patients and recurring with high frequency in 
symptomatic individuals.
VALIDATION STUDIES (Reliability, 
Validity, Responsiveness)
Two major validation studies of the 
WOMAC Index have been completed (14,15). 
The goal was to assess the reliability and 
validity of the Index, and evaluate its 
responsiveness to two different forms of 
intervention (orthopaedic and
pharmacologic). For the purpose of 
validation, responses to WOMAC questions 
were scaled in two different formats. The LK- 
scaled version allowed patients to make their 
responses on 5-point adjectival scales (0 = 
none, 1 = mild, 2 = moderate, 3 = severe, 4 =
extreme). In contrast, the VA-scaled version 
permitted responses to be made on 100 mm 
horizontal visual analogue scales with end 
markers, outwith which were placed the 
following descriptive anchors (left end = 
none, right end = extreme).
Orthopaedic Validation Study
This study employed a quasi- 
experimental, one-group repeated measures 
design (14) in 30 OA patients undergoing 
total arthroplasty of the hip (n=16) or knee 
(n=14). Patients were evaluated the day 
before surgery and at 6 weeks, 3 months and 
6 months post-operatively. In addition to LK- 
and VA-scaled versions of WOMAC, the 
following measures were administered
concurrently for validation purposes: 1) 
Modified Doyle Index, 2) Lequesne Index, 3) 
Bradburn Index of Well Being, and 4) Social 
Component of the MHIQ. Additional 
measures included interviewer global
assessment, patient global assessment, 50' 
walk time, joint range of motion, 
intermalleolar straddle, and intercondylar 
distance.
Validity testing was based on 
construct validity determined using
Pearson's correlation coefficients. Correlation 
coefficients, based on the WOMAC, Doyle, 
Lequesne, Bradburn, and MHIQ Indices, 
supported the construct that the pain, 
stiffness and physical function subscales 
were valid. In particular, WOMAC Index 
items showed statistically significant 
correlations with other indices probing the 
same dimension (i.e., convergent construct 
validity). Furthermore, WOMAC Index items 
showed higher levels of correlation with 
indices probing the same dimension than 
with indices probing other dimensions (i.e., 
divergent construct validity). Construct
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validity was demonstrated for both the LK- 
and VA-scaled versions of the index.
Reliability was determined by 
Cronbach's alpha pre-operatively, and at 6 
weeks and 6 months post-operatively. 
Reliability values for the three subscales at 
the aforementioned times were as follows: 
Pain: LK = 0.80, 0.78, 0.93; VA = 0.88, 0.88, 
0.93; Stiffness: LK = 0.88, 0.75, 0.88; VA = 0.87, 
0.73, 0.96; Physical Function: LK = 0.93, 0.92, 
0.97; VA = 0.88, 0.91, 0.94. These data suggest 
that both the LK- and VA-scaled versions are 
of excellent reliability.
Responsiveness was evaluated by 
examining the p values generated using 
Wilcoxon's test comparing 6 month post­
operative versus pre-operative status. 
Despite the small sample size (n=30), 
statistically significant, clinically-important 
improvements in health status were noted on 
all three subscales. Statistical p values, based 
on summated subscale scores at 6 months 
post-operatively for the LK- and VA-scaled 
versions, respectively, were as follows: Pain: 
LK = < 0.001; VA = <0.001; Stiffness: LK = 
<0.001; VA = <0.001; Physical Function: LK 
=<0.001; VA = <0.001. These data attest to the 
responsiveness of the Index even when 
monitoring effects in small groups of 
patients. It was noted in this study that 
physical function item 18 (getting on/off a 
bus) was less responsive than other items, 
largely due to the fact that very few 
individuals ever travelled by bus. It was not 
included in the pharmacologic validation 
study or the final English-language version of 
the original Index. However, in some parts of 
the world, bus travel is common, and for this 
reason its use has been retained, as an 
alternate travel item, in some later forms of 
the Index.
Pharmacologic Validation Study
The study employed a double-blind, 
randomized, controlled trial design (15) and 
compared two NSAIDs [Isoxicam (n= 28), 
Piroxicam (n = 29)] in 57 patients with OA 
hip (n=18) or knee (n=39). Patients were 
evaluated at enrolment and again one week 
later without any change in therapy in order 
to obtain test-retest reliability estimates at 
steady state. Thereafter, patients underwent a 
one-week NSAID-free washout period. 
Finally they were evaluated after 2, 4 and 6 
weeks of active treatment. In addition to LK- 
and VA-scaled versions of WOMAC, the 
following measures were administered
concurrently for validation purposes: 1) 
Modified Doyle Index, 2) Lequesne Index, 3) 
Bradburn Index of Well Being, and 4) Social 
Component of the MHIQ. Additional
measures included interviewer global
assessment, patient global assessment, 50' 
walk time, total range of motion, and 
intermalleolar straddle. One of the major 
strengths of the validation design was that 
randomization created two groups similar in 
baseline characteristics and response 
potential. Independent evaluations of 
reliability, validity and responsiveness were 
undertaken on these two separate treatment 
groups.
Test-retest reliability by Kendall's tau 
c statistic using a one-week retest interval 
was as follows: Pain (combined groups): LK = 
0.68, VA = 0.64; Stiffness (combined groups): 
LK = 0.48, VA = 0.61; Physical Function 
(combined groups): LK = 0.68, VA = 0.72. 
Internal consistency by Cronbach's alpha was 
as follows: Pain: LK - Isoxicam = 0.86, 
Piroxicam = 0.89; VA - Isoxicam = 0.81, 
Piroxicam = 0.73; Stiffness: LK - Isoxicam =
0.90, Piroxicam = 0.91; VA (not determined); 
Physical Function: LK - Isoxicam = 0.95,
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Piroxicam = 0.95; VA - Isoxicam = 0.91, 
Piroxicam = 0.89. These data suggest that 
both the LK- and VA-scaled versions are of 
excellent reliability. Test-retest coefficients 
are in the mid range due to interval change 
occurring in health status of participating 
patients over the one-week interval.
Validity testing was based on 
construct validity determined using 
Pearson's correlation coefficients. Correlation 
coefficients, based on the WOMAC, Doyle, 
Lequesne, Bradburn, and MHIQ Indices, 
supported the construct that the pain, 
stiffness and physical function subscales 
were valid. In particular, WOMAC Index 
items showed statistically significant 
correlation with other indices probing the 
same dimension (i.e., convergent construct 
validity). Furthermore, WOMAC Index items 
showed higher levels of correlation with 
indices probing the same dimension than 
with indices probing other dimensions (i.e., 
divergent construct validity). Construct 
validity was demonstrated for both the LK- 
and VA-scaled versions of the Index.
Responsiveness was evaluated by 
examining p values generated using 
Wilcoxon's test comparing end of washout 
values with end of 6-week treatment values. 
Despite the small sample sizes (Isoxicam = 28, 
Piroxicam = 29), statistically significant 
improvements in health status were noted on 
all three subscales. Statistical p values, based 
on aggregated subscale scores after 6 weeks 
of active treatment for the LK- and VA-scaled 
versions, respectively, were as follows: Pain: 
LK - Isoxicam = <0.001, Piroxicam = <0,003, 
VA - Isoxicam = <0.001, Piroxicam = <0.003; 
Stiffness: LK - Isoxicam = <0.001, Piroxicam = 
<0.013, VA - Isoxicam = <0.001, Piroxicam = 
<0.013; Physical Function: LK - Isoxicam = 
<0.003, Piroxicam = <0.002, VA - Isoxicam =
<0.003, Piroxicam = <0.002. These data attest 
to the responsiveness of the WOMAC index 
in two separate but similar small groups of 
OA patients.
On the basis of these two validation 
studies, the final version of WOMAC was 
established. Since LK- and VA-scaled formats 
of the Index had been separately validated, 
two versions of the Index were produced: 
WOMAC LK 3.0 and WOMAC VA 3.0. These 
versions are identical with respect to item 
inventory and differ only in the scales on 
which patients respond to the component 
questions.
SPECIFIC CLINIMETRIC ISSUES
The aforementioned validation 
studies established the reliability, validity 
and responsiveness of the Index. Face and 
content validity were ensured by the metlrod 
used to develop the item inventory, while 
construct validity was demonstrated against 
the Doyle, Lequesne, Bradburn and MHIQ 
indices. Having established the basic 
clinimetric properties of the Index, we 
wished to address a number of specific issues 
in order to more fully understand the 
robustness of the instrument (27).
Likert vs Visual Analogue Scaling
In both major validation studies, 
(14,15) WOMAC VA 3.0 was slightly more 
sensitive than WOMAC LK 3.0, as judged by 
the size of the p values generated in parallel 
analyses of concurrent responses made by the 
same patients. It is of note that in a 
subsequent post validation reapplication of 
WOMAC VA 3.0 we were able to detect 
significant differences between two NSAIDs 
on the pain and stiffness subscales, no 
difference being noted in physical function 
(21). Although there has been much debate in 
the literature as to which of these two scales
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is to be preferred, high levels of correlation 
have generally been observed between scores 
made concurrently on LK and VA scales. 
Although some investigators have reported 
difficulty amongst patients using VA scales 
in general, to date we have not encountered 
any difficulty with patients comprehending 
or completing WOMAC VA 3.0.
Since the development of the 
WOMAC Index, we have received requests 
for an NRS scaled version. We have created 
an NRS version from existing LK and VA 
scaled versions. Although we have not 
formerly validated the NRS scaling format, 
previous experience with NRS scales in OA 
(1016, 1074) and RA (1075), suggests that the 
NRS version may offer the simplicity of LK 
scaling with similar responsiveness to VA 
scaling. As a consequence both WOMAC and 
AUSCAN Indices (1076) Indices have been 
made available in LK, VA and NRS scaling 
formats.
Prior Score A vailability
Whether patients should be shown 
their prior scores when repeatedly self- 
assessing health status remains controversial. 
We have had experience using the Index 
under both blind and informed conditions. 
This issue was addressed more formally as 
part of the pharmacologic validation study 
(n=28) (15). At the end of the study, patients 
completed WOMAC blind (i.e., on a blank 
questionnaire without reference to any 
previous data). Then, after having completed 
several other questionnaires, they were given 
a second opportunity to rate their current 
WOMAC status on the same WOMAC 
questionnaire on which they had previously 
marked their end of washout scores at the 
beginning of the study. A comparative 
analysis showed no clinically important or 
statistically significant differences between
the results obtained from the two different 
forms of administration (20). This same issue 
was addressed using WOMAC VA3.0 in a 
double-blind, randomized, controlled trial 
comparing flurbiprofen SR and diclofenac SR 
in 70 patients with OA knee (25). No 
statistically significant differences were noted 
between the severity scores at termination 
under blind versus informed administration. 
The item scores for the two forms of 
administration were highly correlated. We, 
therefore, feel that the Index can be 
administered either with or without prior 
score availability. It is traditional at the 
present time to generally administer such 
questionnaires without prior score 
availability.
Time Frame Dependency
Many questionnaires fail to specify 
the time frame over which patients should 
consider the severity of their symptoms. 
Others specify time frames which exceed the 
interval between reassessments in the study. 
There are few published data on whether 
changing the time frame alters data 
interpretation. It has been demonstrated, 
however, that if the time frame is very short 
(e.g. "now"), circadian variation may affect 
the results obtained. In contrast, if the 
interval is too long, then recall (i.e., pain 
memory) may be faulty. We have performed 
an evaluation of the time frame dependency 
of WOMAC VA 3.0 in a small group (n=19) of 
patients entered into a randomized, 
controlled trial of two NSAIDs (40). At the 
final assessment, patients were asked to 
complete in random order three versions of 
WOMAC differing only in the time frame 
over which they were asked to consider their 
symptoms. The three time frames were: 
previous 24 hours, previous 48 hours, and 
previous 2 weeks. Although limited by the
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relatively small number of patients, we 
observed no time frame dependency of 
questionnaire responses over the 14-day 
period. We feel justified in varying the time 
frame over which questions are asked (at 
least between 1-14 days) when using the 
WOMAC Index, depending on the dynamic 
requirements of any given study. We have 
most frequently selected an interval of the 
previous 48 hours.
Signal vs Aggregate Measurement
There are a number of reports in the 
literature suggesting that signal methods of 
measurement may be realistic alternatives to 
more comprehensive methods. A signal is a 
symptom or sign of disease which acts as the 
sole focus of measurement. Such signals may 
be individualized (i.e., tailored to the 
symptom profile of individual patients). By 
appropriate signal selection, it may be 
possible to improve the efficiency of the 
measurement process by restricting 
measurement to aspects of disease that are 
clinically important and have good response 
potential. We have conducted two such 
studies, one based on WOMAC LK 3.0 (n=30) 
(13), and the other on WOMAC VA 3.0 (n=70) 
(1). We call these alternate versions of the 
Index WOMAC LK 3.0S and WOMAC VA 
3.OS, respectively. They are identical to the 
parent Index with the exception that on the 
last page, having completed the Index, 
patients are instructed as follows: "Now we 
would like you to think again about each of 
the aforementioned symptoms which you 
have just rated. Then select one pain item, 
one stiffness item, and one physical function 
item which are most important to you, i.e., 
which you most hope the treatment you are 
about to receive will improve. Indicate your 
selections by circling the appropriate item 
numbers. Remember to select only one pain
item, and one stiffness item, and one 
physical function item".
In both studies a signal analysis, 
based on one pain, one stiffness and one 
physical function item per patient, was 
compared against the traditional, or 
aggregate analysis, in which three separate 
subscale scores were created by summation 
of component item scores (i.e., 5 pain, 2 
stiffness, 17 physical function). The signal 
method was capable of detecting statistically 
significant improvements in both studies. As 
expected, patients varied considerably in 
which items they selected, not all signals 
selected being the most severely affected 
items. In both studies the statistical efficiency 
of the signal approach was slightly greater 
than that of the aggregate approach and was 
attended by smaller sample size 
requirements. However, there are two 
limitations to the signal approach. Firstly, in 
both studies we noted (albeit at a low 
prevalence) the occurrence of deterioration in 
non-signal items. Secondly, in our study with 
WOMAC VA 3.OS, we administered the 
Index at the beginning and end of the trial, 
and noted that 80% of patients had switched 
signal selection by the end of the trial (1). It 
was unclear from the analysis why this 
occurred, but the data suggested that patients 
may have selected new signals on the basis of 
a lack of improvement in their initial signal 
selections during the course of the trial such 
that the new signals had become subjectively 
more important. We are concerned that 
signal selection may not be stable. At the 
present time the signal approach to 
measurement remains experimental and we 
only recommend use of the complete Index,
i.e., WOMAC LK 3.1, WOMAC VA 3.1 and 
WOMAC NRS 3.1.
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Parametric vs Non-Parametric Analysis
There is some controversy as to 
whether ordinal level data can be analyzed 
using parametric techniques. There is also 
debate as to the nature of the VA scale and 
whether it should be analyzed by non- 
parametric techniques. Parametric 
techniques, for comparisons of continuous 
data, generally require a normal distribution. 
To address some of these issues, we have 
compared the results of parametric (Student's 
t-test) and non-parametric (Wilcoxon's test) 
analysis of data from the WOMAC validation 
studies (14,15) In both studies we observed 
that in many instances parametric and non- 
parametric treatments of the data were in 
agreement. Overall, non-parametric methods 
provide a more conservative estimate of the 
response. Therefore, where data are normally 
distributed, parametric methods may be 
considered appropriate. However, where 
they are not normally distributed, non- 
parametric methods should be used.
Relative Efficiency
The relative efficiency (RE) statistic is 
one estimate of the comparative 
responsiveness of different instruments. It is 
defined by the square of the ratio of two t 
values (or z values), e.g. RE (WOMAC vs 
HAQ) = ( tw o M A c /tH A o ). If the RE is >1,0, then 
the instrument in the numerator can be 
inferred to be the more responsive measure 
of outcome, requiring smaller sample sizes 
and/or detecting smaller effect sizes than the 
instrument in the denominator. The RE value 
is rarely unity and yet there are no standards 
defining the significance of values <1.0 or 
>1.0.
We have examined the RE of 
WOMAC versus other measures in four 
separate studies. The first and second studies
were the validation studies previously 
reported (14,15). The third was a double­
blind, randomized, controlled, clinical trial of 
meclofenamate versus diclofenac sodium in 
OA knee (21), and tire fourth a quasi- 
experimental, one-group repeated measures 
trial of total knee arthroplasty (26). Wlrile we 
have no data on the RE of the stiffness 
subscale against other stiffness measures, our 
data on the relative efficiency of the WOMAC 
pain and physical function subscales are as 
follows: WOMAC pain vs HAQ pain = 1.59, 
AIMS pain = 0.81, Lequesne pain = 0.81, 
Doyle Index = 1.09. WOMAC physical 
function vs HAQ physical function = 1.13, 
AIMS physical function = 1.75, Lequesne 
maximum distance walked = 1.65, Lequesne 
activities of daily living = 1.14, Walk time = 
1.2, 1.3, 3.7, 3.4, Intermalleolar straddle = 4.8,
5.1, 4.9, 2.3, Intercondylar distance = 6.9, 3.3, 
range of motion = 1.3, 1.4, (132.0), (67.9). 
These data suggest that the WOMAC Index is 
more efficient than measures of walk time, 
intermalleolar straddle, intercondylar 
distance, and range of motion. Furthermore, 
RE values for WOMAC are >1.0 for 91% of 
the aforementioned comparisons and suggest 
that overall the WOMAC may be a more 
efficient index for assessing outcomes in OA 
clinical trials.
In a study by Theiler et al a German 
version of the WOMAC appeared to be more 
responsive than the Lequesne Index of 
Clinical Severity (1021).
Recent studies, comparing the 
WOMAC against several different generic 
health-related quality of life (HRQOL) 
measures, have generally concluded that the 
WOMAC Index is more efficient in detecting 
disease-specific changes than the HRQOL 
measure (66,80,92,103). The combination of 
WOMAC and a generic HRQOL index would
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be ideal, in those situations where the 
measurement goal is to evaluate the impact 
of an intervention on both the patient's 
disease (WOMAC) and the patient as a whole 
(HRQOL), since these two different 
approaches to health status assessment are 
mutually complementary.
Weighting and Aggregation
While the three WOMAC subscales 
are usually analysed separately, there are 
occasions when it is desirable to aggregate 
them together into a single score. To 
understand the options available for 
weighting and aggregation, it is necessary to 
consider some basic properties of the Index. 
In particular, it should be noted that all scales 
have a base score of zero. The scale lengths of 
the different subscales and versions of the 
index differ as follows: WOMAC LK3.1- Pain 
= 20, Stiffness = 8, Physical Function = 68; 
VA3.1- Pain = 500, Stiffness = 200, Physical 
Function = 1700, NRS3.1- Pain = 50, Stiffness = 
20, Physical Function = 170. In general, the 
pain subscale is more responsive than the 
physical function subscale, and the stiffness 
subscale assumes an intermediate position. In 
order to assess some of the implications of 
weighting and aggregation, we have 
examined the importance of individual 
symptoms, the relative importance of pain vs 
stiffness vs physical function, and the 
relationship between different symptoms in 
each of the subscales.
Our original evaluation of the 
dimensionality of the symptomatology of OA 
suggested that symptomatic patients tended, 
on average, to regard their symptoms as 
moderately important (3) We subsequently 
studied a small group of OA knee patients 
(n=17) participating in a double-blind, 
randomized, controlled, clinical trial 
comparing flurbiprofen SR and diclofenac
sodium SR using WOMAC VA3.0 (25) At the 
end of the 6-week trial, participants 
completed WOMAC VA 3.0 and shortly 
thereafter completed an alternative form of 
WOMAC on which they were asked to 
separately rate on 10 cm VA scales the 
importance which they attached to being 
completely symptom free on each of the 24 
component items. No statistically significant 
correlation was noted between severity and 
importance scores. Except for two items, no 
significant difference was noted between the 
scores of individual items and the average 
score for the subscale to which that item 
belonged. The level of interitem correlation 
for components on each of the three subscales 
was high: pain = 0.79-0.96, stiffness = 0.83, 
physical function = 0.52-0.98. Principal
component analysis showed that Factor I 
accounted for 88% of the variance in pain and 
83% of the variance in physical function. The 
factor loading was high on each individual 
pain item (0.92-0.95) and each individual 
physical function item (0.70-0.97). There was 
relatively little additional variance accounted 
for by Factor II (pain =7%, physical function = 
6%). Thus, analysis of individual WOMAC 
items within a subscale suggested that, 
although highly correlated, they measured 
different aspects of the disease. Factor 
analysis supported the contention that scores 
from items within a subscale could be 
summated into subscale scores.
We have evaluated the use of a device 
called the "Patient Assessment of the Relative 
Importance of Symptoms (PARIS) sectogram" 
(26). The sectogram is a mechanical device 
consisting of three interlocking, laminated 
360° discs (red = pain, yellow = stiffness, blue 
= physical function), which are riveted 
together. Patients are presented the disc, set 
to display equal 120° segments for pain, 
stiffness, and physical function. The patient is
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then instructed to rate the relative 
importance of being free of pain versus free 
of stiffness versus free of physical disability 
by resetting the relative sizes of the three 
sectors. The patient's preferences are scored 
by reading off the number of degrees 
displayed on the periphery of the sectogram. 
The mean relative importance values at 
baseline, expressed as percentages, in 54 
patients studied in a 12-week, double-blind, 
randomized, controlled, clinical trial of 
tenoxicam vs diclofenac (12), were as follows: 
pain = 42%, stiffness = 21%, physical function 
= 37%. Reliability coefficients, based on test- 
retest at baseline and termination in the trial, 
for this procedure were high: pain = 0.86, 
0.90; stiffness = 0.80, 0.88; and physical 
function = 0.81, 0.83.
Given the aforementioned properties 
of the index, there are five alternative 
approaches to weighting and aggregation.
A) The simplest and most commonly 
employed approach is by simple summation 
of the 24 component item scores (Total 
WOMAC Score). This provides a single value 
weighted according to differential scale 
lengths (ratio = 5:2:17) but without any 
correction for the relative importance of the 
different subscales.
B) Alternatively, a normalization procedure 
can be used to correct for differences in scale 
length (Normalized WOMAC Score). This is 
similar to the procedure employed in a 
normalization of the Arthritis Impact 
Measurement Scales (AIMS).
In order to normalize the LK 3.0 Index 
on 0-10 scales, the following correction 
factors are used where S = sum of raw scores 
of items in dimension: Pain -Score Range: 0- 
20, Normalization = (Sx0.50); Stiffness - Score 
Range: 0-8, Normalization = (Sxl.25); and
Physical Function - Score Range: 0-68, 
Normalization = (SxO.147).
In order to normalize the VA 3.0 
Index on 0-100 scales, the following 
correction factors are used where S = sum of 
raw scores of items in dimension: Pain -Score 
Range: 0-500, Normalization = (Sx0.20); 
Stiffness - Score Range: 0-200, Normalization 
= (Sx0.50); and Physical Function - Score 
Range; 0-1700, Normalization = (SxO.059).
In order to normalize the NRS 3.0 
Index on 0-10 scales, the following correction 
factors are used where S = sum of raw scores 
of items in dimension: Pain -Score Range: 0- 
50, Normalization = (Sx0.20); Stiffness - Score 
Range: 0-20, Normalization = (Sx0.50); and 
Physical Function - Score Range: 0-170, 
Normalization = (SxO.059).
Once subscale values have been 
normalized, they can be summated to 
provide a single value in which the three 
component subscales are equally weighted 
(i.e., ratio 1:1:1). This procedure makes no 
correction for the relative clinical importance 
of different subscales. Since all items are 
individually scored on the same scales, 
averaging scores has a similar effect to 
normalization unless the normalized scale 
length differs from the original.
C) Another method of bringing scores on the 
three subscales to a uniform scale length is 
that employed in the construction of the 
Pooled Index. The correction is made by first 
calculating derived units (DU) for scores on 
each of the three subscales. For example, 
DUpAiN=Change score for pain Standard 
deviation of the change score. The Pooled 
WOMAC Score = D U pa in  +  D U stiffness +  
D U physical fu n c tio n . This procedure does 
correct for differences in scale length but not
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for the relative clinical importance of the 
different subscales.
D) As noted previously, we have recently 
started to address the relative clinical 
importance of different types of symptoms to 
individual patients. While this work is still in 
progress, our preliminary observations 
suggest that individual patients vary in the 
relative importance they assign to being free 
of pain vs free of stiffness vs free of physical 
disability. The PARIS sectogram can be used 
in future studies to derive individualized 
weights which could be factored into the data 
analysis. Alternatively, it is possible to use 
our aforementioned weights derived from a 
group of 54 OA patients. The weighting 
factors are as follows: Pain = 0.42, Stiffness = 
0.21, Physical Function = 0.37. While these 
weights can be applied at a subscale level in 
deriving an Importance- Weighted Total 
WOMAC Score, they might be more 
appropriately applied in deriving 
Importance-Weighted Normalized WOMAC 
or Pooled WOMAC Scores. We are 
continuing to investigate the advantages and 
restrictions of this approach. Our current 
data are limited and, therefore, a firm 
recommendation cannot be made at the 
present time. Nevertheless, weighting, 
according to the relative importance of 
symptoms, offers some interesting 
opportunities.
E) A final approach to combining information 
is in a set of response criteria. In this 
approach the success versus failure of 
treatment in individual patients could be 
adjudicated by the occurrence (or non­
occurrence) of changes exceeding a certain 
magnitude on a defined combination of 
measures. We are currently interested in the 
possibility of using the WOMAC Index as the
core of a set of response criteria for OA
clinical trials.
We have examined the relative
efficiency (RE) of the Total WOMAC Score 
and the Pooled WOMAC Score and observed 
that the weighting and aggregation
procedures may tend, overall, to maintain or 
possibly increase relative efficiency (14,15,21).
Computerization
We have previously validated a
computerized version of WOMAC VA 3.0 
against tire original paper version (18). Thirty 
patients with OA knee completed both forms 
of the Index. Patients were instructed to 
indicate their scores directly on the computer 
screen for each of the 24 WOMAC items 
using a "mouse" to move the cursor. An 
opportunity was provided to review cursor 
placements and modify where necessary. The 
corresponding numerical values between 0 
and 100 were automatically generated for 
each VA scale from the exact cursor 
placements, but were not revealed to the 
patient. The data were downloaded each 
night to a central computer 200 km away. 
Correlation analysis demonstrated excellent 
criterion validity against the original paper 
index: pain = 0.90, stiffness = 0.87, physical 
function = 0.97. Despite wide variation in 
computer literacy skills, all patients 
completed the task and the data were 
successfully transmitted to the central 
computer. These data suggest that the 
computerized version of WOMAC VA3.0 is a 
valid alternative to the paper version. The 
results of this study provide exciting 
opportunities for future trials, particularly 
multicentre studies using remote data entry 
terminals. Since this study, the software has 
been redesigned to run on PC computers.
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We have recently evaluated Likert 
and NRS touch screen versions of the 
WOMAC Index. Initial results have been 
favourable (47-49).
Alternate Language Translations
Originally developed in the English 
language, the WOMAC Osteoarthritis Index 
has been translated into many different 
languages. A list of the more than 60 
authorised alternate language translations, 
currently available through our office, is 
provided in Appendix I. Additional 
authorised alternate language translations of 
the WOMAC VA3-series WOMAC LK 3- 
series and WOMAC NRS 3-series are being 
planned at the present time. It is strongly 
recommended that only original authorised 
alternate-language translations of the 
WOMAC Index be used in clinical research 
and clinical practice applications.
Rasch Analyses
A number of Rasch analyses of 
WOMAC data have been performed 
(33,45,61,62). In a Rasch analysis of 655 OA 
patients Wolfe and Kong (61), noted in a 
study of 2,205 patients, 655 of whom have 
osteoarthritis, that the WOMAC Index 
satisfied the requirements of Rasch item 
response theory across all disorders studied. 
Some items did not fit well, but it was not felt 
likely that removing them would be 
advantageous and might decrease usefulness 
in clinic and epidemiologic studies by 
restricting the range of the scale.
Predictive Value
Lingard et al (679), have reported that 
"low" pre-op WOMAC function scores are 
predictive of worse WOMAC function 12- 
months post total knee replacement (p < 
0.0001). In a separate study by Ethgen et al 
(83) there was a 196% increase in
rheumatologist visits in patients in the worst 
quartile for WOMAC function scores (cf best 
quartile) (p < 0.05).
SF-WOMAC
Several propositions for an SF- 
WOMAC have emerged(l1,32,52,58). Four 
analyses have been based on all three 
WOMAC subscales and two have been based 
on only the function subscale. Sample sizes 
have varied from 224-1545 patients and 
studies have differed in environment 
(ortlTopaedic vs rheumatology), geography 
(European vs non-European), research design 
and analytic strategy. Based on a secondary 
analysis of the aforementioned studies, 
encompassing 4013 patients, we have noted 
differences between the different 
propositions. This disparity may be due to 
differences in clinical environment, 
geography, and methodology. While 
WOMAC questions #1-3, 5-7, 9, 10,12,13 and 
18 have been identified in at least 50% of 
analyses, this exact configuration has not 
been part of any individual proposition. 
Given that all WOMAC items have been 
included in at least one proposition, the 
continued use of all 24 WOMAC questions is 
recommended. There are two potential 
negative consequences of short-forming: 1) 
Content validity may decline, and 2) 
Question deletion, based on data from one 
environment, may have a negative impact on 
index performance in other research and 
clinical environments. The WOMAC Index is 
brief and easily administered, and 
administration of the entire 24-item WOMAC 
questionnaire meets practicality
requirements. These issues notwithstanding 
there may be situations where short forming 
is desirable and in those instances, the use of 
a short form, based on the aforementioned 
propositions, may be preferable (28).
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Applications in non-OA disorders
Although not developed for non-OA 
applications, Hobby (1077) used the WOMAC 
Index in her MSc thesis involving 18 women 
with RA (functional class 2 and 3, mean age 
59,2 years, mean disease duration 11.1 years, 
and which involved aerobic exercise and a 
test battery including a maximal treadmill 
stress test, the Functional Status Index, 
Arthritis Impact Measurement Scale and the 
WOMAC Index, and observed statistically 
significant improvements in WOMAC scores 
post- versus pre-training. No significant 
differences were detected by the FSI or AIMS 
indices. This work may suggest an 
application for the WOMAC Index in non- 
OA disorders of the lower extremity. Further 
research is recommended.
ADMINISTRATIVE ISSUES
Since its development, we have had 
an opportunity to use the WOMAC Index 
under a variety of conditions. A number of 
different versions of the Index have been 
created. It is strongly recommended that 
users only employ original authorised 
versions of the WOMAC Index.
We have provided support to a large 
number of registered users and addressed 
their questions regarding administration of 
the Index. The paragraphs that follow contain 
information which we have found useful in 
meeting the needs of WOMAC users.
Formatting the Index
Osteoarthritis is a very different 
condition from rheumatoid arthritis, and 
consideration should be given to the 
formatting of disease-specific questionnaires. 
While one may wish to assess all affected 
joints in OA, it is often more useful to base 
the evaluation of a new treatment on a single
anatomic region (most often the hips and/ or 
knees). Even with hip and knee OA, one is 
frequently confronted with either a single 
symptomatic affected joint or with bilateral 
disease in which one joint is more 
symptomatic than the other. For this reason, 
we consider it important when using the 
WOMAC Index, to decide whether one 
wishes the patient to report on questions 
regarding: 1) hips and knees in general, or 2) 
hips or knees, or 3) a specific joint (e.g. left 
knee or study knee or more severely affected 
hip, etc.). We have had experience 
administering different questionnaires to 
separately assess the symptoms of OA in the 
signal and non-signal knees in the same 
individual. The use of the term "most 
severely affected joint" is problematic and we 
do not recommend its use, since the most 
symptomatic joint may vary throughout the 
time course of the study. In general, for 
interventional studies, we prefer to specify 
the joint of interest, i.e., the signal or study 
joint.
Another issue previously alluded to is 
time frame. In general, we have instructed 
patients to answer WOMAC questions 
considering their symptoms over the 
preceding 48 hours. For long term studies, 
however, where assessment intervals exceed 
one month, the time frame could be 
lengthened to the last 2 weeks.
Finally, one has to decide whether to 
make prior scores available. Our experience, 
based on two studies, is that in practice it 
makes no difference. If prior scores are not to 
be provided, then the patient will complete a 
blank questionnaire at each assessment point, 
and the Index can be produced in booklet 
form or as part of the case report form 
(CRFs). If patients are to be shown their prior 
scores, then ideally one would print CRFs
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with a separate page for each WOMAC item 
and provide space for serial responses over 
time to be scored on the same page (i.e., 
several rows of response scales applicable to 
a single question on each page).
Once the aforementioned formatting 
issues have been considered, the WOMAC 
booklets or CRFs can be printed. The 
questionnaire has been electronically type­
set, and we have generally directed users to 
our local printer, or suggested they make 
arrangements in their own geographic 
location for questionnaires to be produced. It 
is important to discuss with the publisher the 
fact that the VA scales must be exactly 10 cm 
in length. It is also wise to check, not only the 
galley proofs, but also the final shipment for 
accuracy in the text, as well as in the accuracy 
of reproduction of the 10 cm VA scales. On 
occasion, we have received a batch that has 
been distorted even though previous batches 
had been accurate. When printing from 
electronic files the length may also vary 
unless the page set up is selected correctly.
Finally, scannable and computer 
based forms of the WOMAC Index are in 
development. These will facilitate scoring 
and recording, since data can be quickly 
transcribed and transmitted.
Index Presentation
The WOMAC Index is self­
administered and does not require the 
presence of an interviewer. We have 
occasionally mailed the questionnaire to 
patients who could not attend our clinic, and 
did not encounter any difficulty in their 
completing either the LK 3.0 or VA 3.0 
versions at home. However, the availability 
of an assistant offers several advantages. In 
particular, the assistant can review the 
patient instructions which are provided at
the beginning of the questionnaire. They can 
also check that the patient has completed all 
questions before they leave the clinic. Finally, 
we have prepared a short document which 
explains the meaning of questions in the 
WOMAC inventory in order to clarify any 
ambiguities which may arise from time to 
time (Appendix II). We, ourselves, have not 
found it necessary to refer to this document, 
but it was requested several years ago by one 
investigator conducting a study in a 
multicultural population. We recommend 
that the assistant, if present, avoid 
influencing the patient's scoring of the 
questionnaire. The WOMAC Index has been 
designed and developed to be self­
administered, without reference to any third 
party. Under usual conditions, the Index can 
be completed in approximately five minutes. 
We have recent experience with telephone 
administration of the WOMAC 3.0 index. In a 
cross-over study comparing telephone vs 
office completion of the WOMAC LK3.0 (16), 
and have noted only small between-method 
variation in scores; pain = 0.9%, stiffness = 
2.6%, physical function = 2.6%, total
WOMAC LK3.0 = 2.3%. We conclude that the 
WOMAC LK3.0 remains valid When 
administered by telephone.
Score Calculation
The first step in calculation is to take 
the data off the raw questionnaire. For LK 3.1 
numerical values are assigned to each of the 
five response categories (O=none, l=mild, 
2=moderate, 3=severe, 4=extreme). For each 
WOMAC dimension, a subscale score is 
calculated by simple summation of the 
assigned values scored on component items. 
Thus, the range of possible subscale scores 
for the three dimensions is as follows; pain=0- 
20, stiffness = 0-8, physical function=0-68. [For
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convenience these scores can be normalised, 
and expressed on 0-10 scales (or 0-4 scales)].
For VA 3.1 a ruler is used to 
determine the distance in millimetres from 
the left end marker of each analogue to the 
point at which the patient's mark intersects 
the horizontal line on the analogue. For each 
WOMAC dimension, a subscale score is 
calculated by simple summation of the 
assigned values scored on component items. 
Thus, the range of possible subscale scores 
for the three dimensions is as follows: pain=0- 
500, stiffness=0-200, physical function=0-17G0.
For NRS 3.1 numerical values have 
been pre-assigned to response categories 
between 0 (none) and 10 (extreme).
For each WOMAC dimension, a 
subscale score is calculated by simple 
summation of the assigned values scored on 
component items. Thus, the range of possible 
subscale scores for the three dimensions is as 
follows: pain = 0-50, stiffness = 0-20, physical 
function = 0-170
For convenience all aforementioned 
scores can be normalised and expressed on 0- 
10 or 0-100 scales. As noted previously, we 
recommend that, in general, the dimensions 
be kept separate and the analysis conducted 
on a subscale-by-subscale basis. If it is 
necessary to combine the three subscale 
scores, we recommend readers review the 
section on "Weighting and Aggregation".
Occasionally patients place their mark 
outside designated areas. Fortunately, this 
occurs relatively infrequently. We suggest the 
following scoring rules. If the patient places a 
mark between the response boxes in the LK 
3.0 Index, we attribute the mark to the closest 
box. If it is placed exactly between two boxes, 
we attribute it, by convention, to the higher
category. If the mark is placed to the left of 
tlie "none" box, it scores 0, and if it is to the 
right of the "extreme" box, it scores 4. We 
treat placements outside of the end markers 
of the VA scale in a similar fashion (i.e., 
outside the left end = 0, outside the right end 
= 100). We prefer patients to use an "X" or 
"slash" mark that intersects the analogue 
between the end markers. Sometimes, 
however, patients will use a "V ". We read the 
"V" from the point of inflection. If the mark is 
placed above or below the analogue, such 
that it does not make a discreet intersect, we 
drop a perpendicular, using a set square, 
from the intersect of the "X" or the inflection 
part of the "V " or the midpart of the "slash" 
mark to make a proper intersect. The score is 
determined by measurement from the left 
end marker to the point of intersection.
Occasionally patients fail to complete 
all questions. This should not occur if the 
investigator, or assistant, checks the CRFs for 
completeness prior to the patient leaving the 
clinic. If, however, there are missing values, 
we suggest the following. If > two pain, both 
stiffness, or >four physical function items are 
omitted, the patient's response is regarded as 
invalid and the deficient subscale(s) should 
not be used in the analysis. Where one pain, 
one stiffness, or 1-3 physical function items 
are missing, we suggest substituting the 
average value for the subscale in lieu of the 
missing item value(s). This method is similar 
to that employed for some other indices.
Statistical Issues
Parameters used in sample size 
calculation are often difficult to find. Indeed, 
such parameters vary for different types of 
studies, e.g. the variance estimates may differ 
between populations and anatomical areas of 
interest. Likewise, the minimum clinically 
important difference may differ depending
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on: the trial design (washout- retreatment 
versus continuous therapy, or placebo- 
controlled versus active-controlled trials), the 
intervention (surgical versus pharmacologic 
versus physiotherapy), the anatomic area of 
interest (e.g. hips versus knees), and the 
patient population (allcomers versus the 
elderly). It is recommended that WOMAC 
users review our publications (1-31,34,36, 
37,39,40,47-56), and those of other 
investigators, who have published studies 
using the WOMAC Index (32,33,35,38,41- 
46,57-1041) in order to identify variance 
estimates in groups of patients having similar 
characteristics to those in any newly 
proposed study. Investigators requiring 
further information should contact our office 
at the Centre of National Research on 
Disability and Rehabilitation Medicine (see 
Foreword) for up-to-date information on 
parameters referable to defined study 
populations, and for advice regarding sample 
size calculation, inclusion/exclusion criteria 
and responder criteria.
With respect to data analysis, we 
recommend that the data be tested for 
normality and a decision made whether to 
use parametric versus non-parametric 
statistical methods. Several different 
approaches to analysis are possible with 
WOMAC data. Advice regarding data 
analysis can be provided, and is best 
considered a priori.
Responder Criteria
In addition to traditional subscale-by- 
subscale analysis or Total WOMAC score- 
based analysis of group data, consideration 
might be given to individualised analysis 
using responder criteria, either as change 
criteria or state attainment criteria. The 
OARSI and OMERACT-OARSI responder 
criteria, provide a new consensus-based
approach to response category assignment 
(1056,1068). The criteria are based, in part, on 
WOMAC data, and are applicable to studies 
using outcomes, such as the WOMAC Index 
and patient global assessments (2,8). There 
appears to be convergence between response 
status assignment based on expert opinion, 
OARSI and OMERACT-OARSI criteria and 
patient perception (24).
We have considered the minimum 
perceptible clinical improvement (MFC!) for 
the WOMAC Index based on rofecoxib 
studies and have proposed the following 
values: WOMAC Pain = 9.7 nu, WOMAC 
Stiffness = 10.0 nu, WOMAC function = 9.3 nu 
(37). With MPCI criteria we were able detect 
clinically important and statistically 
significant differences in knee OA patients 
treated with Hylan G-F20 + Appropriate Care 
vs those treated with Appropriate Care alone
(7).
An alternate approach has been taken 
by Tubach et al who have proposed 
definitions for Minimal Clinically Important 
Improvement (MCII), based on pain (visual 
analog scale) and function (WOMAC 
subscale), in knee and hip osteoarthritis 
patients (56). The proposed absolute (and 
relative) values for MCII for knee and hip 
osteoartliritis are as follows: I) -19.9 mm (- 
40.8%) and -15.3 mm (-32.0%) for VA pain,
2) - 18.3 mm (-39.0%) and -15.2 mm (- 
32.6%) for patient’s global assessment 3) -9.1 
(-26.0%) and -7.9 (-21.1%) for WOMAC 
function subscale score (56).
In addition we have considered not 
only the minimum perceptible improvement 
but also proposed a hierarchy of thresholds 
based on WOMAC 20%, 50% and 70% 
improvement criteria. Parallel criteria 
consider percentage improvements in pain 
alone (WOMAC 20P, WOMAC 50P,
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WOMAC 70P), or in pain and either stiffness 
or function (WOMAC 20PFS, WOMAC 
50PFS, WOMAC 70PFS) (6,9,). With these 
criteria we have been able to detect clinically 
important and statistically significant 
differences in knee OA patients treated with 
Hylan G-F20 + Appropriate Care vs those 
treated with Appropriate Care alone (6,9). 
We have subsequently confirmed the success 
of the WOMAC 20 50 70 approach in 
comparing outcomes of hip and knee OA 
patients during treatment with rofecoxib and 
ibuprofen vs placebo (23).
In contrast to defining threshold 
values for minimum levels of improvement 
that are important to patients, a second 
paradigm considers the health state attained, 
rather than the absolute or relative change 
achieved. This follows the philosophy that 
"better is good, but good is best". Tubach et 
al (53,54) have proposed definitions of 
Minimum Clinically Acceptable State 
(MCAS) values for hip and knee OA as 
follows: Pain VAS 36 mm (hip), 33 mm  
(knee) and WOMAC function subscale 35 
points (hip), 33 points (knee). These same 
investigators (55) have also proposed a 
definition for Patient Acceptable Symptom 
State (PASS) values as follows: Pain VAS 
35 mm (hip), 32 mm (knee) and WOMAC 
function sub scale 34 points (hip), 31 points 
(knee). These publications notwithstanding, 
exact definition of what constitutes 
acceptable symptom severity to patients with 
OA remains to be established, across a 
broad spectrum of individuals, disease 
severity, environments, cultures, 
languages, and instruments. The inter­
subject and intra-subject variability also 
require further elaboration. Nevertheless, 
and in the absence of normative data for
the general and OA populations, the 
aforementioned values represent initial 
efforts to understand and quantify the 
complexities of state attainment. We have 
had favourable experience recently in using 
state attainment criteria based on the 
WOMAC Index to differentiate between 
groups of patients. The Bellamy et al Low 
Intensity Symptom Severity (BLISS) Index 
categorises patients according to the velocity, 
magnitude and durability of the therapeutic 
response, based on time (a-time to first being 
in the state, b-ever being in the state, c- 
number of visits or percentage of time in the 
state, and d- in the state at study completion) 
and magnitude (<25nu, <20nu, <15nu, <10nu, 
and <5nu) (10). These low intensity symptom 
severity states, reflect the extent to which 
patients achieve a good state rather than an 
improved state of health. Using the 
aforementioned approach we have been able 
to detect clinically important and statistically 
significant differences in knee OA patients 
treated with Hylan G-F20 + Appropriate Care 
vs those treated with Appropriate Care alone 
(10). We have subsequently confirmed the 
success of the BLISS Index approach in 
comparing outcomes of hip and knee OA 
patients during treatment with rofecoxib and 
ibuprofen vs placebo (22).
The extent to which WOMAC 20 50 70 
responder criteria (6,9,23) and the BLISS 
Index (10,22) approach find applicability 
requires further evaluation. However, high 
level improvements (e.g. WOMAC 70%), and 
BLISS states of <5nu are potentially attainable 
in clinical practice, and in clinical trials may 
be statistically detectable in appropriately 
powered studies (6,9,10,22,23). Indeed the 
capacity to calculate the number needed to 
treat (NNT) from clinical trials data, may in 
the future permit, from a composite of NNT
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values, the derivation of an Index of 
Therapeutic Benefit (ITB).
Outcome assessment in osteoarthritis 
clinical trials is dependent on the use of valid, 
reliable, and responsive measurement 
procedures (1042-1073). The WOMAC Index 
has demonstrated fulfilment of these criteria, 
and is increasingly finding application in 
diverse clinical and research environments in 
different countries.
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APPENDIX I - WOMAC 3.1 Alternate-Lanquaqe Translations
LANGUAGE 3.1 LK 3.1/3.0 VA 3.1 NRS 3.01 LK 3.1 W 3.1 (IK)
Argentina X X
Australia X X X
Austria X X X
Belgium French X X X X
Belgium Flemish X X X X
Brazil X X
Brazil Japanese X
Bulgaria X
Canada English X X X
Canada French X X X
Chile X X
China Mandarin X
Columbia X X
Costa Rica X
Croatia X X X
Czech X X
Denmark X X
Ecuador X
Egypt Arabic X
Estonia X
Finland X X
France X X X X X
Germany X X X X X
Greece X
Guatemala X
Hong Kong X
Hungary X X
Iceland X
Israel X X
Italy X X X
Japan X X
Korea X
Latvia X
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Lebanon X
Lithuania X
Malaysia Cantonese X
Malaysia English X
Malaysia Malay X
Mexico X X
The Netherlands X X X X
New Zealand X X
Norway X X
Peru X X
Peru Japanese X
Philippines (Tagalog) X
Poland X X X
Portugal X X X
Romania X
Russian X
Singapore English X
Singapore Mandarin Chinese X
Slovak X X
Slovenia X X
South Africa (English) X X
South Africa (Afrikaans) X X
Spain X X X X
Sweden X X
Swiss French X
Swiss German X X X
Swiss Italian X
Taiwan Mandarin Chinese X
Thailand X
Turkey X X
United Kingdom X X X X
USA English X X X X
USA Spanish X X
USA Florida X
Venezuela X X
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APPENDIX II - An Explanation Of The Meaning of Questions In The WOMAC 
Osteoarthritis Index Inventory
PA IN
Question 1:
"Walking on flat surface" refers to pain experienced while walking on even rather than 
uneven ground (i.e., walking in a shopping mall or on the sidewalk, or some other surface 
where there is a fair degree of regularity). This question does not refer to walking on 
uneven (i.e., rough) ground.
Question 2:
"Going up or down stairs" is self explanatory. If the pain is different going in one direction 
than the other, patients should rate according to the direction which produces the greatest 
pain.
Question 3:
"At night while in bed" refers to the kind of pain that disturbs sleep rather than that which 
occurs while lying in bed between going to bed and finally falling asleep, or between 
waking up and finally getting out of bed.
Question 4;
"Sitting or lying" refers to pain experienced either while in a position of sitting (i.e., in a 
chair) or while lying awake in bed.
Question 5:
"Standing upright" refers to pain occurring while in the standing position but not moving 
(cf Question 1).
STIFFNESS 
Question 6:
Refers to the severity (rather than the duration) of stiffness which occurs after first 
awakening in the morning. In osteoarthritis this is usually, but not always, of short 
duration and often improves or disappears shortly after arising.
Question 7:
This question refers to the severity (rather than the duration) of stiffness whicli occurs after 
periods of inactivity later in the day. This is termed "gelling" in the literature.
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These two questions have been phrased in this way because some patients seem to have a lot of 
morning stiffness but no gelling, and others have gelling with very little morning stiffness. Still 
other patients have both or neither.
PHYSICAL FU N CTIO N  
Question 8:
Refers to the degree of difficulty descending stairs (irrespective of length, height or 
number).
Question 9:
Refers to the degree of difficulty ascending stairs (irrespective of length, height or number). 
Question 10:
Refers to the degree of difficulty getting out of a chair (i.e., rising from the sitting position). 
Question 11:
Refers to the degree of difficulty in remaining in a standing position and should not be 
confused with Question 13, which includes a dynamic component. It should also not be 
confused with Question 10 (i.e., it is the act of being in the standing position not the act of 
getting from another position to the standing position).
Question 12:
Refers to the degree of difficulty bending to pick something up off the floor. This usually 
involves some ankle movement, flexion of the knee and hip, and also some lumbar spinal 
flexion. Some patients seem to use more lumbar flexion and relatively little knee flexion, 
others appear to squat to pick up objects from the floor.
Question 13:
Refers to the degree of difficulty walking on a flat surface, that is an even surface such as a 
sidewalk or the inside of a shopping mall. It does not refer to walking on uneven (i.e., 
rough) ground.
Question 14:
Refers to the degree of difficulty getting in and out of a car, irrespective of whether this is 
into the driver's seat or a passenger seat. If the degree of difficulty differs between getting 
in versus getting out of a car, then the patient should rate the direction which produces the 
greatest difficulty. In later versions of the questionnaire, for use in a global context, this 
question may also encompass getting on and off a bus or other forms of transportation, 
since in some countries other forms of travel are more usual.
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Question 15:
Refers to a composite activity which involves leaving a place of residence and negotiating 
the various obstacles and musculoskeletal challenges in the act of going shopping. This 
may include such simple impediments as getting on or off a curb, going up a slight rise, 
walking and standing for prolonged periods, and, in addition, is probably modulated by 
various social and emotional factors.
Question 16:
Refers to the degree of difficulty experienced while putting on socks or stockings. This 
question has been phrased to allow both male and female patients to respond.
Question 17:
Refers to the degree of difficulty getting out of bed (i.e., the act of swinging one's legs over 
the side and then getting into the standing position). This question differs from Question 
10, in that the movement is made from a bed rather than a chair.
Question 18:
Refers to the degree of difficulty experienced while taking off socks and /o r stockings and 
again has been modified so that male and female patients can both respond to the question.
Question 19:
Refers to the degree of difficulty lying in bed (i.e., turning from side to side, or maintaining 
one particular position in the lying posture).
Question 20:
Refers to the degree of difficulty in getting in and out of the bath tub. For patients who take 
a shower, this question could refer to the shower rather than the bath. If the difficulty 
differs between getting in and out of the bath, then the patient should rate that activity 
which produces the greatest difficulty.
Question 21:
Refers to the degree of difficultly being in a sitting position, i.e., static positioning or 
shuffling about in a chair during prolonged sitting. This is in contra-distinction to Question 
10, which asks about rising from the sitting position.
Question 22:
Refers to getting on or off the toilet. If tlie degree of difficulty is different for the two 
actions, then the patient should rate that action which produces the most difficulty. In 
countries where toilets are non-Western in style, the question could pertain to the relevant 
biomechanical challenges relating to this activity.
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Question 23:
Refers to heavy domestic duties. It has been phrased in these terms to allow both male and 
female patients to respond. Heavy domestic duties for a male might include mowing the 
lawn, raking leaves, shovelling snow or moving heavy boxes, etc. Heavy domestic duties 
for a female might include vacuuming, moving heavy boxes, scrubbing floors, lifting heavy 
grocery bags, etc. There are, of course, various other examples.
Question 24:
Refers to light domestic duties. Again this has been phrased to allow both male and female 
patients to respond. Light domestic duties for a male might include tidying up a room, 
indulging in crafts or hobbies, laying or clearing a table, etc. Light domestic duties for a 
female might include cooking a meal, laying and clearing a table, dusting, indulging in 
crafts and hobbies etc. There are, of course, various other examples.
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AUSCAN H AND OSTEOARTHRITIS INDEX
The AUSCAN Hand Osteoarthritis Index is a tridimensional, self-administered, patient-centered 
health status questionnaire. Its item inventory has been designed to capture the essential elements 
of pain, stiffness and physical disability in patients with osteoarthritis of the hand joints. The 
AUSCAN Index has been subject to studies examining its basic clinimetric properties of reliability, 
validity and responsiveness and the AUSCAN Index has been translated into over twenty different 
language forms. It is available in 5-point Likert (LK), 100 mm Visual Analogue (VA) and 11-point 
Numerical Rating Scale (NRS) formats.
LANGUAGE 3.1 LK 3.0 VA 3.1 NRS
Australia X X
Austria X
Belgium French X
Belgium Flemish X
Canada English X X
Canada French X X
Czech X
France X X
Finland X
Germany X X
Hungary X
Israel X
Italy X X
Lebanon X
The Netherlands X X
New Zealand X
Norway X
Poland X
Russia X
Slovakia X
South Africa (English) X
South Africa (Afrikaans) X
Spain X X
Sweden X
Turkey X
United Kingdom X
USA English X
USA Spanish X
AUSCAN website: www.auscan.org 
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OSTEOARTHRITIS GLOBAL INDEX (QGI)
The OGI 8.0 is a self-administered questionnaire that a s s e s s e s  the beneficial effects of therapy at three 
different levels (study joint, d isease, person) and grades adverse effects of therapy, using a battery of 8 
questions.
OGI 8.0 u ses  Likert-type scaling, and has been used in whole or in part in two recent Canadian studies.
Bellamy N, Goldstein LD and Tekanoff RA. Continuing medical education-driven skills acquisition and impact 
on improved patient outcom es in family practice setting. The Journal of Continuing Education in the Health 
Professionsyol 20,(1), Winter 2000: pp52-61.
Jean Pierre Raynauld, George W Torrance, Philip A Band, Charles H Goldsmith, Peter Tugwell, Valery 
Walker, Margarita Schultz, and Nicholas Bellamy, In collaboration with the Canadian Knee OA Study Group. 
Osteoarthritis & Cart//age 2002:10(7) ;517-526.
The OGI 8.0 is an initial step in the development of a standard measurement battery for performing patient 
global a ssessm en ts . The OGI 8.0 is currently available in English for North America and French for Canada.
OGI website: w w w .ogiq.org
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s e c t io n  10 -  WOMAC Index; Contemporary Context
Twenty-three years have passed since the original conceptualization of the 
WOMAC Index, and seventeen years since the first WOMAC Index validation studies 
were published. From a rheumatology perspective, the emergence of new measurement 
techniques in the 1980s, the recommendations of the OMERACT and IMMPACT 
groups, the need for regulatory agencies such as the FDA and EMEA to establish 
guidelines and the publication of guidelines for the conduct of clinical trials by societies 
such as the OARSI, has generated increased interest in the field of outcome measurement 
in OA. It is important to understand the WOMAC Index, from the standpoint of its 
contemporary context, that is, its relationship to other indices of osteoarthritis clinical 
severity and impact, particularly with respect to measurement tools developed since 
publication of the WOMAC validation studies in 1988. Although this thesis primarily 
concerns use of the WOMAC Index in rheumatology environments, it is noteworthy that 
the emphasis on certain aspects of measurement, may vary between the health disciplines 
of rheumatology, physical therapy, orthopaedic surgery and rehabilitation medicine. For 
example, while not exclusive to any one discipline, the biomechanical aspects of the 
condition are particularly important in orthopaedic environments, while functional 
independence is especially important in physical therapy and rehabilitation environments. 
As a consequence, a large number of evaluation techniques have evolved to measure the 
impact of various conditions on different health, social, emotional, vocational and 
economic outcomes. In this section, the contemporary context will be considered from 
the perspective of questionnaire-based patient-centred symptom severity evaluation tools 
for hip and knee OA, that have been developed, since the publication in 1988 of the 
WOMAC validation studies, and which are finding application in rheumatology.
The contemporary measurement environment in OA hip and knee assessment in 
rheumatology can be divided according to the continuing evolution of experience with 
patient-centred measurement techniques whose origins predate the WOMAC Index, and 
those entirely new assessment techniques which have emerged since the WOMAC was 
validated. Conceptually the measurement framework in hip and knee OA, includes three 
types of patient-centred measures: Generic HRQOL, General Arthritis Measures and OA- 
Specific Measures (Appendix B).
O f the generic HRQOL measures, the SF-36, Nottingham Health Profile (NHP), 
European Quality of Life (EuroQoL), and the Health Utilities Index (HUI), had already 
found application in OA prior to the development o f the WOMAC Index. The use of 
these measures, their derivatives such as SF-12 and FIUI-3, and alternate-language 
translations, continues to expand opportunities for evaluating HRQOL in OA, from a 
generic perspective. Furthermore, in 1999, Ware and colleagues described a methodology 
for developing an Arthritis-Specific Health Index (ASHI) score form the SF-36. More 
recent additions to the list of generic HRQOL instruments, include the World Health 
Organisation Quality of Life Measure (WHO-QoL), Experience with this measure is 
growing, and its exact position within the hierarchy of generic HRQOL tools, and its use 
in OA, remain to be established. Multinational interest in this measure, suggests that it 
will be of increasing importance, particularly in the public health sector.
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O f the general arthritis measures the HAQ and AIMS instruments, and their 
derivatives such as MHAQ and AIMS2, have remained in common usage, where a broad 
based measurement o f OA status is required. Their position in OA measurement has not 
been seriously challenged in the last 25 years, and they are useful, where attribution to a 
single joint, of the severity and consequence of OA, in patients who have differing 
patterns of multi-joint OA involvement, is not required. The development of variations, 
short forms and multiple alternate-language translations continues, and highlight the 
importance of this group of measures.
The WOMAC Index and the ICS remain the two most commonly used hip and 
knee patient-centred OA-specific outcome measures reported in the rheumatology 
interventional research literature. Nevertheless, several new measures have emerged in 
the last seventeen years, have been validated in OA patients, and are finding application 
in rheumatology (Appendix B).
Brooks and colleagues in Australia have developed an approach to outcome 
measurement in OA, based on reducing respondent burden, by including only four patient 
self-reported global questions, in a measure termed the Comprehensive Osteoarthritis 
Test (COAT) (Appendix B). The construct validity of the COAT has been established 
using the WOMAC Index. The COAT can be completed quickly and scored easily. While 
methods based on patient global impression have merit, the exact process by which the 
patient reviews their symptom experience, and then selects, weights and aggregates the 
information into a global score, is poorly understood in OA patients. Further research on 
the nature o f patient global assessment, and the exact wording of patient global questions, 
has been encouraged by the OARSI Task Force on Guidelines for Clinical Trials (23). 
Given its recent introduction, it is too early to comment on the uptake of the COAT in 
clinical practice or clinical research.
The Joint-Specific Multidimensional Assessment of Pain (J-MAP), is a pain 
measurement tool containing both sensory and affective items (Appendix B). The 6-item 
Pain Sensory and 4-item Pain Affect subscales, are patient self-completed. The measure 
is valid, reliable and responsive, and assesses pain from a joint-specific perspective.
The Knee Injury and Osteoarthritis Outcome Score (KOOS) and the Hip 
Disability and Osteoarthritis Outcome Score (HOOS), have both been developed in 
Sweden (Appendix B). These two patient self-completed questionnaires, attempt to 
encompass the needs of a broader spectrum of patients with OA. Parts of the KOOS and 
HOOS Indices borrow content from the WOMAC Index. The WOMAC Index was used 
by Roos and colleagues, in establishing the content validity of the KOOS Index, while 
Nilsdotter et al used the WOMAC to establish the content validity of the HOOS Index. 
The KOOS and HOOS Indices are valid, reliable and responsive. The KOOS Index is 
being used with increasing frequency in clinical research and clinical practice, more so in 
orthopaedic environments than in rheumatology. To date, uptake of the FÏOOS appears to 
have been limited, although this may, in part, relate to its relatively recent emergence.
The Oxford Knee Score (OKS), and the Oxford Hip Score (OHS), are also valid, 
reliable and responsive measures of outcome, and have found application, particularly in 
orthopaedic environments, to evaluate the impact of total joint replacement surgery 
(Appendix B). Both scales, include 12-items and are patient self-completed. In general, 
these two instruments have performed well, although Whitehouse and colleagues have
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recently questioned, whether the formulation of OKS questions and response categories 
needs reconsideration.
The Short Arthritis Assessment Scale (SAS), has been developed from existing 
measures and includes two WOMAC items (descending stairs and going shopping), 
together with one pain and one patient global item (Appendix B). The measure is brief, 
simple to score, and may find application in routine clinical practice. However, the 
physical function component of the SAS, lacks the content validity of the physical 
function subscale of the WOMAC Index, from which it is derived (2 items vs 17 items).
The German Short Musculoskeletal Function Assessment Questionnaire (SMFA- 
D), contains two subscales (function index and bother index), and includes 46 items 
(Appendix B). The WOMAC Index has been used to establish the construct validity of 
the SMFA-D Index. The SMFA-D is a valid, reliable and responsive measure of outcome 
in OA patients.
The contemporary context within which the WOMAC Index exists, is 
characterized by a) formalized measurement guidelines based on evidence and the 
consensus of expert opinion, b) requirements for assessment tools that are valid, reliable 
and responsive, c) different classes of tools that meet different measurement requirements 
(generic HRQOL, general arthritis and condition specific), and d) within each class a 
choice of tools which differ in their concept, content, application and performance. From 
a conceptual standpoint, the condition specific instruments, like the WOMAC Index, vary 
in the extent to which patient opinion has been incorporated in the index development, 
and whether the instrument generates subscale scores or a composite score. Their content 
varies according to the number and nature o f the dimensions covered by the question 
inventory. With respect to application, the instruments vary in their mode of 
administration (patient self-completed or interviewer administered), mode of delivery 
(paper, telephone, electronic), time frame, scaling format, and the availability of 
alternate-language translations. The clinimetric performance of the various instruments 
differs. While their reliability is generally high, they differ in their sensitivity to change 
(syn: responsiveness), and their validity. Thus, some instruments are more valid for 
certain applications. The existence of measures that differ in concept and content, creates 
measurement opportunities, particularly when multiple measures are used in 
combination. For example the combined use of the WOMAC Index, SF-36 and HUI-3 in 
the studies reported by Raynauld et al (17) and Torrance et al (18), permitted the 
respective issues o f effectiveness, cost-effectiveness and cost-utility to be 
comprehensively addressed.
The WOMAC Index has not only contributed to meeting the measurement needs of 
significant numbers of researchers and clinicians, but it has also played an important role 
in the development and validation of new health status measures. A robust clinimetric 
profile (validity, reliability, responsiveness), flexible delivery, multiple scaling options 
and a large inventory o f linguistically valid alternate-language translations, as well as a 
central role in setting responder and state-attainment criteria, has firmly established the 
relevance and importance of the WOMAC Index in a conventional context, and 
encompassing diverse and evolutionary measurement needs.
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APPENDIX B 
OUTCOME MEASURES FOR HIP AND KNEE OA IN 
RHEUMATOLOGY; CONTEMPORARY CONTEXT
GENERIC HRQOL MEASURES:
European Quality of Life Index (EuroQoL) - Hurst NP et al. Br J Rheumatol. 
1994;33:655-662.
Health Utilities Index (HUI) - Feeny D et al. J Clin Oncol. 1992;10:923-928. 
Nottingham Health Profile (NHP) -  Hunt et al. Soc Sel Med 1981;15A:221-229.
World Health Organisation Quality of Life Index (WHO-QoL)* -  Hawthorne et al. 
Quality of Life Res 1999;8:209-224.
Short Form 36 (SF-36) - Ware JE et al. Med. Care. 1992;30:473-483.
GENERAL ARTHRITIS MEASURES:
Arthritis Impact Measurement Scales (AIMS) - Meenan RF et al Arthritis Rheum. 
1980;23:146-152.
Arthritis Impact Measurement Scales 2 (AIMS2) - Meenan RF et al. Arthritis Rheum. 
1992;35:1-10.
Health Assessment Questionnaire (HAQ) - Fries JF et al. Arthritis Rheum. 
1980;23:137-145.
Modified Health Assessment Questionnaire (MHAQ) — Pincus T et al. Arthritis 
Rheum 1983;26:1346-1353.
CONDITION-SPECIFIC AND JOINT-SPECIFIC MEASURES;
Comprehensive Osteoarthritis Test (COAT)* - Brooks LG et al. J Rlieumatol 
2004;31:1180-1186.
Hip Disability and Osteoarthritis Outcome Score (HOOS)* -  Nilsdotter AK et al. 
BMC Muse Disord 2003;4:10-17.
Index of Clinical Severity (Hip) - Lequesne MG et al. Scand J Rlieumatol. 
1987;65(Suppl):85-89.
Index of Clinical Severity (Knee) - Lequesne MG et al. Scand J Rheumatol. 
1987;65(Suppl):85-89.
Joint-Specific Multidimensional Assessment of Pain (J-MAP)* - O’Malley et al. J 
Rheumatol 2003;30:534-543.
Knee Injury and Osteoarthritis Outcome Score (KOOS)* - Roos EM et al. J Orthop 
Sports Phys 1998;78:88-96.
Oxford Hip Score (OHS)* -  Dawson J et al. J Bone Joint Surg, Br 1996;78-B: 185-190. 
Oxford Knee Score (OKS)* -  Dawson J et al. J Bone Joint Surg, Br 1998;80-B:63-69. 
Short Arthritis Assessment Scale* - Wolfe et al. J Rheumatol. 2004;31:2472-2479. 
Short Musculoskeletal Function Assessment Questionnaire (SMFA-D)* - Kirschner S 
et al. Rheumatol Int 2003;23:15-20.
Western Ontario and McMaster Osteoarthritis Index (WOMAC) - Bellamy N et al.
J Rheumatol, 1988;15:1833-1840.
[* Measures developed since publication of the WOMAC Index validation studies]
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